{"doc_id": "10203437_1", "wnd_id": "10203437_1_1", "text": "Lupus - like syndrome caused by 5 - aminosalicylic acid in patients with inflammatory bowel disease .", "tokens": ["Lupus", "-", "like", "syndrome", "caused", "by", "5", "-", "aminosalicylic", "acid", "in", "patients", "with", "inflammatory", "bowel", "disease", "."], "event_mentions": [{"id": "10203437_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "10203437_1_Ent1", "role": "Effect", "text": "Lupus - like syndrome", "start": 0, "end": 4}, {"entity_id": "10203437_1_Ent2", "role": "Treatment", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "10203437_1_Ent4", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "10203437_1_Ent0", "role": "Subject", "text": "patients with inflammatory bowel disease", "start": 11, "end": 16}, {"entity_id": "10203437_1_Ent3", "role": "Treatment_Disorder", "text": "inflammatory bowel disease", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10203437_1_Ent1", "text": "Lupus - like syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10203437_1_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "10203437_1_Ent4", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "10203437_1_Ent0", "text": "patients with inflammatory bowel disease", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "10203437_1_Ent3", "text": "inflammatory bowel disease", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10225085_1", "wnd_id": "10225085_1_1", "text": "Although the two local anesthetics usually do not cause methemoglobinemia , we suspect that the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants , was the reason for the development of methemoglobinemia .", "tokens": ["Although", "the", "two", "local", "anesthetics", "usually", "do", "not", "cause", "methemoglobinemia", ",", "we", "suspect", "that", "the", "displacement", "of", "lidocaine", "from", "protein", "binding", "by", "bupivacaine", ",", "in", "combination", "with", "metabolic", "acidosis", "and", "treatment", "with", "other", "oxidants", ",", "was", "the", "reason", "for", "the", "development", "of", "methemoglobinemia", "."], "event_mentions": [{"id": "10225085_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reason", "start": 37, "end": 38}, "arguments": [{"entity_id": "10225085_1_Ent1", "role": "Treatment", "text": "the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants", "start": 14, "end": 34}, {"entity_id": "10225085_1_Ent3", "role": "Treatment_Drug", "text": "lidocaine", "start": 17, "end": 18}, {"entity_id": "10225085_1_Ent9", "role": "Combination_Drug", "text": "lidocaine", "start": 17, "end": 18}, {"entity_id": "10225085_1_Ent2", "role": "Treatment_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_1_Ent8", "role": "Combination_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_1_Ent4", "role": "Treatment_Drug", "text": "metabolic acidosis", "start": 27, "end": 29}, {"entity_id": "10225085_1_Ent6", "role": "Combination_Drug", "text": "metabolic acidosis", "start": 27, "end": 29}, {"entity_id": "10225085_1_Ent5", "role": "Treatment_Drug", "text": "oxidants", "start": 33, "end": 34}, {"entity_id": "10225085_1_Ent7", "role": "Combination_Drug", "text": "oxidants", "start": 33, "end": 34}, {"entity_id": "10225085_1_Ent0", "role": "Effect", "text": "methemoglobinemia", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "10225085_1_Ent1", "text": "the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants", "entity_type": "Entity", "start": 14, "end": 34}, {"id": "10225085_1_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10225085_1_Ent9", "text": "lidocaine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10225085_1_Ent2", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_1_Ent8", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_1_Ent4", "text": "metabolic acidosis", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10225085_1_Ent6", "text": "metabolic acidosis", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10225085_1_Ent5", "text": "oxidants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10225085_1_Ent7", "text": "oxidants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10225085_1_Ent0", "text": "methemoglobinemia", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "10410183_3", "wnd_id": "10410183_3_1", "text": "CASE SUMMARY : A 39 - year - old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU / L ( normal < 230 ) .", "tokens": ["CASE", "SUMMARY", ":", "A", "39", "-", "year", "-", "old", "white", "Jewish", "schizophrenic", "man", "treated", "with", "olanzapine", "developed", "an", "elevated", "serum", "CK", "concentration", "with", "a", "peak", "concentration", "of", "4000", "IU", "/", "L", "(", "normal", "<", "230", ")", "."], "event_mentions": [{"id": "10410183_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "10410183_3_Ent0", "role": "Subject", "text": "A 39 - year - old white Jewish schizophrenic man", "start": 3, "end": 13}, {"entity_id": "10410183_3_Ent1", "role": "Subject_Age", "text": "39 - year - old", "start": 4, "end": 9}, {"entity_id": "10410183_3_Ent2", "role": "Subject_Race", "text": "white Jewish", "start": 9, "end": 11}, {"entity_id": "10410183_3_Ent6", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 11, "end": 12}, {"entity_id": "10410183_3_Ent3", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "10410183_3_Ent5", "role": "Treatment", "text": "olanzapine", "start": 15, "end": 16}, {"entity_id": "10410183_3_Ent7", "role": "Treatment_Drug", "text": "olanzapine", "start": 15, "end": 16}, {"entity_id": "10410183_3_Ent4", "role": "Effect", "text": "an elevated serum CK concentration", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "10410183_3_Ent0", "text": "A 39 - year - old white Jewish schizophrenic man", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "10410183_3_Ent1", "text": "39 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10410183_3_Ent2", "text": "white Jewish", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10410183_3_Ent6", "text": "schizophrenic", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10410183_3_Ent3", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10410183_3_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10410183_3_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10410183_3_Ent4", "text": "an elevated serum CK concentration", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "10414481_2", "wnd_id": "10414481_2_1", "text": "This patient , who had a history of osteoarthritis , had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints .", "tokens": ["This", "patient", ",", "who", "had", "a", "history", "of", "osteoarthritis", ",", "had", "severe", "hepatitis", "5", "weeks", "after", "being", "started", "on", "diclofenac", "for", "increasing", "pain", "in", "the", "joints", "."], "event_mentions": [{"id": "10414481_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 10, "end": 11}, "arguments": [{"entity_id": "10414481_2_Ent0", "role": "Subject", "text": "This patient , who had a history of osteoarthritis", "start": 0, "end": 9}, {"entity_id": "10414481_2_Ent1", "role": "Effect", "text": "hepatitis", "start": 12, "end": 13}, {"entity_id": "10414481_2_Ent5", "role": "Treatment_Time_elapsed", "text": "5 weeks", "start": 13, "end": 15}, {"entity_id": "10414481_2_Ent2", "role": "Treatment", "text": "5 weeks after being started on diclofenac", "start": 13, "end": 20}, {"entity_id": "10414481_2_Ent3", "role": "Treatment_Drug", "text": "diclofenac", "start": 19, "end": 20}, {"entity_id": "10414481_2_Ent4", "role": "Treatment_Disorder", "text": "increasing pain in the joints", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "10414481_2_Ent0", "text": "This patient , who had a history of osteoarthritis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "10414481_2_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10414481_2_Ent5", "text": "5 weeks", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10414481_2_Ent2", "text": "5 weeks after being started on diclofenac", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "10414481_2_Ent3", "text": "diclofenac", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10414481_2_Ent4", "text": "increasing pain in the joints", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "10442258_2", "wnd_id": "10442258_2_1", "text": "Alopecia and hair loss are rare side effects of psychotropic drugs .", "tokens": ["Alopecia", "and", "hair", "loss", "are", "rare", "side", "effects", "of", "psychotropic", "drugs", "."], "event_mentions": [{"id": "10442258_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 6, "end": 8}, "arguments": [{"entity_id": "10442258_2_Ent0", "role": "Effect", "text": "Alopecia and hair loss", "start": 0, "end": 4}, {"entity_id": "10442258_2_Ent2", "role": "Treatment_Drug", "text": "psychotropic", "start": 9, "end": 10}, {"entity_id": "10442258_2_Ent1", "role": "Treatment", "text": "psychotropic drugs", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10442258_2_Ent0", "text": "Alopecia and hair loss", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10442258_2_Ent2", "text": "psychotropic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10442258_2_Ent1", "text": "psychotropic drugs", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10452772_1", "wnd_id": "10452772_1_1", "text": "CONCLUSION : Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization , particularly those patients with concomitant protamine allergy .", "tokens": ["CONCLUSION", ":", "Patients", "with", "insulin", "allergy", "may", "not", "have", "complete", "resolution", "of", "their", "symptoms", "after", "standard", "desensitization", ",", "particularly", "those", "patients", "with", "concomitant", "protamine", "allergy", "."], "event_mentions": [{"id": "10452772_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 10, "end": 11}, "arguments": [{"entity_id": "10452772_1_Ent0", "role": "Subject", "text": "Patients with insulin allergy", "start": 2, "end": 6}, {"entity_id": "10452772_1_Ent2", "role": "Subject_Disorder", "text": "insulin allergy", "start": 4, "end": 6}, {"entity_id": "10452772_1_Ent4", "role": "Treatment", "text": "standard desensitization", "start": 15, "end": 17}, {"entity_id": "10452772_1_Ent1", "role": "Subject", "text": "concomitant protamine allergy", "start": 22, "end": 25}, {"entity_id": "10452772_1_Ent3", "role": "Subject_Disorder", "text": "protamine allergy", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "10452772_1_Ent0", "text": "Patients with insulin allergy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10452772_1_Ent2", "text": "insulin allergy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10452772_1_Ent4", "text": "standard desensitization", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10452772_1_Ent1", "text": "concomitant protamine allergy", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "10452772_1_Ent3", "text": "protamine allergy", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "10452772_4", "wnd_id": "10452772_4_1", "text": "Patients receiving neutral protamine Hagedorn ( NPH ) insulin are at increased risk for the development of protamine hypersensitivity .", "tokens": ["Patients", "receiving", "neutral", "protamine", "Hagedorn", "(", "NPH", ")", "insulin", "are", "at", "increased", "risk", "for", "the", "development", "of", "protamine", "hypersensitivity", "."], "event_mentions": [{"id": "10452772_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 15, "end": 16}, "arguments": [{"entity_id": "10452772_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "10452772_4_Ent2", "role": "Treatment", "text": "neutral protamine Hagedorn ( NPH ) insulin", "start": 2, "end": 9}, {"entity_id": "10452772_4_Ent3", "role": "Treatment_Drug", "text": "neutral protamine Hagedorn ( NPH ) insulin", "start": 2, "end": 9}, {"entity_id": "10452772_4_Ent1", "role": "Effect", "text": "protamine hypersensitivity", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "10452772_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10452772_4_Ent2", "text": "neutral protamine Hagedorn ( NPH ) insulin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "10452772_4_Ent3", "text": "neutral protamine Hagedorn ( NPH ) insulin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "10452772_4_Ent1", "text": "protamine hypersensitivity", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "10456487_3", "wnd_id": "10456487_3_1", "text": "One of the monohydroxy - metabolites has been incriminated with tacrine - induced hepatotoxicity .", "tokens": ["One", "of", "the", "monohydroxy", "-", "metabolites", "has", "been", "incriminated", "with", "tacrine", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "10456487_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "10456487_3_Ent1", "role": "Treatment", "text": "tacrine", "start": 10, "end": 11}, {"entity_id": "10456487_3_Ent2", "role": "Treatment_Drug", "text": "tacrine", "start": 10, "end": 11}, {"entity_id": "10456487_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "10456487_3_Ent1", "text": "tacrine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10456487_3_Ent2", "text": "tacrine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10456487_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "10458196_4", "wnd_id": "10458196_4_1", "text": "CONCLUSIONS : Topical brimonidine may be associated with central nervous system depression in infants .", "tokens": ["CONCLUSIONS", ":", "Topical", "brimonidine", "may", "be", "associated", "with", "central", "nervous", "system", "depression", "in", "infants", "."], "event_mentions": [{"id": "10458196_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "10458196_4_Ent5", "role": "Treatment_Route", "text": "Topical", "start": 2, "end": 3}, {"entity_id": "10458196_4_Ent3", "role": "Treatment", "text": "Topical brimonidine", "start": 2, "end": 4}, {"entity_id": "10458196_4_Ent4", "role": "Treatment_Drug", "text": "brimonidine", "start": 3, "end": 4}, {"entity_id": "10458196_4_Ent2", "role": "Effect", "text": "central nervous system depression", "start": 8, "end": 12}, {"entity_id": "10458196_4_Ent0", "role": "Subject", "text": "infants", "start": 13, "end": 14}, {"entity_id": "10458196_4_Ent1", "role": "Subject_Age", "text": "infants", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "10458196_4_Ent5", "text": "Topical", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10458196_4_Ent3", "text": "Topical brimonidine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10458196_4_Ent4", "text": "brimonidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10458196_4_Ent2", "text": "central nervous system depression", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10458196_4_Ent0", "text": "infants", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10458196_4_Ent1", "text": "infants", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "10461415_1", "wnd_id": "10461415_1_1", "text": "Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato - biliary enzymes and transient biliary stasis .", "tokens": ["Ceftriaxone", "was", "approved", "in", "1997", "for", "the", "treatment", "of", "otitis", "media", "despite", "previous", "studies", "that", "documented", "an", "association", "of", "ceftriaxone", "with", "elevated", "hepato", "-", "biliary", "enzymes", "and", "transient", "biliary", "stasis", "."], "event_mentions": [{"id": "10461415_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association of", "start": 17, "end": 19}, "arguments": [{"entity_id": "10461415_1_Ent2", "role": "Treatment_Disorder", "text": "otitis media", "start": 9, "end": 11}, {"entity_id": "10461415_1_Ent1", "role": "Treatment", "text": "ceftriaxone", "start": 19, "end": 20}, {"entity_id": "10461415_1_Ent3", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 19, "end": 20}, {"entity_id": "10461415_1_Ent0", "role": "Effect", "text": "elevated hepato - biliary enzymes and transient biliary stasis", "start": 21, "end": 30}]}], "entity_mentions": [{"id": "10461415_1_Ent2", "text": "otitis media", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10461415_1_Ent1", "text": "ceftriaxone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10461415_1_Ent3", "text": "ceftriaxone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10461415_1_Ent0", "text": "elevated hepato - biliary enzymes and transient biliary stasis", "entity_type": "Entity", "start": 21, "end": 30}], "lang": "en"}
{"doc_id": "10466445_1", "wnd_id": "10466445_1_1", "text": "Successful treatment with arsenic trioxide of a patient with ATRA - resistant relapse of acute promyelocytic leukemia .", "tokens": ["Successful", "treatment", "with", "arsenic", "trioxide", "of", "a", "patient", "with", "ATRA", "-", "resistant", "relapse", "of", "acute", "promyelocytic", "leukemia", "."], "event_mentions": [{"id": "10466445_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 1, "end": 2}, "arguments": [{"entity_id": "10466445_1_Ent1", "role": "Treatment", "text": "arsenic trioxide", "start": 3, "end": 5}, {"entity_id": "10466445_1_Ent2", "role": "Treatment_Drug", "text": "arsenic trioxide", "start": 3, "end": 5}, {"entity_id": "10466445_1_Ent0", "role": "Subject", "text": "a patient with ATRA - resistant relapse of acute promyelocytic leukemia", "start": 6, "end": 17}, {"entity_id": "10466445_1_Ent3", "role": "Treatment_Disorder", "text": "ATRA - resistant relapse of acute promyelocytic leukemia", "start": 9, "end": 17}]}], "entity_mentions": [{"id": "10466445_1_Ent1", "text": "arsenic trioxide", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10466445_1_Ent2", "text": "arsenic trioxide", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10466445_1_Ent0", "text": "a patient with ATRA - resistant relapse of acute promyelocytic leukemia", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "10466445_1_Ent3", "text": "ATRA - resistant relapse of acute promyelocytic leukemia", "entity_type": "Entity", "start": 9, "end": 17}], "lang": "en"}
{"doc_id": "10466445_3", "wnd_id": "10466445_3_1", "text": "In the present study , arsenic trioxide was given intravenously for 42 days to a 56 - year - old female patient suffering from chemotherapy / ATRA - resistant APL , with 43 % APL blasts in the bone marrow and elevated D - dimers .", "tokens": ["In", "the", "present", "study", ",", "arsenic", "trioxide", "was", "given", "intravenously", "for", "42", "days", "to", "a", "56", "-", "year", "-", "old", "female", "patient", "suffering", "from", "chemotherapy", "/", "ATRA", "-", "resistant", "APL", ",", "with", "43", "%", "APL", "blasts", "in", "the", "bone", "marrow", "and", "elevated", "D", "-", "dimers", "."], "event_mentions": [{"id": "10466445_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "given", "start": 8, "end": 9}, "arguments": [{"entity_id": "10466445_3_Ent3", "role": "Treatment", "text": "arsenic trioxide", "start": 5, "end": 7}, {"entity_id": "10466445_3_Ent4", "role": "Treatment_Drug", "text": "arsenic trioxide", "start": 5, "end": 7}, {"entity_id": "10466445_3_Ent6", "role": "Treatment_Duration", "text": "42 days", "start": 11, "end": 13}, {"entity_id": "10466445_3_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 15, "end": 20}, {"entity_id": "10466445_3_Ent0", "role": "Subject", "text": "56 - year - old female patient", "start": 15, "end": 22}, {"entity_id": "10466445_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 20, "end": 21}, {"entity_id": "10466445_3_Ent5", "role": "Treatment_Disorder", "text": "chemotherapy / ATRA - resistant APL", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "10466445_3_Ent3", "text": "arsenic trioxide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10466445_3_Ent4", "text": "arsenic trioxide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10466445_3_Ent6", "text": "42 days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10466445_3_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "10466445_3_Ent0", "text": "56 - year - old female patient", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "10466445_3_Ent2", "text": "female", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10466445_3_Ent5", "text": "chemotherapy / ATRA - resistant APL", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "10473079_1", "wnd_id": "10473079_1_1", "text": "We conclude that the presence of this metabolic defect combined with topical 5 - FU ( a drug demonstrating a narrow therapeutic index ) results in the unusual presentation of life - threatening toxicity after treatment with a topical drug .", "tokens": ["We", "conclude", "that", "the", "presence", "of", "this", "metabolic", "defect", "combined", "with", "topical", "5", "-", "FU", "(", "a", "drug", "demonstrating", "a", "narrow", "therapeutic", "index", ")", "results", "in", "the", "unusual", "presentation", "of", "life", "-", "threatening", "toxicity", "after", "treatment", "with", "a", "topical", "drug", "."], "event_mentions": [{"id": "10473079_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "results in", "start": 24, "end": 26}, "arguments": [{"entity_id": "10473079_1_Ent0", "role": "Subject", "text": "this metabolic defect", "start": 6, "end": 9}, {"entity_id": "10473079_1_Ent1", "role": "Subject_Disorder", "text": "metabolic defect", "start": 7, "end": 9}, {"entity_id": "10473079_1_Ent5", "role": "Treatment_Route", "text": "topical", "start": 11, "end": 12}, {"entity_id": "10473079_1_Ent3", "role": "Treatment", "text": "topical 5 - FU ( a drug demonstrating a narrow therapeutic index )", "start": 11, "end": 24}, {"entity_id": "10473079_1_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 12, "end": 15}, {"entity_id": "10473079_1_Ent2", "role": "Effect", "text": "unusual presentation of life - threatening toxicity", "start": 27, "end": 34}]}], "entity_mentions": [{"id": "10473079_1_Ent0", "text": "this metabolic defect", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10473079_1_Ent1", "text": "metabolic defect", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10473079_1_Ent5", "text": "topical", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10473079_1_Ent3", "text": "topical 5 - FU ( a drug demonstrating a narrow therapeutic index )", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "10473079_1_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10473079_1_Ent2", "text": "unusual presentation of life - threatening toxicity", "entity_type": "Entity", "start": 27, "end": 34}], "lang": "en"}
{"doc_id": "10485779_10", "wnd_id": "10485779_10_1", "text": "Ritonavir can inhibit the metabolism of fentanyl significantly , so caution should be exercised if fentanyl is given to patients receiving ritonavir medication .", "tokens": ["Ritonavir", "can", "inhibit", "the", "metabolism", "of", "fentanyl", "significantly", ",", "so", "caution", "should", "be", "exercised", "if", "fentanyl", "is", "given", "to", "patients", "receiving", "ritonavir", "medication", "."], "event_mentions": [{"id": "10485779_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 10, "end": 11}, "arguments": [{"entity_id": "10485779_10_Ent4", "role": "Treatment_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "10485779_10_Ent6", "role": "Combination_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "10485779_10_Ent1", "role": "Effect", "text": "metabolism of fentanyl significantly", "start": 4, "end": 8}, {"entity_id": "10485779_10_Ent2", "role": "Treatment", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent0", "role": "Subject", "text": "patients receiving ritonavir medication", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "10485779_10_Ent4", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10485779_10_Ent6", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10485779_10_Ent1", "text": "metabolism of fentanyl significantly", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10485779_10_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent0", "text": "patients receiving ritonavir medication", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "10492493_1", "wnd_id": "10492493_1_1", "text": "CONCLUSIONS : This case suggests that losartan can induce late - onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms .", "tokens": ["CONCLUSIONS", ":", "This", "case", "suggests", "that", "losartan", "can", "induce", "late", "-", "onset", "angioedema", "in", "patients", "with", "normal", "renal", "function", "and", "that", "the", "reaction", "can", "recur", "after", "initial", "resolution", "of", "the", "symptoms", "."], "event_mentions": [{"id": "10492493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 8, "end": 9}, "arguments": [{"entity_id": "10492493_1_Ent2", "role": "Treatment", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_1_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_1_Ent1", "role": "Effect", "text": "late - onset angioedema", "start": 9, "end": 13}, {"entity_id": "10492493_1_Ent0", "role": "Subject", "text": "patients with normal renal function", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "10492493_1_Ent2", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_1_Ent3", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_1_Ent1", "text": "late - onset angioedema", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10492493_1_Ent0", "text": "patients with normal renal function", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "10492493_2", "wnd_id": "10492493_2_1", "text": "Losartan - induced angioedema .", "tokens": ["Losartan", "-", "induced", "angioedema", "."], "event_mentions": [{"id": "10492493_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10492493_2_Ent1", "role": "Treatment", "text": "Losartan", "start": 0, "end": 1}, {"entity_id": "10492493_2_Ent2", "role": "Treatment_Drug", "text": "Losartan", "start": 0, "end": 1}, {"entity_id": "10492493_2_Ent0", "role": "Effect", "text": "angioedema", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "10492493_2_Ent1", "text": "Losartan", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10492493_2_Ent2", "text": "Losartan", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10492493_2_Ent0", "text": "angioedema", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "10492493_3", "wnd_id": "10492493_3_1", "text": "OBJECTIVE : To report a case of angioedema associated with losartan administration .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "angioedema", "associated", "with", "losartan", "administration", "."], "event_mentions": [{"id": "10492493_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "10492493_3_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "10492493_3_Ent1", "role": "Effect", "text": "angioedema", "start": 7, "end": 8}, {"entity_id": "10492493_3_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 10, "end": 11}, {"entity_id": "10492493_3_Ent2", "role": "Treatment", "text": "losartan administration", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10492493_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10492493_3_Ent1", "text": "angioedema", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10492493_3_Ent3", "text": "losartan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10492493_3_Ent2", "text": "losartan administration", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10510017_1", "wnd_id": "10510017_1_1", "text": "Heparin - induced thrombocytopenia is a rare and serious complication of anticoagulation therapy .", "tokens": ["Heparin", "-", "induced", "thrombocytopenia", "is", "a", "rare", "and", "serious", "complication", "of", "anticoagulation", "therapy", "."], "event_mentions": [{"id": "10510017_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "10510017_1_Ent2", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "10510017_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}, {"entity_id": "10510017_1_Ent1", "role": "Treatment", "text": "anticoagulation therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10510017_1_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10510017_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10510017_1_Ent1", "text": "anticoagulation therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10510017_4", "wnd_id": "10510017_4_1", "text": "We report the successful treatment of heparin - induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2 - year - old child with Danaparoid ( orgaran ) .", "tokens": ["We", "report", "the", "successful", "treatment", "of", "heparin", "-", "induced", "thrombocytopenia", "and", "subsequent", "hemorrhagic", "complications", "postoperatively", "in", "a", "2", "-", "year", "-", "old", "child", "with", "Danaparoid", "(", "orgaran", ")", "."], "event_mentions": [{"id": "10510017_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 4, "end": 5}, "arguments": [{"entity_id": "10510017_4_Ent8", "role": "Treatment_Disorder", "text": "heparin - induced thrombocytopenia and subsequent hemorrhagic complications", "start": 6, "end": 14}, {"entity_id": "10510017_4_Ent5", "role": "Subject", "text": "a 2 - year - old child", "start": 16, "end": 23}, {"entity_id": "10510017_4_Ent6", "role": "Subject_Age", "text": "2 - year - old child", "start": 17, "end": 23}, {"entity_id": "10510017_4_Ent9", "role": "Treatment_Drug", "text": "Danaparoid", "start": 24, "end": 25}, {"entity_id": "10510017_4_Ent7", "role": "Treatment", "text": "Danaparoid ( orgaran )", "start": 24, "end": 28}]}, {"id": "10510017_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10510017_4_Ent3", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "10510017_4_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "10510017_4_Ent2", "role": "Effect", "text": "thrombocytopenia and subsequent hemorrhagic complications", "start": 9, "end": 14}, {"entity_id": "10510017_4_Ent0", "role": "Subject", "text": "a 2 - year - old child", "start": 16, "end": 23}, {"entity_id": "10510017_4_Ent1", "role": "Subject_Age", "text": "2 - year - old child", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "10510017_4_Ent3", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10510017_4_Ent4", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10510017_4_Ent8", "text": "heparin - induced thrombocytopenia and subsequent hemorrhagic complications", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "10510017_4_Ent2", "text": "thrombocytopenia and subsequent hemorrhagic complications", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "10510017_4_Ent0", "text": "a 2 - year - old child", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "10510017_4_Ent5", "text": "a 2 - year - old child", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "10510017_4_Ent1", "text": "2 - year - old child", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "10510017_4_Ent6", "text": "2 - year - old child", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "10510017_4_Ent9", "text": "Danaparoid", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10510017_4_Ent7", "text": "Danaparoid ( orgaran )", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "10516999_2", "wnd_id": "10516999_2_1", "text": "We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema ) .", "tokens": ["We", "report", "a", "case", "of", "acute", "hyperphosphatemia", "secondary", "to", "rectal", "administration", "of", "sodium", "phosphate", "and", "sodium", "biphosphate", "(", "Fleet", "enema", ")", "."], "event_mentions": [{"id": "10516999_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "10516999_2_Ent0", "role": "Effect", "text": "acute hyperphosphatemia", "start": 5, "end": 7}, {"entity_id": "10516999_2_Ent2", "role": "Treatment_Route", "text": "rectal", "start": 9, "end": 10}, {"entity_id": "10516999_2_Ent1", "role": "Treatment", "text": "rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema )", "start": 9, "end": 21}, {"entity_id": "10516999_2_Ent3", "role": "Treatment_Drug", "text": "sodium phosphate", "start": 12, "end": 14}, {"entity_id": "10516999_2_Ent5", "role": "Combination_Drug", "text": "sodium phosphate", "start": 12, "end": 14}, {"entity_id": "10516999_2_Ent4", "role": "Treatment_Drug", "text": "sodium biphosphate", "start": 15, "end": 17}, {"entity_id": "10516999_2_Ent6", "role": "Combination_Drug", "text": "sodium biphosphate", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "10516999_2_Ent0", "text": "acute hyperphosphatemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10516999_2_Ent2", "text": "rectal", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10516999_2_Ent1", "text": "rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema )", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "10516999_2_Ent3", "text": "sodium phosphate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10516999_2_Ent5", "text": "sodium phosphate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10516999_2_Ent4", "text": "sodium biphosphate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10516999_2_Ent6", "text": "sodium biphosphate", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "10566542_2", "wnd_id": "10566542_2_1", "text": "This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda .", "tokens": ["This", "case", "report", "describes", "a", "patient", "who", "was", "previously", "prescribed", "alendronate", "(", "Fosamax", ")", "and", "presented", "with", "postoperative", "hypophosphatemia", "and", "hypocalcemic", "tetany", "after", "bowel", "preparation", "with", "Fleet", "Phospho", "-", "Soda", "."], "event_mentions": [{"id": "10566542_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "10566542_2_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "10566542_2_Ent4", "role": "Treatment_Drug", "text": "alendronate", "start": 10, "end": 11}, {"entity_id": "10566542_2_Ent6", "role": "Combination_Drug", "text": "alendronate", "start": 10, "end": 11}, {"entity_id": "10566542_2_Ent2", "role": "Treatment", "text": "alendronate ( Fosamax )", "start": 10, "end": 14}, {"entity_id": "10566542_2_Ent1", "role": "Effect", "text": "postoperative hypophosphatemia and hypocalcemic tetany", "start": 17, "end": 22}, {"entity_id": "10566542_2_Ent3", "role": "Treatment", "text": "after bowel preparation with Fleet Phospho - Soda", "start": 22, "end": 30}, {"entity_id": "10566542_2_Ent5", "role": "Treatment_Drug", "text": "Fleet Phospho - Soda", "start": 26, "end": 30}, {"entity_id": "10566542_2_Ent7", "role": "Combination_Drug", "text": "Fleet Phospho - Soda", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "10566542_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10566542_2_Ent4", "text": "alendronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10566542_2_Ent6", "text": "alendronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10566542_2_Ent2", "text": "alendronate ( Fosamax )", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10566542_2_Ent1", "text": "postoperative hypophosphatemia and hypocalcemic tetany", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "10566542_2_Ent3", "text": "after bowel preparation with Fleet Phospho - Soda", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "10566542_2_Ent5", "text": "Fleet Phospho - Soda", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "10566542_2_Ent7", "text": "Fleet Phospho - Soda", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "10573314_14", "wnd_id": "10573314_14_1", "text": "Until further data are available , clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy .", "tokens": ["Until", "further", "data", "are", "available", ",", "clinicians", "should", "be", "vigilant", "for", "a", "possible", "drug", "interaction", "when", "tolterodine", "therapy", "is", "initiated", "in", "a", "patient", "maintained", "on", "warfarin", "therapy", "."], "event_mentions": [{"id": "10573314_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "initiated", "start": 19, "end": 20}, "arguments": [{"entity_id": "10573314_14_Ent1", "role": "Effect", "text": "possible drug interaction", "start": 12, "end": 15}, {"entity_id": "10573314_14_Ent3", "role": "Treatment_Drug", "text": "tolterodine", "start": 16, "end": 17}, {"entity_id": "10573314_14_Ent5", "role": "Combination_Drug", "text": "tolterodine", "start": 16, "end": 17}, {"entity_id": "10573314_14_Ent2", "role": "Treatment", "text": "tolterodine therapy", "start": 16, "end": 18}, {"entity_id": "10573314_14_Ent0", "role": "Subject", "text": "a patient", "start": 21, "end": 23}, {"entity_id": "10573314_14_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 25, "end": 26}, {"entity_id": "10573314_14_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "10573314_14_Ent1", "text": "possible drug interaction", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10573314_14_Ent3", "text": "tolterodine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10573314_14_Ent5", "text": "tolterodine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10573314_14_Ent2", "text": "tolterodine therapy", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "10573314_14_Ent0", "text": "a patient", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "10573314_14_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10573314_14_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "10592946_6", "wnd_id": "10592946_6_1", "text": "We hypothesize that caffeine toxicity injured the muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis .", "tokens": ["We", "hypothesize", "that", "caffeine", "toxicity", "injured", "the", "muscle", "cells", ",", "which", "were", "fragile", "due", "to", "the", "potassium", "depletion", "induced", "by", "the", "coexisting", "hyponatremia", ",", "to", "result", "in", "unusually", "severe", "rhabdomyolysis", "."], "event_mentions": [{"id": "10592946_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "injured", "start": 5, "end": 6}, "arguments": [{"entity_id": "10592946_6_Ent2", "role": "Treatment_Drug", "text": "caffeine", "start": 3, "end": 4}, {"entity_id": "10592946_6_Ent1", "role": "Treatment", "text": "caffeine toxicity", "start": 3, "end": 5}, {"entity_id": "10592946_6_Ent0", "role": "Effect", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "start": 7, "end": 30}]}], "entity_mentions": [{"id": "10592946_6_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10592946_6_Ent1", "text": "caffeine toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_6_Ent0", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 30}], "lang": "en"}
{"doc_id": "10599932_5", "wnd_id": "10599932_5_1", "text": "After the addition of citalopram , a desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease were observed .", "tokens": ["After", "the", "addition", "of", "citalopram", ",", "a", "desmethylclomipramine", "plasma", "level", "increase", "and", "an", "8", "-", "hydroacy", "-", "desmethylclomipramine", "plasma", "level", "decrease", "were", "observed", "."], "event_mentions": [{"id": "10599932_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "10599932_5_Ent1", "role": "Treatment", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "10599932_5_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "10599932_5_Ent0", "role": "Effect", "text": "desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease", "start": 7, "end": 21}]}], "entity_mentions": [{"id": "10599932_5_Ent1", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10599932_5_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10599932_5_Ent0", "text": "desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease", "entity_type": "Entity", "start": 7, "end": 21}], "lang": "en"}
{"doc_id": "10633877_2", "wnd_id": "10633877_2_1", "text": "Salicylate intoxication was excluded , and theophylline was finally incriminated .", "tokens": ["Salicylate", "intoxication", "was", "excluded", ",", "and", "theophylline", "was", "finally", "incriminated", "."], "event_mentions": [{"id": "10633877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incriminated", "start": 9, "end": 10}, "arguments": [{"entity_id": "10633877_2_Ent0", "role": "Treatment", "text": "theophylline", "start": 6, "end": 7}, {"entity_id": "10633877_2_Ent1", "role": "Treatment_Drug", "text": "theophylline", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10633877_2_Ent0", "text": "theophylline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10633877_2_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10646879_1", "wnd_id": "10646879_1_1", "text": "Methylene blue in the treatment and prevention of ifosfamide - induced encephalopathy : report of 12 cases and a review of the literature .", "tokens": ["Methylene", "blue", "in", "the", "treatment", "and", "prevention", "of", "ifosfamide", "-", "induced", "encephalopathy", ":", "report", "of", "12", "cases", "and", "a", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "10646879_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "10646879_1_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_1_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_1_Ent0", "role": "Effect", "text": "encephalopathy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10646879_1_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_1_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_1_Ent0", "text": "encephalopathy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10656221_9", "wnd_id": "10656221_9_1", "text": "We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites .", "tokens": ["We", "believe", "that", "this", "is", "the", "first", "description", "of", "acute", "hepatitis", "caused", "by", "an", "idiosyncratic", "adverse", "reaction", "to", "gliclazide", "or", "to", "one", "of", "its", "metabolites", "."], "event_mentions": [{"id": "10656221_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "idiosyncratic adverse reaction", "start": 14, "end": 17}, "arguments": [{"entity_id": "10656221_9_Ent0", "role": "Effect", "text": "acute hepatitis", "start": 9, "end": 11}, {"entity_id": "10656221_9_Ent1", "role": "Treatment", "text": "gliclazide", "start": 18, "end": 19}, {"entity_id": "10656221_9_Ent2", "role": "Treatment_Drug", "text": "gliclazide", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10656221_9_Ent0", "text": "acute hepatitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10656221_9_Ent1", "text": "gliclazide", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10656221_9_Ent2", "text": "gliclazide", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10660641_7", "wnd_id": "10660641_7_1", "text": "The infection tended to subside with the AMPH administration .", "tokens": ["The", "infection", "tended", "to", "subside", "with", "the", "AMPH", "administration", "."], "event_mentions": [{"id": "10660641_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "subside", "start": 4, "end": 5}, "arguments": [{"entity_id": "10660641_7_Ent0", "role": "Effect", "text": "infection tended", "start": 1, "end": 3}, {"entity_id": "10660641_7_Ent2", "role": "Treatment_Drug", "text": "AMPH", "start": 7, "end": 8}, {"entity_id": "10660641_7_Ent1", "role": "Treatment", "text": "AMPH administration", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "10660641_7_Ent0", "text": "infection tended", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_7_Ent2", "text": "AMPH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10660641_7_Ent1", "text": "AMPH administration", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "10679548_1", "wnd_id": "10679548_1_1", "text": "Both had impaired lung function and abnormal computed tomographic scans , and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced .", "tokens": ["Both", "had", "impaired", "lung", "function", "and", "abnormal", "computed", "tomographic", "scans", ",", "and", "their", "condition", "improved", "when", "nitrofurantoin", "was", "withdrawn", "and", "corticosteroid", "treatment", "commenced", "."], "event_mentions": [{"id": "10679548_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 14, "end": 15}, "arguments": [{"entity_id": "10679548_1_Ent1", "role": "Subject_Population", "text": "Both", "start": 0, "end": 1}, {"entity_id": "10679548_1_Ent0", "role": "Subject", "text": "Both had impaired lung function and abnormal computed tomographic scans", "start": 0, "end": 10}, {"entity_id": "10679548_1_Ent6", "role": "Treatment_Disorder", "text": "impaired lung function", "start": 2, "end": 5}, {"entity_id": "10679548_1_Ent2", "role": "Subject_Disorder", "text": "abnormal computed tomographic scans", "start": 6, "end": 10}, {"entity_id": "10679548_1_Ent5", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 16, "end": 17}, {"entity_id": "10679548_1_Ent3", "role": "Treatment", "text": "nitrofurantoin was withdrawn and corticosteroid treatment commenced", "start": 16, "end": 23}, {"entity_id": "10679548_1_Ent4", "role": "Treatment_Drug", "text": "corticosteroid", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "10679548_1_Ent1", "text": "Both", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10679548_1_Ent0", "text": "Both had impaired lung function and abnormal computed tomographic scans", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10679548_1_Ent6", "text": "impaired lung function", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "10679548_1_Ent2", "text": "abnormal computed tomographic scans", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "10679548_1_Ent5", "text": "nitrofurantoin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10679548_1_Ent3", "text": "nitrofurantoin was withdrawn and corticosteroid treatment commenced", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "10679548_1_Ent4", "text": "corticosteroid", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "1068531_1", "wnd_id": "1068531_1_1", "text": "Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma : report of two cases .", "tokens": ["Acute", "erythroid", "leukemia", "after", "cyclophosphamide", "therapy", "for", "multiple", "myeloma", ":", "report", "of", "two", "cases", "."], "event_mentions": [{"id": "1068531_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "1068531_1_Ent2", "role": "Effect", "text": "Acute erythroid leukemia", "start": 0, "end": 3}, {"entity_id": "1068531_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 4, "end": 5}, {"entity_id": "1068531_1_Ent3", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 4, "end": 6}, {"entity_id": "1068531_1_Ent5", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 7, "end": 9}, {"entity_id": "1068531_1_Ent1", "role": "Subject_Population", "text": "two", "start": 12, "end": 13}, {"entity_id": "1068531_1_Ent0", "role": "Subject", "text": "two cases", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "1068531_1_Ent2", "text": "Acute erythroid leukemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1068531_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1068531_1_Ent3", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1068531_1_Ent5", "text": "multiple myeloma", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "1068531_1_Ent1", "text": "two", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1068531_1_Ent0", "text": "two cases", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "1068531_2", "wnd_id": "1068531_2_1", "text": "The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy .", "tokens": ["The", "development", "of", "erythroid", "leukemia", "plus", "carcinoma", "in", "these", "two", "men", "suggests", "mutagenic", "change", "secondary", "to", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "1068531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suggests", "start": 11, "end": 12}, "arguments": [{"entity_id": "1068531_2_Ent3", "role": "Effect", "text": "development of erythroid leukemia plus carcinoma", "start": 1, "end": 7}, {"entity_id": "1068531_2_Ent1", "role": "Subject_Population", "text": "two", "start": 9, "end": 10}, {"entity_id": "1068531_2_Ent0", "role": "Subject", "text": "two men", "start": 9, "end": 11}, {"entity_id": "1068531_2_Ent2", "role": "Subject_Gender", "text": "men", "start": 10, "end": 11}, {"entity_id": "1068531_2_Ent4", "role": "Effect", "text": "mutagenic change", "start": 12, "end": 14}, {"entity_id": "1068531_2_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 16, "end": 17}, {"entity_id": "1068531_2_Ent5", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1068531_2_Ent3", "text": "development of erythroid leukemia plus carcinoma", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "1068531_2_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1068531_2_Ent0", "text": "two men", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "1068531_2_Ent2", "text": "men", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1068531_2_Ent4", "text": "mutagenic change", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1068531_2_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1068531_2_Ent5", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "10698143_4", "wnd_id": "10698143_4_1", "text": "We report the case of an 11 - month - old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone .", "tokens": ["We", "report", "the", "case", "of", "an", "11", "-", "month", "-", "old", "female", "infant", "with", "a", "depressed", "level", "of", "consciousness", "after", "ingestion", "of", "ibuprofen", "whose", "mental", "status", "markedly", "improved", "with", "administration", "of", "naloxone", "."], "event_mentions": [{"id": "10698143_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "10698143_4_Ent0", "role": "Subject", "text": "an 11 - month - old female infant", "start": 5, "end": 13}, {"entity_id": "10698143_4_Ent1", "role": "Subject_Age", "text": "11 - month - old", "start": 6, "end": 11}, {"entity_id": "10698143_4_Ent3", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "10698143_4_Ent2", "role": "Subject_Age", "text": "infant", "start": 12, "end": 13}, {"entity_id": "10698143_4_Ent4", "role": "Effect", "text": "a depressed level of consciousness", "start": 14, "end": 19}, {"entity_id": "10698143_4_Ent7", "role": "Treatment_Route", "text": "ingestion", "start": 20, "end": 21}, {"entity_id": "10698143_4_Ent5", "role": "Treatment", "text": "ingestion of ibuprofen", "start": 20, "end": 23}, {"entity_id": "10698143_4_Ent6", "role": "Treatment_Drug", "text": "ibuprofen", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "10698143_4_Ent0", "text": "an 11 - month - old female infant", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "10698143_4_Ent1", "text": "11 - month - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10698143_4_Ent3", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10698143_4_Ent2", "text": "infant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10698143_4_Ent4", "text": "a depressed level of consciousness", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10698143_4_Ent7", "text": "ingestion", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10698143_4_Ent5", "text": "ingestion of ibuprofen", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "10698143_4_Ent6", "text": "ibuprofen", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "10707759_1", "wnd_id": "10707759_1_1", "text": "Flecainide - associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome .", "tokens": ["Flecainide", "-", "associated", "pneumonitis", "with", "acute", "respiratory", "failure", "in", "a", "patient", "with", "the", "LEOPARD", "syndrome", "."], "event_mentions": [{"id": "10707759_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10707759_1_Ent2", "role": "Treatment", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_1_Ent3", "role": "Treatment_Drug", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_1_Ent1", "role": "Effect", "text": "pneumonitis with acute respiratory failure", "start": 3, "end": 8}, {"entity_id": "10707759_1_Ent0", "role": "Subject", "text": "a patient with the LEOPARD syndrome", "start": 9, "end": 15}, {"entity_id": "10707759_1_Ent4", "role": "Treatment_Disorder", "text": "LEOPARD syndrome .", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10707759_1_Ent2", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_1_Ent3", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_1_Ent1", "text": "pneumonitis with acute respiratory failure", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10707759_1_Ent0", "text": "a patient with the LEOPARD syndrome", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "10707759_1_Ent4", "text": "LEOPARD syndrome .", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10728450_1", "wnd_id": "10728450_1_1", "text": "We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B.", "tokens": ["We", "report", "2", "patients", "who", "developed", "polyarteritis", "nodosa", "following", "vaccination", "against", "hepatitis", "B."], "event_mentions": [{"id": "10728450_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "10728450_1_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "10728450_1_Ent0", "role": "Subject", "text": "2 patients", "start": 2, "end": 4}, {"entity_id": "10728450_1_Ent2", "role": "Effect", "text": "polyarteritis nodosa", "start": 6, "end": 8}, {"entity_id": "10728450_1_Ent3", "role": "Treatment", "text": "vaccination against hepatitis B.", "start": 9, "end": 13}, {"entity_id": "10728450_1_Ent4", "role": "Treatment_Drug", "text": "vaccination against hepatitis B.", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "10728450_1_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10728450_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10728450_1_Ent2", "text": "polyarteritis nodosa", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10728450_1_Ent3", "text": "vaccination against hepatitis B.", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10728450_1_Ent4", "text": "vaccination against hepatitis B.", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "10749332_4", "wnd_id": "10749332_4_1", "text": "The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury .", "tokens": ["The", "three", "reported", "cases", "demonstrate", "that", "troglitazone", "is", "an", "idiosyncratic", "hepatotoxin", "that", "can", "lead", "to", "irreversible", "liver", "injury", "."], "event_mentions": [{"id": "10749332_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 13, "end": 14}, "arguments": [{"entity_id": "10749332_4_Ent1", "role": "Subject_Population", "text": "three", "start": 1, "end": 2}, {"entity_id": "10749332_4_Ent0", "role": "Subject", "text": "three reported cases", "start": 1, "end": 4}, {"entity_id": "10749332_4_Ent3", "role": "Treatment", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent4", "role": "Treatment_Drug", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent2", "role": "Effect", "text": "irreversible liver injury", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10749332_4_Ent1", "text": "three", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10749332_4_Ent0", "text": "three reported cases", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "10749332_4_Ent3", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent4", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent2", "text": "irreversible liver injury", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10749332_5", "wnd_id": "10749332_5_1", "text": "Troglitazone - induced fulminant hepatic failure .", "tokens": ["Troglitazone", "-", "induced", "fulminant", "hepatic", "failure", "."], "event_mentions": [{"id": "10749332_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10749332_5_Ent1", "role": "Treatment", "text": "Troglitazone", "start": 0, "end": 1}, {"entity_id": "10749332_5_Ent2", "role": "Treatment_Drug", "text": "Troglitazone", "start": 0, "end": 1}, {"entity_id": "10749332_5_Ent0", "role": "Effect", "text": "fulminant hepatic failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "10749332_5_Ent1", "text": "Troglitazone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10749332_5_Ent2", "text": "Troglitazone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10749332_5_Ent0", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "10752888_1", "wnd_id": "10752888_1_1", "text": "Nitrofurantoin - induced lung disease : two cases demonstrating resolution of apparently irreversible CT abnormalities .", "tokens": ["Nitrofurantoin", "-", "induced", "lung", "disease", ":", "two", "cases", "demonstrating", "resolution", "of", "apparently", "irreversible", "CT", "abnormalities", "."], "event_mentions": [{"id": "10752888_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10752888_1_Ent1", "role": "Treatment", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "10752888_1_Ent2", "role": "Treatment_Drug", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "10752888_1_Ent0", "role": "Effect", "text": "lung disease", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "10752888_1_Ent1", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10752888_1_Ent2", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10752888_1_Ent0", "text": "lung disease", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "10772434_1", "wnd_id": "10772434_1_1", "text": "CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses .", "tokens": ["CASE", "SUMMARY", ":", "A", "10", "-", "year", "-", "old", "white", "girl", "with", "bilateral", "optic", "glioma", "developed", "a", "hypersensitivity", "reaction", "to", "carboplatin", "after", "nine", "courses", "."], "event_mentions": [{"id": "10772434_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "10772434_1_Ent0", "role": "Subject", "text": "A 10 - year - old white girl with bilateral optic glioma", "start": 3, "end": 15}, {"entity_id": "10772434_1_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 4, "end": 9}, {"entity_id": "10772434_1_Ent3", "role": "Subject_Race", "text": "white", "start": 9, "end": 10}, {"entity_id": "10772434_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 10, "end": 11}, {"entity_id": "10772434_1_Ent6", "role": "Treatment_Disorder", "text": "bilateral optic glioma", "start": 12, "end": 15}, {"entity_id": "10772434_1_Ent4", "role": "Effect", "text": "hypersensitivity reaction", "start": 17, "end": 19}, {"entity_id": "10772434_1_Ent7", "role": "Treatment_Drug", "text": "carboplatin", "start": 20, "end": 21}, {"entity_id": "10772434_1_Ent5", "role": "Treatment", "text": "carboplatin after nine courses", "start": 20, "end": 24}, {"entity_id": "10772434_1_Ent8", "role": "Treatment_Duration", "text": "nine courses", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "10772434_1_Ent0", "text": "A 10 - year - old white girl with bilateral optic glioma", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "10772434_1_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10772434_1_Ent3", "text": "white", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10772434_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10772434_1_Ent6", "text": "bilateral optic glioma", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10772434_1_Ent4", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10772434_1_Ent7", "text": "carboplatin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10772434_1_Ent5", "text": "carboplatin after nine courses", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "10772434_1_Ent8", "text": "nine courses", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "10840527_1", "wnd_id": "10840527_1_1", "text": "Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials , case reports , and chart reviews , it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms ( EPS ) .", "tokens": ["Although", "the", "literature", "on", "the", "use", "of", "risperidone", "in", "elderly", "patients", "with", "dementia", "consists", "largely", "of", "uncontrolled", "trials", ",", "case", "reports", ",", "and", "chart", "reviews", ",", "it", "appears", "that", "this", "agent", "is", "effective", "for", "managing", "agitation", "in", "this", "population", "and", "does", "so", "with", "a", "low", "frequency", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "."], "event_mentions": [{"id": "10840527_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "is", "start": 31, "end": 32}, "arguments": [{"entity_id": "10840527_1_Ent2", "role": "Treatment", "text": "use of risperidone", "start": 5, "end": 8}, {"entity_id": "10840527_1_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "10840527_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 9, "end": 10}, {"entity_id": "10840527_1_Ent0", "role": "Subject", "text": "elderly patients with dementia", "start": 9, "end": 13}, {"entity_id": "10840527_1_Ent4", "role": "Treatment_Disorder", "text": "dementia", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10840527_1_Ent2", "text": "use of risperidone", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10840527_1_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10840527_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10840527_1_Ent0", "text": "elderly patients with dementia", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10840527_1_Ent4", "text": "dementia", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1087773_2", "wnd_id": "1087773_2_1", "text": "Polyarthritis , hepatitis and anti - native DNA antibodies after treatment with ethambutol and rifampicin .", "tokens": ["Polyarthritis", ",", "hepatitis", "and", "anti", "-", "native", "DNA", "antibodies", "after", "treatment", "with", "ethambutol", "and", "rifampicin", "."], "event_mentions": [{"id": "1087773_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "1087773_2_Ent0", "role": "Effect", "text": "Polyarthritis , hepatitis and anti - native DNA antibodies", "start": 0, "end": 9}, {"entity_id": "1087773_2_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_2_Ent4", "role": "Combination_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_2_Ent1", "role": "Treatment", "text": "ethambutol and rifampicin", "start": 12, "end": 15}, {"entity_id": "1087773_2_Ent3", "role": "Treatment_Drug", "text": "rifampicin", "start": 14, "end": 15}, {"entity_id": "1087773_2_Ent5", "role": "Combination_Drug", "text": "rifampicin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "1087773_2_Ent0", "text": "Polyarthritis , hepatitis and anti - native DNA antibodies", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "1087773_2_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_2_Ent4", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_2_Ent1", "text": "ethambutol and rifampicin", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "1087773_2_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1087773_2_Ent5", "text": "rifampicin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "10891991_1", "wnd_id": "10891991_1_1", "text": "An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy , especially if they develop menstrual cycle disturbances during treatment .", "tokens": ["An", "evaluation", "of", "ovarian", "structure", "and", "function", "should", "be", "considered", "in", "women", "of", "reproductive", "age", "being", "treated", "with", "valproate", "for", "epilepsy", ",", "especially", "if", "they", "develop", "menstrual", "cycle", "disturbances", "during", "treatment", "."], "event_mentions": [{"id": "10891991_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 25, "end": 26}, "arguments": [{"entity_id": "10891991_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}, {"entity_id": "10891991_1_Ent0", "role": "Subject", "text": "women of reproductive age", "start": 11, "end": 15}, {"entity_id": "10891991_1_Ent2", "role": "Subject_Age", "text": "reproductive age", "start": 13, "end": 15}, {"entity_id": "10891991_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 18, "end": 19}, {"entity_id": "10891991_1_Ent4", "role": "Treatment", "text": "valproate for epilepsy", "start": 18, "end": 21}, {"entity_id": "10891991_1_Ent6", "role": "Treatment_Disorder", "text": "epilepsy", "start": 20, "end": 21}, {"entity_id": "10891991_1_Ent3", "role": "Effect", "text": "menstrual cycle disturbances", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "10891991_1_Ent1", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10891991_1_Ent0", "text": "women of reproductive age", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "10891991_1_Ent2", "text": "reproductive age", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10891991_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10891991_1_Ent4", "text": "valproate for epilepsy", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10891991_1_Ent6", "text": "epilepsy", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_1_Ent3", "text": "menstrual cycle disturbances", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "10897389_1", "wnd_id": "10897389_1_1", "text": "However , recurrent staphylococcus aureus sepsis developed during CyA therapy .", "tokens": ["However", ",", "recurrent", "staphylococcus", "aureus", "sepsis", "developed", "during", "CyA", "therapy", "."], "event_mentions": [{"id": "10897389_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "10897389_1_Ent0", "role": "Effect", "text": "staphylococcus aureus sepsis", "start": 3, "end": 6}, {"entity_id": "10897389_1_Ent2", "role": "Treatment_Drug", "text": "CyA", "start": 8, "end": 9}, {"entity_id": "10897389_1_Ent1", "role": "Treatment", "text": "CyA therapy", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "10897389_1_Ent0", "text": "staphylococcus aureus sepsis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "10897389_1_Ent2", "text": "CyA", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10897389_1_Ent1", "text": "CyA therapy", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "10904571_2", "wnd_id": "10904571_2_1", "text": "Colchicine - induced myopathy in renal failure .", "tokens": ["Colchicine", "-", "induced", "myopathy", "in", "renal", "failure", "."], "event_mentions": [{"id": "10904571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10904571_2_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent0", "role": "Effect", "text": "myopathy", "start": 3, "end": 4}, {"entity_id": "10904571_2_Ent3", "role": "Treatment_Disorder", "text": "renal failure", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "10904571_2_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent0", "text": "myopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10904571_2_Ent3", "text": "renal failure", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "10907391_4", "wnd_id": "10907391_4_1", "text": "We describe 2 patients with prior amputation who experienced phantom limb pain ( PLP ) after receiving paclitaxel therapy .", "tokens": ["We", "describe", "2", "patients", "with", "prior", "amputation", "who", "experienced", "phantom", "limb", "pain", "(", "PLP", ")", "after", "receiving", "paclitaxel", "therapy", "."], "event_mentions": [{"id": "10907391_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "10907391_4_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "10907391_4_Ent0", "role": "Subject", "text": "2 patients with prior amputation", "start": 2, "end": 7}, {"entity_id": "10907391_4_Ent2", "role": "Subject_Disorder", "text": "prior amputation", "start": 5, "end": 7}, {"entity_id": "10907391_4_Ent3", "role": "Effect", "text": "phantom limb pain ( PLP )", "start": 9, "end": 15}, {"entity_id": "10907391_4_Ent5", "role": "Treatment_Drug", "text": "paclitaxel", "start": 17, "end": 18}, {"entity_id": "10907391_4_Ent4", "role": "Treatment", "text": "paclitaxel therapy", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "10907391_4_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10907391_4_Ent0", "text": "2 patients with prior amputation", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "10907391_4_Ent2", "text": "prior amputation", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10907391_4_Ent3", "text": "phantom limb pain ( PLP )", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "10907391_4_Ent5", "text": "paclitaxel", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10907391_4_Ent4", "text": "paclitaxel therapy", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "10963515_2", "wnd_id": "10963515_2_1", "text": "We describe a case of EGE manifested as an allergy to gemfibrozil .", "tokens": ["We", "describe", "a", "case", "of", "EGE", "manifested", "as", "an", "allergy", "to", "gemfibrozil", "."], "event_mentions": [{"id": "10963515_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 6, "end": 7}, "arguments": [{"entity_id": "10963515_2_Ent0", "role": "Subject", "text": "a case of EGE", "start": 2, "end": 6}, {"entity_id": "10963515_2_Ent1", "role": "Subject_Disorder", "text": "EGE", "start": 5, "end": 6}, {"entity_id": "10963515_2_Ent2", "role": "Effect", "text": "allergy", "start": 9, "end": 10}, {"entity_id": "10963515_2_Ent3", "role": "Treatment", "text": "gemfibrozil", "start": 11, "end": 12}, {"entity_id": "10963515_2_Ent4", "role": "Treatment_Drug", "text": "gemfibrozil", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10963515_2_Ent0", "text": "a case of EGE", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10963515_2_Ent1", "text": "EGE", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10963515_2_Ent2", "text": "allergy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10963515_2_Ent3", "text": "gemfibrozil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10963515_2_Ent4", "text": "gemfibrozil", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10970989_1", "wnd_id": "10970989_1_1", "text": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine .", "tokens": ["This", "is", "the", "second", "report", "of", "lactic", "acidosis", "in", "a", "patient", "on", "stavudine", "and", "lamivudine", "."], "event_mentions": [{"id": "10970989_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 11, "end": 12}, "arguments": [{"entity_id": "10970989_1_Ent1", "role": "Effect", "text": "lactic acidosis", "start": 6, "end": 8}, {"entity_id": "10970989_1_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "10970989_1_Ent3", "role": "Treatment_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_1_Ent6", "role": "Combination_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_1_Ent2", "role": "Treatment", "text": "stavudine and lamivudine", "start": 12, "end": 15}, {"entity_id": "10970989_1_Ent4", "role": "Treatment_Drug", "text": "lamivudine", "start": 14, "end": 15}, {"entity_id": "10970989_1_Ent5", "role": "Combination_Drug", "text": "lamivudine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "10970989_1_Ent1", "text": "lactic acidosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10970989_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10970989_1_Ent3", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_1_Ent6", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_1_Ent2", "text": "stavudine and lamivudine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10970989_1_Ent4", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10970989_1_Ent5", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "10981493_2", "wnd_id": "10981493_2_1", "text": "A wide variety of adverse central nervous system effects have been reported in association with propafenone ; dizziness is the most common .", "tokens": ["A", "wide", "variety", "of", "adverse", "central", "nervous", "system", "effects", "have", "been", "reported", "in", "association", "with", "propafenone", ";", "dizziness", "is", "the", "most", "common", "."], "event_mentions": [{"id": "10981493_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 13, "end": 14}, "arguments": [{"entity_id": "10981493_2_Ent0", "role": "Effect", "text": "adverse central nervous system effects", "start": 4, "end": 9}, {"entity_id": "10981493_2_Ent2", "role": "Treatment", "text": "propafenone", "start": 15, "end": 16}, {"entity_id": "10981493_2_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 15, "end": 16}, {"entity_id": "10981493_2_Ent1", "role": "Effect", "text": "dizziness", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10981493_2_Ent0", "text": "adverse central nervous system effects", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10981493_2_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10981493_2_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10981493_2_Ent1", "text": "dizziness", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10981493_3", "wnd_id": "10981493_3_1", "text": "Propafenone - induced ataxia : report of three cases .", "tokens": ["Propafenone", "-", "induced", "ataxia", ":", "report", "of", "three", "cases", "."], "event_mentions": [{"id": "10981493_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10981493_3_Ent3", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "10981493_3_Ent4", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "10981493_3_Ent2", "role": "Effect", "text": "ataxia", "start": 3, "end": 4}, {"entity_id": "10981493_3_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "10981493_3_Ent0", "role": "Subject", "text": "three cases", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "10981493_3_Ent3", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10981493_3_Ent4", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10981493_3_Ent2", "text": "ataxia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10981493_3_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10981493_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "10987357_2", "wnd_id": "10987357_2_1", "text": "A 74 - year - old man received oral administration of pilsicainide , a pure sodium channel blocker with slow recovery kinetics , to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later .", "tokens": ["A", "74", "-", "year", "-", "old", "man", "received", "oral", "administration", "of", "pilsicainide", ",", "a", "pure", "sodium", "channel", "blocker", "with", "slow", "recovery", "kinetics", ",", "to", "convert", "paroxysmal", "atrial", "fibrillation", "to", "sinus", "rhythm", "and", "developed", "loss", "of", "consciousness", "two", "days", "later", "."], "event_mentions": [{"id": "10987357_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 32, "end": 33}, "arguments": [{"entity_id": "10987357_2_Ent0", "role": "Subject", "text": "A 74 - year - old man", "start": 0, "end": 7}, {"entity_id": "10987357_2_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 1, "end": 6}, {"entity_id": "10987357_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "10987357_2_Ent6", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "10987357_2_Ent4", "role": "Treatment", "text": "oral administration of pilsicainide", "start": 8, "end": 12}, {"entity_id": "10987357_2_Ent7", "role": "Treatment_Drug", "text": "pilsicainide", "start": 11, "end": 12}, {"entity_id": "10987357_2_Ent8", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 25, "end": 28}, {"entity_id": "10987357_2_Ent3", "role": "Effect", "text": "loss of consciousness", "start": 33, "end": 36}, {"entity_id": "10987357_2_Ent5", "role": "Treatment", "text": "two days later", "start": 36, "end": 39}, {"entity_id": "10987357_2_Ent9", "role": "Treatment_Time_elapsed", "text": "two days later", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "10987357_2_Ent0", "text": "A 74 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10987357_2_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10987357_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10987357_2_Ent6", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10987357_2_Ent4", "text": "oral administration of pilsicainide", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10987357_2_Ent7", "text": "pilsicainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10987357_2_Ent8", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "10987357_2_Ent3", "text": "loss of consciousness", "entity_type": "Entity", "start": 33, "end": 36}, {"id": "10987357_2_Ent5", "text": "two days later", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "10987357_2_Ent9", "text": "two days later", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "11008259_2", "wnd_id": "11008259_2_1", "text": "The events of non - convulsive status epilepticus subsided following reduction in tiagabine dosages .", "tokens": ["The", "events", "of", "non", "-", "convulsive", "status", "epilepticus", "subsided", "following", "reduction", "in", "tiagabine", "dosages", "."], "event_mentions": [{"id": "11008259_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11008259_2_Ent0", "role": "Effect", "text": "non - convulsive status epilepticus subsided", "start": 3, "end": 9}, {"entity_id": "11008259_2_Ent1", "role": "Treatment", "text": "reduction in tiagabine dosages", "start": 10, "end": 14}, {"entity_id": "11008259_2_Ent2", "role": "Treatment_Drug", "text": "tiagabine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11008259_2_Ent0", "text": "non - convulsive status epilepticus subsided", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11008259_2_Ent1", "text": "reduction in tiagabine dosages", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "11008259_2_Ent2", "text": "tiagabine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11022272_4", "wnd_id": "11022272_4_1", "text": "We introduce a case of a sixty years old woman with several previous episodes of rhinitis , conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( Calsynar ) .", "tokens": ["We", "introduce", "a", "case", "of", "a", "sixty", "years", "old", "woman", "with", "several", "previous", "episodes", "of", "rhinitis", ",", "conjunctivitis", "and", "perspiration", "immediately", "after", "the", "administration", "of", "salmon", "calcitonin", "with", "nasal", "spray", "or", "intramuscular", "administration", "(", "Calsynar", ")", "."], "event_mentions": [{"id": "11022272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 21, "end": 22}, "arguments": [{"entity_id": "11022272_4_Ent0", "role": "Subject", "text": "a sixty years old woman", "start": 5, "end": 10}, {"entity_id": "11022272_4_Ent1", "role": "Subject_Age", "text": "sixty years old", "start": 6, "end": 9}, {"entity_id": "11022272_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "11022272_4_Ent3", "role": "Effect", "text": "several previous episodes of rhinitis , conjunctivitis and perspiration immediately", "start": 11, "end": 21}, {"entity_id": "11022272_4_Ent7", "role": "Treatment_Drug", "text": "salmon calcitonin", "start": 25, "end": 27}, {"entity_id": "11022272_4_Ent4", "role": "Treatment", "text": "salmon calcitonin with nasal spray or intramuscular administration ( Calsynar )", "start": 25, "end": 36}, {"entity_id": "11022272_4_Ent5", "role": "Treatment_Route", "text": "nasal spray", "start": 28, "end": 30}, {"entity_id": "11022272_4_Ent6", "role": "Treatment_Route", "text": "intramuscular", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "11022272_4_Ent0", "text": "a sixty years old woman", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "11022272_4_Ent1", "text": "sixty years old", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11022272_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11022272_4_Ent3", "text": "several previous episodes of rhinitis , conjunctivitis and perspiration immediately", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "11022272_4_Ent7", "text": "salmon calcitonin", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11022272_4_Ent4", "text": "salmon calcitonin with nasal spray or intramuscular administration ( Calsynar )", "entity_type": "Entity", "start": 25, "end": 36}, {"id": "11022272_4_Ent5", "text": "nasal spray", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "11022272_4_Ent6", "text": "intramuscular", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "11034877_1", "wnd_id": "11034877_1_1", "text": "Gabapentin - induced mood changes with hypomanic features in adults .", "tokens": ["Gabapentin", "-", "induced", "mood", "changes", "with", "hypomanic", "features", "in", "adults", "."], "event_mentions": [{"id": "11034877_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11034877_1_Ent3", "role": "Treatment", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "11034877_1_Ent4", "role": "Treatment_Drug", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "11034877_1_Ent2", "role": "Effect", "text": "mood changes with hypomanic features", "start": 3, "end": 8}, {"entity_id": "11034877_1_Ent0", "role": "Subject", "text": "adults", "start": 9, "end": 10}, {"entity_id": "11034877_1_Ent1", "role": "Subject_Age", "text": "adults", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11034877_1_Ent3", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11034877_1_Ent4", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11034877_1_Ent2", "text": "mood changes with hypomanic features", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11034877_1_Ent0", "text": "adults", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11034877_1_Ent1", "text": "adults", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11077455_1", "wnd_id": "11077455_1_1", "text": "CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .", "tokens": ["CONCLUSION", ":", "Marked", "visual", "field", "constriction", "appears", "to", "be", "associated", "with", "vigabatrin", "therapy", "."], "event_mentions": [{"id": "11077455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "11077455_1_Ent0", "role": "Effect", "text": "Marked visual field constriction", "start": 2, "end": 6}, {"entity_id": "11077455_1_Ent2", "role": "Treatment_Drug", "text": "vigabatrin", "start": 11, "end": 12}, {"entity_id": "11077455_1_Ent1", "role": "Treatment", "text": "vigabatrin therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "11077455_1_Ent0", "text": "Marked visual field constriction", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11077455_1_Ent2", "text": "vigabatrin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11077455_1_Ent1", "text": "vigabatrin therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "11077455_4", "wnd_id": "11077455_4_1", "text": "The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .", "tokens": ["The", "current", "study", "investigated", "the", "visual", "fields", "and", "visual", "electrophysiology", "of", "eight", "patients", "with", "known", "vigabatrin", "-", "attributed", "visual", "field", "loss", ",", "three", "of", "whom", "were", "reported", "previously", "."], "event_mentions": [{"id": "11077455_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 17, "end": 18}, "arguments": [{"entity_id": "11077455_4_Ent1", "role": "Subject_Population", "text": "eight", "start": 11, "end": 12}, {"entity_id": "11077455_4_Ent0", "role": "Subject", "text": "eight patients", "start": 11, "end": 13}, {"entity_id": "11077455_4_Ent3", "role": "Treatment", "text": "vigabatrin", "start": 15, "end": 16}, {"entity_id": "11077455_4_Ent4", "role": "Treatment_Drug", "text": "vigabatrin", "start": 15, "end": 16}, {"entity_id": "11077455_4_Ent2", "role": "Effect", "text": "visual field loss", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "11077455_4_Ent1", "text": "eight", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11077455_4_Ent0", "text": "eight patients", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11077455_4_Ent3", "text": "vigabatrin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11077455_4_Ent4", "text": "vigabatrin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11077455_4_Ent2", "text": "visual field loss", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "1109248_9", "wnd_id": "1109248_9_1", "text": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy .", "tokens": ["It", "is", "concluded", "that", "chloral", "hydrate", "and", "methaqualone", "may", "be", "administered", "safely", "without", "additional", "caution", "in", "prothrombin", "test", "monitoring", "during", "oral", "anticoagulant", "therapy", "."], "event_mentions": [{"id": "1109248_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 14, "end": 15}, "arguments": [{"entity_id": "1109248_9_Ent2", "role": "Treatment_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent6", "role": "Combination_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent0", "role": "Treatment", "text": "chloral hydrate and methaqualone", "start": 4, "end": 8}, {"entity_id": "1109248_9_Ent3", "role": "Treatment_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent7", "role": "Combination_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent1", "role": "Treatment", "text": "during oral anticoagulant therapy", "start": 19, "end": 23}, {"entity_id": "1109248_9_Ent5", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}, {"entity_id": "1109248_9_Ent4", "role": "Treatment_Drug", "text": "anticoagulant", "start": 21, "end": 22}, {"entity_id": "1109248_9_Ent8", "role": "Combination_Drug", "text": "anticoagulant", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1109248_9_Ent2", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent6", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent0", "text": "chloral hydrate and methaqualone", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "1109248_9_Ent3", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent7", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent1", "text": "during oral anticoagulant therapy", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "1109248_9_Ent5", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1109248_9_Ent4", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1109248_9_Ent8", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11096051_1", "wnd_id": "11096051_1_1", "text": "Intensive high - flux hemodiafiltration is often used in the management of vancomycin toxicity .", "tokens": ["Intensive", "high", "-", "flux", "hemodiafiltration", "is", "often", "used", "in", "the", "management", "of", "vancomycin", "toxicity", "."], "event_mentions": [{"id": "11096051_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "management", "start": 10, "end": 11}, "arguments": [{"entity_id": "11096051_1_Ent0", "role": "Treatment", "text": "Intensive high - flux hemodiafiltration", "start": 0, "end": 5}, {"entity_id": "11096051_1_Ent1", "role": "Treatment_Disorder", "text": "vancomycin toxicity", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11096051_1_Ent0", "text": "Intensive high - flux hemodiafiltration", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11096051_1_Ent1", "text": "vancomycin toxicity", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11109149_3", "wnd_id": "11109149_3_1", "text": "We describe a 57 - year - old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy ( bleomycin and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx .", "tokens": ["We", "describe", "a", "57", "-", "year", "-", "old", "man", "with", "acral", "erythrocyanosis", "progressing", "to", "acute", "digital", "ischemia", "and", "gangrene", "that", "developed", "after", "combined", "chemotherapy", "(", "bleomycin", "and", "methotrexate", ")", "used", "to", "treat", "a", "metastatic", "squamous", "cell", "carcinoma", "of", "the", "hypopharynx", "."], "event_mentions": [{"id": "11109149_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "11109149_3_Ent0", "role": "Subject", "text": "a 57 - year - old man with acral erythrocyanosis", "start": 2, "end": 12}, {"entity_id": "11109149_3_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 3, "end": 8}, {"entity_id": "11109149_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "11109149_3_Ent3", "role": "Subject_Disorder", "text": "acral erythrocyanosis", "start": 10, "end": 12}, {"entity_id": "11109149_3_Ent4", "role": "Effect", "text": "acute digital ischemia and gangrene", "start": 14, "end": 19}, {"entity_id": "11109149_3_Ent5", "role": "Treatment", "text": "combined chemotherapy ( bleomycin and methotrexate )", "start": 22, "end": 29}, {"entity_id": "11109149_3_Ent6", "role": "Treatment_Drug", "text": "bleomycin", "start": 25, "end": 26}, {"entity_id": "11109149_3_Ent9", "role": "Combination_Drug", "text": "bleomycin", "start": 25, "end": 26}, {"entity_id": "11109149_3_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 27, "end": 28}, {"entity_id": "11109149_3_Ent10", "role": "Combination_Drug", "text": "methotrexate", "start": 27, "end": 28}, {"entity_id": "11109149_3_Ent8", "role": "Treatment_Disorder", "text": "metastatic squamous cell carcinoma of the hypopharynx", "start": 33, "end": 40}]}], "entity_mentions": [{"id": "11109149_3_Ent0", "text": "a 57 - year - old man with acral erythrocyanosis", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11109149_3_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11109149_3_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11109149_3_Ent3", "text": "acral erythrocyanosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11109149_3_Ent4", "text": "acute digital ischemia and gangrene", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "11109149_3_Ent5", "text": "combined chemotherapy ( bleomycin and methotrexate )", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "11109149_3_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11109149_3_Ent9", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11109149_3_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11109149_3_Ent10", "text": "methotrexate", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11109149_3_Ent8", "text": "metastatic squamous cell carcinoma of the hypopharynx", "entity_type": "Entity", "start": 33, "end": 40}], "lang": "en"}
{"doc_id": "11111942_2", "wnd_id": "11111942_2_1", "text": "We present a case of significant over - anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy .", "tokens": ["We", "present", "a", "case", "of", "significant", "over", "-", "anticoagulation", "temporally", "associated", "with", "a", "bout", "of", "protracted", "diarrhea", "in", "a", "patient", "on", "warfarin", "therapy", "."], "event_mentions": [{"id": "11111942_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "over - anticoagulation", "start": 6, "end": 9}, "arguments": [{"entity_id": "11111942_2_Ent0", "role": "Effect", "text": "protracted diarrhea", "start": 15, "end": 17}, {"entity_id": "11111942_2_Ent1", "role": "Treatment", "text": "warfarin", "start": 21, "end": 22}, {"entity_id": "11111942_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11111942_2_Ent0", "text": "protracted diarrhea", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "11111942_2_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11111942_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11126885_2", "wnd_id": "11126885_2_1", "text": "Quinine is universally used for the very common symptom of night leg cramps .", "tokens": ["Quinine", "is", "universally", "used", "for", "the", "very", "common", "symptom", "of", "night", "leg", "cramps", "."], "event_mentions": [{"id": "11126885_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "11126885_2_Ent0", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11126885_2_Ent1", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11126885_2_Ent2", "role": "Treatment_Disorder", "text": "night leg cramps", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "11126885_2_Ent0", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11126885_2_Ent1", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11126885_2_Ent2", "text": "night leg cramps", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "11126885_7", "wnd_id": "11126885_7_1", "text": "Only after three subsequent episodes of severe , symptomatic thrombocytopenia over the next four weeks did he say , upon repeat questioning , that he had continued to take quinine for night leg cramps .", "tokens": ["Only", "after", "three", "subsequent", "episodes", "of", "severe", ",", "symptomatic", "thrombocytopenia", "over", "the", "next", "four", "weeks", "did", "he", "say", ",", "upon", "repeat", "questioning", ",", "that", "he", "had", "continued", "to", "take", "quinine", "for", "night", "leg", "cramps", "."], "event_mentions": [{"id": "11126885_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "take", "start": 28, "end": 29}, "arguments": [{"entity_id": "11126885_7_Ent3", "role": "Effect", "text": "symptomatic thrombocytopenia", "start": 8, "end": 10}, {"entity_id": "11126885_7_Ent7", "role": "Treatment_Time_elapsed", "text": "over the next four weeks", "start": 10, "end": 15}, {"entity_id": "11126885_7_Ent0", "role": "Subject", "text": "he", "start": 24, "end": 25}, {"entity_id": "11126885_7_Ent2", "role": "Subject_Gender", "text": "he", "start": 24, "end": 25}, {"entity_id": "11126885_7_Ent4", "role": "Treatment", "text": "continued to take quinine", "start": 26, "end": 30}, {"entity_id": "11126885_7_Ent5", "role": "Treatment_Drug", "text": "quinine", "start": 29, "end": 30}, {"entity_id": "11126885_7_Ent1", "role": "Subject", "text": "night leg cramps", "start": 31, "end": 34}, {"entity_id": "11126885_7_Ent6", "role": "Treatment_Disorder", "text": "night leg cramps", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11126885_7_Ent3", "text": "symptomatic thrombocytopenia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11126885_7_Ent7", "text": "over the next four weeks", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11126885_7_Ent0", "text": "he", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11126885_7_Ent2", "text": "he", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11126885_7_Ent4", "text": "continued to take quinine", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "11126885_7_Ent5", "text": "quinine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11126885_7_Ent1", "text": "night leg cramps", "entity_type": "Entity", "start": 31, "end": 34}, {"id": "11126885_7_Ent6", "text": "night leg cramps", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11131346_3", "wnd_id": "11131346_3_1", "text": "An 8 - year - old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug .", "tokens": ["An", "8", "-", "year", "-", "old", "child", "with", "familial", "Mediterranean", "fever", "exhibited", "signs", "of", "colchicine", "intoxication", "while", "receiving", "prophylactic", "doses", "of", "the", "drug", "."], "event_mentions": [{"id": "11131346_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 11, "end": 12}, "arguments": [{"entity_id": "11131346_3_Ent0", "role": "Subject", "text": "An 8 - year - old child", "start": 0, "end": 7}, {"entity_id": "11131346_3_Ent1", "role": "Subject_Age", "text": "8 - year - old", "start": 1, "end": 6}, {"entity_id": "11131346_3_Ent2", "role": "Subject_Age", "text": "child", "start": 6, "end": 7}, {"entity_id": "11131346_3_Ent6", "role": "Treatment_Disorder", "text": "familial Mediterranean fever", "start": 8, "end": 11}, {"entity_id": "11131346_3_Ent7", "role": "Treatment_Drug", "text": "colchicine", "start": 14, "end": 15}, {"entity_id": "11131346_3_Ent3", "role": "Effect", "text": "colchicine intoxication", "start": 14, "end": 16}, {"entity_id": "11131346_3_Ent5", "role": "Treatment_Dosage", "text": "prophylactic doses", "start": 18, "end": 20}, {"entity_id": "11131346_3_Ent4", "role": "Treatment", "text": "prophylactic doses of the drug", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "11131346_3_Ent0", "text": "An 8 - year - old child", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11131346_3_Ent1", "text": "8 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11131346_3_Ent2", "text": "child", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11131346_3_Ent6", "text": "familial Mediterranean fever", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11131346_3_Ent7", "text": "colchicine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11131346_3_Ent3", "text": "colchicine intoxication", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11131346_3_Ent5", "text": "prophylactic doses", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "11131346_3_Ent4", "text": "prophylactic doses of the drug", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "11142491_1", "wnd_id": "11142491_1_1", "text": "Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem - cell transplantation .", "tokens": ["Acute", "myeloid", "leukemia", "and", "lung", "cancer", "occurring", "in", "a", "chronic", "lymphocytic", "leukemia", "patient", "treated", "with", "fludarabine", "and", "autologous", "peripheral", "blood", "stem", "-", "cell", "transplantation", "."], "event_mentions": [{"id": "11142491_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 6, "end": 7}, "arguments": [{"entity_id": "11142491_1_Ent1", "role": "Effect", "text": "Acute myeloid leukemia and lung cancer", "start": 0, "end": 6}, {"entity_id": "11142491_1_Ent0", "role": "Subject", "text": "a chronic lymphocytic leukemia patient", "start": 8, "end": 13}, {"entity_id": "11142491_1_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 9, "end": 12}, {"entity_id": "11142491_1_Ent3", "role": "Treatment_Drug", "text": "fludarabine", "start": 15, "end": 16}, {"entity_id": "11142491_1_Ent2", "role": "Treatment", "text": "fludarabine and autologous peripheral blood stem - cell transplantation", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "11142491_1_Ent1", "text": "Acute myeloid leukemia and lung cancer", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11142491_1_Ent0", "text": "a chronic lymphocytic leukemia patient", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "11142491_1_Ent4", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11142491_1_Ent3", "text": "fludarabine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11142491_1_Ent2", "text": "fludarabine and autologous peripheral blood stem - cell transplantation", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "11144696_11", "wnd_id": "11144696_11_1", "text": "We hypothesize that a pharmacodynamic or pharmacokinetic drug interaction between venlafaxine and trimipramine involving the CYP2D6 isoenzyme may have played a role in inducing the seizures .", "tokens": ["We", "hypothesize", "that", "a", "pharmacodynamic", "or", "pharmacokinetic", "drug", "interaction", "between", "venlafaxine", "and", "trimipramine", "involving", "the", "CYP2D6", "isoenzyme", "may", "have", "played", "a", "role", "in", "inducing", "the", "seizures", "."], "event_mentions": [{"id": "11144696_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducing", "start": 23, "end": 24}, "arguments": [{"entity_id": "11144696_11_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11144696_11_Ent4", "role": "Combination_Drug", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11144696_11_Ent1", "role": "Treatment", "text": "venlafaxine and trimipramine", "start": 10, "end": 13}, {"entity_id": "11144696_11_Ent3", "role": "Treatment_Drug", "text": "trimipramine", "start": 12, "end": 13}, {"entity_id": "11144696_11_Ent5", "role": "Combination_Drug", "text": "trimipramine", "start": 12, "end": 13}, {"entity_id": "11144696_11_Ent0", "role": "Effect", "text": "seizures", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "11144696_11_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11144696_11_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11144696_11_Ent1", "text": "venlafaxine and trimipramine", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11144696_11_Ent3", "text": "trimipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_11_Ent5", "text": "trimipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_11_Ent0", "text": "seizures", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "11147747_2", "wnd_id": "11147747_2_1", "text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .", "tokens": ["In", "the", "present", "paper", "the", "authors", "describe", "2", "female", "patients", "who", "developed", "incontinence", "secondary", "to", "the", "selective", "serotonin", "reuptake", "inhibitors", "paroxetine", "and", "sertraline", ",", "as", "well", "as", "a", "third", "who", "developed", "this", "side", "effect", "on", "venlafaxine", "."], "event_mentions": [{"id": "11147747_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "11147747_2_Ent1", "role": "Subject_Population", "text": "2", "start": 7, "end": 8}, {"entity_id": "11147747_2_Ent0", "role": "Subject", "text": "2 female patients", "start": 7, "end": 10}, {"entity_id": "11147747_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 8, "end": 9}, {"entity_id": "11147747_2_Ent3", "role": "Effect", "text": "incontinence", "start": 12, "end": 13}, {"entity_id": "11147747_2_Ent4", "role": "Treatment", "text": "the selective serotonin reuptake inhibitors paroxetine and sertraline", "start": 15, "end": 23}, {"entity_id": "11147747_2_Ent5", "role": "Treatment_Drug", "text": "paroxetine", "start": 20, "end": 21}, {"entity_id": "11147747_2_Ent8", "role": "Combination_Drug", "text": "paroxetine", "start": 20, "end": 21}, {"entity_id": "11147747_2_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 22, "end": 23}, {"entity_id": "11147747_2_Ent9", "role": "Combination_Drug", "text": "sertraline", "start": 22, "end": 23}, {"entity_id": "11147747_2_Ent7", "role": "Treatment_Drug", "text": "venlafaxine", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "11147747_2_Ent1", "text": "2", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11147747_2_Ent0", "text": "2 female patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11147747_2_Ent2", "text": "female", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11147747_2_Ent3", "text": "incontinence", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11147747_2_Ent4", "text": "the selective serotonin reuptake inhibitors paroxetine and sertraline", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "11147747_2_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11147747_2_Ent8", "text": "paroxetine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11147747_2_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11147747_2_Ent9", "text": "sertraline", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11147747_2_Ent7", "text": "venlafaxine", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "11160777_1", "wnd_id": "11160777_1_1", "text": "New oral therapies for type 2 diabetes mellitus :", "tokens": ["New", "oral", "therapies", "for", "type", "2", "diabetes", "mellitus", ":"], "event_mentions": [{"id": "11160777_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 3, "end": 4}, "arguments": [{"entity_id": "11160777_1_Ent2", "role": "Treatment_Route", "text": "oral", "start": 1, "end": 2}, {"entity_id": "11160777_1_Ent0", "role": "Treatment", "text": "oral therapies", "start": 1, "end": 3}, {"entity_id": "11160777_1_Ent1", "role": "Treatment_Disorder", "text": "type 2 diabetes mellitus", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "11160777_1_Ent2", "text": "oral", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11160777_1_Ent0", "text": "oral therapies", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11160777_1_Ent1", "text": "type 2 diabetes mellitus", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "11160777_11", "wnd_id": "11160777_11_1", "text": "Long - term studies are needed to determine whether the insulin - sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease , morbidity , and death .", "tokens": ["Long", "-", "term", "studies", "are", "needed", "to", "determine", "whether", "the", "insulin", "-", "sensitizing", "effects", "of", "the", "glitazones", "can", "prevent", "or", "delay", "premature", "atherosclerotic", "cardiovascular", "disease", ",", "morbidity", ",", "and", "death", "."], "event_mentions": [{"id": "11160777_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevent", "start": 18, "end": 19}, "arguments": [{"entity_id": "11160777_11_Ent0", "role": "Treatment", "text": "glitazones", "start": 16, "end": 17}, {"entity_id": "11160777_11_Ent2", "role": "Treatment_Drug", "text": "glitazones", "start": 16, "end": 17}, {"entity_id": "11160777_11_Ent1", "role": "Treatment_Disorder", "text": "premature atherosclerotic cardiovascular disease , morbidity , and death", "start": 21, "end": 30}]}], "entity_mentions": [{"id": "11160777_11_Ent0", "text": "glitazones", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11160777_11_Ent2", "text": "glitazones", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11160777_11_Ent1", "text": "premature atherosclerotic cardiovascular disease , morbidity , and death", "entity_type": "Entity", "start": 21, "end": 30}], "lang": "en"}
{"doc_id": "11171531_3", "wnd_id": "11171531_3_1", "text": "Poorly controlled hypertension in a painter with chronic lead toxicity .", "tokens": ["Poorly", "controlled", "hypertension", "in", "a", "painter", "with", "chronic", "lead", "toxicity", "."], "event_mentions": [{"id": "11171531_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "11171531_3_Ent1", "role": "Effect", "text": "Poorly controlled hypertension", "start": 0, "end": 3}, {"entity_id": "11171531_3_Ent0", "role": "Subject", "text": "a painter", "start": 4, "end": 6}, {"entity_id": "11171531_3_Ent2", "role": "Treatment", "text": "lead", "start": 8, "end": 9}, {"entity_id": "11171531_3_Ent3", "role": "Treatment_Drug", "text": "lead", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11171531_3_Ent1", "text": "Poorly controlled hypertension", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11171531_3_Ent0", "text": "a painter", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11171531_3_Ent2", "text": "lead", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11171531_3_Ent3", "text": "lead", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11174414_2", "wnd_id": "11174414_2_1", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection .", "tokens": ["Nevirapine", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "widely", "used", "in", "combination", "with", "other", "antiretroviral", "agents", "for", "the", "treatment", "of", "HIV", "infection", "."], "event_mentions": [{"id": "11174414_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 19, "end": 20}, "arguments": [{"entity_id": "11174414_2_Ent1", "role": "Treatment_Drug", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "11174414_2_Ent4", "role": "Combination_Drug", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "11174414_2_Ent0", "role": "Treatment", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents", "start": 0, "end": 17}, {"entity_id": "11174414_2_Ent2", "role": "Treatment_Drug", "text": "other antiretroviral agents", "start": 14, "end": 17}, {"entity_id": "11174414_2_Ent5", "role": "Combination_Drug", "text": "other antiretroviral agents", "start": 14, "end": 17}, {"entity_id": "11174414_2_Ent3", "role": "Treatment_Disorder", "text": "HIV infection", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "11174414_2_Ent1", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11174414_2_Ent4", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11174414_2_Ent0", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents", "entity_type": "Entity", "start": 0, "end": 17}, {"id": "11174414_2_Ent2", "text": "other antiretroviral agents", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11174414_2_Ent5", "text": "other antiretroviral agents", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11174414_2_Ent3", "text": "HIV infection", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "11191005_1", "wnd_id": "11191005_1_1", "text": "There is evidence that the angiotensin II receptor antagonist , losartan , increases urate excretion by reducing reabsorption of urate in the renal proximal tubule .", "tokens": ["There", "is", "evidence", "that", "the", "angiotensin", "II", "receptor", "antagonist", ",", "losartan", ",", "increases", "urate", "excretion", "by", "reducing", "reabsorption", "of", "urate", "in", "the", "renal", "proximal", "tubule", "."], "event_mentions": [{"id": "11191005_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increases", "start": 12, "end": 13}, "arguments": [{"entity_id": "11191005_1_Ent2", "role": "Treatment", "text": "angiotensin II receptor antagonist , losartan", "start": 5, "end": 11}, {"entity_id": "11191005_1_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 10, "end": 11}, {"entity_id": "11191005_1_Ent0", "role": "Effect", "text": "increases urate excretion", "start": 12, "end": 15}, {"entity_id": "11191005_1_Ent1", "role": "Effect", "text": "reducing reabsorption of urate in the renal proximal tubule .", "start": 16, "end": 26}]}], "entity_mentions": [{"id": "11191005_1_Ent2", "text": "angiotensin II receptor antagonist , losartan", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11191005_1_Ent3", "text": "losartan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11191005_1_Ent0", "text": "increases urate excretion", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11191005_1_Ent1", "text": "reducing reabsorption of urate in the renal proximal tubule .", "entity_type": "Entity", "start": 16, "end": 26}], "lang": "en"}
{"doc_id": "11200291_1", "wnd_id": "11200291_1_1", "text": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis .", "tokens": ["Atrial", "fibrillation", "occurring", "in", "a", "patient", "taking", "etanercept", "plus", "methotrexate", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "11200291_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 6, "end": 7}, "arguments": [{"entity_id": "11200291_1_Ent1", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "11200291_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "11200291_1_Ent3", "role": "Treatment_Drug", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "11200291_1_Ent6", "role": "Combination_Drug", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "11200291_1_Ent2", "role": "Treatment", "text": "etanercept plus methotrexate for rheumatoid arthritis", "start": 7, "end": 13}, {"entity_id": "11200291_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "11200291_1_Ent7", "role": "Combination_Drug", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "11200291_1_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "11200291_1_Ent1", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11200291_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11200291_1_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11200291_1_Ent6", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11200291_1_Ent2", "text": "etanercept plus methotrexate for rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11200291_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11200291_1_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11200291_1_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "11206417_1", "wnd_id": "11206417_1_1", "text": "Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans .", "tokens": ["Glucose", "and", "insulin", "exert", "additive", "ocular", "and", "renal", "vasodilator", "effects", "on", "healthy", "humans", "."], "event_mentions": [{"id": "11206417_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exert", "start": 3, "end": 4}, "arguments": [{"entity_id": "11206417_1_Ent3", "role": "Treatment_Drug", "text": "Glucose", "start": 0, "end": 1}, {"entity_id": "11206417_1_Ent5", "role": "Combination_Drug", "text": "Glucose", "start": 0, "end": 1}, {"entity_id": "11206417_1_Ent2", "role": "Treatment", "text": "Glucose and insulin", "start": 0, "end": 3}, {"entity_id": "11206417_1_Ent4", "role": "Treatment_Drug", "text": "insulin", "start": 2, "end": 3}, {"entity_id": "11206417_1_Ent6", "role": "Combination_Drug", "text": "insulin", "start": 2, "end": 3}, {"entity_id": "11206417_1_Ent1", "role": "Effect", "text": "additive ocular and renal vasodilator effects", "start": 4, "end": 10}, {"entity_id": "11206417_1_Ent0", "role": "Subject", "text": "healthy humans", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "11206417_1_Ent3", "text": "Glucose", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11206417_1_Ent5", "text": "Glucose", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11206417_1_Ent2", "text": "Glucose and insulin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11206417_1_Ent4", "text": "insulin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11206417_1_Ent6", "text": "insulin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11206417_1_Ent1", "text": "additive ocular and renal vasodilator effects", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "11206417_1_Ent0", "text": "healthy humans", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "11206417_3", "wnd_id": "11206417_3_1", "text": "There is , however , currently no data on the effect of combined hyperglycaemia and hyperinsulinaemia on the renal and ocular blood flow seen in diabetic patients on insulin therapy .", "tokens": ["There", "is", ",", "however", ",", "currently", "no", "data", "on", "the", "effect", "of", "combined", "hyperglycaemia", "and", "hyperinsulinaemia", "on", "the", "renal", "and", "ocular", "blood", "flow", "seen", "in", "diabetic", "patients", "on", "insulin", "therapy", "."], "event_mentions": [{"id": "11206417_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 27, "end": 28}, "arguments": [{"entity_id": "11206417_3_Ent0", "role": "Subject", "text": "combined hyperglycaemia and hyperinsulinaemia", "start": 12, "end": 16}, {"entity_id": "11206417_3_Ent4", "role": "Treatment_Drug", "text": "hyperglycaemia", "start": 13, "end": 14}, {"entity_id": "11206417_3_Ent7", "role": "Combination_Drug", "text": "hyperglycaemia", "start": 13, "end": 14}, {"entity_id": "11206417_3_Ent5", "role": "Treatment_Drug", "text": "hyperinsulinaemia", "start": 15, "end": 16}, {"entity_id": "11206417_3_Ent8", "role": "Combination_Drug", "text": "hyperinsulinaemia", "start": 15, "end": 16}, {"entity_id": "11206417_3_Ent2", "role": "Effect", "text": "renal and ocular blood flow", "start": 18, "end": 23}, {"entity_id": "11206417_3_Ent6", "role": "Treatment_Disorder", "text": "diabetic", "start": 25, "end": 26}, {"entity_id": "11206417_3_Ent1", "role": "Subject", "text": "diabetic patients", "start": 25, "end": 27}, {"entity_id": "11206417_3_Ent3", "role": "Treatment", "text": "insulin therapy", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "11206417_3_Ent0", "text": "combined hyperglycaemia and hyperinsulinaemia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "11206417_3_Ent4", "text": "hyperglycaemia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11206417_3_Ent7", "text": "hyperglycaemia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11206417_3_Ent5", "text": "hyperinsulinaemia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11206417_3_Ent8", "text": "hyperinsulinaemia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11206417_3_Ent2", "text": "renal and ocular blood flow", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "11206417_3_Ent6", "text": "diabetic", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11206417_3_Ent1", "text": "diabetic patients", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11206417_3_Ent3", "text": "insulin therapy", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "11207969_4", "wnd_id": "11207969_4_1", "text": "We report a fatal case of toxic epidermal necrolysis ( TEN ) resulting from a high dose of cytosine arabinoside ( ARA - C ) .", "tokens": ["We", "report", "a", "fatal", "case", "of", "toxic", "epidermal", "necrolysis", "(", "TEN", ")", "resulting", "from", "a", "high", "dose", "of", "cytosine", "arabinoside", "(", "ARA", "-", "C", ")", "."], "event_mentions": [{"id": "11207969_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting from", "start": 12, "end": 14}, "arguments": [{"entity_id": "11207969_4_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis ( TEN )", "start": 6, "end": 12}, {"entity_id": "11207969_4_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 15, "end": 17}, {"entity_id": "11207969_4_Ent1", "role": "Treatment", "text": "high dose of cytosine arabinoside ( ARA - C )", "start": 15, "end": 25}, {"entity_id": "11207969_4_Ent2", "role": "Treatment_Drug", "text": "cytosine arabinoside ( ARA - C )", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "11207969_4_Ent0", "text": "toxic epidermal necrolysis ( TEN )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11207969_4_Ent3", "text": "high dose", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "11207969_4_Ent1", "text": "high dose of cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "11207969_4_Ent2", "text": "cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "11215836_2", "wnd_id": "11215836_2_1", "text": "OBJECTIVE : To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen .", "tokens": ["OBJECTIVE", ":", "To", "report", "on", "the", "possible", "development", "of", "serotonin", "syndrome", "in", "a", "patient", "receiving", "clomipramine", "after", "clozapine", "was", "withdrawn", "from", "the", "treatment", "regimen", "."], "event_mentions": [{"id": "11215836_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 14, "end": 15}, "arguments": [{"entity_id": "11215836_2_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 9, "end": 11}, {"entity_id": "11215836_2_Ent0", "role": "Subject", "text": "patient", "start": 13, "end": 14}, {"entity_id": "11215836_2_Ent2", "role": "Treatment", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent3", "role": "Treatment_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent5", "role": "Combination_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 17, "end": 18}, {"entity_id": "11215836_2_Ent6", "role": "Combination_Drug", "text": "clozapine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11215836_2_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11215836_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11215836_2_Ent2", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent3", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent5", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11215836_2_Ent6", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11215836_3", "wnd_id": "11215836_3_1", "text": "Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine .", "tokens": ["Possible", "serotonin", "syndrome", "associated", "with", "clomipramine", "after", "withdrawal", "of", "clozapine", "."], "event_mentions": [{"id": "11215836_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "11215836_3_Ent0", "role": "Effect", "text": "serotonin syndrome associated with clomipramine", "start": 1, "end": 6}, {"entity_id": "11215836_3_Ent3", "role": "Treatment_Drug", "text": "clomipramine", "start": 5, "end": 6}, {"entity_id": "11215836_3_Ent1", "role": "Treatment", "text": "withdrawal of clozapine", "start": 7, "end": 10}, {"entity_id": "11215836_3_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11215836_3_Ent0", "text": "serotonin syndrome associated with clomipramine", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11215836_3_Ent3", "text": "clomipramine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11215836_3_Ent1", "text": "withdrawal of clozapine", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11215836_3_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11225532_1", "wnd_id": "11225532_1_1", "text": "Quinine induced coagulopathy -- a near fatal experience .", "tokens": ["Quinine", "induced", "coagulopathy", "--", "a", "near", "fatal", "experience", "."], "event_mentions": [{"id": "11225532_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11225532_1_Ent1", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11225532_1_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11225532_1_Ent0", "role": "Effect", "text": "coagulopathy -- a near fatal experience", "start": 2, "end": 8}]}], "entity_mentions": [{"id": "11225532_1_Ent1", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225532_1_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225532_1_Ent0", "text": "coagulopathy -- a near fatal experience", "entity_type": "Entity", "start": 2, "end": 8}], "lang": "en"}
{"doc_id": "11225532_2", "wnd_id": "11225532_2_1", "text": "The cause of his bleeding was a severe thrombocytopoaenia , induced by chronic ingestion of quinine .", "tokens": ["The", "cause", "of", "his", "bleeding", "was", "a", "severe", "thrombocytopoaenia", ",", "induced", "by", "chronic", "ingestion", "of", "quinine", "."], "event_mentions": [{"id": "11225532_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "11225532_2_Ent0", "role": "Effect", "text": "thrombocytopoaenia", "start": 8, "end": 9}, {"entity_id": "11225532_2_Ent1", "role": "Treatment", "text": "chronic ingestion of quinine", "start": 12, "end": 16}, {"entity_id": "11225532_2_Ent2", "role": "Treatment_Route", "text": "ingestion", "start": 13, "end": 14}, {"entity_id": "11225532_2_Ent3", "role": "Treatment_Drug", "text": "quinine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "11225532_2_Ent0", "text": "thrombocytopoaenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11225532_2_Ent1", "text": "chronic ingestion of quinine", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "11225532_2_Ent2", "text": "ingestion", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11225532_2_Ent3", "text": "quinine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "11236070_3", "wnd_id": "11236070_3_1", "text": "We report three cases of patients who developed leukopenia during olanzapine treatment .", "tokens": ["We", "report", "three", "cases", "of", "patients", "who", "developed", "leukopenia", "during", "olanzapine", "treatment", "."], "event_mentions": [{"id": "11236070_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "11236070_3_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "11236070_3_Ent0", "role": "Subject", "text": "three cases of patients", "start": 2, "end": 6}, {"entity_id": "11236070_3_Ent2", "role": "Effect", "text": "leukopenia", "start": 8, "end": 9}, {"entity_id": "11236070_3_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 10, "end": 11}, {"entity_id": "11236070_3_Ent3", "role": "Treatment", "text": "olanzapine treatment", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "11236070_3_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11236070_3_Ent0", "text": "three cases of patients", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11236070_3_Ent2", "text": "leukopenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11236070_3_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11236070_3_Ent3", "text": "olanzapine treatment", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "11243427_3", "wnd_id": "11243427_3_1", "text": "DISCUSSION : Patients with 5 - FU - induced ectropion experience tender , red , scaled lids , making contact lens wear difficult .", "tokens": ["DISCUSSION", ":", "Patients", "with", "5", "-", "FU", "-", "induced", "ectropion", "experience", "tender", ",", "red", ",", "scaled", "lids", ",", "making", "contact", "lens", "wear", "difficult", "."], "event_mentions": [{"id": "11243427_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "11243427_3_Ent0", "role": "Subject", "text": "Patients with 5 - FU - induced ectropion", "start": 2, "end": 10}, {"entity_id": "11243427_3_Ent3", "role": "Treatment", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent1", "role": "Effect", "text": "ectropion", "start": 9, "end": 10}, {"entity_id": "11243427_3_Ent2", "role": "Effect", "text": "tender , red , scaled lids", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "11243427_3_Ent0", "text": "Patients with 5 - FU - induced ectropion", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "11243427_3_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent1", "text": "ectropion", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11243427_3_Ent2", "text": "tender , red , scaled lids", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "11243427_4", "wnd_id": "11243427_4_1", "text": "Ectropion secondary to bolus injection of 5 - fluorouracil .", "tokens": ["Ectropion", "secondary", "to", "bolus", "injection", "of", "5", "-", "fluorouracil", "."], "event_mentions": [{"id": "11243427_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 1, "end": 2}, "arguments": [{"entity_id": "11243427_4_Ent0", "role": "Effect", "text": "Ectropion", "start": 0, "end": 1}, {"entity_id": "11243427_4_Ent2", "role": "Treatment_Route", "text": "bolus injection", "start": 3, "end": 5}, {"entity_id": "11243427_4_Ent1", "role": "Treatment", "text": "bolus injection of 5 - fluorouracil", "start": 3, "end": 9}, {"entity_id": "11243427_4_Ent3", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "11243427_4_Ent0", "text": "Ectropion", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11243427_4_Ent2", "text": "bolus injection", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11243427_4_Ent1", "text": "bolus injection of 5 - fluorouracil", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11243427_4_Ent3", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "11250985_3", "wnd_id": "11250985_3_1", "text": "In some cases this seems to happen because spironolactone causes diarrhoea .", "tokens": ["In", "some", "cases", "this", "seems", "to", "happen", "because", "spironolactone", "causes", "diarrhoea", "."], "event_mentions": [{"id": "11250985_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 9, "end": 10}, "arguments": [{"entity_id": "11250985_3_Ent1", "role": "Treatment", "text": "spironolactone", "start": 8, "end": 9}, {"entity_id": "11250985_3_Ent2", "role": "Treatment_Drug", "text": "spironolactone", "start": 8, "end": 9}, {"entity_id": "11250985_3_Ent0", "role": "Effect", "text": "diarrhoea", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11250985_3_Ent1", "text": "spironolactone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11250985_3_Ent2", "text": "spironolactone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11250985_3_Ent0", "text": "diarrhoea", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11283125_1", "wnd_id": "11283125_1_1", "text": "Value of high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol in increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma : results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial .", "tokens": ["Value", "of", "high", "-", "dose", "cytarabine", "during", "interval", "therapy", "of", "a", "Berlin", "-", "Frankfurt", "-", "Munster", "-", "based", "protocol", "in", "increased", "-", "risk", "children", "with", "acute", "lymphoblastic", "leukemia", "and", "lymphoblastic", "lymphoma", ":", "results", "of", "the", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "58881", "randomized", "phase", "III", "trial", "."], "event_mentions": [{"id": "11283125_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Value", "start": 0, "end": 1}, "arguments": [{"entity_id": "11283125_1_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 2, "end": 5}, {"entity_id": "11283125_1_Ent2", "role": "Treatment", "text": "high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol", "start": 2, "end": 19}, {"entity_id": "11283125_1_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 5, "end": 6}, {"entity_id": "11283125_1_Ent0", "role": "Subject", "text": "increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma", "start": 20, "end": 31}, {"entity_id": "11283125_1_Ent1", "role": "Subject_Age", "text": "children", "start": 23, "end": 24}, {"entity_id": "11283125_1_Ent3", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 25, "end": 28}, {"entity_id": "11283125_1_Ent4", "role": "Treatment_Disorder", "text": "lymphoblastic lymphoma", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "11283125_1_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11283125_1_Ent2", "text": "high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol", "entity_type": "Entity", "start": 2, "end": 19}, {"id": "11283125_1_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11283125_1_Ent0", "text": "increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "11283125_1_Ent1", "text": "children", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11283125_1_Ent3", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "11283125_1_Ent4", "text": "lymphoblastic lymphoma", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "11319599_1", "wnd_id": "11319599_1_1", "text": "Indolent aspergillus arthritis complicating fludarabine - based non - myeloablative stem cell transplantation .", "tokens": ["Indolent", "aspergillus", "arthritis", "complicating", "fludarabine", "-", "based", "non", "-", "myeloablative", "stem", "cell", "transplantation", "."], "event_mentions": [{"id": "11319599_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 3, "end": 4}, "arguments": [{"entity_id": "11319599_1_Ent0", "role": "Effect", "text": "Indolent aspergillus arthritis", "start": 0, "end": 3}, {"entity_id": "11319599_1_Ent1", "role": "Treatment", "text": "fludarabine", "start": 4, "end": 5}, {"entity_id": "11319599_1_Ent2", "role": "Treatment_Drug", "text": "fludarabine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11319599_1_Ent0", "text": "Indolent aspergillus arthritis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11319599_1_Ent1", "text": "fludarabine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11319599_1_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11319599_2", "wnd_id": "11319599_2_1", "text": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine - based non - myeloablative stem cell transplantation .", "tokens": ["We", "describe", "two", "patients", "with", "aspergillus", "arthritis", "of", "the", "knee", "joint", "following", "fludarabine", "-", "based", "non", "-", "myeloablative", "stem", "cell", "transplantation", "."], "event_mentions": [{"id": "11319599_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "11319599_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "11319599_2_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "11319599_2_Ent2", "role": "Effect", "text": "aspergillus arthritis of the knee joint", "start": 5, "end": 11}, {"entity_id": "11319599_2_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 12, "end": 13}, {"entity_id": "11319599_2_Ent3", "role": "Treatment", "text": "fludarabine - based non - myeloablative stem cell transplantation", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "11319599_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11319599_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11319599_2_Ent2", "text": "aspergillus arthritis of the knee joint", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11319599_2_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11319599_2_Ent3", "text": "fludarabine - based non - myeloablative stem cell transplantation", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "11328247_3", "wnd_id": "11328247_3_1", "text": "OBJECTIVE : The aim of this paper is to describe a case of increased libido during fluvoxamine therapy .", "tokens": ["OBJECTIVE", ":", "The", "aim", "of", "this", "paper", "is", "to", "describe", "a", "case", "of", "increased", "libido", "during", "fluvoxamine", "therapy", "."], "event_mentions": [{"id": "11328247_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "11328247_3_Ent0", "role": "Subject", "text": "a case", "start": 10, "end": 12}, {"entity_id": "11328247_3_Ent1", "role": "Effect", "text": "increased libido", "start": 13, "end": 15}, {"entity_id": "11328247_3_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 16, "end": 17}, {"entity_id": "11328247_3_Ent2", "role": "Treatment", "text": "fluvoxamine therapy .", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "11328247_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11328247_3_Ent1", "text": "increased libido", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11328247_3_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11328247_3_Ent2", "text": "fluvoxamine therapy .", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "11328247_4", "wnd_id": "11328247_4_1", "text": "RESULTS : The patient , a 27 - year - old married Japanese woman with borderline personality disorder , developed an increased libido with the administration of fluvoxamine .", "tokens": ["RESULTS", ":", "The", "patient", ",", "a", "27", "-", "year", "-", "old", "married", "Japanese", "woman", "with", "borderline", "personality", "disorder", ",", "developed", "an", "increased", "libido", "with", "the", "administration", "of", "fluvoxamine", "."], "event_mentions": [{"id": "11328247_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "11328247_4_Ent0", "role": "Subject", "text": "The patient , a 27 - year - old married Japanese woman with borderline personality disorder", "start": 2, "end": 18}, {"entity_id": "11328247_4_Ent1", "role": "Subject_Age", "text": "27 - year - old", "start": 6, "end": 11}, {"entity_id": "11328247_4_Ent2", "role": "Subject_Race", "text": "Japanese", "start": 12, "end": 13}, {"entity_id": "11328247_4_Ent3", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "11328247_4_Ent6", "role": "Treatment_Disorder", "text": "borderline personality disorder", "start": 15, "end": 18}, {"entity_id": "11328247_4_Ent4", "role": "Effect", "text": "increased libido", "start": 21, "end": 23}, {"entity_id": "11328247_4_Ent5", "role": "Treatment", "text": "administration of fluvoxamine", "start": 25, "end": 28}, {"entity_id": "11328247_4_Ent7", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "11328247_4_Ent0", "text": "The patient , a 27 - year - old married Japanese woman with borderline personality disorder", "entity_type": "Entity", "start": 2, "end": 18}, {"id": "11328247_4_Ent1", "text": "27 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11328247_4_Ent2", "text": "Japanese", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11328247_4_Ent3", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11328247_4_Ent6", "text": "borderline personality disorder", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11328247_4_Ent4", "text": "increased libido", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "11328247_4_Ent5", "text": "administration of fluvoxamine", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "11328247_4_Ent7", "text": "fluvoxamine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "11352235_4", "wnd_id": "11352235_4_1", "text": "OBJECTIVE : To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center .", "tokens": ["OBJECTIVE", ":", "To", "determine", "the", "frequency", "of", "weight", "loss", "in", "patients", "treated", "with", "leflunomide", "for", "rheumatoid", "arthritis", "at", "an", "arthritis", "referral", "center", "."], "event_mentions": [{"id": "11352235_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "loss", "start": 8, "end": 9}, "arguments": [{"entity_id": "11352235_4_Ent1", "role": "Effect", "text": "weight loss", "start": 7, "end": 9}, {"entity_id": "11352235_4_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "11352235_4_Ent2", "role": "Treatment", "text": "leflunomide", "start": 13, "end": 14}, {"entity_id": "11352235_4_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 13, "end": 14}, {"entity_id": "11352235_4_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11352235_4_Ent1", "text": "weight loss", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11352235_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11352235_4_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11352235_4_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11352235_4_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11359026_3", "wnd_id": "11359026_3_1", "text": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection .", "tokens": ["She", "developed", "neurotoxicity", "with", "an", "adjustment", "dosage", "of", "valacyclovir", "for", "a", "cutaneous", "zoster", "infection", "."], "event_mentions": [{"id": "11359026_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "11359026_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "11359026_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "11359026_3_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 2, "end": 3}, {"entity_id": "11359026_3_Ent4", "role": "Treatment_Dosage", "text": "adjustment dosage", "start": 5, "end": 7}, {"entity_id": "11359026_3_Ent3", "role": "Treatment", "text": "adjustment dosage of valacyclovir", "start": 5, "end": 9}, {"entity_id": "11359026_3_Ent5", "role": "Treatment_Drug", "text": "valacyclovir", "start": 8, "end": 9}, {"entity_id": "11359026_3_Ent6", "role": "Treatment_Disorder", "text": "cutaneous zoster infection", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11359026_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11359026_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11359026_3_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11359026_3_Ent4", "text": "adjustment dosage", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11359026_3_Ent3", "text": "adjustment dosage of valacyclovir", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "11359026_3_Ent5", "text": "valacyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11359026_3_Ent6", "text": "cutaneous zoster infection", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11373877_2", "wnd_id": "11373877_2_1", "text": "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate , both of whom had been treated with steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation , and who subsequently developed femoral head avascular necrosis .", "tokens": ["We", "report", "the", "case", "histories", "of", "two", "patients", "with", "histologically", "confirmed", "adenocarcinoma", "of", "the", "prostate", ",", "both", "of", "whom", "had", "been", "treated", "with", "steroidal", "anti", "-", "androgen", "therapy", "in", "the", "form", "of", "cyproterone", "acetate", "prior", "to", "radical", "or", "palliative", "pelvic", "irradiation", ",", "and", "who", "subsequently", "developed", "femoral", "head", "avascular", "necrosis", "."], "event_mentions": [{"id": "11373877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11373877_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "11373877_2_Ent0", "role": "Subject", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "start": 6, "end": 15}, {"entity_id": "11373877_2_Ent4", "role": "Treatment_Disorder", "text": "adenocarcinoma of the prostate", "start": 11, "end": 15}, {"entity_id": "11373877_2_Ent3", "role": "Treatment", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "start": 23, "end": 41}, {"entity_id": "11373877_2_Ent5", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 32, "end": 34}, {"entity_id": "11373877_2_Ent2", "role": "Effect", "text": "femoral head avascular necrosis .", "start": 46, "end": 51}]}], "entity_mentions": [{"id": "11373877_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11373877_2_Ent0", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "11373877_2_Ent4", "text": "adenocarcinoma of the prostate", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11373877_2_Ent3", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "entity_type": "Entity", "start": 23, "end": 41}, {"id": "11373877_2_Ent5", "text": "cyproterone acetate", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "11373877_2_Ent2", "text": "femoral head avascular necrosis .", "entity_type": "Entity", "start": 46, "end": 51}], "lang": "en"}
{"doc_id": "11424102_3", "wnd_id": "11424102_3_1", "text": "We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous ethanol injection ( PEI ) .", "tokens": ["We", "describe", "a", "case", "of", "needle", "-", "track", "cutaneous", "seeding", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", "after", "sonographically", "guided", "percutaneous", "ethanol", "injection", "(", "PEI", ")", "."], "event_mentions": [{"id": "11424102_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "11424102_3_Ent0", "role": "Effect", "text": "needle - track cutaneous seeding of hepatocellular carcinoma", "start": 5, "end": 13}, {"entity_id": "11424102_3_Ent1", "role": "Treatment", "text": "sonographically guided percutaneous ethanol injection", "start": 17, "end": 22}, {"entity_id": "11424102_3_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 20, "end": 21}, {"entity_id": "11424102_3_Ent2", "role": "Treatment_Route", "text": "injection", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11424102_3_Ent0", "text": "needle - track cutaneous seeding of hepatocellular carcinoma", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "11424102_3_Ent1", "text": "sonographically guided percutaneous ethanol injection", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "11424102_3_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11424102_3_Ent2", "text": "injection", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11424102_5", "wnd_id": "11424102_5_1", "text": "Despite the risk of needle - track seeding , PEI remains useful in the treatment of HCC .", "tokens": ["Despite", "the", "risk", "of", "needle", "-", "track", "seeding", ",", "PEI", "remains", "useful", "in", "the", "treatment", "of", "HCC", "."], "event_mentions": [{"id": "11424102_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "remains", "start": 10, "end": 11}, "arguments": [{"entity_id": "11424102_5_Ent0", "role": "Treatment", "text": "PEI", "start": 9, "end": 10}, {"entity_id": "11424102_5_Ent1", "role": "Treatment_Drug", "text": "PEI", "start": 9, "end": 10}, {"entity_id": "11424102_5_Ent2", "role": "Treatment_Disorder", "text": "HCC", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11424102_5_Ent0", "text": "PEI", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11424102_5_Ent1", "text": "PEI", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11424102_5_Ent2", "text": "HCC", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11443640_1", "wnd_id": "11443640_1_1", "text": "Massive plasmocytosis due to methimazole - induced bone marrow toxicity .", "tokens": ["Massive", "plasmocytosis", "due", "to", "methimazole", "-", "induced", "bone", "marrow", "toxicity", "."], "event_mentions": [{"id": "11443640_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11443640_1_Ent1", "role": "Effect", "text": "Massive plasmocytosis", "start": 0, "end": 2}, {"entity_id": "11443640_1_Ent2", "role": "Treatment", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "11443640_1_Ent3", "role": "Treatment_Drug", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "11443640_1_Ent0", "role": "Effect", "text": "bone marrow toxicity", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "11443640_1_Ent1", "text": "Massive plasmocytosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11443640_1_Ent2", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11443640_1_Ent3", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11443640_1_Ent0", "text": "bone marrow toxicity", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "11443640_2", "wnd_id": "11443640_2_1", "text": "To our knowledge this is the first report of pancytopenia due to MMI , where the usual hypoplasia found is replaced by massive plasmocytosis .", "tokens": ["To", "our", "knowledge", "this", "is", "the", "first", "report", "of", "pancytopenia", "due", "to", "MMI", ",", "where", "the", "usual", "hypoplasia", "found", "is", "replaced", "by", "massive", "plasmocytosis", "."], "event_mentions": [{"id": "11443640_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 10, "end": 11}, "arguments": [{"entity_id": "11443640_2_Ent0", "role": "Effect", "text": "pancytopenia", "start": 9, "end": 10}, {"entity_id": "11443640_2_Ent1", "role": "Treatment", "text": "MMI", "start": 12, "end": 13}, {"entity_id": "11443640_2_Ent2", "role": "Treatment_Drug", "text": "MMI", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11443640_2_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11443640_2_Ent1", "text": "MMI", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11443640_2_Ent2", "text": "MMI", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11450788_1", "wnd_id": "11450788_1_1", "text": "Antiretroviral - induced hepatic steatosis and lactic acidosis : case report and review of the literature .", "tokens": ["Antiretroviral", "-", "induced", "hepatic", "steatosis", "and", "lactic", "acidosis", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "11450788_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11450788_1_Ent2", "role": "Treatment", "text": "Antiretroviral", "start": 0, "end": 1}, {"entity_id": "11450788_1_Ent3", "role": "Treatment_Drug", "text": "Antiretroviral", "start": 0, "end": 1}, {"entity_id": "11450788_1_Ent1", "role": "Effect", "text": "hepatic steatosis and lactic acidosis", "start": 3, "end": 8}, {"entity_id": "11450788_1_Ent0", "role": "Subject", "text": "case", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11450788_1_Ent2", "text": "Antiretroviral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11450788_1_Ent3", "text": "Antiretroviral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11450788_1_Ent1", "text": "hepatic steatosis and lactic acidosis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11450788_1_Ent0", "text": "case", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11452245_11", "wnd_id": "11452245_11_1", "text": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose - lowering effect and increase the risk of hypoglycemia .", "tokens": ["Concomitant", "use", "of", "clarithromycin", "or", "other", "potent", "inhibitors", "of", "CYP3A4", "with", "repaglinide", "may", "enhance", "its", "blood", "glucose", "-", "lowering", "effect", "and", "increase", "the", "risk", "of", "hypoglycemia", "."], "event_mentions": [{"id": "11452245_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhance", "start": 13, "end": 14}, "arguments": [{"entity_id": "11452245_11_Ent1", "role": "Treatment", "text": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide", "start": 0, "end": 12}, {"entity_id": "11452245_11_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 3, "end": 4}, {"entity_id": "11452245_11_Ent5", "role": "Combination_Drug", "text": "clarithromycin", "start": 3, "end": 4}, {"entity_id": "11452245_11_Ent3", "role": "Treatment_Drug", "text": "potent inhibitors of CYP3A4", "start": 6, "end": 10}, {"entity_id": "11452245_11_Ent7", "role": "Combination_Drug", "text": "potent inhibitors of CYP3A4", "start": 6, "end": 10}, {"entity_id": "11452245_11_Ent4", "role": "Treatment_Drug", "text": "repaglinide", "start": 11, "end": 12}, {"entity_id": "11452245_11_Ent6", "role": "Combination_Drug", "text": "repaglinide", "start": 11, "end": 12}, {"entity_id": "11452245_11_Ent0", "role": "Effect", "text": "blood glucose - lowering effect and increase the risk of hypoglycemia", "start": 15, "end": 26}]}], "entity_mentions": [{"id": "11452245_11_Ent1", "text": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "11452245_11_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11452245_11_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11452245_11_Ent3", "text": "potent inhibitors of CYP3A4", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "11452245_11_Ent7", "text": "potent inhibitors of CYP3A4", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "11452245_11_Ent4", "text": "repaglinide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11452245_11_Ent6", "text": "repaglinide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11452245_11_Ent0", "text": "blood glucose - lowering effect and increase the risk of hypoglycemia", "entity_type": "Entity", "start": 15, "end": 26}], "lang": "en"}
{"doc_id": "11468878_2", "wnd_id": "11468878_2_1", "text": "An obese patient , not diabetic , treated with metformin for some weeks , was referred to us with severe inferior digestive hemorrhage , diagnosed with Meckel 's diverticulum .", "tokens": ["An", "obese", "patient", ",", "not", "diabetic", ",", "treated", "with", "metformin", "for", "some", "weeks", ",", "was", "referred", "to", "us", "with", "severe", "inferior", "digestive", "hemorrhage", ",", "diagnosed", "with", "Meckel", "'s", "diverticulum", "."], "event_mentions": [{"id": "11468878_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 24, "end": 25}, "arguments": [{"entity_id": "11468878_2_Ent0", "role": "Subject", "text": "An obese patient , not diabetic", "start": 0, "end": 6}, {"entity_id": "11468878_2_Ent6", "role": "Treatment_Disorder", "text": "obese", "start": 1, "end": 2}, {"entity_id": "11468878_2_Ent4", "role": "Treatment_Drug", "text": "metformin", "start": 9, "end": 10}, {"entity_id": "11468878_2_Ent3", "role": "Treatment", "text": "metformin for some weeks", "start": 9, "end": 13}, {"entity_id": "11468878_2_Ent5", "role": "Treatment_Duration", "text": "some weeks", "start": 11, "end": 13}, {"entity_id": "11468878_2_Ent1", "role": "Effect", "text": "severe inferior digestive hemorrhage", "start": 19, "end": 23}, {"entity_id": "11468878_2_Ent2", "role": "Effect", "text": "Meckel 's diverticulum", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "11468878_2_Ent0", "text": "An obese patient , not diabetic", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11468878_2_Ent6", "text": "obese", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11468878_2_Ent4", "text": "metformin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11468878_2_Ent3", "text": "metformin for some weeks", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "11468878_2_Ent5", "text": "some weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11468878_2_Ent1", "text": "severe inferior digestive hemorrhage", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "11468878_2_Ent2", "text": "Meckel 's diverticulum", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "11483161_1", "wnd_id": "11483161_1_1", "text": "Possible linkage of amprenavir with intracranial bleeding in an HIV - infected hemophiliac .", "tokens": ["Possible", "linkage", "of", "amprenavir", "with", "intracranial", "bleeding", "in", "an", "HIV", "-", "infected", "hemophiliac", "."], "event_mentions": [{"id": "11483161_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "linkage", "start": 1, "end": 2}, "arguments": [{"entity_id": "11483161_1_Ent2", "role": "Treatment", "text": "amprenavir", "start": 3, "end": 4}, {"entity_id": "11483161_1_Ent3", "role": "Treatment_Drug", "text": "amprenavir", "start": 3, "end": 4}, {"entity_id": "11483161_1_Ent1", "role": "Effect", "text": "intracranial bleeding", "start": 5, "end": 7}, {"entity_id": "11483161_1_Ent0", "role": "Subject", "text": "an HIV - infected hemophiliac", "start": 8, "end": 13}, {"entity_id": "11483161_1_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11483161_1_Ent2", "text": "amprenavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11483161_1_Ent3", "text": "amprenavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11483161_1_Ent1", "text": "intracranial bleeding", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11483161_1_Ent0", "text": "an HIV - infected hemophiliac", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "11483161_1_Ent4", "text": "HIV", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11485141_1", "wnd_id": "11485141_1_1", "text": "According to the Naranjo probability scale , the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible .", "tokens": ["According", "to", "the", "Naranjo", "probability", "scale", ",", "the", "relationship", "of", "gemcitabine", "treatment", "with", "cutaneous", "eruption", "in", "our", "patient", "is", "possible", "."], "event_mentions": [{"id": "11485141_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 12, "end": 13}, "arguments": [{"entity_id": "11485141_1_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "11485141_1_Ent2", "role": "Treatment", "text": "gemcitabine treatment", "start": 10, "end": 12}, {"entity_id": "11485141_1_Ent1", "role": "Effect", "text": "cutaneous eruption", "start": 13, "end": 15}, {"entity_id": "11485141_1_Ent0", "role": "Subject", "text": "our patient", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "11485141_1_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11485141_1_Ent2", "text": "gemcitabine treatment", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11485141_1_Ent1", "text": "cutaneous eruption", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11485141_1_Ent0", "text": "our patient", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "11510798_4", "wnd_id": "11510798_4_1", "text": "Once extensive microbiological studies proved negative , corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved .", "tokens": ["Once", "extensive", "microbiological", "studies", "proved", "negative", ",", "corticosteroids", "were", "given", "and", "a", "complete", "remission", "of", "clinical", "and", "radiological", "abnormalities", "was", "achieved", "."], "event_mentions": [{"id": "11510798_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "achieved", "start": 20, "end": 21}, "arguments": [{"entity_id": "11510798_4_Ent1", "role": "Treatment", "text": "corticosteroids", "start": 7, "end": 8}, {"entity_id": "11510798_4_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 7, "end": 8}, {"entity_id": "11510798_4_Ent0", "role": "Effect", "text": "a complete remission of clinical and radiological abnormalities was achieved", "start": 11, "end": 21}, {"entity_id": "11510798_4_Ent3", "role": "Treatment_Disorder", "text": "clinical and radiological abnormalities", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "11510798_4_Ent1", "text": "corticosteroids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11510798_4_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11510798_4_Ent0", "text": "a complete remission of clinical and radiological abnormalities was achieved", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "11510798_4_Ent3", "text": "clinical and radiological abnormalities", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "11514944_1", "wnd_id": "11514944_1_1", "text": "BACKGROUND : Accutane a teratogenic prescription drug licensed to treat severe , recalcitrant nodular acne .", "tokens": ["BACKGROUND", ":", "Accutane", "a", "teratogenic", "prescription", "drug", "licensed", "to", "treat", "severe", ",", "recalcitrant", "nodular", "acne", "."], "event_mentions": [{"id": "11514944_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 9, "end": 10}, "arguments": [{"entity_id": "11514944_1_Ent0", "role": "Treatment", "text": "Accutane", "start": 2, "end": 3}, {"entity_id": "11514944_1_Ent2", "role": "Treatment_Drug", "text": "Accutane", "start": 2, "end": 3}, {"entity_id": "11514944_1_Ent1", "role": "Treatment_Disorder", "text": "severe , recalcitrant nodular acne", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "11514944_1_Ent0", "text": "Accutane", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11514944_1_Ent2", "text": "Accutane", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11514944_1_Ent1", "text": "severe , recalcitrant nodular acne", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "11545487_2", "wnd_id": "11545487_2_1", "text": "Indinavir - associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient .", "tokens": ["Indinavir", "-", "associated", "nephrolithiasis", "and", "chronic", "interstitial", "nephritis", "were", "the", "only", "possible", "causes", "identified", "in", "this", "patient", "."], "event_mentions": [{"id": "11545487_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11545487_2_Ent1", "role": "Treatment", "text": "Indinavir", "start": 0, "end": 1}, {"entity_id": "11545487_2_Ent2", "role": "Treatment_Drug", "text": "Indinavir", "start": 0, "end": 1}, {"entity_id": "11545487_2_Ent0", "role": "Effect", "text": "nephrolithiasis and chronic interstitial nephritis", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "11545487_2_Ent1", "text": "Indinavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11545487_2_Ent2", "text": "Indinavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11545487_2_Ent0", "text": "nephrolithiasis and chronic interstitial nephritis", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "11545487_3", "wnd_id": "11545487_3_1", "text": "Papillary necrosis associated with the HIV protease inhibitor indinavir .", "tokens": ["Papillary", "necrosis", "associated", "with", "the", "HIV", "protease", "inhibitor", "indinavir", "."], "event_mentions": [{"id": "11545487_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11545487_3_Ent0", "role": "Effect", "text": "Papillary necrosis", "start": 0, "end": 2}, {"entity_id": "11545487_3_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 5, "end": 6}, {"entity_id": "11545487_3_Ent1", "role": "Treatment", "text": "indinavir", "start": 8, "end": 9}, {"entity_id": "11545487_3_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11545487_3_Ent0", "text": "Papillary necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11545487_3_Ent3", "text": "HIV", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11545487_3_Ent1", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11545487_3_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11554897_5", "wnd_id": "11554897_5_1", "text": "Stupor from lamotrigine toxicity .", "tokens": ["Stupor", "from", "lamotrigine", "toxicity", "."], "event_mentions": [{"id": "11554897_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 1, "end": 2}, "arguments": [{"entity_id": "11554897_5_Ent0", "role": "Effect", "text": "Stupor", "start": 0, "end": 1}, {"entity_id": "11554897_5_Ent1", "role": "Treatment", "text": "lamotrigine", "start": 2, "end": 3}, {"entity_id": "11554897_5_Ent2", "role": "Treatment_Drug", "text": "lamotrigine", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "11554897_5_Ent0", "text": "Stupor", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11554897_5_Ent1", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11554897_5_Ent2", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "11573852_4", "wnd_id": "11573852_4_1", "text": "Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .", "tokens": ["Despite", "administration", "of", "phenytoin", "and", "lorazepam", ",", "the", "seizures", "persisted", "and", "occurred", "only", "during", "amphotercin", "B", "administration", "."], "event_mentions": [{"id": "11573852_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "11573852_4_Ent0", "role": "Effect", "text": "seizures", "start": 8, "end": 9}, {"entity_id": "11573852_4_Ent1", "role": "Treatment", "text": "amphotercin B", "start": 14, "end": 16}, {"entity_id": "11573852_4_Ent2", "role": "Treatment_Drug", "text": "amphotercin B", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11573852_4_Ent0", "text": "seizures", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11573852_4_Ent1", "text": "amphotercin B", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11573852_4_Ent2", "text": "amphotercin B", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11576059_2", "wnd_id": "11576059_2_1", "text": "We present the case of a 5 - year - old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration .", "tokens": ["We", "present", "the", "case", "of", "a", "5", "-", "year", "-", "old", "girl", "who", "developed", "bilateral", "vocal", "cord", "paralysis", "following", "preoperative", "peritonsillar", "bupivacaine", "infiltration", "."], "event_mentions": [{"id": "11576059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 18, "end": 19}, "arguments": [{"entity_id": "11576059_2_Ent0", "role": "Subject", "text": "a 5 - year - old girl", "start": 5, "end": 12}, {"entity_id": "11576059_2_Ent1", "role": "Subject_Age", "text": "5 - year - old", "start": 6, "end": 11}, {"entity_id": "11576059_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 11, "end": 12}, {"entity_id": "11576059_2_Ent3", "role": "Effect", "text": "bilateral vocal cord paralysis", "start": 14, "end": 18}, {"entity_id": "11576059_2_Ent4", "role": "Treatment", "text": "preoperative peritonsillar bupivacaine infiltration", "start": 19, "end": 23}, {"entity_id": "11576059_2_Ent6", "role": "Treatment_Route", "text": "peritonsillar", "start": 20, "end": 21}, {"entity_id": "11576059_2_Ent5", "role": "Treatment_Drug", "text": "bupivacaine", "start": 21, "end": 22}, {"entity_id": "11576059_2_Ent7", "role": "Treatment_Route", "text": "infiltration", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11576059_2_Ent0", "text": "a 5 - year - old girl", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "11576059_2_Ent1", "text": "5 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11576059_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11576059_2_Ent3", "text": "bilateral vocal cord paralysis", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "11576059_2_Ent4", "text": "preoperative peritonsillar bupivacaine infiltration", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "11576059_2_Ent6", "text": "peritonsillar", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11576059_2_Ent5", "text": "bupivacaine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11576059_2_Ent7", "text": "infiltration", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11590881_2", "wnd_id": "11590881_2_1", "text": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively .", "tokens": ["A", "53", "year", "old", "Greenlandic", "male", "was", "admitted", "twice", "over", "a", "period", "of", "4", "years", "with", "a", "new", "complete", "right", "bundle", "branch", "block", "after", "ingestion", "of", "10", "g", "and", "4", "g", "of", "carbamazepine", "respectively", "."], "event_mentions": [{"id": "11590881_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "11590881_2_Ent0", "role": "Subject", "text": "A 53 year old Greenlandic male", "start": 0, "end": 6}, {"entity_id": "11590881_2_Ent1", "role": "Subject_Age", "text": "53 year old", "start": 1, "end": 4}, {"entity_id": "11590881_2_Ent2", "role": "Subject_Race", "text": "Greenlandic", "start": 4, "end": 5}, {"entity_id": "11590881_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "11590881_2_Ent4", "role": "Effect", "text": "was admitted twice over a period of 4 years with a new complete right bundle branch block", "start": 6, "end": 23}, {"entity_id": "11590881_2_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 24, "end": 25}, {"entity_id": "11590881_2_Ent5", "role": "Treatment", "text": "ingestion of 10 g and 4 g of carbamazepine", "start": 24, "end": 33}, {"entity_id": "11590881_2_Ent7", "role": "Treatment_Dosage", "text": "10 g and 4 g", "start": 26, "end": 31}, {"entity_id": "11590881_2_Ent8", "role": "Treatment_Drug", "text": "carbamazepine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "11590881_2_Ent0", "text": "A 53 year old Greenlandic male", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11590881_2_Ent1", "text": "53 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "11590881_2_Ent2", "text": "Greenlandic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11590881_2_Ent3", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11590881_2_Ent4", "text": "was admitted twice over a period of 4 years with a new complete right bundle branch block", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "11590881_2_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11590881_2_Ent5", "text": "ingestion of 10 g and 4 g of carbamazepine", "entity_type": "Entity", "start": 24, "end": 33}, {"id": "11590881_2_Ent7", "text": "10 g and 4 g", "entity_type": "Entity", "start": 26, "end": 31}, {"id": "11590881_2_Ent8", "text": "carbamazepine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "11597289_14", "wnd_id": "11597289_14_1", "text": "In patients receiving antithrombin III and concomitant heparin , a significantly increased bleeding incidence was observed ( 23.8 % for antithrombin III group vs 13.5 % for placebo group ; P<.001 ) .", "tokens": ["In", "patients", "receiving", "antithrombin", "III", "and", "concomitant", "heparin", ",", "a", "significantly", "increased", "bleeding", "incidence", "was", "observed", "(", "23.8", "%", "for", "antithrombin", "III", "group", "vs", "13.5", "%", "for", "placebo", "group", ";", "P<.001", ")", "."], "event_mentions": [{"id": "11597289_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 11, "end": 12}, "arguments": [{"entity_id": "11597289_14_Ent0", "role": "Subject", "text": "patients", "start": 1, "end": 2}, {"entity_id": "11597289_14_Ent4", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent5", "role": "Combination_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent2", "role": "Treatment", "text": "antithrombin III and concomitant heparin", "start": 3, "end": 8}, {"entity_id": "11597289_14_Ent3", "role": "Treatment_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent6", "role": "Combination_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent1", "role": "Effect", "text": "bleeding incidence", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11597289_14_Ent0", "text": "patients", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11597289_14_Ent4", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent5", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent2", "text": "antithrombin III and concomitant heparin", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11597289_14_Ent3", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent6", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent1", "text": "bleeding incidence", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11597289_2", "wnd_id": "11597289_2_1", "text": "High - dose antithrombin III in severe sepsis : a randomized controlled trial .", "tokens": ["High", "-", "dose", "antithrombin", "III", "in", "severe", "sepsis", ":", "a", "randomized", "controlled", "trial", "."], "event_mentions": [{"id": "11597289_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "11597289_2_Ent2", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "11597289_2_Ent0", "role": "Treatment", "text": "High - dose antithrombin III", "start": 0, "end": 5}, {"entity_id": "11597289_2_Ent3", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_2_Ent1", "role": "Treatment_Disorder", "text": "severe sepsis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "11597289_2_Ent2", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11597289_2_Ent0", "text": "High - dose antithrombin III", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11597289_2_Ent3", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_2_Ent1", "text": "severe sepsis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "11675845_2", "wnd_id": "11675845_2_1", "text": "To report a case of increased international normalized ratio ( INR ) in a geriatric patient receiving warfarin and ropinirole .", "tokens": ["To", "report", "a", "case", "of", "increased", "international", "normalized", "ratio", "(", "INR", ")", "in", "a", "geriatric", "patient", "receiving", "warfarin", "and", "ropinirole", "."], "event_mentions": [{"id": "11675845_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 3, "end": 4}, "arguments": [{"entity_id": "11675845_2_Ent2", "role": "Effect", "text": "increased international normalized ratio ( INR )", "start": 5, "end": 12}, {"entity_id": "11675845_2_Ent0", "role": "Subject", "text": "a geriatric patient", "start": 13, "end": 16}, {"entity_id": "11675845_2_Ent1", "role": "Subject_Age", "text": "geriatric", "start": 14, "end": 15}, {"entity_id": "11675845_2_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 17, "end": 18}, {"entity_id": "11675845_2_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 17, "end": 18}, {"entity_id": "11675845_2_Ent3", "role": "Treatment", "text": "warfarin and ropinirole", "start": 17, "end": 20}, {"entity_id": "11675845_2_Ent5", "role": "Treatment_Drug", "text": "ropinirole", "start": 19, "end": 20}, {"entity_id": "11675845_2_Ent6", "role": "Combination_Drug", "text": "ropinirole", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "11675845_2_Ent2", "text": "increased international normalized ratio ( INR )", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "11675845_2_Ent0", "text": "a geriatric patient", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "11675845_2_Ent1", "text": "geriatric", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11675845_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11675845_2_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11675845_2_Ent3", "text": "warfarin and ropinirole", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "11675845_2_Ent5", "text": "ropinirole", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11675845_2_Ent6", "text": "ropinirole", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "11688826_2", "wnd_id": "11688826_2_1", "text": "Syndrome of inappropriate secretion of ADH ( SIADH ) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion .", "tokens": ["Syndrome", "of", "inappropriate", "secretion", "of", "ADH", "(", "SIADH", ")", "following", "cisplatin", "administration", "in", "a", "pulmonary", "adenocarcinoma", "patient", "with", "a", "malignant", "pleural", "effusion", "."], "event_mentions": [{"id": "11688826_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11688826_2_Ent2", "role": "Effect", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "start": 0, "end": 9}, {"entity_id": "11688826_2_Ent3", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent0", "role": "Subject", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "start": 13, "end": 22}, {"entity_id": "11688826_2_Ent4", "role": "Treatment_Disorder", "text": "pulmonary adenocarcinoma", "start": 14, "end": 16}, {"entity_id": "11688826_2_Ent1", "role": "Subject_Disorder", "text": "malignant pleural effusion", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "11688826_2_Ent2", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "11688826_2_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent0", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "11688826_2_Ent4", "text": "pulmonary adenocarcinoma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11688826_2_Ent1", "text": "malignant pleural effusion", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "11703329_4", "wnd_id": "11703329_4_1", "text": "We report a 31 - year - old women with recurrent Hodgkin 's lymphoma and unrecognized HMSN - 1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine .", "tokens": ["We", "report", "a", "31", "-", "year", "-", "old", "women", "with", "recurrent", "Hodgkin", "'s", "lymphoma", "and", "unrecognized", "HMSN", "-", "1", "who", "developed", "severe", "motor", "neuropathy", "3", "weeks", "after", "the", "first", "cycle", "of", "treatment", "including", "2", "mg", "of", "vincristine", "."], "event_mentions": [{"id": "11703329_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "11703329_4_Ent0", "role": "Subject", "text": "a 31 - year - old women with recurrent Hodgkin 's lymphoma and unrecognized HMSN - 1", "start": 2, "end": 19}, {"entity_id": "11703329_4_Ent1", "role": "Subject_Age", "text": "31 - year - old", "start": 3, "end": 8}, {"entity_id": "11703329_4_Ent2", "role": "Subject_Gender", "text": "women", "start": 8, "end": 9}, {"entity_id": "11703329_4_Ent6", "role": "Treatment_Disorder", "text": "recurrent Hodgkin 's lymphoma", "start": 10, "end": 14}, {"entity_id": "11703329_4_Ent3", "role": "Subject_Disorder", "text": "unrecognized HMSN - 1", "start": 15, "end": 19}, {"entity_id": "11703329_4_Ent4", "role": "Effect", "text": "severe motor neuropathy", "start": 21, "end": 24}, {"entity_id": "11703329_4_Ent7", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 24, "end": 26}, {"entity_id": "11703329_4_Ent5", "role": "Treatment", "text": "3 weeks after the first cycle of treatment including 2 mg of vincristine", "start": 24, "end": 37}, {"entity_id": "11703329_4_Ent8", "role": "Treatment_Dosage", "text": "2 mg", "start": 33, "end": 35}, {"entity_id": "11703329_4_Ent9", "role": "Treatment_Drug", "text": "vincristine", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "11703329_4_Ent0", "text": "a 31 - year - old women with recurrent Hodgkin 's lymphoma and unrecognized HMSN - 1", "entity_type": "Entity", "start": 2, "end": 19}, {"id": "11703329_4_Ent1", "text": "31 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11703329_4_Ent2", "text": "women", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11703329_4_Ent6", "text": "recurrent Hodgkin 's lymphoma", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "11703329_4_Ent3", "text": "unrecognized HMSN - 1", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "11703329_4_Ent4", "text": "severe motor neuropathy", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "11703329_4_Ent7", "text": "3 weeks", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "11703329_4_Ent5", "text": "3 weeks after the first cycle of treatment including 2 mg of vincristine", "entity_type": "Entity", "start": 24, "end": 37}, {"id": "11703329_4_Ent8", "text": "2 mg", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "11703329_4_Ent9", "text": "vincristine", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "11706664_1", "wnd_id": "11706664_1_1", "text": "Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate .", "tokens": ["Acute", "asymptomatic", "hepatitis", "in", "a", "healthy", "normal", "volunteer", "exposed", "to", "2", "oral", "doses", "of", "amodiaquine", "and", "artesunate", "."], "event_mentions": [{"id": "11706664_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 8, "end": 9}, "arguments": [{"entity_id": "11706664_1_Ent1", "role": "Effect", "text": "Acute asymptomatic hepatitis", "start": 0, "end": 3}, {"entity_id": "11706664_1_Ent0", "role": "Subject", "text": "a healthy normal volunteer", "start": 4, "end": 8}, {"entity_id": "11706664_1_Ent4", "role": "Treatment_Dosage", "text": "2", "start": 10, "end": 11}, {"entity_id": "11706664_1_Ent2", "role": "Treatment", "text": "2 oral doses of amodiaquine and artesunate", "start": 10, "end": 17}, {"entity_id": "11706664_1_Ent3", "role": "Treatment_Route", "text": "oral", "start": 11, "end": 12}, {"entity_id": "11706664_1_Ent5", "role": "Treatment_Drug", "text": "amodiaquine", "start": 14, "end": 15}, {"entity_id": "11706664_1_Ent8", "role": "Combination_Drug", "text": "amodiaquine", "start": 14, "end": 15}, {"entity_id": "11706664_1_Ent6", "role": "Treatment_Drug", "text": "artesunate", "start": 16, "end": 17}, {"entity_id": "11706664_1_Ent7", "role": "Combination_Drug", "text": "artesunate", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11706664_1_Ent1", "text": "Acute asymptomatic hepatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11706664_1_Ent0", "text": "a healthy normal volunteer", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "11706664_1_Ent4", "text": "2", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11706664_1_Ent2", "text": "2 oral doses of amodiaquine and artesunate", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "11706664_1_Ent3", "text": "oral", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11706664_1_Ent5", "text": "amodiaquine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11706664_1_Ent8", "text": "amodiaquine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11706664_1_Ent6", "text": "artesunate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11706664_1_Ent7", "text": "artesunate", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11720625_1", "wnd_id": "11720625_1_1", "text": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin .", "tokens": ["Torsades", "de", "pointes", "due", "to", "drug", "interaction", "between", "disopyramide", "and", "clarithromycin", "."], "event_mentions": [{"id": "11720625_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 3, "end": 5}, "arguments": [{"entity_id": "11720625_1_Ent0", "role": "Effect", "text": "Torsades de pointes", "start": 0, "end": 3}, {"entity_id": "11720625_1_Ent1", "role": "Treatment", "text": "drug interaction between disopyramide and clarithromycin", "start": 5, "end": 11}, {"entity_id": "11720625_1_Ent2", "role": "Treatment_Drug", "text": "disopyramide", "start": 8, "end": 9}, {"entity_id": "11720625_1_Ent4", "role": "Combination_Drug", "text": "disopyramide", "start": 8, "end": 9}, {"entity_id": "11720625_1_Ent3", "role": "Treatment_Drug", "text": "clarithromycin", "start": 10, "end": 11}, {"entity_id": "11720625_1_Ent5", "role": "Combination_Drug", "text": "clarithromycin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11720625_1_Ent0", "text": "Torsades de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11720625_1_Ent1", "text": "drug interaction between disopyramide and clarithromycin", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11720625_1_Ent2", "text": "disopyramide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11720625_1_Ent4", "text": "disopyramide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11720625_1_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11720625_1_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11720625_3", "wnd_id": "11720625_3_1", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However , clarithromycin is thought to be less frequently associated with drug induced TdP , because it inactivates hepatic cytochrome P - 450 to a lesser extent than erythromycin .", "tokens": ["Drug", "interactions", "between", "macrolide", "antibiotics", "such", "as", "erythomycin", "and", "pharmacologic", "agents", "that", "prolong", "the", "QT", "interval", "have", "been", "known", "to", "cause", "TdP.", "However", ",", "clarithromycin", "is", "thought", "to", "be", "less", "frequently", "associated", "with", "drug", "induced", "TdP", ",", "because", "it", "inactivates", "hepatic", "cytochrome", "P", "-", "450", "to", "a", "lesser", "extent", "than", "erythromycin", "."], "event_mentions": [{"id": "11720625_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 20, "end": 21}, "arguments": [{"entity_id": "11720625_3_Ent1", "role": "Treatment", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "start": 0, "end": 16}, {"entity_id": "11720625_3_Ent4", "role": "Treatment_Drug", "text": "macrolide antibiotics", "start": 3, "end": 5}, {"entity_id": "11720625_3_Ent2", "role": "Treatment_Drug", "text": "erythomycin", "start": 7, "end": 8}, {"entity_id": "11720625_3_Ent5", "role": "Combination_Drug", "text": "erythomycin", "start": 7, "end": 8}, {"entity_id": "11720625_3_Ent3", "role": "Treatment_Drug", "text": "pharmacologic agents", "start": 9, "end": 11}, {"entity_id": "11720625_3_Ent6", "role": "Combination_Drug", "text": "pharmacologic agents", "start": 9, "end": 11}, {"entity_id": "11720625_3_Ent0", "role": "Effect", "text": "TdP.", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11720625_3_Ent1", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "11720625_3_Ent4", "text": "macrolide antibiotics", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11720625_3_Ent2", "text": "erythomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11720625_3_Ent5", "text": "erythomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11720625_3_Ent3", "text": "pharmacologic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11720625_3_Ent6", "text": "pharmacologic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11720625_3_Ent0", "text": "TdP.", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11722307_4", "wnd_id": "11722307_4_1", "text": "RESULTS : Quetiapine was associated with leucopenia in two patients and clinically apparent agranulocytosis in one patient .", "tokens": ["RESULTS", ":", "Quetiapine", "was", "associated", "with", "leucopenia", "in", "two", "patients", "and", "clinically", "apparent", "agranulocytosis", "in", "one", "patient", "."], "event_mentions": [{"id": "11722307_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "11722307_4_Ent3", "role": "Treatment", "text": "Quetiapine", "start": 2, "end": 3}, {"entity_id": "11722307_4_Ent4", "role": "Treatment_Drug", "text": "Quetiapine", "start": 2, "end": 3}, {"entity_id": "11722307_4_Ent2", "role": "Effect", "text": "leucopenia", "start": 6, "end": 7}, {"entity_id": "11722307_4_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "11722307_4_Ent0", "role": "Subject", "text": "two patients", "start": 8, "end": 10}]}, {"id": "11722307_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "11722307_4_Ent8", "role": "Treatment", "text": "Quetiapine", "start": 2, "end": 3}, {"entity_id": "11722307_4_Ent9", "role": "Treatment_Drug", "text": "Quetiapine", "start": 2, "end": 3}, {"entity_id": "11722307_4_Ent7", "role": "Effect", "text": "clinically apparent agranulocytosis", "start": 11, "end": 14}, {"entity_id": "11722307_4_Ent6", "role": "Subject_Population", "text": "one", "start": 15, "end": 16}, {"entity_id": "11722307_4_Ent5", "role": "Subject", "text": "one patient", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11722307_4_Ent3", "text": "Quetiapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11722307_4_Ent4", "text": "Quetiapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11722307_4_Ent8", "text": "Quetiapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11722307_4_Ent9", "text": "Quetiapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11722307_4_Ent2", "text": "leucopenia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11722307_4_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11722307_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11722307_4_Ent7", "text": "clinically apparent agranulocytosis", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "11722307_4_Ent6", "text": "one", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11722307_4_Ent5", "text": "one patient", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11724089_1", "wnd_id": "11724089_1_1", "text": "CONCLUSIONS : There is very little published information regarding ofloxacin - induced toxic epidermal necrolysis .", "tokens": ["CONCLUSIONS", ":", "There", "is", "very", "little", "published", "information", "regarding", "ofloxacin", "-", "induced", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "11724089_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "11724089_1_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 9, "end": 10}, {"entity_id": "11724089_1_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 9, "end": 10}, {"entity_id": "11724089_1_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "11724089_1_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_1_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_1_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "11724089_2", "wnd_id": "11724089_2_1", "text": "However , a large case - control study included three cases of either Stevens - Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use , but no details of the cases were given .", "tokens": ["However", ",", "a", "large", "case", "-", "control", "study", "included", "three", "cases", "of", "either", "Stevens", "-", "Johnson", "syndrome", "or", "toxic", "epidermal", "necrolysis", "associated", "with", "ofloxacin", "use", ",", "but", "no", "details", "of", "the", "cases", "were", "given", "."], "event_mentions": [{"id": "11724089_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11724089_2_Ent1", "role": "Subject_Population", "text": "three", "start": 9, "end": 10}, {"entity_id": "11724089_2_Ent0", "role": "Subject", "text": "three cases", "start": 9, "end": 11}, {"entity_id": "11724089_2_Ent2", "role": "Effect", "text": "Stevens - Johnson syndrome or toxic epidermal necrolysis", "start": 13, "end": 21}, {"entity_id": "11724089_2_Ent3", "role": "Treatment", "text": "ofloxacin", "start": 23, "end": 24}, {"entity_id": "11724089_2_Ent4", "role": "Treatment_Drug", "text": "ofloxacin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11724089_2_Ent1", "text": "three", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_2_Ent0", "text": "three cases", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11724089_2_Ent2", "text": "Stevens - Johnson syndrome or toxic epidermal necrolysis", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "11724089_2_Ent3", "text": "ofloxacin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11724089_2_Ent4", "text": "ofloxacin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11737689_2", "wnd_id": "11737689_2_1", "text": "A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G - CSF .", "tokens": ["A", "girl", "with", "cystic", "fibrosis", "and", "cyclic", "neutropenia", "developed", "an", "erythematous", "papular", "eruption", "without", "fever", "or", "neutrophilia", "7", "months", "after", "commencing", "therapy", "with", "G", "-", "CSF", "."], "event_mentions": [{"id": "11737689_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "11737689_2_Ent0", "role": "Subject", "text": "A girl with cystic fibrosis and cyclic neutropenia", "start": 0, "end": 8}, {"entity_id": "11737689_2_Ent1", "role": "Subject_Gender", "text": "girl", "start": 1, "end": 2}, {"entity_id": "11737689_2_Ent2", "role": "Subject_Disorder", "text": "cystic fibrosis", "start": 3, "end": 5}, {"entity_id": "11737689_2_Ent5", "role": "Treatment_Disorder", "text": "cyclic neutropenia", "start": 6, "end": 8}, {"entity_id": "11737689_2_Ent3", "role": "Effect", "text": "erythematous papular eruption without fever or neutrophilia", "start": 10, "end": 17}, {"entity_id": "11737689_2_Ent7", "role": "Treatment_Time_elapsed", "text": "7 months", "start": 17, "end": 19}, {"entity_id": "11737689_2_Ent4", "role": "Treatment", "text": "7 months after commencing therapy with G - CSF .", "start": 17, "end": 27}, {"entity_id": "11737689_2_Ent6", "role": "Treatment_Drug", "text": "G - CSF", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "11737689_2_Ent0", "text": "A girl with cystic fibrosis and cyclic neutropenia", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "11737689_2_Ent1", "text": "girl", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11737689_2_Ent2", "text": "cystic fibrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11737689_2_Ent5", "text": "cyclic neutropenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11737689_2_Ent3", "text": "erythematous papular eruption without fever or neutrophilia", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "11737689_2_Ent7", "text": "7 months", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11737689_2_Ent4", "text": "7 months after commencing therapy with G - CSF .", "entity_type": "Entity", "start": 17, "end": 27}, {"id": "11737689_2_Ent6", "text": "G - CSF", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "1174301_1", "wnd_id": "1174301_1_1", "text": "There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism .", "tokens": ["There", "is", "a", "putative", "role", "of", "liothyronine", "administration", "in", "precipitating", "or", "activating", "hyperthyroidism", "."], "event_mentions": [{"id": "1174301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitating or activating", "start": 9, "end": 12}, "arguments": [{"entity_id": "1174301_1_Ent1", "role": "Treatment", "text": "liothyronine", "start": 6, "end": 7}, {"entity_id": "1174301_1_Ent2", "role": "Treatment_Drug", "text": "liothyronine", "start": 6, "end": 7}, {"entity_id": "1174301_1_Ent0", "role": "Effect", "text": "hyperthyroidism", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1174301_1_Ent1", "text": "liothyronine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1174301_1_Ent2", "text": "liothyronine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1174301_1_Ent0", "text": "hyperthyroidism", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11762672_2", "wnd_id": "11762672_2_1", "text": "Reversal of severe methanol - induced visual impairment : no evidence of retinal toxicity due to fomepizole .", "tokens": ["Reversal", "of", "severe", "methanol", "-", "induced", "visual", "impairment", ":", "no", "evidence", "of", "retinal", "toxicity", "due", "to", "fomepizole", "."], "event_mentions": [{"id": "11762672_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "11762672_2_Ent1", "role": "Treatment", "text": "methanol", "start": 3, "end": 4}, {"entity_id": "11762672_2_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 3, "end": 4}, {"entity_id": "11762672_2_Ent0", "role": "Effect", "text": "visual impairment", "start": 6, "end": 8}]}, {"id": "11762672_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 14, "end": 16}, "arguments": [{"entity_id": "11762672_2_Ent3", "role": "Effect", "text": "retinal toxicity", "start": 12, "end": 14}, {"entity_id": "11762672_2_Ent4", "role": "Treatment", "text": "fomepizole", "start": 16, "end": 17}, {"entity_id": "11762672_2_Ent5", "role": "Treatment_Drug", "text": "fomepizole", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11762672_2_Ent1", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11762672_2_Ent2", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11762672_2_Ent0", "text": "visual impairment", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11762672_2_Ent3", "text": "retinal toxicity", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11762672_2_Ent4", "text": "fomepizole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11762672_2_Ent5", "text": "fomepizole", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11804071_2", "wnd_id": "11804071_2_1", "text": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption .", "tokens": ["Isonicotinic", "acid", "hydrazide", "induced", "anagen", "effluvium", "and", "associated", "lichenoid", "eruption", "."], "event_mentions": [{"id": "11804071_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11804071_2_Ent1", "role": "Treatment", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent2", "role": "Treatment_Drug", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent0", "role": "Effect", "text": "anagen effluvium and associated lichenoid eruption", "start": 4, "end": 10}]}], "entity_mentions": [{"id": "11804071_2_Ent1", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent2", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent0", "text": "anagen effluvium and associated lichenoid eruption", "entity_type": "Entity", "start": 4, "end": 10}], "lang": "en"}
{"doc_id": "11804071_3", "wnd_id": "11804071_3_1", "text": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously .", "tokens": ["Such", "anagen", "effluvium", "with", "lichenoid", "eruption", "following", "INH", "therapy", "has", "not", "been", "observed", "previously", "."], "event_mentions": [{"id": "11804071_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "11804071_3_Ent0", "role": "Effect", "text": "anagen effluvium with lichenoid eruption", "start": 1, "end": 6}, {"entity_id": "11804071_3_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "11804071_3_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11804071_3_Ent0", "text": "anagen effluvium with lichenoid eruption", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11804071_3_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11804071_3_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11834188_3", "wnd_id": "11834188_3_1", "text": "Dermatitis to captopril .", "tokens": ["Dermatitis", "to", "captopril", "."], "event_mentions": [{"id": "11834188_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "11834188_3_Ent2", "role": "Treatment_Disorder", "text": "Dermatitis", "start": 0, "end": 1}, {"entity_id": "11834188_3_Ent0", "role": "Treatment", "text": "captopril", "start": 2, "end": 3}, {"entity_id": "11834188_3_Ent1", "role": "Treatment_Drug", "text": "captopril", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "11834188_3_Ent2", "text": "Dermatitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11834188_3_Ent0", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11834188_3_Ent1", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "11868077_2", "wnd_id": "11868077_2_1", "text": "We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection ( PEI ) for treatment of hepatocellular carcinoma .", "tokens": ["We", "describe", "a", "case", "of", "subcutaneous", "metastasis", "along", "the", "needle", "track", "after", "percutaneous", "ethanol", "injection", "(", "PEI", ")", "for", "treatment", "of", "hepatocellular", "carcinoma", "."], "event_mentions": [{"id": "11868077_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "11868077_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "11868077_2_Ent1", "role": "Effect", "text": "subcutaneous metastasis", "start": 5, "end": 7}, {"entity_id": "11868077_2_Ent2", "role": "Treatment", "text": "percutaneous ethanol injection ( PEI )", "start": 12, "end": 18}, {"entity_id": "11868077_2_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 13, "end": 14}, {"entity_id": "11868077_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 14, "end": 15}, {"entity_id": "11868077_2_Ent5", "role": "Treatment_Disorder", "text": "hepatocellular carcinoma", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "11868077_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11868077_2_Ent1", "text": "subcutaneous metastasis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11868077_2_Ent2", "text": "percutaneous ethanol injection ( PEI )", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "11868077_2_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11868077_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11868077_2_Ent5", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "11881322_5", "wnd_id": "11881322_5_1", "text": "The occurrence of acute hepatitis is best known for ketoconazole .", "tokens": ["The", "occurrence", "of", "acute", "hepatitis", "is", "best", "known", "for", "ketoconazole", "."], "event_mentions": [{"id": "11881322_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 8, "end": 9}, "arguments": [{"entity_id": "11881322_5_Ent0", "role": "Effect", "text": "acute hepatitis", "start": 3, "end": 5}, {"entity_id": "11881322_5_Ent1", "role": "Treatment", "text": "ketoconazole", "start": 9, "end": 10}, {"entity_id": "11881322_5_Ent2", "role": "Treatment_Drug", "text": "ketoconazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11881322_5_Ent0", "text": "acute hepatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11881322_5_Ent1", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11881322_5_Ent2", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11886466_3", "wnd_id": "11886466_3_1", "text": "We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII .", "tokens": ["We", "have", "recently", "encountered", "a", "patient", "with", "acquired", "haemophilia", "who", "developed", "a", "thrombotic", "left", "middle", "cerebral", "artery", "distribution", "stroke", "while", "being", "treated", "with", "pFVIII", "."], "event_mentions": [{"id": "11886466_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11886466_3_Ent0", "role": "Subject", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "start": 5, "end": 19}, {"entity_id": "11886466_3_Ent3", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 7, "end": 9}, {"entity_id": "11886466_3_Ent1", "role": "Effect", "text": "thrombotic left middle cerebral artery distribution stroke", "start": 12, "end": 19}, {"entity_id": "11886466_3_Ent2", "role": "Treatment", "text": "pFVIII", "start": 23, "end": 24}, {"entity_id": "11886466_3_Ent4", "role": "Treatment_Drug", "text": "pFVIII", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11886466_3_Ent0", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "11886466_3_Ent3", "text": "acquired haemophilia", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11886466_3_Ent1", "text": "thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "11886466_3_Ent2", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11886466_3_Ent4", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11889149_14", "wnd_id": "11889149_14_1", "text": "RLX+ALN reduced bone turnover more than either drug alone , resulting in greater BMD increment , but whether this difference reflects better fracture risk reduction was not assessed in this study .", "tokens": ["RLX+ALN", "reduced", "bone", "turnover", "more", "than", "either", "drug", "alone", ",", "resulting", "in", "greater", "BMD", "increment", ",", "but", "whether", "this", "difference", "reflects", "better", "fracture", "risk", "reduction", "was", "not", "assessed", "in", "this", "study", "."], "event_mentions": [{"id": "11889149_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11889149_14_Ent1", "role": "Treatment", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent2", "role": "Treatment", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent3", "role": "Treatment_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent4", "role": "Treatment_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent5", "role": "Combination_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent6", "role": "Combination_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent0", "role": "Effect", "text": "bone turnover more than either drug alone , resulting in greater BMD increment", "start": 2, "end": 15}]}], "entity_mentions": [{"id": "11889149_14_Ent1", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent2", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent3", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent4", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent5", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent6", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent0", "text": "bone turnover more than either drug alone , resulting in greater BMD increment", "entity_type": "Entity", "start": 2, "end": 15}], "lang": "en"}
{"doc_id": "11903249_3", "wnd_id": "11903249_3_1", "text": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin .", "tokens": ["We", "report", "two", "new", "cases", "of", "sarcoidosis", "in", "two", "patients", "with", "hepatitis", "C", "virus", "infection", "treated", "with", "interferon", "alfa", "and", "ribavirin", "."], "event_mentions": [{"id": "11903249_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 7, "end": 8}, "arguments": [{"entity_id": "11903249_3_Ent2", "role": "Effect", "text": "sarcoidosis", "start": 6, "end": 7}, {"entity_id": "11903249_3_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "11903249_3_Ent0", "role": "Subject", "text": "two patients with hepatitis C virus infection", "start": 8, "end": 15}, {"entity_id": "11903249_3_Ent4", "role": "Treatment_Disorder", "text": "hepatitis C virus infection", "start": 11, "end": 15}, {"entity_id": "11903249_3_Ent5", "role": "Treatment_Drug", "text": "interferon alfa", "start": 17, "end": 19}, {"entity_id": "11903249_3_Ent7", "role": "Combination_Drug", "text": "interferon alfa", "start": 17, "end": 19}, {"entity_id": "11903249_3_Ent3", "role": "Treatment", "text": "interferon alfa and ribavirin", "start": 17, "end": 21}, {"entity_id": "11903249_3_Ent6", "role": "Treatment_Drug", "text": "ribavirin", "start": 20, "end": 21}, {"entity_id": "11903249_3_Ent8", "role": "Combination_Drug", "text": "ribavirin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11903249_3_Ent2", "text": "sarcoidosis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11903249_3_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11903249_3_Ent0", "text": "two patients with hepatitis C virus infection", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "11903249_3_Ent4", "text": "hepatitis C virus infection", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11903249_3_Ent5", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11903249_3_Ent7", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11903249_3_Ent3", "text": "interferon alfa and ribavirin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11903249_3_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11903249_3_Ent8", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11999915_1", "wnd_id": "11999915_1_1", "text": "Agranulocytosis during clozapine therapy .", "tokens": ["Agranulocytosis", "during", "clozapine", "therapy", "."], "event_mentions": [{"id": "11999915_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "11999915_1_Ent0", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "11999915_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 2, "end": 3}, {"entity_id": "11999915_1_Ent1", "role": "Treatment", "text": "clozapine therapy", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "11999915_1_Ent0", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11999915_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11999915_1_Ent1", "text": "clozapine therapy", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "11999915_2", "wnd_id": "11999915_2_1", "text": "Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine .", "tokens": ["Granulocytopenia", "and", "agranulocytosis", "are", "considered", "among", "the", "most", "dangerous", "adverse", "effects", "of", "clozapine", "."], "event_mentions": [{"id": "11999915_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "among", "start": 5, "end": 6}, "arguments": [{"entity_id": "11999915_2_Ent0", "role": "Effect", "text": "Granulocytopenia and agranulocytosis", "start": 0, "end": 3}, {"entity_id": "11999915_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "11999915_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11999915_2_Ent0", "text": "Granulocytopenia and agranulocytosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11999915_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11999915_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11999915_3", "wnd_id": "11999915_3_1", "text": "The female patient received clozapine in a daily dose of 400 mg , which induced agranulocytosis after 2 months .", "tokens": ["The", "female", "patient", "received", "clozapine", "in", "a", "daily", "dose", "of", "400", "mg", ",", "which", "induced", "agranulocytosis", "after", "2", "months", "."], "event_mentions": [{"id": "11999915_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "11999915_3_Ent0", "role": "Subject", "text": "The female patient", "start": 0, "end": 3}, {"entity_id": "11999915_3_Ent1", "role": "Subject_Gender", "text": "female", "start": 1, "end": 2}, {"entity_id": "11999915_3_Ent8", "role": "Treatment_Drug", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "11999915_3_Ent3", "role": "Treatment", "text": "clozapine in a daily dose of 400 mg", "start": 4, "end": 12}, {"entity_id": "11999915_3_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 7, "end": 8}, {"entity_id": "11999915_3_Ent6", "role": "Treatment_Dosage", "text": "400 mg", "start": 10, "end": 12}, {"entity_id": "11999915_3_Ent2", "role": "Effect", "text": "agranulocytosis", "start": 15, "end": 16}, {"entity_id": "11999915_3_Ent4", "role": "Treatment", "text": "after 2 months", "start": 16, "end": 19}, {"entity_id": "11999915_3_Ent5", "role": "Treatment_Duration", "text": "2 months", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11999915_3_Ent0", "text": "The female patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11999915_3_Ent1", "text": "female", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11999915_3_Ent8", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11999915_3_Ent3", "text": "clozapine in a daily dose of 400 mg", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "11999915_3_Ent7", "text": "daily", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11999915_3_Ent6", "text": "400 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11999915_3_Ent2", "text": "agranulocytosis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11999915_3_Ent4", "text": "after 2 months", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "11999915_3_Ent5", "text": "2 months", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "12013364_1", "wnd_id": "12013364_1_1", "text": "A 53 - year - old man developed NMS without rigidity while taking olanzapine .", "tokens": ["A", "53", "-", "year", "-", "old", "man", "developed", "NMS", "without", "rigidity", "while", "taking", "olanzapine", "."], "event_mentions": [{"id": "12013364_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12013364_1_Ent0", "role": "Subject", "text": "A 53 - year - old man", "start": 0, "end": 7}, {"entity_id": "12013364_1_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 1, "end": 6}, {"entity_id": "12013364_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12013364_1_Ent3", "role": "Effect", "text": "NMS without rigidity", "start": 8, "end": 11}, {"entity_id": "12013364_1_Ent4", "role": "Treatment", "text": "olanzapine", "start": 13, "end": 14}, {"entity_id": "12013364_1_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12013364_1_Ent0", "text": "A 53 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12013364_1_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12013364_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12013364_1_Ent3", "text": "NMS without rigidity", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12013364_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12013364_1_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12022905_2", "wnd_id": "12022905_2_1", "text": "CONCLUSIONS : Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners , as with many other antipsychotics , should be aware of .", "tokens": ["CONCLUSIONS", ":", "Priapism", "is", "an", "uncommon", "but", "potentially", "serious", "adverse", "effect", "of", "zuclopenthixol", "that", "practitioners", ",", "as", "with", "many", "other", "antipsychotics", ",", "should", "be", "aware", "of", "."], "event_mentions": [{"id": "12022905_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "serious adverse effect", "start": 8, "end": 11}, "arguments": [{"entity_id": "12022905_2_Ent0", "role": "Effect", "text": "Priapism", "start": 2, "end": 3}, {"entity_id": "12022905_2_Ent1", "role": "Treatment", "text": "zuclopenthixol", "start": 12, "end": 13}, {"entity_id": "12022905_2_Ent2", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12022905_2_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12022905_2_Ent1", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12022905_2_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12022905_3", "wnd_id": "12022905_3_1", "text": "DISCUSSION : The occurrence of priapism in our patient was related to zuclopenthixol .", "tokens": ["DISCUSSION", ":", "The", "occurrence", "of", "priapism", "in", "our", "patient", "was", "related", "to", "zuclopenthixol", "."], "event_mentions": [{"id": "12022905_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "12022905_3_Ent1", "role": "Effect", "text": "priapism", "start": 5, "end": 6}, {"entity_id": "12022905_3_Ent0", "role": "Subject", "text": "our patient", "start": 7, "end": 9}, {"entity_id": "12022905_3_Ent2", "role": "Treatment", "text": "zuclopenthixol", "start": 12, "end": 13}, {"entity_id": "12022905_3_Ent3", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12022905_3_Ent1", "text": "priapism", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12022905_3_Ent0", "text": "our patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12022905_3_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12022905_3_Ent3", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12053072_2", "wnd_id": "12053072_2_1", "text": "We describe a patient who developed HUS after treatment with mitomycin C ( total dose 144 mg / m2 ) due to a carcinoma of the ascending colon .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "HUS", "after", "treatment", "with", "mitomycin", "C", "(", "total", "dose", "144", "mg", "/", "m2", ")", "due", "to", "a", "carcinoma", "of", "the", "ascending", "colon", "."], "event_mentions": [{"id": "12053072_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "12053072_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12053072_2_Ent1", "role": "Effect", "text": "HUS", "start": 6, "end": 7}, {"entity_id": "12053072_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 10, "end": 12}, {"entity_id": "12053072_2_Ent2", "role": "Treatment", "text": "mitomycin C ( total dose 144 mg / m2 )", "start": 10, "end": 20}, {"entity_id": "12053072_2_Ent4", "role": "Treatment_Dosage", "text": "144 mg / m2", "start": 15, "end": 19}, {"entity_id": "12053072_2_Ent5", "role": "Treatment_Disorder", "text": "carcinoma of the ascending colon", "start": 23, "end": 28}]}], "entity_mentions": [{"id": "12053072_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12053072_2_Ent1", "text": "HUS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12053072_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12053072_2_Ent2", "text": "mitomycin C ( total dose 144 mg / m2 )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "12053072_2_Ent4", "text": "144 mg / m2", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12053072_2_Ent5", "text": "carcinoma of the ascending colon", "entity_type": "Entity", "start": 23, "end": 28}], "lang": "en"}
{"doc_id": "12066972_1", "wnd_id": "12066972_1_1", "text": "Levofloxacin - induced toxic epidermal necrolysis in an elderly patient .", "tokens": ["Levofloxacin", "-", "induced", "toxic", "epidermal", "necrolysis", "in", "an", "elderly", "patient", "."], "event_mentions": [{"id": "12066972_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12066972_1_Ent3", "role": "Treatment", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "12066972_1_Ent4", "role": "Treatment_Drug", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "12066972_1_Ent2", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}, {"entity_id": "12066972_1_Ent0", "role": "Subject", "text": "an elderly patient .", "start": 7, "end": 11}, {"entity_id": "12066972_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12066972_1_Ent3", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12066972_1_Ent4", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12066972_1_Ent2", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12066972_1_Ent0", "text": "an elderly patient .", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "12066972_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12086549_2", "wnd_id": "12086549_2_1", "text": "OBJECTIVE : To report a case of cutaneous and hematologic toxicity in a patient treated with IL - 2 .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "cutaneous", "and", "hematologic", "toxicity", "in", "a", "patient", "treated", "with", "IL", "-", "2", "."], "event_mentions": [{"id": "12086549_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 5, "end": 6}, "arguments": [{"entity_id": "12086549_2_Ent1", "role": "Effect", "text": "cutaneous and hematologic toxicity", "start": 7, "end": 11}, {"entity_id": "12086549_2_Ent0", "role": "Subject", "text": "a patient", "start": 12, "end": 14}, {"entity_id": "12086549_2_Ent2", "role": "Treatment", "text": "IL - 2", "start": 16, "end": 19}, {"entity_id": "12086549_2_Ent3", "role": "Treatment_Drug", "text": "IL - 2", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "12086549_2_Ent1", "text": "cutaneous and hematologic toxicity", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "12086549_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12086549_2_Ent2", "text": "IL - 2", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "12086549_2_Ent3", "text": "IL - 2", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "12095907_2", "wnd_id": "12095907_2_1", "text": "Valproate - induced hyperammonemia as a cause of altered mental status .", "tokens": ["Valproate", "-", "induced", "hyperammonemia", "as", "a", "cause", "of", "altered", "mental", "status", "."], "event_mentions": [{"id": "12095907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12095907_2_Ent2", "role": "Treatment", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent3", "role": "Treatment_Drug", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent1", "role": "Effect", "text": "hyperammonemia", "start": 3, "end": 4}, {"entity_id": "12095907_2_Ent0", "role": "Effect", "text": "altered mental status", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "12095907_2_Ent2", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent3", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent1", "text": "hyperammonemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_2_Ent0", "text": "altered mental status", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "12121061_2", "wnd_id": "12121061_2_1", "text": "A 50 - year - old diabetic and hypertensive male patient is reported who had ticlopidine - induced marrow aplasia partially responsive to colony - stimulating factors and corticosteroids , but experienced complete recovery with cyclosporine .", "tokens": ["A", "50", "-", "year", "-", "old", "diabetic", "and", "hypertensive", "male", "patient", "is", "reported", "who", "had", "ticlopidine", "-", "induced", "marrow", "aplasia", "partially", "responsive", "to", "colony", "-", "stimulating", "factors", "and", "corticosteroids", ",", "but", "experienced", "complete", "recovery", "with", "cyclosporine", "."], "event_mentions": [{"id": "12121061_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "12121061_2_Ent2", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent0", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent1", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent5", "role": "Treatment", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent4", "role": "Effect", "text": "marrow aplasia", "start": 18, "end": 20}]}, {"id": "12121061_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "with", "start": 34, "end": 35}, "arguments": [{"entity_id": "12121061_2_Ent9", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent7", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent8", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent10", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent13", "role": "Treatment_Disorder", "text": "ticlopidine - induced marrow aplasia", "start": 15, "end": 20}, {"entity_id": "12121061_2_Ent11", "role": "Effect", "text": "experienced complete recovery", "start": 31, "end": 34}, {"entity_id": "12121061_2_Ent12", "role": "Treatment", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "12121061_2_Ent14", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "12121061_2_Ent2", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent9", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent0", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent7", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent1", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent8", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent3", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent10", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent5", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent13", "text": "ticlopidine - induced marrow aplasia", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "12121061_2_Ent4", "text": "marrow aplasia", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "12121061_2_Ent11", "text": "experienced complete recovery", "entity_type": "Entity", "start": 31, "end": 34}, {"id": "12121061_2_Ent12", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "12121061_2_Ent14", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "12126225_2", "wnd_id": "12126225_2_1", "text": "A 75 - year - old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone .", "tokens": ["A", "75", "-", "year", "-", "old", "man", "developed", "bilateral", "lower", "leg", "edema", "6", "months", "after", "switching", "from", "troglitazone", "to", "pioglitazone", "."], "event_mentions": [{"id": "12126225_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12126225_2_Ent0", "role": "Subject", "text": "A 75 - year - old man", "start": 0, "end": 7}, {"entity_id": "12126225_2_Ent1", "role": "Subject_Age", "text": "75 - year - old", "start": 1, "end": 6}, {"entity_id": "12126225_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12126225_2_Ent3", "role": "Effect", "text": "bilateral lower leg edema", "start": 8, "end": 12}, {"entity_id": "12126225_2_Ent6", "role": "Treatment_Drug", "text": "6 months", "start": 12, "end": 14}, {"entity_id": "12126225_2_Ent4", "role": "Treatment", "text": "6 months after switching from troglitazone to pioglitazone", "start": 12, "end": 20}, {"entity_id": "12126225_2_Ent7", "role": "Treatment_Drug", "text": "troglitazone", "start": 17, "end": 18}, {"entity_id": "12126225_2_Ent5", "role": "Treatment_Drug", "text": "pioglitazone", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "12126225_2_Ent0", "text": "A 75 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12126225_2_Ent1", "text": "75 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12126225_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12126225_2_Ent3", "text": "bilateral lower leg edema", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "12126225_2_Ent6", "text": "6 months", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12126225_2_Ent4", "text": "6 months after switching from troglitazone to pioglitazone", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "12126225_2_Ent7", "text": "troglitazone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12126225_2_Ent5", "text": "pioglitazone", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "12126225_3", "wnd_id": "12126225_3_1", "text": "A 77 - year - old man developed ankle , hand , and facial swelling 2 weeks after starting rosiglitazone .", "tokens": ["A", "77", "-", "year", "-", "old", "man", "developed", "ankle", ",", "hand", ",", "and", "facial", "swelling", "2", "weeks", "after", "starting", "rosiglitazone", "."], "event_mentions": [{"id": "12126225_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12126225_3_Ent0", "role": "Subject", "text": "A 77 - year - old man", "start": 0, "end": 7}, {"entity_id": "12126225_3_Ent1", "role": "Subject_Age", "text": "77 - year - old", "start": 1, "end": 6}, {"entity_id": "12126225_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12126225_3_Ent3", "role": "Effect", "text": "ankle , hand , and facial swelling", "start": 8, "end": 15}, {"entity_id": "12126225_3_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 15, "end": 17}, {"entity_id": "12126225_3_Ent4", "role": "Treatment", "text": "2 weeks after starting rosiglitazone", "start": 15, "end": 20}, {"entity_id": "12126225_3_Ent6", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "12126225_3_Ent0", "text": "A 77 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12126225_3_Ent1", "text": "77 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12126225_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12126225_3_Ent3", "text": "ankle , hand , and facial swelling", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "12126225_3_Ent5", "text": "2 weeks", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12126225_3_Ent4", "text": "2 weeks after starting rosiglitazone", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "12126225_3_Ent6", "text": "rosiglitazone", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "12135176_3", "wnd_id": "12135176_3_1", "text": "We describe two cases of PSVT that changed to non - sustained polymorphic ventricular tachycardia after administration of verapamil .", "tokens": ["We", "describe", "two", "cases", "of", "PSVT", "that", "changed", "to", "non", "-", "sustained", "polymorphic", "ventricular", "tachycardia", "after", "administration", "of", "verapamil", "."], "event_mentions": [{"id": "12135176_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "changed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12135176_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12135176_3_Ent0", "role": "Subject", "text": "two cases of PSVT", "start": 2, "end": 6}, {"entity_id": "12135176_3_Ent5", "role": "Treatment_Disorder", "text": "PSVT", "start": 5, "end": 6}, {"entity_id": "12135176_3_Ent2", "role": "Effect", "text": "non - sustained polymorphic ventricular tachycardia", "start": 9, "end": 15}, {"entity_id": "12135176_3_Ent3", "role": "Treatment", "text": "administration of verapamil .", "start": 16, "end": 20}, {"entity_id": "12135176_3_Ent4", "role": "Treatment_Drug", "text": "verapamil", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12135176_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12135176_3_Ent0", "text": "two cases of PSVT", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "12135176_3_Ent5", "text": "PSVT", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12135176_3_Ent2", "text": "non - sustained polymorphic ventricular tachycardia", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "12135176_3_Ent3", "text": "administration of verapamil .", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "12135176_3_Ent4", "text": "verapamil", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12149193_2", "wnd_id": "12149193_2_1", "text": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis ( DVT ) .", "tokens": ["Ten", "percent", "of", "newly", "diagnosed", "myeloma", "patients", "treated", "with", "any", "type", "of", "chemotherapy", "develop", "deep", "venous", "thrombosis", "(", "DVT", ")", "."], "event_mentions": [{"id": "12149193_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 13, "end": 14}, "arguments": [{"entity_id": "12149193_2_Ent3", "role": "Treatment_Disorder", "text": "myeloma", "start": 5, "end": 6}, {"entity_id": "12149193_2_Ent0", "role": "Subject", "text": "myeloma patients", "start": 5, "end": 7}, {"entity_id": "12149193_2_Ent2", "role": "Treatment", "text": "any type of chemotherapy", "start": 9, "end": 13}, {"entity_id": "12149193_2_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "12149193_2_Ent1", "role": "Effect", "text": "deep venous thrombosis ( DVT )", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "12149193_2_Ent3", "text": "myeloma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_2_Ent0", "text": "myeloma patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12149193_2_Ent2", "text": "any type of chemotherapy", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "12149193_2_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12149193_2_Ent1", "text": "deep venous thrombosis ( DVT )", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "12149193_4", "wnd_id": "12149193_4_1", "text": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one .", "tokens": ["We", "analyzed", "the", "incidence", "of", "DVT", "in", "232", "MM", "patients", "who", "received", "a", "combination", "of", "chemotherapy", "and", "thalidomide", "on", "2", "protocols", "that", "differed", "only", "by", "the", "inclusion", "of", "doxorubicin", "in", "one", "."], "event_mentions": [{"id": "12149193_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incidence", "start": 3, "end": 4}, "arguments": [{"entity_id": "12149193_4_Ent2", "role": "Effect", "text": "DVT", "start": 5, "end": 6}, {"entity_id": "12149193_4_Ent1", "role": "Subject_Population", "text": "232", "start": 7, "end": 8}, {"entity_id": "12149193_4_Ent0", "role": "Subject", "text": "232 MM patients", "start": 7, "end": 10}, {"entity_id": "12149193_4_Ent5", "role": "Treatment_Disorder", "text": "MM", "start": 8, "end": 9}, {"entity_id": "12149193_4_Ent3", "role": "Treatment", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent6", "role": "Treatment_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent8", "role": "Combination_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent4", "role": "Treatment", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_4_Ent7", "role": "Treatment_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_4_Ent9", "role": "Combination_Drug", "text": "thalidomide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "12149193_4_Ent2", "text": "DVT", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_4_Ent1", "text": "232", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12149193_4_Ent0", "text": "232 MM patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12149193_4_Ent5", "text": "MM", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12149193_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_4_Ent7", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_4_Ent9", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "12149193_8", "wnd_id": "12149193_8_1", "text": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin ( P = .02 ) was observed ; this association was confirmed on multivariate analysis .", "tokens": ["A", "statistical", "association", "between", "the", "incidence", "of", "DVT", "and", "combination", "chemotherapy", "including", "doxorubicin", "(", "P", "=", ".02", ")", "was", "observed", ";", "this", "association", "was", "confirmed", "on", "multivariate", "analysis", "."], "event_mentions": [{"id": "12149193_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "12149193_8_Ent0", "role": "Effect", "text": "DVT", "start": 7, "end": 8}, {"entity_id": "12149193_8_Ent1", "role": "Treatment", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "start": 9, "end": 18}, {"entity_id": "12149193_8_Ent2", "role": "Treatment_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent4", "role": "Combination_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 12, "end": 13}, {"entity_id": "12149193_8_Ent5", "role": "Combination_Drug", "text": "doxorubicin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12149193_8_Ent0", "text": "DVT", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12149193_8_Ent1", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "12149193_8_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12149193_8_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12150593_1", "wnd_id": "12150593_1_1", "text": "Neonatal mydriasis : intravenous lidocaine adverse reaction .", "tokens": ["Neonatal", "mydriasis", ":", "intravenous", "lidocaine", "adverse", "reaction", "."], "event_mentions": [{"id": "12150593_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 5, "end": 7}, "arguments": [{"entity_id": "12150593_1_Ent0", "role": "Subject", "text": "Neonatal", "start": 0, "end": 1}, {"entity_id": "12150593_1_Ent1", "role": "Subject_Age", "text": "Neonatal", "start": 0, "end": 1}, {"entity_id": "12150593_1_Ent2", "role": "Effect", "text": "Neonatal mydriasis", "start": 0, "end": 2}, {"entity_id": "12150593_1_Ent3", "role": "Treatment", "text": "lidocaine", "start": 4, "end": 5}, {"entity_id": "12150593_1_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12150593_1_Ent0", "text": "Neonatal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12150593_1_Ent1", "text": "Neonatal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12150593_1_Ent2", "text": "Neonatal mydriasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12150593_1_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12150593_1_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12150593_3", "wnd_id": "12150593_3_1", "text": "We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine .", "tokens": ["We", "suggest", "adding", "this", "side", "effect", "to", "the", "list", "of", "untoward", "effects", "of", "lidocaine", "and", "to", "the", "differential", "diagnosis", "of", "fixed", "dilated", "pupils", "in", "neonates", "treated", "with", "lidocaine", "."], "event_mentions": [{"id": "12150593_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 25, "end": 26}, "arguments": [{"entity_id": "12150593_3_Ent2", "role": "Effect", "text": "side effect", "start": 4, "end": 6}, {"entity_id": "12150593_3_Ent0", "role": "Subject", "text": "neonates", "start": 24, "end": 25}, {"entity_id": "12150593_3_Ent1", "role": "Subject_Age", "text": "neonates", "start": 24, "end": 25}, {"entity_id": "12150593_3_Ent3", "role": "Treatment", "text": "lidocaine", "start": 27, "end": 28}, {"entity_id": "12150593_3_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "12150593_3_Ent2", "text": "side effect", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "12150593_3_Ent0", "text": "neonates", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12150593_3_Ent1", "text": "neonates", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12150593_3_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12150593_3_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "12163813_2", "wnd_id": "12163813_2_1", "text": "OBJECTIVE : To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low - dose vasopressin in a patient with catecholamine - resistant septic shock .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "severe", "skin", "necrosis", "resulting", "from", "peripheral", "intravenous", "administration", "of", "low", "-", "dose", "vasopressin", "in", "a", "patient", "with", "catecholamine", "-", "resistant", "septic", "shock", "."], "event_mentions": [{"id": "12163813_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 10, "end": 11}, "arguments": [{"entity_id": "12163813_2_Ent1", "role": "Effect", "text": "skin necrosis", "start": 8, "end": 10}, {"entity_id": "12163813_2_Ent3", "role": "Treatment_Route", "text": "peripheral intravenous administration", "start": 12, "end": 15}, {"entity_id": "12163813_2_Ent2", "role": "Treatment", "text": "peripheral intravenous administration of low - dose vasopressin", "start": 12, "end": 20}, {"entity_id": "12163813_2_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 16, "end": 19}, {"entity_id": "12163813_2_Ent5", "role": "Treatment_Drug", "text": "vasopressin", "start": 19, "end": 20}, {"entity_id": "12163813_2_Ent0", "role": "Subject", "text": "a patient with catecholamine - resistant septic shock", "start": 21, "end": 29}, {"entity_id": "12163813_2_Ent6", "role": "Treatment_Disorder", "text": "catecholamine - resistant septic shock", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "12163813_2_Ent1", "text": "skin necrosis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12163813_2_Ent3", "text": "peripheral intravenous administration", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12163813_2_Ent2", "text": "peripheral intravenous administration of low - dose vasopressin", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "12163813_2_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "12163813_2_Ent5", "text": "vasopressin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12163813_2_Ent0", "text": "a patient with catecholamine - resistant septic shock", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "12163813_2_Ent6", "text": "catecholamine - resistant septic shock", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "12166705_2", "wnd_id": "12166705_2_1", "text": "Mitomycin - C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome .", "tokens": ["Mitomycin", "-", "C", "is", "used", "widely", "in", "the", "treatment", "of", "malignancies", "and", "is", "associated", "with", "serious", "dose", "related", "adverse", "effects", "including", "the", "occurrence", "of", "hemolytic", "uremic", "syndrome", "."], "event_mentions": [{"id": "12166705_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "12166705_2_Ent1", "role": "Treatment", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_2_Ent3", "role": "Treatment_Drug", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_2_Ent2", "role": "Treatment_Disorder", "text": "malignancies", "start": 10, "end": 11}, {"entity_id": "12166705_2_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "12166705_2_Ent1", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_2_Ent3", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_2_Ent2", "text": "malignancies", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12166705_2_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "12181031_1", "wnd_id": "12181031_1_1", "text": "Although vasculitis has been reported in the course of hairy cell leukaemia , it has only rarely been reported as the consequence of cladribine treatment .", "tokens": ["Although", "vasculitis", "has", "been", "reported", "in", "the", "course", "of", "hairy", "cell", "leukaemia", ",", "it", "has", "only", "rarely", "been", "reported", "as", "the", "consequence", "of", "cladribine", "treatment", "."], "event_mentions": [{"id": "12181031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consequence", "start": 21, "end": 22}, "arguments": [{"entity_id": "12181031_1_Ent0", "role": "Effect", "text": "vasculitis", "start": 1, "end": 2}, {"entity_id": "12181031_1_Ent2", "role": "Treatment_Disorder", "text": "hairy cell leukaemia", "start": 9, "end": 12}, {"entity_id": "12181031_1_Ent1", "role": "Treatment", "text": "cladribine", "start": 23, "end": 24}, {"entity_id": "12181031_1_Ent3", "role": "Treatment_Drug", "text": "cladribine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12181031_1_Ent0", "text": "vasculitis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12181031_1_Ent2", "text": "hairy cell leukaemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12181031_1_Ent1", "text": "cladribine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12181031_1_Ent3", "text": "cladribine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12196060_2", "wnd_id": "12196060_2_1", "text": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction .", "tokens": ["To", "report", "a", "young", "man", "on", "phenytoin", "who", "developed", "acute", "neurologic", "symptoms", "after", "isradipine", "was", "introduced", "to", "his", "treatment", "regimen", "and", "discuss", "the", "possible", "causes", "of", "this", "drug", "interaction", "."], "event_mentions": [{"id": "12196060_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12196060_2_Ent0", "role": "Subject", "text": "a young man", "start": 2, "end": 5}, {"entity_id": "12196060_2_Ent1", "role": "Subject_Age", "text": "young", "start": 3, "end": 4}, {"entity_id": "12196060_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 4, "end": 5}, {"entity_id": "12196060_2_Ent4", "role": "Treatment", "text": "phenytoin", "start": 6, "end": 7}, {"entity_id": "12196060_2_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 6, "end": 7}, {"entity_id": "12196060_2_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 6, "end": 7}, {"entity_id": "12196060_2_Ent3", "role": "Effect", "text": "acute neurologic symptoms", "start": 9, "end": 12}, {"entity_id": "12196060_2_Ent5", "role": "Treatment", "text": "isradipine", "start": 13, "end": 14}, {"entity_id": "12196060_2_Ent6", "role": "Treatment_Drug", "text": "isradipine", "start": 13, "end": 14}, {"entity_id": "12196060_2_Ent9", "role": "Combination_Drug", "text": "isradipine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12196060_2_Ent0", "text": "a young man", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12196060_2_Ent1", "text": "young", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12196060_2_Ent2", "text": "man", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12196060_2_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12196060_2_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12196060_2_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12196060_2_Ent3", "text": "acute neurologic symptoms", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12196060_2_Ent5", "text": "isradipine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12196060_2_Ent6", "text": "isradipine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12196060_2_Ent9", "text": "isradipine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12196666_1", "wnd_id": "12196666_1_1", "text": "The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid - induced adverse outcome .", "tokens": ["The", "authors", "describe", "three", "families", "in", "whom", "the", "occurrence", "of", "FVS", "in", "all", "the", "siblings", "strongly", "suggests", "hereditary", "susceptibility", "to", "valproic", "acid", "-", "induced", "adverse", "outcome", "."], "event_mentions": [{"id": "12196666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "susceptibility", "start": 18, "end": 19}, "arguments": [{"entity_id": "12196666_1_Ent2", "role": "Subject_Population", "text": "three", "start": 3, "end": 4}, {"entity_id": "12196666_1_Ent0", "role": "Subject", "text": "three families", "start": 3, "end": 5}, {"entity_id": "12196666_1_Ent3", "role": "Effect", "text": "FVS", "start": 10, "end": 11}, {"entity_id": "12196666_1_Ent1", "role": "Subject", "text": "all the siblings", "start": 12, "end": 15}, {"entity_id": "12196666_1_Ent5", "role": "Treatment_Drug", "text": "valproic acid", "start": 20, "end": 22}, {"entity_id": "12196666_1_Ent4", "role": "Treatment", "text": "valproic acid - induced", "start": 20, "end": 24}]}], "entity_mentions": [{"id": "12196666_1_Ent2", "text": "three", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12196666_1_Ent0", "text": "three families", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12196666_1_Ent3", "text": "FVS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12196666_1_Ent1", "text": "all the siblings", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12196666_1_Ent5", "text": "valproic acid", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "12196666_1_Ent4", "text": "valproic acid - induced", "entity_type": "Entity", "start": 20, "end": 24}], "lang": "en"}
{"doc_id": "12221670_1", "wnd_id": "12221670_1_1", "text": "The first case concerns a 70 - year - old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily .", "tokens": ["The", "first", "case", "concerns", "a", "70", "-", "year", "-", "old", "man", "who", "developed", "severe", "aplastic", "anemia", "7", "weeks", "after", "treatment", "with", "500", "mg", "of", "ticlopidine", "daily", "."], "event_mentions": [{"id": "12221670_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "12221670_1_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 5, "end": 10}, {"entity_id": "12221670_1_Ent0", "role": "Subject", "text": "70 - year - old man", "start": 5, "end": 11}, {"entity_id": "12221670_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "12221670_1_Ent3", "role": "Effect", "text": "severe aplastic anemia", "start": 13, "end": 16}, {"entity_id": "12221670_1_Ent5", "role": "Treatment_Time_elapsed", "text": "7 weeks", "start": 16, "end": 18}, {"entity_id": "12221670_1_Ent4", "role": "Treatment", "text": "7 weeks after treatment with 500 mg of ticlopidine daily", "start": 16, "end": 26}, {"entity_id": "12221670_1_Ent6", "role": "Treatment_Dosage", "text": "500 mg", "start": 21, "end": 23}, {"entity_id": "12221670_1_Ent7", "role": "Treatment_Drug", "text": "ticlopidine", "start": 24, "end": 25}, {"entity_id": "12221670_1_Ent8", "role": "Treatment_Freq", "text": "daily", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "12221670_1_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12221670_1_Ent0", "text": "70 - year - old man", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12221670_1_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12221670_1_Ent3", "text": "severe aplastic anemia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12221670_1_Ent5", "text": "7 weeks", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "12221670_1_Ent4", "text": "7 weeks after treatment with 500 mg of ticlopidine daily", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "12221670_1_Ent6", "text": "500 mg", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "12221670_1_Ent7", "text": "ticlopidine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12221670_1_Ent8", "text": "daily", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "12221670_2", "wnd_id": "12221670_2_1", "text": "The second was an 82 - year - old man receiving ticlopidine for 2 years when , during a febrile episode , he was found neutropenic with marrow aplasia .", "tokens": ["The", "second", "was", "an", "82", "-", "year", "-", "old", "man", "receiving", "ticlopidine", "for", "2", "years", "when", ",", "during", "a", "febrile", "episode", ",", "he", "was", "found", "neutropenic", "with", "marrow", "aplasia", "."], "event_mentions": [{"id": "12221670_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "found", "start": 24, "end": 25}, "arguments": [{"entity_id": "12221670_2_Ent1", "role": "Subject_Age", "text": "82 - year - old", "start": 4, "end": 9}, {"entity_id": "12221670_2_Ent0", "role": "Subject", "text": "82 - year - old man", "start": 4, "end": 10}, {"entity_id": "12221670_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "12221670_2_Ent4", "role": "Treatment", "text": "receiving ticlopidine for 2 years", "start": 10, "end": 15}, {"entity_id": "12221670_2_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 11, "end": 12}, {"entity_id": "12221670_2_Ent5", "role": "Treatment_Duration", "text": "2 years", "start": 13, "end": 15}, {"entity_id": "12221670_2_Ent3", "role": "Effect", "text": "neutropenic with marrow aplasia .", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "12221670_2_Ent1", "text": "82 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "12221670_2_Ent0", "text": "82 - year - old man", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "12221670_2_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12221670_2_Ent4", "text": "receiving ticlopidine for 2 years", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "12221670_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12221670_2_Ent5", "text": "2 years", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12221670_2_Ent3", "text": "neutropenic with marrow aplasia .", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "122410_1", "wnd_id": "122410_1_1", "text": "A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal .", "tokens": ["A", "patient", "who", "had", "been", "treated", "with", "large", "doses", "of", "thyroid", "hormone", "for", "several", "years", "developed", "features", "of", "secondary", "hypothyroidism", "after", "thyroid", "hormone", "withdrawal", "."], "event_mentions": [{"id": "122410_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "122410_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "122410_1_Ent1", "role": "Effect", "text": "secondary hypothyroidism", "start": 18, "end": 20}, {"entity_id": "122410_1_Ent3", "role": "Treatment_Drug", "text": "thyroid hormone", "start": 21, "end": 23}, {"entity_id": "122410_1_Ent2", "role": "Treatment", "text": "thyroid hormone withdrawal", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "122410_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "122410_1_Ent1", "text": "secondary hypothyroidism", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "122410_1_Ent3", "text": "thyroid hormone", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "122410_1_Ent2", "text": "thyroid hormone withdrawal", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "12243603_8", "wnd_id": "12243603_8_1", "text": "Rhabdomyolysis resulting from the drug interaction between diltiazem and other HMG - CoA reductase inhibitors has been described in the literature .", "tokens": ["Rhabdomyolysis", "resulting", "from", "the", "drug", "interaction", "between", "diltiazem", "and", "other", "HMG", "-", "CoA", "reductase", "inhibitors", "has", "been", "described", "in", "the", "literature", "."], "event_mentions": [{"id": "12243603_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 1, "end": 2}, "arguments": [{"entity_id": "12243603_8_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "12243603_8_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 7, "end": 8}, {"entity_id": "12243603_8_Ent4", "role": "Combination_Drug", "text": "diltiazem", "start": 7, "end": 8}, {"entity_id": "12243603_8_Ent1", "role": "Treatment", "text": "diltiazem and other HMG - CoA reductase inhibitors", "start": 7, "end": 15}, {"entity_id": "12243603_8_Ent3", "role": "Treatment_Drug", "text": "HMG - CoA reductase inhibitors", "start": 10, "end": 15}, {"entity_id": "12243603_8_Ent5", "role": "Combination_Drug", "text": "HMG - CoA reductase inhibitors", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "12243603_8_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_8_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12243603_8_Ent4", "text": "diltiazem", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12243603_8_Ent1", "text": "diltiazem and other HMG - CoA reductase inhibitors", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "12243603_8_Ent3", "text": "HMG - CoA reductase inhibitors", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "12243603_8_Ent5", "text": "HMG - CoA reductase inhibitors", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "12324937_1", "wnd_id": "12324937_1_1", "text": "BACKGROUND : Gemcitabine has mild renal toxicity , but cases of gemcitabine - associated hemolytic - uremic syndrome ( HUS ) have been reported .", "tokens": ["BACKGROUND", ":", "Gemcitabine", "has", "mild", "renal", "toxicity", ",", "but", "cases", "of", "gemcitabine", "-", "associated", "hemolytic", "-", "uremic", "syndrome", "(", "HUS", ")", "have", "been", "reported", "."], "event_mentions": [{"id": "12324937_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "12324937_1_Ent2", "role": "Effect", "text": "renal toxicity", "start": 5, "end": 7}, {"entity_id": "12324937_1_Ent0", "role": "Subject", "text": "cases", "start": 9, "end": 10}, {"entity_id": "12324937_1_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 11, "end": 12}, {"entity_id": "12324937_1_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 11, "end": 12}, {"entity_id": "12324937_1_Ent1", "role": "Effect", "text": "hemolytic - uremic syndrome ( HUS )", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "12324937_1_Ent2", "text": "renal toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12324937_1_Ent0", "text": "cases", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12324937_1_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12324937_1_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12324937_1_Ent1", "text": "hemolytic - uremic syndrome ( HUS )", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "12324937_2", "wnd_id": "12324937_2_1", "text": "CONCLUSION : There are only a few confirmed cases of gemcitabine - associated HUS despite the widespread use of the drug .", "tokens": ["CONCLUSION", ":", "There", "are", "only", "a", "few", "confirmed", "cases", "of", "gemcitabine", "-", "associated", "HUS", "despite", "the", "widespread", "use", "of", "the", "drug", "."], "event_mentions": [{"id": "12324937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "12324937_2_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "12324937_2_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "12324937_2_Ent0", "role": "Effect", "text": "HUS", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12324937_2_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12324937_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12324937_2_Ent0", "text": "HUS", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12390172_2", "wnd_id": "12390172_2_1", "text": "PURPOSE : To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin .", "tokens": ["PURPOSE", ":", "To", "describe", "the", "clinical", "and", "electrophysiological", "findings", "in", "a", "young", "boy", "with", "decreased", "vision", "possibly", "due", "to", "retinal", "damage", "by", "rifabutin", "."], "event_mentions": [{"id": "12390172_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 17, "end": 18}, "arguments": [{"entity_id": "12390172_2_Ent0", "role": "Subject", "text": "a young boy", "start": 10, "end": 13}, {"entity_id": "12390172_2_Ent1", "role": "Subject_Age", "text": "young", "start": 11, "end": 12}, {"entity_id": "12390172_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 12, "end": 13}, {"entity_id": "12390172_2_Ent3", "role": "Effect", "text": "decreased vision", "start": 14, "end": 16}, {"entity_id": "12390172_2_Ent4", "role": "Effect", "text": "retinal damage", "start": 19, "end": 21}, {"entity_id": "12390172_2_Ent5", "role": "Treatment", "text": "rifabutin", "start": 22, "end": 23}, {"entity_id": "12390172_2_Ent6", "role": "Treatment_Drug", "text": "rifabutin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12390172_2_Ent0", "text": "a young boy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "12390172_2_Ent1", "text": "young", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12390172_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12390172_2_Ent3", "text": "decreased vision", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "12390172_2_Ent4", "text": "retinal damage", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "12390172_2_Ent5", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12390172_2_Ent6", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12390172_3", "wnd_id": "12390172_3_1", "text": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin .", "tokens": ["Retinal", "dysfunction", "and", "anterior", "segment", "deposits", "in", "a", "patient", "treated", "with", "rifabutin", "."], "event_mentions": [{"id": "12390172_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "12390172_3_Ent1", "role": "Effect", "text": "Retinal dysfunction and anterior segment deposits", "start": 0, "end": 6}, {"entity_id": "12390172_3_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "12390172_3_Ent2", "role": "Treatment", "text": "rifabutin", "start": 11, "end": 12}, {"entity_id": "12390172_3_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12390172_3_Ent1", "text": "Retinal dysfunction and anterior segment deposits", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "12390172_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12390172_3_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12390172_3_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12390172_4", "wnd_id": "12390172_4_1", "text": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin .", "tokens": ["We", "suggest", "that", "objective", "evaluation", "of", "retinal", "function", "with", "electrophysiological", "methods", "should", "be", "performed", "in", "patients", "with", "visual", "disturbance", "during", "treatment", "with", "rifabutin", "."], "event_mentions": [{"id": "12390172_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 19, "end": 20}, "arguments": [{"entity_id": "12390172_4_Ent0", "role": "Effect", "text": "visual disturbance", "start": 17, "end": 19}, {"entity_id": "12390172_4_Ent1", "role": "Treatment", "text": "rifabutin", "start": 22, "end": 23}, {"entity_id": "12390172_4_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12390172_4_Ent0", "text": "visual disturbance", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "12390172_4_Ent1", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12390172_4_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12399645_2", "wnd_id": "12399645_2_1", "text": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal , suggesting that bredinin might adversely induce SIADH .", "tokens": ["ADH", "hypersecretion", "in", "relation", "to", "plasma", "osmolality", "was", "reversed", "by", "mizoribin", "withdrawal", ",", "suggesting", "that", "bredinin", "might", "adversely", "induce", "SIADH", "."], "event_mentions": [{"id": "12399645_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12399645_2_Ent3", "role": "Treatment_Disorder", "text": "ADH hypersecretion", "start": 0, "end": 2}, {"entity_id": "12399645_2_Ent0", "role": "Subject", "text": "plasma osmolality", "start": 5, "end": 7}, {"entity_id": "12399645_2_Ent1", "role": "Subject_Disorder", "text": "plasma osmolality", "start": 5, "end": 7}, {"entity_id": "12399645_2_Ent4", "role": "Treatment_Drug", "text": "mizoribin", "start": 10, "end": 11}, {"entity_id": "12399645_2_Ent2", "role": "Treatment", "text": "mizoribin withdrawal", "start": 10, "end": 12}]}, {"id": "12399645_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 18, "end": 19}, "arguments": [{"entity_id": "12399645_2_Ent6", "role": "Treatment", "text": "bredinin", "start": 15, "end": 16}, {"entity_id": "12399645_2_Ent7", "role": "Treatment_Drug", "text": "bredinin", "start": 15, "end": 16}, {"entity_id": "12399645_2_Ent5", "role": "Effect", "text": "adversely induce SIADH", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "12399645_2_Ent3", "text": "ADH hypersecretion", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12399645_2_Ent0", "text": "plasma osmolality", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12399645_2_Ent1", "text": "plasma osmolality", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12399645_2_Ent4", "text": "mizoribin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12399645_2_Ent2", "text": "mizoribin withdrawal", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12399645_2_Ent6", "text": "bredinin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12399645_2_Ent7", "text": "bredinin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12399645_2_Ent5", "text": "adversely induce SIADH", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "12399645_3", "wnd_id": "12399645_3_1", "text": "In summary , we report herein the first case of SIADH believed to be an adverse effect of mizoribin , which may therefore needed to be added to the list of drugs which can induce SIADH .", "tokens": ["In", "summary", ",", "we", "report", "herein", "the", "first", "case", "of", "SIADH", "believed", "to", "be", "an", "adverse", "effect", "of", "mizoribin", ",", "which", "may", "therefore", "needed", "to", "be", "added", "to", "the", "list", "of", "drugs", "which", "can", "induce", "SIADH", "."], "event_mentions": [{"id": "12399645_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 15, "end": 17}, "arguments": [{"entity_id": "12399645_3_Ent0", "role": "Subject", "text": "the first case", "start": 6, "end": 9}, {"entity_id": "12399645_3_Ent1", "role": "Effect", "text": "SIADH", "start": 10, "end": 11}, {"entity_id": "12399645_3_Ent2", "role": "Treatment", "text": "mizoribin", "start": 18, "end": 19}, {"entity_id": "12399645_3_Ent3", "role": "Treatment_Drug", "text": "mizoribin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12399645_3_Ent0", "text": "the first case", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12399645_3_Ent1", "text": "SIADH", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12399645_3_Ent2", "text": "mizoribin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12399645_3_Ent3", "text": "mizoribin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12424571_2", "wnd_id": "12424571_2_1", "text": "We herein report this rare case of acute onset of nephrotic syndrome during interferon - alpha retreatment .", "tokens": ["We", "herein", "report", "this", "rare", "case", "of", "acute", "onset", "of", "nephrotic", "syndrome", "during", "interferon", "-", "alpha", "retreatment", "."], "event_mentions": [{"id": "12424571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "12424571_2_Ent0", "role": "Effect", "text": "acute onset of nephrotic syndrome", "start": 7, "end": 12}, {"entity_id": "12424571_2_Ent1", "role": "Treatment", "text": "interferon - alpha", "start": 13, "end": 16}, {"entity_id": "12424571_2_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12424571_2_Ent0", "text": "acute onset of nephrotic syndrome", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12424571_2_Ent1", "text": "interferon - alpha", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12424571_2_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12460237_1", "wnd_id": "12460237_1_1", "text": "Recurrent palmar - plantar erythrodysaesthesia following high - dose cytarabine treatment for acute lymphoblastic leukemia .", "tokens": ["Recurrent", "palmar", "-", "plantar", "erythrodysaesthesia", "following", "high", "-", "dose", "cytarabine", "treatment", "for", "acute", "lymphoblastic", "leukemia", "."], "event_mentions": [{"id": "12460237_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 10, "end": 11}, "arguments": [{"entity_id": "12460237_1_Ent0", "role": "Effect", "text": "palmar - plantar erythrodysaesthesia", "start": 1, "end": 5}, {"entity_id": "12460237_1_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "12460237_1_Ent1", "role": "Treatment", "text": "high - dose cytarabine", "start": 6, "end": 10}, {"entity_id": "12460237_1_Ent2", "role": "Treatment_Drug", "text": "cytarabine", "start": 9, "end": 10}, {"entity_id": "12460237_1_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "12460237_1_Ent0", "text": "palmar - plantar erythrodysaesthesia", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12460237_1_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12460237_1_Ent1", "text": "high - dose cytarabine", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "12460237_1_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12460237_1_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "12460237_2", "wnd_id": "12460237_2_1", "text": "Palmar - plantar erythrodysaesthesia ( PPE ) is an uncommon cutaneous complication of cytotoxic chemotherapy which generally presents as a painful erythema involving the palms and soles .", "tokens": ["Palmar", "-", "plantar", "erythrodysaesthesia", "(", "PPE", ")", "is", "an", "uncommon", "cutaneous", "complication", "of", "cytotoxic", "chemotherapy", "which", "generally", "presents", "as", "a", "painful", "erythema", "involving", "the", "palms", "and", "soles", "."], "event_mentions": [{"id": "12460237_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "12460237_2_Ent0", "role": "Effect", "text": "Palmar - plantar erythrodysaesthesia ( PPE )", "start": 0, "end": 7}, {"entity_id": "12460237_2_Ent1", "role": "Effect", "text": "an uncommon cutaneous complication", "start": 8, "end": 12}, {"entity_id": "12460237_2_Ent4", "role": "Treatment_Drug", "text": "cytotoxic", "start": 13, "end": 14}, {"entity_id": "12460237_2_Ent3", "role": "Treatment", "text": "cytotoxic chemotherapy", "start": 13, "end": 15}, {"entity_id": "12460237_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 14, "end": 15}, {"entity_id": "12460237_2_Ent2", "role": "Effect", "text": "a painful erythema involving the palms and soles", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "12460237_2_Ent0", "text": "Palmar - plantar erythrodysaesthesia ( PPE )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12460237_2_Ent1", "text": "an uncommon cutaneous complication", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "12460237_2_Ent4", "text": "cytotoxic", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12460237_2_Ent3", "text": "cytotoxic chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12460237_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12460237_2_Ent2", "text": "a painful erythema involving the palms and soles", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "12460237_5", "wnd_id": "12460237_5_1", "text": "Contrary to previous recommendations , our experience cautions against the further use of high - dose cytarabine in patients who develop PPE , and is a timely reminder of the potential toxicity of this agent , which is now increasingly being used as first - line treatment in the management of haematologic malignancies .", "tokens": ["Contrary", "to", "previous", "recommendations", ",", "our", "experience", "cautions", "against", "the", "further", "use", "of", "high", "-", "dose", "cytarabine", "in", "patients", "who", "develop", "PPE", ",", "and", "is", "a", "timely", "reminder", "of", "the", "potential", "toxicity", "of", "this", "agent", ",", "which", "is", "now", "increasingly", "being", "used", "as", "first", "-", "line", "treatment", "in", "the", "management", "of", "haematologic", "malignancies", "."], "event_mentions": [{"id": "12460237_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 31, "end": 32}, "arguments": [{"entity_id": "12460237_5_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 13, "end": 16}, {"entity_id": "12460237_5_Ent1", "role": "Treatment", "text": "high - dose cytarabine", "start": 13, "end": 17}, {"entity_id": "12460237_5_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 16, "end": 17}, {"entity_id": "12460237_5_Ent0", "role": "Effect", "text": "PPE", "start": 21, "end": 22}, {"entity_id": "12460237_5_Ent4", "role": "Treatment_Disorder", "text": "haematologic malignancies", "start": 51, "end": 53}]}], "entity_mentions": [{"id": "12460237_5_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12460237_5_Ent1", "text": "high - dose cytarabine", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "12460237_5_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12460237_5_Ent0", "text": "PPE", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12460237_5_Ent4", "text": "haematologic malignancies", "entity_type": "Entity", "start": 51, "end": 53}], "lang": "en"}
{"doc_id": "12488741_1", "wnd_id": "12488741_1_1", "text": "Clinical , spectroscopic , and imaging abnormalities resolved with discontinuation of metronidazole .", "tokens": ["Clinical", ",", "spectroscopic", ",", "and", "imaging", "abnormalities", "resolved", "with", "discontinuation", "of", "metronidazole", "."], "event_mentions": [{"id": "12488741_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 7, "end": 8}, "arguments": [{"entity_id": "12488741_1_Ent0", "role": "Effect", "text": "Clinical , spectroscopic , and imaging abnormalities", "start": 0, "end": 7}, {"entity_id": "12488741_1_Ent1", "role": "Treatment", "text": "metronidazole", "start": 11, "end": 12}, {"entity_id": "12488741_1_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12488741_1_Ent0", "text": "Clinical , spectroscopic , and imaging abnormalities", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12488741_1_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12488741_1_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12488741_3", "wnd_id": "12488741_3_1", "text": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy .", "tokens": ["Reversible", "MR", "imaging", "and", "MR", "spectroscopy", "abnormalities", "in", "association", "with", "metronidazole", "therapy", "."], "event_mentions": [{"id": "12488741_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 8, "end": 9}, "arguments": [{"entity_id": "12488741_3_Ent0", "role": "Effect", "text": "Reversible MR imaging and MR spectroscopy abnormalities", "start": 0, "end": 7}, {"entity_id": "12488741_3_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 10, "end": 11}, {"entity_id": "12488741_3_Ent1", "role": "Treatment", "text": "metronidazole therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "12488741_3_Ent0", "text": "Reversible MR imaging and MR spectroscopy abnormalities", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12488741_3_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12488741_3_Ent1", "text": "metronidazole therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "12503933_5", "wnd_id": "12503933_5_1", "text": "Fulminant liver failure associated with clarithromycin .", "tokens": ["Fulminant", "liver", "failure", "associated", "with", "clarithromycin", "."], "event_mentions": [{"id": "12503933_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12503933_5_Ent0", "role": "Effect", "text": "Fulminant liver failure", "start": 0, "end": 3}, {"entity_id": "12503933_5_Ent1", "role": "Treatment", "text": "clarithromycin", "start": 5, "end": 6}, {"entity_id": "12503933_5_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12503933_5_Ent0", "text": "Fulminant liver failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12503933_5_Ent1", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12503933_5_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12504711_1", "wnd_id": "12504711_1_1", "text": "A paradoxical ocular effect of brimonidine .", "tokens": ["A", "paradoxical", "ocular", "effect", "of", "brimonidine", "."], "event_mentions": [{"id": "12504711_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 4, "end": 5}, "arguments": [{"entity_id": "12504711_1_Ent0", "role": "Effect", "text": "paradoxical ocular effect", "start": 1, "end": 4}, {"entity_id": "12504711_1_Ent1", "role": "Treatment", "text": "brimonidine", "start": 5, "end": 6}, {"entity_id": "12504711_1_Ent2", "role": "Treatment_Drug", "text": "brimonidine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12504711_1_Ent0", "text": "paradoxical ocular effect", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12504711_1_Ent1", "text": "brimonidine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12504711_1_Ent2", "text": "brimonidine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12507063_2", "wnd_id": "12507063_2_1", "text": "Gabapentin withdrawal presenting as status epilepticus .", "tokens": ["Gabapentin", "withdrawal", "presenting", "as", "status", "epilepticus", "."], "event_mentions": [{"id": "12507063_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 2, "end": 3}, "arguments": [{"entity_id": "12507063_2_Ent2", "role": "Treatment_Drug", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "12507063_2_Ent1", "role": "Treatment", "text": "Gabapentin withdrawal", "start": 0, "end": 2}, {"entity_id": "12507063_2_Ent0", "role": "Effect", "text": "status epilepticus", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "12507063_2_Ent2", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12507063_2_Ent1", "text": "Gabapentin withdrawal", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12507063_2_Ent0", "text": "status epilepticus", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "12540009_1", "wnd_id": "12540009_1_1", "text": "Doxycycline - induced hypoglycemia in a nondiabetic young man .", "tokens": ["Doxycycline", "-", "induced", "hypoglycemia", "in", "a", "nondiabetic", "young", "man", "."], "event_mentions": [{"id": "12540009_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12540009_1_Ent4", "role": "Treatment", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "12540009_1_Ent5", "role": "Treatment_Drug", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "12540009_1_Ent3", "role": "Effect", "text": "hypoglycemia", "start": 3, "end": 4}, {"entity_id": "12540009_1_Ent0", "role": "Subject", "text": "a nondiabetic young man", "start": 5, "end": 9}, {"entity_id": "12540009_1_Ent2", "role": "Subject_Age", "text": "young", "start": 7, "end": 8}, {"entity_id": "12540009_1_Ent1", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12540009_1_Ent4", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12540009_1_Ent5", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12540009_1_Ent3", "text": "hypoglycemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12540009_1_Ent0", "text": "a nondiabetic young man", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12540009_1_Ent2", "text": "young", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12540009_1_Ent1", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12546343_3", "wnd_id": "12546343_3_1", "text": "He was later skin tested to confirm allergy to MTX .", "tokens": ["He", "was", "later", "skin", "tested", "to", "confirm", "allergy", "to", "MTX", "."], "event_mentions": [{"id": "12546343_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 8, "end": 9}, "arguments": [{"entity_id": "12546343_3_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "12546343_3_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "12546343_3_Ent2", "role": "Effect", "text": "allergy", "start": 7, "end": 8}, {"entity_id": "12546343_3_Ent3", "role": "Treatment", "text": "MTX", "start": 9, "end": 10}, {"entity_id": "12546343_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12546343_3_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12546343_3_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12546343_3_Ent2", "text": "allergy", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12546343_3_Ent3", "text": "MTX", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12546343_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12621956_2", "wnd_id": "12621956_2_1", "text": "This is a case report of subtle , mild hypothermia in a 54 - year old female patient receiving risperidone for schizophrenia .", "tokens": ["This", "is", "a", "case", "report", "of", "subtle", ",", "mild", "hypothermia", "in", "a", "54", "-", "year", "old", "female", "patient", "receiving", "risperidone", "for", "schizophrenia", "."], "event_mentions": [{"id": "12621956_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "12621956_2_Ent3", "role": "Effect", "text": "mild hypothermia", "start": 8, "end": 10}, {"entity_id": "12621956_2_Ent0", "role": "Subject", "text": "a 54 - year old female patient", "start": 11, "end": 18}, {"entity_id": "12621956_2_Ent1", "role": "Subject_Age", "text": "54 - year old", "start": 12, "end": 16}, {"entity_id": "12621956_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 16, "end": 17}, {"entity_id": "12621956_2_Ent4", "role": "Treatment", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "12621956_2_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "12621956_2_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12621956_2_Ent3", "text": "mild hypothermia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12621956_2_Ent0", "text": "a 54 - year old female patient", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "12621956_2_Ent1", "text": "54 - year old", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12621956_2_Ent2", "text": "female", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12621956_2_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12621956_2_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12621956_2_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12635752_1", "wnd_id": "12635752_1_1", "text": "Antithyroid treatment with propylthiouracil ( PTU ) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole ( CBZ ) .", "tokens": ["Antithyroid", "treatment", "with", "propylthiouracil", "(", "PTU", ")", "resulted", "in", "elevated", "hepatic", "enzymes", "and", "after", "the", "12th", "week", "of", "pregnancy", "treatment", "was", "changed", "to", "carbimazole", "(", "CBZ", ")", "."], "event_mentions": [{"id": "12635752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 7, "end": 8}, "arguments": [{"entity_id": "12635752_1_Ent4", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 3, "end": 4}, {"entity_id": "12635752_1_Ent3", "role": "Treatment", "text": "propylthiouracil ( PTU )", "start": 3, "end": 7}, {"entity_id": "12635752_1_Ent2", "role": "Effect", "text": "elevated hepatic enzymes", "start": 9, "end": 12}, {"entity_id": "12635752_1_Ent0", "role": "Subject", "text": "12th week of pregnancy", "start": 15, "end": 19}, {"entity_id": "12635752_1_Ent1", "role": "Subject_Disorder", "text": "pregnancy", "start": 18, "end": 19}]}, {"id": "12635752_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "changed", "start": 21, "end": 22}, "arguments": [{"entity_id": "12635752_1_Ent8", "role": "Treatment_Disorder", "text": "Antithyroid", "start": 0, "end": 1}, {"entity_id": "12635752_1_Ent5", "role": "Subject", "text": "12th week of pregnancy", "start": 15, "end": 19}, {"entity_id": "12635752_1_Ent6", "role": "Subject_Disorder", "text": "pregnancy", "start": 18, "end": 19}, {"entity_id": "12635752_1_Ent9", "role": "Treatment_Drug", "text": "carbimazole", "start": 23, "end": 24}, {"entity_id": "12635752_1_Ent7", "role": "Treatment", "text": "carbimazole ( CBZ )", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "12635752_1_Ent8", "text": "Antithyroid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12635752_1_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12635752_1_Ent3", "text": "propylthiouracil ( PTU )", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "12635752_1_Ent2", "text": "elevated hepatic enzymes", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12635752_1_Ent0", "text": "12th week of pregnancy", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12635752_1_Ent5", "text": "12th week of pregnancy", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12635752_1_Ent1", "text": "pregnancy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12635752_1_Ent6", "text": "pregnancy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12635752_1_Ent9", "text": "carbimazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12635752_1_Ent7", "text": "carbimazole ( CBZ )", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "12635752_2", "wnd_id": "12635752_2_1", "text": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration : a case report .", "tokens": ["Successful", "treatment", "with", "carbimazole", "of", "a", "hyperthyroid", "pregnancy", "with", "hepatic", "impairment", "after", "propylthiouracil", "administration", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12635752_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Successful treatment", "start": 0, "end": 2}, "arguments": [{"entity_id": "12635752_2_Ent0", "role": "Treatment", "text": "carbimazole", "start": 3, "end": 4}, {"entity_id": "12635752_2_Ent2", "role": "Treatment_Drug", "text": "carbimazole", "start": 3, "end": 4}, {"entity_id": "12635752_2_Ent1", "role": "Treatment_Disorder", "text": "a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration", "start": 5, "end": 14}]}, {"id": "12635752_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "12635752_2_Ent3", "role": "Effect", "text": "a hyperthyroid pregnancy with hepatic impairment", "start": 5, "end": 11}, {"entity_id": "12635752_2_Ent4", "role": "Treatment", "text": "propylthiouracil", "start": 12, "end": 13}, {"entity_id": "12635752_2_Ent5", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12635752_2_Ent0", "text": "carbimazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12635752_2_Ent2", "text": "carbimazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12635752_2_Ent3", "text": "a hyperthyroid pregnancy with hepatic impairment", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12635752_2_Ent1", "text": "a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "12635752_2_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12635752_2_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12656748_2", "wnd_id": "12656748_2_1", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia .", "tokens": ["Emergence", "of", "Philadelphia", "positive", "chronic", "myeloid", "leukaemia", "during", "treatment", "with", "hydroxyurea", "for", "Philadelphia", "negative", "essential", "thrombocythaemia", "."], "event_mentions": [{"id": "12656748_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "12656748_2_Ent0", "role": "Effect", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "start": 0, "end": 7}, {"entity_id": "12656748_2_Ent1", "role": "Treatment", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent3", "role": "Treatment_Disorder", "text": "Philadelphia negative essential thrombocythaemia", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "12656748_2_Ent0", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12656748_2_Ent1", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent3", "text": "Philadelphia negative essential thrombocythaemia", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "12659609_1", "wnd_id": "12659609_1_1", "text": "Toxicity related to chloroquine treatment of resistant vivax malaria .", "tokens": ["Toxicity", "related", "to", "chloroquine", "treatment", "of", "resistant", "vivax", "malaria", "."], "event_mentions": [{"id": "12659609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 1, "end": 2}, "arguments": [{"entity_id": "12659609_1_Ent0", "role": "Effect", "text": "Toxicity", "start": 0, "end": 1}, {"entity_id": "12659609_1_Ent1", "role": "Treatment", "text": "chloroquine", "start": 3, "end": 4}, {"entity_id": "12659609_1_Ent2", "role": "Treatment_Drug", "text": "chloroquine", "start": 3, "end": 4}, {"entity_id": "12659609_1_Ent3", "role": "Treatment_Disorder", "text": "resistant vivax malaria", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "12659609_1_Ent0", "text": "Toxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12659609_1_Ent1", "text": "chloroquine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12659609_1_Ent2", "text": "chloroquine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12659609_1_Ent3", "text": "resistant vivax malaria", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "12659609_2", "wnd_id": "12659609_2_1", "text": "OBJECTIVE : To report a case of severe chloroquine toxicity in the presence of high - grade chloroquine - resistant Plasmodium vivax .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "severe", "chloroquine", "toxicity", "in", "the", "presence", "of", "high", "-", "grade", "chloroquine", "-", "resistant", "Plasmodium", "vivax", "."], "event_mentions": [{"id": "12659609_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 9, "end": 10}, "arguments": [{"entity_id": "12659609_2_Ent2", "role": "Effect", "text": "severe chloroquine toxicity", "start": 7, "end": 10}, {"entity_id": "12659609_2_Ent3", "role": "Treatment", "text": "chloroquine", "start": 8, "end": 9}, {"entity_id": "12659609_2_Ent4", "role": "Treatment_Drug", "text": "chloroquine", "start": 8, "end": 9}, {"entity_id": "12659609_2_Ent0", "role": "Subject", "text": "high - grade chloroquine - resistant Plasmodium vivax", "start": 14, "end": 22}, {"entity_id": "12659609_2_Ent1", "role": "Subject_Disorder", "text": "high - grade chloroquine - resistant Plasmodium vivax", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "12659609_2_Ent2", "text": "severe chloroquine toxicity", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12659609_2_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12659609_2_Ent4", "text": "chloroquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12659609_2_Ent0", "text": "high - grade chloroquine - resistant Plasmodium vivax", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "12659609_2_Ent1", "text": "high - grade chloroquine - resistant Plasmodium vivax", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "12659609_4", "wnd_id": "12659609_4_1", "text": "His fever resolved , but he developed symptoms consistent with those of chloroquine toxicity .", "tokens": ["His", "fever", "resolved", ",", "but", "he", "developed", "symptoms", "consistent", "with", "those", "of", "chloroquine", "toxicity", "."], "event_mentions": [{"id": "12659609_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12659609_4_Ent0", "role": "Subject", "text": "he", "start": 5, "end": 6}, {"entity_id": "12659609_4_Ent1", "role": "Subject_Gender", "text": "he", "start": 5, "end": 6}, {"entity_id": "12659609_4_Ent2", "role": "Effect", "text": "symptoms consistent with those of chloroquine toxicity", "start": 7, "end": 14}, {"entity_id": "12659609_4_Ent3", "role": "Treatment", "text": "chloroquine", "start": 12, "end": 13}, {"entity_id": "12659609_4_Ent4", "role": "Treatment_Drug", "text": "chloroquine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12659609_4_Ent0", "text": "he", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12659609_4_Ent1", "text": "he", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12659609_4_Ent2", "text": "symptoms consistent with those of chloroquine toxicity", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "12659609_4_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12659609_4_Ent4", "text": "chloroquine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12659609_9", "wnd_id": "12659609_9_1", "text": "Pharmacokinetic modeling suggested that the patient 's initial over - treatment was as reported and that the predicted maximum serum concentration of chloroquine ( 902 micro g / L ) was within the range seen in fatal chloroquine overdose .", "tokens": ["Pharmacokinetic", "modeling", "suggested", "that", "the", "patient", "'s", "initial", "over", "-", "treatment", "was", "as", "reported", "and", "that", "the", "predicted", "maximum", "serum", "concentration", "of", "chloroquine", "(", "902", "micro", "g", "/", "L", ")", "was", "within", "the", "range", "seen", "in", "fatal", "chloroquine", "overdose", "."], "event_mentions": [{"id": "12659609_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "over - treatment", "start": 8, "end": 11}, "arguments": [{"entity_id": "12659609_9_Ent0", "role": "Subject", "text": "the patient 's", "start": 4, "end": 7}, {"entity_id": "12659609_9_Ent3", "role": "Treatment_Drug", "text": "chloroquine", "start": 22, "end": 23}, {"entity_id": "12659609_9_Ent2", "role": "Treatment", "text": "chloroquine ( 902 micro g / L )", "start": 22, "end": 30}, {"entity_id": "12659609_9_Ent4", "role": "Treatment_Dosage", "text": "902 micro g / L", "start": 24, "end": 29}, {"entity_id": "12659609_9_Ent1", "role": "Effect", "text": "fatal", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "12659609_9_Ent0", "text": "the patient 's", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "12659609_9_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12659609_9_Ent2", "text": "chloroquine ( 902 micro g / L )", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "12659609_9_Ent4", "text": "902 micro g / L", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "12659609_9_Ent1", "text": "fatal", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "12661801_2", "wnd_id": "12661801_2_1", "text": "Treatment of carbimazole - induced agranulocytosis and sepsis with granulocyte colony stimulating factor .", "tokens": ["Treatment", "of", "carbimazole", "-", "induced", "agranulocytosis", "and", "sepsis", "with", "granulocyte", "colony", "stimulating", "factor", "."], "event_mentions": [{"id": "12661801_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Treatment", "start": 0, "end": 1}, "arguments": [{"entity_id": "12661801_2_Ent1", "role": "Treatment_Disorder", "text": "carbimazole - induced agranulocytosis and sepsis", "start": 2, "end": 8}, {"entity_id": "12661801_2_Ent0", "role": "Treatment", "text": "granulocyte colony stimulating factor", "start": 9, "end": 13}, {"entity_id": "12661801_2_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony stimulating factor", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "12661801_2_Ent1", "text": "carbimazole - induced agranulocytosis and sepsis", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "12661801_2_Ent0", "text": "granulocyte colony stimulating factor", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "12661801_2_Ent2", "text": "granulocyte colony stimulating factor", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "12665232_2", "wnd_id": "12665232_2_1", "text": "To the best of our knowledge , corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported .", "tokens": ["To", "the", "best", "of", "our", "knowledge", ",", "corneoscleral", "melting", "in", "the", "first", "postoperative", "week", "after", "a", "single", "intraoperative", "application", "of", "mitomycin", "C", "has", "not", "been", "reported", "."], "event_mentions": [{"id": "12665232_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "12665232_2_Ent0", "role": "Effect", "text": "corneoscleral melting", "start": 7, "end": 9}, {"entity_id": "12665232_2_Ent2", "role": "Treatment_Dosage", "text": "a single intraoperative application", "start": 15, "end": 19}, {"entity_id": "12665232_2_Ent1", "role": "Treatment", "text": "a single intraoperative application of mitomycin C", "start": 15, "end": 22}, {"entity_id": "12665232_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "12665232_2_Ent0", "text": "corneoscleral melting", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12665232_2_Ent2", "text": "a single intraoperative application", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12665232_2_Ent1", "text": "a single intraoperative application of mitomycin C", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "12665232_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "1267457_3", "wnd_id": "1267457_3_1", "text": "The sulfonamides are the best verified drug - trigger for erythema multiforme and Stevens - Johnson syndrome .", "tokens": ["The", "sulfonamides", "are", "the", "best", "verified", "drug", "-", "trigger", "for", "erythema", "multiforme", "and", "Stevens", "-", "Johnson", "syndrome", "."], "event_mentions": [{"id": "1267457_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "drug - trigger", "start": 6, "end": 9}, "arguments": [{"entity_id": "1267457_3_Ent1", "role": "Treatment", "text": "sulfonamides", "start": 1, "end": 2}, {"entity_id": "1267457_3_Ent2", "role": "Treatment_Drug", "text": "sulfonamides", "start": 1, "end": 2}, {"entity_id": "1267457_3_Ent0", "role": "Effect", "text": "erythema multiforme and Stevens - Johnson syndrome", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "1267457_3_Ent1", "text": "sulfonamides", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1267457_3_Ent2", "text": "sulfonamides", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1267457_3_Ent0", "text": "erythema multiforme and Stevens - Johnson syndrome", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "12680486_2", "wnd_id": "12680486_2_1", "text": "Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced polyuria and nephrogenic diabetes insipidus .", "tokens": ["Clinicians", "have", "been", "aware", "of", "lithium", "toxicity", "for", "many", "years", "and", "traditionally", "have", "administered", "thiazide", "diuretics", "for", "lithium", "-", "induced", "polyuria", "and", "nephrogenic", "diabetes", "insipidus", "."], "event_mentions": [{"id": "12680486_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 13, "end": 14}, "arguments": [{"entity_id": "12680486_2_Ent0", "role": "Treatment", "text": "thiazide diuretics", "start": 14, "end": 16}, {"entity_id": "12680486_2_Ent3", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 14, "end": 16}, {"entity_id": "12680486_2_Ent1", "role": "Treatment_Disorder", "text": "polyuria", "start": 20, "end": 21}, {"entity_id": "12680486_2_Ent2", "role": "Treatment_Disorder", "text": "nephrogenic diabetes insipidus", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "12680486_2_Ent0", "text": "thiazide diuretics", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "12680486_2_Ent3", "text": "thiazide diuretics", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "12680486_2_Ent1", "text": "polyuria", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12680486_2_Ent2", "text": "nephrogenic diabetes insipidus", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "12692521_1", "wnd_id": "12692521_1_1", "text": "Systemic capillary leak syndrome after granulocyte colony - stimulating factor ( G - CSF ) .", "tokens": ["Systemic", "capillary", "leak", "syndrome", "after", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "12692521_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "12692521_1_Ent0", "role": "Effect", "text": "Systemic capillary leak syndrome", "start": 0, "end": 4}, {"entity_id": "12692521_1_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 5, "end": 10}, {"entity_id": "12692521_1_Ent1", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 5, "end": 15}]}], "entity_mentions": [{"id": "12692521_1_Ent0", "text": "Systemic capillary leak syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12692521_1_Ent2", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12692521_1_Ent1", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 5, "end": 15}], "lang": "en"}
{"doc_id": "12699871_2", "wnd_id": "12699871_2_1", "text": "Rapid identification of speech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss .", "tokens": ["Rapid", "identification", "of", "speech", "loss", "linked", "to", "FK506", "may", "be", "important", "because", "reduction", "or", "cessation", "of", "the", "drug", "may", "be", "associated", "with", "reverse", "of", "speech", "loss", "."], "event_mentions": [{"id": "12699871_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "linked", "start": 5, "end": 6}, "arguments": [{"entity_id": "12699871_2_Ent0", "role": "Effect", "text": "speech loss", "start": 3, "end": 5}, {"entity_id": "12699871_2_Ent1", "role": "Treatment", "text": "FK506", "start": 7, "end": 8}, {"entity_id": "12699871_2_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12699871_2_Ent0", "text": "speech loss", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12699871_2_Ent1", "text": "FK506", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12699871_2_Ent2", "text": "FK506", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12702914_4", "wnd_id": "12702914_4_1", "text": "We conjectured that the side effects of insulin , such as anti - natriuresis and increased vascular permeability , might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity , hyperinsulinaemia and hypoalbuminaemia .", "tokens": ["We", "conjectured", "that", "the", "side", "effects", "of", "insulin", ",", "such", "as", "anti", "-", "natriuresis", "and", "increased", "vascular", "permeability", ",", "might", "be", "pronounced", "in", "the", "presence", "of", "the", "hepatic", "dysfunction", "that", "accompanies", "insulin", "insensitivity", ",", "hyperinsulinaemia", "and", "hypoalbuminaemia", "."], "event_mentions": [{"id": "12702914_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 4, "end": 6}, "arguments": [{"entity_id": "12702914_4_Ent1", "role": "Treatment", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "12702914_4_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "12702914_4_Ent0", "role": "Effect", "text": "anti - natriuresis and increased vascular permeability", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "12702914_4_Ent1", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_4_Ent0", "text": "anti - natriuresis and increased vascular permeability", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "12729371_1", "wnd_id": "12729371_1_1", "text": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration .", "tokens": ["Angioimmunoblastic", "lymphadenopathy", "with", "dysproteinemia", "following", "doxycycline", "administration", "."], "event_mentions": [{"id": "12729371_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "12729371_1_Ent0", "role": "Effect", "text": "Angioimmunoblastic lymphadenopathy with dysproteinemia", "start": 0, "end": 4}, {"entity_id": "12729371_1_Ent2", "role": "Treatment_Drug", "text": "doxycycline", "start": 5, "end": 6}, {"entity_id": "12729371_1_Ent1", "role": "Treatment", "text": "doxycycline administration", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "12729371_1_Ent0", "text": "Angioimmunoblastic lymphadenopathy with dysproteinemia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12729371_1_Ent2", "text": "doxycycline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12729371_1_Ent1", "text": "doxycycline administration", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "12806509_1", "wnd_id": "12806509_1_1", "text": "Early - onset acute transverse myelitis following hepatitis B vaccination and respiratory infection : case report .", "tokens": ["Early", "-", "onset", "acute", "transverse", "myelitis", "following", "hepatitis", "B", "vaccination", "and", "respiratory", "infection", ":", "case", "report", "."], "event_mentions": [{"id": "12806509_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "12806509_1_Ent1", "role": "Effect", "text": "Early - onset acute transverse myelitis", "start": 0, "end": 6}, {"entity_id": "12806509_1_Ent2", "role": "Treatment", "text": "hepatitis B vaccination", "start": 7, "end": 10}, {"entity_id": "12806509_1_Ent3", "role": "Treatment_Drug", "text": "hepatitis B vaccination", "start": 7, "end": 10}, {"entity_id": "12806509_1_Ent0", "role": "Subject", "text": "case", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12806509_1_Ent1", "text": "Early - onset acute transverse myelitis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "12806509_1_Ent2", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12806509_1_Ent3", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12806509_1_Ent0", "text": "case", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12806509_2", "wnd_id": "12806509_2_1", "text": "In this paper , we report a case of 3 years - old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination .", "tokens": ["In", "this", "paper", ",", "we", "report", "a", "case", "of", "3", "years", "-", "old", "boy", "who", "developed", "acute", "onset", "tetraparesia", "following", "a", "viral", "respiratory", "infecction", "and", "hepatitis", "B", "vaccination", "."], "event_mentions": [{"id": "12806509_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "12806509_2_Ent1", "role": "Subject_Age", "text": "3 years - old", "start": 9, "end": 13}, {"entity_id": "12806509_2_Ent0", "role": "Subject", "text": "3 years - old boy", "start": 9, "end": 14}, {"entity_id": "12806509_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 13, "end": 14}, {"entity_id": "12806509_2_Ent4", "role": "Effect", "text": "acute onset tetraparesia", "start": 16, "end": 19}, {"entity_id": "12806509_2_Ent3", "role": "Subject_Disorder", "text": "a viral respiratory infecction", "start": 20, "end": 24}, {"entity_id": "12806509_2_Ent5", "role": "Treatment", "text": "hepatitis B vaccination", "start": 25, "end": 28}, {"entity_id": "12806509_2_Ent6", "role": "Treatment_Drug", "text": "hepatitis B vaccination", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "12806509_2_Ent1", "text": "3 years - old", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "12806509_2_Ent0", "text": "3 years - old boy", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12806509_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12806509_2_Ent4", "text": "acute onset tetraparesia", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "12806509_2_Ent3", "text": "a viral respiratory infecction", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "12806509_2_Ent5", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "12806509_2_Ent6", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "12836099_1", "wnd_id": "12836099_1_1", "text": "Stevens - Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy .", "tokens": ["Stevens", "-", "Johnson", "syndrome", "in", "a", "boy", "with", "nephrotic", "syndrome", "during", "prednisolone", "therapy", "."], "event_mentions": [{"id": "12836099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "12836099_1_Ent2", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 0, "end": 4}, {"entity_id": "12836099_1_Ent0", "role": "Subject", "text": "a boy with nephrotic syndrome", "start": 5, "end": 10}, {"entity_id": "12836099_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12836099_1_Ent5", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "12836099_1_Ent3", "role": "Treatment", "text": "prednisolone", "start": 11, "end": 12}, {"entity_id": "12836099_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12836099_1_Ent2", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12836099_1_Ent0", "text": "a boy with nephrotic syndrome", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12836099_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12836099_1_Ent5", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12836099_1_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12836099_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12854039_6", "wnd_id": "12854039_6_1", "text": "PURPOSE : To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration .", "tokens": ["PURPOSE", ":", "To", "describe", "bilateral", "optic", "neuritis", "that", "occurred", "as", "an", "adverse", "effect", "of", "recombinant", "and", "natural", "interferon", "alpha", "administration", "."], "event_mentions": [{"id": "12854039_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 8, "end": 9}, "arguments": [{"entity_id": "12854039_6_Ent0", "role": "Effect", "text": "bilateral optic neuritis", "start": 4, "end": 7}, {"entity_id": "12854039_6_Ent2", "role": "Treatment_Drug", "text": "recombinant and natural interferon alpha", "start": 14, "end": 19}, {"entity_id": "12854039_6_Ent1", "role": "Treatment", "text": "recombinant and natural interferon alpha administration", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "12854039_6_Ent0", "text": "bilateral optic neuritis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "12854039_6_Ent2", "text": "recombinant and natural interferon alpha", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "12854039_6_Ent1", "text": "recombinant and natural interferon alpha administration", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "12860350_1", "wnd_id": "12860350_1_1", "text": "Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen .", "tokens": ["Acute", "abdomen", "due", "to", "endometriosis", "in", "a", "premenopausal", "woman", "taking", "tamoxifen", "."], "event_mentions": [{"id": "12860350_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 9, "end": 10}, "arguments": [{"entity_id": "12860350_1_Ent0", "role": "Effect", "text": "Acute abdomen due to endometriosis", "start": 0, "end": 5}, {"entity_id": "12860350_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 10, "end": 11}, {"entity_id": "12860350_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12860350_1_Ent0", "text": "Acute abdomen due to endometriosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12860350_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12860350_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12860350_2", "wnd_id": "12860350_2_1", "text": "We describe a premenopausal woman who , while having tamoxifen due to a diagnosis of in situ ductal carcinoma , developed endometriosis requiring surgery .", "tokens": ["We", "describe", "a", "premenopausal", "woman", "who", ",", "while", "having", "tamoxifen", "due", "to", "a", "diagnosis", "of", "in", "situ", "ductal", "carcinoma", ",", "developed", "endometriosis", "requiring", "surgery", "."], "event_mentions": [{"id": "12860350_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "12860350_2_Ent0", "role": "Subject", "text": "a premenopausal woman", "start": 2, "end": 5}, {"entity_id": "12860350_2_Ent2", "role": "Subject_Age", "text": "premenopausal", "start": 3, "end": 4}, {"entity_id": "12860350_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "12860350_2_Ent4", "role": "Treatment", "text": "tamoxifen", "start": 9, "end": 10}, {"entity_id": "12860350_2_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 9, "end": 10}, {"entity_id": "12860350_2_Ent6", "role": "Treatment_Disorder", "text": "in situ ductal carcinoma", "start": 15, "end": 19}, {"entity_id": "12860350_2_Ent3", "role": "Effect", "text": "endometriosis", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12860350_2_Ent0", "text": "a premenopausal woman", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12860350_2_Ent2", "text": "premenopausal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12860350_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12860350_2_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12860350_2_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12860350_2_Ent6", "text": "in situ ductal carcinoma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12860350_2_Ent3", "text": "endometriosis", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12862258_2", "wnd_id": "12862258_2_1", "text": "Fatal agranulocytosis in an Indian male receiving 100 mg of dapsone daily , hospitalized for mid - borderline leprosy in type I reaction with triple nerve paralysis is reported .", "tokens": ["Fatal", "agranulocytosis", "in", "an", "Indian", "male", "receiving", "100", "mg", "of", "dapsone", "daily", ",", "hospitalized", "for", "mid", "-", "borderline", "leprosy", "in", "type", "I", "reaction", "with", "triple", "nerve", "paralysis", "is", "reported", "."], "event_mentions": [{"id": "12862258_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 6, "end": 7}, "arguments": [{"entity_id": "12862258_2_Ent3", "role": "Effect", "text": "Fatal agranulocytosis", "start": 0, "end": 2}, {"entity_id": "12862258_2_Ent1", "role": "Subject_Race", "text": "Indian", "start": 4, "end": 5}, {"entity_id": "12862258_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "12862258_2_Ent5", "role": "Treatment_Dosage", "text": "100 mg", "start": 7, "end": 9}, {"entity_id": "12862258_2_Ent4", "role": "Treatment", "text": "100 mg of dapsone daily", "start": 7, "end": 12}, {"entity_id": "12862258_2_Ent6", "role": "Treatment_Drug", "text": "dapsone", "start": 10, "end": 11}, {"entity_id": "12862258_2_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 11, "end": 12}, {"entity_id": "12862258_2_Ent0", "role": "Subject", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "start": 15, "end": 27}, {"entity_id": "12862258_2_Ent8", "role": "Treatment_Disorder", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "start": 15, "end": 27}]}], "entity_mentions": [{"id": "12862258_2_Ent3", "text": "Fatal agranulocytosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12862258_2_Ent1", "text": "Indian", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_2_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12862258_2_Ent5", "text": "100 mg", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12862258_2_Ent4", "text": "100 mg of dapsone daily", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12862258_2_Ent6", "text": "dapsone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12862258_2_Ent7", "text": "daily", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12862258_2_Ent0", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "12862258_2_Ent8", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "entity_type": "Entity", "start": 15, "end": 27}], "lang": "en"}
{"doc_id": "12862258_3", "wnd_id": "12862258_3_1", "text": "Various case reports concerning dapsone - induced agranulocytosis are reviewed .", "tokens": ["Various", "case", "reports", "concerning", "dapsone", "-", "induced", "agranulocytosis", "are", "reviewed", "."], "event_mentions": [{"id": "12862258_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "12862258_3_Ent1", "role": "Treatment", "text": "dapsone", "start": 4, "end": 5}, {"entity_id": "12862258_3_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 4, "end": 5}, {"entity_id": "12862258_3_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12862258_3_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_3_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_3_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12869178_2", "wnd_id": "12869178_2_1", "text": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin - induced thrombocytopenia ( HIT ) postoperatively .", "tokens": ["Most", "cardiac", "surgical", "patients", "have", "had", "previous", "exposure", "to", "heparin", "for", "diagnostic", "or", "therapeutic", "interventions", "and", "hence", "have", "an", "increased", "susceptibility", "to", "developing", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "postoperatively", "."], "event_mentions": [{"id": "12869178_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 22, "end": 23}, "arguments": [{"entity_id": "12869178_2_Ent0", "role": "Subject", "text": "Most cardiac surgical patients", "start": 0, "end": 4}, {"entity_id": "12869178_2_Ent1", "role": "Subject_Disorder", "text": "cardiac surgical", "start": 1, "end": 3}, {"entity_id": "12869178_2_Ent3", "role": "Treatment", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "12869178_2_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "12869178_2_Ent2", "role": "Effect", "text": "heparin - induced thrombocytopenia ( HIT )", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "12869178_2_Ent0", "text": "Most cardiac surgical patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12869178_2_Ent1", "text": "cardiac surgical", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12869178_2_Ent3", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12869178_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12869178_2_Ent2", "text": "heparin - induced thrombocytopenia ( HIT )", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "12875956_1", "wnd_id": "12875956_1_1", "text": "Acute psychosis associated with levetiracetam .", "tokens": ["Acute", "psychosis", "associated", "with", "levetiracetam", "."], "event_mentions": [{"id": "12875956_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "12875956_1_Ent0", "role": "Effect", "text": "Acute psychosis", "start": 0, "end": 2}, {"entity_id": "12875956_1_Ent1", "role": "Treatment", "text": "levetiracetam", "start": 4, "end": 5}, {"entity_id": "12875956_1_Ent2", "role": "Treatment_Drug", "text": "levetiracetam", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12875956_1_Ent0", "text": "Acute psychosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12875956_1_Ent1", "text": "levetiracetam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12875956_1_Ent2", "text": "levetiracetam", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "1288290_1", "wnd_id": "1288290_1_1", "text": "Proliferation of abnormal bone marrow histiocytes , an undesired effect of granulocyte macrophage - colony - stimulating factor therapy in a patient with Hurler 's syndrome undergoing bone marrow transplantation .", "tokens": ["Proliferation", "of", "abnormal", "bone", "marrow", "histiocytes", ",", "an", "undesired", "effect", "of", "granulocyte", "macrophage", "-", "colony", "-", "stimulating", "factor", "therapy", "in", "a", "patient", "with", "Hurler", "'s", "syndrome", "undergoing", "bone", "marrow", "transplantation", "."], "event_mentions": [{"id": "1288290_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undesired effect", "start": 8, "end": 10}, "arguments": [{"entity_id": "1288290_1_Ent1", "role": "Effect", "text": "Proliferation of abnormal bone marrow histiocytes", "start": 0, "end": 6}, {"entity_id": "1288290_1_Ent2", "role": "Treatment", "text": "granulocyte macrophage - colony - stimulating factor", "start": 11, "end": 18}, {"entity_id": "1288290_1_Ent3", "role": "Treatment_Drug", "text": "granulocyte macrophage - colony - stimulating factor", "start": 11, "end": 18}, {"entity_id": "1288290_1_Ent0", "role": "Subject", "text": "a patient with Hurler 's syndrome", "start": 20, "end": 26}, {"entity_id": "1288290_1_Ent4", "role": "Treatment_Disorder", "text": "Hurler 's syndrome", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "1288290_1_Ent1", "text": "Proliferation of abnormal bone marrow histiocytes", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1288290_1_Ent2", "text": "granulocyte macrophage - colony - stimulating factor", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "1288290_1_Ent3", "text": "granulocyte macrophage - colony - stimulating factor", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "1288290_1_Ent0", "text": "a patient with Hurler 's syndrome", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "1288290_1_Ent4", "text": "Hurler 's syndrome", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "12915840_2", "wnd_id": "12915840_2_1", "text": "We report the first case of IHA associated with cefuroxime administration .", "tokens": ["We", "report", "the", "first", "case", "of", "IHA", "associated", "with", "cefuroxime", "administration", "."], "event_mentions": [{"id": "12915840_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "12915840_2_Ent0", "role": "Subject", "text": "the first case", "start": 2, "end": 5}, {"entity_id": "12915840_2_Ent1", "role": "Effect", "text": "IHA", "start": 6, "end": 7}, {"entity_id": "12915840_2_Ent2", "role": "Treatment", "text": "cefuroxime", "start": 9, "end": 10}, {"entity_id": "12915840_2_Ent3", "role": "Treatment_Drug", "text": "cefuroxime", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12915840_2_Ent0", "text": "the first case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12915840_2_Ent1", "text": "IHA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12915840_2_Ent2", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12915840_2_Ent3", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12932249_1", "wnd_id": "12932249_1_1", "text": "Hyperpigmentation during interferon - alpha therapy for chronic hepatitis C virus infection .", "tokens": ["Hyperpigmentation", "during", "interferon", "-", "alpha", "therapy", "for", "chronic", "hepatitis", "C", "virus", "infection", "."], "event_mentions": [{"id": "12932249_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "12932249_1_Ent0", "role": "Effect", "text": "Hyperpigmentation", "start": 0, "end": 1}, {"entity_id": "12932249_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 2, "end": 5}, {"entity_id": "12932249_1_Ent1", "role": "Treatment", "text": "interferon - alpha therapy", "start": 2, "end": 6}, {"entity_id": "12932249_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C virus infection", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "12932249_1_Ent0", "text": "Hyperpigmentation", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12932249_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12932249_1_Ent1", "text": "interferon - alpha therapy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "12932249_1_Ent3", "text": "chronic hepatitis C virus infection", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "12932249_2", "wnd_id": "12932249_2_1", "text": "These skin lesions may be induced or worsened during antiviral therapy with interferon - alpha ( IFN ) .", "tokens": ["These", "skin", "lesions", "may", "be", "induced", "or", "worsened", "during", "antiviral", "therapy", "with", "interferon", "-", "alpha", "(", "IFN", ")", "."], "event_mentions": [{"id": "12932249_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "12932249_2_Ent0", "role": "Effect", "text": "skin lesions", "start": 1, "end": 3}, {"entity_id": "12932249_2_Ent1", "role": "Treatment", "text": "antiviral therapy with interferon - alpha ( IFN )", "start": 9, "end": 18}, {"entity_id": "12932249_2_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha ( IFN ) .", "start": 12, "end": 19}]}], "entity_mentions": [{"id": "12932249_2_Ent0", "text": "skin lesions", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12932249_2_Ent1", "text": "antiviral therapy with interferon - alpha ( IFN )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "12932249_2_Ent2", "text": "interferon - alpha ( IFN ) .", "entity_type": "Entity", "start": 12, "end": 19}], "lang": "en"}
{"doc_id": "12944250_1", "wnd_id": "12944250_1_1", "text": "It is concluded that simultaneous administration of ciprofloxacin and tazobactam / piperacillin may cause marked thrombocytosis .", "tokens": ["It", "is", "concluded", "that", "simultaneous", "administration", "of", "ciprofloxacin", "and", "tazobactam", "/", "piperacillin", "may", "cause", "marked", "thrombocytosis", "."], "event_mentions": [{"id": "12944250_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "12944250_1_Ent1", "role": "Treatment", "text": "simultaneous administration of ciprofloxacin and tazobactam / piperacillin", "start": 4, "end": 12}, {"entity_id": "12944250_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "12944250_1_Ent4", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "12944250_1_Ent3", "role": "Treatment_Drug", "text": "tazobactam / piperacillin", "start": 9, "end": 12}, {"entity_id": "12944250_1_Ent5", "role": "Combination_Drug", "text": "tazobactam / piperacillin", "start": 9, "end": 12}, {"entity_id": "12944250_1_Ent0", "role": "Effect", "text": "marked thrombocytosis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12944250_1_Ent1", "text": "simultaneous administration of ciprofloxacin and tazobactam / piperacillin", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "12944250_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12944250_1_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12944250_1_Ent3", "text": "tazobactam / piperacillin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12944250_1_Ent5", "text": "tazobactam / piperacillin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12944250_1_Ent0", "text": "marked thrombocytosis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "129501_1", "wnd_id": "129501_1_1", "text": "Anaphylaxis after the injection of chymopapain occurs in about 1 % of such cases .", "tokens": ["Anaphylaxis", "after", "the", "injection", "of", "chymopapain", "occurs", "in", "about", "1", "%", "of", "such", "cases", "."], "event_mentions": [{"id": "129501_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 6, "end": 7}, "arguments": [{"entity_id": "129501_1_Ent1", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "129501_1_Ent2", "role": "Treatment", "text": "the injection of chymopapain", "start": 2, "end": 6}, {"entity_id": "129501_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 3, "end": 4}, {"entity_id": "129501_1_Ent4", "role": "Treatment_Drug", "text": "chymopapain", "start": 5, "end": 6}, {"entity_id": "129501_1_Ent0", "role": "Subject", "text": "cases", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "129501_1_Ent1", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "129501_1_Ent2", "text": "the injection of chymopapain", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "129501_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "129501_1_Ent4", "text": "chymopapain", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "129501_1_Ent0", "text": "cases", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12951892_1", "wnd_id": "12951892_1_1", "text": "Lethargy in a newborn : lithium toxicity or lab error ?", "tokens": ["Lethargy", "in", "a", "newborn", ":", "lithium", "toxicity", "or", "lab", "error", "?"], "event_mentions": [{"id": "12951892_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 6, "end": 7}, "arguments": [{"entity_id": "12951892_1_Ent2", "role": "Effect", "text": "Lethargy", "start": 0, "end": 1}, {"entity_id": "12951892_1_Ent0", "role": "Subject", "text": "a newborn", "start": 2, "end": 4}, {"entity_id": "12951892_1_Ent1", "role": "Subject_Age", "text": "newborn", "start": 3, "end": 4}, {"entity_id": "12951892_1_Ent3", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "12951892_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12951892_1_Ent2", "text": "Lethargy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12951892_1_Ent0", "text": "a newborn", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12951892_1_Ent1", "text": "newborn", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12951892_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12951892_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12962465_1", "wnd_id": "12962465_1_1", "text": "After four months , while receiving RH , he developed painful bilateral gynaecomastia .", "tokens": ["After", "four", "months", ",", "while", "receiving", "RH", ",", "he", "developed", "painful", "bilateral", "gynaecomastia", "."], "event_mentions": [{"id": "12962465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "12962465_1_Ent3", "role": "Treatment_Time_elapsed", "text": "After four months", "start": 0, "end": 3}, {"entity_id": "12962465_1_Ent1", "role": "Treatment", "text": "receiving RH", "start": 5, "end": 7}, {"entity_id": "12962465_1_Ent2", "role": "Treatment_Drug", "text": "RH", "start": 6, "end": 7}, {"entity_id": "12962465_1_Ent0", "role": "Effect", "text": "painful bilateral gynaecomastia", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "12962465_1_Ent3", "text": "After four months", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12962465_1_Ent1", "text": "receiving RH", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12962465_1_Ent2", "text": "RH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12962465_1_Ent0", "text": "painful bilateral gynaecomastia", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "12962465_2", "wnd_id": "12962465_2_1", "text": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy .", "tokens": ["Gynaecomastia", "is", "a", "rarely", "reported", "adverse", "drug", "reaction", "due", "to", "isoniazid", "therapy", "."], "event_mentions": [{"id": "12962465_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse drug reaction", "start": 5, "end": 8}, "arguments": [{"entity_id": "12962465_2_Ent0", "role": "Effect", "text": "Gynaecomastia", "start": 0, "end": 1}, {"entity_id": "12962465_2_Ent2", "role": "Treatment_Drug", "text": "isoniazid", "start": 10, "end": 11}, {"entity_id": "12962465_2_Ent1", "role": "Treatment", "text": "isoniazid therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "12962465_2_Ent0", "text": "Gynaecomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12962465_2_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12962465_2_Ent1", "text": "isoniazid therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "12962465_3", "wnd_id": "12962465_3_1", "text": "Isoniazid associated , painful , bilateral gynaecomastia .", "tokens": ["Isoniazid", "associated", ",", "painful", ",", "bilateral", "gynaecomastia", "."], "event_mentions": [{"id": "12962465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "12962465_3_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12962465_3_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12962465_3_Ent0", "role": "Effect", "text": "painful , bilateral gynaecomastia", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "12962465_3_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12962465_3_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12962465_3_Ent0", "text": "painful , bilateral gynaecomastia", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "1316047_1", "wnd_id": "1316047_1_1", "text": "Hemodynamic collapse following labetalol administration in preeclampsia .", "tokens": ["Hemodynamic", "collapse", "following", "labetalol", "administration", "in", "preeclampsia", "."], "event_mentions": [{"id": "1316047_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "1316047_1_Ent0", "role": "Effect", "text": "Hemodynamic collapse", "start": 0, "end": 2}, {"entity_id": "1316047_1_Ent1", "role": "Treatment", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent2", "role": "Treatment_Drug", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent3", "role": "Treatment_Disorder", "text": "preeclampsia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "1316047_1_Ent0", "text": "Hemodynamic collapse", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1316047_1_Ent1", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent2", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent3", "text": "preeclampsia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1359782_1", "wnd_id": "1359782_1_1", "text": "A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology , while taking sulfasalazine .", "tokens": ["A", "patient", "with", "ulcerative", "colitis", "developed", "skin", "pigmentation", "and", "diffuse", "pulmonary", "shadowing", "without", "respiratory", "symptomatology", ",", "while", "taking", "sulfasalazine", "."], "event_mentions": [{"id": "1359782_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "1359782_1_Ent0", "role": "Subject", "text": "A patient with ulcerative colitis", "start": 0, "end": 5}, {"entity_id": "1359782_1_Ent4", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 3, "end": 5}, {"entity_id": "1359782_1_Ent1", "role": "Effect", "text": "skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology", "start": 6, "end": 15}, {"entity_id": "1359782_1_Ent2", "role": "Treatment", "text": "sulfasalazine", "start": 18, "end": 19}, {"entity_id": "1359782_1_Ent3", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "1359782_1_Ent0", "text": "A patient with ulcerative colitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1359782_1_Ent4", "text": "ulcerative colitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1359782_1_Ent1", "text": "skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "1359782_1_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1359782_1_Ent3", "text": "sulfasalazine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "1388041_2", "wnd_id": "1388041_2_1", "text": "Paroxetine is a selective serotonin reuptake inhibitor possessing anti - depressant activity .", "tokens": ["Paroxetine", "is", "a", "selective", "serotonin", "reuptake", "inhibitor", "possessing", "anti", "-", "depressant", "activity", "."], "event_mentions": [{"id": "1388041_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "possessing", "start": 7, "end": 8}, "arguments": [{"entity_id": "1388041_2_Ent0", "role": "Treatment", "text": "Paroxetine", "start": 0, "end": 1}, {"entity_id": "1388041_2_Ent2", "role": "Treatment_Drug", "text": "Paroxetine", "start": 0, "end": 1}, {"entity_id": "1388041_2_Ent1", "role": "Treatment_Disorder", "text": "anti - depressant activity", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "1388041_2_Ent0", "text": "Paroxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1388041_2_Ent2", "text": "Paroxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1388041_2_Ent1", "text": "anti - depressant activity", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "1389744_1", "wnd_id": "1389744_1_1", "text": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler .", "tokens": ["A", "patient", "presented", "with", "dilated", "cardiomyopathy", "after", "many", "years", "of", "overusing", "an", "adrenaline", "inhaler", "."], "event_mentions": [{"id": "1389744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "1389744_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "1389744_1_Ent1", "role": "Effect", "text": "dilated cardiomyopathy", "start": 4, "end": 6}, {"entity_id": "1389744_1_Ent2", "role": "Treatment", "text": "many years of overusing an adrenaline inhaler", "start": 7, "end": 14}, {"entity_id": "1389744_1_Ent3", "role": "Treatment_Dosage", "text": "overusing", "start": 10, "end": 11}, {"entity_id": "1389744_1_Ent4", "role": "Treatment_Drug", "text": "adrenaline", "start": 12, "end": 13}, {"entity_id": "1389744_1_Ent5", "role": "Treatment_Route", "text": "inhaler", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "1389744_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1389744_1_Ent1", "text": "dilated cardiomyopathy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1389744_1_Ent2", "text": "many years of overusing an adrenaline inhaler", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "1389744_1_Ent3", "text": "overusing", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1389744_1_Ent4", "text": "adrenaline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1389744_1_Ent5", "text": "inhaler", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1389744_2", "wnd_id": "1389744_2_1", "text": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler .", "tokens": ["Dilated", "cardiomyopathy", "associated", "with", "chronic", "overuse", "of", "an", "adrenaline", "inhaler", "."], "event_mentions": [{"id": "1389744_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1389744_2_Ent0", "role": "Effect", "text": "Dilated cardiomyopathy", "start": 0, "end": 2}, {"entity_id": "1389744_2_Ent3", "role": "Treatment_Dosage", "text": "chronic overuse", "start": 4, "end": 6}, {"entity_id": "1389744_2_Ent1", "role": "Treatment", "text": "chronic overuse of an adrenaline inhaler", "start": 4, "end": 10}, {"entity_id": "1389744_2_Ent2", "role": "Treatment_Drug", "text": "adrenaline", "start": 8, "end": 9}, {"entity_id": "1389744_2_Ent4", "role": "Treatment_Route", "text": "inhaler", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "1389744_2_Ent0", "text": "Dilated cardiomyopathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1389744_2_Ent3", "text": "chronic overuse", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1389744_2_Ent1", "text": "chronic overuse of an adrenaline inhaler", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "1389744_2_Ent2", "text": "adrenaline", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1389744_2_Ent4", "text": "inhaler", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "1420650_2", "wnd_id": "1420650_2_1", "text": "In this report we present four patients treated with a combination of different psychotropic drugs , in whom asterixis was triggered either by adding carbamazepine ( CBZ ) to a treatment regimen , or by increasing its dosage .", "tokens": ["In", "this", "report", "we", "present", "four", "patients", "treated", "with", "a", "combination", "of", "different", "psychotropic", "drugs", ",", "in", "whom", "asterixis", "was", "triggered", "either", "by", "adding", "carbamazepine", "(", "CBZ", ")", "to", "a", "treatment", "regimen", ",", "or", "by", "increasing", "its", "dosage", "."], "event_mentions": [{"id": "1420650_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 20, "end": 21}, "arguments": [{"entity_id": "1420650_2_Ent1", "role": "Subject_Population", "text": "four", "start": 5, "end": 6}, {"entity_id": "1420650_2_Ent0", "role": "Subject", "text": "four patients", "start": 5, "end": 7}, {"entity_id": "1420650_2_Ent2", "role": "Effect", "text": "asterixis", "start": 18, "end": 19}, {"entity_id": "1420650_2_Ent3", "role": "Treatment", "text": "carbamazepine", "start": 24, "end": 25}, {"entity_id": "1420650_2_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "1420650_2_Ent1", "text": "four", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1420650_2_Ent0", "text": "four patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1420650_2_Ent2", "text": "asterixis", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1420650_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "1420650_2_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "1420650_3", "wnd_id": "1420650_3_1", "text": "We consider asterixis to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with CBZ .", "tokens": ["We", "consider", "asterixis", "to", "be", "an", "easily", "overlooked", "sign", "of", "neurotoxicity", ",", "which", "may", "occur", "even", "at", "low", "or", "moderate", "dosage", "levels", ",", "if", "certain", "drugs", "as", "lithium", "or", "clozapine", "are", "used", "in", "combination", "with", "CBZ", "."], "event_mentions": [{"id": "1420650_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 14, "end": 15}, "arguments": [{"entity_id": "1420650_3_Ent0", "role": "Effect", "text": "asterixis", "start": 2, "end": 3}, {"entity_id": "1420650_3_Ent1", "role": "Treatment", "text": "even at low or moderate dosage levels", "start": 15, "end": 22}, {"entity_id": "1420650_3_Ent6", "role": "Treatment_Dosage", "text": "low or moderate dosage", "start": 17, "end": 21}, {"entity_id": "1420650_3_Ent2", "role": "Treatment", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "start": 24, "end": 36}, {"entity_id": "1420650_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent10", "role": "Combination_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent3", "role": "Treatment_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent7", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent9", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "1420650_3_Ent0", "text": "asterixis", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1420650_3_Ent1", "text": "even at low or moderate dosage levels", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1420650_3_Ent6", "text": "low or moderate dosage", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "1420650_3_Ent2", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "entity_type": "Entity", "start": 24, "end": 36}, {"id": "1420650_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent8", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent10", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent3", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent7", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent9", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "1422497_2", "wnd_id": "1422497_2_1", "text": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy .", "tokens": ["Hemorrhagic", "cystitis", "is", "a", "significant", "toxic", "effect", "of", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "1422497_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "significant toxic effect", "start": 4, "end": 7}, "arguments": [{"entity_id": "1422497_2_Ent0", "role": "Effect", "text": "Hemorrhagic cystitis", "start": 0, "end": 2}, {"entity_id": "1422497_2_Ent1", "role": "Treatment", "text": "cyclophosphamide", "start": 8, "end": 9}, {"entity_id": "1422497_2_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1422497_2_Ent0", "text": "Hemorrhagic cystitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1422497_2_Ent1", "text": "cyclophosphamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1422497_2_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1422497_3", "wnd_id": "1422497_3_1", "text": "Continuous bladder irrigation of a 1 % alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium .", "tokens": ["Continuous", "bladder", "irrigation", "of", "a", "1", "%", "alum", "solution", "is", "a", "simple", "and", "generally", "safe", "method", "of", "chemical", "cautery", "to", "treat", "the", "bleeding", "urothelium", "."], "event_mentions": [{"id": "1422497_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 20, "end": 21}, "arguments": [{"entity_id": "1422497_3_Ent4", "role": "Treatment_Freq", "text": "Continuous", "start": 0, "end": 1}, {"entity_id": "1422497_3_Ent0", "role": "Treatment", "text": "Continuous bladder irrigation of a 1 % alum solution", "start": 0, "end": 9}, {"entity_id": "1422497_3_Ent3", "role": "Treatment_Route", "text": "bladder irrigation", "start": 1, "end": 3}, {"entity_id": "1422497_3_Ent2", "role": "Treatment_Drug", "text": "1 % alum", "start": 5, "end": 8}, {"entity_id": "1422497_3_Ent1", "role": "Treatment_Disorder", "text": "bleeding urothelium", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "1422497_3_Ent4", "text": "Continuous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1422497_3_Ent0", "text": "Continuous bladder irrigation of a 1 % alum solution", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "1422497_3_Ent3", "text": "bladder irrigation", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "1422497_3_Ent2", "text": "1 % alum", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1422497_3_Ent1", "text": "bleeding urothelium", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "1445134_1", "wnd_id": "1445134_1_1", "text": "Gestational diabetes was no less severe ( degree of hyperglycaemia , need for insulin therapy ) when associated with norethisterone .", "tokens": ["Gestational", "diabetes", "was", "no", "less", "severe", "(", "degree", "of", "hyperglycaemia", ",", "need", "for", "insulin", "therapy", ")", "when", "associated", "with", "norethisterone", "."], "event_mentions": [{"id": "1445134_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "1445134_1_Ent0", "role": "Effect", "text": "Gestational diabetes", "start": 0, "end": 2}, {"entity_id": "1445134_1_Ent1", "role": "Treatment", "text": "norethisterone", "start": 19, "end": 20}, {"entity_id": "1445134_1_Ent2", "role": "Treatment_Drug", "text": "norethisterone", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "1445134_1_Ent0", "text": "Gestational diabetes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1445134_1_Ent1", "text": "norethisterone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1445134_1_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "1445134_3", "wnd_id": "1445134_3_1", "text": "In a single practice during the 21 years 1971 - 1991 , the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4 % ( 22 of 69 ) in comparison with 7.1 % in pregnancies in which the women did not take norethisterone ( 137 of 1,684 ) ( p < 0.001 ) .", "tokens": ["In", "a", "single", "practice", "during", "the", "21", "years", "1971", "-", "1991", ",", "the", "incidence", "of", "gestational", "diabetes", "in", "pregnancies", "in", "which", "norethisterone", "was", "prescribed", "was", "32.4", "%", "(", "22", "of", "69", ")", "in", "comparison", "with", "7.1", "%", "in", "pregnancies", "in", "which", "the", "women", "did", "not", "take", "norethisterone", "(", "137", "of", "1,684", ")", "(", "p", "<", "0.001", ")", "."], "event_mentions": [{"id": "1445134_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incidence", "start": 13, "end": 14}, "arguments": [{"entity_id": "1445134_3_Ent1", "role": "Effect", "text": "gestational diabetes", "start": 15, "end": 17}, {"entity_id": "1445134_3_Ent0", "role": "Subject", "text": "pregnancies", "start": 18, "end": 19}, {"entity_id": "1445134_3_Ent2", "role": "Treatment", "text": "norethisterone", "start": 21, "end": 22}, {"entity_id": "1445134_3_Ent3", "role": "Treatment_Drug", "text": "norethisterone", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1445134_3_Ent1", "text": "gestational diabetes", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "1445134_3_Ent0", "text": "pregnancies", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1445134_3_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1445134_3_Ent3", "text": "norethisterone", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "14522628_1", "wnd_id": "14522628_1_1", "text": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature .", "tokens": ["Generalised", "cutaneous", "rash", "associated", "with", "ganciclovir", "therapy", "has", "rarely", "been", "reported", "in", "literature", "."], "event_mentions": [{"id": "14522628_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 3, "end": 5}, "arguments": [{"entity_id": "14522628_1_Ent0", "role": "Effect", "text": "Generalised cutaneous rash", "start": 0, "end": 3}, {"entity_id": "14522628_1_Ent2", "role": "Treatment_Drug", "text": "ganciclovir", "start": 5, "end": 6}, {"entity_id": "14522628_1_Ent1", "role": "Treatment", "text": "ganciclovir therapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "14522628_1_Ent0", "text": "Generalised cutaneous rash", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14522628_1_Ent2", "text": "ganciclovir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14522628_1_Ent1", "text": "ganciclovir therapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "14522628_2", "wnd_id": "14522628_2_1", "text": "Skin rash and splinter hemorrhages from ganciclovir .", "tokens": ["Skin", "rash", "and", "splinter", "hemorrhages", "from", "ganciclovir", "."], "event_mentions": [{"id": "14522628_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 5, "end": 6}, "arguments": [{"entity_id": "14522628_2_Ent0", "role": "Effect", "text": "Skin rash and splinter hemorrhages", "start": 0, "end": 5}, {"entity_id": "14522628_2_Ent1", "role": "Treatment", "text": "ganciclovir", "start": 6, "end": 7}, {"entity_id": "14522628_2_Ent2", "role": "Treatment_Drug", "text": "ganciclovir", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14522628_2_Ent0", "text": "Skin rash and splinter hemorrhages", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14522628_2_Ent1", "text": "ganciclovir", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14522628_2_Ent2", "text": "ganciclovir", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14530108_5", "wnd_id": "14530108_5_1", "text": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed , and the dosage of FK506 should also be reduced if possible .", "tokens": ["The", "treatment", "for", "acidosis", "and", "hyperkalaemia", "should", "be", "started", "as", "soon", "as", "RTA", "is", "diagnosed", ",", "and", "the", "dosage", "of", "FK506", "should", "also", "be", "reduced", "if", "possible", "."], "event_mentions": [{"id": "14530108_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 19, "end": 20}, "arguments": [{"entity_id": "14530108_5_Ent0", "role": "Effect", "text": "acidosis and hyperkalaemia", "start": 3, "end": 6}, {"entity_id": "14530108_5_Ent1", "role": "Effect", "text": "RTA", "start": 12, "end": 13}, {"entity_id": "14530108_5_Ent2", "role": "Treatment", "text": "FK506", "start": 20, "end": 21}, {"entity_id": "14530108_5_Ent3", "role": "Treatment_Drug", "text": "FK506", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "14530108_5_Ent0", "text": "acidosis and hyperkalaemia", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "14530108_5_Ent1", "text": "RTA", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "14530108_5_Ent2", "text": "FK506", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "14530108_5_Ent3", "text": "FK506", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14632592_5", "wnd_id": "14632592_5_1", "text": "OBJECTIVE : To report a case of colchicine - induced myopathy in a teenager with familial Mediterranean fever ( FMF ) .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "colchicine", "-", "induced", "myopathy", "in", "a", "teenager", "with", "familial", "Mediterranean", "fever", "(", "FMF", ")", "."], "event_mentions": [{"id": "14632592_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "14632592_5_Ent3", "role": "Treatment", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "14632592_5_Ent5", "role": "Treatment_Drug", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "14632592_5_Ent2", "role": "Effect", "text": "myopathy", "start": 10, "end": 11}, {"entity_id": "14632592_5_Ent0", "role": "Subject", "text": "a teenager with familial Mediterranean fever ( FMF )", "start": 12, "end": 21}, {"entity_id": "14632592_5_Ent1", "role": "Subject_Age", "text": "teenager", "start": 13, "end": 14}, {"entity_id": "14632592_5_Ent4", "role": "Treatment_Disorder", "text": "familial Mediterranean fever", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "14632592_5_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14632592_5_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14632592_5_Ent2", "text": "myopathy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "14632592_5_Ent0", "text": "a teenager with familial Mediterranean fever ( FMF )", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "14632592_5_Ent1", "text": "teenager", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14632592_5_Ent4", "text": "familial Mediterranean fever", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "14641354_1", "wnd_id": "14641354_1_1", "text": "Angioedema and dysphagia caused by contact allergy to inhaled budesonide .", "tokens": ["Angioedema", "and", "dysphagia", "caused", "by", "contact", "allergy", "to", "inhaled", "budesonide", "."], "event_mentions": [{"id": "14641354_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhaled", "start": 8, "end": 9}, "arguments": [{"entity_id": "14641354_1_Ent1", "role": "Effect", "text": "Angioedema and dysphagia", "start": 0, "end": 3}, {"entity_id": "14641354_1_Ent0", "role": "Effect", "text": "contact allergy", "start": 5, "end": 7}, {"entity_id": "14641354_1_Ent2", "role": "Treatment", "text": "budesonide", "start": 9, "end": 10}, {"entity_id": "14641354_1_Ent3", "role": "Treatment_Drug", "text": "budesonide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "14641354_1_Ent1", "text": "Angioedema and dysphagia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14641354_1_Ent0", "text": "contact allergy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14641354_1_Ent2", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14641354_1_Ent3", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "14674674_2", "wnd_id": "14674674_2_1", "text": "Infliximab - induced lupus in Crohn 's disease : a case report .", "tokens": ["Infliximab", "-", "induced", "lupus", "in", "Crohn", "'s", "disease", ":", "a", "case", "report", "."], "event_mentions": [{"id": "14674674_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14674674_2_Ent2", "role": "Treatment", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "14674674_2_Ent3", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "14674674_2_Ent1", "role": "Effect", "text": "lupus", "start": 3, "end": 4}, {"entity_id": "14674674_2_Ent0", "role": "Subject", "text": "a case", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14674674_2_Ent2", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14674674_2_Ent3", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14674674_2_Ent1", "text": "lupus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14674674_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14674674_3", "wnd_id": "14674674_3_1", "text": "This is the first case , to our knowledge , of onset of prolonged infliximab - induced lupus .", "tokens": ["This", "is", "the", "first", "case", ",", "to", "our", "knowledge", ",", "of", "onset", "of", "prolonged", "infliximab", "-", "induced", "lupus", "."], "event_mentions": [{"id": "14674674_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "14674674_3_Ent2", "role": "Treatment_Duration", "text": "prolonged", "start": 13, "end": 14}, {"entity_id": "14674674_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 14, "end": 15}, {"entity_id": "14674674_3_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 14, "end": 15}, {"entity_id": "14674674_3_Ent0", "role": "Effect", "text": "lupus", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "14674674_3_Ent2", "text": "prolonged", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14674674_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14674674_3_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14674674_3_Ent0", "text": "lupus", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "14684937_1", "wnd_id": "14684937_1_1", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions , both the serum level of calcium and urinary excretion of calcium increased gradually .", "tokens": ["After", "initiation", "of", "topical", "vitamin", "D3", "ointment", "(", "20", "micro", "g", "/", "g", "of", "tacalcitol", ")", "10", "g", "/", "day", "for", "the", "skin", "lesions", ",", "both", "the", "serum", "level", "of", "calcium", "and", "urinary", "excretion", "of", "calcium", "increased", "gradually", "."], "event_mentions": [{"id": "14684937_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 36, "end": 37}, "arguments": [{"entity_id": "14684937_1_Ent1", "role": "Treatment", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day", "start": 0, "end": 20}, {"entity_id": "14684937_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 3, "end": 4}, {"entity_id": "14684937_1_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_1_Ent5", "role": "Treatment_Dosage", "text": "20 micro g / g", "start": 8, "end": 13}, {"entity_id": "14684937_1_Ent6", "role": "Treatment_Dosage", "text": "10 g", "start": 16, "end": 18}, {"entity_id": "14684937_1_Ent7", "role": "Treatment_Freq", "text": "10 g / day", "start": 16, "end": 20}, {"entity_id": "14684937_1_Ent2", "role": "Treatment_Disorder", "text": "skin lesions ,", "start": 22, "end": 25}, {"entity_id": "14684937_1_Ent0", "role": "Effect", "text": "serum level of calcium and urinary excretion of calcium increased", "start": 27, "end": 37}]}], "entity_mentions": [{"id": "14684937_1_Ent1", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "14684937_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14684937_1_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_1_Ent5", "text": "20 micro g / g", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "14684937_1_Ent6", "text": "10 g", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "14684937_1_Ent7", "text": "10 g / day", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "14684937_1_Ent2", "text": "skin lesions ,", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "14684937_1_Ent0", "text": "serum level of calcium and urinary excretion of calcium increased", "entity_type": "Entity", "start": 27, "end": 37}], "lang": "en"}
{"doc_id": "1469187_2", "wnd_id": "1469187_2_1", "text": "A massive digitoxin ( DGTX ) intoxication in a 36 - year - old man ( 35 mg DGTX ) was treated by prolonged and repeated i.v .- infusions of Fab fragments of anti - digitalis antibodies ( FAB ) .", "tokens": ["A", "massive", "digitoxin", "(", "DGTX", ")", "intoxication", "in", "a", "36", "-", "year", "-", "old", "man", "(", "35", "mg", "DGTX", ")", "was", "treated", "by", "prolonged", "and", "repeated", "i.v", ".-", "infusions", "of", "Fab", "fragments", "of", "anti", "-", "digitalis", "antibodies", "(", "FAB", ")", "."], "event_mentions": [{"id": "1469187_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "1469187_2_Ent0", "role": "Subject", "text": "A massive digitoxin ( DGTX ) intoxication in a 36 - year - old man ( 35 mg DGTX )", "start": 0, "end": 20}, {"entity_id": "1469187_2_Ent4", "role": "Treatment_Disorder", "text": "massive digitoxin ( DGTX ) intoxication", "start": 1, "end": 7}, {"entity_id": "1469187_2_Ent1", "role": "Subject_Age", "text": "36 - year - old", "start": 9, "end": 14}, {"entity_id": "1469187_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "1469187_2_Ent3", "role": "Treatment", "text": "prolonged and repeated i.v .- infusions of Fab fragments of anti - digitalis antibodies ( FAB )", "start": 23, "end": 40}, {"entity_id": "1469187_2_Ent5", "role": "Treatment_Route", "text": "i.v .- infusions", "start": 26, "end": 29}, {"entity_id": "1469187_2_Ent6", "role": "Treatment_Drug", "text": "anti - digitalis antibodies", "start": 33, "end": 37}]}], "entity_mentions": [{"id": "1469187_2_Ent0", "text": "A massive digitoxin ( DGTX ) intoxication in a 36 - year - old man ( 35 mg DGTX )", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "1469187_2_Ent4", "text": "massive digitoxin ( DGTX ) intoxication", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "1469187_2_Ent1", "text": "36 - year - old", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "1469187_2_Ent2", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1469187_2_Ent3", "text": "prolonged and repeated i.v .- infusions of Fab fragments of anti - digitalis antibodies ( FAB )", "entity_type": "Entity", "start": 23, "end": 40}, {"id": "1469187_2_Ent5", "text": "i.v .- infusions", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "1469187_2_Ent6", "text": "anti - digitalis antibodies", "entity_type": "Entity", "start": 33, "end": 37}], "lang": "en"}
{"doc_id": "1469187_3", "wnd_id": "1469187_3_1", "text": "Since this amount of FAB was insufficient to bind all DGTX present in the serum , cardiac DGTX toxicity ( total AV - block ) persisted .", "tokens": ["Since", "this", "amount", "of", "FAB", "was", "insufficient", "to", "bind", "all", "DGTX", "present", "in", "the", "serum", ",", "cardiac", "DGTX", "toxicity", "(", "total", "AV", "-", "block", ")", "persisted", "."], "event_mentions": [{"id": "1469187_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "persisted", "start": 25, "end": 26}, "arguments": [{"entity_id": "1469187_3_Ent3", "role": "Treatment_Drug", "text": "FAB", "start": 4, "end": 5}, {"entity_id": "1469187_3_Ent1", "role": "Treatment", "text": "DGTX", "start": 10, "end": 11}, {"entity_id": "1469187_3_Ent2", "role": "Treatment_Drug", "text": "DGTX", "start": 10, "end": 11}, {"entity_id": "1469187_3_Ent0", "role": "Effect", "text": "cardiac DGTX toxicity ( total AV - block )", "start": 16, "end": 25}]}], "entity_mentions": [{"id": "1469187_3_Ent3", "text": "FAB", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1469187_3_Ent1", "text": "DGTX", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1469187_3_Ent2", "text": "DGTX", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1469187_3_Ent0", "text": "cardiac DGTX toxicity ( total AV - block )", "entity_type": "Entity", "start": 16, "end": 25}], "lang": "en"}
{"doc_id": "14693027_1", "wnd_id": "14693027_1_1", "text": "All patients had taken phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 ) and were on the medication when the skin lesions first appeared .", "tokens": ["All", "patients", "had", "taken", "phenytoin", "for", "variable", "time", "periods", "(", "range", "16", "-", "80", "days", ";", "mean", ":", "40", ")", "and", "were", "on", "the", "medication", "when", "the", "skin", "lesions", "first", "appeared", "."], "event_mentions": [{"id": "14693027_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 30, "end": 31}, "arguments": [{"entity_id": "14693027_1_Ent0", "role": "Subject", "text": "All patients", "start": 0, "end": 2}, {"entity_id": "14693027_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "14693027_1_Ent2", "role": "Treatment", "text": "phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 )", "start": 4, "end": 20}, {"entity_id": "14693027_1_Ent4", "role": "Treatment_Duration", "text": "16 - 80 days ;", "start": 11, "end": 16}, {"entity_id": "14693027_1_Ent5", "role": "Treatment_Duration", "text": "40", "start": 18, "end": 19}, {"entity_id": "14693027_1_Ent1", "role": "Effect", "text": "skin lesions", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "14693027_1_Ent0", "text": "All patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14693027_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14693027_1_Ent2", "text": "phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 )", "entity_type": "Entity", "start": 4, "end": 20}, {"id": "14693027_1_Ent4", "text": "16 - 80 days ;", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "14693027_1_Ent5", "text": "40", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "14693027_1_Ent1", "text": "skin lesions", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "14697943_1", "wnd_id": "14697943_1_1", "text": "In conclusion , RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( CyA or tacrolimus ) , even under monotherapy or with a low steroid dose .", "tokens": ["In", "conclusion", ",", "RSDS", "is", "a", "relevant", "osteoarticular", "complication", "in", "patients", "receiving", "either", "anticalcineurinic", "drug", "(", "CyA", "or", "tacrolimus", ")", ",", "even", "under", "monotherapy", "or", "with", "a", "low", "steroid", "dose", "."], "event_mentions": [{"id": "14697943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "osteoarticular complication", "start": 7, "end": 9}, "arguments": [{"entity_id": "14697943_1_Ent0", "role": "Effect", "text": "RSDS", "start": 3, "end": 4}, {"entity_id": "14697943_1_Ent1", "role": "Treatment", "text": "anticalcineurinic drug ( CyA or tacrolimus )", "start": 13, "end": 20}, {"entity_id": "14697943_1_Ent2", "role": "Treatment_Drug", "text": "CyA", "start": 16, "end": 17}, {"entity_id": "14697943_1_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "14697943_1_Ent0", "text": "RSDS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14697943_1_Ent1", "text": "anticalcineurinic drug ( CyA or tacrolimus )", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "14697943_1_Ent2", "text": "CyA", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "14697943_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "14697943_2", "wnd_id": "14697943_2_1", "text": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus .", "tokens": ["Reflex", "sympathetic", "dystrophy", "syndrome", "in", "renal", "transplanted", "patients", "under", "immunosuppression", "with", "tacrolimus", "."], "event_mentions": [{"id": "14697943_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "14697943_2_Ent2", "role": "Effect", "text": "Reflex sympathetic dystrophy syndrome", "start": 0, "end": 4}, {"entity_id": "14697943_2_Ent1", "role": "Subject_Disorder", "text": "renal transplanted", "start": 5, "end": 7}, {"entity_id": "14697943_2_Ent0", "role": "Subject", "text": "renal transplanted patients", "start": 5, "end": 8}, {"entity_id": "14697943_2_Ent3", "role": "Treatment", "text": "tacrolimus", "start": 11, "end": 12}, {"entity_id": "14697943_2_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "14697943_2_Ent2", "text": "Reflex sympathetic dystrophy syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "14697943_2_Ent1", "text": "renal transplanted", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14697943_2_Ent0", "text": "renal transplanted patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "14697943_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14697943_2_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "14697943_3", "wnd_id": "14697943_3_1", "text": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus .", "tokens": ["We", "now", "present", "four", "cases", "of", "RSDS", "in", "kidney", "transplant", "recipients", "treated", "with", "tacrolimus", "."], "event_mentions": [{"id": "14697943_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "14697943_3_Ent3", "role": "Subject_Population", "text": "four", "start": 3, "end": 4}, {"entity_id": "14697943_3_Ent0", "role": "Subject", "text": "four cases", "start": 3, "end": 5}, {"entity_id": "14697943_3_Ent4", "role": "Effect", "text": "RSDS", "start": 6, "end": 7}, {"entity_id": "14697943_3_Ent2", "role": "Subject_Disorder", "text": "kidney transplant", "start": 8, "end": 10}, {"entity_id": "14697943_3_Ent1", "role": "Subject", "text": "kidney transplant recipients", "start": 8, "end": 11}, {"entity_id": "14697943_3_Ent5", "role": "Treatment", "text": "tacrolimus", "start": 13, "end": 14}, {"entity_id": "14697943_3_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "14697943_3_Ent3", "text": "four", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14697943_3_Ent0", "text": "four cases", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14697943_3_Ent4", "text": "RSDS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14697943_3_Ent2", "text": "kidney transplant", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14697943_3_Ent1", "text": "kidney transplant recipients", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "14697943_3_Ent5", "text": "tacrolimus", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14697943_3_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "14700673_3", "wnd_id": "14700673_3_1", "text": "METHODS : In an institutional practice setting , two women , aged 25 and 45 , developed acute myopia after starting topiramate for epilepsy .", "tokens": ["METHODS", ":", "In", "an", "institutional", "practice", "setting", ",", "two", "women", ",", "aged", "25", "and", "45", ",", "developed", "acute", "myopia", "after", "starting", "topiramate", "for", "epilepsy", "."], "event_mentions": [{"id": "14700673_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "14700673_3_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "14700673_3_Ent0", "role": "Subject", "text": "two women , aged 25 and 45", "start": 8, "end": 15}, {"entity_id": "14700673_3_Ent2", "role": "Subject_Gender", "text": "women", "start": 9, "end": 10}, {"entity_id": "14700673_3_Ent3", "role": "Subject_Age", "text": "aged 25 and 45", "start": 11, "end": 15}, {"entity_id": "14700673_3_Ent4", "role": "Effect", "text": "acute myopia", "start": 17, "end": 19}, {"entity_id": "14700673_3_Ent5", "role": "Treatment", "text": "topiramate", "start": 21, "end": 22}, {"entity_id": "14700673_3_Ent6", "role": "Treatment_Drug", "text": "topiramate", "start": 21, "end": 22}, {"entity_id": "14700673_3_Ent7", "role": "Treatment_Disorder", "text": "epilepsy", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "14700673_3_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14700673_3_Ent0", "text": "two women , aged 25 and 45", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "14700673_3_Ent2", "text": "women", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14700673_3_Ent3", "text": "aged 25 and 45", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "14700673_3_Ent4", "text": "acute myopia", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "14700673_3_Ent5", "text": "topiramate", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14700673_3_Ent6", "text": "topiramate", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14700673_3_Ent7", "text": "epilepsy", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "14723711_3", "wnd_id": "14723711_3_1", "text": "Three distinct types of minocycline - induced cutaneous pigmentation have been described .", "tokens": ["Three", "distinct", "types", "of", "minocycline", "-", "induced", "cutaneous", "pigmentation", "have", "been", "described", "."], "event_mentions": [{"id": "14723711_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "14723711_3_Ent1", "role": "Treatment", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_3_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_3_Ent0", "role": "Effect", "text": "cutaneous pigmentation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "14723711_3_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_3_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_3_Ent0", "text": "cutaneous pigmentation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "14735388_2", "wnd_id": "14735388_2_1", "text": "We report here a case of TEN after administration of ciprofloxacin .", "tokens": ["We", "report", "here", "a", "case", "of", "TEN", "after", "administration", "of", "ciprofloxacin", "."], "event_mentions": [{"id": "14735388_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 8, "end": 9}, "arguments": [{"entity_id": "14735388_2_Ent0", "role": "Subject", "text": "a case", "start": 3, "end": 5}, {"entity_id": "14735388_2_Ent1", "role": "Effect", "text": "TEN", "start": 6, "end": 7}, {"entity_id": "14735388_2_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 10, "end": 11}, {"entity_id": "14735388_2_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "14735388_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14735388_2_Ent1", "text": "TEN", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14735388_2_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "14735388_2_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "14742791_2", "wnd_id": "14742791_2_1", "text": "After 5 weeks of therapy , she stopped taking pantoprazole due to general malaise .", "tokens": ["After", "5", "weeks", "of", "therapy", ",", "she", "stopped", "taking", "pantoprazole", "due", "to", "general", "malaise", "."], "event_mentions": [{"id": "14742791_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 10, "end": 12}, "arguments": [{"entity_id": "14742791_2_Ent2", "role": "Treatment", "text": "After 5 weeks of therapy", "start": 0, "end": 5}, {"entity_id": "14742791_2_Ent3", "role": "Treatment_Time_elapsed", "text": "5 weeks", "start": 1, "end": 3}, {"entity_id": "14742791_2_Ent1", "role": "Treatment", "text": "taking pantoprazole", "start": 8, "end": 10}, {"entity_id": "14742791_2_Ent4", "role": "Treatment_Drug", "text": "pantoprazole", "start": 9, "end": 10}, {"entity_id": "14742791_2_Ent0", "role": "Effect", "text": "general malaise", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "14742791_2_Ent2", "text": "After 5 weeks of therapy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14742791_2_Ent3", "text": "5 weeks", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14742791_2_Ent1", "text": "taking pantoprazole", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14742791_2_Ent4", "text": "pantoprazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14742791_2_Ent0", "text": "general malaise", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "14742791_5", "wnd_id": "14742791_5_1", "text": "There have been several reported cases of omeprazole - induced AIN .", "tokens": ["There", "have", "been", "several", "reported", "cases", "of", "omeprazole", "-", "induced", "AIN", "."], "event_mentions": [{"id": "14742791_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "14742791_5_Ent1", "role": "Treatment", "text": "omeprazole", "start": 7, "end": 8}, {"entity_id": "14742791_5_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 7, "end": 8}, {"entity_id": "14742791_5_Ent0", "role": "Effect", "text": "AIN", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "14742791_5_Ent1", "text": "omeprazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14742791_5_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14742791_5_Ent0", "text": "AIN", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "14964753_2", "wnd_id": "14964753_2_1", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction .", "tokens": ["A", "61", "-", "year", "-", "old", "patient", "who", "had", "been", "treated", "with", "lisinopril", "in", "the", "past", "without", "any", "problems", "was", "commenced", "on", "ramipril", "for", "left", "ventricular", "dysfunction", "."], "event_mentions": [{"id": "14964753_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "commenced", "start": 20, "end": 21}, "arguments": [{"entity_id": "14964753_2_Ent0", "role": "Subject", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems", "start": 0, "end": 19}, {"entity_id": "14964753_2_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "14964753_2_Ent2", "role": "Treatment", "text": "ramipril", "start": 22, "end": 23}, {"entity_id": "14964753_2_Ent3", "role": "Treatment_Drug", "text": "ramipril", "start": 22, "end": 23}, {"entity_id": "14964753_2_Ent4", "role": "Treatment_Disorder", "text": "left ventricular dysfunction", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "14964753_2_Ent0", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems", "entity_type": "Entity", "start": 0, "end": 19}, {"id": "14964753_2_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14964753_2_Ent2", "text": "ramipril", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "14964753_2_Ent3", "text": "ramipril", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "14964753_2_Ent4", "text": "left ventricular dysfunction", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "14964753_6", "wnd_id": "14964753_6_1", "text": "The ACE inhibitors can cause various skin side effects ; however , it rarely causes cutaneous vasculitis .", "tokens": ["The", "ACE", "inhibitors", "can", "cause", "various", "skin", "side", "effects", ";", "however", ",", "it", "rarely", "causes", "cutaneous", "vasculitis", "."], "event_mentions": [{"id": "14964753_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "14964753_6_Ent1", "role": "Treatment", "text": "ACE inhibitors", "start": 1, "end": 3}, {"entity_id": "14964753_6_Ent2", "role": "Treatment_Drug", "text": "ACE inhibitors", "start": 1, "end": 3}, {"entity_id": "14964753_6_Ent0", "role": "Effect", "text": "skin side effects", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "14964753_6_Ent1", "text": "ACE inhibitors", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14964753_6_Ent2", "text": "ACE inhibitors", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14964753_6_Ent0", "text": "skin side effects", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "14968106_1", "wnd_id": "14968106_1_1", "text": "CONCLUSION : This is , to our knowledge , the first report of severe myelopathy following accidental intrathecal administration of doxorubicin .", "tokens": ["CONCLUSION", ":", "This", "is", ",", "to", "our", "knowledge", ",", "the", "first", "report", "of", "severe", "myelopathy", "following", "accidental", "intrathecal", "administration", "of", "doxorubicin", "."], "event_mentions": [{"id": "14968106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "14968106_1_Ent0", "role": "Effect", "text": "severe myelopathy", "start": 13, "end": 15}, {"entity_id": "14968106_1_Ent3", "role": "Treatment_Route", "text": "intrathecal administration", "start": 17, "end": 19}, {"entity_id": "14968106_1_Ent1", "role": "Treatment", "text": "intrathecal administration of doxorubicin", "start": 17, "end": 21}, {"entity_id": "14968106_1_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "14968106_1_Ent0", "text": "severe myelopathy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "14968106_1_Ent3", "text": "intrathecal administration", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "14968106_1_Ent1", "text": "intrathecal administration of doxorubicin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "14968106_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14998226_2", "wnd_id": "14998226_2_1", "text": "A 67 - year - old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio ( INR ) without bleeding when his atorvastatin therapy was switched to fluvastatin .", "tokens": ["A", "67", "-", "year", "-", "old", "man", "receiving", "a", "stable", "maintenance", "dosage", "of", "warfarin", "experienced", "an", "increased", "international", "normalized", "ratio", "(", "INR", ")", "without", "bleeding", "when", "his", "atorvastatin", "therapy", "was", "switched", "to", "fluvastatin", "."], "event_mentions": [{"id": "14998226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 14, "end": 15}, "arguments": [{"entity_id": "14998226_2_Ent0", "role": "Subject", "text": "A 67 - year - old man", "start": 0, "end": 7}, {"entity_id": "14998226_2_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 1, "end": 6}, {"entity_id": "14998226_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "14998226_2_Ent4", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14998226_2_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14998226_2_Ent3", "role": "Effect", "text": "increased international normalized ratio ( INR )", "start": 16, "end": 23}]}, {"id": "14998226_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "switched", "start": 30, "end": 31}, "arguments": [{"entity_id": "14998226_2_Ent9", "role": "Treatment_Disorder", "text": "bleeding", "start": 24, "end": 25}, {"entity_id": "14998226_2_Ent8", "role": "Treatment_Drug", "text": "atorvastatin", "start": 27, "end": 28}, {"entity_id": "14998226_2_Ent6", "role": "Treatment", "text": "atorvastatin therapy was switched to fluvastatin", "start": 27, "end": 33}, {"entity_id": "14998226_2_Ent7", "role": "Treatment_Drug", "text": "fluvastatin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "14998226_2_Ent0", "text": "A 67 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "14998226_2_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14998226_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14998226_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14998226_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14998226_2_Ent3", "text": "increased international normalized ratio ( INR )", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "14998226_2_Ent9", "text": "bleeding", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "14998226_2_Ent8", "text": "atorvastatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "14998226_2_Ent6", "text": "atorvastatin therapy was switched to fluvastatin", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "14998226_2_Ent7", "text": "fluvastatin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "14998226_7", "wnd_id": "14998226_7_1", "text": "Lovastatin also reportedly has caused increases in INR when coadministered with warfarin .", "tokens": ["Lovastatin", "also", "reportedly", "has", "caused", "increases", "in", "INR", "when", "coadministered", "with", "warfarin", "."], "event_mentions": [{"id": "14998226_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "14998226_7_Ent1", "role": "Treatment", "text": "Lovastatin", "start": 0, "end": 1}, {"entity_id": "14998226_7_Ent2", "role": "Treatment_Drug", "text": "Lovastatin", "start": 0, "end": 1}, {"entity_id": "14998226_7_Ent0", "role": "Effect", "text": "increases in INR", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "14998226_7_Ent1", "text": "Lovastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_7_Ent2", "text": "Lovastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_7_Ent0", "text": "increases in INR", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "15013892_2", "wnd_id": "15013892_2_1", "text": "CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed , severe maculopathy indistinguishable from chloroquine maculopathy in certain patients .", "tokens": ["CONCLUSIONS", ":", "Low", "dosages", "of", "quinacrine", "used", "for", "malaria", "prophylaxis", "can", "be", "associated", "with", "a", "delayed", ",", "severe", "maculopathy", "indistinguishable", "from", "chloroquine", "maculopathy", "in", "certain", "patients", "."], "event_mentions": [{"id": "15013892_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "15013892_2_Ent3", "role": "Treatment_Dosage", "text": "Low dosages", "start": 2, "end": 4}, {"entity_id": "15013892_2_Ent1", "role": "Treatment", "text": "Low dosages of quinacrine used for malaria prophylaxis", "start": 2, "end": 10}, {"entity_id": "15013892_2_Ent4", "role": "Treatment_Drug", "text": "quinacrine", "start": 5, "end": 6}, {"entity_id": "15013892_2_Ent5", "role": "Treatment_Disorder", "text": "malaria prophylaxis", "start": 8, "end": 10}, {"entity_id": "15013892_2_Ent0", "role": "Effect", "text": "a delayed , severe maculopathy", "start": 14, "end": 19}, {"entity_id": "15013892_2_Ent2", "role": "Treatment_Time_elapsed", "text": "delayed", "start": 15, "end": 16}]}, {"id": "15013892_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "15013892_2_Ent10", "role": "Treatment_Dosage", "text": "Low dosages", "start": 2, "end": 4}, {"entity_id": "15013892_2_Ent8", "role": "Treatment", "text": "Low dosages of quinacrine used for malaria prophylaxis", "start": 2, "end": 10}, {"entity_id": "15013892_2_Ent11", "role": "Treatment_Drug", "text": "quinacrine", "start": 5, "end": 6}, {"entity_id": "15013892_2_Ent12", "role": "Treatment_Disorder", "text": "malaria prophylaxis", "start": 8, "end": 10}, {"entity_id": "15013892_2_Ent9", "role": "Treatment_Time_elapsed", "text": "delayed", "start": 15, "end": 16}, {"entity_id": "15013892_2_Ent7", "role": "Effect", "text": "chloroquine maculopathy", "start": 21, "end": 23}, {"entity_id": "15013892_2_Ent6", "role": "Subject", "text": "certain patients .", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "15013892_2_Ent3", "text": "Low dosages", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_2_Ent10", "text": "Low dosages", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_2_Ent1", "text": "Low dosages of quinacrine used for malaria prophylaxis", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "15013892_2_Ent8", "text": "Low dosages of quinacrine used for malaria prophylaxis", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "15013892_2_Ent4", "text": "quinacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15013892_2_Ent11", "text": "quinacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15013892_2_Ent5", "text": "malaria prophylaxis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15013892_2_Ent12", "text": "malaria prophylaxis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15013892_2_Ent0", "text": "a delayed , severe maculopathy", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "15013892_2_Ent2", "text": "delayed", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15013892_2_Ent9", "text": "delayed", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15013892_2_Ent7", "text": "chloroquine maculopathy", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15013892_2_Ent6", "text": "certain patients .", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "15013892_3", "wnd_id": "15013892_3_1", "text": "RESULTS : A patient developed a bilaterally symmetric bull's - eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria .", "tokens": ["RESULTS", ":", "A", "patient", "developed", "a", "bilaterally", "symmetric", "bull's", "-", "eye", "maculopathy", "45", "years", "after", "taking", "quinacrine", "for", "18", "months", "as", "prophylaxis", "against", "malaria", "."], "event_mentions": [{"id": "15013892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_3_Ent0", "role": "Effect", "text": "A patient", "start": 2, "end": 4}, {"entity_id": "15013892_3_Ent1", "role": "Effect", "text": "bilaterally symmetric bull's - eye maculopathy", "start": 6, "end": 12}, {"entity_id": "15013892_3_Ent3", "role": "Treatment_Time_elapsed", "text": "45 years after", "start": 12, "end": 15}, {"entity_id": "15013892_3_Ent2", "role": "Treatment", "text": "45 years after taking quinacrine for 18 months", "start": 12, "end": 20}, {"entity_id": "15013892_3_Ent5", "role": "Treatment_Drug", "text": "quinacrine", "start": 16, "end": 17}, {"entity_id": "15013892_3_Ent4", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 18, "end": 20}, {"entity_id": "15013892_3_Ent6", "role": "Treatment_Disorder", "text": "malaria", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15013892_3_Ent0", "text": "A patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_3_Ent1", "text": "bilaterally symmetric bull's - eye maculopathy", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "15013892_3_Ent3", "text": "45 years after", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15013892_3_Ent2", "text": "45 years after taking quinacrine for 18 months", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15013892_3_Ent5", "text": "quinacrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15013892_3_Ent4", "text": "18 months", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15013892_3_Ent6", "text": "malaria", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15028328_2", "wnd_id": "15028328_2_1", "text": "Phenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of stroke and other neurologic events .", "tokens": ["Phenylpropanolamine", "(", "PPA", ")", "recently", "has", "been", "publicly", "implicated", "as", "a", "cause", "of", "stroke", "and", "other", "neurologic", "events", "."], "event_mentions": [{"id": "15028328_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "15028328_2_Ent2", "role": "Treatment_Drug", "text": "Phenylpropanolamine", "start": 0, "end": 1}, {"entity_id": "15028328_2_Ent1", "role": "Treatment", "text": "Phenylpropanolamine ( PPA )", "start": 0, "end": 4}, {"entity_id": "15028328_2_Ent0", "role": "Effect", "text": "stroke and other neurologic events", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "15028328_2_Ent2", "text": "Phenylpropanolamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15028328_2_Ent1", "text": "Phenylpropanolamine ( PPA )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15028328_2_Ent0", "text": "stroke and other neurologic events", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "15028964_5", "wnd_id": "15028964_5_1", "text": "We describe 3 patients on concomitant amiodarone and warfarin who developed amiodarone - induced thyrotoxicosis heralded by a significant decrease in warfarin requirements .", "tokens": ["We", "describe", "3", "patients", "on", "concomitant", "amiodarone", "and", "warfarin", "who", "developed", "amiodarone", "-", "induced", "thyrotoxicosis", "heralded", "by", "a", "significant", "decrease", "in", "warfarin", "requirements", "."], "event_mentions": [{"id": "15028964_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15028964_5_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "15028964_5_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "15028964_5_Ent3", "role": "Treatment", "text": "concomitant amiodarone and warfarin", "start": 5, "end": 9}, {"entity_id": "15028964_5_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "15028964_5_Ent6", "role": "Combination_Drug", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "15028964_5_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 8, "end": 9}, {"entity_id": "15028964_5_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 8, "end": 9}, {"entity_id": "15028964_5_Ent2", "role": "Effect", "text": "amiodarone - induced thyrotoxicosis", "start": 11, "end": 15}]}, {"id": "15028964_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "15028964_5_Ent9", "role": "Treatment", "text": "amiodarone", "start": 11, "end": 12}, {"entity_id": "15028964_5_Ent10", "role": "Treatment_Drug", "text": "amiodarone", "start": 11, "end": 12}, {"entity_id": "15028964_5_Ent8", "role": "Effect", "text": "thyrotoxicosis", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15028964_5_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15028964_5_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15028964_5_Ent3", "text": "concomitant amiodarone and warfarin", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "15028964_5_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15028964_5_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15028964_5_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15028964_5_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15028964_5_Ent9", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15028964_5_Ent10", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15028964_5_Ent2", "text": "amiodarone - induced thyrotoxicosis", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15028964_5_Ent8", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1504404_3", "wnd_id": "1504404_3_1", "text": "DATA SYNTHESIS : A 49 - year - old man developed symptoms of severe psychosis concomitant with ciprofloxacin ( 250 mg bid ) treatment .", "tokens": ["DATA", "SYNTHESIS", ":", "A", "49", "-", "year", "-", "old", "man", "developed", "symptoms", "of", "severe", "psychosis", "concomitant", "with", "ciprofloxacin", "(", "250", "mg", "bid", ")", "treatment", "."], "event_mentions": [{"id": "1504404_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "1504404_3_Ent0", "role": "Subject", "text": "A 49 - year - old man", "start": 3, "end": 10}, {"entity_id": "1504404_3_Ent1", "role": "Subject_Age", "text": "49 - year - old", "start": 4, "end": 9}, {"entity_id": "1504404_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "1504404_3_Ent3", "role": "Effect", "text": "psychosis", "start": 14, "end": 15}, {"entity_id": "1504404_3_Ent4", "role": "Treatment", "text": "ciprofloxacin", "start": 17, "end": 18}, {"entity_id": "1504404_3_Ent5", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 17, "end": 18}, {"entity_id": "1504404_3_Ent6", "role": "Treatment_Dosage", "text": "250 mg bid", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "1504404_3_Ent0", "text": "A 49 - year - old man", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "1504404_3_Ent1", "text": "49 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1504404_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1504404_3_Ent3", "text": "psychosis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1504404_3_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1504404_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1504404_3_Ent6", "text": "250 mg bid", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "15107195_1", "wnd_id": "15107195_1_1", "text": "A case of heatstroke is reported in a 32 - year - old man diagnosed with schizophrenia and on clozapine monotherapy .", "tokens": ["A", "case", "of", "heatstroke", "is", "reported", "in", "a", "32", "-", "year", "-", "old", "man", "diagnosed", "with", "schizophrenia", "and", "on", "clozapine", "monotherapy", "."], "event_mentions": [{"id": "15107195_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 5, "end": 6}, "arguments": [{"entity_id": "15107195_1_Ent3", "role": "Effect", "text": "heatstroke", "start": 3, "end": 4}, {"entity_id": "15107195_1_Ent0", "role": "Subject", "text": "a 32 - year - old man diagnosed with schizophrenia", "start": 7, "end": 17}, {"entity_id": "15107195_1_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 8, "end": 13}, {"entity_id": "15107195_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 13, "end": 14}, {"entity_id": "15107195_1_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "15107195_1_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 19, "end": 20}, {"entity_id": "15107195_1_Ent4", "role": "Treatment", "text": "clozapine monotherapy", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15107195_1_Ent3", "text": "heatstroke", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15107195_1_Ent0", "text": "a 32 - year - old man diagnosed with schizophrenia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "15107195_1_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15107195_1_Ent2", "text": "man", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15107195_1_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15107195_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15107195_1_Ent4", "text": "clozapine monotherapy", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "15112258_14", "wnd_id": "15112258_14_1", "text": "In contrast , other common agents for the most part trigger cutaneous inflammation .", "tokens": ["In", "contrast", ",", "other", "common", "agents", "for", "the", "most", "part", "trigger", "cutaneous", "inflammation", "."], "event_mentions": [{"id": "15112258_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 10, "end": 11}, "arguments": [{"entity_id": "15112258_14_Ent2", "role": "Treatment_Drug", "text": "other common agents", "start": 3, "end": 6}, {"entity_id": "15112258_14_Ent1", "role": "Treatment", "text": "other common agents for the most part", "start": 3, "end": 10}, {"entity_id": "15112258_14_Ent0", "role": "Effect", "text": "cutaneous inflammation", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "15112258_14_Ent2", "text": "other common agents", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15112258_14_Ent1", "text": "other common agents for the most part", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "15112258_14_Ent0", "text": "cutaneous inflammation", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15112258_6", "wnd_id": "15112258_6_1", "text": "The authors performed a literature search using PubMed and the search terms \" gemcitabine \" and \" radiation recall \" to find prior cases of radiation recall attributed to gemcitabine .", "tokens": ["The", "authors", "performed", "a", "literature", "search", "using", "PubMed", "and", "the", "search", "terms", "\"", "gemcitabine", "\"", "and", "\"", "radiation", "recall", "\"", "to", "find", "prior", "cases", "of", "radiation", "recall", "attributed", "to", "gemcitabine", "."], "event_mentions": [{"id": "15112258_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 27, "end": 28}, "arguments": [{"entity_id": "15112258_6_Ent0", "role": "Subject", "text": "prior cases", "start": 22, "end": 24}, {"entity_id": "15112258_6_Ent1", "role": "Effect", "text": "radiation recall", "start": 25, "end": 27}, {"entity_id": "15112258_6_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 29, "end": 30}, {"entity_id": "15112258_6_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "15112258_6_Ent0", "text": "prior cases", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15112258_6_Ent1", "text": "radiation recall", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "15112258_6_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15112258_6_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "15112258_8", "wnd_id": "15112258_8_1", "text": "The literature search found 12 cases of radiation recall caused by gemcitabine .", "tokens": ["The", "literature", "search", "found", "12", "cases", "of", "radiation", "recall", "caused", "by", "gemcitabine", "."], "event_mentions": [{"id": "15112258_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "15112258_8_Ent1", "role": "Subject_Population", "text": "12", "start": 4, "end": 5}, {"entity_id": "15112258_8_Ent0", "role": "Subject", "text": "12 cases", "start": 4, "end": 6}, {"entity_id": "15112258_8_Ent2", "role": "Effect", "text": "radiation recall", "start": 7, "end": 9}, {"entity_id": "15112258_8_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 11, "end": 12}, {"entity_id": "15112258_8_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15112258_8_Ent1", "text": "12", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15112258_8_Ent0", "text": "12 cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15112258_8_Ent2", "text": "radiation recall", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15112258_8_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15112258_8_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15112258_9", "wnd_id": "15112258_9_1", "text": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall , thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13 .", "tokens": ["The", "authors", "also", "determined", "that", "their", "case", "of", "myositis", "developing", "in", "the", "rectus", "abdominus", "muscle", "of", "a", "patient", "with", "pancreatic", "adenocarcinoma", "was", "the", "manifestation", "of", "radiation", "recall", ",", "thereby", "bringing", "the", "number", "of", "patients", "who", "developed", "radiation", "recall", "to", "gemcitabine", "and", "were", "discussed", "in", "the", "current", "study", "to", "13", "."], "event_mentions": [{"id": "15112258_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 35, "end": 36}, "arguments": [{"entity_id": "15112258_9_Ent1", "role": "Effect", "text": "myositis developing in the rectus abdominus muscle", "start": 8, "end": 15}, {"entity_id": "15112258_9_Ent0", "role": "Subject", "text": "a patient with pancreatic adenocarcinoma", "start": 16, "end": 21}, {"entity_id": "15112258_9_Ent4", "role": "Treatment_Disorder", "text": "pancreatic adenocarcinoma", "start": 19, "end": 21}, {"entity_id": "15112258_9_Ent2", "role": "Effect", "text": "radiation recall", "start": 36, "end": 38}, {"entity_id": "15112258_9_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 39, "end": 40}, {"entity_id": "15112258_9_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 39, "end": 40}]}], "entity_mentions": [{"id": "15112258_9_Ent1", "text": "myositis developing in the rectus abdominus muscle", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "15112258_9_Ent0", "text": "a patient with pancreatic adenocarcinoma", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "15112258_9_Ent4", "text": "pancreatic adenocarcinoma", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "15112258_9_Ent2", "text": "radiation recall", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "15112258_9_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15112258_9_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 39, "end": 40}], "lang": "en"}
{"doc_id": "15224368_3", "wnd_id": "15224368_3_1", "text": "We report a case of Sweet 's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia .", "tokens": ["We", "report", "a", "case", "of", "Sweet", "'s", "syndrome", "in", "association", "with", "sargramostim", "treatment", "following", "chemotherapy", "for", "acute", "myelogenous", "leukemia", "."], "event_mentions": [{"id": "15224368_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 9, "end": 10}, "arguments": [{"entity_id": "15224368_3_Ent0", "role": "Effect", "text": "Sweet 's syndrome", "start": 5, "end": 8}, {"entity_id": "15224368_3_Ent2", "role": "Treatment_Drug", "text": "sargramostim", "start": 11, "end": 12}, {"entity_id": "15224368_3_Ent1", "role": "Treatment", "text": "sargramostim treatment following chemotherapy", "start": 11, "end": 15}, {"entity_id": "15224368_3_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 14, "end": 15}, {"entity_id": "15224368_3_Ent4", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "15224368_3_Ent0", "text": "Sweet 's syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15224368_3_Ent2", "text": "sargramostim", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15224368_3_Ent1", "text": "sargramostim treatment following chemotherapy", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15224368_3_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15224368_3_Ent4", "text": "acute myelogenous leukemia", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "15235919_2", "wnd_id": "15235919_2_1", "text": "The autopsy findings and a detailed medical history supported the conclusion that clozapine - induced hypersensitivity myocarditis was the most likely cause of death .", "tokens": ["The", "autopsy", "findings", "and", "a", "detailed", "medical", "history", "supported", "the", "conclusion", "that", "clozapine", "-", "induced", "hypersensitivity", "myocarditis", "was", "the", "most", "likely", "cause", "of", "death", "."], "event_mentions": [{"id": "15235919_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "15235919_2_Ent2", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "15235919_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "15235919_2_Ent0", "role": "Effect", "text": "hypersensitivity myocarditis", "start": 15, "end": 17}, {"entity_id": "15235919_2_Ent1", "role": "Effect", "text": "death", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15235919_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15235919_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15235919_2_Ent0", "text": "hypersensitivity myocarditis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15235919_2_Ent1", "text": "death", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15235919_3", "wnd_id": "15235919_3_1", "text": "The case concerns the sudden death of a 29 - year - old male during clozapine therapy started 2 weeks before .", "tokens": ["The", "case", "concerns", "the", "sudden", "death", "of", "a", "29", "-", "year", "-", "old", "male", "during", "clozapine", "therapy", "started", "2", "weeks", "before", "."], "event_mentions": [{"id": "15235919_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "15235919_3_Ent3", "role": "Effect", "text": "sudden death", "start": 4, "end": 6}, {"entity_id": "15235919_3_Ent0", "role": "Subject", "text": "a 29 - year - old male", "start": 7, "end": 14}, {"entity_id": "15235919_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 8, "end": 13}, {"entity_id": "15235919_3_Ent2", "role": "Subject_Population", "text": "male", "start": 13, "end": 14}, {"entity_id": "15235919_3_Ent4", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks before", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "15235919_3_Ent3", "text": "sudden death", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15235919_3_Ent0", "text": "a 29 - year - old male", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15235919_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15235919_3_Ent2", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15235919_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent6", "text": "2 weeks before", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "15286697_1", "wnd_id": "15286697_1_1", "text": "Fatal pulmonary fibrosis associated with BCNU : the relative role of platelet - derived growth factor - B , insulin - like growth factor I , transforming growth factor - beta1 and cyclooxygenase - 2 .", "tokens": ["Fatal", "pulmonary", "fibrosis", "associated", "with", "BCNU", ":", "the", "relative", "role", "of", "platelet", "-", "derived", "growth", "factor", "-", "B", ",", "insulin", "-", "like", "growth", "factor", "I", ",", "transforming", "growth", "factor", "-", "beta1", "and", "cyclooxygenase", "-", "2", "."], "event_mentions": [{"id": "15286697_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15286697_1_Ent0", "role": "Effect", "text": "pulmonary fibrosis", "start": 1, "end": 3}, {"entity_id": "15286697_1_Ent1", "role": "Treatment", "text": "BCNU", "start": 5, "end": 6}, {"entity_id": "15286697_1_Ent2", "role": "Treatment_Drug", "text": "BCNU", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15286697_1_Ent0", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "15286697_1_Ent1", "text": "BCNU", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15286697_1_Ent2", "text": "BCNU", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15289139_3", "wnd_id": "15289139_3_1", "text": "We document the abrupt development of an extensive choroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open - angle glaucoma .", "tokens": ["We", "document", "the", "abrupt", "development", "of", "an", "extensive", "choroidal", "detachment", "after", "initiation", "of", "dorzolamide", "therapy", "in", "a", "surgically", "untreated", "eye", "with", "primary", "open", "-", "angle", "glaucoma", "."], "event_mentions": [{"id": "15289139_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 4, "end": 5}, "arguments": [{"entity_id": "15289139_3_Ent1", "role": "Effect", "text": "extensive choroidal detachment", "start": 7, "end": 10}, {"entity_id": "15289139_3_Ent3", "role": "Treatment_Drug", "text": "dorzolamide", "start": 13, "end": 14}, {"entity_id": "15289139_3_Ent2", "role": "Treatment", "text": "dorzolamide therapy", "start": 13, "end": 15}, {"entity_id": "15289139_3_Ent0", "role": "Subject", "text": "surgically untreated eye with primary open - angle glaucoma", "start": 17, "end": 26}, {"entity_id": "15289139_3_Ent4", "role": "Treatment_Disorder", "text": "surgically untreated eye with primary open - angle glaucoma", "start": 17, "end": 26}]}], "entity_mentions": [{"id": "15289139_3_Ent1", "text": "extensive choroidal detachment", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15289139_3_Ent3", "text": "dorzolamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15289139_3_Ent2", "text": "dorzolamide therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15289139_3_Ent0", "text": "surgically untreated eye with primary open - angle glaucoma", "entity_type": "Entity", "start": 17, "end": 26}, {"id": "15289139_3_Ent4", "text": "surgically untreated eye with primary open - angle glaucoma", "entity_type": "Entity", "start": 17, "end": 26}], "lang": "en"}
{"doc_id": "15300114_1", "wnd_id": "15300114_1_1", "text": "Deepening of lid sulcus from topical bimatoprost therapy .", "tokens": ["Deepening", "of", "lid", "sulcus", "from", "topical", "bimatoprost", "therapy", "."], "event_mentions": [{"id": "15300114_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 4, "end": 5}, "arguments": [{"entity_id": "15300114_1_Ent0", "role": "Effect", "text": "Deepening of lid sulcus", "start": 0, "end": 4}, {"entity_id": "15300114_1_Ent1", "role": "Treatment", "text": "bimatoprost", "start": 6, "end": 7}, {"entity_id": "15300114_1_Ent2", "role": "Treatment_Drug", "text": "bimatoprost", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15300114_1_Ent0", "text": "Deepening of lid sulcus", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15300114_1_Ent1", "text": "bimatoprost", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15300114_1_Ent2", "text": "bimatoprost", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15304176_1", "wnd_id": "15304176_1_1", "text": "Lichen planus induced by hepatitis B vaccination : a new case and review of the literature .", "tokens": ["Lichen", "planus", "induced", "by", "hepatitis", "B", "vaccination", ":", "a", "new", "case", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15304176_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15304176_1_Ent0", "role": "Effect", "text": "Lichen planus", "start": 0, "end": 2}, {"entity_id": "15304176_1_Ent1", "role": "Treatment", "text": "hepatitis B vaccination", "start": 4, "end": 7}, {"entity_id": "15304176_1_Ent2", "role": "Treatment_Drug", "text": "hepatitis B vaccination", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "15304176_1_Ent0", "text": "Lichen planus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15304176_1_Ent1", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15304176_1_Ent2", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "15316423_2", "wnd_id": "15316423_2_1", "text": "Here we describe a patient with Crohn 's disease who developed a severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion .", "tokens": ["Here", "we", "describe", "a", "patient", "with", "Crohn", "'s", "disease", "who", "developed", "a", "severe", "infliximab", "infusion", "reaction", "(", "IIR", ")", ",", "complicated", "1", "day", "later", "by", "severe", "swelling", "of", "the", "forearm", "and", "hand", "ipsilateral", "to", "the", "site", "of", "infliximab", "infusion", "."], "event_mentions": [{"id": "15316423_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15316423_2_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 3, "end": 9}, {"entity_id": "15316423_2_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 6, "end": 9}, {"entity_id": "15316423_2_Ent1", "role": "Effect", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "start": 12, "end": 33}, {"entity_id": "15316423_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 37, "end": 38}, {"entity_id": "15316423_2_Ent2", "role": "Treatment", "text": "infliximab infusion", "start": 37, "end": 39}, {"entity_id": "15316423_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "15316423_2_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "15316423_2_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15316423_2_Ent1", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "entity_type": "Entity", "start": 12, "end": 33}, {"id": "15316423_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "15316423_2_Ent2", "text": "infliximab infusion", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "15316423_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "15338554_4", "wnd_id": "15338554_4_1", "text": "OBJECTIVES : To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature .", "tokens": ["OBJECTIVES", ":", "To", "describe", "the", "clinicopathologic", "features", "of", "3", "patients", "with", "CML", "who", "rapidly", "progressed", "from", "chronic", "phase", "to", "blast", "crisis", "while", "taking", "imatinib", "and", "to", "perform", "a", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15338554_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "progressed", "start": 14, "end": 15}, "arguments": [{"entity_id": "15338554_4_Ent1", "role": "Subject_Population", "text": "3", "start": 8, "end": 9}, {"entity_id": "15338554_4_Ent0", "role": "Subject", "text": "3 patients with CML", "start": 8, "end": 12}, {"entity_id": "15338554_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 11, "end": 12}, {"entity_id": "15338554_4_Ent2", "role": "Effect", "text": "from chronic phase to blast crisis", "start": 15, "end": 21}, {"entity_id": "15338554_4_Ent3", "role": "Treatment", "text": "imatinib", "start": 23, "end": 24}, {"entity_id": "15338554_4_Ent5", "role": "Treatment_Drug", "text": "imatinib", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15338554_4_Ent1", "text": "3", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15338554_4_Ent0", "text": "3 patients with CML", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15338554_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15338554_4_Ent2", "text": "from chronic phase to blast crisis", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "15338554_4_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15338554_4_Ent5", "text": "imatinib", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15362597_1", "wnd_id": "15362597_1_1", "text": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction .", "tokens": ["Refractory", "hypoglycemia", "from", "ciprofloxacin", "and", "glyburide", "interaction", "."], "event_mentions": [{"id": "15362597_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "15362597_1_Ent0", "role": "Effect", "text": "Refractory hypoglycemia", "start": 0, "end": 2}, {"entity_id": "15362597_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent1", "role": "Treatment", "text": "ciprofloxacin and glyburide interaction", "start": 3, "end": 7}, {"entity_id": "15362597_1_Ent3", "role": "Treatment_Drug", "text": "glyburide", "start": 5, "end": 6}, {"entity_id": "15362597_1_Ent4", "role": "Combination_Drug", "text": "glyburide", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15362597_1_Ent0", "text": "Refractory hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15362597_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent1", "text": "ciprofloxacin and glyburide interaction", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15362597_1_Ent3", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15362597_1_Ent4", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "1536494_2", "wnd_id": "1536494_2_1", "text": "We present a case of ethylenediamine - induced delayed hypersensitivity reaction in a 46 - year - old woman who received parenteral aminophylline for an acute asthma exacerbation .", "tokens": ["We", "present", "a", "case", "of", "ethylenediamine", "-", "induced", "delayed", "hypersensitivity", "reaction", "in", "a", "46", "-", "year", "-", "old", "woman", "who", "received", "parenteral", "aminophylline", "for", "an", "acute", "asthma", "exacerbation", "."], "event_mentions": [{"id": "1536494_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1536494_2_Ent4", "role": "Treatment", "text": "ethylenediamine", "start": 5, "end": 6}, {"entity_id": "1536494_2_Ent5", "role": "Treatment_Drug", "text": "ethylenediamine", "start": 5, "end": 6}, {"entity_id": "1536494_2_Ent3", "role": "Effect", "text": "delayed hypersensitivity reaction", "start": 8, "end": 11}, {"entity_id": "1536494_2_Ent0", "role": "Subject", "text": "a 46 - year - old woman", "start": 12, "end": 19}, {"entity_id": "1536494_2_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 13, "end": 18}, {"entity_id": "1536494_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 18, "end": 19}]}, {"id": "1536494_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "1536494_2_Ent6", "role": "Subject", "text": "a 46 - year - old woman", "start": 12, "end": 19}, {"entity_id": "1536494_2_Ent7", "role": "Subject_Age", "text": "46 - year - old", "start": 13, "end": 18}, {"entity_id": "1536494_2_Ent8", "role": "Subject_Gender", "text": "woman", "start": 18, "end": 19}, {"entity_id": "1536494_2_Ent11", "role": "Treatment_Route", "text": "parenteral", "start": 21, "end": 22}, {"entity_id": "1536494_2_Ent9", "role": "Treatment", "text": "parenteral aminophylline", "start": 21, "end": 23}, {"entity_id": "1536494_2_Ent12", "role": "Treatment_Drug", "text": "aminophylline", "start": 22, "end": 23}, {"entity_id": "1536494_2_Ent10", "role": "Treatment_Disorder", "text": "acute asthma exacerbation", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "1536494_2_Ent4", "text": "ethylenediamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1536494_2_Ent5", "text": "ethylenediamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1536494_2_Ent3", "text": "delayed hypersensitivity reaction", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "1536494_2_Ent0", "text": "a 46 - year - old woman", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "1536494_2_Ent6", "text": "a 46 - year - old woman", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "1536494_2_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "1536494_2_Ent7", "text": "46 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "1536494_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1536494_2_Ent8", "text": "woman", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1536494_2_Ent11", "text": "parenteral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1536494_2_Ent9", "text": "parenteral aminophylline", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1536494_2_Ent12", "text": "aminophylline", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1536494_2_Ent10", "text": "acute asthma exacerbation", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "15368548_2", "wnd_id": "15368548_2_1", "text": "L - asparaginase - induced severe necrotizing pancreatitis successfully treated with percutaneous drainage .", "tokens": ["L", "-", "asparaginase", "-", "induced", "severe", "necrotizing", "pancreatitis", "successfully", "treated", "with", "percutaneous", "drainage", "."], "event_mentions": [{"id": "15368548_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15368548_2_Ent3", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_2_Ent4", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_2_Ent2", "role": "Effect", "text": "severe necrotizing pancreatitis", "start": 5, "end": 8}]}, {"id": "15368548_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "15368548_2_Ent1", "role": "Treatment_Disorder", "text": "L - asparaginase - induced severe necrotizing pancreatitis", "start": 0, "end": 8}, {"entity_id": "15368548_2_Ent0", "role": "Treatment", "text": "percutaneous drainage", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "15368548_2_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_2_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_2_Ent1", "text": "L - asparaginase - induced severe necrotizing pancreatitis", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15368548_2_Ent2", "text": "severe necrotizing pancreatitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15368548_2_Ent0", "text": "percutaneous drainage", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15383642_14", "wnd_id": "15383642_14_1", "text": "With its characteristics , tizanidine has the potential to compromise hemodynamic stability during concomitant angiotensin - converting enzyme inhibitor use .", "tokens": ["With", "its", "characteristics", ",", "tizanidine", "has", "the", "potential", "to", "compromise", "hemodynamic", "stability", "during", "concomitant", "angiotensin", "-", "converting", "enzyme", "inhibitor", "use", "."], "event_mentions": [{"id": "15383642_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "compromise", "start": 9, "end": 10}, "arguments": [{"entity_id": "15383642_14_Ent1", "role": "Treatment", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent0", "role": "Effect", "text": "compromise hemodynamic stability", "start": 9, "end": 12}, {"entity_id": "15383642_14_Ent2", "role": "Treatment", "text": "during concomitant angiotensin - converting enzyme inhibitor use", "start": 12, "end": 20}, {"entity_id": "15383642_14_Ent4", "role": "Treatment_Drug", "text": "angiotensin - converting enzyme inhibitor", "start": 14, "end": 19}, {"entity_id": "15383642_14_Ent6", "role": "Combination_Drug", "text": "angiotensin - converting enzyme inhibitor", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "15383642_14_Ent1", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent0", "text": "compromise hemodynamic stability", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15383642_14_Ent2", "text": "during concomitant angiotensin - converting enzyme inhibitor use", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15383642_14_Ent4", "text": "angiotensin - converting enzyme inhibitor", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "15383642_14_Ent6", "text": "angiotensin - converting enzyme inhibitor", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "15383642_15", "wnd_id": "15383642_15_1", "text": "Based upon the literature review , the hypotension in this patient was possibly due to the interaction between tizanidine and lisinopril .", "tokens": ["Based", "upon", "the", "literature", "review", ",", "the", "hypotension", "in", "this", "patient", "was", "possibly", "due", "to", "the", "interaction", "between", "tizanidine", "and", "lisinopril", "."], "event_mentions": [{"id": "15383642_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 13, "end": 14}, "arguments": [{"entity_id": "15383642_15_Ent1", "role": "Effect", "text": "the hypotension", "start": 6, "end": 8}, {"entity_id": "15383642_15_Ent0", "role": "Subject", "text": "this patient", "start": 9, "end": 11}, {"entity_id": "15383642_15_Ent2", "role": "Treatment", "text": "the interaction between tizanidine and lisinopril", "start": 15, "end": 21}, {"entity_id": "15383642_15_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 18, "end": 19}, {"entity_id": "15383642_15_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 18, "end": 19}, {"entity_id": "15383642_15_Ent4", "role": "Treatment_Drug", "text": "lisinopril", "start": 20, "end": 21}, {"entity_id": "15383642_15_Ent6", "role": "Combination_Drug", "text": "lisinopril", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "15383642_15_Ent1", "text": "the hypotension", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15383642_15_Ent0", "text": "this patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15383642_15_Ent2", "text": "the interaction between tizanidine and lisinopril", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "15383642_15_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15383642_15_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15383642_15_Ent4", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15383642_15_Ent6", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "15461766_2", "wnd_id": "15461766_2_1", "text": "The harlequin color change and association with prostaglandin E1 .", "tokens": ["The", "harlequin", "color", "change", "and", "association", "with", "prostaglandin", "E1", "."], "event_mentions": [{"id": "15461766_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 5, "end": 6}, "arguments": [{"entity_id": "15461766_2_Ent0", "role": "Effect", "text": "harlequin color change", "start": 1, "end": 4}, {"entity_id": "15461766_2_Ent1", "role": "Treatment", "text": "prostaglandin E1", "start": 7, "end": 9}, {"entity_id": "15461766_2_Ent2", "role": "Treatment_Drug", "text": "prostaglandin E1", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "15461766_2_Ent0", "text": "harlequin color change", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15461766_2_Ent1", "text": "prostaglandin E1", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15461766_2_Ent2", "text": "prostaglandin E1", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "15463865_3", "wnd_id": "15463865_3_1", "text": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2 - 3 weeks of oral ciprofloxacin therapy .", "tokens": ["We", "report", "two", "young", "patients", "with", "cystic", "fibrosis", "who", "presented", "with", "acute", "renal", "insufficiency", "after", "2", "-", "3", "weeks", "of", "oral", "ciprofloxacin", "therapy", "."], "event_mentions": [{"id": "15463865_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 9, "end": 10}, "arguments": [{"entity_id": "15463865_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "15463865_3_Ent0", "role": "Subject", "text": "two young patients with cystic fibrosis", "start": 2, "end": 8}, {"entity_id": "15463865_3_Ent2", "role": "Subject_Age", "text": "young", "start": 3, "end": 4}, {"entity_id": "15463865_3_Ent5", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 6, "end": 8}, {"entity_id": "15463865_3_Ent3", "role": "Effect", "text": "acute renal insufficiency", "start": 11, "end": 14}, {"entity_id": "15463865_3_Ent6", "role": "Treatment_Time_elapsed", "text": "2 - 3 weeks", "start": 15, "end": 19}, {"entity_id": "15463865_3_Ent4", "role": "Treatment", "text": "2 - 3 weeks of oral ciprofloxacin therapy", "start": 15, "end": 23}, {"entity_id": "15463865_3_Ent8", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}, {"entity_id": "15463865_3_Ent7", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15463865_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15463865_3_Ent0", "text": "two young patients with cystic fibrosis", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "15463865_3_Ent2", "text": "young", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15463865_3_Ent5", "text": "cystic fibrosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15463865_3_Ent3", "text": "acute renal insufficiency", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15463865_3_Ent6", "text": "2 - 3 weeks", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "15463865_3_Ent4", "text": "2 - 3 weeks of oral ciprofloxacin therapy", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "15463865_3_Ent8", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15463865_3_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15494638_18", "wnd_id": "15494638_18_1", "text": "The etiology of neurotoxicity in our two patients remains unclear ; however , as CAP is rapidly metabolized to 5 - FU in patients with normal liver function , it is likely that 5 - FU or its active metabolites ( fluoro - beta - alanine ) were contributing factors .", "tokens": ["The", "etiology", "of", "neurotoxicity", "in", "our", "two", "patients", "remains", "unclear", ";", "however", ",", "as", "CAP", "is", "rapidly", "metabolized", "to", "5", "-", "FU", "in", "patients", "with", "normal", "liver", "function", ",", "it", "is", "likely", "that", "5", "-", "FU", "or", "its", "active", "metabolites", "(", "fluoro", "-", "beta", "-", "alanine", ")", "were", "contributing", "factors", "."], "event_mentions": [{"id": "15494638_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributing", "start": 48, "end": 49}, "arguments": [{"entity_id": "15494638_18_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 3, "end": 4}, {"entity_id": "15494638_18_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "15494638_18_Ent0", "role": "Subject", "text": "two patients", "start": 6, "end": 8}, {"entity_id": "15494638_18_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 33, "end": 36}, {"entity_id": "15494638_18_Ent3", "role": "Treatment", "text": "5 - FU or its active metabolites ( fluoro - beta - alanine )", "start": 33, "end": 47}, {"entity_id": "15494638_18_Ent5", "role": "Treatment_Drug", "text": "fluoro - beta - alanine", "start": 41, "end": 46}]}], "entity_mentions": [{"id": "15494638_18_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15494638_18_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_18_Ent0", "text": "two patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15494638_18_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 33, "end": 36}, {"id": "15494638_18_Ent3", "text": "5 - FU or its active metabolites ( fluoro - beta - alanine )", "entity_type": "Entity", "start": 33, "end": 47}, {"id": "15494638_18_Ent5", "text": "fluoro - beta - alanine", "entity_type": "Entity", "start": 41, "end": 46}], "lang": "en"}
{"doc_id": "15494638_20", "wnd_id": "15494638_20_1", "text": "Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A , with no recurrence after reinitiating CAP alone at 2000 mg / m2 .", "tokens": ["Neurologic", "symptoms", "resolved", "after", "stopping", "CAP", "for", "4", "weeks", "in", "Patient", "A", ",", "with", "no", "recurrence", "after", "reinitiating", "CAP", "alone", "at", "2000", "mg", "/", "m2", "."], "event_mentions": [{"id": "15494638_20_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "15494638_20_Ent0", "role": "Effect", "text": "Neurologic symptoms resolved", "start": 0, "end": 3}, {"entity_id": "15494638_20_Ent1", "role": "Treatment", "text": "stopping CAP for 4 weeks", "start": 4, "end": 9}, {"entity_id": "15494638_20_Ent2", "role": "Treatment_Drug", "text": "CAP", "start": 5, "end": 6}, {"entity_id": "15494638_20_Ent3", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "15494638_20_Ent0", "text": "Neurologic symptoms resolved", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_20_Ent1", "text": "stopping CAP for 4 weeks", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15494638_20_Ent2", "text": "CAP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15494638_20_Ent3", "text": "4 weeks", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "15494638_4", "wnd_id": "15494638_4_1", "text": "During analysis of 28 patients receiving CAP with concomitant radiation ( XRT ) for pancreatic cancer ( resected or locally advanced ) , two patients developed signs and symptoms consistent with peripheral neuropathy .", "tokens": ["During", "analysis", "of", "28", "patients", "receiving", "CAP", "with", "concomitant", "radiation", "(", "XRT", ")", "for", "pancreatic", "cancer", "(", "resected", "or", "locally", "advanced", ")", ",", "two", "patients", "developed", "signs", "and", "symptoms", "consistent", "with", "peripheral", "neuropathy", "."], "event_mentions": [{"id": "15494638_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "15494638_4_Ent5", "role": "Treatment_Drug", "text": "CAP", "start": 6, "end": 7}, {"entity_id": "15494638_4_Ent3", "role": "Treatment", "text": "CAP with concomitant radiation ( XRT )", "start": 6, "end": 13}, {"entity_id": "15494638_4_Ent6", "role": "Treatment_Route", "text": "concomitant radiation", "start": 8, "end": 10}, {"entity_id": "15494638_4_Ent4", "role": "Treatment_Disorder", "text": "pancreatic cancer", "start": 14, "end": 16}, {"entity_id": "15494638_4_Ent1", "role": "Subject_Population", "text": "two", "start": 23, "end": 24}, {"entity_id": "15494638_4_Ent0", "role": "Subject", "text": "two patients", "start": 23, "end": 25}, {"entity_id": "15494638_4_Ent2", "role": "Effect", "text": "peripheral neuropathy", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "15494638_4_Ent5", "text": "CAP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_4_Ent3", "text": "CAP with concomitant radiation ( XRT )", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "15494638_4_Ent6", "text": "concomitant radiation", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15494638_4_Ent4", "text": "pancreatic cancer", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15494638_4_Ent1", "text": "two", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15494638_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "15494638_4_Ent2", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "15494638_8", "wnd_id": "15494638_8_1", "text": "Patient B developed perioral and upper extremity paresthesias during the fourth cycle of CAP alone ( 2500 mg / m2 ) .", "tokens": ["Patient", "B", "developed", "perioral", "and", "upper", "extremity", "paresthesias", "during", "the", "fourth", "cycle", "of", "CAP", "alone", "(", "2500", "mg", "/", "m2", ")", "."], "event_mentions": [{"id": "15494638_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15494638_8_Ent0", "role": "Subject", "text": "Patient B", "start": 0, "end": 2}, {"entity_id": "15494638_8_Ent1", "role": "Effect", "text": "perioral and upper extremity paresthesias", "start": 3, "end": 8}, {"entity_id": "15494638_8_Ent4", "role": "Treatment_Freq", "text": "the fourth cycle", "start": 9, "end": 12}, {"entity_id": "15494638_8_Ent2", "role": "Treatment", "text": "the fourth cycle of CAP alone ( 2500 mg / m2 )", "start": 9, "end": 21}, {"entity_id": "15494638_8_Ent3", "role": "Treatment_Drug", "text": "CAP", "start": 13, "end": 14}, {"entity_id": "15494638_8_Ent5", "role": "Treatment_Dosage", "text": "2500 mg / m2", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "15494638_8_Ent0", "text": "Patient B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15494638_8_Ent1", "text": "perioral and upper extremity paresthesias", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15494638_8_Ent4", "text": "the fourth cycle", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15494638_8_Ent2", "text": "the fourth cycle of CAP alone ( 2500 mg / m2 )", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "15494638_8_Ent3", "text": "CAP", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15494638_8_Ent5", "text": "2500 mg / m2", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "15507779_2", "wnd_id": "15507779_2_1", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus ( HIV) - infected patients and in post - exposure prophylaxis .", "tokens": ["Nevirapine", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "used", "in", "the", "treatment", "of", "human", "immunodeficiency", "virus", "(", "HIV)", "-", "infected", "patients", "and", "in", "post", "-", "exposure", "prophylaxis", "."], "event_mentions": [{"id": "15507779_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 12, "end": 13}, "arguments": [{"entity_id": "15507779_2_Ent1", "role": "Treatment", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "15507779_2_Ent2", "role": "Treatment_Drug", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "15507779_2_Ent0", "role": "Subject", "text": "human immunodeficiency virus ( HIV) - infected patients", "start": 14, "end": 22}, {"entity_id": "15507779_2_Ent3", "role": "Treatment_Disorder", "text": "immunodeficiency virus", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "15507779_2_Ent1", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15507779_2_Ent2", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15507779_2_Ent0", "text": "human immunodeficiency virus ( HIV) - infected patients", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "15507779_2_Ent3", "text": "immunodeficiency virus", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15516308_1", "wnd_id": "15516308_1_1", "text": "Fatal overdoses associated with quetiapine .", "tokens": ["Fatal", "overdoses", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "15516308_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15516308_1_Ent0", "role": "Effect", "text": "Fatal overdoses", "start": 0, "end": 2}, {"entity_id": "15516308_1_Ent1", "role": "Treatment", "text": "quetiapine", "start": 4, "end": 5}, {"entity_id": "15516308_1_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "15516308_1_Ent0", "text": "Fatal overdoses", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15516308_1_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15516308_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "15516308_3", "wnd_id": "15516308_3_1", "text": "We present three cases from the Provincial Toxicology Center of British Columbia , Canada in which suicidal overdose deaths were associated with quetiapine .", "tokens": ["We", "present", "three", "cases", "from", "the", "Provincial", "Toxicology", "Center", "of", "British", "Columbia", ",", "Canada", "in", "which", "suicidal", "overdose", "deaths", "were", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "15516308_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15516308_3_Ent0", "role": "Effect", "text": "suicidal overdose deaths", "start": 16, "end": 19}, {"entity_id": "15516308_3_Ent1", "role": "Treatment", "text": "quetiapine", "start": 22, "end": 23}, {"entity_id": "15516308_3_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15516308_3_Ent0", "text": "suicidal overdose deaths", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15516308_3_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15516308_3_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15522120_4", "wnd_id": "15522120_4_1", "text": "SSRI - drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects .", "tokens": ["SSRI", "-", "drugs", "increase", "serotonin", "concentrations", "and", "are", "known", "to", "have", "pruritus", "and", "other", "dermal", "side", "effects", "."], "event_mentions": [{"id": "15522120_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 3, "end": 4}, "arguments": [{"entity_id": "15522120_4_Ent3", "role": "Treatment_Drug", "text": "SSRI", "start": 0, "end": 1}, {"entity_id": "15522120_4_Ent2", "role": "Treatment", "text": "SSRI - drugs", "start": 0, "end": 3}, {"entity_id": "15522120_4_Ent0", "role": "Effect", "text": "increase serotonin concentrations", "start": 3, "end": 6}, {"entity_id": "15522120_4_Ent1", "role": "Effect", "text": "pruritus and other dermal side effects .", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "15522120_4_Ent3", "text": "SSRI", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15522120_4_Ent2", "text": "SSRI - drugs", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15522120_4_Ent0", "text": "increase serotonin concentrations", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15522120_4_Ent1", "text": "pruritus and other dermal side effects .", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "15533031_2", "wnd_id": "15533031_2_1", "text": "We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine , a centrally acting analgesic and antispastic drug .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "increased", "cerebral", "cortical", "excitability", "following", "intoxication", "with", "flupirtine", ",", "a", "centrally", "acting", "analgesic", "and", "antispastic", "drug", "."], "event_mentions": [{"id": "15533031_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 12, "end": 13}, "arguments": [{"entity_id": "15533031_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "15533031_2_Ent1", "role": "Effect", "text": "increased cerebral cortical excitability", "start": 8, "end": 12}, {"entity_id": "15533031_2_Ent2", "role": "Treatment", "text": "flupirtine", "start": 15, "end": 16}, {"entity_id": "15533031_2_Ent3", "role": "Treatment_Drug", "text": "flupirtine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15533031_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15533031_2_Ent1", "text": "increased cerebral cortical excitability", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15533031_2_Ent2", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15533031_2_Ent3", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15543388_2", "wnd_id": "15543388_2_1", "text": "Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.", "tokens": ["Celiac", "disease", "onset", "after", "pegylated", "interferon", "and", "ribavirin", "treatment", "of", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15543388_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 2, "end": 3}, "arguments": [{"entity_id": "15543388_2_Ent0", "role": "Effect", "text": "Celiac disease", "start": 0, "end": 2}, {"entity_id": "15543388_2_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent5", "role": "Combination_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent1", "role": "Treatment", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "start": 4, "end": 13}, {"entity_id": "15543388_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent6", "role": "Combination_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "15543388_2_Ent0", "text": "Celiac disease", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15543388_2_Ent2", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent5", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent1", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15543388_2_Ent3", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent6", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "15549981_1", "wnd_id": "15549981_1_1", "text": "We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine , but occurred following the administration of the alpha - agonist metaraminol .", "tokens": ["We", "present", "two", "cases", "of", "anaphylaxis", "under", "anaesthesia", "where", "return", "of", "spontaneous", "circulation", "was", "refractory", "to", "epinephrine", ",", "but", "occurred", "following", "the", "administration", "of", "the", "alpha", "-", "agonist", "metaraminol", "."], "event_mentions": [{"id": "15549981_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "occurred", "start": 19, "end": 20}, "arguments": [{"entity_id": "15549981_1_Ent3", "role": "Treatment_Disorder", "text": "anaphylaxis under anaesthesia", "start": 5, "end": 8}, {"entity_id": "15549981_1_Ent0", "role": "Effect", "text": "return of spontaneous circulation", "start": 9, "end": 13}, {"entity_id": "15549981_1_Ent1", "role": "Treatment", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent5", "role": "Treatment_Drug", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent6", "role": "Combination_Drug", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent2", "role": "Treatment", "text": "administration of the alpha - agonist metaraminol", "start": 22, "end": 29}, {"entity_id": "15549981_1_Ent4", "role": "Treatment_Drug", "text": "metaraminol", "start": 28, "end": 29}, {"entity_id": "15549981_1_Ent7", "role": "Combination_Drug", "text": "metaraminol", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "15549981_1_Ent3", "text": "anaphylaxis under anaesthesia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15549981_1_Ent0", "text": "return of spontaneous circulation", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "15549981_1_Ent1", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent5", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent6", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent2", "text": "administration of the alpha - agonist metaraminol", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "15549981_1_Ent4", "text": "metaraminol", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "15549981_1_Ent7", "text": "metaraminol", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "15580406_3", "wnd_id": "15580406_3_1", "text": "Vogt - Koyanagi - Harada disease occurring during interferon alpha therapy for chronic hepatitis C.", "tokens": ["Vogt", "-", "Koyanagi", "-", "Harada", "disease", "occurring", "during", "interferon", "alpha", "therapy", "for", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15580406_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 6, "end": 7}, "arguments": [{"entity_id": "15580406_3_Ent0", "role": "Effect", "text": "Vogt - Koyanagi - Harada disease", "start": 0, "end": 6}, {"entity_id": "15580406_3_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 8, "end": 10}, {"entity_id": "15580406_3_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 8, "end": 10}, {"entity_id": "15580406_3_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "15580406_3_Ent0", "text": "Vogt - Koyanagi - Harada disease", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15580406_3_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15580406_3_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15580406_3_Ent3", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "15588385_1", "wnd_id": "15588385_1_1", "text": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil ( PTU ) use for hyperthyroidism .", "tokens": ["Acute", "hepatic", "failure", "is", "a", "rare", "and", "potentially", "lethal", "complication", "of", "propylthiouracil", "(", "PTU", ")", "use", "for", "hyperthyroidism", "."], "event_mentions": [{"id": "15588385_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "15588385_1_Ent0", "role": "Effect", "text": "Acute hepatic failure", "start": 0, "end": 3}, {"entity_id": "15588385_1_Ent3", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 11, "end": 12}, {"entity_id": "15588385_1_Ent1", "role": "Treatment", "text": "propylthiouracil ( PTU )", "start": 11, "end": 15}, {"entity_id": "15588385_1_Ent2", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15588385_1_Ent0", "text": "Acute hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15588385_1_Ent3", "text": "propylthiouracil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15588385_1_Ent1", "text": "propylthiouracil ( PTU )", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15588385_1_Ent2", "text": "hyperthyroidism", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15588385_2", "wnd_id": "15588385_2_1", "text": "After an extensive review of the literature , we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU - induced fulminant hepatitis .", "tokens": ["After", "an", "extensive", "review", "of", "the", "literature", ",", "we", "believe", "that", "this", "is", "the", "first", "communication", "of", "the", "successful", "use", "of", "amiodarone", "to", "control", "hyperthyroidism", "in", "a", "patient", "with", "PTU", "-", "induced", "fulminant", "hepatitis", "."], "event_mentions": [{"id": "15588385_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "control", "start": 23, "end": 24}, "arguments": [{"entity_id": "15588385_2_Ent2", "role": "Treatment", "text": "amiodarone", "start": 21, "end": 22}, {"entity_id": "15588385_2_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 21, "end": 22}, {"entity_id": "15588385_2_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 24, "end": 25}, {"entity_id": "15588385_2_Ent0", "role": "Subject", "text": "a patient with PTU - induced fulminant hepatitis", "start": 26, "end": 34}, {"entity_id": "15588385_2_Ent1", "role": "Subject_Disorder", "text": "PTU - induced fulminant hepatitis", "start": 29, "end": 34}]}, {"id": "15588385_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 31, "end": 32}, "arguments": [{"entity_id": "15588385_2_Ent6", "role": "Treatment", "text": "PTU", "start": 29, "end": 30}, {"entity_id": "15588385_2_Ent7", "role": "Treatment_Drug", "text": "PTU", "start": 29, "end": 30}, {"entity_id": "15588385_2_Ent5", "role": "Effect", "text": "fulminant hepatitis", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "15588385_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15588385_2_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15588385_2_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15588385_2_Ent0", "text": "a patient with PTU - induced fulminant hepatitis", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "15588385_2_Ent6", "text": "PTU", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15588385_2_Ent7", "text": "PTU", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15588385_2_Ent1", "text": "PTU - induced fulminant hepatitis", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "15588385_2_Ent5", "text": "fulminant hepatitis", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "15588385_3", "wnd_id": "15588385_3_1", "text": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil - induced acute hepatic failure .", "tokens": ["Successful", "treatment", "of", "hyperthyroidism", "with", "amiodarone", "in", "a", "patient", "with", "propylthiouracil", "-", "induced", "acute", "hepatic", "failure", "."], "event_mentions": [{"id": "15588385_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 1, "end": 2}, "arguments": [{"entity_id": "15588385_3_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 3, "end": 4}, {"entity_id": "15588385_3_Ent2", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "15588385_3_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "15588385_3_Ent0", "role": "Subject", "text": "a patient with propylthiouracil - induced acute hepatic failure", "start": 7, "end": 16}, {"entity_id": "15588385_3_Ent1", "role": "Subject_Disorder", "text": "propylthiouracil - induced acute hepatic failure", "start": 10, "end": 16}]}, {"id": "15588385_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "15588385_3_Ent6", "role": "Treatment", "text": "propylthiouracil", "start": 10, "end": 11}, {"entity_id": "15588385_3_Ent7", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 10, "end": 11}, {"entity_id": "15588385_3_Ent5", "role": "Effect", "text": "acute hepatic failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15588385_3_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15588385_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15588385_3_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15588385_3_Ent0", "text": "a patient with propylthiouracil - induced acute hepatic failure", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15588385_3_Ent6", "text": "propylthiouracil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15588385_3_Ent7", "text": "propylthiouracil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15588385_3_Ent1", "text": "propylthiouracil - induced acute hepatic failure", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "15588385_3_Ent5", "text": "acute hepatic failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15595320_2", "wnd_id": "15595320_2_1", "text": "Methotrexate ( MTX ) is a commonly used second line agent for RA , and there have been several recent reports of Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder in MTX - treated RA patients .", "tokens": ["Methotrexate", "(", "MTX", ")", "is", "a", "commonly", "used", "second", "line", "agent", "for", "RA", ",", "and", "there", "have", "been", "several", "recent", "reports", "of", "Epstein", "-", "Barr", "virus", "(", "EBV)", "-", "associated", "polyclonal", "B", "cell", "lymphoproliferative", "disorder", "in", "MTX", "-", "treated", "RA", "patients", "."], "event_mentions": [{"id": "15595320_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reports", "start": 20, "end": 21}, "arguments": [{"entity_id": "15595320_2_Ent1", "role": "Effect", "text": "Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder", "start": 22, "end": 35}, {"entity_id": "15595320_2_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 36, "end": 37}, {"entity_id": "15595320_2_Ent2", "role": "Treatment", "text": "MTX - treated", "start": 36, "end": 39}, {"entity_id": "15595320_2_Ent4", "role": "Treatment_Disorder", "text": "RA", "start": 39, "end": 40}, {"entity_id": "15595320_2_Ent0", "role": "Subject", "text": "RA patients", "start": 39, "end": 41}]}], "entity_mentions": [{"id": "15595320_2_Ent1", "text": "Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder", "entity_type": "Entity", "start": 22, "end": 35}, {"id": "15595320_2_Ent3", "text": "MTX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15595320_2_Ent2", "text": "MTX - treated", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "15595320_2_Ent4", "text": "RA", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15595320_2_Ent0", "text": "RA patients", "entity_type": "Entity", "start": 39, "end": 41}], "lang": "en"}
{"doc_id": "15606443_2", "wnd_id": "15606443_2_1", "text": "Rosiglitazone , a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus , is predominantly metabolized by the cytochrome P450 ( CYP ) enzyme CYP2C8 .", "tokens": ["Rosiglitazone", ",", "a", "thiazolidinedione", "antidiabetic", "medication", "used", "in", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus", ",", "is", "predominantly", "metabolized", "by", "the", "cytochrome", "P450", "(", "CYP", ")", "enzyme", "CYP2C8", "."], "event_mentions": [{"id": "15606443_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 6, "end": 7}, "arguments": [{"entity_id": "15606443_2_Ent0", "role": "Treatment", "text": "Rosiglitazone", "start": 0, "end": 1}, {"entity_id": "15606443_2_Ent2", "role": "Treatment_Drug", "text": "Rosiglitazone", "start": 0, "end": 1}, {"entity_id": "15606443_2_Ent1", "role": "Treatment", "text": "a thiazolidinedione antidiabetic medication", "start": 2, "end": 6}, {"entity_id": "15606443_2_Ent3", "role": "Treatment_Drug", "text": "thiazolidinedione antidiabetic medication", "start": 3, "end": 6}, {"entity_id": "15606443_2_Ent4", "role": "Treatment_Disorder", "text": "Type 2 diabetes mellitus", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "15606443_2_Ent0", "text": "Rosiglitazone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15606443_2_Ent2", "text": "Rosiglitazone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15606443_2_Ent1", "text": "a thiazolidinedione antidiabetic medication", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "15606443_2_Ent3", "text": "thiazolidinedione antidiabetic medication", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15606443_2_Ent4", "text": "Type 2 diabetes mellitus", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "15628319_1", "wnd_id": "15628319_1_1", "text": "Allergic side effects of AZA are rare , and reported allergic skin eruptions from AZA are very limited in Japan .", "tokens": ["Allergic", "side", "effects", "of", "AZA", "are", "rare", ",", "and", "reported", "allergic", "skin", "eruptions", "from", "AZA", "are", "very", "limited", "in", "Japan", "."], "event_mentions": [{"id": "15628319_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 13, "end": 14}, "arguments": [{"entity_id": "15628319_1_Ent0", "role": "Effect", "text": "allergic skin eruptions", "start": 10, "end": 13}, {"entity_id": "15628319_1_Ent1", "role": "Treatment", "text": "AZA", "start": 14, "end": 15}, {"entity_id": "15628319_1_Ent2", "role": "Treatment_Drug", "text": "AZA", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15628319_1_Ent0", "text": "allergic skin eruptions", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15628319_1_Ent1", "text": "AZA", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15628319_1_Ent2", "text": "AZA", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15628319_3", "wnd_id": "15628319_3_1", "text": "Drug eruption caused by azathioprine : value of using the drug - induced lymphocytes stimulation test for diagnosis .", "tokens": ["Drug", "eruption", "caused", "by", "azathioprine", ":", "value", "of", "using", "the", "drug", "-", "induced", "lymphocytes", "stimulation", "test", "for", "diagnosis", "."], "event_mentions": [{"id": "15628319_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "15628319_3_Ent0", "role": "Effect", "text": "Drug eruption", "start": 0, "end": 2}, {"entity_id": "15628319_3_Ent1", "role": "Treatment", "text": "azathioprine", "start": 4, "end": 5}, {"entity_id": "15628319_3_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "15628319_3_Ent0", "text": "Drug eruption", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15628319_3_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15628319_3_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "15628319_4", "wnd_id": "15628319_4_1", "text": "We report AZA - induced drug eruption that developed in two cases of systemic scleroderma with polymyositis .", "tokens": ["We", "report", "AZA", "-", "induced", "drug", "eruption", "that", "developed", "in", "two", "cases", "of", "systemic", "scleroderma", "with", "polymyositis", "."], "event_mentions": [{"id": "15628319_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15628319_4_Ent3", "role": "Treatment", "text": "AZA", "start": 2, "end": 3}, {"entity_id": "15628319_4_Ent4", "role": "Treatment_Drug", "text": "AZA", "start": 2, "end": 3}, {"entity_id": "15628319_4_Ent2", "role": "Effect", "text": "drug eruption", "start": 5, "end": 7}, {"entity_id": "15628319_4_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "15628319_4_Ent0", "role": "Subject", "text": "two cases of systemic scleroderma with polymyositis", "start": 10, "end": 17}, {"entity_id": "15628319_4_Ent5", "role": "Treatment_Disorder", "text": "systemic scleroderma with polymyositis", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "15628319_4_Ent3", "text": "AZA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15628319_4_Ent4", "text": "AZA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15628319_4_Ent2", "text": "drug eruption", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15628319_4_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15628319_4_Ent0", "text": "two cases of systemic scleroderma with polymyositis", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "15628319_4_Ent5", "text": "systemic scleroderma with polymyositis", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "15663666_1", "wnd_id": "15663666_1_1", "text": "Scrotal ulceration induced by all - trans retinoic acid in a patient with acute promyelocytic leukemia .", "tokens": ["Scrotal", "ulceration", "induced", "by", "all", "-", "trans", "retinoic", "acid", "in", "a", "patient", "with", "acute", "promyelocytic", "leukemia", "."], "event_mentions": [{"id": "15663666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15663666_1_Ent1", "role": "Effect", "text": "Scrotal ulceration", "start": 0, "end": 2}, {"entity_id": "15663666_1_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "15663666_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "15663666_1_Ent0", "role": "Subject", "text": "a patient with acute promyelocytic leukemia .", "start": 10, "end": 17}, {"entity_id": "15663666_1_Ent4", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15663666_1_Ent1", "text": "Scrotal ulceration", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15663666_1_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15663666_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15663666_1_Ent0", "text": "a patient with acute promyelocytic leukemia .", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "15663666_1_Ent4", "text": "acute promyelocytic leukemia", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15694139_7", "wnd_id": "15694139_7_1", "text": "Children treated with thalidomide should undergo regular neurophysiologic studies in order to detect presymptomatic or progressive peripheral neuropathy .", "tokens": ["Children", "treated", "with", "thalidomide", "should", "undergo", "regular", "neurophysiologic", "studies", "in", "order", "to", "detect", "presymptomatic", "or", "progressive", "peripheral", "neuropathy", "."], "event_mentions": [{"id": "15694139_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "detect", "start": 12, "end": 13}, "arguments": [{"entity_id": "15694139_7_Ent0", "role": "Subject", "text": "Children", "start": 0, "end": 1}, {"entity_id": "15694139_7_Ent1", "role": "Subject_Age", "text": "Children", "start": 0, "end": 1}, {"entity_id": "15694139_7_Ent3", "role": "Treatment", "text": "thalidomide", "start": 3, "end": 4}, {"entity_id": "15694139_7_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 3, "end": 4}, {"entity_id": "15694139_7_Ent2", "role": "Effect", "text": "presymptomatic or progressive peripheral neuropathy", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "15694139_7_Ent0", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_7_Ent1", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_7_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15694139_7_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15694139_7_Ent2", "text": "presymptomatic or progressive peripheral neuropathy", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "15701285_1", "wnd_id": "15701285_1_1", "text": "Cerebral edema associated with Gliadel wafers : two case studies .", "tokens": ["Cerebral", "edema", "associated", "with", "Gliadel", "wafers", ":", "two", "case", "studies", "."], "event_mentions": [{"id": "15701285_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15701285_1_Ent0", "role": "Effect", "text": "Cerebral edema", "start": 0, "end": 2}, {"entity_id": "15701285_1_Ent2", "role": "Treatment_Drug", "text": "Gliadel", "start": 4, "end": 5}, {"entity_id": "15701285_1_Ent1", "role": "Treatment", "text": "Gliadel wafers", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "15701285_1_Ent0", "text": "Cerebral edema", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15701285_1_Ent2", "text": "Gliadel", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15701285_1_Ent1", "text": "Gliadel wafers", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "15735923_1", "wnd_id": "15735923_1_1", "text": "Treatment - related myelodysplastic syndrome after temozolomide for recurrent high - grade glioma .", "tokens": ["Treatment", "-", "related", "myelodysplastic", "syndrome", "after", "temozolomide", "for", "recurrent", "high", "-", "grade", "glioma", "."], "event_mentions": [{"id": "15735923_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "15735923_1_Ent0", "role": "Effect", "text": "myelodysplastic syndrome", "start": 3, "end": 5}, {"entity_id": "15735923_1_Ent1", "role": "Treatment", "text": "temozolomide", "start": 6, "end": 7}, {"entity_id": "15735923_1_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 6, "end": 7}, {"entity_id": "15735923_1_Ent3", "role": "Treatment_Disorder", "text": "recurrent high - grade glioma", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "15735923_1_Ent0", "text": "myelodysplastic syndrome", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15735923_1_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15735923_1_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15735923_1_Ent3", "text": "recurrent high - grade glioma", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "15735923_3", "wnd_id": "15735923_3_1", "text": "We report a 44 - year - old woman with t - MDS ( refractory anemia with excess blasts ) following treatment of recurrent anaplastic astrocytoma with temozolomide ( TMZ ) .", "tokens": ["We", "report", "a", "44", "-", "year", "-", "old", "woman", "with", "t", "-", "MDS", "(", "refractory", "anemia", "with", "excess", "blasts", ")", "following", "treatment", "of", "recurrent", "anaplastic", "astrocytoma", "with", "temozolomide", "(", "TMZ", ")", "."], "event_mentions": [{"id": "15735923_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "15735923_3_Ent3", "role": "Subject_Population", "text": "a", "start": 2, "end": 3}, {"entity_id": "15735923_3_Ent0", "role": "Subject", "text": "a 44 - year - old woman", "start": 2, "end": 9}, {"entity_id": "15735923_3_Ent1", "role": "Subject_Age", "text": "44 - year - old", "start": 3, "end": 8}, {"entity_id": "15735923_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "15735923_3_Ent4", "role": "Effect", "text": "t - MDS ( refractory anemia with excess blasts )", "start": 10, "end": 20}, {"entity_id": "15735923_3_Ent5", "role": "Treatment", "text": "treatment of recurrent anaplastic astrocytoma with temozolomide ( TMZ )", "start": 21, "end": 31}, {"entity_id": "15735923_3_Ent6", "role": "Treatment_Disorder", "text": "recurrent anaplastic astrocytoma", "start": 23, "end": 26}, {"entity_id": "15735923_3_Ent7", "role": "Treatment_Drug", "text": "temozolomide", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "15735923_3_Ent3", "text": "a", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15735923_3_Ent0", "text": "a 44 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "15735923_3_Ent1", "text": "44 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15735923_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15735923_3_Ent4", "text": "t - MDS ( refractory anemia with excess blasts )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "15735923_3_Ent5", "text": "treatment of recurrent anaplastic astrocytoma with temozolomide ( TMZ )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "15735923_3_Ent6", "text": "recurrent anaplastic astrocytoma", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15735923_3_Ent7", "text": "temozolomide", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "1575118_1", "wnd_id": "1575118_1_1", "text": "Typically , drug - induced neutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more .", "tokens": ["Typically", ",", "drug", "-", "induced", "neutropenia", "occurs", "in", "a", "patient", "receiving", "a", "semisynthetic", "penicillin", "for", "two", "weeks", "or", "more", "."], "event_mentions": [{"id": "1575118_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 6, "end": 7}, "arguments": [{"entity_id": "1575118_1_Ent1", "role": "Effect", "text": "drug - induced neutropenia", "start": 2, "end": 6}, {"entity_id": "1575118_1_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "1575118_1_Ent2", "role": "Treatment", "text": "a semisynthetic penicillin for two weeks or more", "start": 11, "end": 19}, {"entity_id": "1575118_1_Ent3", "role": "Treatment_Drug", "text": "semisynthetic penicillin", "start": 12, "end": 14}, {"entity_id": "1575118_1_Ent4", "role": "Treatment_Duration", "text": "two weeks", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "1575118_1_Ent1", "text": "drug - induced neutropenia", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "1575118_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1575118_1_Ent2", "text": "a semisynthetic penicillin for two weeks or more", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "1575118_1_Ent3", "text": "semisynthetic penicillin", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1575118_1_Ent4", "text": "two weeks", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15760792_1", "wnd_id": "15760792_1_1", "text": "CONCLUSION : This rare case of PTU - induced ANCA - associated vasculitis manifested with ototoxicity in combination with systemic involvement .", "tokens": ["CONCLUSION", ":", "This", "rare", "case", "of", "PTU", "-", "induced", "ANCA", "-", "associated", "vasculitis", "manifested", "with", "ototoxicity", "in", "combination", "with", "systemic", "involvement", "."], "event_mentions": [{"id": "15760792_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "15760792_1_Ent1", "role": "Treatment", "text": "PTU", "start": 6, "end": 7}, {"entity_id": "15760792_1_Ent2", "role": "Treatment_Drug", "text": "PTU", "start": 6, "end": 7}, {"entity_id": "15760792_1_Ent0", "role": "Effect", "text": "ANCA - associated vasculitis manifested with ototoxicity in combination with systemic involvement", "start": 9, "end": 21}]}], "entity_mentions": [{"id": "15760792_1_Ent1", "text": "PTU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15760792_1_Ent2", "text": "PTU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15760792_1_Ent0", "text": "ANCA - associated vasculitis manifested with ototoxicity in combination with systemic involvement", "entity_type": "Entity", "start": 9, "end": 21}], "lang": "en"}
{"doc_id": "15760792_2", "wnd_id": "15760792_2_1", "text": "OBJECTIVE : To report the case of a young woman with Graves ' disease in whom ototoxicity developed because of propylthiouracil ( PTU) - induced antineutrophil cytoplasmic antibody ( ANCA) - associated vasculitis .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "case", "of", "a", "young", "woman", "with", "Graves", "'", "disease", "in", "whom", "ototoxicity", "developed", "because", "of", "propylthiouracil", "(", "PTU)", "-", "induced", "antineutrophil", "cytoplasmic", "antibody", "(", "ANCA)", "-", "associated", "vasculitis", "."], "event_mentions": [{"id": "15760792_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 24, "end": 25}, "arguments": [{"entity_id": "15760792_2_Ent1", "role": "Subject_Age", "text": "young", "start": 8, "end": 9}, {"entity_id": "15760792_2_Ent0", "role": "Subject", "text": "young woman with Graves ' disease", "start": 8, "end": 14}, {"entity_id": "15760792_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15760792_2_Ent6", "role": "Treatment_Disorder", "text": "Graves ' disease", "start": 11, "end": 14}, {"entity_id": "15760792_2_Ent3", "role": "Effect", "text": "ototoxicity developed", "start": 16, "end": 18}, {"entity_id": "15760792_2_Ent5", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 20, "end": 21}, {"entity_id": "15760792_2_Ent4", "role": "Treatment", "text": "propylthiouracil ( PTU)", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "15760792_2_Ent1", "text": "young", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15760792_2_Ent0", "text": "young woman with Graves ' disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "15760792_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15760792_2_Ent6", "text": "Graves ' disease", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15760792_2_Ent3", "text": "ototoxicity developed", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15760792_2_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15760792_2_Ent4", "text": "propylthiouracil ( PTU)", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "15770343_1", "wnd_id": "15770343_1_1", "text": "Anti - tuberculous drugs had been stopped on the 2nd day of therapy due to development of optic neuritis secondary to ethambutol administration at another hospital .", "tokens": ["Anti", "-", "tuberculous", "drugs", "had", "been", "stopped", "on", "the", "2nd", "day", "of", "therapy", "due", "to", "development", "of", "optic", "neuritis", "secondary", "to", "ethambutol", "administration", "at", "another", "hospital", "."], "event_mentions": [{"id": "15770343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 20, "end": 21}, "arguments": [{"entity_id": "15770343_1_Ent0", "role": "Effect", "text": "optic neuritis secondary", "start": 17, "end": 20}, {"entity_id": "15770343_1_Ent1", "role": "Treatment", "text": "ethambutol", "start": 21, "end": 22}, {"entity_id": "15770343_1_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15770343_1_Ent0", "text": "optic neuritis secondary", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "15770343_1_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15770343_1_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15770343_2", "wnd_id": "15770343_2_1", "text": "During the anti - tuberculous therapy , visual loss can be related to ethambutol toxicity or the tuberculosis infection itself .", "tokens": ["During", "the", "anti", "-", "tuberculous", "therapy", ",", "visual", "loss", "can", "be", "related", "to", "ethambutol", "toxicity", "or", "the", "tuberculosis", "infection", "itself", "."], "event_mentions": [{"id": "15770343_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "15770343_2_Ent0", "role": "Effect", "text": "visual loss", "start": 7, "end": 9}, {"entity_id": "15770343_2_Ent1", "role": "Treatment", "text": "ethambutol", "start": 13, "end": 14}, {"entity_id": "15770343_2_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 13, "end": 14}, {"entity_id": "15770343_2_Ent3", "role": "Treatment_Disorder", "text": "tuberculosis infection", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "15770343_2_Ent0", "text": "visual loss", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15770343_2_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15770343_2_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15770343_2_Ent3", "text": "tuberculosis infection", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15779196_1", "wnd_id": "15779196_1_1", "text": "Four days after intravenous Zoledronic acid , the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm .", "tokens": ["Four", "days", "after", "intravenous", "Zoledronic", "acid", ",", "the", "patient", "presented", "to", "emergency", "room", "with", "complaints", "of", "carpopedal", "spasm", "and", "bronchospasm", "."], "event_mentions": [{"id": "15779196_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complaints", "start": 14, "end": 15}, "arguments": [{"entity_id": "15779196_1_Ent3", "role": "Treatment_Time_elapsed", "text": "Four days after", "start": 0, "end": 3}, {"entity_id": "15779196_1_Ent2", "role": "Treatment", "text": "Four days after intravenous Zoledronic acid", "start": 0, "end": 6}, {"entity_id": "15779196_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 3, "end": 4}, {"entity_id": "15779196_1_Ent5", "role": "Treatment_Drug", "text": "Zoledronic acid", "start": 4, "end": 6}, {"entity_id": "15779196_1_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "15779196_1_Ent1", "role": "Effect", "text": "carpopedal spasm and bronchospasm", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "15779196_1_Ent3", "text": "Four days after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15779196_1_Ent2", "text": "Four days after intravenous Zoledronic acid", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15779196_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15779196_1_Ent5", "text": "Zoledronic acid", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15779196_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15779196_1_Ent1", "text": "carpopedal spasm and bronchospasm", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "1580986_1", "wnd_id": "1580986_1_1", "text": "Enalapril - induced anemia in two kidney transplant recipients .", "tokens": ["Enalapril", "-", "induced", "anemia", "in", "two", "kidney", "transplant", "recipients", "."], "event_mentions": [{"id": "1580986_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1580986_1_Ent2", "role": "Treatment", "text": "Enalapril", "start": 0, "end": 1}, {"entity_id": "1580986_1_Ent3", "role": "Treatment_Drug", "text": "Enalapril", "start": 0, "end": 1}, {"entity_id": "1580986_1_Ent1", "role": "Effect", "text": "anemia", "start": 3, "end": 4}, {"entity_id": "1580986_1_Ent0", "role": "Subject", "text": "two kidney transplant recipients", "start": 5, "end": 9}, {"entity_id": "1580986_1_Ent4", "role": "Treatment_Disorder", "text": "kidney transplant", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "1580986_1_Ent2", "text": "Enalapril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1580986_1_Ent3", "text": "Enalapril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1580986_1_Ent1", "text": "anemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1580986_1_Ent0", "text": "two kidney transplant recipients", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "1580986_1_Ent4", "text": "kidney transplant", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "1580986_2", "wnd_id": "1580986_2_1", "text": "Two renal transplant patients developed anemia during treatment of hypertension with enalapril medication .", "tokens": ["Two", "renal", "transplant", "patients", "developed", "anemia", "during", "treatment", "of", "hypertension", "with", "enalapril", "medication", "."], "event_mentions": [{"id": "1580986_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "1580986_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "1580986_2_Ent0", "role": "Subject", "text": "Two renal transplant patients", "start": 0, "end": 4}, {"entity_id": "1580986_2_Ent2", "role": "Subject_Disorder", "text": "renal transplant", "start": 1, "end": 3}, {"entity_id": "1580986_2_Ent3", "role": "Effect", "text": "anemia", "start": 5, "end": 6}, {"entity_id": "1580986_2_Ent5", "role": "Treatment_Disorder", "text": "hypertension", "start": 9, "end": 10}, {"entity_id": "1580986_2_Ent6", "role": "Treatment_Drug", "text": "enalapril", "start": 11, "end": 12}, {"entity_id": "1580986_2_Ent4", "role": "Treatment", "text": "enalapril medication", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "1580986_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1580986_2_Ent0", "text": "Two renal transplant patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "1580986_2_Ent2", "text": "renal transplant", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "1580986_2_Ent3", "text": "anemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1580986_2_Ent5", "text": "hypertension", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1580986_2_Ent6", "text": "enalapril", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1580986_2_Ent4", "text": "enalapril medication", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15811174_1", "wnd_id": "15811174_1_1", "text": "A 74 - year - old hypercholestrerolaemic woman taking cerivastatin ( 0.15 mg / day ) for 22 days complained of general muscle weakness and muscle pain .", "tokens": ["A", "74", "-", "year", "-", "old", "hypercholestrerolaemic", "woman", "taking", "cerivastatin", "(", "0.15", "mg", "/", "day", ")", "for", "22", "days", "complained", "of", "general", "muscle", "weakness", "and", "muscle", "pain", "."], "event_mentions": [{"id": "15811174_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 19, "end": 20}, "arguments": [{"entity_id": "15811174_1_Ent0", "role": "Subject", "text": "A 74 - year - old hypercholestrerolaemic woman", "start": 0, "end": 8}, {"entity_id": "15811174_1_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 1, "end": 6}, {"entity_id": "15811174_1_Ent8", "role": "Treatment_Disorder", "text": "hypercholestrerolaemic", "start": 6, "end": 7}, {"entity_id": "15811174_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "15811174_1_Ent5", "role": "Treatment_Drug", "text": "cerivastatin", "start": 9, "end": 10}, {"entity_id": "15811174_1_Ent4", "role": "Treatment", "text": "cerivastatin ( 0.15 mg / day )", "start": 9, "end": 16}, {"entity_id": "15811174_1_Ent6", "role": "Treatment_Dosage", "text": "0.15 mg / day", "start": 11, "end": 15}, {"entity_id": "15811174_1_Ent7", "role": "Treatment_Duration", "text": "22 days", "start": 17, "end": 19}, {"entity_id": "15811174_1_Ent3", "role": "Effect", "text": "general muscle weakness and muscle pain .", "start": 21, "end": 28}]}], "entity_mentions": [{"id": "15811174_1_Ent0", "text": "A 74 - year - old hypercholestrerolaemic woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15811174_1_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15811174_1_Ent8", "text": "hypercholestrerolaemic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15811174_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15811174_1_Ent5", "text": "cerivastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15811174_1_Ent4", "text": "cerivastatin ( 0.15 mg / day )", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "15811174_1_Ent6", "text": "0.15 mg / day", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15811174_1_Ent7", "text": "22 days", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15811174_1_Ent3", "text": "general muscle weakness and muscle pain .", "entity_type": "Entity", "start": 21, "end": 28}], "lang": "en"}
{"doc_id": "15811174_2", "wnd_id": "15811174_2_1", "text": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin - induced rhabdomyolysis .", "tokens": ["Clearance", "rates", "of", "cerivastatin", "metabolites", "in", "a", "patient", "with", "cerivastatin", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "15811174_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "15811174_2_Ent1", "role": "Treatment", "text": "cerivastatin", "start": 9, "end": 10}, {"entity_id": "15811174_2_Ent2", "role": "Treatment_Drug", "text": "cerivastatin", "start": 9, "end": 10}, {"entity_id": "15811174_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15811174_2_Ent1", "text": "cerivastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15811174_2_Ent2", "text": "cerivastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15811174_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15836666_2", "wnd_id": "15836666_2_1", "text": "We report a case of a 64 - year - old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome .", "tokens": ["We", "report", "a", "case", "of", "a", "64", "-", "year", "-", "old", "man", "with", "secondary", "adrenocortical", "insufficiency", "who", "has", "been", "on", "a", "chronic", "transdermal", "fentanyl", "treatment", "because", "of", "sciatic", "pain", "syndrome", "."], "event_mentions": [{"id": "15836666_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 12, "end": 13}, "arguments": [{"entity_id": "15836666_2_Ent0", "role": "Subject", "text": "a 64 - year - old man", "start": 5, "end": 12}, {"entity_id": "15836666_2_Ent1", "role": "Subject_Age", "text": "64 - year - old", "start": 6, "end": 11}, {"entity_id": "15836666_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "15836666_2_Ent3", "role": "Effect", "text": "secondary adrenocortical insufficiency", "start": 13, "end": 16}, {"entity_id": "15836666_2_Ent4", "role": "Treatment", "text": "a chronic transdermal fentanyl treatment", "start": 20, "end": 25}, {"entity_id": "15836666_2_Ent8", "role": "Treatment_Freq", "text": "chronic", "start": 21, "end": 22}, {"entity_id": "15836666_2_Ent7", "role": "Treatment_Route", "text": "transdermal", "start": 22, "end": 23}, {"entity_id": "15836666_2_Ent5", "role": "Treatment_Drug", "text": "fentanyl", "start": 23, "end": 24}, {"entity_id": "15836666_2_Ent6", "role": "Treatment_Disorder", "text": "sciatic pain syndrome", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "15836666_2_Ent0", "text": "a 64 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "15836666_2_Ent1", "text": "64 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15836666_2_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15836666_2_Ent3", "text": "secondary adrenocortical insufficiency", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15836666_2_Ent4", "text": "a chronic transdermal fentanyl treatment", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "15836666_2_Ent8", "text": "chronic", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15836666_2_Ent7", "text": "transdermal", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15836666_2_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15836666_2_Ent6", "text": "sciatic pain syndrome", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "1584367_2", "wnd_id": "1584367_2_1", "text": "We propose a mechanism of vancomycin - induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE .", "tokens": ["We", "propose", "a", "mechanism", "of", "vancomycin", "-", "induced", "mast", "cell", "degranulation", "and", "subsequent", "release", "of", "eosinophil", "chemotactic", "factor", "as", "a", "cause", "of", "CSFE", "."], "event_mentions": [{"id": "1584367_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1584367_2_Ent1", "role": "Treatment", "text": "vancomycin", "start": 5, "end": 6}, {"entity_id": "1584367_2_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 5, "end": 6}, {"entity_id": "1584367_2_Ent0", "role": "Effect", "text": "mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE", "start": 8, "end": 23}]}], "entity_mentions": [{"id": "1584367_2_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1584367_2_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1584367_2_Ent0", "text": "mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE", "entity_type": "Entity", "start": 8, "end": 23}], "lang": "en"}
{"doc_id": "15852680_1", "wnd_id": "15852680_1_1", "text": "Successful recovery from interstitial pneumonitis , induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer .", "tokens": ["Successful", "recovery", "from", "interstitial", "pneumonitis", ",", "induced", "by", "bicalutamide", "and", "leuprorelin", "acetate", "given", "as", "treatment", "for", "prostate", "cancer", "."], "event_mentions": [{"id": "15852680_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "15852680_1_Ent0", "role": "Effect", "text": "interstitial pneumonitis", "start": 3, "end": 5}, {"entity_id": "15852680_1_Ent2", "role": "Treatment_Drug", "text": "bicalutamide", "start": 8, "end": 9}, {"entity_id": "15852680_1_Ent5", "role": "Combination_Drug", "text": "bicalutamide", "start": 8, "end": 9}, {"entity_id": "15852680_1_Ent1", "role": "Treatment", "text": "bicalutamide and leuprorelin acetate", "start": 8, "end": 12}, {"entity_id": "15852680_1_Ent3", "role": "Treatment_Drug", "text": "leuprorelin acetate", "start": 10, "end": 12}, {"entity_id": "15852680_1_Ent6", "role": "Combination_Drug", "text": "leuprorelin acetate", "start": 10, "end": 12}, {"entity_id": "15852680_1_Ent4", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "15852680_1_Ent0", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15852680_1_Ent2", "text": "bicalutamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15852680_1_Ent5", "text": "bicalutamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15852680_1_Ent1", "text": "bicalutamide and leuprorelin acetate", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15852680_1_Ent3", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15852680_1_Ent6", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15852680_1_Ent4", "text": "prostate cancer", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "15857283_1", "wnd_id": "15857283_1_1", "text": "CONCLUSIONS : In these 3 cases , the unique positive ocular finding was corneal endothelial deposits , which may be related to the use of rifabutin .", "tokens": ["CONCLUSIONS", ":", "In", "these", "3", "cases", ",", "the", "unique", "positive", "ocular", "finding", "was", "corneal", "endothelial", "deposits", ",", "which", "may", "be", "related", "to", "the", "use", "of", "rifabutin", "."], "event_mentions": [{"id": "15857283_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 20, "end": 21}, "arguments": [{"entity_id": "15857283_1_Ent0", "role": "Effect", "text": "corneal endothelial deposits", "start": 13, "end": 16}, {"entity_id": "15857283_1_Ent1", "role": "Treatment", "text": "rifabutin", "start": 25, "end": 26}, {"entity_id": "15857283_1_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15857283_1_Ent0", "text": "corneal endothelial deposits", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15857283_1_Ent1", "text": "rifabutin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15857283_1_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15863610_1", "wnd_id": "15863610_1_1", "text": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene .", "tokens": ["Malignant", "mixed", "mullerian", "tumor", "of", "the", "uterus", "in", "a", "patient", "taking", "raloxifene", "."], "event_mentions": [{"id": "15863610_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 10, "end": 11}, "arguments": [{"entity_id": "15863610_1_Ent1", "role": "Effect", "text": "Malignant mixed mullerian tumor of the uterus", "start": 0, "end": 7}, {"entity_id": "15863610_1_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "15863610_1_Ent2", "role": "Treatment", "text": "raloxifene", "start": 11, "end": 12}, {"entity_id": "15863610_1_Ent3", "role": "Treatment_Drug", "text": "raloxifene", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15863610_1_Ent1", "text": "Malignant mixed mullerian tumor of the uterus", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "15863610_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15863610_1_Ent2", "text": "raloxifene", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15863610_1_Ent3", "text": "raloxifene", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15863610_7", "wnd_id": "15863610_7_1", "text": "CONCLUSION : There may be an association between raloxifene and the development of malignant mixed mesodermal tumor .", "tokens": ["CONCLUSION", ":", "There", "may", "be", "an", "association", "between", "raloxifene", "and", "the", "development", "of", "malignant", "mixed", "mesodermal", "tumor", "."], "event_mentions": [{"id": "15863610_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 6, "end": 7}, "arguments": [{"entity_id": "15863610_7_Ent1", "role": "Treatment", "text": "raloxifene", "start": 8, "end": 9}, {"entity_id": "15863610_7_Ent2", "role": "Treatment_Drug", "text": "raloxifene", "start": 8, "end": 9}, {"entity_id": "15863610_7_Ent0", "role": "Effect", "text": "malignant mixed mesodermal tumor", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "15863610_7_Ent1", "text": "raloxifene", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15863610_7_Ent2", "text": "raloxifene", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15863610_7_Ent0", "text": "malignant mixed mesodermal tumor", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "15866658_1", "wnd_id": "15866658_1_1", "text": "Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF .", "tokens": ["Herein", "we", "report", "four", "patients", "who", "underwent", "liver", "transplantation", "and", "developed", "neutropenia", "while", "receiving", "MMF", "."], "event_mentions": [{"id": "15866658_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15866658_1_Ent1", "role": "Subject_Population", "text": "four", "start": 3, "end": 4}, {"entity_id": "15866658_1_Ent0", "role": "Subject", "text": "four patients who underwent liver transplantation", "start": 3, "end": 9}, {"entity_id": "15866658_1_Ent2", "role": "Subject_Disorder", "text": "liver transplantation", "start": 7, "end": 9}, {"entity_id": "15866658_1_Ent3", "role": "Effect", "text": "neutropenia", "start": 11, "end": 12}, {"entity_id": "15866658_1_Ent4", "role": "Treatment", "text": "MMF", "start": 14, "end": 15}, {"entity_id": "15866658_1_Ent5", "role": "Treatment_Drug", "text": "MMF", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15866658_1_Ent1", "text": "four", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15866658_1_Ent0", "text": "four patients who underwent liver transplantation", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "15866658_1_Ent2", "text": "liver transplantation", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15866658_1_Ent3", "text": "neutropenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15866658_1_Ent4", "text": "MMF", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15866658_1_Ent5", "text": "MMF", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15878975_1", "wnd_id": "15878975_1_1", "text": "A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti - D IGIV administration for ITP or secondary thrombocytopenia .", "tokens": ["A", "previous", "review", "described", "data", "on", "15", "patients", "who", "experienced", "acute", "hemoglobinemia", "or", "hemoglobinuria", "following", "anti", "-", "D", "IGIV", "administration", "for", "ITP", "or", "secondary", "thrombocytopenia", "."], "event_mentions": [{"id": "15878975_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 14, "end": 15}, "arguments": [{"entity_id": "15878975_1_Ent1", "role": "Subject_Population", "text": "15", "start": 6, "end": 7}, {"entity_id": "15878975_1_Ent0", "role": "Subject", "text": "15 patients", "start": 6, "end": 8}, {"entity_id": "15878975_1_Ent2", "role": "Effect", "text": "acute hemoglobinemia or hemoglobinuria", "start": 10, "end": 14}, {"entity_id": "15878975_1_Ent3", "role": "Treatment", "text": "anti - D IGIV", "start": 15, "end": 19}, {"entity_id": "15878975_1_Ent5", "role": "Treatment_Drug", "text": "anti - D IGIV", "start": 15, "end": 19}, {"entity_id": "15878975_1_Ent6", "role": "Treatment_Route", "text": "administration", "start": 19, "end": 20}, {"entity_id": "15878975_1_Ent4", "role": "Treatment_Disorder", "text": "ITP or secondary thrombocytopenia", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "15878975_1_Ent1", "text": "15", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15878975_1_Ent0", "text": "15 patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15878975_1_Ent2", "text": "acute hemoglobinemia or hemoglobinuria", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "15878975_1_Ent3", "text": "anti - D IGIV", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "15878975_1_Ent5", "text": "anti - D IGIV", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "15878975_1_Ent6", "text": "administration", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15878975_1_Ent4", "text": "ITP or secondary thrombocytopenia", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "15907341_2", "wnd_id": "15907341_2_1", "text": "Six patients developed peripheral neuropathy and five patients bone marrow depression , blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid .", "tokens": ["Six", "patients", "developed", "peripheral", "neuropathy", "and", "five", "patients", "bone", "marrow", "depression", ",", "blood", "transfusions", "were", "given", "to", "three", "patients", "and", "in", "all", "five", "patients", "bone", "marrow", "function", "normalized", "after", "cessation", "of", "linezolid", "."], "event_mentions": [{"id": "15907341_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15907341_2_Ent6", "role": "Subject_Population", "text": "Six", "start": 0, "end": 1}, {"entity_id": "15907341_2_Ent5", "role": "Subject", "text": "Six patients", "start": 0, "end": 2}, {"entity_id": "15907341_2_Ent7", "role": "Effect", "text": "peripheral neuropathy", "start": 3, "end": 5}, {"entity_id": "15907341_2_Ent8", "role": "Treatment", "text": "linezolid", "start": 31, "end": 32}, {"entity_id": "15907341_2_Ent9", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}, {"id": "15907341_2_Evt2", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15907341_2_Ent11", "role": "Subject_Population", "text": "five", "start": 6, "end": 7}, {"entity_id": "15907341_2_Ent10", "role": "Subject", "text": "five patients", "start": 6, "end": 8}, {"entity_id": "15907341_2_Ent12", "role": "Effect", "text": "bone marrow depression", "start": 8, "end": 11}, {"entity_id": "15907341_2_Ent13", "role": "Treatment", "text": "linezolid", "start": 31, "end": 32}, {"entity_id": "15907341_2_Ent14", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}, {"id": "15907341_2_Evt3", "event_type": "Potential_therapeutic_event", "trigger": {"text": "given", "start": 15, "end": 16}, "arguments": [{"entity_id": "15907341_2_Ent17", "role": "Treatment", "text": "blood transfusions", "start": 12, "end": 14}, {"entity_id": "15907341_2_Ent16", "role": "Subject_Population", "text": "three", "start": 17, "end": 18}, {"entity_id": "15907341_2_Ent15", "role": "Subject", "text": "three patients", "start": 17, "end": 19}, {"entity_id": "15907341_2_Ent18", "role": "Treatment", "text": "cessation of linezolid", "start": 29, "end": 32}, {"entity_id": "15907341_2_Ent19", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}, {"id": "15907341_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "normalized", "start": 27, "end": 28}, "arguments": [{"entity_id": "15907341_2_Ent3", "role": "Treatment_Disorder", "text": "bone marrow depression", "start": 8, "end": 11}, {"entity_id": "15907341_2_Ent0", "role": "Subject", "text": "all five patients", "start": 21, "end": 24}, {"entity_id": "15907341_2_Ent1", "role": "Subject_Population", "text": "five", "start": 22, "end": 23}, {"entity_id": "15907341_2_Ent2", "role": "Treatment", "text": "cessation of linezolid", "start": 29, "end": 32}, {"entity_id": "15907341_2_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "15907341_2_Ent6", "text": "Six", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15907341_2_Ent5", "text": "Six patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15907341_2_Ent7", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15907341_2_Ent11", "text": "five", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15907341_2_Ent10", "text": "five patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15907341_2_Ent3", "text": "bone marrow depression", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15907341_2_Ent12", "text": "bone marrow depression", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15907341_2_Ent17", "text": "blood transfusions", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "15907341_2_Ent16", "text": "three", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15907341_2_Ent15", "text": "three patients", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15907341_2_Ent0", "text": "all five patients", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "15907341_2_Ent1", "text": "five", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15907341_2_Ent2", "text": "cessation of linezolid", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "15907341_2_Ent18", "text": "cessation of linezolid", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "15907341_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent8", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent9", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent13", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent14", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent19", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "15920338_1", "wnd_id": "15920338_1_1", "text": "A case of high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth , in a woman with a history of breast cancer who was treated with adjuvant tamoxifen .", "tokens": ["A", "case", "of", "high", "-", "grade", "endometrial", "stromal", "sarcoma", ",", "confined", "into", "an", "intrauterine", "polypoid", "growth", ",", "in", "a", "woman", "with", "a", "history", "of", "breast", "cancer", "who", "was", "treated", "with", "adjuvant", "tamoxifen", "."], "event_mentions": [{"id": "15920338_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 28, "end": 29}, "arguments": [{"entity_id": "15920338_1_Ent3", "role": "Subject_Population", "text": "A", "start": 0, "end": 1}, {"entity_id": "15920338_1_Ent0", "role": "Subject", "text": "A case of high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth , in a woman with a history of breast cancer", "start": 0, "end": 26}, {"entity_id": "15920338_1_Ent6", "role": "Treatment_Disorder", "text": "high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth", "start": 3, "end": 16}, {"entity_id": "15920338_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 19, "end": 20}, {"entity_id": "15920338_1_Ent2", "role": "Subject_Disorder", "text": "breast cancer", "start": 24, "end": 26}, {"entity_id": "15920338_1_Ent4", "role": "Treatment", "text": "adjuvant tamoxifen", "start": 30, "end": 32}, {"entity_id": "15920338_1_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "15920338_1_Ent3", "text": "A", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15920338_1_Ent0", "text": "A case of high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth , in a woman with a history of breast cancer", "entity_type": "Entity", "start": 0, "end": 26}, {"id": "15920338_1_Ent6", "text": "high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "15920338_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15920338_1_Ent2", "text": "breast cancer", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "15920338_1_Ent4", "text": "adjuvant tamoxifen", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "15920338_1_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "15920338_3", "wnd_id": "15920338_3_1", "text": "In deciding if tamoxifen therapy is warranted , all potentially life - threatening adverse events associated with tamoxifen should be considered , including endometrial adenocarcinoma or uterine sarcoma .", "tokens": ["In", "deciding", "if", "tamoxifen", "therapy", "is", "warranted", ",", "all", "potentially", "life", "-", "threatening", "adverse", "events", "associated", "with", "tamoxifen", "should", "be", "considered", ",", "including", "endometrial", "adenocarcinoma", "or", "uterine", "sarcoma", "."], "event_mentions": [{"id": "15920338_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 15, "end": 17}, "arguments": [{"entity_id": "15920338_3_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 3, "end": 4}, {"entity_id": "15920338_3_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 3, "end": 4}, {"entity_id": "15920338_3_Ent0", "role": "Effect", "text": "potentially life - threatening adverse events", "start": 9, "end": 15}, {"entity_id": "15920338_3_Ent2", "role": "Treatment", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "15920338_3_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "15920338_3_Ent1", "role": "Effect", "text": "including endometrial adenocarcinoma or uterine sarcoma", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "15920338_3_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15920338_3_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15920338_3_Ent0", "text": "potentially life - threatening adverse events", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "15920338_3_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15920338_3_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15920338_3_Ent1", "text": "including endometrial adenocarcinoma or uterine sarcoma", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "15944830_2", "wnd_id": "15944830_2_1", "text": "Clinical course of macular edema in two cases of interferon - associated retinopathy observed by optical coherence tomography .", "tokens": ["Clinical", "course", "of", "macular", "edema", "in", "two", "cases", "of", "interferon", "-", "associated", "retinopathy", "observed", "by", "optical", "coherence", "tomography", "."], "event_mentions": [{"id": "15944830_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15944830_2_Ent2", "role": "Effect", "text": "macular edema", "start": 3, "end": 5}, {"entity_id": "15944830_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "15944830_2_Ent0", "role": "Subject", "text": "two cases", "start": 6, "end": 8}, {"entity_id": "15944830_2_Ent4", "role": "Treatment", "text": "interferon", "start": 9, "end": 10}, {"entity_id": "15944830_2_Ent5", "role": "Treatment_Drug", "text": "interferon", "start": 9, "end": 10}, {"entity_id": "15944830_2_Ent3", "role": "Effect", "text": "retinopathy", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15944830_2_Ent2", "text": "macular edema", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15944830_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15944830_2_Ent0", "text": "two cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15944830_2_Ent4", "text": "interferon", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15944830_2_Ent5", "text": "interferon", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15944830_2_Ent3", "text": "retinopathy", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15961942_1", "wnd_id": "15961942_1_1", "text": "Late development of diabetes mellitus after interferon - alfa and ribavirin therapy for chronic hepatitis C : a case report .", "tokens": ["Late", "development", "of", "diabetes", "mellitus", "after", "interferon", "-", "alfa", "and", "ribavirin", "therapy", "for", "chronic", "hepatitis", "C", ":", "a", "case", "report", "."], "event_mentions": [{"id": "15961942_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "15961942_1_Ent0", "role": "Effect", "text": "diabetes mellitus", "start": 3, "end": 5}, {"entity_id": "15961942_1_Ent1", "role": "Treatment", "text": "interferon - alfa", "start": 6, "end": 9}, {"entity_id": "15961942_1_Ent5", "role": "Treatment_Drug", "text": "interferon - alfa", "start": 6, "end": 9}, {"entity_id": "15961942_1_Ent7", "role": "Combination_Drug", "text": "interferon - alfa", "start": 6, "end": 9}, {"entity_id": "15961942_1_Ent2", "role": "Treatment", "text": "ribavirin", "start": 10, "end": 11}, {"entity_id": "15961942_1_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 10, "end": 11}, {"entity_id": "15961942_1_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 10, "end": 11}, {"entity_id": "15961942_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15961942_1_Ent0", "text": "diabetes mellitus", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15961942_1_Ent1", "text": "interferon - alfa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15961942_1_Ent5", "text": "interferon - alfa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15961942_1_Ent7", "text": "interferon - alfa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15961942_1_Ent2", "text": "ribavirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15961942_1_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15961942_1_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15961942_1_Ent3", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15965422_3", "wnd_id": "15965422_3_1", "text": "We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa - 2b in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses .", "tokens": ["We", "report", "5", "patients", "(", "3", "patients", "with", "chronic", "hepatitis", "C", "treated", "with", "pegylated", "interferon", "alfa", "-", "2b", "in", "association", "with", "oral", "ribavirin", "and", "two", "patients", "with", "chronic", "myelocytic", "leukemia", ")", "who", "developed", "local", "cutaneous", "reactions", "at", "sites", "of", "injection", "after", "the", "administration", "of", "weekly", "subcutaneous", "injections", "of", "pegylated", "interferon", "alfa", "-", "2b", "at", "different", "doses", "."], "event_mentions": [{"id": "15965422_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 32, "end": 33}, "arguments": [{"entity_id": "15965422_3_Ent0", "role": "Subject", "text": "two patients with chronic myelocytic leukemia", "start": 24, "end": 30}, {"entity_id": "15965422_3_Ent3", "role": "Treatment_Disorder", "text": "chronic myelocytic leukemia", "start": 27, "end": 30}, {"entity_id": "15965422_3_Ent1", "role": "Effect", "text": "local cutaneous reactions at sites of injection", "start": 33, "end": 40}, {"entity_id": "15965422_3_Ent2", "role": "Treatment", "text": "administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses", "start": 42, "end": 56}, {"entity_id": "15965422_3_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 44, "end": 45}, {"entity_id": "15965422_3_Ent7", "role": "Treatment_Route", "text": "subcutaneous injections", "start": 45, "end": 47}, {"entity_id": "15965422_3_Ent4", "role": "Treatment_Drug", "text": "pegylated interferon alfa - 2b", "start": 48, "end": 53}, {"entity_id": "15965422_3_Ent5", "role": "Treatment_Dosage", "text": "different doses", "start": 54, "end": 56}]}, {"id": "15965422_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 32, "end": 33}, "arguments": [{"entity_id": "15965422_3_Ent8", "role": "Subject", "text": "3 patients with chronic hepatitis C", "start": 5, "end": 11}, {"entity_id": "15965422_3_Ent11", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 8, "end": 11}, {"entity_id": "15965422_3_Ent12", "role": "Treatment_Drug", "text": "pegylated interferon alfa - 2b", "start": 13, "end": 18}, {"entity_id": "15965422_3_Ent15", "role": "Combination_Drug", "text": "pegylated interferon alfa - 2b", "start": 13, "end": 18}, {"entity_id": "15965422_3_Ent10", "role": "Treatment", "text": "pegylated interferon alfa - 2b in association with oral ribavirin", "start": 13, "end": 23}, {"entity_id": "15965422_3_Ent14", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "15965422_3_Ent13", "role": "Treatment_Drug", "text": "ribavirin", "start": 22, "end": 23}, {"entity_id": "15965422_3_Ent16", "role": "Combination_Drug", "text": "ribavirin", "start": 22, "end": 23}, {"entity_id": "15965422_3_Ent9", "role": "Effect", "text": "local cutaneous reactions at sites of injection", "start": 33, "end": 40}]}], "entity_mentions": [{"id": "15965422_3_Ent8", "text": "3 patients with chronic hepatitis C", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "15965422_3_Ent11", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15965422_3_Ent12", "text": "pegylated interferon alfa - 2b", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "15965422_3_Ent15", "text": "pegylated interferon alfa - 2b", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "15965422_3_Ent10", "text": "pegylated interferon alfa - 2b in association with oral ribavirin", "entity_type": "Entity", "start": 13, "end": 23}, {"id": "15965422_3_Ent14", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15965422_3_Ent13", "text": "ribavirin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15965422_3_Ent16", "text": "ribavirin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15965422_3_Ent0", "text": "two patients with chronic myelocytic leukemia", "entity_type": "Entity", "start": 24, "end": 30}, {"id": "15965422_3_Ent3", "text": "chronic myelocytic leukemia", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "15965422_3_Ent1", "text": "local cutaneous reactions at sites of injection", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "15965422_3_Ent9", "text": "local cutaneous reactions at sites of injection", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "15965422_3_Ent2", "text": "administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses", "entity_type": "Entity", "start": 42, "end": 56}, {"id": "15965422_3_Ent6", "text": "weekly", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "15965422_3_Ent7", "text": "subcutaneous injections", "entity_type": "Entity", "start": 45, "end": 47}, {"id": "15965422_3_Ent4", "text": "pegylated interferon alfa - 2b", "entity_type": "Entity", "start": 48, "end": 53}, {"id": "15965422_3_Ent5", "text": "different doses", "entity_type": "Entity", "start": 54, "end": 56}], "lang": "en"}
{"doc_id": "16001348_9", "wnd_id": "16001348_9_1", "text": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis .", "tokens": ["The", "reported", "case", "represents", "an", "unusual", "association", "between", "medication", "with", "the", "proton", "pump", "inhibitor", "lansoprazole", "and", "the", "development", "of", "collagenous", "colitis", "suggesting", "the", "importance", "of", "evaluation", "of", "drug", "use", "in", "patients", "with", "microscopic", "colitis", "."], "event_mentions": [{"id": "16001348_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 6, "end": 7}, "arguments": [{"entity_id": "16001348_9_Ent3", "role": "Treatment", "text": "proton pump inhibitor lansoprazole", "start": 11, "end": 15}, {"entity_id": "16001348_9_Ent4", "role": "Treatment_Drug", "text": "lansoprazole", "start": 14, "end": 15}, {"entity_id": "16001348_9_Ent2", "role": "Effect", "text": "collagenous colitis", "start": 19, "end": 21}, {"entity_id": "16001348_9_Ent0", "role": "Subject", "text": "patients with microscopic colitis", "start": 30, "end": 34}, {"entity_id": "16001348_9_Ent1", "role": "Subject_Disorder", "text": "microscopic colitis", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "16001348_9_Ent3", "text": "proton pump inhibitor lansoprazole", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "16001348_9_Ent4", "text": "lansoprazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16001348_9_Ent2", "text": "collagenous colitis", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16001348_9_Ent0", "text": "patients with microscopic colitis", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "16001348_9_Ent1", "text": "microscopic colitis", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "16012330_9", "wnd_id": "16012330_9_1", "text": "Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children .", "tokens": ["Nineteen", "cases", "of", "unusual", "enhanced", "vincristine", "neurotoxicity", "related", "to", "itraconazole", "have", "been", "reported", "in", "children", "."], "event_mentions": [{"id": "16012330_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "16012330_9_Ent2", "role": "Subject_Population", "text": "Nineteen", "start": 0, "end": 1}, {"entity_id": "16012330_9_Ent0", "role": "Subject", "text": "Nineteen cases", "start": 0, "end": 2}, {"entity_id": "16012330_9_Ent4", "role": "Effect", "text": "unusual enhanced vincristine neurotoxicity", "start": 3, "end": 7}, {"entity_id": "16012330_9_Ent5", "role": "Treatment", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "16012330_9_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "16012330_9_Ent1", "role": "Subject", "text": "children", "start": 14, "end": 15}, {"entity_id": "16012330_9_Ent3", "role": "Subject_Age", "text": "children", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16012330_9_Ent2", "text": "Nineteen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_9_Ent0", "text": "Nineteen cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16012330_9_Ent4", "text": "unusual enhanced vincristine neurotoxicity", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16012330_9_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16012330_9_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16012330_9_Ent1", "text": "children", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16012330_9_Ent3", "text": "children", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16018164_1", "wnd_id": "16018164_1_1", "text": "CASE REPORT : We report a case of intracerebral hemorrhage occurring in a middle - aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year .", "tokens": ["CASE", "REPORT", ":", "We", "report", "a", "case", "of", "intracerebral", "hemorrhage", "occurring", "in", "a", "middle", "-", "aged", "man", "who", "suffered", "from", "chronic", "sinusitis", "and", "had", "been", "ingesting", "pseudoephedrine", "daily", "for", "one", "year", "."], "event_mentions": [{"id": "16018164_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 10, "end": 11}, "arguments": [{"entity_id": "16018164_1_Ent3", "role": "Effect", "text": "intracerebral hemorrhage", "start": 8, "end": 10}, {"entity_id": "16018164_1_Ent1", "role": "Subject_Age", "text": "middle - aged", "start": 13, "end": 16}, {"entity_id": "16018164_1_Ent0", "role": "Subject", "text": "middle - aged man who suffered from chronic sinusitis", "start": 13, "end": 22}, {"entity_id": "16018164_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 16, "end": 17}, {"entity_id": "16018164_1_Ent9", "role": "Treatment_Disorder", "text": "chronic sinusitis", "start": 20, "end": 22}, {"entity_id": "16018164_1_Ent5", "role": "Treatment_Route", "text": "ingesting", "start": 25, "end": 26}, {"entity_id": "16018164_1_Ent4", "role": "Treatment", "text": "ingesting pseudoephedrine daily for one year", "start": 25, "end": 31}, {"entity_id": "16018164_1_Ent6", "role": "Treatment_Drug", "text": "pseudoephedrine", "start": 26, "end": 27}, {"entity_id": "16018164_1_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 27, "end": 28}, {"entity_id": "16018164_1_Ent8", "role": "Treatment_Duration", "text": "for one year", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "16018164_1_Ent3", "text": "intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16018164_1_Ent1", "text": "middle - aged", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "16018164_1_Ent0", "text": "middle - aged man who suffered from chronic sinusitis", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "16018164_1_Ent2", "text": "man", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16018164_1_Ent9", "text": "chronic sinusitis", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16018164_1_Ent5", "text": "ingesting", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16018164_1_Ent4", "text": "ingesting pseudoephedrine daily for one year", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "16018164_1_Ent6", "text": "pseudoephedrine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16018164_1_Ent7", "text": "daily", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "16018164_1_Ent8", "text": "for one year", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "16018164_2", "wnd_id": "16018164_2_1", "text": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM .", "tokens": ["Only", "one", "report", "links", "phenylpropanolamine", "consumption", "to", "an", "intracerebral", "hemorrhage", "in", "a", "patient", "with", "an", "AVM", "."], "event_mentions": [{"id": "16018164_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "links", "start": 3, "end": 4}, "arguments": [{"entity_id": "16018164_2_Ent3", "role": "Treatment", "text": "phenylpropanolamine", "start": 4, "end": 5}, {"entity_id": "16018164_2_Ent4", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 4, "end": 5}, {"entity_id": "16018164_2_Ent2", "role": "Effect", "text": "intracerebral hemorrhage", "start": 8, "end": 10}, {"entity_id": "16018164_2_Ent0", "role": "Subject", "text": "a patient with an AVM", "start": 11, "end": 16}, {"entity_id": "16018164_2_Ent1", "role": "Subject_Disorder", "text": "AVM", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16018164_2_Ent3", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16018164_2_Ent4", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16018164_2_Ent2", "text": "intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16018164_2_Ent0", "text": "a patient with an AVM", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16018164_2_Ent1", "text": "AVM", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1602800_1", "wnd_id": "1602800_1_1", "text": "Pulmonary leukostasis secondary to all - trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse .", "tokens": ["Pulmonary", "leukostasis", "secondary", "to", "all", "-", "trans", "retinoic", "acid", "in", "the", "treatment", "of", "acute", "promyelocytic", "leukemia", "in", "first", "relapse", "."], "event_mentions": [{"id": "1602800_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "1602800_1_Ent0", "role": "Effect", "text": "Pulmonary leukostasis", "start": 0, "end": 2}, {"entity_id": "1602800_1_Ent1", "role": "Treatment", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "1602800_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "1602800_1_Ent2", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia in first relapse", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "1602800_1_Ent0", "text": "Pulmonary leukostasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1602800_1_Ent1", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1602800_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1602800_1_Ent2", "text": "acute promyelocytic leukemia in first relapse", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "16092915_1", "wnd_id": "16092915_1_1", "text": "CONCLUSIONS : This observation of \" on - off \" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent .", "tokens": ["CONCLUSIONS", ":", "This", "observation", "of", "\"", "on", "-", "off", "\"", "risperidone", "treatment", "suggests", "that", "risperidone", "may", "have", "worsened", "both", "psychiatric", "and", "physical", "manifestations", "of", "the", "mitochondrial", "disorder", "in", "this", "adolescent", "."], "event_mentions": [{"id": "16092915_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have worsened", "start": 16, "end": 18}, "arguments": [{"entity_id": "16092915_1_Ent4", "role": "Treatment", "text": "risperidone", "start": 14, "end": 15}, {"entity_id": "16092915_1_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 14, "end": 15}, {"entity_id": "16092915_1_Ent3", "role": "Effect", "text": "psychiatric and physical manifestations", "start": 19, "end": 23}, {"entity_id": "16092915_1_Ent2", "role": "Subject_Disorder", "text": "mitochondrial disorder", "start": 25, "end": 27}, {"entity_id": "16092915_1_Ent0", "role": "Subject", "text": "mitochondrial disorder in this adolescent", "start": 25, "end": 30}, {"entity_id": "16092915_1_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "16092915_1_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16092915_1_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16092915_1_Ent3", "text": "psychiatric and physical manifestations", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "16092915_1_Ent2", "text": "mitochondrial disorder", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16092915_1_Ent0", "text": "mitochondrial disorder in this adolescent", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "16092915_1_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "16097572_1", "wnd_id": "16097572_1_1", "text": "Fatal radiation myelopathy after high - dose busulfan and melphalan chemotherapy and radiotherapy for Ewing 's sarcoma : a review of the literature and implications for practice .", "tokens": ["Fatal", "radiation", "myelopathy", "after", "high", "-", "dose", "busulfan", "and", "melphalan", "chemotherapy", "and", "radiotherapy", "for", "Ewing", "'s", "sarcoma", ":", "a", "review", "of", "the", "literature", "and", "implications", "for", "practice", "."], "event_mentions": [{"id": "16097572_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "16097572_1_Ent0", "role": "Effect", "text": "radiation myelopathy", "start": 1, "end": 3}, {"entity_id": "16097572_1_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 4, "end": 7}, {"entity_id": "16097572_1_Ent1", "role": "Treatment", "text": "high - dose busulfan", "start": 4, "end": 8}, {"entity_id": "16097572_1_Ent4", "role": "Treatment_Drug", "text": "busulfan", "start": 7, "end": 8}, {"entity_id": "16097572_1_Ent7", "role": "Combination_Drug", "text": "busulfan", "start": 7, "end": 8}, {"entity_id": "16097572_1_Ent2", "role": "Treatment", "text": "melphalan", "start": 9, "end": 10}, {"entity_id": "16097572_1_Ent5", "role": "Treatment_Drug", "text": "melphalan", "start": 9, "end": 10}, {"entity_id": "16097572_1_Ent8", "role": "Combination_Drug", "text": "melphalan", "start": 9, "end": 10}, {"entity_id": "16097572_1_Ent6", "role": "Treatment_Disorder", "text": "Ewing 's sarcoma :", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "16097572_1_Ent0", "text": "radiation myelopathy", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16097572_1_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16097572_1_Ent1", "text": "high - dose busulfan", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16097572_1_Ent4", "text": "busulfan", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16097572_1_Ent7", "text": "busulfan", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16097572_1_Ent2", "text": "melphalan", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16097572_1_Ent5", "text": "melphalan", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16097572_1_Ent8", "text": "melphalan", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16097572_1_Ent6", "text": "Ewing 's sarcoma :", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "16099004_2", "wnd_id": "16099004_2_1", "text": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world .", "tokens": ["Quinine", "remains", "a", "reliable", "treatment", "for", "falciparum", "malaria", "in", "most", "parts", "of", "the", "world", "."], "event_mentions": [{"id": "16099004_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 4, "end": 5}, "arguments": [{"entity_id": "16099004_2_Ent0", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "16099004_2_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "16099004_2_Ent1", "role": "Treatment_Disorder", "text": "falciparum malaria", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16099004_2_Ent0", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16099004_2_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16099004_2_Ent1", "text": "falciparum malaria", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16109609_4", "wnd_id": "16109609_4_1", "text": "We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine , all of whom had a history of mediastinal radiation without subcarinal blocking .", "tokens": ["We", "report", "four", "cases", "of", "hemodynamically", "significant", "pericardial", "effusion", "in", "patients", "with", "refractory", "lymphoma", "who", "were", "receiving", "gemcitabine", ",", "all", "of", "whom", "had", "a", "history", "of", "mediastinal", "radiation", "without", "subcarinal", "blocking", "."], "event_mentions": [{"id": "16109609_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "16109609_4_Ent2", "role": "Subject_Population", "text": "four", "start": 2, "end": 3}, {"entity_id": "16109609_4_Ent3", "role": "Effect", "text": "hemodynamically significant pericardial effusion", "start": 5, "end": 9}, {"entity_id": "16109609_4_Ent5", "role": "Treatment_Disorder", "text": "refractory lymphoma", "start": 12, "end": 14}, {"entity_id": "16109609_4_Ent4", "role": "Treatment", "text": "gemcitabine", "start": 17, "end": 18}, {"entity_id": "16109609_4_Ent6", "role": "Treatment_Drug", "text": "gemcitabine", "start": 17, "end": 18}, {"entity_id": "16109609_4_Ent0", "role": "Subject", "text": "had a history of mediastinal radiation without subcarinal blocking", "start": 22, "end": 31}, {"entity_id": "16109609_4_Ent1", "role": "Subject_Disorder", "text": "mediastinal radiation without subcarinal blocking", "start": 26, "end": 31}]}], "entity_mentions": [{"id": "16109609_4_Ent2", "text": "four", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16109609_4_Ent3", "text": "hemodynamically significant pericardial effusion", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16109609_4_Ent5", "text": "refractory lymphoma", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16109609_4_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16109609_4_Ent6", "text": "gemcitabine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16109609_4_Ent0", "text": "had a history of mediastinal radiation without subcarinal blocking", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "16109609_4_Ent1", "text": "mediastinal radiation without subcarinal blocking", "entity_type": "Entity", "start": 26, "end": 31}], "lang": "en"}
{"doc_id": "16119501_1", "wnd_id": "16119501_1_1", "text": "Baclofen withdrawal : a cause of prolonged fever in the intensive care unit .", "tokens": ["Baclofen", "withdrawal", ":", "a", "cause", "of", "prolonged", "fever", "in", "the", "intensive", "care", "unit", "."], "event_mentions": [{"id": "16119501_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "16119501_1_Ent2", "role": "Treatment_Drug", "text": "Baclofen", "start": 0, "end": 1}, {"entity_id": "16119501_1_Ent1", "role": "Treatment", "text": "Baclofen withdrawal", "start": 0, "end": 2}, {"entity_id": "16119501_1_Ent0", "role": "Effect", "text": "prolonged fever", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16119501_1_Ent2", "text": "Baclofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16119501_1_Ent1", "text": "Baclofen withdrawal", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16119501_1_Ent0", "text": "prolonged fever", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16119501_2", "wnd_id": "16119501_2_1", "text": "Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit .", "tokens": ["Baclofen", "withdrawal", "syndrome", "resulting", "from", "underdosing", "of", "oral", "baclofen", "should", "be", "considered", "as", "a", "potential", "source", "of", "prolonged", "fever", "in", "the", "intensive", "care", "unit", "."], "event_mentions": [{"id": "16119501_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "16119501_2_Ent0", "role": "Effect", "text": "Baclofen withdrawal syndrome", "start": 0, "end": 3}, {"entity_id": "16119501_2_Ent2", "role": "Treatment", "text": "underdosing of oral baclofen", "start": 5, "end": 9}, {"entity_id": "16119501_2_Ent3", "role": "Treatment_Route", "text": "oral", "start": 7, "end": 8}, {"entity_id": "16119501_2_Ent4", "role": "Treatment_Drug", "text": "baclofen", "start": 8, "end": 9}, {"entity_id": "16119501_2_Ent1", "role": "Effect", "text": "prolonged fever in the intensive care unit", "start": 17, "end": 24}]}], "entity_mentions": [{"id": "16119501_2_Ent0", "text": "Baclofen withdrawal syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16119501_2_Ent2", "text": "underdosing of oral baclofen", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16119501_2_Ent3", "text": "oral", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16119501_2_Ent4", "text": "baclofen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16119501_2_Ent1", "text": "prolonged fever in the intensive care unit", "entity_type": "Entity", "start": 17, "end": 24}], "lang": "en"}
{"doc_id": "16122280_3", "wnd_id": "16122280_3_1", "text": "Clinical experience in infectious patients has shown that oral telithromycin 800 mg once daily for 5 - 10 days is effective for the treatment of community - acquired upper and lower respiratory tract infections .", "tokens": ["Clinical", "experience", "in", "infectious", "patients", "has", "shown", "that", "oral", "telithromycin", "800", "mg", "once", "daily", "for", "5", "-", "10", "days", "is", "effective", "for", "the", "treatment", "of", "community", "-", "acquired", "upper", "and", "lower", "respiratory", "tract", "infections", "."], "event_mentions": [{"id": "16122280_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 23, "end": 24}, "arguments": [{"entity_id": "16122280_3_Ent1", "role": "Subject_Disorder", "text": "infectious", "start": 3, "end": 4}, {"entity_id": "16122280_3_Ent0", "role": "Subject", "text": "infectious patients", "start": 3, "end": 5}, {"entity_id": "16122280_3_Ent8", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "16122280_3_Ent2", "role": "Treatment", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "start": 8, "end": 19}, {"entity_id": "16122280_3_Ent3", "role": "Treatment_Drug", "text": "telithromycin", "start": 9, "end": 10}, {"entity_id": "16122280_3_Ent4", "role": "Treatment_Dosage", "text": "800 mg", "start": 10, "end": 12}, {"entity_id": "16122280_3_Ent5", "role": "Treatment_Freq", "text": "once daily", "start": 12, "end": 14}, {"entity_id": "16122280_3_Ent6", "role": "Treatment_Duration", "text": "5 - 10 days", "start": 15, "end": 19}, {"entity_id": "16122280_3_Ent7", "role": "Treatment_Disorder", "text": "community - acquired upper and lower respiratory tract infections", "start": 25, "end": 34}]}], "entity_mentions": [{"id": "16122280_3_Ent1", "text": "infectious", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16122280_3_Ent0", "text": "infectious patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16122280_3_Ent8", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16122280_3_Ent2", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "16122280_3_Ent3", "text": "telithromycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16122280_3_Ent4", "text": "800 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16122280_3_Ent5", "text": "once daily", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16122280_3_Ent6", "text": "5 - 10 days", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16122280_3_Ent7", "text": "community - acquired upper and lower respiratory tract infections", "entity_type": "Entity", "start": 25, "end": 34}], "lang": "en"}
{"doc_id": "16156485_1", "wnd_id": "16156485_1_1", "text": "Since recent studies have reported no negative interactions with concurrent use , we here report three cases ( one case of a prolonged seizure , a serotonin syndrome and a focal seizure ) of severe lithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic .", "tokens": ["Since", "recent", "studies", "have", "reported", "no", "negative", "interactions", "with", "concurrent", "use", ",", "we", "here", "report", "three", "cases", "(", "one", "case", "of", "a", "prolonged", "seizure", ",", "a", "serotonin", "syndrome", "and", "a", "focal", "seizure", ")", "of", "severe", "lithium", "-", "induced", "side", "effects", "while", "patients", "underwent", "ECT", "without", "complications", "and", "lithium", "serum", "levels", "were", "still", "subtherapeutic", "."], "event_mentions": [{"id": "16156485_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 37, "end": 38}, "arguments": [{"entity_id": "16156485_1_Ent0", "role": "Effect", "text": "a prolonged seizure", "start": 21, "end": 24}, {"entity_id": "16156485_1_Ent1", "role": "Treatment", "text": "lithium", "start": 35, "end": 36}, {"entity_id": "16156485_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 35, "end": 36}]}, {"id": "16156485_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 37, "end": 38}, "arguments": [{"entity_id": "16156485_1_Ent3", "role": "Effect", "text": "a serotonin syndrome", "start": 25, "end": 28}, {"entity_id": "16156485_1_Ent4", "role": "Treatment", "text": "lithium", "start": 35, "end": 36}, {"entity_id": "16156485_1_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 35, "end": 36}]}, {"id": "16156485_1_Evt2", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 37, "end": 38}, "arguments": [{"entity_id": "16156485_1_Ent6", "role": "Effect", "text": "a focal seizure", "start": 29, "end": 32}, {"entity_id": "16156485_1_Ent7", "role": "Treatment", "text": "lithium", "start": 35, "end": 36}, {"entity_id": "16156485_1_Ent8", "role": "Treatment_Drug", "text": "lithium", "start": 35, "end": 36}]}, {"id": "16156485_1_Evt3", "event_type": "Potential_therapeutic_event", "trigger": {"text": "underwent", "start": 42, "end": 43}, "arguments": [{"entity_id": "16156485_1_Ent11", "role": "Treatment_Disorder", "text": "lithium - induced side effects", "start": 35, "end": 40}, {"entity_id": "16156485_1_Ent10", "role": "Treatment", "text": "ECT", "start": 43, "end": 44}, {"entity_id": "16156485_1_Ent12", "role": "Treatment_Drug", "text": "ECT", "start": 43, "end": 44}, {"entity_id": "16156485_1_Ent9", "role": "Effect", "text": "without complications and lithium serum levels were still subtherapeutic", "start": 44, "end": 53}]}], "entity_mentions": [{"id": "16156485_1_Ent0", "text": "a prolonged seizure", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "16156485_1_Ent3", "text": "a serotonin syndrome", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "16156485_1_Ent6", "text": "a focal seizure", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "16156485_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16156485_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16156485_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16156485_1_Ent5", "text": "lithium", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16156485_1_Ent7", "text": "lithium", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16156485_1_Ent8", "text": "lithium", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16156485_1_Ent11", "text": "lithium - induced side effects", "entity_type": "Entity", "start": 35, "end": 40}, {"id": "16156485_1_Ent10", "text": "ECT", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "16156485_1_Ent12", "text": "ECT", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "16156485_1_Ent9", "text": "without complications and lithium serum levels were still subtherapeutic", "entity_type": "Entity", "start": 44, "end": 53}], "lang": "en"}
{"doc_id": "16164579_2", "wnd_id": "16164579_2_1", "text": "To our knowledge , our report is one of the first on shock and angio - oedema from irbesartan .", "tokens": ["To", "our", "knowledge", ",", "our", "report", "is", "one", "of", "the", "first", "on", "shock", "and", "angio", "-", "oedema", "from", "irbesartan", "."], "event_mentions": [{"id": "16164579_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 17, "end": 18}, "arguments": [{"entity_id": "16164579_2_Ent0", "role": "Effect", "text": "shock and angio - oedema", "start": 12, "end": 17}, {"entity_id": "16164579_2_Ent1", "role": "Treatment", "text": "irbesartan", "start": 18, "end": 19}, {"entity_id": "16164579_2_Ent2", "role": "Treatment_Drug", "text": "irbesartan", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16164579_2_Ent0", "text": "shock and angio - oedema", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "16164579_2_Ent1", "text": "irbesartan", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16164579_2_Ent2", "text": "irbesartan", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16211208_2", "wnd_id": "16211208_2_1", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation : a cautionary tale .", "tokens": ["Marked", "QT", "prolongation", "and", "torsades", "de", "pointes", "secondary", "to", "acute", "ischemia", "in", "an", "elderly", "man", "taking", "dofetilide", "for", "atrial", "fibrillation", ":", "a", "cautionary", "tale", "."], "event_mentions": [{"id": "16211208_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 15, "end": 16}, "arguments": [{"entity_id": "16211208_2_Ent3", "role": "Effect", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia", "start": 0, "end": 11}, {"entity_id": "16211208_2_Ent0", "role": "Subject", "text": "an elderly man", "start": 12, "end": 15}, {"entity_id": "16211208_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "16211208_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "16211208_2_Ent4", "role": "Treatment", "text": "dofetilide", "start": 16, "end": 17}, {"entity_id": "16211208_2_Ent5", "role": "Treatment_Drug", "text": "dofetilide", "start": 16, "end": 17}, {"entity_id": "16211208_2_Ent6", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16211208_2_Ent3", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "16211208_2_Ent0", "text": "an elderly man", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16211208_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16211208_2_Ent2", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16211208_2_Ent4", "text": "dofetilide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16211208_2_Ent5", "text": "dofetilide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16211208_2_Ent6", "text": "atrial fibrillation", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16225183_10", "wnd_id": "16225183_10_1", "text": "This latest ( third ) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.", "tokens": ["This", "latest", "(", "third", ")", "report", "suggests", "that", "the", "safety", "profile", "should", "be", "reexamined", "and", "at", "least", "raises", "the", "question", "of", "potential", "renal", "toxicity", "of", "interferons", "in", "MS."], "event_mentions": [{"id": "16225183_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "raises", "start": 17, "end": 18}, "arguments": [{"entity_id": "16225183_10_Ent0", "role": "Effect", "text": "potential renal toxicity", "start": 21, "end": 24}, {"entity_id": "16225183_10_Ent1", "role": "Treatment", "text": "interferons", "start": 25, "end": 26}, {"entity_id": "16225183_10_Ent2", "role": "Treatment_Drug", "text": "interferons", "start": 25, "end": 26}, {"entity_id": "16225183_10_Ent3", "role": "Treatment_Disorder", "text": "MS.", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16225183_10_Ent0", "text": "potential renal toxicity", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "16225183_10_Ent1", "text": "interferons", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16225183_10_Ent2", "text": "interferons", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16225183_10_Ent3", "text": "MS.", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16225183_7", "wnd_id": "16225183_7_1", "text": "SUBSEQUENT COURSE : The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment .", "tokens": ["SUBSEQUENT", "COURSE", ":", "The", "nephrosis", "resolved", "almost", "completely", "once", "the", "interferon", "was", "stopped", "and", "after", "immunosuppressive", "treatment", "."], "event_mentions": [{"id": "16225183_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "16225183_7_Ent3", "role": "Treatment_Disorder", "text": "nephrosis", "start": 4, "end": 5}, {"entity_id": "16225183_7_Ent1", "role": "Treatment_Drug", "text": "interferon", "start": 10, "end": 11}, {"entity_id": "16225183_7_Ent0", "role": "Treatment", "text": "interferon was stopped and after immunosuppressive treatment", "start": 10, "end": 17}, {"entity_id": "16225183_7_Ent2", "role": "Treatment_Drug", "text": "immunosuppressive", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16225183_7_Ent3", "text": "nephrosis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16225183_7_Ent1", "text": "interferon", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16225183_7_Ent0", "text": "interferon was stopped and after immunosuppressive treatment", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "16225183_7_Ent2", "text": "immunosuppressive", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16237130_1", "wnd_id": "16237130_1_1", "text": "Capecitabine - induced multifocal leukoencephalopathy : a report of five cases .", "tokens": ["Capecitabine", "-", "induced", "multifocal", "leukoencephalopathy", ":", "a", "report", "of", "five", "cases", "."], "event_mentions": [{"id": "16237130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16237130_1_Ent3", "role": "Treatment", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent4", "role": "Treatment_Drug", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent2", "role": "Effect", "text": "multifocal leukoencephalopathy", "start": 3, "end": 5}, {"entity_id": "16237130_1_Ent1", "role": "Subject_Population", "text": "five", "start": 9, "end": 10}, {"entity_id": "16237130_1_Ent0", "role": "Subject", "text": "five cases", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16237130_1_Ent3", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent4", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent2", "text": "multifocal leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16237130_1_Ent1", "text": "five", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16237130_1_Ent0", "text": "five cases", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16239768_2", "wnd_id": "16239768_2_1", "text": "The authors report a case of urinary incontinence ( UI ) that occurred in a woman after administration of venlafaxine .", "tokens": ["The", "authors", "report", "a", "case", "of", "urinary", "incontinence", "(", "UI", ")", "that", "occurred", "in", "a", "woman", "after", "administration", "of", "venlafaxine", "."], "event_mentions": [{"id": "16239768_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 12, "end": 13}, "arguments": [{"entity_id": "16239768_2_Ent2", "role": "Effect", "text": "urinary incontinence ( UI )", "start": 6, "end": 11}, {"entity_id": "16239768_2_Ent0", "role": "Subject", "text": "a woman", "start": 14, "end": 16}, {"entity_id": "16239768_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 15, "end": 16}, {"entity_id": "16239768_2_Ent3", "role": "Treatment", "text": "venlafaxine", "start": 19, "end": 20}, {"entity_id": "16239768_2_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16239768_2_Ent2", "text": "urinary incontinence ( UI )", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16239768_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16239768_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16239768_2_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16239768_2_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16239768_3", "wnd_id": "16239768_3_1", "text": "Venlafaxine - induced urinary incontinence resolved after switching to sertraline .", "tokens": ["Venlafaxine", "-", "induced", "urinary", "incontinence", "resolved", "after", "switching", "to", "sertraline", "."], "event_mentions": [{"id": "16239768_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16239768_3_Ent1", "role": "Treatment", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "16239768_3_Ent2", "role": "Treatment_Drug", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "16239768_3_Ent0", "role": "Effect", "text": "urinary incontinence", "start": 3, "end": 5}]}, {"id": "16239768_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "16239768_3_Ent4", "role": "Treatment_Disorder", "text": "Venlafaxine - induced urinary incontinence", "start": 0, "end": 5}, {"entity_id": "16239768_3_Ent3", "role": "Treatment", "text": "sertraline", "start": 9, "end": 10}, {"entity_id": "16239768_3_Ent5", "role": "Treatment_Drug", "text": "sertraline", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16239768_3_Ent1", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16239768_3_Ent2", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16239768_3_Ent4", "text": "Venlafaxine - induced urinary incontinence", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16239768_3_Ent0", "text": "urinary incontinence", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16239768_3_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16239768_3_Ent5", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "1624172_2", "wnd_id": "1624172_2_1", "text": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "tokens": ["Sustained", "hypothyroidism", "induced", "by", "recombinant", "alpha", "interferon", "in", "patients", "with", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "1624172_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1624172_2_Ent1", "role": "Effect", "text": "Sustained hypothyroidism", "start": 0, "end": 2}, {"entity_id": "1624172_2_Ent2", "role": "Treatment", "text": "recombinant alpha interferon", "start": 4, "end": 7}, {"entity_id": "1624172_2_Ent4", "role": "Treatment_Drug", "text": "recombinant alpha interferon", "start": 4, "end": 7}, {"entity_id": "1624172_2_Ent0", "role": "Subject", "text": "patients with chronic hepatitis C.", "start": 8, "end": 13}, {"entity_id": "1624172_2_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1624172_2_Ent1", "text": "Sustained hypothyroidism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1624172_2_Ent2", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1624172_2_Ent4", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1624172_2_Ent0", "text": "patients with chronic hepatitis C.", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "1624172_2_Ent3", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "1624172_4", "wnd_id": "1624172_4_1", "text": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported .", "tokens": ["Two", "cases", "of", "hypothyroidism", "in", "patients", "with", "chronic", "hepatitis", "C", "treated", "with", "recombinant", "alpha", "interferon", "are", "reported", "."], "event_mentions": [{"id": "1624172_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "1624172_4_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "1624172_4_Ent0", "role": "Subject", "text": "Two cases", "start": 0, "end": 2}, {"entity_id": "1624172_4_Ent2", "role": "Effect", "text": "hypothyroidism", "start": 3, "end": 4}, {"entity_id": "1624172_4_Ent5", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 7, "end": 10}, {"entity_id": "1624172_4_Ent3", "role": "Treatment", "text": "recombinant alpha interferon", "start": 12, "end": 15}, {"entity_id": "1624172_4_Ent4", "role": "Treatment_Drug", "text": "recombinant alpha interferon", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "1624172_4_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1624172_4_Ent0", "text": "Two cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1624172_4_Ent2", "text": "hypothyroidism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1624172_4_Ent5", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1624172_4_Ent3", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "1624172_4_Ent4", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "16268429_2", "wnd_id": "16268429_2_1", "text": "Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation .", "tokens": ["Subacute", "cholestatic", "hepatitis", "likely", "related", "to", "the", "use", "of", "senna", "for", "chronic", "constipation", "."], "event_mentions": [{"id": "16268429_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 4, "end": 6}, "arguments": [{"entity_id": "16268429_2_Ent0", "role": "Effect", "text": "Subacute cholestatic hepatitis", "start": 0, "end": 3}, {"entity_id": "16268429_2_Ent1", "role": "Treatment", "text": "use of senna", "start": 7, "end": 10}, {"entity_id": "16268429_2_Ent2", "role": "Treatment_Drug", "text": "senna", "start": 9, "end": 10}, {"entity_id": "16268429_2_Ent3", "role": "Treatment_Disorder", "text": "chronic constipation .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16268429_2_Ent0", "text": "Subacute cholestatic hepatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16268429_2_Ent1", "text": "use of senna", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16268429_2_Ent2", "text": "senna", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16268429_2_Ent3", "text": "chronic constipation .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16298824_2", "wnd_id": "16298824_2_1", "text": "ARDS has been associated with the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines .", "tokens": ["ARDS", "has", "been", "associated", "with", "the", "administration", "of", "other", "monoclonal", "antibodies", ",", "such", "as", "infliximab", ",", "gemtuzumab", "ozogamicin", ",", "and", "OKT3", "and", "is", "believed", "to", "be", "directly", "mediated", "by", "release", "of", "proinflammatory", "cytokines", "."], "event_mentions": [{"id": "16298824_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16298824_2_Ent0", "role": "Effect", "text": "ARDS", "start": 0, "end": 1}, {"entity_id": "16298824_2_Ent1", "role": "Treatment", "text": "the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3", "start": 5, "end": 21}, {"entity_id": "16298824_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 14, "end": 15}, {"entity_id": "16298824_2_Ent3", "role": "Treatment_Drug", "text": "gemtuzumab", "start": 16, "end": 17}, {"entity_id": "16298824_2_Ent4", "role": "Treatment_Drug", "text": "ozogamicin", "start": 17, "end": 18}, {"entity_id": "16298824_2_Ent5", "role": "Treatment_Drug", "text": "OKT3", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "16298824_2_Ent0", "text": "ARDS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16298824_2_Ent1", "text": "the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3", "entity_type": "Entity", "start": 5, "end": 21}, {"id": "16298824_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16298824_2_Ent3", "text": "gemtuzumab", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16298824_2_Ent4", "text": "ozogamicin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16298824_2_Ent5", "text": "OKT3", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "16313549_1", "wnd_id": "16313549_1_1", "text": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma .", "tokens": ["Symptomatic", "hypocalcaemia", "and", "renal", "impairment", "associated", "with", "bisphosphonate", "treatment", "in", "patients", "with", "multiple", "myeloma", "."], "event_mentions": [{"id": "16313549_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "16313549_1_Ent1", "role": "Effect", "text": "Symptomatic hypocalcaemia and renal impairment", "start": 0, "end": 5}, {"entity_id": "16313549_1_Ent3", "role": "Treatment_Drug", "text": "bisphosphonate", "start": 7, "end": 8}, {"entity_id": "16313549_1_Ent2", "role": "Treatment", "text": "bisphosphonate treatment", "start": 7, "end": 9}, {"entity_id": "16313549_1_Ent0", "role": "Subject", "text": "patients with multiple myeloma", "start": 10, "end": 14}, {"entity_id": "16313549_1_Ent4", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16313549_1_Ent1", "text": "Symptomatic hypocalcaemia and renal impairment", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16313549_1_Ent3", "text": "bisphosphonate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16313549_1_Ent2", "text": "bisphosphonate treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16313549_1_Ent0", "text": "patients with multiple myeloma", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16313549_1_Ent4", "text": "multiple myeloma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16317298_2", "wnd_id": "16317298_2_1", "text": "Gemcitabine should be added to the list of drugs known to cause radiation recall .", "tokens": ["Gemcitabine", "should", "be", "added", "to", "the", "list", "of", "drugs", "known", "to", "cause", "radiation", "recall", "."], "event_mentions": [{"id": "16317298_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "16317298_2_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_2_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_2_Ent0", "role": "Effect", "text": "radiation recall", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16317298_2_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_2_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_2_Ent0", "text": "radiation recall", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16317298_5", "wnd_id": "16317298_5_1", "text": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation - recall related to gemcitabine and review literature .", "tokens": ["We", "report", "a", "patient", "with", "inoperable", "pancreatic", "cancer", "who", "developed", "gastrointestinal", "bleeding", "secondary", "to", "radiation", "-", "recall", "related", "to", "gemcitabine", "and", "review", "literature", "."], "event_mentions": [{"id": "16317298_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "16317298_5_Ent0", "role": "Subject", "text": "a patient with inoperable pancreatic cancer", "start": 2, "end": 8}, {"entity_id": "16317298_5_Ent4", "role": "Treatment_Disorder", "text": "inoperable pancreatic cancer", "start": 5, "end": 8}, {"entity_id": "16317298_5_Ent1", "role": "Effect", "text": "gastrointestinal bleeding", "start": 10, "end": 12}, {"entity_id": "16317298_5_Ent2", "role": "Effect", "text": "radiation - recall", "start": 14, "end": 17}, {"entity_id": "16317298_5_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 19, "end": 20}, {"entity_id": "16317298_5_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16317298_5_Ent0", "text": "a patient with inoperable pancreatic cancer", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "16317298_5_Ent4", "text": "inoperable pancreatic cancer", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16317298_5_Ent1", "text": "gastrointestinal bleeding", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16317298_5_Ent2", "text": "radiation - recall", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16317298_5_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16317298_5_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16317298_6", "wnd_id": "16317298_6_1", "text": "We suggest discontinuing gemcitabine if radiation recall is observed .", "tokens": ["We", "suggest", "discontinuing", "gemcitabine", "if", "radiation", "recall", "is", "observed", "."], "event_mentions": [{"id": "16317298_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "if", "start": 4, "end": 5}, "arguments": [{"entity_id": "16317298_6_Ent1", "role": "Treatment", "text": "discontinuing gemcitabine", "start": 2, "end": 4}, {"entity_id": "16317298_6_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 3, "end": 4}, {"entity_id": "16317298_6_Ent0", "role": "Effect", "text": "radiation recall", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16317298_6_Ent1", "text": "discontinuing gemcitabine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16317298_6_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16317298_6_Ent0", "text": "radiation recall", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16326413_2", "wnd_id": "16326413_2_1", "text": "High - dose methotrexate - associated acute renal failure may be an avoidable complication .", "tokens": ["High", "-", "dose", "methotrexate", "-", "associated", "acute", "renal", "failure", "may", "be", "an", "avoidable", "complication", "."], "event_mentions": [{"id": "16326413_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "16326413_2_Ent2", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "16326413_2_Ent1", "role": "Treatment", "text": "High - dose methotrexate", "start": 0, "end": 4}, {"entity_id": "16326413_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "16326413_2_Ent0", "role": "Effect", "text": "acute renal failure", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16326413_2_Ent2", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16326413_2_Ent1", "text": "High - dose methotrexate", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16326413_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16326413_2_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16355099_4", "wnd_id": "16355099_4_1", "text": "When thrombosis develops during heparin treatment , it is important to suspect HITTs and to assay for the associated antibodies , regardless of the actual platelet count .", "tokens": ["When", "thrombosis", "develops", "during", "heparin", "treatment", ",", "it", "is", "important", "to", "suspect", "HITTs", "and", "to", "assay", "for", "the", "associated", "antibodies", ",", "regardless", "of", "the", "actual", "platelet", "count", "."], "event_mentions": [{"id": "16355099_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develops", "start": 2, "end": 3}, "arguments": [{"entity_id": "16355099_4_Ent0", "role": "Effect", "text": "thrombosis", "start": 1, "end": 2}, {"entity_id": "16355099_4_Ent2", "role": "Treatment", "text": "heparin", "start": 4, "end": 5}, {"entity_id": "16355099_4_Ent3", "role": "Treatment_Drug", "text": "heparin", "start": 4, "end": 5}, {"entity_id": "16355099_4_Ent1", "role": "Effect", "text": "HITTs", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16355099_4_Ent0", "text": "thrombosis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16355099_4_Ent2", "text": "heparin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16355099_4_Ent3", "text": "heparin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16355099_4_Ent1", "text": "HITTs", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16371793_12", "wnd_id": "16371793_12_1", "text": "After intravitreal injection of triamcinolone acetonide , cataract may rapidly develop in eyes that have been intensively treated , topically and systemically , by corticosteroids for several years .", "tokens": ["After", "intravitreal", "injection", "of", "triamcinolone", "acetonide", ",", "cataract", "may", "rapidly", "develop", "in", "eyes", "that", "have", "been", "intensively", "treated", ",", "topically", "and", "systemically", ",", "by", "corticosteroids", "for", "several", "years", "."], "event_mentions": [{"id": "16371793_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 10, "end": 11}, "arguments": [{"entity_id": "16371793_12_Ent2", "role": "Treatment_Route", "text": "intravitreal injection", "start": 1, "end": 3}, {"entity_id": "16371793_12_Ent1", "role": "Treatment", "text": "intravitreal injection of triamcinolone acetonide", "start": 1, "end": 6}, {"entity_id": "16371793_12_Ent3", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 4, "end": 6}, {"entity_id": "16371793_12_Ent0", "role": "Effect", "text": "cataract", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16371793_12_Ent2", "text": "intravitreal injection", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16371793_12_Ent1", "text": "intravitreal injection of triamcinolone acetonide", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16371793_12_Ent3", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16371793_12_Ent0", "text": "cataract", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16436462_1", "wnd_id": "16436462_1_1", "text": "Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer .", "tokens": ["Neutropenic", "colitis", "during", "standard", "dose", "combination", "chemotherapy", "with", "nedaplatin", "and", "irinotecan", "for", "testicular", "cancer", "."], "event_mentions": [{"id": "16436462_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "16436462_1_Ent0", "role": "Effect", "text": "Neutropenic colitis", "start": 0, "end": 2}, {"entity_id": "16436462_1_Ent3", "role": "Treatment_Dosage", "text": "standard dose", "start": 3, "end": 5}, {"entity_id": "16436462_1_Ent1", "role": "Treatment", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "start": 3, "end": 14}, {"entity_id": "16436462_1_Ent4", "role": "Treatment_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent6", "role": "Combination_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent5", "role": "Treatment_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent7", "role": "Combination_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent2", "role": "Treatment_Disorder", "text": "testicular cancer", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16436462_1_Ent0", "text": "Neutropenic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16436462_1_Ent3", "text": "standard dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16436462_1_Ent1", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "16436462_1_Ent4", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent6", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent5", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent7", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent2", "text": "testicular cancer", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16446228_2", "wnd_id": "16446228_2_1", "text": "Reversible sirolimus - associated pneumonitis after heart transplantation .", "tokens": ["Reversible", "sirolimus", "-", "associated", "pneumonitis", "after", "heart", "transplantation", "."], "event_mentions": [{"id": "16446228_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16446228_2_Ent1", "role": "Treatment", "text": "sirolimus", "start": 1, "end": 2}, {"entity_id": "16446228_2_Ent2", "role": "Treatment_Drug", "text": "sirolimus", "start": 1, "end": 2}, {"entity_id": "16446228_2_Ent0", "role": "Effect", "text": "pneumonitis", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "16446228_2_Ent1", "text": "sirolimus", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16446228_2_Ent2", "text": "sirolimus", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16446228_2_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "16453964_1", "wnd_id": "16453964_1_1", "text": "We describe a case of intraoperative gelatine - induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient 's medical records .", "tokens": ["We", "describe", "a", "case", "of", "intraoperative", "gelatine", "-", "induced", "anaphylaxis", "whose", "diagnosis", "was", "delayed", "as", "the", "use", "of", "gelatine", "during", "surgical", "procedures", "was", "omitted", "for", "two", "times", "in", "patient", "'s", "medical", "records", "."], "event_mentions": [{"id": "16453964_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16453964_1_Ent3", "role": "Treatment_Route", "text": "intraoperative", "start": 5, "end": 6}, {"entity_id": "16453964_1_Ent1", "role": "Treatment", "text": "intraoperative gelatine", "start": 5, "end": 7}, {"entity_id": "16453964_1_Ent2", "role": "Treatment_Drug", "text": "gelatine", "start": 6, "end": 7}, {"entity_id": "16453964_1_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16453964_1_Ent3", "text": "intraoperative", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16453964_1_Ent1", "text": "intraoperative gelatine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16453964_1_Ent2", "text": "gelatine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16453964_1_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16490518_4", "wnd_id": "16490518_4_1", "text": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid - induced glaucoma .", "tokens": ["This", "treatment", "has", "the", "potential", "to", "cause", "severe", "vision", "loss", "as", "a", "result", "of", "intractable", "corticosteroid", "-", "induced", "glaucoma", "."], "event_mentions": [{"id": "16490518_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "16490518_4_Ent0", "role": "Effect", "text": "severe vision loss", "start": 7, "end": 10}, {"entity_id": "16490518_4_Ent2", "role": "Treatment", "text": "corticosteroid", "start": 15, "end": 16}, {"entity_id": "16490518_4_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 15, "end": 16}, {"entity_id": "16490518_4_Ent1", "role": "Effect", "text": "glaucoma", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16490518_4_Ent0", "text": "severe vision loss", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16490518_4_Ent2", "text": "corticosteroid", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16490518_4_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16490518_4_Ent1", "text": "glaucoma", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16498048_2", "wnd_id": "16498048_2_1", "text": "Destructive thyrotoxicosis appeared 4 - 6 months after starting IFN - alpha , followed by Graves ' hyperthyroidism within 8 to 11 months .", "tokens": ["Destructive", "thyrotoxicosis", "appeared", "4", "-", "6", "months", "after", "starting", "IFN", "-", "alpha", ",", "followed", "by", "Graves", "'", "hyperthyroidism", "within", "8", "to", "11", "months", "."], "event_mentions": [{"id": "16498048_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "16498048_2_Ent0", "role": "Effect", "text": "Destructive thyrotoxicosis", "start": 0, "end": 2}, {"entity_id": "16498048_2_Ent4", "role": "Treatment_Time_elapsed", "text": "4 - 6 months", "start": 3, "end": 7}, {"entity_id": "16498048_2_Ent2", "role": "Treatment", "text": "IFN - alpha", "start": 9, "end": 12}, {"entity_id": "16498048_2_Ent3", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 9, "end": 12}, {"entity_id": "16498048_2_Ent1", "role": "Effect", "text": "Graves ' hyperthyroidism", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "16498048_2_Ent0", "text": "Destructive thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16498048_2_Ent4", "text": "4 - 6 months", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16498048_2_Ent2", "text": "IFN - alpha", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16498048_2_Ent3", "text": "IFN - alpha", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16498048_2_Ent1", "text": "Graves ' hyperthyroidism", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "16503727_3", "wnd_id": "16503727_3_1", "text": "We describe a patient who developed granulocytopenia and fever after taking dipyrone and discuss the available literature .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "granulocytopenia", "and", "fever", "after", "taking", "dipyrone", "and", "discuss", "the", "available", "literature", "."], "event_mentions": [{"id": "16503727_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "16503727_3_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "16503727_3_Ent1", "role": "Effect", "text": "granulocytopenia and fever", "start": 6, "end": 9}, {"entity_id": "16503727_3_Ent2", "role": "Treatment", "text": "taking dipyrone", "start": 10, "end": 12}, {"entity_id": "16503727_3_Ent3", "role": "Treatment_Drug", "text": "dipyrone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16503727_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16503727_3_Ent1", "text": "granulocytopenia and fever", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16503727_3_Ent2", "text": "taking dipyrone", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16503727_3_Ent3", "text": "dipyrone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16511396_1", "wnd_id": "16511396_1_1", "text": "A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever , severe cutaneous involvement , swelling , abdominal pain and transaminitis , persisting weeks after withholding medicines .", "tokens": ["A", "7", "-", "year", "-", "old", "with", "congenital", "toxoplasmosis", "who", "took", "pyrimethamine", "and", "sulfadiazine", "for", "reactivated", "chorioretinitis", "developed", "fever", ",", "severe", "cutaneous", "involvement", ",", "swelling", ",", "abdominal", "pain", "and", "transaminitis", ",", "persisting", "weeks", "after", "withholding", "medicines", "."], "event_mentions": [{"id": "16511396_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "16511396_1_Ent0", "role": "Subject", "text": "A 7 - year - old with congenital toxoplasmosis", "start": 0, "end": 9}, {"entity_id": "16511396_1_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 1, "end": 6}, {"entity_id": "16511396_1_Ent5", "role": "Treatment_Disorder", "text": "congenital toxoplasmosis", "start": 7, "end": 9}, {"entity_id": "16511396_1_Ent6", "role": "Treatment_Drug", "text": "pyrimethamine", "start": 11, "end": 12}, {"entity_id": "16511396_1_Ent8", "role": "Combination_Drug", "text": "pyrimethamine", "start": 11, "end": 12}, {"entity_id": "16511396_1_Ent3", "role": "Treatment", "text": "pyrimethamine and sulfadiazine for reactivated chorioretinitis", "start": 11, "end": 17}, {"entity_id": "16511396_1_Ent7", "role": "Treatment_Drug", "text": "sulfadiazine", "start": 13, "end": 14}, {"entity_id": "16511396_1_Ent9", "role": "Combination_Drug", "text": "sulfadiazine", "start": 13, "end": 14}, {"entity_id": "16511396_1_Ent4", "role": "Treatment_Disorder", "text": "reactivated chorioretinitis", "start": 15, "end": 17}, {"entity_id": "16511396_1_Ent2", "role": "Effect", "text": "fever , severe cutaneous involvement , swelling , abdominal pain and transaminitis", "start": 18, "end": 30}]}], "entity_mentions": [{"id": "16511396_1_Ent0", "text": "A 7 - year - old with congenital toxoplasmosis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "16511396_1_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16511396_1_Ent5", "text": "congenital toxoplasmosis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16511396_1_Ent6", "text": "pyrimethamine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16511396_1_Ent8", "text": "pyrimethamine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16511396_1_Ent3", "text": "pyrimethamine and sulfadiazine for reactivated chorioretinitis", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "16511396_1_Ent7", "text": "sulfadiazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16511396_1_Ent9", "text": "sulfadiazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16511396_1_Ent4", "text": "reactivated chorioretinitis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16511396_1_Ent2", "text": "fever , severe cutaneous involvement , swelling , abdominal pain and transaminitis", "entity_type": "Entity", "start": 18, "end": 30}], "lang": "en"}
{"doc_id": "16515630_1", "wnd_id": "16515630_1_1", "text": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report , we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer .", "tokens": ["Fatal", "lung", "fibrosis", "caused", "by", "paclitaxel", "toxicity", "has", "not", "been", "reported", "In", "this", "report", ",", "we", "describe", "the", "case", "of", "a", "62", "-", "year", "-", "old", "woman", "who", "received", "six", "cycles", "of", "paclitaxel", "and", "carboplatin", "as", "combination", "chemotherapy", "for", "advanced", "ovarian", "cancer", "."], "event_mentions": [{"id": "16515630_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 28, "end": 29}, "arguments": [{"entity_id": "16515630_1_Ent4", "role": "Effect", "text": "Fatal lung fibrosis", "start": 0, "end": 3}, {"entity_id": "16515630_1_Ent2", "role": "Subject_Age", "text": "62 - year - old", "start": 21, "end": 26}, {"entity_id": "16515630_1_Ent0", "role": "Subject", "text": "62 - year - old woman", "start": 21, "end": 27}, {"entity_id": "16515630_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 26, "end": 27}, {"entity_id": "16515630_1_Ent6", "role": "Treatment_Dosage", "text": "six cycles", "start": 29, "end": 31}, {"entity_id": "16515630_1_Ent5", "role": "Treatment", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "start": 29, "end": 38}, {"entity_id": "16515630_1_Ent7", "role": "Treatment_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent11", "role": "Combination_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent8", "role": "Treatment_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent12", "role": "Combination_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent10", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}, {"entity_id": "16515630_1_Ent1", "role": "Subject", "text": "advanced ovarian cancer", "start": 39, "end": 42}, {"entity_id": "16515630_1_Ent9", "role": "Treatment_Disorder", "text": "advanced ovarian cancer", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "16515630_1_Ent4", "text": "Fatal lung fibrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16515630_1_Ent2", "text": "62 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "16515630_1_Ent0", "text": "62 - year - old woman", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "16515630_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16515630_1_Ent6", "text": "six cycles", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16515630_1_Ent5", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "entity_type": "Entity", "start": 29, "end": 38}, {"id": "16515630_1_Ent7", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent11", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent8", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent12", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16515630_1_Ent1", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "16515630_1_Ent9", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "16515630_3", "wnd_id": "16515630_3_1", "text": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis .", "tokens": ["Physicians", "should", "keep", "in", "mind", "that", "taxanes", "such", "as", "paclitaxel", "have", "the", "potential", "to", "cause", "pneumonitis", "and", "lung", "fibrosis", "."], "event_mentions": [{"id": "16515630_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 14, "end": 15}, "arguments": [{"entity_id": "16515630_3_Ent2", "role": "Treatment_Drug", "text": "taxanes", "start": 6, "end": 7}, {"entity_id": "16515630_3_Ent1", "role": "Treatment", "text": "taxanes such as paclitaxel", "start": 6, "end": 10}, {"entity_id": "16515630_3_Ent0", "role": "Effect", "text": "pneumonitis and lung fibrosis", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "16515630_3_Ent2", "text": "taxanes", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16515630_3_Ent1", "text": "taxanes such as paclitaxel", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16515630_3_Ent0", "text": "pneumonitis and lung fibrosis", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "16521231_3", "wnd_id": "16521231_3_1", "text": "Subfulminant hepatitis B after infliximab in Crohn 's disease : need for HBV - screening ?", "tokens": ["Subfulminant", "hepatitis", "B", "after", "infliximab", "in", "Crohn", "'s", "disease", ":", "need", "for", "HBV", "-", "screening", "?"], "event_mentions": [{"id": "16521231_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "16521231_3_Ent0", "role": "Effect", "text": "Subfulminant hepatitis B", "start": 0, "end": 3}, {"entity_id": "16521231_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "16521231_3_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "16521231_3_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16521231_3_Ent0", "text": "Subfulminant hepatitis B", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16521231_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16521231_3_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16521231_3_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16527771_3", "wnd_id": "16527771_3_1", "text": "We report a 78 - year - old man who had acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia .", "tokens": ["We", "report", "a", "78", "-", "year", "-", "old", "man", "who", "had", "acute", "unilateral", "total", "visual", "loss", "after", "retrogasserian", "phenol", "injection", "for", "the", "treatment", "of", "trigeminal", "neuralgia", "."], "event_mentions": [{"id": "16527771_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "16527771_3_Ent0", "role": "Subject", "text": "a 78 - year - old man", "start": 2, "end": 9}, {"entity_id": "16527771_3_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 3, "end": 8}, {"entity_id": "16527771_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "16527771_3_Ent3", "role": "Effect", "text": "acute unilateral total visual loss", "start": 11, "end": 16}, {"entity_id": "16527771_3_Ent4", "role": "Treatment", "text": "retrogasserian phenol injection", "start": 17, "end": 20}, {"entity_id": "16527771_3_Ent7", "role": "Treatment_Drug", "text": "phenol", "start": 18, "end": 19}, {"entity_id": "16527771_3_Ent6", "role": "Treatment_Route", "text": "injection", "start": 19, "end": 20}, {"entity_id": "16527771_3_Ent5", "role": "Treatment_Disorder", "text": "trigeminal neuralgia", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "16527771_3_Ent0", "text": "a 78 - year - old man", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "16527771_3_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16527771_3_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16527771_3_Ent3", "text": "acute unilateral total visual loss", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16527771_3_Ent4", "text": "retrogasserian phenol injection", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "16527771_3_Ent7", "text": "phenol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16527771_3_Ent6", "text": "injection", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16527771_3_Ent5", "text": "trigeminal neuralgia", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "16531969_1", "wnd_id": "16531969_1_1", "text": "Drug induced liver injury secondary to interferon - beta ( IFN - beta ) in multiple sclerosis .", "tokens": ["Drug", "induced", "liver", "injury", "secondary", "to", "interferon", "-", "beta", "(", "IFN", "-", "beta", ")", "in", "multiple", "sclerosis", "."], "event_mentions": [{"id": "16531969_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 4, "end": 5}, "arguments": [{"entity_id": "16531969_1_Ent0", "role": "Effect", "text": "liver injury", "start": 2, "end": 4}, {"entity_id": "16531969_1_Ent2", "role": "Treatment_Drug", "text": "interferon - beta", "start": 6, "end": 9}, {"entity_id": "16531969_1_Ent1", "role": "Treatment", "text": "interferon - beta ( IFN - beta )", "start": 6, "end": 14}, {"entity_id": "16531969_1_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16531969_1_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16531969_1_Ent2", "text": "interferon - beta", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16531969_1_Ent1", "text": "interferon - beta ( IFN - beta )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "16531969_1_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16531969_3", "wnd_id": "16531969_3_1", "text": "Post marketing studies of Interferon - beta ( IFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of hepatotoxicity .", "tokens": ["Post", "marketing", "studies", "of", "Interferon", "-", "beta", "(", "IFN", "beta", ")", "therapy", "in", "multiple", "sclerosis", "(", "MS", ")", "have", "demonstrated", "surprisingly", "high", "rates", "of", "hepatotoxicity", "."], "event_mentions": [{"id": "16531969_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 19, "end": 20}, "arguments": [{"entity_id": "16531969_3_Ent1", "role": "Treatment", "text": "Interferon - beta", "start": 4, "end": 7}, {"entity_id": "16531969_3_Ent2", "role": "Treatment_Drug", "text": "Interferon - beta ( IFN beta )", "start": 4, "end": 11}, {"entity_id": "16531969_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16531969_3_Ent1", "text": "Interferon - beta", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16531969_3_Ent2", "text": "Interferon - beta ( IFN beta )", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "16531969_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16531969_4", "wnd_id": "16531969_4_1", "text": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug - induced liver injury .", "tokens": ["We", "report", "three", "cases", "of", "IFN", "beta", "induced", "hepatitis", "in", "MS", "and", "discuss", "the", "pathology", "findings", "and", "possible", "mechanisms", "of", "drug", "-", "induced", "liver", "injury", "."], "event_mentions": [{"id": "16531969_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16531969_4_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "16531969_4_Ent0", "role": "Subject", "text": "three cases", "start": 2, "end": 4}, {"entity_id": "16531969_4_Ent3", "role": "Treatment", "text": "IFN beta", "start": 5, "end": 7}, {"entity_id": "16531969_4_Ent4", "role": "Treatment_Drug", "text": "IFN beta", "start": 5, "end": 7}, {"entity_id": "16531969_4_Ent2", "role": "Effect", "text": "hepatitis in MS", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "16531969_4_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16531969_4_Ent0", "text": "three cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16531969_4_Ent3", "text": "IFN beta", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16531969_4_Ent4", "text": "IFN beta", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16531969_4_Ent2", "text": "hepatitis in MS", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "16609346_2", "wnd_id": "16609346_2_1", "text": "Statin - associated myasthenia gravis : report of 4 cases and review of the literature .", "tokens": ["Statin", "-", "associated", "myasthenia", "gravis", ":", "report", "of", "4", "cases", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "16609346_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16609346_2_Ent3", "role": "Treatment", "text": "Statin", "start": 0, "end": 1}, {"entity_id": "16609346_2_Ent4", "role": "Treatment_Drug", "text": "Statin", "start": 0, "end": 1}, {"entity_id": "16609346_2_Ent2", "role": "Effect", "text": "myasthenia gravis", "start": 3, "end": 5}, {"entity_id": "16609346_2_Ent1", "role": "Subject_Population", "text": "4", "start": 8, "end": 9}, {"entity_id": "16609346_2_Ent0", "role": "Subject", "text": "4 cases", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16609346_2_Ent3", "text": "Statin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16609346_2_Ent4", "text": "Statin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16609346_2_Ent2", "text": "myasthenia gravis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16609346_2_Ent1", "text": "4", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16609346_2_Ent0", "text": "4 cases", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16615675_2", "wnd_id": "16615675_2_1", "text": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia .", "tokens": ["Chronic", "hydroxychloroquine", "use", "associated", "with", "QT", "prolongation", "and", "refractory", "ventricular", "arrhythmia", "."], "event_mentions": [{"id": "16615675_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16615675_2_Ent1", "role": "Treatment", "text": "Chronic hydroxychloroquine", "start": 0, "end": 2}, {"entity_id": "16615675_2_Ent2", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 1, "end": 2}, {"entity_id": "16615675_2_Ent0", "role": "Effect", "text": "QT prolongation and refractory ventricular arrhythmia", "start": 5, "end": 11}]}], "entity_mentions": [{"id": "16615675_2_Ent1", "text": "Chronic hydroxychloroquine", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16615675_2_Ent2", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16615675_2_Ent0", "text": "QT prolongation and refractory ventricular arrhythmia", "entity_type": "Entity", "start": 5, "end": 11}], "lang": "en"}
{"doc_id": "16615675_3", "wnd_id": "16615675_3_1", "text": "CONCLUSION : The chronic use of HCQ for rheumatic diseases , or as an anti - malarial drug , should be balanced against the risk of developing potentially lethal cardiac arrhythmias .", "tokens": ["CONCLUSION", ":", "The", "chronic", "use", "of", "HCQ", "for", "rheumatic", "diseases", ",", "or", "as", "an", "anti", "-", "malarial", "drug", ",", "should", "be", "balanced", "against", "the", "risk", "of", "developing", "potentially", "lethal", "cardiac", "arrhythmias", "."], "event_mentions": [{"id": "16615675_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "against", "start": 22, "end": 23}, "arguments": [{"entity_id": "16615675_3_Ent4", "role": "Treatment_Duration", "text": "chronic", "start": 3, "end": 4}, {"entity_id": "16615675_3_Ent1", "role": "Treatment", "text": "chronic use of HCQ", "start": 3, "end": 7}, {"entity_id": "16615675_3_Ent3", "role": "Treatment_Drug", "text": "HCQ", "start": 6, "end": 7}, {"entity_id": "16615675_3_Ent2", "role": "Treatment_Disorder", "text": "rheumatic diseases", "start": 8, "end": 10}, {"entity_id": "16615675_3_Ent0", "role": "Effect", "text": "lethal cardiac arrhythmias", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "16615675_3_Ent4", "text": "chronic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16615675_3_Ent1", "text": "chronic use of HCQ", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16615675_3_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16615675_3_Ent2", "text": "rheumatic diseases", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16615675_3_Ent0", "text": "lethal cardiac arrhythmias", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "16623611_1", "wnd_id": "16623611_1_1", "text": "Case report : lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine .", "tokens": ["Case", "report", ":", "lack", "of", "control", "of", "diabetes", "and", "weight", "gain", "in", "a", "patient", "on", "initiation", "and", "rechallenge", "of", "therapy", "with", "olanzapine", "."], "event_mentions": [{"id": "16623611_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "initiation and rechallenge", "start": 15, "end": 18}, "arguments": [{"entity_id": "16623611_1_Ent1", "role": "Effect", "text": "diabetes", "start": 7, "end": 8}, {"entity_id": "16623611_1_Ent2", "role": "Effect", "text": "weight gain", "start": 9, "end": 11}, {"entity_id": "16623611_1_Ent0", "role": "Subject", "text": "a patient", "start": 12, "end": 14}, {"entity_id": "16623611_1_Ent3", "role": "Treatment", "text": "olanzapine", "start": 21, "end": 22}, {"entity_id": "16623611_1_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16623611_1_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16623611_1_Ent2", "text": "weight gain", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16623611_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16623611_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16623611_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16637972_2", "wnd_id": "16637972_2_1", "text": "An unusual presentation of spontaneous sub - conjunctival haematoma in a patient receiving warfarin .", "tokens": ["An", "unusual", "presentation", "of", "spontaneous", "sub", "-", "conjunctival", "haematoma", "in", "a", "patient", "receiving", "warfarin", "."], "event_mentions": [{"id": "16637972_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "16637972_2_Ent1", "role": "Effect", "text": "spontaneous sub - conjunctival haematoma", "start": 4, "end": 9}, {"entity_id": "16637972_2_Ent0", "role": "Subject", "text": "a patient", "start": 10, "end": 12}, {"entity_id": "16637972_2_Ent2", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "16637972_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16637972_2_Ent1", "text": "spontaneous sub - conjunctival haematoma", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16637972_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16637972_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16637972_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16641839_4", "wnd_id": "16641839_4_1", "text": "Cutaneous rashes and eruptions can be caused by many medications , including carbamazepine .", "tokens": ["Cutaneous", "rashes", "and", "eruptions", "can", "be", "caused", "by", "many", "medications", ",", "including", "carbamazepine", "."], "event_mentions": [{"id": "16641839_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "16641839_4_Ent0", "role": "Effect", "text": "Cutaneous rashes and eruptions", "start": 0, "end": 4}, {"entity_id": "16641839_4_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 12, "end": 13}, {"entity_id": "16641839_4_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16641839_4_Ent0", "text": "Cutaneous rashes and eruptions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16641839_4_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16641839_4_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16649344_2", "wnd_id": "16649344_2_1", "text": "Current immunosuppressive therapies are effective but can be associated with significant adverse reactions .", "tokens": ["Current", "immunosuppressive", "therapies", "are", "effective", "but", "can", "be", "associated", "with", "significant", "adverse", "reactions", "."], "event_mentions": [{"id": "16649344_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "16649344_2_Ent1", "role": "Treatment", "text": "Current immunosuppressive therapies", "start": 0, "end": 3}, {"entity_id": "16649344_2_Ent2", "role": "Treatment_Drug", "text": "immunosuppressive", "start": 1, "end": 2}, {"entity_id": "16649344_2_Ent0", "role": "Effect", "text": "significant adverse reactions .", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "16649344_2_Ent1", "text": "Current immunosuppressive therapies", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16649344_2_Ent2", "text": "immunosuppressive", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16649344_2_Ent0", "text": "significant adverse reactions .", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "16649344_3", "wnd_id": "16649344_3_1", "text": "Sirolimus works differently from the immunosuppressants currently available , and except for increased lipid levels , the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus .", "tokens": ["Sirolimus", "works", "differently", "from", "the", "immunosuppressants", "currently", "available", ",", "and", "except", "for", "increased", "lipid", "levels", ",", "the", "adverse", "reaction", "profile", "of", "sirolimus", "does", "not", "appear", "to", "overlap", "to", "any", "great", "extent", "with", "that", "associated", "with", "cyclosporine", "or", "tacrolimus", "."], "event_mentions": [{"id": "16649344_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "16649344_3_Ent2", "role": "Treatment_Drug", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16649344_3_Ent1", "role": "Treatment", "text": "Sirolimus works differently from the immunosuppressants currently available", "start": 0, "end": 8}, {"entity_id": "16649344_3_Ent3", "role": "Treatment_Drug", "text": "immunosuppressants", "start": 5, "end": 6}, {"entity_id": "16649344_3_Ent0", "role": "Effect", "text": "increased lipid levels", "start": 12, "end": 15}, {"entity_id": "16649344_3_Ent4", "role": "Treatment_Drug", "text": "sirolimus", "start": 21, "end": 22}, {"entity_id": "16649344_3_Ent5", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "16649344_3_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "16649344_3_Ent2", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16649344_3_Ent1", "text": "Sirolimus works differently from the immunosuppressants currently available", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16649344_3_Ent3", "text": "immunosuppressants", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16649344_3_Ent0", "text": "increased lipid levels", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16649344_3_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16649344_3_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16649344_3_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "16678268_2", "wnd_id": "16678268_2_1", "text": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn 's disease ( CD ) .", "tokens": ["We", "report", "a", "case", "of", "severe", "AVP", "three", "weeks", "following", "the", "administration", "of", "infliximab", "for", "the", "treatment", "of", "Crohn", "'s", "disease", "(", "CD", ")", "."], "event_mentions": [{"id": "16678268_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "16678268_2_Ent0", "role": "Effect", "text": "AVP", "start": 6, "end": 7}, {"entity_id": "16678268_2_Ent2", "role": "Treatment_Time_elapsed", "text": "three weeks", "start": 7, "end": 9}, {"entity_id": "16678268_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 13, "end": 14}, {"entity_id": "16678268_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 13, "end": 14}, {"entity_id": "16678268_2_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "16678268_2_Ent0", "text": "AVP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16678268_2_Ent2", "text": "three weeks", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16678268_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16678268_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16678268_2_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "16718947_2", "wnd_id": "16718947_2_1", "text": "53 - year - old woman with a history of deep vein thrombosis and pulmonary embolism was receiving warfarin to prevent thromboembolic complications ; her international normalized ratio ( INR ) had been stable for 1 month .", "tokens": ["53", "-", "year", "-", "old", "woman", "with", "a", "history", "of", "deep", "vein", "thrombosis", "and", "pulmonary", "embolism", "was", "receiving", "warfarin", "to", "prevent", "thromboembolic", "complications", ";", "her", "international", "normalized", "ratio", "(", "INR", ")", "had", "been", "stable", "for", "1", "month", "."], "event_mentions": [{"id": "16718947_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevent", "start": 20, "end": 21}, "arguments": [{"entity_id": "16718947_2_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 0, "end": 5}, {"entity_id": "16718947_2_Ent0", "role": "Subject", "text": "53 - year - old woman with a history of deep vein thrombosis and pulmonary embolism", "start": 0, "end": 16}, {"entity_id": "16718947_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "16718947_2_Ent5", "role": "Treatment_Disorder", "text": "deep vein thrombosis", "start": 10, "end": 13}, {"entity_id": "16718947_2_Ent6", "role": "Treatment_Disorder", "text": "pulmonary embolism", "start": 14, "end": 16}, {"entity_id": "16718947_2_Ent3", "role": "Treatment", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "16718947_2_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "16718947_2_Ent7", "role": "Treatment_Disorder", "text": "thromboembolic complications ;", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "16718947_2_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16718947_2_Ent0", "text": "53 - year - old woman with a history of deep vein thrombosis and pulmonary embolism", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "16718947_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16718947_2_Ent5", "text": "deep vein thrombosis", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16718947_2_Ent6", "text": "pulmonary embolism", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16718947_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16718947_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16718947_2_Ent7", "text": "thromboembolic complications ;", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "16718947_3", "wnd_id": "16718947_3_1", "text": "Extended - release tolterodine 4 mg / day was then prescribed to manage overactive bladder .", "tokens": ["Extended", "-", "release", "tolterodine", "4", "mg", "/", "day", "was", "then", "prescribed", "to", "manage", "overactive", "bladder", "."], "event_mentions": [{"id": "16718947_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 10, "end": 11}, "arguments": [{"entity_id": "16718947_3_Ent2", "role": "Treatment_Drug", "text": "Extended - release tolterodine", "start": 0, "end": 4}, {"entity_id": "16718947_3_Ent0", "role": "Treatment", "text": "Extended - release tolterodine 4 mg / day", "start": 0, "end": 8}, {"entity_id": "16718947_3_Ent3", "role": "Treatment_Dosage", "text": "4 mg / day", "start": 4, "end": 8}, {"entity_id": "16718947_3_Ent1", "role": "Treatment_Disorder", "text": "overactive bladder", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16718947_3_Ent2", "text": "Extended - release tolterodine", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16718947_3_Ent0", "text": "Extended - release tolterodine 4 mg / day", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16718947_3_Ent3", "text": "4 mg / day", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16718947_3_Ent1", "text": "overactive bladder", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16728538_2", "wnd_id": "16728538_2_1", "text": "Drug - induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long - acting repeatable attributed to the use of pegvisomant .", "tokens": ["Drug", "-", "induced", "hepatitis", "in", "an", "acromegalic", "patient", "during", "combined", "treatment", "with", "pegvisomant", "and", "octreotide", "long", "-", "acting", "repeatable", "attributed", "to", "the", "use", "of", "pegvisomant", "."], "event_mentions": [{"id": "16728538_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16728538_2_Ent1", "role": "Effect", "text": "hepatitis", "start": 3, "end": 4}, {"entity_id": "16728538_2_Ent0", "role": "Subject", "text": "an acromegalic patient", "start": 5, "end": 8}, {"entity_id": "16728538_2_Ent3", "role": "Treatment_Disorder", "text": "acromegalic", "start": 6, "end": 7}, {"entity_id": "16728538_2_Ent2", "role": "Treatment", "text": "combined treatment with pegvisomant and octreotide long - acting repeatable", "start": 9, "end": 19}, {"entity_id": "16728538_2_Ent4", "role": "Treatment_Drug", "text": "pegvisomant", "start": 12, "end": 13}, {"entity_id": "16728538_2_Ent6", "role": "Combination_Drug", "text": "pegvisomant", "start": 12, "end": 13}, {"entity_id": "16728538_2_Ent5", "role": "Treatment_Drug", "text": "octreotide", "start": 14, "end": 15}, {"entity_id": "16728538_2_Ent7", "role": "Combination_Drug", "text": "octreotide", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16728538_2_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16728538_2_Ent0", "text": "an acromegalic patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16728538_2_Ent3", "text": "acromegalic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16728538_2_Ent2", "text": "combined treatment with pegvisomant and octreotide long - acting repeatable", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "16728538_2_Ent4", "text": "pegvisomant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16728538_2_Ent6", "text": "pegvisomant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16728538_2_Ent5", "text": "octreotide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16728538_2_Ent7", "text": "octreotide", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16765687_1", "wnd_id": "16765687_1_1", "text": "PURPOSE : Topiramate - induced angle - closure glaucoma ( TiACG ) is believed to be related to its sulfonamide moiety .", "tokens": ["PURPOSE", ":", "Topiramate", "-", "induced", "angle", "-", "closure", "glaucoma", "(", "TiACG", ")", "is", "believed", "to", "be", "related", "to", "its", "sulfonamide", "moiety", "."], "event_mentions": [{"id": "16765687_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16765687_1_Ent1", "role": "Treatment", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "16765687_1_Ent2", "role": "Treatment_Drug", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "16765687_1_Ent0", "role": "Effect", "text": "angle - closure glaucoma ( TiACG )", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "16765687_1_Ent1", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16765687_1_Ent2", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16765687_1_Ent0", "text": "angle - closure glaucoma ( TiACG )", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "16765687_2", "wnd_id": "16765687_2_1", "text": "Rapid resolution of topiramate - induced angle - closure glaucoma with methylprednisolone and mannitol .", "tokens": ["Rapid", "resolution", "of", "topiramate", "-", "induced", "angle", "-", "closure", "glaucoma", "with", "methylprednisolone", "and", "mannitol", "."], "event_mentions": [{"id": "16765687_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 1, "end": 2}, "arguments": [{"entity_id": "16765687_2_Ent1", "role": "Treatment_Disorder", "text": "topiramate - induced angle - closure glaucoma", "start": 3, "end": 10}, {"entity_id": "16765687_2_Ent2", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 11, "end": 12}, {"entity_id": "16765687_2_Ent4", "role": "Combination_Drug", "text": "methylprednisolone", "start": 11, "end": 12}, {"entity_id": "16765687_2_Ent0", "role": "Treatment", "text": "methylprednisolone and mannitol", "start": 11, "end": 14}, {"entity_id": "16765687_2_Ent3", "role": "Treatment_Drug", "text": "mannitol", "start": 13, "end": 14}, {"entity_id": "16765687_2_Ent5", "role": "Combination_Drug", "text": "mannitol", "start": 13, "end": 14}]}, {"id": "16765687_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "16765687_2_Ent7", "role": "Treatment", "text": "topiramate", "start": 3, "end": 4}, {"entity_id": "16765687_2_Ent8", "role": "Treatment_Drug", "text": "topiramate", "start": 3, "end": 4}, {"entity_id": "16765687_2_Ent6", "role": "Effect", "text": "angle - closure glaucoma", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "16765687_2_Ent7", "text": "topiramate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16765687_2_Ent8", "text": "topiramate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16765687_2_Ent1", "text": "topiramate - induced angle - closure glaucoma", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "16765687_2_Ent6", "text": "angle - closure glaucoma", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16765687_2_Ent2", "text": "methylprednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16765687_2_Ent4", "text": "methylprednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16765687_2_Ent0", "text": "methylprednisolone and mannitol", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16765687_2_Ent3", "text": "mannitol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16765687_2_Ent5", "text": "mannitol", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16767537_1", "wnd_id": "16767537_1_1", "text": "Spontaneous splenic infarction associated with sumatriptan use .", "tokens": ["Spontaneous", "splenic", "infarction", "associated", "with", "sumatriptan", "use", "."], "event_mentions": [{"id": "16767537_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16767537_1_Ent0", "role": "Effect", "text": "Spontaneous splenic infarction", "start": 0, "end": 3}, {"entity_id": "16767537_1_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 5, "end": 6}, {"entity_id": "16767537_1_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16767537_1_Ent0", "text": "Spontaneous splenic infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16767537_1_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16767537_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16816519_4", "wnd_id": "16816519_4_1", "text": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII .", "tokens": ["She", "received", "chemotherapy", "according", "to", "the", "previously", "described", "modified", "St.", "Jude", "total", "therapy", "studies", "XIII", "."], "event_mentions": [{"id": "16816519_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 1, "end": 2}, "arguments": [{"entity_id": "16816519_4_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "16816519_4_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "16816519_4_Ent2", "role": "Treatment", "text": "chemotherapy", "start": 2, "end": 3}, {"entity_id": "16816519_4_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "16816519_4_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16816519_4_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16816519_4_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16816519_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "16816519_7", "wnd_id": "16816519_7_1", "text": "She received 3.8 mg cumulative dose of vincristin before development of ptosis .", "tokens": ["She", "received", "3.8", "mg", "cumulative", "dose", "of", "vincristin", "before", "development", "of", "ptosis", "."], "event_mentions": [{"id": "16816519_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "16816519_7_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "16816519_7_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "16816519_7_Ent4", "role": "Treatment_Dosage", "text": "3.8 mg", "start": 2, "end": 4}, {"entity_id": "16816519_7_Ent3", "role": "Treatment", "text": "3.8 mg cumulative dose of vincristin", "start": 2, "end": 8}, {"entity_id": "16816519_7_Ent5", "role": "Treatment_Drug", "text": "vincristin", "start": 7, "end": 8}, {"entity_id": "16816519_7_Ent2", "role": "Effect", "text": "ptosis", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16816519_7_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16816519_7_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16816519_7_Ent4", "text": "3.8 mg", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16816519_7_Ent3", "text": "3.8 mg cumulative dose of vincristin", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "16816519_7_Ent5", "text": "vincristin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16816519_7_Ent2", "text": "ptosis", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16816519_9", "wnd_id": "16816519_9_1", "text": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks .", "tokens": ["The", "bilateral", "ptosis", "markedly", "improved", "after", "7", "days", "of", "pyridoxine", "and", "pyridostigmine", "treatment", "and", "completely", "resolved", "after", "two", "weeks", "."], "event_mentions": [{"id": "16816519_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 4, "end": 5}, "arguments": [{"entity_id": "16816519_9_Ent1", "role": "Treatment_Time_elapsed", "text": "7 days", "start": 6, "end": 8}, {"entity_id": "16816519_9_Ent2", "role": "Treatment_Drug", "text": "pyridoxine", "start": 9, "end": 10}, {"entity_id": "16816519_9_Ent4", "role": "Combination_Drug", "text": "pyridoxine", "start": 9, "end": 10}, {"entity_id": "16816519_9_Ent0", "role": "Treatment", "text": "pyridoxine and pyridostigmine treatment", "start": 9, "end": 13}, {"entity_id": "16816519_9_Ent3", "role": "Treatment_Drug", "text": "pyridostigmine", "start": 11, "end": 12}, {"entity_id": "16816519_9_Ent5", "role": "Combination_Drug", "text": "pyridostigmine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16816519_9_Ent1", "text": "7 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16816519_9_Ent2", "text": "pyridoxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16816519_9_Ent4", "text": "pyridoxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16816519_9_Ent0", "text": "pyridoxine and pyridostigmine treatment", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16816519_9_Ent3", "text": "pyridostigmine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16816519_9_Ent5", "text": "pyridostigmine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16843118_2", "wnd_id": "16843118_2_1", "text": "Morphine , an opium alkaloid , frequently causes side effects such as hyperhidrosis and facial flushing , but serious cutaneous adverse drug reactions are seldom observed .", "tokens": ["Morphine", ",", "an", "opium", "alkaloid", ",", "frequently", "causes", "side", "effects", "such", "as", "hyperhidrosis", "and", "facial", "flushing", ",", "but", "serious", "cutaneous", "adverse", "drug", "reactions", "are", "seldom", "observed", "."], "event_mentions": [{"id": "16843118_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 7, "end": 8}, "arguments": [{"entity_id": "16843118_2_Ent2", "role": "Treatment", "text": "Morphine", "start": 0, "end": 1}, {"entity_id": "16843118_2_Ent3", "role": "Treatment_Drug", "text": "Morphine", "start": 0, "end": 1}, {"entity_id": "16843118_2_Ent0", "role": "Effect", "text": "hyperhidrosis", "start": 12, "end": 13}, {"entity_id": "16843118_2_Ent1", "role": "Effect", "text": "facial flushing", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "16843118_2_Ent2", "text": "Morphine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16843118_2_Ent3", "text": "Morphine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16843118_2_Ent0", "text": "hyperhidrosis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16843118_2_Ent1", "text": "facial flushing", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "16882112_4", "wnd_id": "16882112_4_1", "text": "We report a case of the serotonin syndrome during treatment with lithium and venlafaxine , an antidepressant with a dual selective re - uptake inhibition mechanism , and review the literature for similar cases .", "tokens": ["We", "report", "a", "case", "of", "the", "serotonin", "syndrome", "during", "treatment", "with", "lithium", "and", "venlafaxine", ",", "an", "antidepressant", "with", "a", "dual", "selective", "re", "-", "uptake", "inhibition", "mechanism", ",", "and", "review", "the", "literature", "for", "similar", "cases", "."], "event_mentions": [{"id": "16882112_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "16882112_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "16882112_4_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "16882112_4_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "16882112_4_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "16882112_4_Ent2", "role": "Treatment", "text": "lithium and venlafaxine", "start": 11, "end": 14}, {"entity_id": "16882112_4_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 13, "end": 14}, {"entity_id": "16882112_4_Ent6", "role": "Combination_Drug", "text": "venlafaxine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16882112_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16882112_4_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16882112_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16882112_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16882112_4_Ent2", "text": "lithium and venlafaxine", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16882112_4_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16882112_4_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1688693_3", "wnd_id": "1688693_3_1", "text": "She manifested all the clinical symptoms and signs of caffeine toxicity .", "tokens": ["She", "manifested", "all", "the", "clinical", "symptoms", "and", "signs", "of", "caffeine", "toxicity", "."], "event_mentions": [{"id": "1688693_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 1, "end": 2}, "arguments": [{"entity_id": "1688693_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "1688693_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "1688693_3_Ent2", "role": "Effect", "text": "all the clinical symptoms and signs of caffeine toxicity .", "start": 2, "end": 12}, {"entity_id": "1688693_3_Ent3", "role": "Treatment", "text": "caffeine", "start": 9, "end": 10}, {"entity_id": "1688693_3_Ent4", "role": "Treatment_Drug", "text": "caffeine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "1688693_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1688693_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1688693_3_Ent2", "text": "all the clinical symptoms and signs of caffeine toxicity .", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "1688693_3_Ent3", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1688693_3_Ent4", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16901609_1", "wnd_id": "16901609_1_1", "text": "Anaphylaxis to intrathecal diamorphine .", "tokens": ["Anaphylaxis", "to", "intrathecal", "diamorphine", "."], "event_mentions": [{"id": "16901609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16901609_1_Ent0", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "16901609_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "16901609_1_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 2, "end": 4}, {"entity_id": "16901609_1_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16901609_1_Ent0", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16901609_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16901609_1_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16901609_1_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16923659_6", "wnd_id": "16923659_6_1", "text": "METHOD : Case analysis of a poly - drug overdose ( venlafaxine , topiramate , divalproex sodium , risperidone , and carbamazepine ) presenting with mixed SS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings .", "tokens": ["METHOD", ":", "Case", "analysis", "of", "a", "poly", "-", "drug", "overdose", "(", "venlafaxine", ",", "topiramate", ",", "divalproex", "sodium", ",", "risperidone", ",", "and", "carbamazepine", ")", "presenting", "with", "mixed", "SS", "/", "NMS", "features", "and", "whose", "clinical", "management", "suggests", "a", "practical", "algorithm", "for", "treatment", "of", "undifferentiated", "SS", "/", "NMS", "in", "critical", "care", "settings", "."], "event_mentions": [{"id": "16923659_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 23, "end": 24}, "arguments": [{"entity_id": "16923659_6_Ent1", "role": "Treatment", "text": "a poly - drug overdose ( venlafaxine , topiramate , divalproex sodium , risperidone , and carbamazepine )", "start": 5, "end": 23}, {"entity_id": "16923659_6_Ent7", "role": "Treatment_Dosage", "text": "overdose", "start": 9, "end": 10}, {"entity_id": "16923659_6_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 11, "end": 12}, {"entity_id": "16923659_6_Ent3", "role": "Treatment_Drug", "text": "topiramate", "start": 13, "end": 14}, {"entity_id": "16923659_6_Ent4", "role": "Treatment_Drug", "text": "divalproex sodium", "start": 15, "end": 17}, {"entity_id": "16923659_6_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 18, "end": 19}, {"entity_id": "16923659_6_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 21, "end": 22}, {"entity_id": "16923659_6_Ent0", "role": "Effect", "text": "mixed SS / NMS features", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "16923659_6_Ent1", "text": "a poly - drug overdose ( venlafaxine , topiramate , divalproex sodium , risperidone , and carbamazepine )", "entity_type": "Entity", "start": 5, "end": 23}, {"id": "16923659_6_Ent7", "text": "overdose", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16923659_6_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16923659_6_Ent3", "text": "topiramate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16923659_6_Ent4", "text": "divalproex sodium", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16923659_6_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16923659_6_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16923659_6_Ent0", "text": "mixed SS / NMS features", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "16935446_1", "wnd_id": "16935446_1_1", "text": "Fever and maculopapular rashes appeared at 10 days after phenytoin initiation , and then the drug was discontinued .", "tokens": ["Fever", "and", "maculopapular", "rashes", "appeared", "at", "10", "days", "after", "phenytoin", "initiation", ",", "and", "then", "the", "drug", "was", "discontinued", "."], "event_mentions": [{"id": "16935446_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 4, "end": 5}, "arguments": [{"entity_id": "16935446_1_Ent0", "role": "Effect", "text": "Fever and maculopapular rashes", "start": 0, "end": 4}, {"entity_id": "16935446_1_Ent2", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 6, "end": 8}, {"entity_id": "16935446_1_Ent1", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "16935446_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16935446_1_Ent0", "text": "Fever and maculopapular rashes", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16935446_1_Ent2", "text": "10 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16935446_1_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16935446_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16939867_2", "wnd_id": "16939867_2_1", "text": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine - induced drug reaction .", "tokens": ["This", "case", "study", "is", "the", "second", "report", "of", "localized", "purpura", "after", "prolonged", "lamotrigine", "treatment", "suggesting", "this", "may", "be", "an", "atypical", "lamotrigine", "-", "induced", "drug", "reaction", "."], "event_mentions": [{"id": "16939867_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 22, "end": 23}, "arguments": [{"entity_id": "16939867_2_Ent0", "role": "Effect", "text": "localized purpura", "start": 8, "end": 10}, {"entity_id": "16939867_2_Ent4", "role": "Treatment_Duration", "text": "prolonged", "start": 11, "end": 12}, {"entity_id": "16939867_2_Ent2", "role": "Treatment", "text": "lamotrigine", "start": 20, "end": 21}, {"entity_id": "16939867_2_Ent3", "role": "Treatment_Drug", "text": "lamotrigine", "start": 20, "end": 21}, {"entity_id": "16939867_2_Ent1", "role": "Effect", "text": "drug reaction", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "16939867_2_Ent0", "text": "localized purpura", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16939867_2_Ent4", "text": "prolonged", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16939867_2_Ent2", "text": "lamotrigine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16939867_2_Ent3", "text": "lamotrigine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16939867_2_Ent1", "text": "drug reaction", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "1694575_1", "wnd_id": "1694575_1_1", "text": "Reversible corneal keratinization following trabeculectomy and treatment with 5 - fluorouracil .", "tokens": ["Reversible", "corneal", "keratinization", "following", "trabeculectomy", "and", "treatment", "with", "5", "-", "fluorouracil", "."], "event_mentions": [{"id": "1694575_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "1694575_1_Ent0", "role": "Effect", "text": "Reversible corneal keratinization", "start": 0, "end": 3}, {"entity_id": "1694575_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 8, "end": 11}, {"entity_id": "1694575_1_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil .", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "1694575_1_Ent0", "text": "Reversible corneal keratinization", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1694575_1_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "1694575_1_Ent2", "text": "5 - fluorouracil .", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "16948177_1", "wnd_id": "16948177_1_1", "text": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non - Hodgkin 's lymphoma .", "tokens": ["Bronchiolitis", "obliterans", "with", "organizing", "pneumonia", "after", "rituximab", "therapy", "for", "non", "-", "Hodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "16948177_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "16948177_1_Ent0", "role": "Effect", "text": "Bronchiolitis obliterans with organizing pneumonia", "start": 0, "end": 5}, {"entity_id": "16948177_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 6, "end": 7}, {"entity_id": "16948177_1_Ent1", "role": "Treatment", "text": "rituximab therapy", "start": 6, "end": 8}, {"entity_id": "16948177_1_Ent3", "role": "Treatment_Disorder", "text": "non - Hodgkin 's lymphoma", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "16948177_1_Ent0", "text": "Bronchiolitis obliterans with organizing pneumonia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16948177_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16948177_1_Ent1", "text": "rituximab therapy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16948177_1_Ent3", "text": "non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "16948177_3", "wnd_id": "16948177_3_1", "text": "This is the first reported case of BOOP associated with single - agent rituximab , and along with two other patients we describe , as well as two prior reports of BOOP in NHL patients receiving rituximab - based combinations , strengthens the possibility of a causal relationship .", "tokens": ["This", "is", "the", "first", "reported", "case", "of", "BOOP", "associated", "with", "single", "-", "agent", "rituximab", ",", "and", "along", "with", "two", "other", "patients", "we", "describe", ",", "as", "well", "as", "two", "prior", "reports", "of", "BOOP", "in", "NHL", "patients", "receiving", "rituximab", "-", "based", "combinations", ",", "strengthens", "the", "possibility", "of", "a", "causal", "relationship", "."], "event_mentions": [{"id": "16948177_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "16948177_3_Ent0", "role": "Effect", "text": "BOOP", "start": 7, "end": 8}, {"entity_id": "16948177_3_Ent1", "role": "Treatment", "text": "single - agent rituximab", "start": 10, "end": 14}, {"entity_id": "16948177_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16948177_3_Ent0", "text": "BOOP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16948177_3_Ent1", "text": "single - agent rituximab", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16948177_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16968538_8", "wnd_id": "16968538_8_1", "text": "CONCLUSION : The hemolytic - uremic syndrome may be a rare complication of oxaliplatin - based chemotherapy .", "tokens": ["CONCLUSION", ":", "The", "hemolytic", "-", "uremic", "syndrome", "may", "be", "a", "rare", "complication", "of", "oxaliplatin", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "16968538_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "16968538_8_Ent0", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 3, "end": 7}, {"entity_id": "16968538_8_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 13, "end": 14}, {"entity_id": "16968538_8_Ent1", "role": "Treatment", "text": "oxaliplatin - based chemotherapy", "start": 13, "end": 17}, {"entity_id": "16968538_8_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16968538_8_Ent0", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16968538_8_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16968538_8_Ent1", "text": "oxaliplatin - based chemotherapy", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16968538_8_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16978752_1", "wnd_id": "16978752_1_1", "text": "First , a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine ( Zyprexa ) reported in a total of 24 publications .", "tokens": ["First", ",", "a", "review", "of", "the", "literature", "produced", "41", "anecdotic", "cases", "of", "neutropenia", "or", "agranulocytosis", "during", "treatment", "with", "olanzapine", "(", "Zyprexa", ")", "reported", "in", "a", "total", "of", "24", "publications", "."], "event_mentions": [{"id": "16978752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "16978752_1_Ent1", "role": "Subject_Population", "text": "41", "start": 8, "end": 9}, {"entity_id": "16978752_1_Ent0", "role": "Subject", "text": "41 anecdotic cases", "start": 8, "end": 11}, {"entity_id": "16978752_1_Ent2", "role": "Effect", "text": "neutropenia or agranulocytosis", "start": 12, "end": 15}, {"entity_id": "16978752_1_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 18, "end": 19}, {"entity_id": "16978752_1_Ent3", "role": "Treatment", "text": "olanzapine ( Zyprexa )", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "16978752_1_Ent1", "text": "41", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16978752_1_Ent0", "text": "41 anecdotic cases", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "16978752_1_Ent2", "text": "neutropenia or agranulocytosis", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16978752_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16978752_1_Ent3", "text": "olanzapine ( Zyprexa )", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "16978752_3", "wnd_id": "16978752_3_1", "text": "Second , we report a case of neutropenia , which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide .", "tokens": ["Second", ",", "we", "report", "a", "case", "of", "neutropenia", ",", "which", "proved", "to", "be", "fatal", "in", "a", "schizophrenia", "patient", "receiving", "olanzapine", "and", "thiazide", "."], "event_mentions": [{"id": "16978752_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "16978752_3_Ent1", "role": "Effect", "text": "neutropenia", "start": 7, "end": 8}, {"entity_id": "16978752_3_Ent0", "role": "Subject", "text": "a schizophrenia patient", "start": 15, "end": 18}, {"entity_id": "16978752_3_Ent3", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "16978752_3_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent6", "role": "Combination_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent2", "role": "Treatment", "text": "olanzapine and thiazide", "start": 19, "end": 22}, {"entity_id": "16978752_3_Ent5", "role": "Treatment_Drug", "text": "thiazide", "start": 21, "end": 22}, {"entity_id": "16978752_3_Ent7", "role": "Combination_Drug", "text": "thiazide", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16978752_3_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16978752_3_Ent0", "text": "a schizophrenia patient", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16978752_3_Ent3", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16978752_3_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent6", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent2", "text": "olanzapine and thiazide", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16978752_3_Ent5", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16978752_3_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16997047_3", "wnd_id": "16997047_3_1", "text": "Recurrent hyponatremia associated with citalopram and mirtazapine .", "tokens": ["Recurrent", "hyponatremia", "associated", "with", "citalopram", "and", "mirtazapine", "."], "event_mentions": [{"id": "16997047_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16997047_3_Ent0", "role": "Effect", "text": "Recurrent hyponatremia", "start": 0, "end": 2}, {"entity_id": "16997047_3_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "16997047_3_Ent1", "role": "Treatment", "text": "citalopram and mirtazapine", "start": 4, "end": 7}, {"entity_id": "16997047_3_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "16997047_3_Ent0", "text": "Recurrent hyponatremia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16997047_3_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16997047_3_Ent1", "text": "citalopram and mirtazapine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16997047_3_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17060191_2", "wnd_id": "17060191_2_1", "text": "Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects , including premature closure of the ductus arteriosus .", "tokens": ["Exposure", "of", "the", "fetus", "to", "indomethacin", "by", "administration", "of", "the", "drug", "to", "the", "mother", "may", "cause", "many", "side", "effects", ",", "including", "premature", "closure", "of", "the", "ductus", "arteriosus", "."], "event_mentions": [{"id": "17060191_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 17, "end": 19}, "arguments": [{"entity_id": "17060191_2_Ent0", "role": "Subject", "text": "fetus", "start": 3, "end": 4}, {"entity_id": "17060191_2_Ent1", "role": "Subject_Age", "text": "fetus", "start": 3, "end": 4}, {"entity_id": "17060191_2_Ent3", "role": "Treatment", "text": "indomethacin", "start": 5, "end": 6}, {"entity_id": "17060191_2_Ent4", "role": "Treatment_Drug", "text": "indomethacin", "start": 5, "end": 6}, {"entity_id": "17060191_2_Ent2", "role": "Effect", "text": "premature closure of the ductus arteriosus", "start": 21, "end": 27}]}], "entity_mentions": [{"id": "17060191_2_Ent0", "text": "fetus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17060191_2_Ent1", "text": "fetus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17060191_2_Ent3", "text": "indomethacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17060191_2_Ent4", "text": "indomethacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17060191_2_Ent2", "text": "premature closure of the ductus arteriosus", "entity_type": "Entity", "start": 21, "end": 27}], "lang": "en"}
{"doc_id": "17060191_3", "wnd_id": "17060191_3_1", "text": "Hypoxia is a predisposing factor for premature ductal closure and often occurs after maternal indomethacin therapy .", "tokens": ["Hypoxia", "is", "a", "predisposing", "factor", "for", "premature", "ductal", "closure", "and", "often", "occurs", "after", "maternal", "indomethacin", "therapy", "."], "event_mentions": [{"id": "17060191_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "17060191_3_Ent0", "role": "Effect", "text": "premature ductal closure", "start": 6, "end": 9}, {"entity_id": "17060191_3_Ent3", "role": "Treatment_Route", "text": "maternal", "start": 13, "end": 14}, {"entity_id": "17060191_3_Ent1", "role": "Treatment", "text": "maternal indomethacin therapy", "start": 13, "end": 16}, {"entity_id": "17060191_3_Ent2", "role": "Treatment_Drug", "text": "indomethacin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "17060191_3_Ent0", "text": "premature ductal closure", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17060191_3_Ent3", "text": "maternal", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17060191_3_Ent1", "text": "maternal indomethacin therapy", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17060191_3_Ent2", "text": "indomethacin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "17083890_1", "wnd_id": "17083890_1_1", "text": "Distinct patterns of chromonychia , Beau 's lines , and melanoderma seen with vincristine , adriamycin , dexamethasone therapy for multiple myeloma .", "tokens": ["Distinct", "patterns", "of", "chromonychia", ",", "Beau", "'s", "lines", ",", "and", "melanoderma", "seen", "with", "vincristine", ",", "adriamycin", ",", "dexamethasone", "therapy", "for", "multiple", "myeloma", "."], "event_mentions": [{"id": "17083890_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 11, "end": 12}, "arguments": [{"entity_id": "17083890_1_Ent0", "role": "Effect", "text": "Distinct patterns of chromonychia , Beau 's lines , and melanoderma", "start": 0, "end": 11}, {"entity_id": "17083890_1_Ent2", "role": "Treatment_Drug", "text": "vincristine", "start": 13, "end": 14}, {"entity_id": "17083890_1_Ent1", "role": "Treatment", "text": "vincristine , adriamycin , dexamethasone", "start": 13, "end": 18}, {"entity_id": "17083890_1_Ent3", "role": "Treatment_Drug", "text": "adriamycin", "start": 15, "end": 16}, {"entity_id": "17083890_1_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 17, "end": 18}, {"entity_id": "17083890_1_Ent5", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "17083890_1_Ent0", "text": "Distinct patterns of chromonychia , Beau 's lines , and melanoderma", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "17083890_1_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17083890_1_Ent1", "text": "vincristine , adriamycin , dexamethasone", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "17083890_1_Ent3", "text": "adriamycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17083890_1_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_1_Ent5", "text": "multiple myeloma", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "17083890_2", "wnd_id": "17083890_2_1", "text": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes .", "tokens": ["Nail", "and", "skin", "alterations", "associated", "with", "the", "use", "of", "chemotherapy", "have", "been", "described", "in", "the", "last", "decade", "involving", "various", "combinations", "of", "two", "different", "types", "of", "nail", "changes", "."], "event_mentions": [{"id": "17083890_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "17083890_2_Ent0", "role": "Effect", "text": "Nail and skin alterations", "start": 0, "end": 4}, {"entity_id": "17083890_2_Ent1", "role": "Treatment", "text": "chemotherapy", "start": 9, "end": 10}, {"entity_id": "17083890_2_Ent2", "role": "Treatment_Route", "text": "chemotherapy", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17083890_2_Ent0", "text": "Nail and skin alterations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17083890_2_Ent1", "text": "chemotherapy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17083890_2_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17090724_2", "wnd_id": "17090724_2_1", "text": "OBJECTIVE : To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "clinical", "course", "of", "a", "woman", "with", "cryptococcal", "meningitis", "and", "no", "previous", "cardiac", "disease", "who", "developed", "a", "fatal", "cardiac", "arrhythmia", "after", "an", "acute", "overdose", "of", "amphotericin", "B", "and", "to", "review", "its", "toxicity", "."], "event_mentions": [{"id": "17090724_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "17090724_2_Ent0", "role": "Subject", "text": "a woman with cryptococcal meningitis and no previous cardiac disease", "start": 8, "end": 18}, {"entity_id": "17090724_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "17090724_2_Ent4", "role": "Treatment_Disorder", "text": "cryptococcal meningitis", "start": 11, "end": 13}, {"entity_id": "17090724_2_Ent2", "role": "Effect", "text": "a fatal cardiac arrhythmia", "start": 20, "end": 24}, {"entity_id": "17090724_2_Ent3", "role": "Treatment", "text": "an acute overdose of amphotericin B", "start": 25, "end": 31}, {"entity_id": "17090724_2_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 27, "end": 28}, {"entity_id": "17090724_2_Ent5", "role": "Treatment_Drug", "text": "amphotericin B", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "17090724_2_Ent0", "text": "a woman with cryptococcal meningitis and no previous cardiac disease", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "17090724_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17090724_2_Ent4", "text": "cryptococcal meningitis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17090724_2_Ent2", "text": "a fatal cardiac arrhythmia", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "17090724_2_Ent3", "text": "an acute overdose of amphotericin B", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "17090724_2_Ent6", "text": "overdose", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17090724_2_Ent5", "text": "amphotericin B", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "17122225_4", "wnd_id": "17122225_4_1", "text": "We report two cases of severe serotonin syndrome induced by the administration of cyclobenzaprine in postoperative patients already receiving another proserotoninergic drug ( phenelzine in one case and duloxetine in the other ) .", "tokens": ["We", "report", "two", "cases", "of", "severe", "serotonin", "syndrome", "induced", "by", "the", "administration", "of", "cyclobenzaprine", "in", "postoperative", "patients", "already", "receiving", "another", "proserotoninergic", "drug", "(", "phenelzine", "in", "one", "case", "and", "duloxetine", "in", "the", "other", ")", "."], "event_mentions": [{"id": "17122225_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17122225_4_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "17122225_4_Ent3", "role": "Treatment", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent6", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent1", "role": "Subject_Disorder", "text": "postoperative", "start": 15, "end": 16}, {"entity_id": "17122225_4_Ent0", "role": "Subject", "text": "postoperative patients", "start": 15, "end": 17}, {"entity_id": "17122225_4_Ent4", "role": "Treatment", "text": "duloxetine", "start": 28, "end": 29}, {"entity_id": "17122225_4_Ent5", "role": "Treatment_Drug", "text": "duloxetine", "start": 28, "end": 29}, {"entity_id": "17122225_4_Ent7", "role": "Combination_Drug", "text": "duloxetine", "start": 28, "end": 29}]}, {"id": "17122225_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17122225_4_Ent10", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "17122225_4_Ent11", "role": "Treatment", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent13", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent15", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent9", "role": "Subject_Disorder", "text": "postoperative", "start": 15, "end": 16}, {"entity_id": "17122225_4_Ent8", "role": "Subject", "text": "postoperative patients", "start": 15, "end": 17}, {"entity_id": "17122225_4_Ent12", "role": "Treatment", "text": "phenelzine", "start": 23, "end": 24}, {"entity_id": "17122225_4_Ent14", "role": "Treatment_Drug", "text": "phenelzine", "start": 23, "end": 24}, {"entity_id": "17122225_4_Ent16", "role": "Combination_Drug", "text": "phenelzine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17122225_4_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17122225_4_Ent10", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17122225_4_Ent3", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent6", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent11", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent13", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent15", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent1", "text": "postoperative", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_4_Ent9", "text": "postoperative", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_4_Ent0", "text": "postoperative patients", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17122225_4_Ent8", "text": "postoperative patients", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17122225_4_Ent12", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent14", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent16", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent4", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17122225_4_Ent5", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17122225_4_Ent7", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17157086_1", "wnd_id": "17157086_1_1", "text": "Fatal liver failure following food supplements during chronic treatment with montelukast .", "tokens": ["Fatal", "liver", "failure", "following", "food", "supplements", "during", "chronic", "treatment", "with", "montelukast", "."], "event_mentions": [{"id": "17157086_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "17157086_1_Ent0", "role": "Effect", "text": "Fatal liver failure", "start": 0, "end": 3}, {"entity_id": "17157086_1_Ent2", "role": "Treatment_Drug", "text": "food supplements", "start": 4, "end": 6}, {"entity_id": "17157086_1_Ent4", "role": "Combination_Drug", "text": "food supplements", "start": 4, "end": 6}, {"entity_id": "17157086_1_Ent1", "role": "Treatment", "text": "food supplements during chronic treatment with montelukast", "start": 4, "end": 11}, {"entity_id": "17157086_1_Ent3", "role": "Treatment_Drug", "text": "montelukast", "start": 10, "end": 11}, {"entity_id": "17157086_1_Ent5", "role": "Combination_Drug", "text": "montelukast", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17157086_1_Ent0", "text": "Fatal liver failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17157086_1_Ent2", "text": "food supplements", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17157086_1_Ent4", "text": "food supplements", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17157086_1_Ent1", "text": "food supplements during chronic treatment with montelukast", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17157086_1_Ent3", "text": "montelukast", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17157086_1_Ent5", "text": "montelukast", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17163271_1", "wnd_id": "17163271_1_1", "text": "Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin .", "tokens": ["Cholelithiasis", "and", "thrombosis", "of", "the", "central", "retinal", "vein", "in", "a", "renal", "transplant", "recipient", "treated", "with", "cyclosporin", "."], "event_mentions": [{"id": "17163271_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "17163271_1_Ent2", "role": "Effect", "text": "Cholelithiasis and thrombosis of the central retinal vein", "start": 0, "end": 8}, {"entity_id": "17163271_1_Ent0", "role": "Subject", "text": "a renal transplant recipient", "start": 9, "end": 13}, {"entity_id": "17163271_1_Ent1", "role": "Subject_Disorder", "text": "renal transplant", "start": 10, "end": 12}, {"entity_id": "17163271_1_Ent3", "role": "Treatment", "text": "cyclosporin", "start": 15, "end": 16}, {"entity_id": "17163271_1_Ent4", "role": "Treatment_Drug", "text": "cyclosporin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17163271_1_Ent2", "text": "Cholelithiasis and thrombosis of the central retinal vein", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17163271_1_Ent0", "text": "a renal transplant recipient", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "17163271_1_Ent1", "text": "renal transplant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17163271_1_Ent3", "text": "cyclosporin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17163271_1_Ent4", "text": "cyclosporin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "17189581_2", "wnd_id": "17189581_2_1", "text": "A case of serotonin syndrome that developed during concurrent linezolid and fluoxetine is presented .", "tokens": ["A", "case", "of", "serotonin", "syndrome", "that", "developed", "during", "concurrent", "linezolid", "and", "fluoxetine", "is", "presented", "."], "event_mentions": [{"id": "17189581_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "17189581_2_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 3, "end": 5}, {"entity_id": "17189581_2_Ent1", "role": "Treatment", "text": "concurrent linezolid and fluoxetine", "start": 8, "end": 12}, {"entity_id": "17189581_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 9, "end": 10}, {"entity_id": "17189581_2_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 9, "end": 10}, {"entity_id": "17189581_2_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 11, "end": 12}, {"entity_id": "17189581_2_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "17189581_2_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17189581_2_Ent1", "text": "concurrent linezolid and fluoxetine", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17189581_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17189581_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17189581_2_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17189581_2_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "17189581_3", "wnd_id": "17189581_3_1", "text": "A 23 - year - old white male patient was originally admitted to receive intravenous chemotherapy for acute myelogenous leukemia .", "tokens": ["A", "23", "-", "year", "-", "old", "white", "male", "patient", "was", "originally", "admitted", "to", "receive", "intravenous", "chemotherapy", "for", "acute", "myelogenous", "leukemia", "."], "event_mentions": [{"id": "17189581_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 13, "end": 14}, "arguments": [{"entity_id": "17189581_3_Ent0", "role": "Subject", "text": "A 23 - year - old white male patient", "start": 0, "end": 9}, {"entity_id": "17189581_3_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 1, "end": 6}, {"entity_id": "17189581_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "17189581_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "17189581_3_Ent7", "role": "Treatment_Route", "text": "intravenous", "start": 14, "end": 15}, {"entity_id": "17189581_3_Ent4", "role": "Treatment", "text": "intravenous chemotherapy", "start": 14, "end": 16}, {"entity_id": "17189581_3_Ent5", "role": "Treatment_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "17189581_3_Ent6", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "17189581_3_Ent0", "text": "A 23 - year - old white male patient", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "17189581_3_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17189581_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17189581_3_Ent3", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17189581_3_Ent7", "text": "intravenous", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17189581_3_Ent4", "text": "intravenous chemotherapy", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17189581_3_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17189581_3_Ent6", "text": "acute myelogenous leukemia", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "17195428_2", "wnd_id": "17195428_2_1", "text": "A case of oculogyric crisis induced by metoclopramide is described in this paper .", "tokens": ["A", "case", "of", "oculogyric", "crisis", "induced", "by", "metoclopramide", "is", "described", "in", "this", "paper", "."], "event_mentions": [{"id": "17195428_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17195428_2_Ent0", "role": "Effect", "text": "oculogyric crisis", "start": 3, "end": 5}, {"entity_id": "17195428_2_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 7, "end": 8}, {"entity_id": "17195428_2_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "17195428_2_Ent0", "text": "oculogyric crisis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17195428_2_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17195428_2_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "17228132_3", "wnd_id": "17228132_3_1", "text": "Hepatotoxicity seen with erlotinib , a small molecule tyrosine kinase inhibitor to EGFR , is usually transient with mild elevation of transaminases .", "tokens": ["Hepatotoxicity", "seen", "with", "erlotinib", ",", "a", "small", "molecule", "tyrosine", "kinase", "inhibitor", "to", "EGFR", ",", "is", "usually", "transient", "with", "mild", "elevation", "of", "transaminases", "."], "event_mentions": [{"id": "17228132_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 1, "end": 2}, "arguments": [{"entity_id": "17228132_3_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17228132_3_Ent2", "role": "Treatment", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_3_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_3_Ent1", "role": "Effect", "text": "transient with mild elevation of transaminases", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "17228132_3_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17228132_3_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_3_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_3_Ent1", "text": "transient with mild elevation of transaminases", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "17266059_2", "wnd_id": "17266059_2_1", "text": "Thrombotic thrombocytopenic purpura induced by trimethoprim - sulfamethoxazole in a Jehovah 's Witness .", "tokens": ["Thrombotic", "thrombocytopenic", "purpura", "induced", "by", "trimethoprim", "-", "sulfamethoxazole", "in", "a", "Jehovah", "'s", "Witness", "."], "event_mentions": [{"id": "17266059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17266059_2_Ent1", "role": "Effect", "text": "Thrombotic thrombocytopenic purpura", "start": 0, "end": 3}, {"entity_id": "17266059_2_Ent2", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 5, "end": 8}, {"entity_id": "17266059_2_Ent3", "role": "Treatment_Drug", "text": "trimethoprim - sulfamethoxazole", "start": 5, "end": 8}, {"entity_id": "17266059_2_Ent0", "role": "Subject", "text": "a Jehovah 's Witness", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "17266059_2_Ent1", "text": "Thrombotic thrombocytopenic purpura", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17266059_2_Ent2", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17266059_2_Ent3", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17266059_2_Ent0", "text": "a Jehovah 's Witness", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "17275666_1", "wnd_id": "17275666_1_1", "text": "Juvenile absence epilepsy exacerbated by valproic acid .", "tokens": ["Juvenile", "absence", "epilepsy", "exacerbated", "by", "valproic", "acid", "."], "event_mentions": [{"id": "17275666_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17275666_1_Ent1", "role": "Subject_Age", "text": "Juvenile", "start": 0, "end": 1}, {"entity_id": "17275666_1_Ent0", "role": "Subject", "text": "Juvenile absence epilepsy", "start": 0, "end": 3}, {"entity_id": "17275666_1_Ent2", "role": "Effect", "text": "Juvenile absence epilepsy exacerbated", "start": 0, "end": 4}, {"entity_id": "17275666_1_Ent5", "role": "Treatment_Disorder", "text": "absence epilepsy", "start": 1, "end": 3}, {"entity_id": "17275666_1_Ent3", "role": "Treatment", "text": "valproic acid", "start": 5, "end": 7}, {"entity_id": "17275666_1_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17275666_1_Ent1", "text": "Juvenile", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17275666_1_Ent0", "text": "Juvenile absence epilepsy", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17275666_1_Ent2", "text": "Juvenile absence epilepsy exacerbated", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17275666_1_Ent5", "text": "absence epilepsy", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17275666_1_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17275666_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17285101_3", "wnd_id": "17285101_3_1", "text": "This is the first report of pulmonary hypertension in an adult patient during lithium therapy .", "tokens": ["This", "is", "the", "first", "report", "of", "pulmonary", "hypertension", "in", "an", "adult", "patient", "during", "lithium", "therapy", "."], "event_mentions": [{"id": "17285101_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "17285101_3_Ent2", "role": "Effect", "text": "pulmonary hypertension", "start": 6, "end": 8}, {"entity_id": "17285101_3_Ent0", "role": "Subject", "text": "an adult patient", "start": 9, "end": 12}, {"entity_id": "17285101_3_Ent1", "role": "Subject_Age", "text": "adult", "start": 10, "end": 11}, {"entity_id": "17285101_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "17285101_3_Ent3", "role": "Treatment", "text": "lithium therapy .", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "17285101_3_Ent2", "text": "pulmonary hypertension", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17285101_3_Ent0", "text": "an adult patient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "17285101_3_Ent1", "text": "adult", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17285101_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17285101_3_Ent3", "text": "lithium therapy .", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "17329303_6", "wnd_id": "17329303_6_1", "text": "The second patient was a girl of 6 , already on risperidone for ADHD and borderline intellectual functioning when referred .", "tokens": ["The", "second", "patient", "was", "a", "girl", "of", "6", ",", "already", "on", "risperidone", "for", "ADHD", "and", "borderline", "intellectual", "functioning", "when", "referred", "."], "event_mentions": [{"id": "17329303_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "on", "start": 10, "end": 11}, "arguments": [{"entity_id": "17329303_6_Ent0", "role": "Subject", "text": "a girl of 6", "start": 4, "end": 8}, {"entity_id": "17329303_6_Ent1", "role": "Subject_Gender", "text": "girl", "start": 5, "end": 6}, {"entity_id": "17329303_6_Ent2", "role": "Subject_Age", "text": "6", "start": 7, "end": 8}, {"entity_id": "17329303_6_Ent3", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent5", "role": "Treatment_Disorder", "text": "ADHD", "start": 13, "end": 14}, {"entity_id": "17329303_6_Ent6", "role": "Treatment_Disorder", "text": "borderline intellectual functioning", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "17329303_6_Ent0", "text": "a girl of 6", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17329303_6_Ent1", "text": "girl", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17329303_6_Ent2", "text": "6", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17329303_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent5", "text": "ADHD", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17329303_6_Ent6", "text": "borderline intellectual functioning", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "17331261_3", "wnd_id": "17331261_3_1", "text": "Inhaled tobramycin solution - associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis : a case report .", "tokens": ["Inhaled", "tobramycin", "solution", "-", "associated", "recurrent", "eosinophilia", "and", "severe", "persistent", "bronchospasm", "in", "a", "patient", "with", "cystic", "fibrosis", ":", "a", "case", "report", "."], "event_mentions": [{"id": "17331261_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "17331261_3_Ent5", "role": "Treatment_Route", "text": "Inhaled", "start": 0, "end": 1}, {"entity_id": "17331261_3_Ent2", "role": "Treatment", "text": "Inhaled tobramycin", "start": 0, "end": 2}, {"entity_id": "17331261_3_Ent4", "role": "Treatment_Drug", "text": "tobramycin", "start": 1, "end": 2}, {"entity_id": "17331261_3_Ent1", "role": "Effect", "text": "recurrent eosinophilia and severe persistent bronchospasm", "start": 5, "end": 11}, {"entity_id": "17331261_3_Ent0", "role": "Subject", "text": "a patient with cystic fibrosis", "start": 12, "end": 17}, {"entity_id": "17331261_3_Ent3", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17331261_3_Ent5", "text": "Inhaled", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17331261_3_Ent2", "text": "Inhaled tobramycin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17331261_3_Ent4", "text": "tobramycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17331261_3_Ent1", "text": "recurrent eosinophilia and severe persistent bronchospasm", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "17331261_3_Ent0", "text": "a patient with cystic fibrosis", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "17331261_3_Ent3", "text": "cystic fibrosis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17366681_1", "wnd_id": "17366681_1_1", "text": "A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer .", "tokens": ["A", "complex", "pattern", "of", "melanonychia", "and", "onycholysis", "after", "treatment", "with", "pemetrexed", "for", "lung", "cancer", "."], "event_mentions": [{"id": "17366681_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "17366681_1_Ent0", "role": "Effect", "text": "melanonychia and onycholysis", "start": 4, "end": 7}, {"entity_id": "17366681_1_Ent3", "role": "Treatment_Drug", "text": "pemetrexed", "start": 10, "end": 11}, {"entity_id": "17366681_1_Ent1", "role": "Treatment", "text": "pemetrexed for lung cancer", "start": 10, "end": 14}, {"entity_id": "17366681_1_Ent2", "role": "Treatment_Disorder", "text": "lung cancer", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "17366681_1_Ent0", "text": "melanonychia and onycholysis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17366681_1_Ent3", "text": "pemetrexed", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17366681_1_Ent1", "text": "pemetrexed for lung cancer", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "17366681_1_Ent2", "text": "lung cancer", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "17381671_7", "wnd_id": "17381671_7_1", "text": "SSRIs and fentanyl are commonly co - administered , especially in the setting of chronic or malignant pain , as underlying depression may contribute to the pathogenesis of pain .", "tokens": ["SSRIs", "and", "fentanyl", "are", "commonly", "co", "-", "administered", ",", "especially", "in", "the", "setting", "of", "chronic", "or", "malignant", "pain", ",", "as", "underlying", "depression", "may", "contribute", "to", "the", "pathogenesis", "of", "pain", "."], "event_mentions": [{"id": "17381671_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "17381671_7_Ent3", "role": "Treatment_Drug", "text": "SSRIs", "start": 0, "end": 1}, {"entity_id": "17381671_7_Ent5", "role": "Combination_Drug", "text": "SSRIs", "start": 0, "end": 1}, {"entity_id": "17381671_7_Ent0", "role": "Treatment", "text": "SSRIs and fentanyl are commonly co - administered", "start": 0, "end": 8}, {"entity_id": "17381671_7_Ent4", "role": "Treatment_Drug", "text": "fentanyl", "start": 2, "end": 3}, {"entity_id": "17381671_7_Ent6", "role": "Combination_Drug", "text": "fentanyl", "start": 2, "end": 3}, {"entity_id": "17381671_7_Ent1", "role": "Treatment_Disorder", "text": "chronic or malignant pain", "start": 14, "end": 18}, {"entity_id": "17381671_7_Ent2", "role": "Treatment_Disorder", "text": "underlying depression", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "17381671_7_Ent3", "text": "SSRIs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17381671_7_Ent5", "text": "SSRIs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17381671_7_Ent0", "text": "SSRIs and fentanyl are commonly co - administered", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17381671_7_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17381671_7_Ent6", "text": "fentanyl", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17381671_7_Ent1", "text": "chronic or malignant pain", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "17381671_7_Ent2", "text": "underlying depression", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "17383767_2", "wnd_id": "17383767_2_1", "text": "Brain metastases are a frequent finding in patients with advanced non - small cell lung cancer and concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor is necessary in many cases .", "tokens": ["Brain", "metastases", "are", "a", "frequent", "finding", "in", "patients", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "and", "concomitant", "administration", "of", "antiepileptic", "and", "chemotherapeutic", "drugs", "or", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "inhibitor", "is", "necessary", "in", "many", "cases", "."], "event_mentions": [{"id": "17383767_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "necessary", "start": 34, "end": 35}, "arguments": [{"entity_id": "17383767_2_Ent6", "role": "Treatment_Disorder", "text": "Brain metastases", "start": 0, "end": 2}, {"entity_id": "17383767_2_Ent0", "role": "Subject", "text": "patients with advanced non - small cell lung cancer", "start": 7, "end": 16}, {"entity_id": "17383767_2_Ent1", "role": "Subject_Disorder", "text": "advanced non - small cell lung cancer", "start": 9, "end": 16}, {"entity_id": "17383767_2_Ent2", "role": "Treatment", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "start": 17, "end": 33}, {"entity_id": "17383767_2_Ent3", "role": "Treatment_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent7", "role": "Combination_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent4", "role": "Treatment_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent8", "role": "Combination_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent5", "role": "Treatment_Drug", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "start": 25, "end": 33}]}], "entity_mentions": [{"id": "17383767_2_Ent6", "text": "Brain metastases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17383767_2_Ent0", "text": "patients with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "17383767_2_Ent1", "text": "advanced non - small cell lung cancer", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17383767_2_Ent2", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 17, "end": 33}, {"id": "17383767_2_Ent3", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent7", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent4", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent8", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent5", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 25, "end": 33}], "lang": "en"}
{"doc_id": "17404582_1", "wnd_id": "17404582_1_1", "text": "Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past .", "tokens": ["Docetaxel", "induced", "Meibomian", "duct", "inflammation", "and", "blockage", "is", "the", "likely", "cause", "of", "this", "presentation", "in", "a", "patient", "with", "no", "history", "of", "eyelid", "masses", "in", "the", "past", "."], "event_mentions": [{"id": "17404582_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "17404582_1_Ent2", "role": "Treatment", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_1_Ent3", "role": "Treatment_Drug", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_1_Ent1", "role": "Effect", "text": "Meibomian duct inflammation and blockage", "start": 2, "end": 7}, {"entity_id": "17404582_1_Ent0", "role": "Subject", "text": "a patient with no history of eyelid masses in the past", "start": 15, "end": 26}]}], "entity_mentions": [{"id": "17404582_1_Ent2", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_1_Ent3", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_1_Ent1", "text": "Meibomian duct inflammation and blockage", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "17404582_1_Ent0", "text": "a patient with no history of eyelid masses in the past", "entity_type": "Entity", "start": 15, "end": 26}], "lang": "en"}
{"doc_id": "17406804_3", "wnd_id": "17406804_3_1", "text": "CONCLUSION : Gemcitabine - induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy .", "tokens": ["CONCLUSION", ":", "Gemcitabine", "-", "induced", "recall", "pneumonitis", "is", "a", "rarely", "reported", "phenomenon", "and", "should", "be", "taken", "into", "account", "even", "after", "extended", "time", "interval", "to", "the", "previous", "radiotherapy", "."], "event_mentions": [{"id": "17406804_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17406804_3_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 2, "end": 3}, {"entity_id": "17406804_3_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 2, "end": 3}, {"entity_id": "17406804_3_Ent0", "role": "Effect", "text": "recall pneumonitis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17406804_3_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17406804_3_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17406804_3_Ent0", "text": "recall pneumonitis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17420198_17", "wnd_id": "17420198_17_1", "text": "The patient 's movements resolved following diphenhydramine administration .", "tokens": ["The", "patient", "'s", "movements", "resolved", "following", "diphenhydramine", "administration", "."], "event_mentions": [{"id": "17420198_17_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 4, "end": 5}, "arguments": [{"entity_id": "17420198_17_Ent2", "role": "Treatment_Disorder", "text": "movements", "start": 3, "end": 4}, {"entity_id": "17420198_17_Ent0", "role": "Treatment", "text": "diphenhydramine", "start": 6, "end": 7}, {"entity_id": "17420198_17_Ent1", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17420198_17_Ent2", "text": "movements", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17420198_17_Ent0", "text": "diphenhydramine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17420198_17_Ent1", "text": "diphenhydramine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17426073_4", "wnd_id": "17426073_4_1", "text": "Teicoplanin - induced agranulocytosis that followed vancomycin - induced agranulocytosis suggests a possible cross - reactivity between the 2 drugs .", "tokens": ["Teicoplanin", "-", "induced", "agranulocytosis", "that", "followed", "vancomycin", "-", "induced", "agranulocytosis", "suggests", "a", "possible", "cross", "-", "reactivity", "between", "the", "2", "drugs", "."], "event_mentions": [{"id": "17426073_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17426073_4_Ent1", "role": "Treatment", "text": "Teicoplanin", "start": 0, "end": 1}, {"entity_id": "17426073_4_Ent3", "role": "Treatment_Drug", "text": "Teicoplanin", "start": 0, "end": 1}, {"entity_id": "17426073_4_Ent5", "role": "Combination_Drug", "text": "Teicoplanin", "start": 0, "end": 1}, {"entity_id": "17426073_4_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 3, "end": 4}, {"entity_id": "17426073_4_Ent2", "role": "Treatment", "text": "followed vancomycin", "start": 5, "end": 7}, {"entity_id": "17426073_4_Ent4", "role": "Treatment_Drug", "text": "vancomycin", "start": 6, "end": 7}, {"entity_id": "17426073_4_Ent6", "role": "Combination_Drug", "text": "vancomycin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17426073_4_Ent1", "text": "Teicoplanin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17426073_4_Ent3", "text": "Teicoplanin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17426073_4_Ent5", "text": "Teicoplanin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17426073_4_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17426073_4_Ent2", "text": "followed vancomycin", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17426073_4_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17426073_4_Ent6", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1743388_2", "wnd_id": "1743388_2_1", "text": "This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and ulceration following the extravasation of intravenous pentamidine into the soft tissues of the left hand and forearm .", "tokens": ["This", "is", "a", "report", "of", "a", "renal", "transplant", "patient", "with", "Pneumocystis", "pneumonia", "who", "developed", "chemical", "cellulitis", "and", "ulceration", "following", "the", "extravasation", "of", "intravenous", "pentamidine", "into", "the", "soft", "tissues", "of", "the", "left", "hand", "and", "forearm", "."], "event_mentions": [{"id": "1743388_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "1743388_2_Ent0", "role": "Subject", "text": "a renal transplant patient with Pneumocystis pneumonia", "start": 5, "end": 12}, {"entity_id": "1743388_2_Ent1", "role": "Subject_Disorder", "text": "renal transplant", "start": 6, "end": 8}, {"entity_id": "1743388_2_Ent4", "role": "Treatment_Disorder", "text": "Pneumocystis pneumonia", "start": 10, "end": 12}, {"entity_id": "1743388_2_Ent2", "role": "Effect", "text": "chemical cellulitis and ulceration", "start": 14, "end": 18}, {"entity_id": "1743388_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 22, "end": 23}, {"entity_id": "1743388_2_Ent3", "role": "Treatment", "text": "intravenous pentamidine into the soft tissues of the left hand and forearm", "start": 22, "end": 34}, {"entity_id": "1743388_2_Ent6", "role": "Treatment_Drug", "text": "pentamidine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "1743388_2_Ent0", "text": "a renal transplant patient with Pneumocystis pneumonia", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "1743388_2_Ent1", "text": "renal transplant", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "1743388_2_Ent4", "text": "Pneumocystis pneumonia", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "1743388_2_Ent2", "text": "chemical cellulitis and ulceration", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "1743388_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1743388_2_Ent3", "text": "intravenous pentamidine into the soft tissues of the left hand and forearm", "entity_type": "Entity", "start": 22, "end": 34}, {"id": "1743388_2_Ent6", "text": "pentamidine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "17444802_2", "wnd_id": "17444802_2_1", "text": "AIMS : The aim of this study was to report on the effectiveness and tumor side effects of topical interferon ( INF ) alpha 2 - beta in a case of conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure .", "tokens": ["AIMS", ":", "The", "aim", "of", "this", "study", "was", "to", "report", "on", "the", "effectiveness", "and", "tumor", "side", "effects", "of", "topical", "interferon", "(", "INF", ")", "alpha", "2", "-", "beta", "in", "a", "case", "of", "conjunctiva", "-", "cornea", "intraepithelial", "neoplasia", "(", "CIN", ")", "of", "a", "patient", "that", "rejected", "any", "surgical", "procedure", "."], "event_mentions": [{"id": "17444802_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 15, "end": 17}, "arguments": [{"entity_id": "17444802_2_Ent1", "role": "Effect", "text": "tumor side effects", "start": 14, "end": 17}, {"entity_id": "17444802_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 18, "end": 19}, {"entity_id": "17444802_2_Ent2", "role": "Treatment", "text": "topical interferon ( INF ) alpha 2 - beta", "start": 18, "end": 27}, {"entity_id": "17444802_2_Ent4", "role": "Treatment_Drug", "text": "interferon", "start": 19, "end": 20}, {"entity_id": "17444802_2_Ent5", "role": "Treatment_Drug", "text": "alpha 2 - beta", "start": 23, "end": 27}, {"entity_id": "17444802_2_Ent6", "role": "Treatment_Disorder", "text": "conjunctiva - cornea intraepithelial neoplasia", "start": 31, "end": 36}, {"entity_id": "17444802_2_Ent0", "role": "Subject", "text": "conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure", "start": 31, "end": 47}]}], "entity_mentions": [{"id": "17444802_2_Ent1", "text": "tumor side effects", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "17444802_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17444802_2_Ent2", "text": "topical interferon ( INF ) alpha 2 - beta", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "17444802_2_Ent4", "text": "interferon", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17444802_2_Ent5", "text": "alpha 2 - beta", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "17444802_2_Ent6", "text": "conjunctiva - cornea intraepithelial neoplasia", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "17444802_2_Ent0", "text": "conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure", "entity_type": "Entity", "start": 31, "end": 47}], "lang": "en"}
{"doc_id": "17473493_1", "wnd_id": "17473493_1_1", "text": "Selective estrogen receptor modulator raloxifene - associated aggravation of nonalcoholic steatohepatitis .", "tokens": ["Selective", "estrogen", "receptor", "modulator", "raloxifene", "-", "associated", "aggravation", "of", "nonalcoholic", "steatohepatitis", "."], "event_mentions": [{"id": "17473493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "17473493_1_Ent1", "role": "Treatment", "text": "raloxifene", "start": 4, "end": 5}, {"entity_id": "17473493_1_Ent2", "role": "Treatment_Drug", "text": "raloxifene", "start": 4, "end": 5}, {"entity_id": "17473493_1_Ent0", "role": "Effect", "text": "aggravation of nonalcoholic steatohepatitis", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "17473493_1_Ent1", "text": "raloxifene", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17473493_1_Ent2", "text": "raloxifene", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17473493_1_Ent0", "text": "aggravation of nonalcoholic steatohepatitis", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "17473920_8", "wnd_id": "17473920_8_1", "text": "After starting nevirapine treatment , nine out of ten patients experienced symptoms of abstinence syndrome , and methadone dose had to be increased by 20 % on average during the course of the study .", "tokens": ["After", "starting", "nevirapine", "treatment", ",", "nine", "out", "of", "ten", "patients", "experienced", "symptoms", "of", "abstinence", "syndrome", ",", "and", "methadone", "dose", "had", "to", "be", "increased", "by", "20", "%", "on", "average", "during", "the", "course", "of", "the", "study", "."], "event_mentions": [{"id": "17473920_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17473920_8_Ent3", "role": "Treatment", "text": "nevirapine", "start": 2, "end": 3}, {"entity_id": "17473920_8_Ent4", "role": "Treatment_Drug", "text": "nevirapine", "start": 2, "end": 3}, {"entity_id": "17473920_8_Ent1", "role": "Subject_Population", "text": "nine out of ten", "start": 5, "end": 9}, {"entity_id": "17473920_8_Ent0", "role": "Subject", "text": "nine out of ten patients", "start": 5, "end": 10}, {"entity_id": "17473920_8_Ent2", "role": "Effect", "text": "abstinence syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17473920_8_Ent3", "text": "nevirapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_8_Ent4", "text": "nevirapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_8_Ent1", "text": "nine out of ten", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17473920_8_Ent0", "text": "nine out of ten patients", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "17473920_8_Ent2", "text": "abstinence syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17504225_3", "wnd_id": "17504225_3_1", "text": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae .", "tokens": ["In", "this", "paper", "it", "is", "reported", "an", "evidence", "of", "pharmacokinetic", "interaction", "between", "clarithromycin", "and", "sirolimus", "in", "a", "kidney", "transplanted", "woman", ",", "suffering", "from", "pulmonary", "infection", "sustained", "by", "a", "bacterial", "pathogen", ",", "in", "particular", "Hemophilus", "Influenzae", "."], "event_mentions": [{"id": "17504225_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 11, "end": 12}, "arguments": [{"entity_id": "17504225_3_Ent3", "role": "Effect", "text": "pharmacokinetic interaction", "start": 9, "end": 11}, {"entity_id": "17504225_3_Ent5", "role": "Treatment_Drug", "text": "clarithromycin", "start": 12, "end": 13}, {"entity_id": "17504225_3_Ent8", "role": "Combination_Drug", "text": "clarithromycin", "start": 12, "end": 13}, {"entity_id": "17504225_3_Ent4", "role": "Treatment", "text": "clarithromycin and sirolimus", "start": 12, "end": 15}, {"entity_id": "17504225_3_Ent6", "role": "Treatment_Drug", "text": "sirolimus", "start": 14, "end": 15}, {"entity_id": "17504225_3_Ent9", "role": "Combination_Drug", "text": "sirolimus", "start": 14, "end": 15}, {"entity_id": "17504225_3_Ent0", "role": "Subject", "text": "a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae", "start": 16, "end": 35}, {"entity_id": "17504225_3_Ent1", "role": "Subject_Disorder", "text": "kidney transplanted", "start": 17, "end": 19}, {"entity_id": "17504225_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 19, "end": 20}, {"entity_id": "17504225_3_Ent7", "role": "Treatment_Disorder", "text": "pulmonary infection", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "17504225_3_Ent3", "text": "pharmacokinetic interaction", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17504225_3_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17504225_3_Ent8", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17504225_3_Ent4", "text": "clarithromycin and sirolimus", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17504225_3_Ent6", "text": "sirolimus", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17504225_3_Ent9", "text": "sirolimus", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17504225_3_Ent0", "text": "a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae", "entity_type": "Entity", "start": 16, "end": 35}, {"id": "17504225_3_Ent1", "text": "kidney transplanted", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17504225_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17504225_3_Ent7", "text": "pulmonary infection", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "17509184_1", "wnd_id": "17509184_1_1", "text": "A 40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection experienced rapid cognitive decline after commencement of ethambutol , and symptoms fully resolved with cessation .", "tokens": ["A", "40", "-", "year", "-", "old", "man", "with", "advanced", "HIV", "infection", "and", "Mycobacterium", "avium", "complex", "infection", "experienced", "rapid", "cognitive", "decline", "after", "commencement", "of", "ethambutol", ",", "and", "symptoms", "fully", "resolved", "with", "cessation", "."], "event_mentions": [{"id": "17509184_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "17509184_1_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 1, "end": 6}, {"entity_id": "17509184_1_Ent0", "role": "Subject", "text": "40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection", "start": 1, "end": 16}, {"entity_id": "17509184_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17509184_1_Ent8", "role": "Treatment_Disorder", "text": "HIV infection", "start": 9, "end": 11}, {"entity_id": "17509184_1_Ent7", "role": "Treatment_Disorder", "text": "Mycobacterium avium complex infection", "start": 12, "end": 16}, {"entity_id": "17509184_1_Ent3", "role": "Effect", "text": "rapid cognitive decline", "start": 17, "end": 20}, {"entity_id": "17509184_1_Ent4", "role": "Treatment", "text": "commencement of ethambutol", "start": 21, "end": 24}, {"entity_id": "17509184_1_Ent5", "role": "Treatment_Drug", "text": "ethambutol", "start": 23, "end": 24}, {"entity_id": "17509184_1_Ent6", "role": "Treatment_Disorder", "text": "ethambutol", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17509184_1_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17509184_1_Ent0", "text": "40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection", "entity_type": "Entity", "start": 1, "end": 16}, {"id": "17509184_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17509184_1_Ent8", "text": "HIV infection", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17509184_1_Ent7", "text": "Mycobacterium avium complex infection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17509184_1_Ent3", "text": "rapid cognitive decline", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17509184_1_Ent4", "text": "commencement of ethambutol", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "17509184_1_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17509184_1_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "1751354_1", "wnd_id": "1751354_1_1", "text": "Psoriasis induced by interferon - alpha .", "tokens": ["Psoriasis", "induced", "by", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "1751354_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "1751354_1_Ent0", "role": "Effect", "text": "Psoriasis", "start": 0, "end": 1}, {"entity_id": "1751354_1_Ent1", "role": "Treatment", "text": "interferon - alpha", "start": 3, "end": 6}, {"entity_id": "1751354_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "1751354_1_Ent0", "text": "Psoriasis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1751354_1_Ent1", "text": "interferon - alpha", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1751354_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "17519584_1", "wnd_id": "17519584_1_1", "text": "A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking sulfamethoxazole / trimethoprim .", "tokens": ["A", "61", "-", "year", "-", "old", "man", "with", "early", "diffuse", "cutaneous", "scleroderma", "with", "myositis", "and", "progressive", "interstitial", "pneumonia", "developed", "generalized", "erythema", "with", "high", "fever", "3", "weeks", "after", "taking", "sulfamethoxazole", "/", "trimethoprim", "."], "event_mentions": [{"id": "17519584_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 27, "end": 28}, "arguments": [{"entity_id": "17519584_1_Ent0", "role": "Subject", "text": "A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia", "start": 0, "end": 18}, {"entity_id": "17519584_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "17519584_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17519584_1_Ent3", "role": "Subject_Disorder", "text": "early diffuse cutaneous scleroderma with myositis", "start": 8, "end": 14}, {"entity_id": "17519584_1_Ent4", "role": "Subject_Disorder", "text": "progressive interstitial pneumonia", "start": 15, "end": 18}, {"entity_id": "17519584_1_Ent5", "role": "Effect", "text": "generalized erythema with high fever", "start": 19, "end": 24}, {"entity_id": "17519584_1_Ent9", "role": "Treatment_Time_elapsed", "text": "3 weeks after", "start": 24, "end": 27}, {"entity_id": "17519584_1_Ent7", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 28, "end": 29}, {"entity_id": "17519584_1_Ent11", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 28, "end": 29}, {"entity_id": "17519584_1_Ent6", "role": "Treatment", "text": "sulfamethoxazole / trimethoprim", "start": 28, "end": 31}, {"entity_id": "17519584_1_Ent8", "role": "Treatment_Drug", "text": "trimethoprim", "start": 30, "end": 31}, {"entity_id": "17519584_1_Ent10", "role": "Combination_Drug", "text": "trimethoprim", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "17519584_1_Ent0", "text": "A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "17519584_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17519584_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17519584_1_Ent3", "text": "early diffuse cutaneous scleroderma with myositis", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17519584_1_Ent4", "text": "progressive interstitial pneumonia", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17519584_1_Ent5", "text": "generalized erythema with high fever", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "17519584_1_Ent9", "text": "3 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17519584_1_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17519584_1_Ent11", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17519584_1_Ent6", "text": "sulfamethoxazole / trimethoprim", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "17519584_1_Ent8", "text": "trimethoprim", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "17519584_1_Ent10", "text": "trimethoprim", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "17526968_1", "wnd_id": "17526968_1_1", "text": "Bleomycin induced hyperpigmentation with yolk sac tumor .", "tokens": ["Bleomycin", "induced", "hyperpigmentation", "with", "yolk", "sac", "tumor", "."], "event_mentions": [{"id": "17526968_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "17526968_1_Ent1", "role": "Treatment", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "17526968_1_Ent2", "role": "Treatment_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "17526968_1_Ent0", "role": "Effect", "text": "hyperpigmentation with yolk sac tumor", "start": 2, "end": 7}]}], "entity_mentions": [{"id": "17526968_1_Ent1", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17526968_1_Ent2", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17526968_1_Ent0", "text": "hyperpigmentation with yolk sac tumor", "entity_type": "Entity", "start": 2, "end": 7}], "lang": "en"}
{"doc_id": "17536204_3", "wnd_id": "17536204_3_1", "text": "Capecitabine - induced headache responding to diltiazem .", "tokens": ["Capecitabine", "-", "induced", "headache", "responding", "to", "diltiazem", "."], "event_mentions": [{"id": "17536204_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17536204_3_Ent1", "role": "Treatment", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "17536204_3_Ent2", "role": "Treatment_Drug", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "17536204_3_Ent0", "role": "Effect", "text": "headache", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17536204_3_Ent1", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17536204_3_Ent2", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17536204_3_Ent0", "text": "headache", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "17547624_1", "wnd_id": "17547624_1_1", "text": "Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff - Parkinson - White syndrome .", "tokens": ["Brugada", "type", "electrocardiographic", "changes", "induced", "by", "concomitant", "use", "of", "lithium", "and", "propafenone", "in", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "."], "event_mentions": [{"id": "17547624_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17547624_1_Ent1", "role": "Effect", "text": "Brugada type electrocardiographic changes", "start": 0, "end": 4}, {"entity_id": "17547624_1_Ent2", "role": "Treatment", "text": "concomitant use of lithium and propafenone", "start": 6, "end": 12}, {"entity_id": "17547624_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17547624_1_Ent6", "role": "Combination_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17547624_1_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 11, "end": 12}, {"entity_id": "17547624_1_Ent7", "role": "Combination_Drug", "text": "propafenone", "start": 11, "end": 12}, {"entity_id": "17547624_1_Ent0", "role": "Subject", "text": "patient with Wolff - Parkinson - White syndrome", "start": 13, "end": 21}, {"entity_id": "17547624_1_Ent3", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "17547624_1_Ent1", "text": "Brugada type electrocardiographic changes", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17547624_1_Ent2", "text": "concomitant use of lithium and propafenone", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "17547624_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17547624_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17547624_1_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17547624_1_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17547624_1_Ent0", "text": "patient with Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "17547624_1_Ent3", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "1756352_1", "wnd_id": "1756352_1_1", "text": "A woman developed delusional parasitosis when taking phenelzine .", "tokens": ["A", "woman", "developed", "delusional", "parasitosis", "when", "taking", "phenelzine", "."], "event_mentions": [{"id": "1756352_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "1756352_1_Ent0", "role": "Subject", "text": "A woman", "start": 0, "end": 2}, {"entity_id": "1756352_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 1, "end": 2}, {"entity_id": "1756352_1_Ent2", "role": "Effect", "text": "delusional parasitosis", "start": 3, "end": 5}, {"entity_id": "1756352_1_Ent3", "role": "Treatment", "text": "phenelzine", "start": 7, "end": 8}, {"entity_id": "1756352_1_Ent4", "role": "Treatment_Drug", "text": "phenelzine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1756352_1_Ent0", "text": "A woman", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1756352_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1756352_1_Ent2", "text": "delusional parasitosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1756352_1_Ent3", "text": "phenelzine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1756352_1_Ent4", "text": "phenelzine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "17610180_2", "wnd_id": "17610180_2_1", "text": "The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of gastric mucosa foveolar hyperplasia due to prolonged PGE1 therapy .", "tokens": ["The", "results", "of", "the", "ultrasound", "examination", "combined", "with", "clinical", "anamnesis", "allowed", "diagnosis", "of", "gastric", "mucosa", "foveolar", "hyperplasia", "due", "to", "prolonged", "PGE1", "therapy", "."], "event_mentions": [{"id": "17610180_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 17, "end": 18}, "arguments": [{"entity_id": "17610180_2_Ent0", "role": "Effect", "text": "gastric mucosa foveolar hyperplasia", "start": 13, "end": 17}, {"entity_id": "17610180_2_Ent3", "role": "Treatment_Duration", "text": "prolonged", "start": 19, "end": 20}, {"entity_id": "17610180_2_Ent1", "role": "Treatment", "text": "prolonged PGE1 therapy", "start": 19, "end": 22}, {"entity_id": "17610180_2_Ent2", "role": "Treatment_Drug", "text": "PGE1", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17610180_2_Ent0", "text": "gastric mucosa foveolar hyperplasia", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "17610180_2_Ent3", "text": "prolonged", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17610180_2_Ent1", "text": "prolonged PGE1 therapy", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "17610180_2_Ent2", "text": "PGE1", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "17619811_4", "wnd_id": "17619811_4_1", "text": "Colchicine - induced rhabdomyolysis .", "tokens": ["Colchicine", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "17619811_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17619811_4_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_4_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_4_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17619811_4_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_4_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_4_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "17655376_2", "wnd_id": "17655376_2_1", "text": "Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris ; however , the oral formulation is known to cause dose - dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen 's disease .", "tokens": ["Oral", "dapsone", "has", "been", "available", "for", "over", "60", "years", "and", "has", "been", "used", "to", "treat", "severe", "acne", "vulgaris", ";", "however", ",", "the", "oral", "formulation", "is", "known", "to", "cause", "dose", "-", "dependent", "haematological", "reactions", "and", "is", "currently", "indicated", "only", "for", "diseases", "such", "as", "dermatitis", "herpetiformis", "and", "Hansen", "'s", "disease", "."], "event_mentions": [{"id": "17655376_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 27, "end": 28}, "arguments": [{"entity_id": "17655376_2_Ent3", "role": "Treatment_Route", "text": "Oral", "start": 0, "end": 1}, {"entity_id": "17655376_2_Ent1", "role": "Treatment", "text": "Oral dapsone", "start": 0, "end": 2}, {"entity_id": "17655376_2_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 1, "end": 2}, {"entity_id": "17655376_2_Ent0", "role": "Effect", "text": "dose - dependent haematological reactions", "start": 28, "end": 33}, {"entity_id": "17655376_2_Ent4", "role": "Treatment_Disorder", "text": "dermatitis herpetiformis", "start": 42, "end": 44}, {"entity_id": "17655376_2_Ent5", "role": "Treatment_Disorder", "text": "Hansen 's disease", "start": 45, "end": 48}]}], "entity_mentions": [{"id": "17655376_2_Ent3", "text": "Oral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655376_2_Ent1", "text": "Oral dapsone", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17655376_2_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17655376_2_Ent0", "text": "dose - dependent haematological reactions", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "17655376_2_Ent4", "text": "dermatitis herpetiformis", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "17655376_2_Ent5", "text": "Hansen 's disease", "entity_type": "Entity", "start": 45, "end": 48}], "lang": "en"}
{"doc_id": "17655517_8", "wnd_id": "17655517_8_1", "text": "Linezolid should be discontinued immediately in patients experiencing these adverse effects .", "tokens": ["Linezolid", "should", "be", "discontinued", "immediately", "in", "patients", "experiencing", "these", "adverse", "effects", "."], "event_mentions": [{"id": "17655517_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinued", "start": 3, "end": 4}, "arguments": [{"entity_id": "17655517_8_Ent2", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_8_Ent3", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_8_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "17655517_8_Ent1", "role": "Effect", "text": "adverse effects", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17655517_8_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_8_Ent3", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17655517_8_Ent1", "text": "adverse effects", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "1765991_2", "wnd_id": "1765991_2_1", "text": "The development of systemic lupus erythematosus ( SLE ) after 38 months of therapy with recombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis .", "tokens": ["The", "development", "of", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "after", "38", "months", "of", "therapy", "with", "recombinant", "human", "interferon", "gamma", "(", "rIFN", "-", "gamma", ")", "was", "observed", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "1765991_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "1765991_2_Ent1", "role": "Effect", "text": "systemic lupus erythematosus", "start": 3, "end": 6}, {"entity_id": "1765991_2_Ent2", "role": "Treatment", "text": "after 38 months", "start": 9, "end": 12}, {"entity_id": "1765991_2_Ent4", "role": "Treatment_Time_elapsed", "text": "after 38 months", "start": 9, "end": 12}, {"entity_id": "1765991_2_Ent3", "role": "Treatment", "text": "recombinant human interferon gamma", "start": 15, "end": 19}, {"entity_id": "1765991_2_Ent5", "role": "Treatment_Drug", "text": "recombinant human interferon gamma", "start": 15, "end": 19}, {"entity_id": "1765991_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis .", "start": 27, "end": 33}, {"entity_id": "1765991_2_Ent6", "role": "Treatment_Disorder", "text": "rheumatoid arthritis .", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "1765991_2_Ent1", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_2_Ent2", "text": "after 38 months", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1765991_2_Ent4", "text": "after 38 months", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1765991_2_Ent3", "text": "recombinant human interferon gamma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "1765991_2_Ent5", "text": "recombinant human interferon gamma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "1765991_2_Ent0", "text": "a patient with rheumatoid arthritis .", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "1765991_2_Ent6", "text": "rheumatoid arthritis .", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "17665812_2", "wnd_id": "17665812_2_1", "text": "Drug - induced eosinophilia is a non - dose - dependent side effect of clozapine .", "tokens": ["Drug", "-", "induced", "eosinophilia", "is", "a", "non", "-", "dose", "-", "dependent", "side", "effect", "of", "clozapine", "."], "event_mentions": [{"id": "17665812_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17665812_2_Ent0", "role": "Effect", "text": "eosinophilia", "start": 3, "end": 4}, {"entity_id": "17665812_2_Ent3", "role": "Treatment_Dosage", "text": "non - dose - dependent", "start": 6, "end": 11}, {"entity_id": "17665812_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 14, "end": 15}, {"entity_id": "17665812_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "17665812_2_Ent0", "text": "eosinophilia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17665812_2_Ent3", "text": "non - dose - dependent", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "17665812_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17665812_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "17671884_8", "wnd_id": "17671884_8_1", "text": "The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus .", "tokens": ["The", "dermatology", "literature", "heretofore", "has", "not", "noted", "that", "anemia", "is", "a", "side", "effect", "of", "patients", "taking", "MMF", "to", "treat", "pemphigus", "."], "event_mentions": [{"id": "17671884_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "is", "start": 9, "end": 10}, "arguments": [{"entity_id": "17671884_8_Ent1", "role": "Effect", "text": "anemia", "start": 8, "end": 9}, {"entity_id": "17671884_8_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "17671884_8_Ent2", "role": "Treatment", "text": "MMF", "start": 16, "end": 17}, {"entity_id": "17671884_8_Ent3", "role": "Treatment_Disorder", "text": "pemphigus", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17671884_8_Ent1", "text": "anemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17671884_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_8_Ent2", "text": "MMF", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_8_Ent3", "text": "pemphigus", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17705565_1", "wnd_id": "17705565_1_1", "text": "Carbamazepine hypersensitivity syndrome is a rare , life - threatening condition .", "tokens": ["Carbamazepine", "hypersensitivity", "syndrome", "is", "a", "rare", ",", "life", "-", "threatening", "condition", "."], "event_mentions": [{"id": "17705565_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "is", "start": 3, "end": 4}, "arguments": [{"entity_id": "17705565_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "17705565_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "17705565_1_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 1, "end": 3}]}], "entity_mentions": [{"id": "17705565_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17705565_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17705565_1_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 1, "end": 3}], "lang": "en"}
{"doc_id": "17710018_3", "wnd_id": "17710018_3_1", "text": "PET scintigraphy of etoposide - induced pulmonary toxicity .", "tokens": ["PET", "scintigraphy", "of", "etoposide", "-", "induced", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "17710018_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17710018_3_Ent1", "role": "Treatment", "text": "etoposide", "start": 3, "end": 4}, {"entity_id": "17710018_3_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 3, "end": 4}, {"entity_id": "17710018_3_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "17710018_3_Ent1", "text": "etoposide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17710018_3_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17710018_3_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "17725438_1", "wnd_id": "17725438_1_1", "text": "Here , we report a case of RFP - induced hypothyroidism without underlying thyroid disease .", "tokens": ["Here", ",", "we", "report", "a", "case", "of", "RFP", "-", "induced", "hypothyroidism", "without", "underlying", "thyroid", "disease", "."], "event_mentions": [{"id": "17725438_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "17725438_1_Ent1", "role": "Treatment", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent2", "role": "Treatment_Drug", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent0", "role": "Effect", "text": "hypothyroidism without underlying thyroid disease", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "17725438_1_Ent1", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent2", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent0", "text": "hypothyroidism without underlying thyroid disease", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "17763133_2", "wnd_id": "17763133_2_1", "text": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function .", "tokens": ["Discontinuation", "of", "simvastatin", "and", "cyclosporine", "resulted", "in", "resolution", "of", "rhabdomyolysis", "and", "normalization", "of", "renal", "function", "."], "event_mentions": [{"id": "17763133_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 5, "end": 6}, "arguments": [{"entity_id": "17763133_2_Ent1", "role": "Treatment", "text": "Discontinuation of simvastatin and cyclosporine", "start": 0, "end": 5}, {"entity_id": "17763133_2_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 2, "end": 3}, {"entity_id": "17763133_2_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 4, "end": 5}, {"entity_id": "17763133_2_Ent2", "role": "Treatment_Disorder", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "17763133_2_Ent0", "role": "Effect", "text": "normalization of renal function", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "17763133_2_Ent1", "text": "Discontinuation of simvastatin and cyclosporine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "17763133_2_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17763133_2_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17763133_2_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17763133_2_Ent0", "text": "normalization of renal function", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "17823522_1", "wnd_id": "17823522_1_1", "text": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment .", "tokens": ["Generalized", "lichen", "nitidus", "with", "involvement", "of", "the", "palms", "following", "interferon", "alpha", "treatment", "."], "event_mentions": [{"id": "17823522_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "17823522_1_Ent0", "role": "Effect", "text": "Generalized lichen nitidus with involvement of the palms", "start": 0, "end": 8}, {"entity_id": "17823522_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 9, "end": 11}, {"entity_id": "17823522_1_Ent1", "role": "Treatment", "text": "interferon alpha treatment", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17823522_1_Ent0", "text": "Generalized lichen nitidus with involvement of the palms", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17823522_1_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17823522_1_Ent1", "text": "interferon alpha treatment", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17852449_1", "wnd_id": "17852449_1_1", "text": "Outcome of pregnancy in women treated with all - trans retinoic acid ; a case report and review of literature .", "tokens": ["Outcome", "of", "pregnancy", "in", "women", "treated", "with", "all", "-", "trans", "retinoic", "acid", ";", "a", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "17852449_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "17852449_1_Ent4", "role": "Treatment_Disorder", "text": "pregnancy", "start": 2, "end": 3}, {"entity_id": "17852449_1_Ent0", "role": "Subject", "text": "pregnancy in women", "start": 2, "end": 5}, {"entity_id": "17852449_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 4, "end": 5}, {"entity_id": "17852449_1_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 7, "end": 12}, {"entity_id": "17852449_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "17852449_1_Ent4", "text": "pregnancy", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17852449_1_Ent0", "text": "pregnancy in women", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17852449_1_Ent1", "text": "women", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17852449_1_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17852449_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "17873198_2", "wnd_id": "17873198_2_1", "text": "Pulmonary toxicity associated with erlotinib .", "tokens": ["Pulmonary", "toxicity", "associated", "with", "erlotinib", "."], "event_mentions": [{"id": "17873198_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17873198_2_Ent0", "role": "Effect", "text": "Pulmonary toxicity", "start": 0, "end": 2}, {"entity_id": "17873198_2_Ent1", "role": "Treatment", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "17873198_2_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "17873198_2_Ent0", "text": "Pulmonary toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17873198_2_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17873198_2_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "17907595_6", "wnd_id": "17907595_6_1", "text": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy .", "tokens": ["The", "FK", "506", "dose", "was", "constant", "within", "21", "days", "after", "discontinuing", "phenytoin", "in", "Patient", "1", "who", "had", "36", "days", "of", "phenytoin", "therapy", "."], "event_mentions": [{"id": "17907595_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuing", "start": 10, "end": 11}, "arguments": [{"entity_id": "17907595_6_Ent2", "role": "Effect", "text": "The FK 506 dose was constant within 21 days", "start": 0, "end": 9}, {"entity_id": "17907595_6_Ent3", "role": "Treatment", "text": "phenytoin", "start": 11, "end": 12}, {"entity_id": "17907595_6_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 11, "end": 12}, {"entity_id": "17907595_6_Ent0", "role": "Subject", "text": "Patient 1", "start": 13, "end": 15}, {"entity_id": "17907595_6_Ent1", "role": "Subject_Population", "text": "1", "start": 14, "end": 15}, {"entity_id": "17907595_6_Ent6", "role": "Treatment_Time_elapsed", "text": "36 days", "start": 17, "end": 19}, {"entity_id": "17907595_6_Ent5", "role": "Treatment_Drug", "text": "phenytoin therapy", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "17907595_6_Ent2", "text": "The FK 506 dose was constant within 21 days", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "17907595_6_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17907595_6_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17907595_6_Ent0", "text": "Patient 1", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17907595_6_Ent1", "text": "1", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17907595_6_Ent6", "text": "36 days", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17907595_6_Ent5", "text": "phenytoin therapy", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "17921794_1", "wnd_id": "17921794_1_1", "text": "Both colchicine and statin therapy may be associated with myopathy , which usually occurs after several months of therapy .", "tokens": ["Both", "colchicine", "and", "statin", "therapy", "may", "be", "associated", "with", "myopathy", ",", "which", "usually", "occurs", "after", "several", "months", "of", "therapy", "."], "event_mentions": [{"id": "17921794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17921794_1_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 1, "end": 2}, {"entity_id": "17921794_1_Ent4", "role": "Combination_Drug", "text": "colchicine", "start": 1, "end": 2}, {"entity_id": "17921794_1_Ent1", "role": "Treatment", "text": "colchicine and statin therapy", "start": 1, "end": 5}, {"entity_id": "17921794_1_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 3, "end": 4}, {"entity_id": "17921794_1_Ent5", "role": "Combination_Drug", "text": "statin", "start": 3, "end": 4}, {"entity_id": "17921794_1_Ent0", "role": "Effect", "text": "myopathy", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17921794_1_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17921794_1_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17921794_1_Ent1", "text": "colchicine and statin therapy", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "17921794_1_Ent3", "text": "statin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17921794_1_Ent5", "text": "statin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17921794_1_Ent0", "text": "myopathy", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17937473_2", "wnd_id": "17937473_2_1", "text": "Leflunomide - associated infections in rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "associated", "infections", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "17937473_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17937473_2_Ent1", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent2", "role": "Treatment_Drug", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent0", "role": "Effect", "text": "infections", "start": 3, "end": 4}, {"entity_id": "17937473_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17937473_2_Ent1", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent2", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent0", "text": "infections", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17937473_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17952482_1", "wnd_id": "17952482_1_1", "text": "A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever , skin eruptions , leukocytopenia , and thrombocytopenia , 3 weeks after treatment with sulfasalazine .", "tokens": ["A", "58", "-", "year", "-", "old", "woman", "with", "rheumatoid", "arthritis", "(", "RA", ")", "developed", "fever", ",", "skin", "eruptions", ",", "leukocytopenia", ",", "and", "thrombocytopenia", ",", "3", "weeks", "after", "treatment", "with", "sulfasalazine", "."], "event_mentions": [{"id": "17952482_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "17952482_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "17952482_1_Ent0", "role": "Subject", "text": "58 - year - old woman with rheumatoid arthritis ( RA )", "start": 1, "end": 13}, {"entity_id": "17952482_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "17952482_1_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis ( RA )", "start": 8, "end": 13}, {"entity_id": "17952482_1_Ent3", "role": "Effect", "text": "fever , skin eruptions , leukocytopenia , and thrombocytopenia", "start": 14, "end": 23}, {"entity_id": "17952482_1_Ent6", "role": "Treatment_Time_elapsed", "text": "3 weeks after", "start": 24, "end": 27}, {"entity_id": "17952482_1_Ent4", "role": "Treatment", "text": "3 weeks after treatment with sulfasalazine", "start": 24, "end": 30}, {"entity_id": "17952482_1_Ent5", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "17952482_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17952482_1_Ent0", "text": "58 - year - old woman with rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 1, "end": 13}, {"id": "17952482_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17952482_1_Ent7", "text": "rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17952482_1_Ent3", "text": "fever , skin eruptions , leukocytopenia , and thrombocytopenia", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "17952482_1_Ent6", "text": "3 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17952482_1_Ent4", "text": "3 weeks after treatment with sulfasalazine", "entity_type": "Entity", "start": 24, "end": 30}, {"id": "17952482_1_Ent5", "text": "sulfasalazine", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "17959575_16", "wnd_id": "17959575_16_1", "text": "CONCLUSION : A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v .", "tokens": ["CONCLUSION", ":", "A", "patient", "with", "CHF", "and", "ESRD", "developed", "myoclonic", "muscle", "spasms", "after", "receiving", "dobutamine", "by", "continuous", "i.v", "."], "event_mentions": [{"id": "17959575_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "17959575_16_Ent0", "role": "Subject", "text": "A patient with CHF and ESRD", "start": 2, "end": 8}, {"entity_id": "17959575_16_Ent7", "role": "Treatment_Disorder", "text": "CHF", "start": 5, "end": 6}, {"entity_id": "17959575_16_Ent1", "role": "Subject_Disorder", "text": "ESRD", "start": 7, "end": 8}, {"entity_id": "17959575_16_Ent2", "role": "Effect", "text": "myoclonic muscle spasms", "start": 9, "end": 12}, {"entity_id": "17959575_16_Ent4", "role": "Treatment_Drug", "text": "dobutamine", "start": 14, "end": 15}, {"entity_id": "17959575_16_Ent3", "role": "Treatment", "text": "dobutamine by continuous i.v", "start": 14, "end": 18}, {"entity_id": "17959575_16_Ent5", "role": "Treatment_Freq", "text": "continuous", "start": 16, "end": 17}, {"entity_id": "17959575_16_Ent6", "role": "Treatment_Route", "text": "i.v", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17959575_16_Ent0", "text": "A patient with CHF and ESRD", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17959575_16_Ent7", "text": "CHF", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17959575_16_Ent1", "text": "ESRD", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17959575_16_Ent2", "text": "myoclonic muscle spasms", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "17959575_16_Ent4", "text": "dobutamine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17959575_16_Ent3", "text": "dobutamine by continuous i.v", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "17959575_16_Ent5", "text": "continuous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17959575_16_Ent6", "text": "i.v", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17959575_18", "wnd_id": "17959575_18_1", "text": "PURPOSE : The occurrence of myoclonus associated with continuous i.v . infusion of dobutamine in a patient with end - stage renal disease ( ESRD ) is described .", "tokens": ["PURPOSE", ":", "The", "occurrence", "of", "myoclonus", "associated", "with", "continuous", "i.v", ".", "infusion", "of", "dobutamine", "in", "a", "patient", "with", "end", "-", "stage", "renal", "disease", "(", "ESRD", ")", "is", "described", "."], "event_mentions": [{"id": "17959575_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 6, "end": 8}, "arguments": [{"entity_id": "17959575_18_Ent2", "role": "Effect", "text": "myoclonus", "start": 5, "end": 6}, {"entity_id": "17959575_18_Ent3", "role": "Treatment", "text": "continuous i.v . infusion of dobutamine", "start": 8, "end": 14}, {"entity_id": "17959575_18_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 11, "end": 12}, {"entity_id": "17959575_18_Ent4", "role": "Treatment_Drug", "text": "dobutamine", "start": 13, "end": 14}, {"entity_id": "17959575_18_Ent0", "role": "Subject", "text": "a patient with end - stage renal disease ( ESRD )", "start": 15, "end": 26}, {"entity_id": "17959575_18_Ent1", "role": "Subject_Disorder", "text": "end - stage renal disease ( ESRD )", "start": 18, "end": 26}]}], "entity_mentions": [{"id": "17959575_18_Ent2", "text": "myoclonus", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17959575_18_Ent3", "text": "continuous i.v . infusion of dobutamine", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17959575_18_Ent5", "text": "infusion", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17959575_18_Ent4", "text": "dobutamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17959575_18_Ent0", "text": "a patient with end - stage renal disease ( ESRD )", "entity_type": "Entity", "start": 15, "end": 26}, {"id": "17959575_18_Ent1", "text": "end - stage renal disease ( ESRD )", "entity_type": "Entity", "start": 18, "end": 26}], "lang": "en"}
{"doc_id": "17965530_2", "wnd_id": "17965530_2_1", "text": "We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol .", "tokens": ["We", "concluded", "that", "the", "colonic", "ulcer", "and", "the", "sigmoidovesical", "fistula", "had", "been", "caused", "by", "the", "administration", "of", "calcium", "polystyrene", "sulfonate", "and", "sorbitol", "."], "event_mentions": [{"id": "17965530_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 12, "end": 13}, "arguments": [{"entity_id": "17965530_2_Ent0", "role": "Effect", "text": "colonic ulcer and the sigmoidovesical fistula", "start": 4, "end": 10}, {"entity_id": "17965530_2_Ent2", "role": "Treatment_Drug", "text": "calcium polystyrene sulfonate", "start": 17, "end": 20}, {"entity_id": "17965530_2_Ent5", "role": "Combination_Drug", "text": "calcium polystyrene sulfonate", "start": 17, "end": 20}, {"entity_id": "17965530_2_Ent1", "role": "Treatment", "text": "calcium polystyrene sulfonate and sorbitol", "start": 17, "end": 22}, {"entity_id": "17965530_2_Ent3", "role": "Treatment_Drug", "text": "sorbitol", "start": 21, "end": 22}, {"entity_id": "17965530_2_Ent4", "role": "Combination_Drug", "text": "sorbitol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "17965530_2_Ent0", "text": "colonic ulcer and the sigmoidovesical fistula", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "17965530_2_Ent2", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17965530_2_Ent5", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17965530_2_Ent1", "text": "calcium polystyrene sulfonate and sorbitol", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "17965530_2_Ent3", "text": "sorbitol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17965530_2_Ent4", "text": "sorbitol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17983451_1", "wnd_id": "17983451_1_1", "text": "Mycobacterium marinum infection complicating Crohn 's disease , treated with infliximab .", "tokens": ["Mycobacterium", "marinum", "infection", "complicating", "Crohn", "'s", "disease", ",", "treated", "with", "infliximab", "."], "event_mentions": [{"id": "17983451_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "17983451_1_Ent1", "role": "Treatment_Disorder", "text": "Mycobacterium marinum infection complicating Crohn 's disease", "start": 0, "end": 7}, {"entity_id": "17983451_1_Ent0", "role": "Treatment", "text": "infliximab", "start": 10, "end": 11}, {"entity_id": "17983451_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17983451_1_Ent1", "text": "Mycobacterium marinum infection complicating Crohn 's disease", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "17983451_1_Ent0", "text": "infliximab", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17983451_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18020545_1", "wnd_id": "18020545_1_1", "text": "Surprisingly , we found that three patients appeared to develop tardive OGC while taking clozapine .", "tokens": ["Surprisingly", ",", "we", "found", "that", "three", "patients", "appeared", "to", "develop", "tardive", "OGC", "while", "taking", "clozapine", "."], "event_mentions": [{"id": "18020545_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "18020545_1_Ent1", "role": "Subject_Population", "text": "three", "start": 5, "end": 6}, {"entity_id": "18020545_1_Ent0", "role": "Subject", "text": "three patients", "start": 5, "end": 7}, {"entity_id": "18020545_1_Ent2", "role": "Effect", "text": "tardive OGC", "start": 10, "end": 12}, {"entity_id": "18020545_1_Ent3", "role": "Treatment", "text": "clozapine", "start": 14, "end": 15}, {"entity_id": "18020545_1_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18020545_1_Ent1", "text": "three", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18020545_1_Ent0", "text": "three patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18020545_1_Ent2", "text": "tardive OGC", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18020545_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18020545_1_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18034202_1", "wnd_id": "18034202_1_1", "text": "We report a case of a patient with rheumatoid arthritis treated with low - dose methotrexate ( 15 mg / week ) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "rheumatoid", "arthritis", "treated", "with", "low", "-", "dose", "methotrexate", "(", "15", "mg", "/", "week", ")", "who", "developed", "infection", "with", "both", "M.", "tuberculosis", "and", "M.", "chelonae", "after", "the", "revision", "of", "a", "prosthetic", "hip", "."], "event_mentions": [{"id": "18034202_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "18034202_1_Ent0", "role": "Subject", "text": "patient with rheumatoid arthritis", "start": 6, "end": 10}, {"entity_id": "18034202_1_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}, {"entity_id": "18034202_1_Ent2", "role": "Treatment", "text": "low - dose methotrexate ( 15 mg / week )", "start": 12, "end": 22}, {"entity_id": "18034202_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 15, "end": 16}, {"entity_id": "18034202_1_Ent3", "role": "Treatment_Dosage", "text": "15 mg / week", "start": 17, "end": 21}, {"entity_id": "18034202_1_Ent1", "role": "Effect", "text": "infection with both M. tuberculosis and M. chelonae", "start": 24, "end": 32}]}], "entity_mentions": [{"id": "18034202_1_Ent0", "text": "patient with rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18034202_1_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18034202_1_Ent2", "text": "low - dose methotrexate ( 15 mg / week )", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "18034202_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18034202_1_Ent3", "text": "15 mg / week", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "18034202_1_Ent1", "text": "infection with both M. tuberculosis and M. chelonae", "entity_type": "Entity", "start": 24, "end": 32}], "lang": "en"}
{"doc_id": "18037876_1", "wnd_id": "18037876_1_1", "text": "DIAGNOSIS : Sustained ventricular tachycardia possibly owing to thalidomide treatment .", "tokens": ["DIAGNOSIS", ":", "Sustained", "ventricular", "tachycardia", "possibly", "owing", "to", "thalidomide", "treatment", "."], "event_mentions": [{"id": "18037876_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "owing to", "start": 6, "end": 8}, "arguments": [{"entity_id": "18037876_1_Ent0", "role": "Effect", "text": "Sustained ventricular tachycardia", "start": 2, "end": 5}, {"entity_id": "18037876_1_Ent1", "role": "Treatment", "text": "thalidomide", "start": 8, "end": 9}, {"entity_id": "18037876_1_Ent2", "role": "Treatment_Drug", "text": "thalidomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18037876_1_Ent0", "text": "Sustained ventricular tachycardia", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "18037876_1_Ent1", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18037876_1_Ent2", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18042092_2", "wnd_id": "18042092_2_1", "text": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate .", "tokens": ["Embolia", "cutis", "medicamentosa", "following", "subcutaneous", "injection", "of", "glatiramer", "acetate", "."], "event_mentions": [{"id": "18042092_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "18042092_2_Ent0", "role": "Effect", "text": "Embolia cutis medicamentosa", "start": 0, "end": 3}, {"entity_id": "18042092_2_Ent3", "role": "Treatment_Route", "text": "subcutaneous injection", "start": 4, "end": 6}, {"entity_id": "18042092_2_Ent1", "role": "Treatment", "text": "subcutaneous injection of glatiramer acetate", "start": 4, "end": 9}, {"entity_id": "18042092_2_Ent2", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "18042092_2_Ent0", "text": "Embolia cutis medicamentosa", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18042092_2_Ent3", "text": "subcutaneous injection", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18042092_2_Ent1", "text": "subcutaneous injection of glatiramer acetate", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18042092_2_Ent2", "text": "glatiramer acetate", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "18067642_1", "wnd_id": "18067642_1_1", "text": "Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case , it is reasonable to presume that this histopathology is associated with amiodarone - induced hypothyroidism and that involution changes represent the hypofunctional status of this drug - induced disorder .", "tokens": ["Although", "it", "is", "difficult", "to", "be", "certain", "of", "the", "direct", "link", "of", "amiodarone", "on", "the", "basis", "of", "a", "single", "case", ",", "it", "is", "reasonable", "to", "presume", "that", "this", "histopathology", "is", "associated", "with", "amiodarone", "-", "induced", "hypothyroidism", "and", "that", "involution", "changes", "represent", "the", "hypofunctional", "status", "of", "this", "drug", "-", "induced", "disorder", "."], "event_mentions": [{"id": "18067642_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 34, "end": 35}, "arguments": [{"entity_id": "18067642_1_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 12, "end": 13}, {"entity_id": "18067642_1_Ent0", "role": "Subject", "text": "a single case", "start": 17, "end": 20}, {"entity_id": "18067642_1_Ent1", "role": "Subject_Population", "text": "single", "start": 18, "end": 19}, {"entity_id": "18067642_1_Ent3", "role": "Treatment", "text": "amiodarone", "start": 32, "end": 33}, {"entity_id": "18067642_1_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 32, "end": 33}, {"entity_id": "18067642_1_Ent2", "role": "Effect", "text": "hypothyroidism", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "18067642_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18067642_1_Ent0", "text": "a single case", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18067642_1_Ent1", "text": "single", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18067642_1_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18067642_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18067642_1_Ent2", "text": "hypothyroidism", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "18079582_3", "wnd_id": "18079582_3_1", "text": "We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion 5 - FU .", "tokens": ["We", "report", "such", "a", "series", "of", "patients", "who", "had", "transient", "asymptomatic", "bradycardia", "after", "being", "treated", "with", "continuous", "infusion", "5", "-", "FU", "."], "event_mentions": [{"id": "18079582_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "18079582_3_Ent1", "role": "Subject_Population", "text": "a series", "start": 3, "end": 5}, {"entity_id": "18079582_3_Ent0", "role": "Subject", "text": "a series of patients", "start": 3, "end": 7}, {"entity_id": "18079582_3_Ent2", "role": "Effect", "text": "transient asymptomatic bradycardia", "start": 9, "end": 12}, {"entity_id": "18079582_3_Ent4", "role": "Treatment_Freq", "text": "continuous", "start": 16, "end": 17}, {"entity_id": "18079582_3_Ent3", "role": "Treatment", "text": "continuous infusion 5 - FU", "start": 16, "end": 21}, {"entity_id": "18079582_3_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 17, "end": 18}, {"entity_id": "18079582_3_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "18079582_3_Ent1", "text": "a series", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18079582_3_Ent0", "text": "a series of patients", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "18079582_3_Ent2", "text": "transient asymptomatic bradycardia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18079582_3_Ent4", "text": "continuous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18079582_3_Ent3", "text": "continuous infusion 5 - FU", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "18079582_3_Ent6", "text": "infusion", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18079582_3_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "18094347_3", "wnd_id": "18094347_3_1", "text": "DISCUSSION : Methotrexate - induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases .", "tokens": ["DISCUSSION", ":", "Methotrexate", "-", "induced", "papular", "eruption", "is", "rarely", "reported", "shortly", "after", "beginning", "methotrexate", "therapy", "in", "patients", "with", "acute", "exacerbation", "of", "collagen", "vascular", "diseases", "."], "event_mentions": [{"id": "18094347_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18094347_3_Ent3", "role": "Treatment", "text": "Methotrexate", "start": 2, "end": 3}, {"entity_id": "18094347_3_Ent4", "role": "Treatment_Drug", "text": "Methotrexate", "start": 2, "end": 3}, {"entity_id": "18094347_3_Ent2", "role": "Effect", "text": "papular eruption", "start": 5, "end": 7}, {"entity_id": "18094347_3_Ent5", "role": "Treatment_Time_elapsed", "text": "shortly after", "start": 10, "end": 12}, {"entity_id": "18094347_3_Ent0", "role": "Subject", "text": "patients with acute exacerbation of collagen vascular diseases", "start": 16, "end": 24}, {"entity_id": "18094347_3_Ent1", "role": "Subject_Disorder", "text": "acute exacerbation of collagen vascular diseases", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "18094347_3_Ent3", "text": "Methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18094347_3_Ent4", "text": "Methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18094347_3_Ent2", "text": "papular eruption", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18094347_3_Ent5", "text": "shortly after", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18094347_3_Ent0", "text": "patients with acute exacerbation of collagen vascular diseases", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "18094347_3_Ent1", "text": "acute exacerbation of collagen vascular diseases", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "18094347_4", "wnd_id": "18094347_4_1", "text": "Methotrexate - induced papular eruption following treatment of psoriasis has not been previously reported .", "tokens": ["Methotrexate", "-", "induced", "papular", "eruption", "following", "treatment", "of", "psoriasis", "has", "not", "been", "previously", "reported", "."], "event_mentions": [{"id": "18094347_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18094347_4_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "18094347_4_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "18094347_4_Ent0", "role": "Effect", "text": "papular eruption", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "18094347_4_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18094347_4_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18094347_4_Ent0", "text": "papular eruption", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "18094347_5", "wnd_id": "18094347_5_1", "text": "Methotrexate - induced papular eruption following treatment of psoriasis .", "tokens": ["Methotrexate", "-", "induced", "papular", "eruption", "following", "treatment", "of", "psoriasis", "."], "event_mentions": [{"id": "18094347_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18094347_5_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "18094347_5_Ent3", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "18094347_5_Ent0", "role": "Effect", "text": "papular eruption", "start": 3, "end": 5}, {"entity_id": "18094347_5_Ent2", "role": "Treatment_Disorder", "text": "psoriasis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18094347_5_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18094347_5_Ent3", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18094347_5_Ent0", "text": "papular eruption", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18094347_5_Ent2", "text": "psoriasis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18094347_6", "wnd_id": "18094347_6_1", "text": "OBJECTIVE : To report a case of a diffuse papular eruption following treatment of psoriasis with methotrexate injections .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "a", "diffuse", "papular", "eruption", "following", "treatment", "of", "psoriasis", "with", "methotrexate", "injections", "."], "event_mentions": [{"id": "18094347_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "18094347_6_Ent0", "role": "Effect", "text": "diffuse papular eruption", "start": 8, "end": 11}, {"entity_id": "18094347_6_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 14, "end": 15}, {"entity_id": "18094347_6_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "18094347_6_Ent1", "role": "Treatment", "text": "methotrexate injections", "start": 16, "end": 18}, {"entity_id": "18094347_6_Ent3", "role": "Treatment_Route", "text": "injections", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "18094347_6_Ent0", "text": "diffuse papular eruption", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18094347_6_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18094347_6_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18094347_6_Ent1", "text": "methotrexate injections", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "18094347_6_Ent3", "text": "injections", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "18094347_8", "wnd_id": "18094347_8_1", "text": "Ten hours after the second methotrexate injection , the patient experienced a diffuse pruritic papular eruption located mainly on the limbs .", "tokens": ["Ten", "hours", "after", "the", "second", "methotrexate", "injection", ",", "the", "patient", "experienced", "a", "diffuse", "pruritic", "papular", "eruption", "located", "mainly", "on", "the", "limbs", "."], "event_mentions": [{"id": "18094347_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 10, "end": 11}, "arguments": [{"entity_id": "18094347_8_Ent5", "role": "Treatment_Time_elapsed", "text": "Ten hours", "start": 0, "end": 2}, {"entity_id": "18094347_8_Ent2", "role": "Treatment", "text": "Ten hours after the second methotrexate injection", "start": 0, "end": 7}, {"entity_id": "18094347_8_Ent6", "role": "Treatment_Time_elapsed", "text": "second", "start": 4, "end": 5}, {"entity_id": "18094347_8_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "18094347_8_Ent4", "role": "Treatment_Route", "text": "injection", "start": 6, "end": 7}, {"entity_id": "18094347_8_Ent0", "role": "Subject", "text": "the patient", "start": 8, "end": 10}, {"entity_id": "18094347_8_Ent1", "role": "Effect", "text": "diffuse pruritic papular eruption located mainly on the limbs", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "18094347_8_Ent5", "text": "Ten hours", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18094347_8_Ent2", "text": "Ten hours after the second methotrexate injection", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18094347_8_Ent6", "text": "second", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18094347_8_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18094347_8_Ent4", "text": "injection", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18094347_8_Ent0", "text": "the patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18094347_8_Ent1", "text": "diffuse pruritic papular eruption located mainly on the limbs", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "18166746_7", "wnd_id": "18166746_7_1", "text": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome .", "tokens": ["An", "interaction", "between", "methylene", "blue", "and", "serotonergic", "agents", "may", "give", "rise", "to", "the", "serotonin", "syndrome", "."], "event_mentions": [{"id": "18166746_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "rise", "start": 10, "end": 11}, "arguments": [{"entity_id": "18166746_7_Ent2", "role": "Treatment_Drug", "text": "methylene blue", "start": 3, "end": 5}, {"entity_id": "18166746_7_Ent5", "role": "Combination_Drug", "text": "methylene blue", "start": 3, "end": 5}, {"entity_id": "18166746_7_Ent1", "role": "Treatment", "text": "methylene blue and serotonergic agents", "start": 3, "end": 8}, {"entity_id": "18166746_7_Ent3", "role": "Treatment_Drug", "text": "serotonergic agents", "start": 6, "end": 8}, {"entity_id": "18166746_7_Ent4", "role": "Combination_Drug", "text": "serotonergic agents", "start": 6, "end": 8}, {"entity_id": "18166746_7_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "18166746_7_Ent2", "text": "methylene blue", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18166746_7_Ent5", "text": "methylene blue", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18166746_7_Ent1", "text": "methylene blue and serotonergic agents", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18166746_7_Ent3", "text": "serotonergic agents", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18166746_7_Ent4", "text": "serotonergic agents", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18166746_7_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "18171260_1", "wnd_id": "18171260_1_1", "text": "Serotonin syndrome after concomitant treatment with linezolid and meperidine .", "tokens": ["Serotonin", "syndrome", "after", "concomitant", "treatment", "with", "linezolid", "and", "meperidine", "."], "event_mentions": [{"id": "18171260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "18171260_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "18171260_1_Ent1", "role": "Treatment", "text": "concomitant treatment with linezolid and meperidine", "start": 3, "end": 9}, {"entity_id": "18171260_1_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "18171260_1_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "18171260_1_Ent3", "role": "Treatment_Drug", "text": "meperidine", "start": 8, "end": 9}, {"entity_id": "18171260_1_Ent5", "role": "Combination_Drug", "text": "meperidine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18171260_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18171260_1_Ent1", "text": "concomitant treatment with linezolid and meperidine", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "18171260_1_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18171260_1_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18171260_1_Ent3", "text": "meperidine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_1_Ent5", "text": "meperidine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18171260_2", "wnd_id": "18171260_2_1", "text": "Serotonin syndrome has been reported with administration of linezolid and serotonin reuptake inhibitors .", "tokens": ["Serotonin", "syndrome", "has", "been", "reported", "with", "administration", "of", "linezolid", "and", "serotonin", "reuptake", "inhibitors", "."], "event_mentions": [{"id": "18171260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported with", "start": 4, "end": 6}, "arguments": [{"entity_id": "18171260_2_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "18171260_2_Ent1", "role": "Treatment", "text": "administration of linezolid and serotonin reuptake inhibitors", "start": 6, "end": 13}, {"entity_id": "18171260_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_2_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_2_Ent3", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitors", "start": 10, "end": 13}, {"entity_id": "18171260_2_Ent5", "role": "Combination_Drug", "text": "serotonin reuptake inhibitors", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "18171260_2_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18171260_2_Ent1", "text": "administration of linezolid and serotonin reuptake inhibitors", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18171260_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_2_Ent3", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18171260_2_Ent5", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "18176653_1", "wnd_id": "18176653_1_1", "text": "Oral adverse effects due to the use of Nevirapine .", "tokens": ["Oral", "adverse", "effects", "due", "to", "the", "use", "of", "Nevirapine", "."], "event_mentions": [{"id": "18176653_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 3, "end": 4}, "arguments": [{"entity_id": "18176653_1_Ent2", "role": "Treatment_Route", "text": "Oral", "start": 0, "end": 1}, {"entity_id": "18176653_1_Ent0", "role": "Effect", "text": "adverse effects", "start": 1, "end": 3}, {"entity_id": "18176653_1_Ent1", "role": "Treatment", "text": "Nevirapine", "start": 8, "end": 9}, {"entity_id": "18176653_1_Ent3", "role": "Treatment_Drug", "text": "Nevirapine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18176653_1_Ent2", "text": "Oral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18176653_1_Ent0", "text": "adverse effects", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "18176653_1_Ent1", "text": "Nevirapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18176653_1_Ent3", "text": "Nevirapine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18176653_11", "wnd_id": "18176653_11_1", "text": "This paper contributed to the identification of possible reactions in the oral cavity due to antiretroviral medication .", "tokens": ["This", "paper", "contributed", "to", "the", "identification", "of", "possible", "reactions", "in", "the", "oral", "cavity", "due", "to", "antiretroviral", "medication", "."], "event_mentions": [{"id": "18176653_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 13, "end": 14}, "arguments": [{"entity_id": "18176653_11_Ent0", "role": "Effect", "text": "reactions in the oral cavity", "start": 8, "end": 13}, {"entity_id": "18176653_11_Ent1", "role": "Treatment", "text": "antiretroviral medication", "start": 15, "end": 17}, {"entity_id": "18176653_11_Ent2", "role": "Treatment_Drug", "text": "antiretroviral medication", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "18176653_11_Ent0", "text": "reactions in the oral cavity", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "18176653_11_Ent1", "text": "antiretroviral medication", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "18176653_11_Ent2", "text": "antiretroviral medication", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18176653_12", "wnd_id": "18176653_12_1", "text": "Although HAART is very important in the treatment of HIV , its side effects are responsible for patients ' non - adherence to medications .", "tokens": ["Although", "HAART", "is", "very", "important", "in", "the", "treatment", "of", "HIV", ",", "its", "side", "effects", "are", "responsible", "for", "patients", "'", "non", "-", "adherence", "to", "medications", "."], "event_mentions": [{"id": "18176653_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 12, "end": 14}, "arguments": [{"entity_id": "18176653_12_Ent2", "role": "Treatment", "text": "HAART", "start": 1, "end": 2}, {"entity_id": "18176653_12_Ent4", "role": "Treatment_Drug", "text": "HAART", "start": 1, "end": 2}, {"entity_id": "18176653_12_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 9, "end": 10}, {"entity_id": "18176653_12_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "18176653_12_Ent1", "role": "Effect", "text": "non - adherence to medications", "start": 19, "end": 24}]}], "entity_mentions": [{"id": "18176653_12_Ent2", "text": "HAART", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18176653_12_Ent4", "text": "HAART", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18176653_12_Ent3", "text": "HIV", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18176653_12_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18176653_12_Ent1", "text": "non - adherence to medications", "entity_type": "Entity", "start": 19, "end": 24}], "lang": "en"}
{"doc_id": "18203308_1", "wnd_id": "18203308_1_1", "text": "New onset of CD may be considered as an immune - mediated injury induced by etanercept .", "tokens": ["New", "onset", "of", "CD", "may", "be", "considered", "as", "an", "immune", "-", "mediated", "injury", "induced", "by", "etanercept", "."], "event_mentions": [{"id": "18203308_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "18203308_1_Ent0", "role": "Effect", "text": "CD", "start": 3, "end": 4}, {"entity_id": "18203308_1_Ent1", "role": "Effect", "text": "immune - mediated injury", "start": 9, "end": 13}, {"entity_id": "18203308_1_Ent2", "role": "Treatment", "text": "etanercept", "start": 15, "end": 16}, {"entity_id": "18203308_1_Ent3", "role": "Treatment_Drug", "text": "etanercept", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18203308_1_Ent0", "text": "CD", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18203308_1_Ent1", "text": "immune - mediated injury", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "18203308_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18203308_1_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18203308_2", "wnd_id": "18203308_2_1", "text": "New onset of Crohn 's disease during treatment of active ankylosing spondylitis with etanercept .", "tokens": ["New", "onset", "of", "Crohn", "'s", "disease", "during", "treatment", "of", "active", "ankylosing", "spondylitis", "with", "etanercept", "."], "event_mentions": [{"id": "18203308_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "18203308_2_Ent0", "role": "Effect", "text": "New onset of Crohn 's disease", "start": 0, "end": 6}, {"entity_id": "18203308_2_Ent3", "role": "Treatment_Disorder", "text": "active ankylosing spondylitis", "start": 9, "end": 12}, {"entity_id": "18203308_2_Ent1", "role": "Treatment", "text": "etanercept", "start": 13, "end": 14}, {"entity_id": "18203308_2_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18203308_2_Ent0", "text": "New onset of Crohn 's disease", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18203308_2_Ent3", "text": "active ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18203308_2_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18203308_2_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18203308_4", "wnd_id": "18203308_4_1", "text": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept .", "tokens": ["We", "describe", "3", "AS", "patients", "treated", "with", "etanercept", "for", "active", "AS", "who", "developed", "new", "onset", "of", "CD", "while", "AS", "related", "symptoms", "responded", "well", "to", "etanercept", "."], "event_mentions": [{"id": "18203308_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "18203308_4_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "18203308_4_Ent0", "role": "Subject", "text": "3 AS patients", "start": 2, "end": 5}, {"entity_id": "18203308_4_Ent5", "role": "Treatment_Disorder", "text": "AS", "start": 3, "end": 4}, {"entity_id": "18203308_4_Ent6", "role": "Treatment_Drug", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "18203308_4_Ent3", "role": "Treatment", "text": "etanercept for active AS", "start": 7, "end": 11}, {"entity_id": "18203308_4_Ent4", "role": "Treatment_Disorder", "text": "active AS", "start": 9, "end": 11}, {"entity_id": "18203308_4_Ent2", "role": "Effect", "text": "CD", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18203308_4_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18203308_4_Ent0", "text": "3 AS patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "18203308_4_Ent5", "text": "AS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18203308_4_Ent6", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18203308_4_Ent3", "text": "etanercept for active AS", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "18203308_4_Ent4", "text": "active AS", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18203308_4_Ent2", "text": "CD", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18258513_1", "wnd_id": "18258513_1_1", "text": "While doxorubicin was administered , the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum .", "tokens": ["While", "doxorubicin", "was", "administered", ",", "the", "patient", "presented", "thoracic", "pain", "and", "breathing", "distress", "due", "to", "superior", "vena", "cava", "perforation", "by", "the", "central", "catheter", "and", "subsequent", "extravasation", "of", "the", "drug", "into", "the", "mediastinum", "."], "event_mentions": [{"id": "18258513_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "18258513_1_Ent2", "role": "Treatment", "text": "doxorubicin", "start": 1, "end": 2}, {"entity_id": "18258513_1_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 1, "end": 2}, {"entity_id": "18258513_1_Ent0", "role": "Subject", "text": "patient", "start": 6, "end": 7}, {"entity_id": "18258513_1_Ent1", "role": "Effect", "text": "thoracic pain and breathing distress", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "18258513_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18258513_1_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18258513_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18258513_1_Ent1", "text": "thoracic pain and breathing distress", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "18262450_14", "wnd_id": "18262450_14_1", "text": "This study provides the first evidence that co - administration of prolonged - release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy .", "tokens": ["This", "study", "provides", "the", "first", "evidence", "that", "co", "-", "administration", "of", "prolonged", "-", "release", "oxycodone", "and", "existing", "gabapentin", "therapy", "has", "a", "clinically", "meaningful", "effect", "in", "painful", "diabetic", "neuropathy", "."], "event_mentions": [{"id": "18262450_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "has", "start": 19, "end": 20}, "arguments": [{"entity_id": "18262450_14_Ent1", "role": "Treatment", "text": "co - administration of prolonged - release oxycodone and existing gabapentin therapy", "start": 7, "end": 19}, {"entity_id": "18262450_14_Ent3", "role": "Treatment_Drug", "text": "oxycodone", "start": 14, "end": 15}, {"entity_id": "18262450_14_Ent5", "role": "Combination_Drug", "text": "oxycodone", "start": 14, "end": 15}, {"entity_id": "18262450_14_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 17, "end": 18}, {"entity_id": "18262450_14_Ent6", "role": "Combination_Drug", "text": "gabapentin", "start": 17, "end": 18}, {"entity_id": "18262450_14_Ent0", "role": "Effect", "text": "clinically meaningful effect", "start": 21, "end": 24}, {"entity_id": "18262450_14_Ent2", "role": "Treatment_Disorder", "text": "painful diabetic neuropathy", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "18262450_14_Ent1", "text": "co - administration of prolonged - release oxycodone and existing gabapentin therapy", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "18262450_14_Ent3", "text": "oxycodone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18262450_14_Ent5", "text": "oxycodone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18262450_14_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18262450_14_Ent6", "text": "gabapentin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18262450_14_Ent0", "text": "clinically meaningful effect", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "18262450_14_Ent2", "text": "painful diabetic neuropathy", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "1827039_2", "wnd_id": "1827039_2_1", "text": "We report 3 patients with severe hepatocellular damage due to CPA therapy , 2 with fatal fulminant hepatitis .", "tokens": ["We", "report", "3", "patients", "with", "severe", "hepatocellular", "damage", "due", "to", "CPA", "therapy", ",", "2", "with", "fatal", "fulminant", "hepatitis", "."], "event_mentions": [{"id": "1827039_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "1827039_2_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "1827039_2_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "1827039_2_Ent2", "role": "Effect", "text": "severe hepatocellular damage", "start": 5, "end": 8}, {"entity_id": "1827039_2_Ent3", "role": "Treatment", "text": "CPA", "start": 10, "end": 11}, {"entity_id": "1827039_2_Ent4", "role": "Treatment_Drug", "text": "CPA", "start": 10, "end": 11}]}, {"id": "1827039_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "1827039_2_Ent8", "role": "Treatment", "text": "CPA", "start": 10, "end": 11}, {"entity_id": "1827039_2_Ent9", "role": "Treatment_Drug", "text": "CPA", "start": 10, "end": 11}, {"entity_id": "1827039_2_Ent5", "role": "Subject", "text": "2", "start": 13, "end": 14}, {"entity_id": "1827039_2_Ent6", "role": "Subject_Population", "text": "2", "start": 13, "end": 14}, {"entity_id": "1827039_2_Ent7", "role": "Effect", "text": "fatal fulminant hepatitis", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "1827039_2_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1827039_2_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1827039_2_Ent2", "text": "severe hepatocellular damage", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1827039_2_Ent3", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent4", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent8", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent9", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent5", "text": "2", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1827039_2_Ent6", "text": "2", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1827039_2_Ent7", "text": "fatal fulminant hepatitis", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "18294121_3", "wnd_id": "18294121_3_1", "text": "Due to the severity of the rash , temozolomide was permanently discontinued .", "tokens": ["Due", "to", "the", "severity", "of", "the", "rash", ",", "temozolomide", "was", "permanently", "discontinued", "."], "event_mentions": [{"id": "18294121_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Due", "start": 0, "end": 1}, "arguments": [{"entity_id": "18294121_3_Ent0", "role": "Effect", "text": "rash", "start": 6, "end": 7}, {"entity_id": "18294121_3_Ent1", "role": "Treatment", "text": "temozolomide", "start": 8, "end": 9}, {"entity_id": "18294121_3_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18294121_3_Ent0", "text": "rash", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18294121_3_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18294121_3_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18294121_5", "wnd_id": "18294121_5_1", "text": "Temozolomide was restarted 2 months later ; the patient again developed a fever .", "tokens": ["Temozolomide", "was", "restarted", "2", "months", "later", ";", "the", "patient", "again", "developed", "a", "fever", "."], "event_mentions": [{"id": "18294121_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "18294121_5_Ent2", "role": "Treatment", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_5_Ent3", "role": "Treatment_Drug", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_5_Ent0", "role": "Subject", "text": "the patient", "start": 7, "end": 9}, {"entity_id": "18294121_5_Ent1", "role": "Effect", "text": "fever", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18294121_5_Ent2", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_5_Ent3", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_5_Ent0", "text": "the patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18294121_5_Ent1", "text": "fever", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1829999_1", "wnd_id": "1829999_1_1", "text": "Exfoliative dermatitis secondary to tobramycin sulfate .", "tokens": ["Exfoliative", "dermatitis", "secondary", "to", "tobramycin", "sulfate", "."], "event_mentions": [{"id": "1829999_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 2, "end": 4}, "arguments": [{"entity_id": "1829999_1_Ent0", "role": "Effect", "text": "Exfoliative dermatitis", "start": 0, "end": 2}, {"entity_id": "1829999_1_Ent2", "role": "Treatment_Drug", "text": "tobramycin sulfate", "start": 4, "end": 6}, {"entity_id": "1829999_1_Ent1", "role": "Treatment", "text": "tobramycin sulfate .", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "1829999_1_Ent0", "text": "Exfoliative dermatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1829999_1_Ent2", "text": "tobramycin sulfate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1829999_1_Ent1", "text": "tobramycin sulfate .", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "18354950_1", "wnd_id": "18354950_1_1", "text": "Hyponatraemia developed after rechallenge with controlled release carbamazepine .", "tokens": ["Hyponatraemia", "developed", "after", "rechallenge", "with", "controlled", "release", "carbamazepine", "."], "event_mentions": [{"id": "18354950_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "18354950_1_Ent0", "role": "Effect", "text": "Hyponatraemia", "start": 0, "end": 1}, {"entity_id": "18354950_1_Ent1", "role": "Treatment", "text": "rechallenge with controlled release carbamazepine", "start": 3, "end": 8}, {"entity_id": "18354950_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18354950_1_Ent0", "text": "Hyponatraemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18354950_1_Ent1", "text": "rechallenge with controlled release carbamazepine", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18354950_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18354950_2", "wnd_id": "18354950_2_1", "text": "Hyponatraemia during low - dose carbamazepine therapy .", "tokens": ["Hyponatraemia", "during", "low", "-", "dose", "carbamazepine", "therapy", "."], "event_mentions": [{"id": "18354950_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "18354950_2_Ent0", "role": "Effect", "text": "Hyponatraemia", "start": 0, "end": 1}, {"entity_id": "18354950_2_Ent1", "role": "Treatment", "text": "low - dose carbamazepine", "start": 2, "end": 6}, {"entity_id": "18354950_2_Ent2", "role": "Treatment_Drug", "text": "low - dose carbamazepine", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "18354950_2_Ent0", "text": "Hyponatraemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18354950_2_Ent1", "text": "low - dose carbamazepine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "18354950_2_Ent2", "text": "low - dose carbamazepine", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "18359591_1", "wnd_id": "18359591_1_1", "text": "In the present paper , we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine .", "tokens": ["In", "the", "present", "paper", ",", "we", "describe", "two", "patients", "with", "active", "UC", "who", "developed", "a", "severe", "systemic", "CMV", "infection", "during", "a", "treatment", "with", "an", "oral", "microemulsion", "form", "of", "cyclosporine", "."], "event_mentions": [{"id": "18359591_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 21, "end": 22}, "arguments": [{"entity_id": "18359591_1_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "18359591_1_Ent0", "role": "Subject", "text": "two patients with active UC", "start": 7, "end": 12}, {"entity_id": "18359591_1_Ent6", "role": "Treatment_Disorder", "text": "active UC", "start": 10, "end": 12}, {"entity_id": "18359591_1_Ent2", "role": "Effect", "text": "severe systemic CMV infection", "start": 15, "end": 19}, {"entity_id": "18359591_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 24, "end": 25}, {"entity_id": "18359591_1_Ent3", "role": "Treatment", "text": "oral microemulsion form of cyclosporine", "start": 24, "end": 29}, {"entity_id": "18359591_1_Ent5", "role": "Treatment_Drug", "text": "cyclosporine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18359591_1_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18359591_1_Ent0", "text": "two patients with active UC", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18359591_1_Ent6", "text": "active UC", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18359591_1_Ent2", "text": "severe systemic CMV infection", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "18359591_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18359591_1_Ent3", "text": "oral microemulsion form of cyclosporine", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "18359591_1_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18362995_2", "wnd_id": "18362995_2_1", "text": "Imatinib mesylate - related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection .", "tokens": ["Imatinib", "mesylate", "-", "related", "fatal", "acute", "hepatic", "failure", "in", "a", "patient", "with", "chronic", "myeloid", "leukaemia", "and", "chronic", "hepatitis", "B", "infection", "."], "event_mentions": [{"id": "18362995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 3, "end": 4}, "arguments": [{"entity_id": "18362995_2_Ent3", "role": "Treatment", "text": "Imatinib mesylate", "start": 0, "end": 2}, {"entity_id": "18362995_2_Ent4", "role": "Treatment_Drug", "text": "Imatinib mesylate", "start": 0, "end": 2}, {"entity_id": "18362995_2_Ent2", "role": "Effect", "text": "fatal acute hepatic failure", "start": 4, "end": 8}, {"entity_id": "18362995_2_Ent0", "role": "Subject", "text": "a patient with chronic myeloid leukaemia and chronic hepatitis B infection", "start": 9, "end": 20}, {"entity_id": "18362995_2_Ent5", "role": "Treatment_Disorder", "text": "chronic myeloid leukaemia", "start": 12, "end": 15}, {"entity_id": "18362995_2_Ent1", "role": "Subject_Disorder", "text": "chronic hepatitis B infection", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "18362995_2_Ent3", "text": "Imatinib mesylate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18362995_2_Ent4", "text": "Imatinib mesylate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18362995_2_Ent2", "text": "fatal acute hepatic failure", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "18362995_2_Ent0", "text": "a patient with chronic myeloid leukaemia and chronic hepatitis B infection", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "18362995_2_Ent5", "text": "chronic myeloid leukaemia", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18362995_2_Ent1", "text": "chronic hepatitis B infection", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "18364401_5", "wnd_id": "18364401_5_1", "text": "There have been numerous case reports of hyperglycemia with olanzapine in the literature , but none reported hyperglycemia within days of initiation of the medication .", "tokens": ["There", "have", "been", "numerous", "case", "reports", "of", "hyperglycemia", "with", "olanzapine", "in", "the", "literature", ",", "but", "none", "reported", "hyperglycemia", "within", "days", "of", "initiation", "of", "the", "medication", "."], "event_mentions": [{"id": "18364401_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "18364401_5_Ent0", "role": "Effect", "text": "hyperglycemia", "start": 7, "end": 8}, {"entity_id": "18364401_5_Ent1", "role": "Treatment", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18364401_5_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18364401_5_Ent3", "role": "Treatment_Time_elapsed", "text": "within days of initiation", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "18364401_5_Ent0", "text": "hyperglycemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18364401_5_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_5_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_5_Ent3", "text": "within days of initiation", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "18371508_1", "wnd_id": "18371508_1_1", "text": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha - 2a and ribavirin .", "tokens": ["Adult", "respiratory", "distress", "syndrome", "after", "treatment", "with", "pegylated", "interferon", "alpha", "-", "2a", "and", "ribavirin", "."], "event_mentions": [{"id": "18371508_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "18371508_1_Ent0", "role": "Effect", "text": "Adult respiratory distress syndrome", "start": 0, "end": 4}, {"entity_id": "18371508_1_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon alpha - 2a", "start": 7, "end": 12}, {"entity_id": "18371508_1_Ent4", "role": "Combination_Drug", "text": "pegylated interferon alpha - 2a", "start": 7, "end": 12}, {"entity_id": "18371508_1_Ent1", "role": "Treatment", "text": "pegylated interferon alpha - 2a and ribavirin", "start": 7, "end": 14}, {"entity_id": "18371508_1_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 13, "end": 14}, {"entity_id": "18371508_1_Ent5", "role": "Combination_Drug", "text": "ribavirin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18371508_1_Ent0", "text": "Adult respiratory distress syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18371508_1_Ent2", "text": "pegylated interferon alpha - 2a", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18371508_1_Ent4", "text": "pegylated interferon alpha - 2a", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18371508_1_Ent1", "text": "pegylated interferon alpha - 2a and ribavirin", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "18371508_1_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18371508_1_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18379937_2", "wnd_id": "18379937_2_1", "text": "PURPOSE : To report a case of bilateral anterior uveitis associated with ovulation induction therapy using clomiphene citrate .", "tokens": ["PURPOSE", ":", "To", "report", "a", "case", "of", "bilateral", "anterior", "uveitis", "associated", "with", "ovulation", "induction", "therapy", "using", "clomiphene", "citrate", "."], "event_mentions": [{"id": "18379937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "18379937_2_Ent0", "role": "Subject", "text": "case", "start": 5, "end": 6}, {"entity_id": "18379937_2_Ent1", "role": "Effect", "text": "bilateral anterior uveitis", "start": 7, "end": 10}, {"entity_id": "18379937_2_Ent2", "role": "Treatment", "text": "ovulation induction therapy using clomiphene citrate", "start": 12, "end": 18}, {"entity_id": "18379937_2_Ent3", "role": "Treatment_Drug", "text": "clomiphene citrate", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "18379937_2_Ent0", "text": "case", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18379937_2_Ent1", "text": "bilateral anterior uveitis", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18379937_2_Ent2", "text": "ovulation induction therapy using clomiphene citrate", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "18379937_2_Ent3", "text": "clomiphene citrate", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "18396749_3", "wnd_id": "18396749_3_1", "text": "The case of a patient under tibolone therapy for two years who developed a mixed - type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome following a ten weeks treatment with St. John wort ( Hypericum Perforatum ) infusions is reported .", "tokens": ["The", "case", "of", "a", "patient", "under", "tibolone", "therapy", "for", "two", "years", "who", "developed", "a", "mixed", "-", "type", "liver", "injury", "with", "prolonged", "cholestasis", "and", "features", "of", "the", "vanishing", "bile", "duct", "syndrome", "following", "a", "ten", "weeks", "treatment", "with", "St.", "John", "wort", "(", "Hypericum", "Perforatum", ")", "infusions", "is", "reported", "."], "event_mentions": [{"id": "18396749_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "18396749_3_Ent0", "role": "Subject", "text": "a patient under tibolone therapy", "start": 3, "end": 8}, {"entity_id": "18396749_3_Ent2", "role": "Treatment", "text": "under tibolone therapy", "start": 5, "end": 8}, {"entity_id": "18396749_3_Ent5", "role": "Treatment_Drug", "text": "tibolone", "start": 6, "end": 7}, {"entity_id": "18396749_3_Ent8", "role": "Combination_Drug", "text": "tibolone", "start": 6, "end": 7}, {"entity_id": "18396749_3_Ent1", "role": "Effect", "text": "a mixed - type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome", "start": 13, "end": 30}, {"entity_id": "18396749_3_Ent3", "role": "Treatment", "text": "a ten weeks treatment with St. John wort ( Hypericum Perforatum ) infusions", "start": 31, "end": 44}, {"entity_id": "18396749_3_Ent7", "role": "Treatment_Duration", "text": "ten weeks", "start": 32, "end": 34}, {"entity_id": "18396749_3_Ent4", "role": "Treatment_Drug", "text": "Hypericum Perforatum", "start": 40, "end": 42}, {"entity_id": "18396749_3_Ent9", "role": "Combination_Drug", "text": "Hypericum Perforatum", "start": 40, "end": 42}, {"entity_id": "18396749_3_Ent6", "role": "Treatment_Route", "text": "infusions", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "18396749_3_Ent0", "text": "a patient under tibolone therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18396749_3_Ent2", "text": "under tibolone therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18396749_3_Ent5", "text": "tibolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18396749_3_Ent8", "text": "tibolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18396749_3_Ent1", "text": "a mixed - type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome", "entity_type": "Entity", "start": 13, "end": 30}, {"id": "18396749_3_Ent3", "text": "a ten weeks treatment with St. John wort ( Hypericum Perforatum ) infusions", "entity_type": "Entity", "start": 31, "end": 44}, {"id": "18396749_3_Ent7", "text": "ten weeks", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18396749_3_Ent4", "text": "Hypericum Perforatum", "entity_type": "Entity", "start": 40, "end": 42}, {"id": "18396749_3_Ent9", "text": "Hypericum Perforatum", "entity_type": "Entity", "start": 40, "end": 42}, {"id": "18396749_3_Ent6", "text": "infusions", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "18408649_2", "wnd_id": "18408649_2_1", "text": "There are , however , case studies describing patients experiencing recurrences of tics following treatment with atomoxetine .", "tokens": ["There", "are", ",", "however", ",", "case", "studies", "describing", "patients", "experiencing", "recurrences", "of", "tics", "following", "treatment", "with", "atomoxetine", "."], "event_mentions": [{"id": "18408649_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "18408649_2_Ent0", "role": "Effect", "text": "recurrences of tics", "start": 10, "end": 13}, {"entity_id": "18408649_2_Ent1", "role": "Treatment", "text": "treatment with atomoxetine", "start": 14, "end": 17}, {"entity_id": "18408649_2_Ent2", "role": "Treatment_Drug", "text": "atomoxetine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18408649_2_Ent0", "text": "recurrences of tics", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18408649_2_Ent1", "text": "treatment with atomoxetine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "18408649_2_Ent2", "text": "atomoxetine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18453852_4", "wnd_id": "18453852_4_1", "text": "A total of 40 healthy volunteers were planned to start with 600 mg rifampicin once daily from days 1 - 5 .", "tokens": ["A", "total", "of", "40", "healthy", "volunteers", "were", "planned", "to", "start", "with", "600", "mg", "rifampicin", "once", "daily", "from", "days", "1", "-", "5", "."], "event_mentions": [{"id": "18453852_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "start", "start": 9, "end": 10}, "arguments": [{"entity_id": "18453852_4_Ent1", "role": "Subject_Population", "text": "40", "start": 3, "end": 4}, {"entity_id": "18453852_4_Ent0", "role": "Subject", "text": "40 healthy volunteers", "start": 3, "end": 6}, {"entity_id": "18453852_4_Ent3", "role": "Treatment_Dosage", "text": "600 mg", "start": 11, "end": 13}, {"entity_id": "18453852_4_Ent2", "role": "Treatment", "text": "600 mg rifampicin once daily from days 1 - 5", "start": 11, "end": 21}, {"entity_id": "18453852_4_Ent4", "role": "Treatment_Drug", "text": "rifampicin", "start": 13, "end": 14}, {"entity_id": "18453852_4_Ent5", "role": "Treatment_Freq", "text": "once daily", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "18453852_4_Ent1", "text": "40", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_4_Ent0", "text": "40 healthy volunteers", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_4_Ent3", "text": "600 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18453852_4_Ent2", "text": "600 mg rifampicin once daily from days 1 - 5", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "18453852_4_Ent4", "text": "rifampicin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18453852_4_Ent5", "text": "once daily", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "18476934_3", "wnd_id": "18476934_3_1", "text": "We report a 4 - year - old girl who presented with acute bilateral blindness , a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis .", "tokens": ["We", "report", "a", "4", "-", "year", "-", "old", "girl", "who", "presented", "with", "acute", "bilateral", "blindness", ",", "a", "focal", "seizure", "and", "hypertension", "10", "days", "after", "commencing", "oxybutynin", "to", "treat", "enuresis", "."], "event_mentions": [{"id": "18476934_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "18476934_3_Ent0", "role": "Subject", "text": "a 4 - year - old girl", "start": 2, "end": 9}, {"entity_id": "18476934_3_Ent1", "role": "Subject_Age", "text": "4 - year - old", "start": 3, "end": 8}, {"entity_id": "18476934_3_Ent2", "role": "Subject_Gender", "text": "girl", "start": 8, "end": 9}, {"entity_id": "18476934_3_Ent3", "role": "Effect", "text": "acute bilateral blindness , a focal seizure and hypertension", "start": 12, "end": 21}, {"entity_id": "18476934_3_Ent5", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 21, "end": 23}, {"entity_id": "18476934_3_Ent4", "role": "Treatment", "text": "oxybutynin", "start": 25, "end": 26}, {"entity_id": "18476934_3_Ent6", "role": "Treatment_Drug", "text": "oxybutynin", "start": 25, "end": 26}, {"entity_id": "18476934_3_Ent7", "role": "Treatment_Disorder", "text": "enuresis", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18476934_3_Ent0", "text": "a 4 - year - old girl", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "18476934_3_Ent1", "text": "4 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18476934_3_Ent2", "text": "girl", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18476934_3_Ent3", "text": "acute bilateral blindness , a focal seizure and hypertension", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "18476934_3_Ent5", "text": "10 days", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "18476934_3_Ent4", "text": "oxybutynin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18476934_3_Ent6", "text": "oxybutynin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18476934_3_Ent7", "text": "enuresis", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18487000_3", "wnd_id": "18487000_3_1", "text": "We describe a case of life - threatening hyponatremia associated with sibutramine use in an obese woman .", "tokens": ["We", "describe", "a", "case", "of", "life", "-", "threatening", "hyponatremia", "associated", "with", "sibutramine", "use", "in", "an", "obese", "woman", "."], "event_mentions": [{"id": "18487000_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "18487000_3_Ent1", "role": "Effect", "text": "hyponatremia", "start": 8, "end": 9}, {"entity_id": "18487000_3_Ent2", "role": "Treatment", "text": "sibutramine", "start": 11, "end": 12}, {"entity_id": "18487000_3_Ent3", "role": "Treatment_Drug", "text": "sibutramine", "start": 11, "end": 12}, {"entity_id": "18487000_3_Ent4", "role": "Treatment_Disorder", "text": "obese", "start": 15, "end": 16}, {"entity_id": "18487000_3_Ent0", "role": "Subject", "text": "obese woman", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "18487000_3_Ent1", "text": "hyponatremia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18487000_3_Ent2", "text": "sibutramine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18487000_3_Ent3", "text": "sibutramine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18487000_3_Ent4", "text": "obese", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18487000_3_Ent0", "text": "obese woman", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18492617_1", "wnd_id": "18492617_1_1", "text": "Our findings reveal that even in patients without a history of seizures , pregabalin can cause a cortical negative myoclonus .", "tokens": ["Our", "findings", "reveal", "that", "even", "in", "patients", "without", "a", "history", "of", "seizures", ",", "pregabalin", "can", "cause", "a", "cortical", "negative", "myoclonus", "."], "event_mentions": [{"id": "18492617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "18492617_1_Ent0", "role": "Subject", "text": "patients without a history of seizures", "start": 6, "end": 12}, {"entity_id": "18492617_1_Ent2", "role": "Treatment", "text": "pregabalin", "start": 13, "end": 14}, {"entity_id": "18492617_1_Ent3", "role": "Treatment_Drug", "text": "pregabalin", "start": 13, "end": 14}, {"entity_id": "18492617_1_Ent1", "role": "Effect", "text": "cortical negative myoclonus", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "18492617_1_Ent0", "text": "patients without a history of seizures", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "18492617_1_Ent2", "text": "pregabalin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18492617_1_Ent3", "text": "pregabalin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18492617_1_Ent1", "text": "cortical negative myoclonus", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "18504683_3", "wnd_id": "18504683_3_1", "text": "We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L - asparaginase therapy .", "tokens": ["We", "report", "3", "cases", "of", "children", "with", "acute", "lymphoblastic", "leukemia", "who", "developed", "seizures", "and", "altered", "sensorium", "after", "L", "-", "asparaginase", "therapy", "."], "event_mentions": [{"id": "18504683_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "18504683_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "18504683_3_Ent0", "role": "Subject", "text": "3 cases of children with acute lymphoblastic leukemia", "start": 2, "end": 10}, {"entity_id": "18504683_3_Ent2", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "18504683_3_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 7, "end": 10}, {"entity_id": "18504683_3_Ent3", "role": "Effect", "text": "seizures and altered sensorium", "start": 12, "end": 16}, {"entity_id": "18504683_3_Ent4", "role": "Treatment", "text": "L - asparaginase", "start": 17, "end": 20}, {"entity_id": "18504683_3_Ent6", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "18504683_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18504683_3_Ent0", "text": "3 cases of children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "18504683_3_Ent2", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18504683_3_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18504683_3_Ent3", "text": "seizures and altered sensorium", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "18504683_3_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18504683_3_Ent6", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "18505911_13", "wnd_id": "18505911_13_1", "text": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance .", "tokens": ["This", "case", "report", "and", "several", "others", "point", "toward", "azathioprine", "as", "a", "clinically", "significant", "inducer", "of", "warfarin", "resistance", "."], "event_mentions": [{"id": "18505911_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducer", "start": 13, "end": 14}, "arguments": [{"entity_id": "18505911_13_Ent1", "role": "Treatment", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent3", "role": "Treatment_Drug", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 15, "end": 16}, {"entity_id": "18505911_13_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "18505911_13_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent3", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18505911_13_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18523232_1", "wnd_id": "18523232_1_1", "text": "CASE SUMMARY : A 61 - year - old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk ) for onychomycosis .", "tokens": ["CASE", "SUMMARY", ":", "A", "61", "-", "year", "-", "old", "woman", "with", "no", "apparent", "risk", "factors", "for", "liver", "injury", "developed", "acute", "hepatitis", "one", "week", "after", "the", "final", "dose", "of", "a", "long", "-", "term", "course", "of", "pulse", "itraconazole", "therapy", "(", "200", "mg", "orally", "twice", "daily", ",", "1", "wk", "on", ",", "3", "wk", "off", ",", "for", "24", "wk", ")", "for", "onychomycosis", "."], "event_mentions": [{"id": "18523232_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "18523232_1_Ent0", "role": "Subject", "text": "A 61 - year - old woman with no apparent risk factors for liver injury", "start": 3, "end": 18}, {"entity_id": "18523232_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 4, "end": 9}, {"entity_id": "18523232_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "18523232_1_Ent3", "role": "Effect", "text": "acute hepatitis", "start": 19, "end": 21}, {"entity_id": "18523232_1_Ent4", "role": "Treatment", "text": "long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk )", "start": 29, "end": 56}, {"entity_id": "18523232_1_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 35, "end": 36}, {"entity_id": "18523232_1_Ent7", "role": "Treatment_Dosage", "text": "200 mg", "start": 38, "end": 40}, {"entity_id": "18523232_1_Ent8", "role": "Treatment_Route", "text": "orally", "start": 40, "end": 41}, {"entity_id": "18523232_1_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 41, "end": 43}, {"entity_id": "18523232_1_Ent5", "role": "Treatment_Disorder", "text": "onychomycosis", "start": 57, "end": 58}]}], "entity_mentions": [{"id": "18523232_1_Ent0", "text": "A 61 - year - old woman with no apparent risk factors for liver injury", "entity_type": "Entity", "start": 3, "end": 18}, {"id": "18523232_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18523232_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18523232_1_Ent3", "text": "acute hepatitis", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "18523232_1_Ent4", "text": "long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk )", "entity_type": "Entity", "start": 29, "end": 56}, {"id": "18523232_1_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "18523232_1_Ent7", "text": "200 mg", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "18523232_1_Ent8", "text": "orally", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "18523232_1_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 41, "end": 43}, {"id": "18523232_1_Ent5", "text": "onychomycosis", "entity_type": "Entity", "start": 57, "end": 58}], "lang": "en"}
{"doc_id": "18523232_2", "wnd_id": "18523232_2_1", "text": "CONCLUSIONS : Prolonged exposure to itraconazole , administered either continuously or intermittently , may precipitate severe and irreversible hepatotoxic events .", "tokens": ["CONCLUSIONS", ":", "Prolonged", "exposure", "to", "itraconazole", ",", "administered", "either", "continuously", "or", "intermittently", ",", "may", "precipitate", "severe", "and", "irreversible", "hepatotoxic", "events", "."], "event_mentions": [{"id": "18523232_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 14, "end": 15}, "arguments": [{"entity_id": "18523232_2_Ent3", "role": "Treatment_Dosage", "text": "Prolonged exposure", "start": 2, "end": 4}, {"entity_id": "18523232_2_Ent1", "role": "Treatment", "text": "Prolonged exposure to itraconazole , administered either continuously or intermittently", "start": 2, "end": 12}, {"entity_id": "18523232_2_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 5, "end": 6}, {"entity_id": "18523232_2_Ent4", "role": "Treatment_Route", "text": "continuously or intermittently", "start": 9, "end": 12}, {"entity_id": "18523232_2_Ent0", "role": "Effect", "text": "severe and irreversible hepatotoxic events", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "18523232_2_Ent3", "text": "Prolonged exposure", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18523232_2_Ent1", "text": "Prolonged exposure to itraconazole , administered either continuously or intermittently", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "18523232_2_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18523232_2_Ent4", "text": "continuously or intermittently", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18523232_2_Ent0", "text": "severe and irreversible hepatotoxic events", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "18533420_1", "wnd_id": "18533420_1_1", "text": "CONCLUSIONS : Intrathecal baclofen can impair sexual function and ejaculation in some patients .", "tokens": ["CONCLUSIONS", ":", "Intrathecal", "baclofen", "can", "impair", "sexual", "function", "and", "ejaculation", "in", "some", "patients", "."], "event_mentions": [{"id": "18533420_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "impair", "start": 5, "end": 6}, "arguments": [{"entity_id": "18533420_1_Ent3", "role": "Treatment_Route", "text": "Intrathecal", "start": 2, "end": 3}, {"entity_id": "18533420_1_Ent2", "role": "Treatment", "text": "Intrathecal baclofen", "start": 2, "end": 4}, {"entity_id": "18533420_1_Ent4", "role": "Treatment_Drug", "text": "baclofen", "start": 3, "end": 4}, {"entity_id": "18533420_1_Ent1", "role": "Effect", "text": "impair sexual function and ejaculation", "start": 5, "end": 10}, {"entity_id": "18533420_1_Ent0", "role": "Subject", "text": "some patients", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "18533420_1_Ent3", "text": "Intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18533420_1_Ent2", "text": "Intrathecal baclofen", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18533420_1_Ent4", "text": "baclofen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18533420_1_Ent1", "text": "impair sexual function and ejaculation", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18533420_1_Ent0", "text": "some patients", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18556970_1", "wnd_id": "18556970_1_1", "text": "Anaphylactic reaction to recombinant insulin - like growth factor - I.", "tokens": ["Anaphylactic", "reaction", "to", "recombinant", "insulin", "-", "like", "growth", "factor", "-", "I."], "event_mentions": [{"id": "18556970_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "18556970_1_Ent0", "role": "Effect", "text": "Anaphylactic reaction", "start": 0, "end": 2}, {"entity_id": "18556970_1_Ent1", "role": "Treatment", "text": "recombinant insulin - like growth factor - I.", "start": 3, "end": 11}, {"entity_id": "18556970_1_Ent2", "role": "Treatment_Drug", "text": "recombinant insulin - like growth factor - I.", "start": 3, "end": 11}]}], "entity_mentions": [{"id": "18556970_1_Ent0", "text": "Anaphylactic reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18556970_1_Ent1", "text": "recombinant insulin - like growth factor - I.", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "18556970_1_Ent2", "text": "recombinant insulin - like growth factor - I.", "entity_type": "Entity", "start": 3, "end": 11}], "lang": "en"}
{"doc_id": "18562412_3", "wnd_id": "18562412_3_1", "text": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation .", "tokens": ["The", "fifth", "patient", "exhibited", "paraesthesia", "and", "agitation", "caused", "by", "olanzapine", "that", "was", "misdiagnosed", "as", "psychotic", "agitation", "."], "event_mentions": [{"id": "18562412_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "18562412_3_Ent0", "role": "Subject", "text": "The fifth patient", "start": 0, "end": 3}, {"entity_id": "18562412_3_Ent1", "role": "Effect", "text": "paraesthesia and agitation", "start": 4, "end": 7}, {"entity_id": "18562412_3_Ent2", "role": "Treatment", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18562412_3_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "18562412_3_Ent0", "text": "The fifth patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_3_Ent1", "text": "paraesthesia and agitation", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "18562412_3_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18562412_3_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "18607107_2", "wnd_id": "18607107_2_1", "text": "Development of Crohn 's disease in a patient with multiple sclerosis treated with copaxone .", "tokens": ["Development", "of", "Crohn", "'s", "disease", "in", "a", "patient", "with", "multiple", "sclerosis", "treated", "with", "copaxone", "."], "event_mentions": [{"id": "18607107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "18607107_2_Ent1", "role": "Effect", "text": "Crohn 's disease", "start": 2, "end": 5}, {"entity_id": "18607107_2_Ent0", "role": "Subject", "text": "a patient with multiple sclerosis", "start": 6, "end": 11}, {"entity_id": "18607107_2_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 9, "end": 11}, {"entity_id": "18607107_2_Ent2", "role": "Treatment", "text": "copaxone", "start": 13, "end": 14}, {"entity_id": "18607107_2_Ent4", "role": "Treatment_Drug", "text": "copaxone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18607107_2_Ent1", "text": "Crohn 's disease", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "18607107_2_Ent0", "text": "a patient with multiple sclerosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18607107_2_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18607107_2_Ent2", "text": "copaxone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18607107_2_Ent4", "text": "copaxone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18607107_4", "wnd_id": "18607107_4_1", "text": "She had been on Copaxone 20 mg / day treatment for 2 years when she first exhibited gastrointestinal symptoms .", "tokens": ["She", "had", "been", "on", "Copaxone", "20", "mg", "/", "day", "treatment", "for", "2", "years", "when", "she", "first", "exhibited", "gastrointestinal", "symptoms", "."], "event_mentions": [{"id": "18607107_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 16, "end": 17}, "arguments": [{"entity_id": "18607107_4_Ent4", "role": "Treatment_Drug", "text": "Copaxone", "start": 4, "end": 5}, {"entity_id": "18607107_4_Ent3", "role": "Treatment", "text": "Copaxone 20 mg / day treatment for 2 years", "start": 4, "end": 13}, {"entity_id": "18607107_4_Ent5", "role": "Treatment_Dosage", "text": "20 mg / day", "start": 5, "end": 9}, {"entity_id": "18607107_4_Ent6", "role": "Treatment_Duration", "text": "2 years", "start": 11, "end": 13}, {"entity_id": "18607107_4_Ent0", "role": "Subject", "text": "she", "start": 14, "end": 15}, {"entity_id": "18607107_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 14, "end": 15}, {"entity_id": "18607107_4_Ent2", "role": "Effect", "text": "gastrointestinal symptoms", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18607107_4_Ent4", "text": "Copaxone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18607107_4_Ent3", "text": "Copaxone 20 mg / day treatment for 2 years", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "18607107_4_Ent5", "text": "20 mg / day", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "18607107_4_Ent6", "text": "2 years", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18607107_4_Ent0", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18607107_4_Ent1", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18607107_4_Ent2", "text": "gastrointestinal symptoms", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18609153_1", "wnd_id": "18609153_1_1", "text": "Terlipressin - induced ventricular arrhythmia .", "tokens": ["Terlipressin", "-", "induced", "ventricular", "arrhythmia", "."], "event_mentions": [{"id": "18609153_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18609153_1_Ent1", "role": "Treatment", "text": "Terlipressin", "start": 0, "end": 1}, {"entity_id": "18609153_1_Ent2", "role": "Treatment_Drug", "text": "Terlipressin", "start": 0, "end": 1}, {"entity_id": "18609153_1_Ent0", "role": "Effect", "text": "ventricular arrhythmia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "18609153_1_Ent1", "text": "Terlipressin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18609153_1_Ent2", "text": "Terlipressin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18609153_1_Ent0", "text": "ventricular arrhythmia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "18633310_2", "wnd_id": "18633310_2_1", "text": "The patient experienced hallucinations , agitation , vomiting , tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion .", "tokens": ["The", "patient", "experienced", "hallucinations", ",", "agitation", ",", "vomiting", ",", "tachycardia", "and", "seizures", "after", "ingestion", "of", "1050", "(", "48", "mg", "/", "kg", ")", "of", "extended", "-", "release", "bupropion", "."], "event_mentions": [{"id": "18633310_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18633310_2_Ent0", "role": "Effect", "text": "hallucinations , agitation , vomiting , tachycardia and seizures", "start": 3, "end": 12}, {"entity_id": "18633310_2_Ent2", "role": "Treatment_Route", "text": "ingestion", "start": 13, "end": 14}, {"entity_id": "18633310_2_Ent1", "role": "Treatment", "text": "ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion", "start": 13, "end": 27}, {"entity_id": "18633310_2_Ent3", "role": "Treatment_Dosage", "text": "1050 ( 48 mg / kg )", "start": 15, "end": 22}, {"entity_id": "18633310_2_Ent4", "role": "Treatment_Drug", "text": "bupropion", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18633310_2_Ent0", "text": "hallucinations , agitation , vomiting , tachycardia and seizures", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "18633310_2_Ent2", "text": "ingestion", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18633310_2_Ent1", "text": "ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "18633310_2_Ent3", "text": "1050 ( 48 mg / kg )", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "18633310_2_Ent4", "text": "bupropion", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18665833_1", "wnd_id": "18665833_1_1", "text": "Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency .", "tokens": ["Stuttering", "priapism", "complicating", "warfarin", "therapy", "in", "a", "patient", "with", "protein", "C", "deficiency", "."], "event_mentions": [{"id": "18665833_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "18665833_1_Ent1", "role": "Effect", "text": "Stuttering priapism", "start": 0, "end": 2}, {"entity_id": "18665833_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent0", "role": "Subject", "text": "a patient with protein C deficiency", "start": 6, "end": 12}, {"entity_id": "18665833_1_Ent3", "role": "Treatment_Disorder", "text": "protein C deficiency", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "18665833_1_Ent1", "text": "Stuttering priapism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18665833_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent0", "text": "a patient with protein C deficiency", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "18665833_1_Ent3", "text": "protein C deficiency", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "18665833_2", "wnd_id": "18665833_2_1", "text": "This therapy was also complicated by Warfarin - induced skin necrosis .", "tokens": ["This", "therapy", "was", "also", "complicated", "by", "Warfarin", "-", "induced", "skin", "necrosis", "."], "event_mentions": [{"id": "18665833_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "18665833_2_Ent1", "role": "Treatment", "text": "Warfarin", "start": 6, "end": 7}, {"entity_id": "18665833_2_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 6, "end": 7}, {"entity_id": "18665833_2_Ent0", "role": "Effect", "text": "skin necrosis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "18665833_2_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18665833_2_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18665833_2_Ent0", "text": "skin necrosis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "18675768_13", "wnd_id": "18675768_13_1", "text": "This is the first report of a possible interaction between propafenone and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "possible", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "propafenone", "adverse", "effects", "(", "eg", ",", "dizziness", ",", "falls", ")", "and", "mimicked", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "18675768_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "18675768_13_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent6", "role": "Combination_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent1", "role": "Treatment", "text": "propafenone and citalopram", "start": 10, "end": 13}, {"entity_id": "18675768_13_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent7", "role": "Combination_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent2", "role": "Treatment", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent0", "role": "Effect", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "start": 16, "end": 31}]}], "entity_mentions": [{"id": "18675768_13_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent6", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent1", "text": "propafenone and citalopram", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18675768_13_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent7", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent0", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "entity_type": "Entity", "start": 16, "end": 31}], "lang": "en"}
{"doc_id": "18691992_1", "wnd_id": "18691992_1_1", "text": "BACKGROUND : Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation .", "tokens": ["BACKGROUND", ":", "Hydroxyurea", "is", "a", "cytostatic", "agent", "used", "to", "treat", "myeloproliferative", "disorders", "and", "long", "-", "term", "treatment", "is", "associated", "with", "mucocutaneous", "adverse", "events", "and", "nail", "hyperpigmentation", "."], "event_mentions": [{"id": "18691992_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "18691992_1_Ent2", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 2, "end": 3}, {"entity_id": "18691992_1_Ent1", "role": "Treatment", "text": "Hydroxyurea is a cytostatic agent", "start": 2, "end": 7}, {"entity_id": "18691992_1_Ent3", "role": "Treatment_Disorder", "text": "myeloproliferative disorders", "start": 10, "end": 12}, {"entity_id": "18691992_1_Ent0", "role": "Effect", "text": "mucocutaneous adverse events and nail hyperpigmentation", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "18691992_1_Ent2", "text": "Hydroxyurea", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18691992_1_Ent1", "text": "Hydroxyurea is a cytostatic agent", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18691992_1_Ent3", "text": "myeloproliferative disorders", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18691992_1_Ent0", "text": "mucocutaneous adverse events and nail hyperpigmentation", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "18691992_5", "wnd_id": "18691992_5_1", "text": "Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject .", "tokens": ["Hydroxyurea", "associated", "with", "concomitant", "occurrence", "of", "diffuse", "longitudinal", "melanonychia", "and", "multiple", "squamous", "cell", "carcinomas", "in", "an", "elderly", "subject", "."], "event_mentions": [{"id": "18691992_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "18691992_5_Ent3", "role": "Treatment", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "18691992_5_Ent4", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "18691992_5_Ent2", "role": "Effect", "text": "concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas", "start": 3, "end": 14}, {"entity_id": "18691992_5_Ent0", "role": "Subject", "text": "an elderly subject", "start": 15, "end": 18}, {"entity_id": "18691992_5_Ent1", "role": "Subject_Age", "text": "elderly", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18691992_5_Ent3", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18691992_5_Ent4", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18691992_5_Ent2", "text": "concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "18691992_5_Ent0", "text": "an elderly subject", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "18691992_5_Ent1", "text": "elderly", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18698687_2", "wnd_id": "18698687_2_1", "text": "Vanishing bile duct and Stevens - Johnson syndrome associated with ciprofloxacin treated with tacrolimus .", "tokens": ["Vanishing", "bile", "duct", "and", "Stevens", "-", "Johnson", "syndrome", "associated", "with", "ciprofloxacin", "treated", "with", "tacrolimus", "."], "event_mentions": [{"id": "18698687_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "18698687_2_Ent0", "role": "Effect", "text": "Vanishing bile duct and Stevens - Johnson syndrome", "start": 0, "end": 8}, {"entity_id": "18698687_2_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 10, "end": 11}, {"entity_id": "18698687_2_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18698687_2_Ent0", "text": "Vanishing bile duct and Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18698687_2_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18698687_2_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18707772_1", "wnd_id": "18707772_1_1", "text": "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel .", "tokens": ["A", "64", "year", "old", "woman", "with", "previous", "history", "of", "coronary", "stenting", "five", "days", "before", "was", "admitted", "in", "our", "institution", "for", "intracranial", "bleeding", "while", "receiving", "aspirin", "and", "clopidogrel", "."], "event_mentions": [{"id": "18707772_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 23, "end": 24}, "arguments": [{"entity_id": "18707772_1_Ent0", "role": "Subject", "text": "A 64 year old woman with previous history of coronary stenting", "start": 0, "end": 11}, {"entity_id": "18707772_1_Ent1", "role": "Subject_Age", "text": "64 year old", "start": 1, "end": 4}, {"entity_id": "18707772_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "18707772_1_Ent8", "role": "Treatment_Disorder", "text": "coronary stenting", "start": 9, "end": 11}, {"entity_id": "18707772_1_Ent9", "role": "Treatment_Time_elapsed", "text": "five days", "start": 11, "end": 13}, {"entity_id": "18707772_1_Ent4", "role": "Treatment", "text": "five days before", "start": 11, "end": 14}, {"entity_id": "18707772_1_Ent3", "role": "Effect", "text": "intracranial bleeding", "start": 20, "end": 22}, {"entity_id": "18707772_1_Ent7", "role": "Treatment_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent10", "role": "Combination_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent5", "role": "Treatment", "text": "aspirin and clopidogrel", "start": 24, "end": 27}, {"entity_id": "18707772_1_Ent6", "role": "Treatment_Drug", "text": "clopidogrel", "start": 26, "end": 27}, {"entity_id": "18707772_1_Ent11", "role": "Combination_Drug", "text": "clopidogrel", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18707772_1_Ent0", "text": "A 64 year old woman with previous history of coronary stenting", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "18707772_1_Ent1", "text": "64 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "18707772_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18707772_1_Ent8", "text": "coronary stenting", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18707772_1_Ent9", "text": "five days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18707772_1_Ent4", "text": "five days before", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18707772_1_Ent3", "text": "intracranial bleeding", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "18707772_1_Ent7", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent10", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent5", "text": "aspirin and clopidogrel", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "18707772_1_Ent6", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18707772_1_Ent11", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18755414_1", "wnd_id": "18755414_1_1", "text": "Hemorrhage from a falx meningioma after internal use of low - dose aspirin .", "tokens": ["Hemorrhage", "from", "a", "falx", "meningioma", "after", "internal", "use", "of", "low", "-", "dose", "aspirin", "."], "event_mentions": [{"id": "18755414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "18755414_1_Ent0", "role": "Effect", "text": "Hemorrhage from a falx meningioma", "start": 0, "end": 5}, {"entity_id": "18755414_1_Ent5", "role": "Treatment_Disorder", "text": "falx meningioma", "start": 3, "end": 5}, {"entity_id": "18755414_1_Ent4", "role": "Treatment_Route", "text": "internal", "start": 6, "end": 7}, {"entity_id": "18755414_1_Ent1", "role": "Treatment", "text": "internal use of low - dose aspirin", "start": 6, "end": 13}, {"entity_id": "18755414_1_Ent3", "role": "Treatment_Dosage", "text": "low - dose", "start": 9, "end": 12}, {"entity_id": "18755414_1_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18755414_1_Ent0", "text": "Hemorrhage from a falx meningioma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18755414_1_Ent5", "text": "falx meningioma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18755414_1_Ent4", "text": "internal", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18755414_1_Ent1", "text": "internal use of low - dose aspirin", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18755414_1_Ent3", "text": "low - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18755414_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18765315_1", "wnd_id": "18765315_1_1", "text": "Acute coronary syndromes can be associated with the infusion of rituximab .", "tokens": ["Acute", "coronary", "syndromes", "can", "be", "associated", "with", "the", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "18765315_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "18765315_1_Ent0", "role": "Effect", "text": "Acute coronary syndromes", "start": 0, "end": 3}, {"entity_id": "18765315_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}, {"entity_id": "18765315_1_Ent1", "role": "Treatment", "text": "infusion of rituximab", "start": 8, "end": 11}, {"entity_id": "18765315_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18765315_1_Ent0", "text": "Acute coronary syndromes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18765315_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18765315_1_Ent1", "text": "infusion of rituximab", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18765315_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18765315_5", "wnd_id": "18765315_5_1", "text": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab .", "tokens": ["We", "reviewed", "the", "records", "of", "3", "patients", "with", "lymphoproliferative", "disorders", "who", "experienced", "acute", "coronary", "syndromes", "associated", "with", "their", "initial", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "18765315_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "18765315_5_Ent1", "role": "Subject_Population", "text": "3", "start": 5, "end": 6}, {"entity_id": "18765315_5_Ent0", "role": "Subject", "text": "3 patients with lymphoproliferative disorders", "start": 5, "end": 10}, {"entity_id": "18765315_5_Ent4", "role": "Treatment_Disorder", "text": "lymphoproliferative disorders", "start": 8, "end": 10}, {"entity_id": "18765315_5_Ent2", "role": "Effect", "text": "acute coronary syndromes", "start": 12, "end": 15}, {"entity_id": "18765315_5_Ent3", "role": "Treatment", "text": "their initial infusion of rituximab", "start": 17, "end": 22}, {"entity_id": "18765315_5_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}, {"entity_id": "18765315_5_Ent5", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "18765315_5_Ent1", "text": "3", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18765315_5_Ent0", "text": "3 patients with lymphoproliferative disorders", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18765315_5_Ent4", "text": "lymphoproliferative disorders", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18765315_5_Ent2", "text": "acute coronary syndromes", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18765315_5_Ent3", "text": "their initial infusion of rituximab", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "18765315_5_Ent6", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18765315_5_Ent5", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "18855892_8", "wnd_id": "18855892_8_1", "text": "Thus , we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate - induced anaphylaxis .", "tokens": ["Thus", ",", "we", "confirm", "that", "desensitization", "may", "be", "a", "safe", "procedure", "in", "patients", "with", "cancer", "who", "experience", "methotrexate", "-", "induced", "anaphylaxis", "."], "event_mentions": [{"id": "18855892_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "18855892_8_Ent0", "role": "Subject", "text": "patients with cancer", "start": 12, "end": 15}, {"entity_id": "18855892_8_Ent1", "role": "Subject_Disorder", "text": "cancer", "start": 14, "end": 15}, {"entity_id": "18855892_8_Ent3", "role": "Treatment", "text": "methotrexate", "start": 17, "end": 18}, {"entity_id": "18855892_8_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 17, "end": 18}, {"entity_id": "18855892_8_Ent2", "role": "Effect", "text": "anaphylaxis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18855892_8_Ent0", "text": "patients with cancer", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18855892_8_Ent1", "text": "cancer", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18855892_8_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18855892_8_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18855892_8_Ent2", "text": "anaphylaxis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "19018868_2", "wnd_id": "19018868_2_1", "text": "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide , aplastic anemia has not previously been reported to be associated with this agent .", "tokens": ["Although", "moderate", "myelosuppression", "is", "not", "uncommonly", "seen", "in", "patients", "treated", "with", "lenalidomide", ",", "aplastic", "anemia", "has", "not", "previously", "been", "reported", "to", "be", "associated", "with", "this", "agent", "."], "event_mentions": [{"id": "19018868_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 22, "end": 23}, "arguments": [{"entity_id": "19018868_2_Ent1", "role": "Treatment", "text": "lenalidomide", "start": 11, "end": 12}, {"entity_id": "19018868_2_Ent2", "role": "Treatment_Drug", "text": "lenalidomide", "start": 11, "end": 12}, {"entity_id": "19018868_2_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "19018868_2_Ent1", "text": "lenalidomide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19018868_2_Ent2", "text": "lenalidomide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19018868_2_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "19034138_4", "wnd_id": "19034138_4_1", "text": "Corneal endothelial dysfunction associated with amantadine toxicity .", "tokens": ["Corneal", "endothelial", "dysfunction", "associated", "with", "amantadine", "toxicity", "."], "event_mentions": [{"id": "19034138_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19034138_4_Ent0", "role": "Effect", "text": "Corneal endothelial dysfunction", "start": 0, "end": 3}, {"entity_id": "19034138_4_Ent1", "role": "Treatment", "text": "amantadine", "start": 5, "end": 6}, {"entity_id": "19034138_4_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "19034138_4_Ent0", "text": "Corneal endothelial dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19034138_4_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19034138_4_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "19034138_5", "wnd_id": "19034138_5_1", "text": "PURPOSE : To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long - term amantadine .", "tokens": ["PURPOSE", ":", "To", "describe", "bilateral", "corneal", "endothelial", "dysfunction", "in", "a", "patient", "with", "Parkinson", "disease", "who", "was", "treated", "with", "long", "-", "term", "amantadine", "."], "event_mentions": [{"id": "19034138_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "19034138_5_Ent1", "role": "Effect", "text": "bilateral corneal endothelial dysfunction", "start": 4, "end": 8}, {"entity_id": "19034138_5_Ent0", "role": "Subject", "text": "a patient with Parkinson disease", "start": 9, "end": 14}, {"entity_id": "19034138_5_Ent3", "role": "Treatment_Disorder", "text": "Parkinson disease", "start": 12, "end": 14}, {"entity_id": "19034138_5_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 18, "end": 21}, {"entity_id": "19034138_5_Ent2", "role": "Treatment", "text": "long - term amantadine", "start": 18, "end": 22}, {"entity_id": "19034138_5_Ent4", "role": "Treatment_Drug", "text": "amantadine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19034138_5_Ent1", "text": "bilateral corneal endothelial dysfunction", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19034138_5_Ent0", "text": "a patient with Parkinson disease", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "19034138_5_Ent3", "text": "Parkinson disease", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19034138_5_Ent5", "text": "long - term", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19034138_5_Ent2", "text": "long - term amantadine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "19034138_5_Ent4", "text": "amantadine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "19116715_3", "wnd_id": "19116715_3_1", "text": "Rituximab - based therapy for gemcitabine - induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma : a case report .", "tokens": ["Rituximab", "-", "based", "therapy", "for", "gemcitabine", "-", "induced", "hemolytic", "uremic", "syndrome", "in", "a", "patient", "with", "metastatic", "pancreatic", "adenocarcinoma", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19116715_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "19116715_3_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 5, "end": 6}, {"entity_id": "19116715_3_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 5, "end": 6}, {"entity_id": "19116715_3_Ent1", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 8, "end": 11}, {"entity_id": "19116715_3_Ent0", "role": "Subject", "text": "patient with metastatic pancreatic adenocarcinoma", "start": 13, "end": 18}, {"entity_id": "19116715_3_Ent4", "role": "Treatment_Disorder", "text": "metastatic pancreatic adenocarcinoma", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "19116715_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19116715_3_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19116715_3_Ent1", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19116715_3_Ent0", "text": "patient with metastatic pancreatic adenocarcinoma", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19116715_3_Ent4", "text": "metastatic pancreatic adenocarcinoma", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "19122478_7", "wnd_id": "19122478_7_1", "text": "The condition improved slowly after stopping medication and systemic steroids .", "tokens": ["The", "condition", "improved", "slowly", "after", "stopping", "medication", "and", "systemic", "steroids", "."], "event_mentions": [{"id": "19122478_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "stopping", "start": 5, "end": 6}, "arguments": [{"entity_id": "19122478_7_Ent0", "role": "Effect", "text": "condition improved", "start": 1, "end": 3}, {"entity_id": "19122478_7_Ent1", "role": "Treatment", "text": "steroids", "start": 9, "end": 10}, {"entity_id": "19122478_7_Ent2", "role": "Treatment_Drug", "text": "steroids", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19122478_7_Ent0", "text": "condition improved", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19122478_7_Ent1", "text": "steroids", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19122478_7_Ent2", "text": "steroids", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19145124_3", "wnd_id": "19145124_3_1", "text": "Two patients who developed decreased visual acuity after several months of ethambutol treatment for Mycobacterium avium - intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage .", "tokens": ["Two", "patients", "who", "developed", "decreased", "visual", "acuity", "after", "several", "months", "of", "ethambutol", "treatment", "for", "Mycobacterium", "avium", "-", "intracellulare", "infection", "had", "bitemporal", "visual", "field", "defects", "that", "suggested", "optic", "chiasm", "damage", "."], "event_mentions": [{"id": "19145124_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "19145124_3_Ent2", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "19145124_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "19145124_3_Ent3", "role": "Effect", "text": "decreased visual acuity", "start": 4, "end": 7}, {"entity_id": "19145124_3_Ent6", "role": "Treatment", "text": "ethambutol", "start": 11, "end": 12}, {"entity_id": "19145124_3_Ent8", "role": "Treatment_Drug", "text": "ethambutol", "start": 11, "end": 12}, {"entity_id": "19145124_3_Ent1", "role": "Subject", "text": "Mycobacterium avium - intracellulare infection", "start": 14, "end": 19}, {"entity_id": "19145124_3_Ent7", "role": "Treatment_Disorder", "text": "Mycobacterium avium - intracellulare infection", "start": 14, "end": 19}, {"entity_id": "19145124_3_Ent4", "role": "Effect", "text": "bitemporal visual field defects", "start": 20, "end": 24}, {"entity_id": "19145124_3_Ent5", "role": "Effect", "text": "optic chiasm damage", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "19145124_3_Ent2", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19145124_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19145124_3_Ent3", "text": "decreased visual acuity", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19145124_3_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19145124_3_Ent8", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19145124_3_Ent1", "text": "Mycobacterium avium - intracellulare infection", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "19145124_3_Ent7", "text": "Mycobacterium avium - intracellulare infection", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "19145124_3_Ent4", "text": "bitemporal visual field defects", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "19145124_3_Ent5", "text": "optic chiasm damage", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "19151423_3", "wnd_id": "19151423_3_1", "text": "The addition of ciprofloxacin to chronic simvastatin therapy led to the development of rhabdomyolysis .", "tokens": ["The", "addition", "of", "ciprofloxacin", "to", "chronic", "simvastatin", "therapy", "led", "to", "the", "development", "of", "rhabdomyolysis", "."], "event_mentions": [{"id": "19151423_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 8, "end": 9}, "arguments": [{"entity_id": "19151423_3_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "19151423_3_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "19151423_3_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "19151423_3_Ent2", "role": "Treatment", "text": "chronic simvastatin", "start": 5, "end": 7}, {"entity_id": "19151423_3_Ent4", "role": "Treatment_Drug", "text": "chronic simvastatin", "start": 5, "end": 7}, {"entity_id": "19151423_3_Ent6", "role": "Combination_Drug", "text": "chronic simvastatin", "start": 5, "end": 7}, {"entity_id": "19151423_3_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19151423_3_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19151423_3_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19151423_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19151423_3_Ent2", "text": "chronic simvastatin", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19151423_3_Ent4", "text": "chronic simvastatin", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19151423_3_Ent6", "text": "chronic simvastatin", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19151423_3_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1918672_1", "wnd_id": "1918672_1_1", "text": "In this case , discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment plan helped resolve a patient 's ulcers .", "tokens": ["In", "this", "case", ",", "discontinuing", "piroxicam", ",", "a", "nonsteroidal", "anti", "-", "inflammatory", "drug", ",", "and", "starting", "a", "palliative", "treatment", "plan", "helped", "resolve", "a", "patient", "'s", "ulcers", "."], "event_mentions": [{"id": "1918672_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolve", "start": 21, "end": 22}, "arguments": [{"entity_id": "1918672_1_Ent1", "role": "Treatment", "text": "discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment", "start": 4, "end": 19}, {"entity_id": "1918672_1_Ent3", "role": "Treatment_Drug", "text": "piroxicam", "start": 5, "end": 6}, {"entity_id": "1918672_1_Ent0", "role": "Subject", "text": "a patient 's", "start": 22, "end": 25}, {"entity_id": "1918672_1_Ent2", "role": "Treatment_Disorder", "text": "ulcers", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "1918672_1_Ent1", "text": "discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment", "entity_type": "Entity", "start": 4, "end": 19}, {"id": "1918672_1_Ent3", "text": "piroxicam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1918672_1_Ent0", "text": "a patient 's", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "1918672_1_Ent2", "text": "ulcers", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19224802_6", "wnd_id": "19224802_6_1", "text": "glycopyrrolate ( 5.0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure .", "tokens": ["glycopyrrolate", "(", "5.0", "microg", "/", "kg", ")", "not", "only", "resulting", "in", "resolution", "of", "bradycardia", "but", "also", "resulting", "in", "an", "exaggerated", "increase", "of", "arterial", "blood", "pressure", "."], "event_mentions": [{"id": "19224802_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 9, "end": 10}, "arguments": [{"entity_id": "19224802_6_Ent3", "role": "Treatment_Drug", "text": "glycopyrrolate", "start": 0, "end": 1}, {"entity_id": "19224802_6_Ent2", "role": "Treatment", "text": "glycopyrrolate ( 5.0 microg / kg )", "start": 0, "end": 7}, {"entity_id": "19224802_6_Ent4", "role": "Treatment_Dosage", "text": "5.0 microg / kg", "start": 2, "end": 6}, {"entity_id": "19224802_6_Ent0", "role": "Effect", "text": "resolution of bradycardia", "start": 11, "end": 14}, {"entity_id": "19224802_6_Ent1", "role": "Effect", "text": "an exaggerated increase of arterial blood pressure", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "19224802_6_Ent3", "text": "glycopyrrolate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19224802_6_Ent2", "text": "glycopyrrolate ( 5.0 microg / kg )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19224802_6_Ent4", "text": "5.0 microg / kg", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19224802_6_Ent0", "text": "resolution of bradycardia", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "19224802_6_Ent1", "text": "an exaggerated increase of arterial blood pressure", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "19249953_10", "wnd_id": "19249953_10_1", "text": "To our knowledge , however , this is the first case report of a possible sitagliptin - lovastatin interaction that may have caused rhabdomyolysis .", "tokens": ["To", "our", "knowledge", ",", "however", ",", "this", "is", "the", "first", "case", "report", "of", "a", "possible", "sitagliptin", "-", "lovastatin", "interaction", "that", "may", "have", "caused", "rhabdomyolysis", "."], "event_mentions": [{"id": "19249953_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 22, "end": 23}, "arguments": [{"entity_id": "19249953_10_Ent2", "role": "Treatment_Drug", "text": "sitagliptin", "start": 15, "end": 16}, {"entity_id": "19249953_10_Ent5", "role": "Combination_Drug", "text": "sitagliptin", "start": 15, "end": 16}, {"entity_id": "19249953_10_Ent1", "role": "Treatment", "text": "sitagliptin - lovastatin interaction", "start": 15, "end": 19}, {"entity_id": "19249953_10_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 17, "end": 18}, {"entity_id": "19249953_10_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 17, "end": 18}, {"entity_id": "19249953_10_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "19249953_10_Ent2", "text": "sitagliptin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19249953_10_Ent5", "text": "sitagliptin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19249953_10_Ent1", "text": "sitagliptin - lovastatin interaction", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19249953_10_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19249953_10_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19249953_10_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "19260037_4", "wnd_id": "19260037_4_1", "text": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine - associated TTP / HUS , the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP ( i.e. , severely decreased ADAMTS13 with an inhibitor ) .", "tokens": ["We", "conclude", "that", "while", "thrombocytopenia", "and", "schistocytosis", "can", "be", "seen", "in", "quinine", "-", "associated", "TTP", "/", "HUS", ",", "the", "pathophysiology", "seems", "to", "be", "distinct", "from", "that", "seen", "in", "most", "cases", "of", "idiopathic", "TTP", "(", "i.e.", ",", "severely", "decreased", "ADAMTS13", "with", "an", "inhibitor", ")", "."], "event_mentions": [{"id": "19260037_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "19260037_4_Ent0", "role": "Effect", "text": "thrombocytopenia and schistocytosis", "start": 4, "end": 7}, {"entity_id": "19260037_4_Ent2", "role": "Treatment", "text": "quinine", "start": 11, "end": 12}, {"entity_id": "19260037_4_Ent3", "role": "Treatment_Drug", "text": "quinine", "start": 11, "end": 12}, {"entity_id": "19260037_4_Ent1", "role": "Effect", "text": "TTP / HUS", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "19260037_4_Ent0", "text": "thrombocytopenia and schistocytosis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19260037_4_Ent2", "text": "quinine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19260037_4_Ent3", "text": "quinine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19260037_4_Ent1", "text": "TTP / HUS", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "19260037_5", "wnd_id": "19260037_5_1", "text": "We recommend that a TMA in association with quinine be consistently referred to as quinine - associated thrombotic microangiopathy ( quinine - TMA ) to better distinguish this entity from idiopathic TTP .", "tokens": ["We", "recommend", "that", "a", "TMA", "in", "association", "with", "quinine", "be", "consistently", "referred", "to", "as", "quinine", "-", "associated", "thrombotic", "microangiopathy", "(", "quinine", "-", "TMA", ")", "to", "better", "distinguish", "this", "entity", "from", "idiopathic", "TTP", "."], "event_mentions": [{"id": "19260037_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "19260037_5_Ent1", "role": "Treatment", "text": "quinine", "start": 14, "end": 15}, {"entity_id": "19260037_5_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 14, "end": 15}, {"entity_id": "19260037_5_Ent0", "role": "Effect", "text": "quinine - associated thrombotic microangiopathy ( quinine - TMA )", "start": 14, "end": 24}]}], "entity_mentions": [{"id": "19260037_5_Ent1", "text": "quinine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19260037_5_Ent2", "text": "quinine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19260037_5_Ent0", "text": "quinine - associated thrombotic microangiopathy ( quinine - TMA )", "entity_type": "Entity", "start": 14, "end": 24}], "lang": "en"}
{"doc_id": "19266307_2", "wnd_id": "19266307_2_1", "text": "MATERIALS AND METHODS : We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin .", "tokens": ["MATERIALS", "AND", "METHODS", ":", "We", "present", "two", "cases", "of", "significant", "morbidity", "related", "to", "primary", "and", "secondary", "perforation", "of", "the", "bladder", "following", "two", "instillations", "of", "epirubicin", "."], "event_mentions": [{"id": "19266307_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "19266307_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "19266307_2_Ent0", "role": "Subject", "text": "two cases", "start": 6, "end": 8}, {"entity_id": "19266307_2_Ent2", "role": "Effect", "text": "significant morbidity related to primary and secondary perforation of the bladder", "start": 9, "end": 20}, {"entity_id": "19266307_2_Ent3", "role": "Treatment", "text": "two instillations of epirubicin", "start": 21, "end": 25}, {"entity_id": "19266307_2_Ent4", "role": "Treatment_Route", "text": "instillations", "start": 22, "end": 23}, {"entity_id": "19266307_2_Ent5", "role": "Treatment_Drug", "text": "epirubicin", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19266307_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19266307_2_Ent0", "text": "two cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19266307_2_Ent2", "text": "significant morbidity related to primary and secondary perforation of the bladder", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "19266307_2_Ent3", "text": "two instillations of epirubicin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "19266307_2_Ent4", "text": "instillations", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19266307_2_Ent5", "text": "epirubicin", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19299370_3", "wnd_id": "19299370_3_1", "text": "Probable enoxaparin - induced hepatotoxicity .", "tokens": ["Probable", "enoxaparin", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "19299370_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19299370_3_Ent1", "role": "Treatment", "text": "enoxaparin", "start": 1, "end": 2}, {"entity_id": "19299370_3_Ent2", "role": "Treatment_Drug", "text": "enoxaparin", "start": 1, "end": 2}, {"entity_id": "19299370_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "19299370_3_Ent1", "text": "enoxaparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19299370_3_Ent2", "text": "enoxaparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19299370_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "19357764_2", "wnd_id": "19357764_2_1", "text": "DISCUSSION : This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse .", "tokens": ["DISCUSSION", ":", "This", "case", "shows", "that", "switching", "to", "zidovudine", "potentially", "can", "lead", "to", "a", "hyperlactatemia", "relapse", "."], "event_mentions": [{"id": "19357764_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 11, "end": 12}, "arguments": [{"entity_id": "19357764_2_Ent0", "role": "Subject", "text": "This case", "start": 2, "end": 4}, {"entity_id": "19357764_2_Ent2", "role": "Treatment", "text": "zidovudine", "start": 8, "end": 9}, {"entity_id": "19357764_2_Ent3", "role": "Treatment_Drug", "text": "zidovudine", "start": 8, "end": 9}, {"entity_id": "19357764_2_Ent1", "role": "Effect", "text": "hyperlactatemia relapse", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19357764_2_Ent0", "text": "This case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19357764_2_Ent2", "text": "zidovudine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19357764_2_Ent3", "text": "zidovudine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19357764_2_Ent1", "text": "hyperlactatemia relapse", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19363904_1", "wnd_id": "19363904_1_1", "text": "Anaphylactic reaction to bacitracin ointment .", "tokens": ["Anaphylactic", "reaction", "to", "bacitracin", "ointment", "."], "event_mentions": [{"id": "19363904_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 1, "end": 2}, "arguments": [{"entity_id": "19363904_1_Ent0", "role": "Effect", "text": "Anaphylactic", "start": 0, "end": 1}, {"entity_id": "19363904_1_Ent2", "role": "Treatment_Drug", "text": "bacitracin", "start": 3, "end": 4}, {"entity_id": "19363904_1_Ent1", "role": "Treatment", "text": "bacitracin ointment", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19363904_1_Ent0", "text": "Anaphylactic", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19363904_1_Ent2", "text": "bacitracin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19363904_1_Ent1", "text": "bacitracin ointment", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19363904_2", "wnd_id": "19363904_2_1", "text": "We report a case of an 11 - year - old boy who experienced an anaphylactic reaction after administration of bacitracin ointment .", "tokens": ["We", "report", "a", "case", "of", "an", "11", "-", "year", "-", "old", "boy", "who", "experienced", "an", "anaphylactic", "reaction", "after", "administration", "of", "bacitracin", "ointment", "."], "event_mentions": [{"id": "19363904_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 13, "end": 14}, "arguments": [{"entity_id": "19363904_2_Ent0", "role": "Subject", "text": "an 11 - year - old boy", "start": 5, "end": 12}, {"entity_id": "19363904_2_Ent1", "role": "Subject_Age", "text": "11 - year - old", "start": 6, "end": 11}, {"entity_id": "19363904_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 11, "end": 12}, {"entity_id": "19363904_2_Ent3", "role": "Effect", "text": "an anaphylactic reaction", "start": 14, "end": 17}, {"entity_id": "19363904_2_Ent4", "role": "Treatment", "text": "after administration of bacitracin ointment", "start": 17, "end": 22}, {"entity_id": "19363904_2_Ent5", "role": "Treatment_Drug", "text": "bacitracin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "19363904_2_Ent0", "text": "an 11 - year - old boy", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19363904_2_Ent1", "text": "11 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19363904_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19363904_2_Ent3", "text": "an anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19363904_2_Ent4", "text": "after administration of bacitracin ointment", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "19363904_2_Ent5", "text": "bacitracin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "19365885_2", "wnd_id": "19365885_2_1", "text": "Hypoglycemia induced by long - acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor .", "tokens": ["Hypoglycemia", "induced", "by", "long", "-", "acting", "somatostatin", "analogues", "in", "a", "patient", "with", "nonfunctional", "neuroendocrine", "tumor", "."], "event_mentions": [{"id": "19365885_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19365885_2_Ent1", "role": "Effect", "text": "Hypoglycemia", "start": 0, "end": 1}, {"entity_id": "19365885_2_Ent2", "role": "Treatment", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent4", "role": "Treatment_Drug", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent0", "role": "Subject", "text": "a patient with nonfunctional neuroendocrine tumor", "start": 9, "end": 15}, {"entity_id": "19365885_2_Ent3", "role": "Treatment_Disorder", "text": "nonfunctional neuroendocrine tumor", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "19365885_2_Ent1", "text": "Hypoglycemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19365885_2_Ent2", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent4", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent0", "text": "a patient with nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19365885_2_Ent3", "text": "nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "19390192_3", "wnd_id": "19390192_3_1", "text": "We present the case of an adult Crohn 's disease patient with a parvovirus B19 infection and leukopenia during long - term AZA therapy .", "tokens": ["We", "present", "the", "case", "of", "an", "adult", "Crohn", "'s", "disease", "patient", "with", "a", "parvovirus", "B19", "infection", "and", "leukopenia", "during", "long", "-", "term", "AZA", "therapy", "."], "event_mentions": [{"id": "19390192_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "19390192_3_Ent1", "role": "Subject_Age", "text": "adult", "start": 6, "end": 7}, {"entity_id": "19390192_3_Ent0", "role": "Subject", "text": "adult Crohn 's disease patient", "start": 6, "end": 11}, {"entity_id": "19390192_3_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 7, "end": 10}, {"entity_id": "19390192_3_Ent2", "role": "Effect", "text": "a parvovirus B19 infection and leukopenia", "start": 12, "end": 18}, {"entity_id": "19390192_3_Ent6", "role": "Treatment_Duration", "text": "long - term", "start": 19, "end": 22}, {"entity_id": "19390192_3_Ent3", "role": "Treatment", "text": "long - term AZA therapy", "start": 19, "end": 24}, {"entity_id": "19390192_3_Ent5", "role": "Treatment_Drug", "text": "AZA", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19390192_3_Ent1", "text": "adult", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19390192_3_Ent0", "text": "adult Crohn 's disease patient", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19390192_3_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19390192_3_Ent2", "text": "a parvovirus B19 infection and leukopenia", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19390192_3_Ent6", "text": "long - term", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19390192_3_Ent3", "text": "long - term AZA therapy", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "19390192_3_Ent5", "text": "AZA", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19423476_1", "wnd_id": "19423476_1_1", "text": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab : case report and review of the literature .", "tokens": ["Cryptococcus", "neoformans", "fatal", "sepsis", "in", "a", "chronic", "lymphocytic", "leukemia", "patient", "treated", "with", "alemtuzumab", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "19423476_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "19423476_1_Ent1", "role": "Effect", "text": "Cryptococcus neoformans fatal sepsis", "start": 0, "end": 4}, {"entity_id": "19423476_1_Ent0", "role": "Subject", "text": "a chronic lymphocytic leukemia patient", "start": 5, "end": 10}, {"entity_id": "19423476_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 6, "end": 9}, {"entity_id": "19423476_1_Ent2", "role": "Treatment", "text": "alemtuzumab", "start": 12, "end": 13}, {"entity_id": "19423476_1_Ent4", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19423476_1_Ent1", "text": "Cryptococcus neoformans fatal sepsis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19423476_1_Ent0", "text": "a chronic lymphocytic leukemia patient", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19423476_1_Ent3", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19423476_1_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19423476_1_Ent4", "text": "alemtuzumab", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19423476_4", "wnd_id": "19423476_4_1", "text": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab .", "tokens": ["We", "report", "a", "case", "of", "fatal", "C.", "neoformans", "fungemia", "in", "a", "neutropenic", "patient", "with", "a", "history", "of", "chronic", "lymphocytic", "leukemia", "treated", "with", "alemtuzumab", "."], "event_mentions": [{"id": "19423476_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 20, "end": 22}, "arguments": [{"entity_id": "19423476_4_Ent1", "role": "Effect", "text": "fatal C. neoformans fungemia", "start": 5, "end": 9}, {"entity_id": "19423476_4_Ent0", "role": "Subject", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "start": 10, "end": 20}, {"entity_id": "19423476_4_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 17, "end": 20}, {"entity_id": "19423476_4_Ent2", "role": "Treatment", "text": "alemtuzumab", "start": 22, "end": 23}, {"entity_id": "19423476_4_Ent3", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19423476_4_Ent1", "text": "fatal C. neoformans fungemia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19423476_4_Ent0", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "19423476_4_Ent4", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "19423476_4_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19423476_4_Ent3", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19423610_9", "wnd_id": "19423610_9_1", "text": "Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia .", "tokens": ["Methylene", "blue", "is", "used", "in", "a", "variety", "of", "surgical", "settings", "as", "well", "as", "for", "treatment", "of", "various", "types", "of", "hypotensive", "shock", "and", "methemoglobinaemia", "."], "event_mentions": [{"id": "19423610_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "19423610_9_Ent0", "role": "Treatment", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_9_Ent3", "role": "Treatment_Drug", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_9_Ent1", "role": "Treatment_Disorder", "text": "hypotensive shock", "start": 19, "end": 21}, {"entity_id": "19423610_9_Ent2", "role": "Treatment_Disorder", "text": "methemoglobinaemia", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19423610_9_Ent0", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_9_Ent3", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_9_Ent1", "text": "hypotensive shock", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "19423610_9_Ent2", "text": "methemoglobinaemia", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19434733_1", "wnd_id": "19434733_1_1", "text": "Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis .", "tokens": ["Secondary", "acute", "myeloid", "leukemia", "after", "etoposide", "therapy", "for", "haemophagocytic", "lymphohistiocytosis", "."], "event_mentions": [{"id": "19434733_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "19434733_1_Ent0", "role": "Effect", "text": "Secondary acute myeloid leukemia", "start": 0, "end": 4}, {"entity_id": "19434733_1_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 5, "end": 6}, {"entity_id": "19434733_1_Ent1", "role": "Treatment", "text": "etoposide therapy", "start": 5, "end": 7}, {"entity_id": "19434733_1_Ent3", "role": "Treatment_Disorder", "text": "haemophagocytic lymphohistiocytosis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19434733_1_Ent0", "text": "Secondary acute myeloid leukemia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19434733_1_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19434733_1_Ent1", "text": "etoposide therapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19434733_1_Ent3", "text": "haemophagocytic lymphohistiocytosis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19448237_1", "wnd_id": "19448237_1_1", "text": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia .", "tokens": ["Polymyoclonus", "seizure", "resulting", "from", "accidental", "injection", "of", "tranexamic", "acid", "in", "spinal", "anesthesia", "."], "event_mentions": [{"id": "19448237_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 2, "end": 3}, "arguments": [{"entity_id": "19448237_1_Ent0", "role": "Effect", "text": "Polymyoclonus seizure", "start": 0, "end": 2}, {"entity_id": "19448237_1_Ent1", "role": "Treatment", "text": "accidental injection of tranexamic acid in spinal anesthesia", "start": 4, "end": 12}, {"entity_id": "19448237_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 5, "end": 6}, {"entity_id": "19448237_1_Ent2", "role": "Treatment_Drug", "text": "tranexamic acid", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "19448237_1_Ent0", "text": "Polymyoclonus seizure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19448237_1_Ent1", "text": "accidental injection of tranexamic acid in spinal anesthesia", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "19448237_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19448237_1_Ent2", "text": "tranexamic acid", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "19474653_2", "wnd_id": "19474653_2_1", "text": "We report the first case of rhabdomyolysis related to the administration of clarithromycin without concurrent use of other medications .", "tokens": ["We", "report", "the", "first", "case", "of", "rhabdomyolysis", "related", "to", "the", "administration", "of", "clarithromycin", "without", "concurrent", "use", "of", "other", "medications", "."], "event_mentions": [{"id": "19474653_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 7, "end": 9}, "arguments": [{"entity_id": "19474653_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 6, "end": 7}, {"entity_id": "19474653_2_Ent1", "role": "Treatment", "text": "administration of clarithromycin without concurrent use of other medications", "start": 10, "end": 19}, {"entity_id": "19474653_2_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19474653_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19474653_2_Ent1", "text": "administration of clarithromycin without concurrent use of other medications", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "19474653_2_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19499966_4", "wnd_id": "19499966_4_1", "text": "The mechanism by which sunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors .", "tokens": ["The", "mechanism", "by", "which", "sunitinib", "induces", "gynaecomastia", "is", "thought", "to", "be", "associated", "with", "an", "unknown", "direct", "action", "on", "breast", "hormonal", "receptors", "."], "event_mentions": [{"id": "19499966_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induces", "start": 5, "end": 6}, "arguments": [{"entity_id": "19499966_4_Ent1", "role": "Treatment", "text": "sunitinib", "start": 4, "end": 5}, {"entity_id": "19499966_4_Ent2", "role": "Treatment_Drug", "text": "sunitinib", "start": 4, "end": 5}, {"entity_id": "19499966_4_Ent0", "role": "Effect", "text": "gynaecomastia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "19499966_4_Ent1", "text": "sunitinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19499966_4_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19499966_4_Ent0", "text": "gynaecomastia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1951476_2", "wnd_id": "1951476_2_1", "text": "We report a case of biopsy - proven acute tubulointerstitial nephritis associated with a second course of flurbiprofen , a nonsteroidal anti - inflammatory drug of the propionic acid class .", "tokens": ["We", "report", "a", "case", "of", "biopsy", "-", "proven", "acute", "tubulointerstitial", "nephritis", "associated", "with", "a", "second", "course", "of", "flurbiprofen", ",", "a", "nonsteroidal", "anti", "-", "inflammatory", "drug", "of", "the", "propionic", "acid", "class", "."], "event_mentions": [{"id": "1951476_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "1951476_2_Ent0", "role": "Effect", "text": "biopsy - proven acute tubulointerstitial nephritis", "start": 5, "end": 11}, {"entity_id": "1951476_2_Ent1", "role": "Treatment", "text": "a second course of flurbiprofen", "start": 13, "end": 18}, {"entity_id": "1951476_2_Ent3", "role": "Treatment_Freq", "text": "second course", "start": 14, "end": 16}, {"entity_id": "1951476_2_Ent2", "role": "Treatment_Drug", "text": "flurbiprofen", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "1951476_2_Ent0", "text": "biopsy - proven acute tubulointerstitial nephritis", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "1951476_2_Ent1", "text": "a second course of flurbiprofen", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "1951476_2_Ent3", "text": "second course", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "1951476_2_Ent2", "text": "flurbiprofen", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "19520277_1", "wnd_id": "19520277_1_1", "text": "Stupor and fast activity on electroencephalography in a child treated with valproate .", "tokens": ["Stupor", "and", "fast", "activity", "on", "electroencephalography", "in", "a", "child", "treated", "with", "valproate", "."], "event_mentions": [{"id": "19520277_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "19520277_1_Ent2", "role": "Effect", "text": "Stupor", "start": 0, "end": 1}, {"entity_id": "19520277_1_Ent3", "role": "Effect", "text": "fast activity on electroencephalography", "start": 2, "end": 6}, {"entity_id": "19520277_1_Ent0", "role": "Subject", "text": "a child", "start": 7, "end": 9}, {"entity_id": "19520277_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "19520277_1_Ent4", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19520277_1_Ent2", "text": "Stupor", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19520277_1_Ent3", "text": "fast activity on electroencephalography", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19520277_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19520277_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19520277_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19531695_14", "wnd_id": "19531695_14_1", "text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors , flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors .", "tokens": ["Because", "toxicity", "may", "occur", "when", "flecainide", "is", "prescribed", "with", "paroxetine", "and", "other", "potent", "CYP2D6", "inhibitors", ",", "flecainide", "plasma", "concentrations", "should", "be", "monitored", "closely", "with", "commencement", "of", "CYP2D6", "inhibitors", "."], "event_mentions": [{"id": "19531695_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 3, "end": 4}, "arguments": [{"entity_id": "19531695_14_Ent0", "role": "Effect", "text": "toxicity", "start": 1, "end": 2}, {"entity_id": "19531695_14_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent4", "role": "Combination_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent1", "role": "Treatment", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "start": 5, "end": 15}, {"entity_id": "19531695_14_Ent3", "role": "Treatment_Drug", "text": "paroxetine", "start": 9, "end": 10}, {"entity_id": "19531695_14_Ent5", "role": "Combination_Drug", "text": "paroxetine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19531695_14_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19531695_14_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent1", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "19531695_14_Ent3", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531695_14_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19540093_4", "wnd_id": "19540093_4_1", "text": "Tigecycline - induced acute pancreatitis : case report and literature review .", "tokens": ["Tigecycline", "-", "induced", "acute", "pancreatitis", ":", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "19540093_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19540093_4_Ent1", "role": "Treatment", "text": "Tigecycline", "start": 0, "end": 1}, {"entity_id": "19540093_4_Ent2", "role": "Treatment_Drug", "text": "Tigecycline", "start": 0, "end": 1}, {"entity_id": "19540093_4_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19540093_4_Ent1", "text": "Tigecycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19540093_4_Ent2", "text": "Tigecycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19540093_4_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19540093_5", "wnd_id": "19540093_5_1", "text": "We recommend that clinicians monitor patients for signs and symptoms of pancreatitis , including abdominal pain , during treatment with tigecycline .", "tokens": ["We", "recommend", "that", "clinicians", "monitor", "patients", "for", "signs", "and", "symptoms", "of", "pancreatitis", ",", "including", "abdominal", "pain", ",", "during", "treatment", "with", "tigecycline", "."], "event_mentions": [{"id": "19540093_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 18, "end": 19}, "arguments": [{"entity_id": "19540093_5_Ent0", "role": "Effect", "text": "pancreatitis , including abdominal pain", "start": 11, "end": 16}, {"entity_id": "19540093_5_Ent1", "role": "Treatment", "text": "tigecycline", "start": 20, "end": 21}, {"entity_id": "19540093_5_Ent2", "role": "Treatment_Drug", "text": "tigecycline", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "19540093_5_Ent0", "text": "pancreatitis , including abdominal pain", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19540093_5_Ent1", "text": "tigecycline", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19540093_5_Ent2", "text": "tigecycline", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "19555801_1", "wnd_id": "19555801_1_1", "text": "Aripiprazole - induced hiccups : a case report .", "tokens": ["Aripiprazole", "-", "induced", "hiccups", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19555801_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19555801_1_Ent1", "role": "Treatment", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "19555801_1_Ent2", "role": "Treatment_Drug", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "19555801_1_Ent0", "role": "Effect", "text": "hiccups", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "19555801_1_Ent1", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19555801_1_Ent2", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19555801_1_Ent0", "text": "hiccups", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "19567656_2", "wnd_id": "19567656_2_1", "text": "DISCUSSION : The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of rhabdomyolysis .", "tokens": ["DISCUSSION", ":", "The", "Naranjo", "probability", "scale", "indicated", "a", "probable", "relationship", "between", "sertraline", "treatment", "and", "the", "onset", "of", "rhabdomyolysis", "."], "event_mentions": [{"id": "19567656_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 9, "end": 10}, "arguments": [{"entity_id": "19567656_2_Ent1", "role": "Treatment", "text": "sertraline", "start": 11, "end": 12}, {"entity_id": "19567656_2_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 11, "end": 12}, {"entity_id": "19567656_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "19567656_2_Ent1", "text": "sertraline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19567656_2_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19567656_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "19579947_2", "wnd_id": "19579947_2_1", "text": "Priapism associated with olanzapine .", "tokens": ["Priapism", "associated", "with", "olanzapine", "."], "event_mentions": [{"id": "19579947_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "19579947_2_Ent0", "role": "Effect", "text": "Priapism", "start": 0, "end": 1}, {"entity_id": "19579947_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 3, "end": 4}, {"entity_id": "19579947_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "19579947_2_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19579947_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19579947_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "19648225_1", "wnd_id": "19648225_1_1", "text": "Can ketamine prescribed for pain cause damage to the urinary tract ?", "tokens": ["Can", "ketamine", "prescribed", "for", "pain", "cause", "damage", "to", "the", "urinary", "tract", "?"], "event_mentions": [{"id": "19648225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "19648225_1_Ent1", "role": "Treatment", "text": "ketamine", "start": 1, "end": 2}, {"entity_id": "19648225_1_Ent3", "role": "Treatment_Drug", "text": "ketamine", "start": 1, "end": 2}, {"entity_id": "19648225_1_Ent2", "role": "Treatment_Disorder", "text": "pain", "start": 4, "end": 5}, {"entity_id": "19648225_1_Ent0", "role": "Effect", "text": "damage to the urinary tract", "start": 6, "end": 11}]}], "entity_mentions": [{"id": "19648225_1_Ent1", "text": "ketamine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19648225_1_Ent3", "text": "ketamine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19648225_1_Ent2", "text": "pain", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19648225_1_Ent0", "text": "damage to the urinary tract", "entity_type": "Entity", "start": 6, "end": 11}], "lang": "en"}
{"doc_id": "19660974_4", "wnd_id": "19660974_4_1", "text": "We describe a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn 's disease in a TNF - alpha inhibitor recipient .", "tokens": ["We", "describe", "a", "unique", "case", "of", "disseminated", "cryptococcosis", "presenting", "as", "colitis", "that", "mimicked", "an", "exacerbation", "of", "Crohn", "'s", "disease", "in", "a", "TNF", "-", "alpha", "inhibitor", "recipient", "."], "event_mentions": [{"id": "19660974_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 19, "end": 20}, "arguments": [{"entity_id": "19660974_4_Ent1", "role": "Effect", "text": "an exacerbation of Crohn 's disease", "start": 13, "end": 19}, {"entity_id": "19660974_4_Ent2", "role": "Treatment", "text": "a TNF - alpha inhibitor", "start": 20, "end": 25}, {"entity_id": "19660974_4_Ent3", "role": "Treatment_Drug", "text": "TNF - alpha inhibitor", "start": 21, "end": 25}, {"entity_id": "19660974_4_Ent0", "role": "Subject", "text": "recipient", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19660974_4_Ent1", "text": "an exacerbation of Crohn 's disease", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "19660974_4_Ent2", "text": "a TNF - alpha inhibitor", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "19660974_4_Ent3", "text": "TNF - alpha inhibitor", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "19660974_4_Ent0", "text": "recipient", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19667003_3", "wnd_id": "19667003_3_1", "text": "SUMMARY : A 26 - year - old man with bipolar disorder , seizures , and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control .", "tokens": ["SUMMARY", ":", "A", "26", "-", "year", "-", "old", "man", "with", "bipolar", "disorder", ",", "seizures", ",", "and", "mild", "mental", "retardation", "secondary", "to", "a", "traumatic", "brain", "injury", "began", "treatment", "with", "carbamazepine", "for", "aggression", "and", "seizure", "control", "."], "event_mentions": [{"id": "19667003_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 26, "end": 27}, "arguments": [{"entity_id": "19667003_3_Ent0", "role": "Subject", "text": "A 26 - year - old man with bipolar disorder , seizures , and mild mental retardation secondary to a traumatic brain injury", "start": 2, "end": 25}, {"entity_id": "19667003_3_Ent4", "role": "Subject_Age", "text": "26 - year - old", "start": 3, "end": 8}, {"entity_id": "19667003_3_Ent5", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "19667003_3_Ent1", "role": "Subject_Disorder", "text": "bipolar disorder", "start": 10, "end": 12}, {"entity_id": "19667003_3_Ent2", "role": "Subject_Disorder", "text": "seizures", "start": 13, "end": 14}, {"entity_id": "19667003_3_Ent3", "role": "Subject_Disorder", "text": "mild mental retardation secondary to a traumatic brain injury", "start": 16, "end": 25}, {"entity_id": "19667003_3_Ent6", "role": "Treatment", "text": "carbamazepine", "start": 28, "end": 29}, {"entity_id": "19667003_3_Ent7", "role": "Treatment_Drug", "text": "carbamazepine", "start": 28, "end": 29}, {"entity_id": "19667003_3_Ent8", "role": "Treatment_Disorder", "text": "aggression", "start": 30, "end": 31}, {"entity_id": "19667003_3_Ent9", "role": "Treatment_Disorder", "text": "seizure", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "19667003_3_Ent0", "text": "A 26 - year - old man with bipolar disorder , seizures , and mild mental retardation secondary to a traumatic brain injury", "entity_type": "Entity", "start": 2, "end": 25}, {"id": "19667003_3_Ent4", "text": "26 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19667003_3_Ent5", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19667003_3_Ent1", "text": "bipolar disorder", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19667003_3_Ent2", "text": "seizures", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19667003_3_Ent3", "text": "mild mental retardation secondary to a traumatic brain injury", "entity_type": "Entity", "start": 16, "end": 25}, {"id": "19667003_3_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "19667003_3_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "19667003_3_Ent8", "text": "aggression", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19667003_3_Ent9", "text": "seizure", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "1966850_2", "wnd_id": "1966850_2_1", "text": "Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity .", "tokens": ["Complications", "of", "chemotherapy", "for", "a", "synovial", "sarcoma", "in", "an", "eight", "-", "year", "old", "boy", "included", "cisplatinum", "nephrotoxicity", "and", "adriamycin", "cardiotoxicity", "."], "event_mentions": [{"id": "1966850_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "nephrotoxicity", "start": 16, "end": 17}, "arguments": [{"entity_id": "1966850_2_Ent0", "role": "Subject", "text": "an eight - year old boy", "start": 8, "end": 14}, {"entity_id": "1966850_2_Ent2", "role": "Subject_Age", "text": "eight - year old", "start": 9, "end": 13}, {"entity_id": "1966850_2_Ent1", "role": "Subject_Gender", "text": "boy", "start": 13, "end": 14}, {"entity_id": "1966850_2_Ent4", "role": "Treatment", "text": "cisplatinum", "start": 15, "end": 16}, {"entity_id": "1966850_2_Ent5", "role": "Treatment_Drug", "text": "cisplatinum", "start": 15, "end": 16}, {"entity_id": "1966850_2_Ent3", "role": "Effect", "text": "nephrotoxicity", "start": 16, "end": 17}]}, {"id": "1966850_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "cardiotoxicity", "start": 19, "end": 20}, "arguments": [{"entity_id": "1966850_2_Ent11", "role": "Treatment_Disorder", "text": "synovial sarcoma", "start": 5, "end": 7}, {"entity_id": "1966850_2_Ent6", "role": "Subject", "text": "an eight - year old boy", "start": 8, "end": 14}, {"entity_id": "1966850_2_Ent8", "role": "Subject_Age", "text": "eight - year old", "start": 9, "end": 13}, {"entity_id": "1966850_2_Ent7", "role": "Subject_Gender", "text": "boy", "start": 13, "end": 14}, {"entity_id": "1966850_2_Ent10", "role": "Treatment", "text": "adriamycin", "start": 18, "end": 19}, {"entity_id": "1966850_2_Ent12", "role": "Treatment_Drug", "text": "adriamycin", "start": 18, "end": 19}, {"entity_id": "1966850_2_Ent9", "role": "Effect", "text": "cardiotoxicity", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "1966850_2_Ent11", "text": "synovial sarcoma", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1966850_2_Ent0", "text": "an eight - year old boy", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "1966850_2_Ent6", "text": "an eight - year old boy", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "1966850_2_Ent2", "text": "eight - year old", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1966850_2_Ent8", "text": "eight - year old", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1966850_2_Ent1", "text": "boy", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1966850_2_Ent7", "text": "boy", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1966850_2_Ent4", "text": "cisplatinum", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "1966850_2_Ent5", "text": "cisplatinum", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "1966850_2_Ent3", "text": "nephrotoxicity", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1966850_2_Ent10", "text": "adriamycin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1966850_2_Ent12", "text": "adriamycin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1966850_2_Ent9", "text": "cardiotoxicity", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19745701_2", "wnd_id": "19745701_2_1", "text": "Reversible methotrexate - associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis .", "tokens": ["Reversible", "methotrexate", "-", "associated", "lymphoproliferative", "disorder", "resembling", "advanced", "gastric", "cancer", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "19745701_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19745701_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "19745701_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "19745701_2_Ent1", "role": "Effect", "text": "lymphoproliferative disorder", "start": 4, "end": 6}, {"entity_id": "19745701_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 11, "end": 16}, {"entity_id": "19745701_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19745701_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19745701_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19745701_2_Ent1", "text": "lymphoproliferative disorder", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19745701_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19745701_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "1977935_4", "wnd_id": "1977935_4_1", "text": "This report describes the first association ( exclusive of drug overdose ) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor , ketoconazole , and medroxyprogesterone .", "tokens": ["This", "report", "describes", "the", "first", "association", "(", "exclusive", "of", "drug", "overdose", ")", "of", "symptomatic", "torsades", "de", "pointes", "occurring", "with", "the", "use", "of", "terfenadine", "in", "a", "patient", "who", "was", "taking", "the", "recommended", "prescribed", "dose", "of", "this", "drug", "in", "addition", "to", "cefaclor", ",", "ketoconazole", ",", "and", "medroxyprogesterone", "."], "event_mentions": [{"id": "1977935_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 17, "end": 18}, "arguments": [{"entity_id": "1977935_4_Ent1", "role": "Effect", "text": "symptomatic torsades de pointes", "start": 13, "end": 17}, {"entity_id": "1977935_4_Ent2", "role": "Treatment", "text": "terfenadine", "start": 22, "end": 23}, {"entity_id": "1977935_4_Ent7", "role": "Treatment_Drug", "text": "terfenadine", "start": 22, "end": 23}, {"entity_id": "1977935_4_Ent8", "role": "Combination_Drug", "text": "terfenadine", "start": 22, "end": 23}, {"entity_id": "1977935_4_Ent0", "role": "Subject", "text": "a patient", "start": 24, "end": 26}, {"entity_id": "1977935_4_Ent3", "role": "Treatment", "text": "taking the recommended prescribed dose of this drug in addition to cefaclor , ketoconazole , and medroxyprogesterone", "start": 28, "end": 45}, {"entity_id": "1977935_4_Ent4", "role": "Treatment_Drug", "text": "cefaclor", "start": 39, "end": 40}, {"entity_id": "1977935_4_Ent9", "role": "Combination_Drug", "text": "cefaclor", "start": 39, "end": 40}, {"entity_id": "1977935_4_Ent5", "role": "Treatment_Drug", "text": "ketoconazole", "start": 41, "end": 42}, {"entity_id": "1977935_4_Ent10", "role": "Combination_Drug", "text": "ketoconazole", "start": 41, "end": 42}, {"entity_id": "1977935_4_Ent6", "role": "Treatment_Drug", "text": "medroxyprogesterone", "start": 44, "end": 45}, {"entity_id": "1977935_4_Ent11", "role": "Combination_Drug", "text": "medroxyprogesterone", "start": 44, "end": 45}]}], "entity_mentions": [{"id": "1977935_4_Ent1", "text": "symptomatic torsades de pointes", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "1977935_4_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1977935_4_Ent7", "text": "terfenadine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1977935_4_Ent8", "text": "terfenadine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1977935_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "1977935_4_Ent3", "text": "taking the recommended prescribed dose of this drug in addition to cefaclor , ketoconazole , and medroxyprogesterone", "entity_type": "Entity", "start": 28, "end": 45}, {"id": "1977935_4_Ent4", "text": "cefaclor", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "1977935_4_Ent9", "text": "cefaclor", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "1977935_4_Ent5", "text": "ketoconazole", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "1977935_4_Ent10", "text": "ketoconazole", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "1977935_4_Ent6", "text": "medroxyprogesterone", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "1977935_4_Ent11", "text": "medroxyprogesterone", "entity_type": "Entity", "start": 44, "end": 45}], "lang": "en"}
{"doc_id": "19789166_1", "wnd_id": "19789166_1_1", "text": "Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels , restoring most of them to normal , we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin .", "tokens": ["Given", "that", "discontinuation", "of", "nitrofurantoin", "and", "introduction", "of", "methylprednisolon", "therapy", "significantly", "lowered", "liver", "enzyme", "levels", ",", "restoring", "most", "of", "them", "to", "normal", ",", "we", "concluded", "that", "this", "was", "probably", "the", "case", "of", "toxic", "liver", "damage", "caused", "by", "nitrofurantoin", "."], "event_mentions": [{"id": "19789166_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 35, "end": 36}, "arguments": [{"entity_id": "19789166_1_Ent0", "role": "Effect", "text": "toxic liver damage", "start": 32, "end": 35}, {"entity_id": "19789166_1_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 37, "end": 38}, {"entity_id": "19789166_1_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "19789166_1_Ent0", "text": "toxic liver damage", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "19789166_1_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19789166_1_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "19789166_2", "wnd_id": "19789166_2_1", "text": "Nitrofurantoin - induced acute liver damage in pregnancy .", "tokens": ["Nitrofurantoin", "-", "induced", "acute", "liver", "damage", "in", "pregnancy", "."], "event_mentions": [{"id": "19789166_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19789166_2_Ent2", "role": "Treatment", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "19789166_2_Ent3", "role": "Treatment_Drug", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "19789166_2_Ent1", "role": "Effect", "text": "acute liver damage", "start": 3, "end": 6}, {"entity_id": "19789166_2_Ent0", "role": "Subject", "text": "pregnancy", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19789166_2_Ent2", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19789166_2_Ent3", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19789166_2_Ent1", "text": "acute liver damage", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "19789166_2_Ent0", "text": "pregnancy", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19789372_7", "wnd_id": "19789372_7_1", "text": "Present results suggested that coadministration of mexiletine increased blood tizanidine concentrations and enhanced tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms .", "tokens": ["Present", "results", "suggested", "that", "coadministration", "of", "mexiletine", "increased", "blood", "tizanidine", "concentrations", "and", "enhanced", "tizanidine", "pharmacodynamics", "in", "terms", "of", "reduction", "in", "blood", "pressure", "and", "adverse", "symptoms", "."], "event_mentions": [{"id": "19789372_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "enhanced", "start": 12, "end": 13}, "arguments": [{"entity_id": "19789372_7_Ent1", "role": "Treatment", "text": "coadministration of mexiletine increased blood tizanidine concentrations", "start": 4, "end": 11}, {"entity_id": "19789372_7_Ent2", "role": "Treatment_Drug", "text": "mexiletine", "start": 6, "end": 7}, {"entity_id": "19789372_7_Ent4", "role": "Combination_Drug", "text": "mexiletine", "start": 6, "end": 7}, {"entity_id": "19789372_7_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 9, "end": 10}, {"entity_id": "19789372_7_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 9, "end": 10}, {"entity_id": "19789372_7_Ent0", "role": "Effect", "text": "tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms", "start": 13, "end": 25}]}], "entity_mentions": [{"id": "19789372_7_Ent1", "text": "coadministration of mexiletine increased blood tizanidine concentrations", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "19789372_7_Ent2", "text": "mexiletine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19789372_7_Ent4", "text": "mexiletine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19789372_7_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19789372_7_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19789372_7_Ent0", "text": "tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms", "entity_type": "Entity", "start": 13, "end": 25}], "lang": "en"}
{"doc_id": "19826099_1", "wnd_id": "19826099_1_1", "text": "OBJECTIVE : To report a case of severe apnea in an infant exposed to lamotrigine through breast - feeding .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "severe", "apnea", "in", "an", "infant", "exposed", "to", "lamotrigine", "through", "breast", "-", "feeding", "."], "event_mentions": [{"id": "19826099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "19826099_1_Ent2", "role": "Effect", "text": "severe apnea", "start": 7, "end": 9}, {"entity_id": "19826099_1_Ent0", "role": "Subject", "text": "an infant", "start": 10, "end": 12}, {"entity_id": "19826099_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 11, "end": 12}, {"entity_id": "19826099_1_Ent3", "role": "Treatment", "text": "exposed to lamotrigine through breast - feeding", "start": 12, "end": 19}, {"entity_id": "19826099_1_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "19826099_1_Ent5", "role": "Treatment_Route", "text": "breast - feeding", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "19826099_1_Ent2", "text": "severe apnea", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19826099_1_Ent0", "text": "an infant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19826099_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19826099_1_Ent3", "text": "exposed to lamotrigine through breast - feeding", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19826099_1_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19826099_1_Ent5", "text": "breast - feeding", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "19838099_1", "wnd_id": "19838099_1_1", "text": "Although there have been numerous reports of effusions , none have provided complete pleural fluid analysis ; therefore , we report 2 patients with dasatinib - induced pleural effusion with complete pleural fluid analysis .", "tokens": ["Although", "there", "have", "been", "numerous", "reports", "of", "effusions", ",", "none", "have", "provided", "complete", "pleural", "fluid", "analysis", ";", "therefore", ",", "we", "report", "2", "patients", "with", "dasatinib", "-", "induced", "pleural", "effusion", "with", "complete", "pleural", "fluid", "analysis", "."], "event_mentions": [{"id": "19838099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 26, "end": 27}, "arguments": [{"entity_id": "19838099_1_Ent1", "role": "Subject_Population", "text": "2", "start": 21, "end": 22}, {"entity_id": "19838099_1_Ent0", "role": "Subject", "text": "2 patients", "start": 21, "end": 23}, {"entity_id": "19838099_1_Ent3", "role": "Treatment", "text": "dasatinib", "start": 24, "end": 25}, {"entity_id": "19838099_1_Ent4", "role": "Treatment_Drug", "text": "dasatinib", "start": 24, "end": 25}, {"entity_id": "19838099_1_Ent2", "role": "Effect", "text": "pleural effusion", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "19838099_1_Ent1", "text": "2", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19838099_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "19838099_1_Ent3", "text": "dasatinib", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19838099_1_Ent4", "text": "dasatinib", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19838099_1_Ent2", "text": "pleural effusion", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "19875411_1", "wnd_id": "19875411_1_1", "text": "One week after the initial - dose of adalimumab ( 160 mg ) , which was initiated due to an acute exacerbation of Crohn 's disease , the patient developed a fulminant cardiomyopathy .", "tokens": ["One", "week", "after", "the", "initial", "-", "dose", "of", "adalimumab", "(", "160", "mg", ")", ",", "which", "was", "initiated", "due", "to", "an", "acute", "exacerbation", "of", "Crohn", "'s", "disease", ",", "the", "patient", "developed", "a", "fulminant", "cardiomyopathy", "."], "event_mentions": [{"id": "19875411_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "19875411_1_Ent6", "role": "Treatment_Time_elapsed", "text": "One week", "start": 0, "end": 2}, {"entity_id": "19875411_1_Ent2", "role": "Treatment", "text": "One week after the initial - dose of adalimumab ( 160 mg )", "start": 0, "end": 13}, {"entity_id": "19875411_1_Ent4", "role": "Treatment_Drug", "text": "adalimumab", "start": 8, "end": 9}, {"entity_id": "19875411_1_Ent5", "role": "Treatment_Dosage", "text": "160 mg", "start": 10, "end": 12}, {"entity_id": "19875411_1_Ent0", "role": "Subject", "text": "an acute exacerbation of Crohn 's disease , the patient", "start": 19, "end": 29}, {"entity_id": "19875411_1_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 23, "end": 26}, {"entity_id": "19875411_1_Ent1", "role": "Effect", "text": "fulminant cardiomyopathy", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "19875411_1_Ent6", "text": "One week", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19875411_1_Ent2", "text": "One week after the initial - dose of adalimumab ( 160 mg )", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "19875411_1_Ent4", "text": "adalimumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19875411_1_Ent5", "text": "160 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19875411_1_Ent0", "text": "an acute exacerbation of Crohn 's disease , the patient", "entity_type": "Entity", "start": 19, "end": 29}, {"id": "19875411_1_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "19875411_1_Ent1", "text": "fulminant cardiomyopathy", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "19884751_3", "wnd_id": "19884751_3_1", "text": "We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin , resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria .", "tokens": ["We", "discuss", "a", "patient", "who", "developed", "severe", "renal", "tubular", "dysfunction", "secondary", "to", "short", "-", "term", "therapy", "with", "Amikacin", ",", "resulting", "in", "refractory", "hypokalemia", ",", "hypocalcemia", ",", "hypomagnesemia", ",", "metabolic", "alkalosis", ",", "and", "polyuria", "."], "event_mentions": [{"id": "19884751_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "19884751_3_Ent0", "role": "Effect", "text": "severe renal tubular dysfunction", "start": 6, "end": 10}, {"entity_id": "19884751_3_Ent4", "role": "Treatment_Duration", "text": "short - term", "start": 12, "end": 15}, {"entity_id": "19884751_3_Ent2", "role": "Treatment", "text": "short - term therapy with Amikacin", "start": 12, "end": 18}, {"entity_id": "19884751_3_Ent3", "role": "Treatment_Drug", "text": "Amikacin", "start": 17, "end": 18}, {"entity_id": "19884751_3_Ent1", "role": "Effect", "text": "resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria", "start": 19, "end": 33}]}], "entity_mentions": [{"id": "19884751_3_Ent0", "text": "severe renal tubular dysfunction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19884751_3_Ent4", "text": "short - term", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "19884751_3_Ent2", "text": "short - term therapy with Amikacin", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19884751_3_Ent3", "text": "Amikacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19884751_3_Ent1", "text": "resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria", "entity_type": "Entity", "start": 19, "end": 33}], "lang": "en"}
{"doc_id": "19892516_2", "wnd_id": "19892516_2_1", "text": "Ciprofloxacin - induced hemorrhagic vasculitis is a rare side effect .", "tokens": ["Ciprofloxacin", "-", "induced", "hemorrhagic", "vasculitis", "is", "a", "rare", "side", "effect", "."], "event_mentions": [{"id": "19892516_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19892516_2_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "19892516_2_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "19892516_2_Ent0", "role": "Effect", "text": "hemorrhagic vasculitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19892516_2_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19892516_2_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19892516_2_Ent0", "text": "hemorrhagic vasculitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19892516_4", "wnd_id": "19892516_4_1", "text": "In one patient the vasculitis resolved after termination of the ciprofloxacin therapy ; in the other patient the ciprofloxacin - induced hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation .", "tokens": ["In", "one", "patient", "the", "vasculitis", "resolved", "after", "termination", "of", "the", "ciprofloxacin", "therapy", ";", "in", "the", "other", "patient", "the", "ciprofloxacin", "-", "induced", "hemorrhagic", "vasculitis", "was", "superimposed", "on", "a", "severe", "forefoot", "infection", ",", "leading", "to", "progressive", "gangrene", "and", "a", "below", "-", "knee", "amputation", "."], "event_mentions": [{"id": "19892516_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "19892516_4_Ent5", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "19892516_4_Ent4", "role": "Subject", "text": "one patient the vasculitis", "start": 1, "end": 5}, {"entity_id": "19892516_4_Ent8", "role": "Treatment_Disorder", "text": "vasculitis", "start": 4, "end": 5}, {"entity_id": "19892516_4_Ent6", "role": "Treatment", "text": "termination of the ciprofloxacin therapy", "start": 7, "end": 12}, {"entity_id": "19892516_4_Ent7", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 10, "end": 11}]}, {"id": "19892516_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "19892516_4_Ent0", "role": "Subject", "text": "patient", "start": 16, "end": 17}, {"entity_id": "19892516_4_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 18, "end": 19}, {"entity_id": "19892516_4_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 18, "end": 19}, {"entity_id": "19892516_4_Ent1", "role": "Effect", "text": "hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation", "start": 21, "end": 41}]}], "entity_mentions": [{"id": "19892516_4_Ent5", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19892516_4_Ent4", "text": "one patient the vasculitis", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "19892516_4_Ent8", "text": "vasculitis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19892516_4_Ent6", "text": "termination of the ciprofloxacin therapy", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "19892516_4_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19892516_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19892516_4_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19892516_4_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19892516_4_Ent1", "text": "hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation", "entity_type": "Entity", "start": 21, "end": 41}], "lang": "en"}
{"doc_id": "19897274_4", "wnd_id": "19897274_4_1", "text": "Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease , although this might depend on racial differences .", "tokens": ["Oncologists", "supervising", "future", "clinical", "trials", "for", "lung", "cancer", "should", "be", "alert", "to", "the", "fact", "that", "sorafenib", "can", "potentially", "induce", "serious", "interstitial", "lung", "disease", ",", "although", "this", "might", "depend", "on", "racial", "differences", "."], "event_mentions": [{"id": "19897274_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 18, "end": 19}, "arguments": [{"entity_id": "19897274_4_Ent3", "role": "Treatment_Disorder", "text": "lung cancer", "start": 6, "end": 8}, {"entity_id": "19897274_4_Ent1", "role": "Treatment", "text": "sorafenib", "start": 15, "end": 16}, {"entity_id": "19897274_4_Ent2", "role": "Treatment_Drug", "text": "sorafenib", "start": 15, "end": 16}, {"entity_id": "19897274_4_Ent0", "role": "Effect", "text": "serious interstitial lung disease", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "19897274_4_Ent3", "text": "lung cancer", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19897274_4_Ent1", "text": "sorafenib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19897274_4_Ent2", "text": "sorafenib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19897274_4_Ent0", "text": "serious interstitial lung disease", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "19904536_10", "wnd_id": "19904536_10_1", "text": "A helicoidal CT scan showed diffuse and severe interstitial pneumonitis , and lung biopsy confirmed accelerated usual interstitial pneumonia consistent with drug - induced toxicity .", "tokens": ["A", "helicoidal", "CT", "scan", "showed", "diffuse", "and", "severe", "interstitial", "pneumonitis", ",", "and", "lung", "biopsy", "confirmed", "accelerated", "usual", "interstitial", "pneumonia", "consistent", "with", "drug", "-", "induced", "toxicity", "."], "event_mentions": [{"id": "19904536_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "19904536_10_Ent0", "role": "Effect", "text": "diffuse and severe interstitial pneumonitis", "start": 5, "end": 10}, {"entity_id": "19904536_10_Ent1", "role": "Effect", "text": "accelerated usual interstitial pneumonia", "start": 15, "end": 19}, {"entity_id": "19904536_10_Ent3", "role": "Treatment", "text": "drug", "start": 21, "end": 22}, {"entity_id": "19904536_10_Ent4", "role": "Treatment_Drug", "text": "drug", "start": 21, "end": 22}, {"entity_id": "19904536_10_Ent2", "role": "Effect", "text": "toxicity", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19904536_10_Ent0", "text": "diffuse and severe interstitial pneumonitis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19904536_10_Ent1", "text": "accelerated usual interstitial pneumonia", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19904536_10_Ent3", "text": "drug", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19904536_10_Ent4", "text": "drug", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19904536_10_Ent2", "text": "toxicity", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19934385_3", "wnd_id": "19934385_3_1", "text": "A 34 - year - old HIV - infected man who had recently initiated efavirenz - based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection .", "tokens": ["A", "34", "-", "year", "-", "old", "HIV", "-", "infected", "man", "who", "had", "recently", "initiated", "efavirenz", "-", "based", "antiretroviral", "therapy", "was", "diagnosed", "with", "disseminated", "Histoplasma", "capsulatum", "infection", "."], "event_mentions": [{"id": "19934385_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 13, "end": 14}, "arguments": [{"entity_id": "19934385_3_Ent0", "role": "Subject", "text": "A 34 - year - old HIV - infected man", "start": 0, "end": 10}, {"entity_id": "19934385_3_Ent2", "role": "Subject_Age", "text": "34 - year - old", "start": 1, "end": 6}, {"entity_id": "19934385_3_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 6, "end": 7}, {"entity_id": "19934385_3_Ent3", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "19934385_3_Ent4", "role": "Treatment", "text": "initiated efavirenz - based antiretroviral therapy", "start": 13, "end": 19}, {"entity_id": "19934385_3_Ent6", "role": "Treatment_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "19934385_3_Ent8", "role": "Combination_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "19934385_3_Ent7", "role": "Treatment_Drug", "text": "antiretroviral", "start": 17, "end": 18}, {"entity_id": "19934385_3_Ent9", "role": "Combination_Drug", "text": "antiretroviral", "start": 17, "end": 18}, {"entity_id": "19934385_3_Ent1", "role": "Subject_Disorder", "text": "disseminated Histoplasma capsulatum infection", "start": 22, "end": 26}]}], "entity_mentions": [{"id": "19934385_3_Ent0", "text": "A 34 - year - old HIV - infected man", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "19934385_3_Ent2", "text": "34 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19934385_3_Ent5", "text": "HIV", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19934385_3_Ent3", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_3_Ent4", "text": "initiated efavirenz - based antiretroviral therapy", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "19934385_3_Ent6", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19934385_3_Ent8", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19934385_3_Ent7", "text": "antiretroviral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_3_Ent9", "text": "antiretroviral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_3_Ent1", "text": "disseminated Histoplasma capsulatum infection", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "19935411_1", "wnd_id": "19935411_1_1", "text": "Hepatotoxicity after high - dose methylprednisolone for demyelinating disease .", "tokens": ["Hepatotoxicity", "after", "high", "-", "dose", "methylprednisolone", "for", "demyelinating", "disease", "."], "event_mentions": [{"id": "19935411_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "19935411_1_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "19935411_1_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 2, "end": 5}, {"entity_id": "19935411_1_Ent1", "role": "Treatment", "text": "high - dose methylprednisolone", "start": 2, "end": 6}, {"entity_id": "19935411_1_Ent3", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 5, "end": 6}, {"entity_id": "19935411_1_Ent4", "role": "Treatment_Disorder", "text": "demyelinating disease", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "19935411_1_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19935411_1_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19935411_1_Ent1", "text": "high - dose methylprednisolone", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19935411_1_Ent3", "text": "methylprednisolone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19935411_1_Ent4", "text": "demyelinating disease", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "19949685_3", "wnd_id": "19949685_3_1", "text": "Two days after administration of Kalimate enema , he had profuse hematochezia , and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon .", "tokens": ["Two", "days", "after", "administration", "of", "Kalimate", "enema", ",", "he", "had", "profuse", "hematochezia", ",", "and", "a", "sigmoidoscopy", "showed", "diffuse", "colonic", "mucosal", "necrosis", "in", "the", "rectum", "and", "sigmoid", "colon", "."], "event_mentions": [{"id": "19949685_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "19949685_3_Ent7", "role": "Treatment_Time_elapsed", "text": "Two days", "start": 0, "end": 2}, {"entity_id": "19949685_3_Ent4", "role": "Treatment", "text": "Two days after administration of Kalimate enema", "start": 0, "end": 7}, {"entity_id": "19949685_3_Ent6", "role": "Treatment_Drug", "text": "Kalimate", "start": 5, "end": 6}, {"entity_id": "19949685_3_Ent5", "role": "Treatment_Route", "text": "enema", "start": 6, "end": 7}, {"entity_id": "19949685_3_Ent0", "role": "Subject", "text": "he", "start": 8, "end": 9}, {"entity_id": "19949685_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 8, "end": 9}, {"entity_id": "19949685_3_Ent2", "role": "Effect", "text": "profuse hematochezia", "start": 10, "end": 12}, {"entity_id": "19949685_3_Ent3", "role": "Effect", "text": "diffuse colonic mucosal necrosis in the rectum", "start": 17, "end": 24}]}], "entity_mentions": [{"id": "19949685_3_Ent7", "text": "Two days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19949685_3_Ent4", "text": "Two days after administration of Kalimate enema", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19949685_3_Ent6", "text": "Kalimate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19949685_3_Ent5", "text": "enema", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19949685_3_Ent0", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19949685_3_Ent1", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19949685_3_Ent2", "text": "profuse hematochezia", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19949685_3_Ent3", "text": "diffuse colonic mucosal necrosis in the rectum", "entity_type": "Entity", "start": 17, "end": 24}], "lang": "en"}
{"doc_id": "19995222_1", "wnd_id": "19995222_1_1", "text": "Clozapine - induced tardive dyskinesia in schizophrenic patients taking clozapine as a first - line antipsychotic drug .", "tokens": ["Clozapine", "-", "induced", "tardive", "dyskinesia", "in", "schizophrenic", "patients", "taking", "clozapine", "as", "a", "first", "-", "line", "antipsychotic", "drug", "."], "event_mentions": [{"id": "19995222_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19995222_1_Ent2", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "19995222_1_Ent3", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "19995222_1_Ent1", "role": "Effect", "text": "tardive dyskinesia", "start": 3, "end": 5}, {"entity_id": "19995222_1_Ent4", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 6, "end": 7}, {"entity_id": "19995222_1_Ent0", "role": "Subject", "text": "schizophrenic patients", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "19995222_1_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19995222_1_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19995222_1_Ent1", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19995222_1_Ent4", "text": "schizophrenic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_1_Ent0", "text": "schizophrenic patients", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "20076952_11", "wnd_id": "20076952_11_1", "text": "The clinical use of itraconazole in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid - associated adverse effects .", "tokens": ["The", "clinical", "use", "of", "itraconazole", "in", "patients", "receiving", "multiple", "doses", "of", "oxycodone", "for", "pain", "relief", "may", "increase", "the", "risk", "of", "opioid", "-", "associated", "adverse", "effects", "."], "event_mentions": [{"id": "20076952_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 16, "end": 17}, "arguments": [{"entity_id": "20076952_11_Ent2", "role": "Treatment", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent8", "role": "Combination_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "20076952_11_Ent3", "role": "Treatment", "text": "receiving multiple doses of oxycodone", "start": 7, "end": 12}, {"entity_id": "20076952_11_Ent7", "role": "Treatment_Dosage", "text": "multiple doses", "start": 8, "end": 10}, {"entity_id": "20076952_11_Ent5", "role": "Treatment_Drug", "text": "oxycodone", "start": 11, "end": 12}, {"entity_id": "20076952_11_Ent9", "role": "Combination_Drug", "text": "oxycodone", "start": 11, "end": 12}, {"entity_id": "20076952_11_Ent4", "role": "Treatment_Disorder", "text": "pain relief", "start": 13, "end": 15}, {"entity_id": "20076952_11_Ent1", "role": "Effect", "text": "opioid - associated adverse effects", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "20076952_11_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent8", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20076952_11_Ent3", "text": "receiving multiple doses of oxycodone", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "20076952_11_Ent7", "text": "multiple doses", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "20076952_11_Ent5", "text": "oxycodone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20076952_11_Ent9", "text": "oxycodone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20076952_11_Ent4", "text": "pain relief", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "20076952_11_Ent1", "text": "opioid - associated adverse effects", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "20110001_1", "wnd_id": "20110001_1_1", "text": "CONCLUSIONS : We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg / d .", "tokens": ["CONCLUSIONS", ":", "We", "present", "a", "case", "of", "a", "patient", "with", "CML", "who", "developed", "KS", "12", "months", "after", "starting", "treatment", "with", "imatinib", "400", "mg", "/", "d", "."], "event_mentions": [{"id": "20110001_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "20110001_1_Ent0", "role": "Subject", "text": "a patient", "start": 7, "end": 9}, {"entity_id": "20110001_1_Ent1", "role": "Effect", "text": "KS", "start": 13, "end": 14}, {"entity_id": "20110001_1_Ent2", "role": "Treatment", "text": "12 months", "start": 14, "end": 16}, {"entity_id": "20110001_1_Ent4", "role": "Treatment_Time_elapsed", "text": "12 months", "start": 14, "end": 16}, {"entity_id": "20110001_1_Ent5", "role": "Treatment_Drug", "text": "imatinib", "start": 20, "end": 21}, {"entity_id": "20110001_1_Ent3", "role": "Treatment", "text": "imatinib 400 mg / d", "start": 20, "end": 25}, {"entity_id": "20110001_1_Ent6", "role": "Treatment_Dosage", "text": "400 mg / d", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "20110001_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20110001_1_Ent1", "text": "KS", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20110001_1_Ent2", "text": "12 months", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "20110001_1_Ent4", "text": "12 months", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "20110001_1_Ent5", "text": "imatinib", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20110001_1_Ent3", "text": "imatinib 400 mg / d", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "20110001_1_Ent6", "text": "400 mg / d", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "20110001_4", "wnd_id": "20110001_4_1", "text": "OBJECTIVE : We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib .", "tokens": ["OBJECTIVE", ":", "We", "report", "a", "case", "of", "cutaneous", "KS", "lesions", "in", "a", "patient", "affected", "by", "CML", "treated", "with", "imatinib", "."], "event_mentions": [{"id": "20110001_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "20110001_4_Ent1", "role": "Effect", "text": "cutaneous KS lesions", "start": 7, "end": 10}, {"entity_id": "20110001_4_Ent0", "role": "Subject", "text": "a patient affected by CML", "start": 11, "end": 16}, {"entity_id": "20110001_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 15, "end": 16}, {"entity_id": "20110001_4_Ent2", "role": "Treatment", "text": "imatinib", "start": 18, "end": 19}, {"entity_id": "20110001_4_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "20110001_4_Ent1", "text": "cutaneous KS lesions", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "20110001_4_Ent0", "text": "a patient affected by CML", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "20110001_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20110001_4_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20110001_4_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "20120657_2", "wnd_id": "20120657_2_1", "text": "We report a case of Zidovudine induced anaemia and bone marrow aplasia in a patient infected with HIV .", "tokens": ["We", "report", "a", "case", "of", "Zidovudine", "induced", "anaemia", "and", "bone", "marrow", "aplasia", "in", "a", "patient", "infected", "with", "HIV", "."], "event_mentions": [{"id": "20120657_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "20120657_2_Ent2", "role": "Treatment", "text": "Zidovudine", "start": 5, "end": 6}, {"entity_id": "20120657_2_Ent3", "role": "Treatment_Drug", "text": "Zidovudine", "start": 5, "end": 6}, {"entity_id": "20120657_2_Ent1", "role": "Effect", "text": "anaemia and bone marrow aplasia", "start": 7, "end": 12}, {"entity_id": "20120657_2_Ent0", "role": "Subject", "text": "a patient infected with HIV", "start": 13, "end": 18}, {"entity_id": "20120657_2_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "20120657_2_Ent2", "text": "Zidovudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20120657_2_Ent3", "text": "Zidovudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20120657_2_Ent1", "text": "anaemia and bone marrow aplasia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "20120657_2_Ent0", "text": "a patient infected with HIV", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "20120657_2_Ent4", "text": "HIV", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "20130478_2", "wnd_id": "20130478_2_1", "text": "Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis .", "tokens": ["Reversible", "heart", "failure", "in", "a", "patient", "receiving", "etanercept", "for", "ankylosing", "spondylitis", "."], "event_mentions": [{"id": "20130478_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "20130478_2_Ent1", "role": "Effect", "text": "Reversible heart failure", "start": 0, "end": 3}, {"entity_id": "20130478_2_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "20130478_2_Ent2", "role": "Treatment", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "20130478_2_Ent3", "role": "Treatment_Drug", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "20130478_2_Ent4", "role": "Treatment_Disorder", "text": "ankylosing spondylitis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "20130478_2_Ent1", "text": "Reversible heart failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20130478_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "20130478_2_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20130478_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20130478_2_Ent4", "text": "ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "20178709_2", "wnd_id": "20178709_2_1", "text": "Methotrexate may rarely provoke serositis , even with low doses and after just a few weeks of therapy .", "tokens": ["Methotrexate", "may", "rarely", "provoke", "serositis", ",", "even", "with", "low", "doses", "and", "after", "just", "a", "few", "weeks", "of", "therapy", "."], "event_mentions": [{"id": "20178709_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoke", "start": 3, "end": 4}, "arguments": [{"entity_id": "20178709_2_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "20178709_2_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "20178709_2_Ent0", "role": "Effect", "text": "serositis", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "20178709_2_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20178709_2_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20178709_2_Ent0", "text": "serositis", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "20178709_3", "wnd_id": "20178709_3_1", "text": "We report here a rare case of pleuropericarditis due to methotrexate .", "tokens": ["We", "report", "here", "a", "rare", "case", "of", "pleuropericarditis", "due", "to", "methotrexate", "."], "event_mentions": [{"id": "20178709_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "20178709_3_Ent0", "role": "Subject", "text": "a rare case", "start": 3, "end": 6}, {"entity_id": "20178709_3_Ent1", "role": "Effect", "text": "pleuropericarditis", "start": 7, "end": 8}, {"entity_id": "20178709_3_Ent2", "role": "Treatment", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "20178709_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20178709_3_Ent0", "text": "a rare case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "20178709_3_Ent1", "text": "pleuropericarditis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20178709_3_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20178709_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20180933_5", "wnd_id": "20180933_5_1", "text": "In a randomised , investigator - blinded , multicentre phase III efficacy trial , 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets ( Coartem ) or as dispersible tablets .", "tokens": ["In", "a", "randomised", ",", "investigator", "-", "blinded", ",", "multicentre", "phase", "III", "efficacy", "trial", ",", "899", "infants", "and", "children", "with", "acute", "uncomplicated", "Plasmodium", "falciparum", "malaria", "received", "six", "doses", "of", "AL", "according", "to", "body", "weight", "over", "3", "days", "either", "as", "crushed", "tablets", "(", "Coartem", ")", "or", "as", "dispersible", "tablets", "."], "event_mentions": [{"id": "20180933_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 24, "end": 25}, "arguments": [{"entity_id": "20180933_5_Ent1", "role": "Subject_Population", "text": "899", "start": 14, "end": 15}, {"entity_id": "20180933_5_Ent0", "role": "Subject", "text": "899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "start": 14, "end": 24}, {"entity_id": "20180933_5_Ent2", "role": "Subject_Age", "text": "infants and children", "start": 15, "end": 18}, {"entity_id": "20180933_5_Ent7", "role": "Treatment_Disorder", "text": "Plasmodium falciparum malaria", "start": 21, "end": 24}, {"entity_id": "20180933_5_Ent6", "role": "Treatment_Dosage", "text": "six doses", "start": 25, "end": 27}, {"entity_id": "20180933_5_Ent3", "role": "Treatment", "text": "six doses of AL according to body weight over 3 days either as crushed tablets ( Coartem ) or as dispersible tablets", "start": 25, "end": 47}, {"entity_id": "20180933_5_Ent4", "role": "Treatment_Drug", "text": "AL", "start": 28, "end": 29}, {"entity_id": "20180933_5_Ent5", "role": "Treatment_Duration", "text": "3 days", "start": 34, "end": 36}, {"entity_id": "20180933_5_Ent8", "role": "Treatment_Route", "text": "crushed tablets", "start": 38, "end": 40}, {"entity_id": "20180933_5_Ent9", "role": "Treatment_Route", "text": "dispersible tablets", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "20180933_5_Ent1", "text": "899", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20180933_5_Ent0", "text": "899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "20180933_5_Ent2", "text": "infants and children", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "20180933_5_Ent7", "text": "Plasmodium falciparum malaria", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "20180933_5_Ent6", "text": "six doses", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "20180933_5_Ent3", "text": "six doses of AL according to body weight over 3 days either as crushed tablets ( Coartem ) or as dispersible tablets", "entity_type": "Entity", "start": 25, "end": 47}, {"id": "20180933_5_Ent4", "text": "AL", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "20180933_5_Ent5", "text": "3 days", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "20180933_5_Ent8", "text": "crushed tablets", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "20180933_5_Ent9", "text": "dispersible tablets", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "20190474_3", "wnd_id": "20190474_3_1", "text": "The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash , acute kidney injury , high - grade fever , eosinophilia , liver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer .", "tokens": ["The", "current", "report", "describes", "a", "man", "who", "was", "prescribed", "zonisamide", "for", "epilepsy", "and", "subsequently", "developed", "widespread", "skin", "rash", ",", "acute", "kidney", "injury", ",", "high", "-", "grade", "fever", ",", "eosinophilia", ",", "liver", "dysfunction", ",", "lymphadenopathy", "and", "an", "increase", "in", "antihuman", "herpesvirus", "-", "6", "immunoglobulin", "G", "titer", "."], "event_mentions": [{"id": "20190474_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "20190474_3_Ent0", "role": "Subject", "text": "a man", "start": 4, "end": 6}, {"entity_id": "20190474_3_Ent1", "role": "Subject_Gender", "text": "man", "start": 5, "end": 6}, {"entity_id": "20190474_3_Ent5", "role": "Treatment_Drug", "text": "zonisamide", "start": 9, "end": 10}, {"entity_id": "20190474_3_Ent3", "role": "Treatment", "text": "zonisamide for epilepsy", "start": 9, "end": 12}, {"entity_id": "20190474_3_Ent4", "role": "Treatment_Disorder", "text": "epilepsy", "start": 11, "end": 12}, {"entity_id": "20190474_3_Ent2", "role": "Effect", "text": "widespread skin rash , acute kidney injury , high - grade fever , eosinophilia , liver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer", "start": 15, "end": 45}]}], "entity_mentions": [{"id": "20190474_3_Ent0", "text": "a man", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "20190474_3_Ent1", "text": "man", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20190474_3_Ent5", "text": "zonisamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20190474_3_Ent3", "text": "zonisamide for epilepsy", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "20190474_3_Ent4", "text": "epilepsy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20190474_3_Ent2", "text": "widespread skin rash , acute kidney injury , high - grade fever , eosinophilia , liver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer", "entity_type": "Entity", "start": 15, "end": 45}], "lang": "en"}
{"doc_id": "20199429_1", "wnd_id": "20199429_1_1", "text": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature , and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol - a component of the Aquaphor emollient they were using to treat their atopic dermatitis .", "tokens": ["Only", "two", "case", "reports", "of", "adults", "with", "allergic", "contact", "dermatitis", "to", "this", "chemical", "exist", "in", "the", "literature", ",", "and", "we", "describe", "three", "more", "cases", "of", "children", "with", "recalcitrant", "atopic", "dermatitis", "found", "to", "have", "potential", "allergic", "contact", "dermatitis", "to", "bisabolol", "-", "a", "component", "of", "the", "Aquaphor", "emollient", "they", "were", "using", "to", "treat", "their", "atopic", "dermatitis", "."], "event_mentions": [{"id": "20199429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 32, "end": 33}, "arguments": [{"entity_id": "20199429_1_Ent1", "role": "Subject_Population", "text": "three", "start": 21, "end": 22}, {"entity_id": "20199429_1_Ent0", "role": "Subject", "text": "three more cases of children with recalcitrant atopic dermatitis", "start": 21, "end": 30}, {"entity_id": "20199429_1_Ent2", "role": "Subject_Age", "text": "children", "start": 25, "end": 26}, {"entity_id": "20199429_1_Ent5", "role": "Treatment_Disorder", "text": "recalcitrant atopic dermatitis", "start": 27, "end": 30}, {"entity_id": "20199429_1_Ent3", "role": "Effect", "text": "potential allergic contact dermatitis", "start": 33, "end": 37}, {"entity_id": "20199429_1_Ent6", "role": "Treatment_Drug", "text": "bisabolol", "start": 38, "end": 39}, {"entity_id": "20199429_1_Ent4", "role": "Treatment", "text": "bisabolol - a component of the Aquaphor emollient", "start": 38, "end": 46}]}], "entity_mentions": [{"id": "20199429_1_Ent1", "text": "three", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "20199429_1_Ent0", "text": "three more cases of children with recalcitrant atopic dermatitis", "entity_type": "Entity", "start": 21, "end": 30}, {"id": "20199429_1_Ent2", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "20199429_1_Ent5", "text": "recalcitrant atopic dermatitis", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "20199429_1_Ent3", "text": "potential allergic contact dermatitis", "entity_type": "Entity", "start": 33, "end": 37}, {"id": "20199429_1_Ent6", "text": "bisabolol", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "20199429_1_Ent4", "text": "bisabolol - a component of the Aquaphor emollient", "entity_type": "Entity", "start": 38, "end": 46}], "lang": "en"}
{"doc_id": "20234160_2", "wnd_id": "20234160_2_1", "text": "Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis .", "tokens": ["Vancomycin", "is", "widely", "used", "against", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "infections", ",", "but", "it", "is", "associated", "with", "many", "adverse", "effects", "such", "as", "nephrotoxicity", ",", "ototoxicity", ",", "gastrointestinal", "disturbances", ",", "blood", "disorders", ",", "and", "two", "types", "of", "hypersensitivity", "reactions", "-", "an", "anaphylactoid", "reaction", "known", "as", "\"", "red", "man", "syndrome", "\"", "and", "anaphylaxis", "."], "event_mentions": [{"id": "20234160_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "20234160_2_Ent1", "role": "Treatment", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "20234160_2_Ent3", "role": "Treatment_Drug", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "20234160_2_Ent2", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus infections", "start": 5, "end": 11}, {"entity_id": "20234160_2_Ent0", "role": "Effect", "text": "nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis", "start": 22, "end": 51}]}], "entity_mentions": [{"id": "20234160_2_Ent1", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20234160_2_Ent3", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20234160_2_Ent2", "text": "methicillin - resistant Staphylococcus aureus infections", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "20234160_2_Ent0", "text": "nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis", "entity_type": "Entity", "start": 22, "end": 51}], "lang": "en"}
{"doc_id": "20234160_3", "wnd_id": "20234160_3_1", "text": "We report a case of a 23 - year - old man who developed a vancomycin - induced anaphylactic reaction in the treatment of methicillin - resistant Staphylococcus aureus infection .", "tokens": ["We", "report", "a", "case", "of", "a", "23", "-", "year", "-", "old", "man", "who", "developed", "a", "vancomycin", "-", "induced", "anaphylactic", "reaction", "in", "the", "treatment", "of", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "infection", "."], "event_mentions": [{"id": "20234160_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "20234160_3_Ent0", "role": "Subject", "text": "a 23 - year - old man", "start": 5, "end": 12}, {"entity_id": "20234160_3_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 6, "end": 11}, {"entity_id": "20234160_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "20234160_3_Ent3", "role": "Effect", "text": "a vancomycin - induced anaphylactic reaction", "start": 14, "end": 20}, {"entity_id": "20234160_3_Ent4", "role": "Treatment", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent6", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus infection", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "20234160_3_Ent0", "text": "a 23 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "20234160_3_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20234160_3_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20234160_3_Ent3", "text": "a vancomycin - induced anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "20234160_3_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent6", "text": "methicillin - resistant Staphylococcus aureus infection", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "20298401_1", "wnd_id": "20298401_1_1", "text": "Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis .", "tokens": ["Fatal", "interstitial", "lung", "disease", "after", "erlotinib", "administration", "in", "a", "patient", "with", "radiation", "fibrosis", "."], "event_mentions": [{"id": "20298401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "20298401_1_Ent2", "role": "Effect", "text": "interstitial lung disease", "start": 1, "end": 4}, {"entity_id": "20298401_1_Ent3", "role": "Treatment", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent0", "role": "Subject", "text": "a patient with radiation fibrosis", "start": 8, "end": 13}, {"entity_id": "20298401_1_Ent1", "role": "Subject_Disorder", "text": "radiation fibrosis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "20298401_1_Ent2", "text": "interstitial lung disease", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "20298401_1_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent0", "text": "a patient with radiation fibrosis", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "20298401_1_Ent1", "text": "radiation fibrosis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "20298401_10", "wnd_id": "20298401_10_1", "text": "CONCLUSION : Our case shows a fatal side effect of erlotinib .", "tokens": ["CONCLUSION", ":", "Our", "case", "shows", "a", "fatal", "side", "effect", "of", "erlotinib", "."], "event_mentions": [{"id": "20298401_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 9, "end": 10}, "arguments": [{"entity_id": "20298401_10_Ent0", "role": "Effect", "text": "side effect", "start": 7, "end": 9}, {"entity_id": "20298401_10_Ent1", "role": "Treatment", "text": "erlotinib", "start": 10, "end": 11}, {"entity_id": "20298401_10_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20298401_10_Ent0", "text": "side effect", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20298401_10_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20298401_10_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20298401_7", "wnd_id": "20298401_7_1", "text": "Six days after taking erlotinib , a chest radiograph showed rapid progression of reticular infiltration in both lung fields .", "tokens": ["Six", "days", "after", "taking", "erlotinib", ",", "a", "chest", "radiograph", "showed", "rapid", "progression", "of", "reticular", "infiltration", "in", "both", "lung", "fields", "."], "event_mentions": [{"id": "20298401_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "20298401_7_Ent1", "role": "Treatment", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent3", "role": "Treatment_Time_elapsed", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent2", "role": "Treatment", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent0", "role": "Effect", "text": "rapid progression of reticular infiltration in both lung fields", "start": 10, "end": 19}]}], "entity_mentions": [{"id": "20298401_7_Ent1", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent3", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent0", "text": "rapid progression of reticular infiltration in both lung fields", "entity_type": "Entity", "start": 10, "end": 19}], "lang": "en"}
{"doc_id": "20298401_9", "wnd_id": "20298401_9_1", "text": "The patient died of respiratory failure after 8 days of steroid infusion and erlotinib discontinuation .", "tokens": ["The", "patient", "died", "of", "respiratory", "failure", "after", "8", "days", "of", "steroid", "infusion", "and", "erlotinib", "discontinuation", "."], "event_mentions": [{"id": "20298401_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "20298401_9_Ent1", "role": "Subject", "text": "The", "start": 0, "end": 1}, {"entity_id": "20298401_9_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "20298401_9_Ent2", "role": "Effect", "text": "died of respiratory failure", "start": 2, "end": 6}, {"entity_id": "20298401_9_Ent4", "role": "Treatment_Time_elapsed", "text": "after 8 days", "start": 6, "end": 9}, {"entity_id": "20298401_9_Ent3", "role": "Treatment", "text": "8 days of steroid infusion and erlotinib discontinuation .", "start": 7, "end": 16}, {"entity_id": "20298401_9_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 10, "end": 11}, {"entity_id": "20298401_9_Ent7", "role": "Treatment_Route", "text": "infusion", "start": 11, "end": 12}, {"entity_id": "20298401_9_Ent6", "role": "Treatment_Drug", "text": "erlotinib", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "20298401_9_Ent1", "text": "The", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20298401_9_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_9_Ent2", "text": "died of respiratory failure", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "20298401_9_Ent4", "text": "after 8 days", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "20298401_9_Ent3", "text": "8 days of steroid infusion and erlotinib discontinuation .", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "20298401_9_Ent5", "text": "steroid", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20298401_9_Ent7", "text": "infusion", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20298401_9_Ent6", "text": "erlotinib", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "20338114_1", "wnd_id": "20338114_1_1", "text": "One patient suffered coronary artery vasospasm , attributed to the use of topical 1:1000 epinephrine during surgery .", "tokens": ["One", "patient", "suffered", "coronary", "artery", "vasospasm", ",", "attributed", "to", "the", "use", "of", "topical", "1:1000", "epinephrine", "during", "surgery", "."], "event_mentions": [{"id": "20338114_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 7, "end": 8}, "arguments": [{"entity_id": "20338114_1_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "20338114_1_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "20338114_1_Ent2", "role": "Effect", "text": "coronary artery vasospasm", "start": 3, "end": 6}, {"entity_id": "20338114_1_Ent3", "role": "Treatment", "text": "topical 1:1000 epinephrine during surgery", "start": 12, "end": 17}, {"entity_id": "20338114_1_Ent4", "role": "Treatment_Dosage", "text": "1:1000", "start": 13, "end": 14}, {"entity_id": "20338114_1_Ent5", "role": "Treatment_Drug", "text": "epinephrine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "20338114_1_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20338114_1_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20338114_1_Ent2", "text": "coronary artery vasospasm", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "20338114_1_Ent3", "text": "topical 1:1000 epinephrine during surgery", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "20338114_1_Ent4", "text": "1:1000", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20338114_1_Ent5", "text": "epinephrine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "20367573_3", "wnd_id": "20367573_3_1", "text": "Thrombocytosis induced by enoxaparin has been reported as a rare adverse effect of this medication in adults .", "tokens": ["Thrombocytosis", "induced", "by", "enoxaparin", "has", "been", "reported", "as", "a", "rare", "adverse", "effect", "of", "this", "medication", "in", "adults", "."], "event_mentions": [{"id": "20367573_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "20367573_3_Ent0", "role": "Effect", "text": "Thrombocytosis", "start": 0, "end": 1}, {"entity_id": "20367573_3_Ent1", "role": "Treatment", "text": "enoxaparin", "start": 3, "end": 4}, {"entity_id": "20367573_3_Ent2", "role": "Treatment_Drug", "text": "enoxaparin", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "20367573_3_Ent0", "text": "Thrombocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20367573_3_Ent1", "text": "enoxaparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20367573_3_Ent2", "text": "enoxaparin", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "20378385_2", "wnd_id": "20378385_2_1", "text": "Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab .", "tokens": ["Visceral", "leishmaniasis", "and", "macrophagic", "activation", "syndrome", "in", "a", "patient", "with", "rheumatoid", "arthritis", "under", "treatment", "with", "adalimumab", "."], "event_mentions": [{"id": "20378385_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 12, "end": 13}, "arguments": [{"entity_id": "20378385_2_Ent1", "role": "Effect", "text": "Visceral leishmaniasis and macrophagic activation syndrome", "start": 0, "end": 6}, {"entity_id": "20378385_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "20378385_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}, {"entity_id": "20378385_2_Ent2", "role": "Treatment", "text": "adalimumab", "start": 15, "end": 16}, {"entity_id": "20378385_2_Ent4", "role": "Treatment_Drug", "text": "adalimumab", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "20378385_2_Ent1", "text": "Visceral leishmaniasis and macrophagic activation syndrome", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "20378385_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "20378385_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20378385_2_Ent2", "text": "adalimumab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20378385_2_Ent4", "text": "adalimumab", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20412003_5", "wnd_id": "20412003_5_1", "text": "Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship ( score of 5 ) between the patient 's development of hepatotoxicity and the TMP - SMX therapy .", "tokens": ["Use", "of", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", "indicated", "a", "probable", "relationship", "(", "score", "of", "5", ")", "between", "the", "patient", "'s", "development", "of", "hepatotoxicity", "and", "the", "TMP", "-", "SMX", "therapy", "."], "event_mentions": [{"id": "20412003_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 22, "end": 23}, "arguments": [{"entity_id": "20412003_5_Ent0", "role": "Subject", "text": "patient 's", "start": 20, "end": 22}, {"entity_id": "20412003_5_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 24, "end": 25}, {"entity_id": "20412003_5_Ent3", "role": "Treatment_Drug", "text": "TMP - SMX", "start": 27, "end": 30}, {"entity_id": "20412003_5_Ent2", "role": "Treatment", "text": "TMP - SMX therapy", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "20412003_5_Ent0", "text": "patient 's", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "20412003_5_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "20412003_5_Ent3", "text": "TMP - SMX", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "20412003_5_Ent2", "text": "TMP - SMX therapy", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "20465622_2", "wnd_id": "20465622_2_1", "text": "BACKGROUND : Aphthous stomatitis , a common mucocutaneous disorder , is a well accepted complication of sirolimus therapy .", "tokens": ["BACKGROUND", ":", "Aphthous", "stomatitis", ",", "a", "common", "mucocutaneous", "disorder", ",", "is", "a", "well", "accepted", "complication", "of", "sirolimus", "therapy", "."], "event_mentions": [{"id": "20465622_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 14, "end": 15}, "arguments": [{"entity_id": "20465622_2_Ent0", "role": "Effect", "text": "Aphthous stomatitis", "start": 2, "end": 4}, {"entity_id": "20465622_2_Ent1", "role": "Treatment", "text": "sirolimus", "start": 16, "end": 17}, {"entity_id": "20465622_2_Ent2", "role": "Treatment_Drug", "text": "sirolimus", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "20465622_2_Ent0", "text": "Aphthous stomatitis", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "20465622_2_Ent1", "text": "sirolimus", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20465622_2_Ent2", "text": "sirolimus", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "20666169_1", "wnd_id": "20666169_1_1", "text": "Atorvastatin induced multiple organ failure .", "tokens": ["Atorvastatin", "induced", "multiple", "organ", "failure", "."], "event_mentions": [{"id": "20666169_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "20666169_1_Ent1", "role": "Treatment", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "20666169_1_Ent2", "role": "Treatment_Drug", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "20666169_1_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "20666169_1_Ent1", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20666169_1_Ent2", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20666169_1_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "20925534_1", "wnd_id": "20925534_1_1", "text": "Clopidogrel with or without omeprazole in coronary artery disease .", "tokens": ["Clopidogrel", "with", "or", "without", "omeprazole", "in", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "20925534_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "20925534_1_Ent2", "role": "Treatment_Drug", "text": "Clopidogrel", "start": 0, "end": 1}, {"entity_id": "20925534_1_Ent4", "role": "Treatment_Drug", "text": "Clopidogrel", "start": 0, "end": 1}, {"entity_id": "20925534_1_Ent5", "role": "Combination_Drug", "text": "Clopidogrel", "start": 0, "end": 1}, {"entity_id": "20925534_1_Ent0", "role": "Treatment", "text": "Clopidogrel with or without omeprazole", "start": 0, "end": 5}, {"entity_id": "20925534_1_Ent3", "role": "Treatment_Drug", "text": "omeprazole", "start": 4, "end": 5}, {"entity_id": "20925534_1_Ent6", "role": "Combination_Drug", "text": "omeprazole", "start": 4, "end": 5}, {"entity_id": "20925534_1_Ent1", "role": "Treatment_Disorder", "text": "coronary artery disease", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "20925534_1_Ent2", "text": "Clopidogrel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20925534_1_Ent4", "text": "Clopidogrel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20925534_1_Ent5", "text": "Clopidogrel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20925534_1_Ent0", "text": "Clopidogrel with or without omeprazole", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "20925534_1_Ent3", "text": "omeprazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20925534_1_Ent6", "text": "omeprazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20925534_1_Ent1", "text": "coronary artery disease", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "20979526_8", "wnd_id": "20979526_8_1", "text": "Because at the end of the first month the patient 's platelet counts were normal and the thrombocytopenia developed after the co - medication with conventional drugs , it was suspected that the thrombocytopenia might not be attributed to the use of FHP .", "tokens": ["Because", "at", "the", "end", "of", "the", "first", "month", "the", "patient", "'s", "platelet", "counts", "were", "normal", "and", "the", "thrombocytopenia", "developed", "after", "the", "co", "-", "medication", "with", "conventional", "drugs", ",", "it", "was", "suspected", "that", "the", "thrombocytopenia", "might", "not", "be", "attributed", "to", "the", "use", "of", "FHP", "."], "event_mentions": [{"id": "20979526_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 37, "end": 38}, "arguments": [{"entity_id": "20979526_8_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 33, "end": 34}, {"entity_id": "20979526_8_Ent1", "role": "Treatment", "text": "FHP", "start": 42, "end": 43}, {"entity_id": "20979526_8_Ent2", "role": "Treatment_Drug", "text": "FHP", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "20979526_8_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "20979526_8_Ent1", "text": "FHP", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "20979526_8_Ent2", "text": "FHP", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "21045170_3", "wnd_id": "21045170_3_1", "text": "A 47 - year - old HIV - infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device was prescribed subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended - release niacin 500 mg / day for a high - density lipoprotein level of 8 mg / dL. After 1 week of concomitant therapy , the patient began experiencing extreme redness , edema , and swelling at the injection site that corresponded with the flushing sensation due to niacin .", "tokens": ["A", "47", "-", "year", "-", "old", "HIV", "-", "infected", "man", "with", "dilated", "cardiomyopathy", "and", "prolonged", "QT", "syndrome", "with", "an", "automatic", "implantable", "cardiovascular", "defibrillator", "device", "was", "prescribed", "subcutaneous", "enfuvirtide", "90", "mg", "twice", "daily", "as", "part", "of", "his", "antiretroviral", "regimen", "and", "oral", "extended", "-", "release", "niacin", "500", "mg", "/", "day", "for", "a", "high", "-", "density", "lipoprotein", "level", "of", "8", "mg", "/", "dL.", "After", "1", "week", "of", "concomitant", "therapy", ",", "the", "patient", "began", "experiencing", "extreme", "redness", ",", "edema", ",", "and", "swelling", "at", "the", "injection", "site", "that", "corresponded", "with", "the", "flushing", "sensation", "due", "to", "niacin", "."], "event_mentions": [{"id": "21045170_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experiencing", "start": 70, "end": 71}, "arguments": [{"entity_id": "21045170_3_Ent0", "role": "Subject", "text": "A 47 - year - old HIV - infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device", "start": 0, "end": 24}, {"entity_id": "21045170_3_Ent3", "role": "Subject_Age", "text": "47 - year - old", "start": 1, "end": 6}, {"entity_id": "21045170_3_Ent7", "role": "Treatment_Disorder", "text": "HIV - infected", "start": 6, "end": 9}, {"entity_id": "21045170_3_Ent4", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "21045170_3_Ent1", "role": "Subject_Disorder", "text": "dilated cardiomyopathy", "start": 11, "end": 13}, {"entity_id": "21045170_3_Ent2", "role": "Subject_Disorder", "text": "prolonged QT syndrome", "start": 14, "end": 17}, {"entity_id": "21045170_3_Ent14", "role": "Treatment_Route", "text": "subcutaneous", "start": 26, "end": 27}, {"entity_id": "21045170_3_Ent6", "role": "Treatment", "text": "subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended - release niacin 500 mg / day for a high - density lipoprotein level of 8 mg / dL.", "start": 26, "end": 60}, {"entity_id": "21045170_3_Ent12", "role": "Treatment_Drug", "text": "enfuvirtide", "start": 27, "end": 28}, {"entity_id": "21045170_3_Ent18", "role": "Combination_Drug", "text": "enfuvirtide", "start": 27, "end": 28}, {"entity_id": "21045170_3_Ent8", "role": "Treatment_Dosage", "text": "90 mg", "start": 28, "end": 30}, {"entity_id": "21045170_3_Ent10", "role": "Treatment_Freq", "text": "twice daily", "start": 30, "end": 32}, {"entity_id": "21045170_3_Ent15", "role": "Treatment_Route", "text": "oral", "start": 39, "end": 40}, {"entity_id": "21045170_3_Ent13", "role": "Treatment_Drug", "text": "niacin", "start": 43, "end": 44}, {"entity_id": "21045170_3_Ent17", "role": "Combination_Drug", "text": "niacin", "start": 43, "end": 44}, {"entity_id": "21045170_3_Ent9", "role": "Treatment_Dosage", "text": "500 mg", "start": 44, "end": 46}, {"entity_id": "21045170_3_Ent11", "role": "Treatment_Freq", "text": "day", "start": 47, "end": 48}, {"entity_id": "21045170_3_Ent16", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 61, "end": 63}, {"entity_id": "21045170_3_Ent5", "role": "Effect", "text": "extreme redness , edema , and swelling at the injection site that corresponded with the flushing sensation due to niacin", "start": 71, "end": 91}]}], "entity_mentions": [{"id": "21045170_3_Ent0", "text": "A 47 - year - old HIV - infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device", "entity_type": "Entity", "start": 0, "end": 24}, {"id": "21045170_3_Ent3", "text": "47 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21045170_3_Ent7", "text": "HIV - infected", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "21045170_3_Ent4", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21045170_3_Ent1", "text": "dilated cardiomyopathy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21045170_3_Ent2", "text": "prolonged QT syndrome", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "21045170_3_Ent14", "text": "subcutaneous", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "21045170_3_Ent6", "text": "subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended - release niacin 500 mg / day for a high - density lipoprotein level of 8 mg / dL.", "entity_type": "Entity", "start": 26, "end": 60}, {"id": "21045170_3_Ent12", "text": "enfuvirtide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "21045170_3_Ent18", "text": "enfuvirtide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "21045170_3_Ent8", "text": "90 mg", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "21045170_3_Ent10", "text": "twice daily", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "21045170_3_Ent15", "text": "oral", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "21045170_3_Ent13", "text": "niacin", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "21045170_3_Ent17", "text": "niacin", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "21045170_3_Ent9", "text": "500 mg", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "21045170_3_Ent11", "text": "day", "entity_type": "Entity", "start": 47, "end": 48}, {"id": "21045170_3_Ent16", "text": "1 week", "entity_type": "Entity", "start": 61, "end": 63}, {"id": "21045170_3_Ent5", "text": "extreme redness , edema , and swelling at the injection site that corresponded with the flushing sensation due to niacin", "entity_type": "Entity", "start": 71, "end": 91}], "lang": "en"}
{"doc_id": "21045170_9", "wnd_id": "21045170_9_1", "text": "When these cells are exposed to nicotinic acid , an exaggerated immune response is produced that may lead to pain , redness , and swelling at the injection site .", "tokens": ["When", "these", "cells", "are", "exposed", "to", "nicotinic", "acid", ",", "an", "exaggerated", "immune", "response", "is", "produced", "that", "may", "lead", "to", "pain", ",", "redness", ",", "and", "swelling", "at", "the", "injection", "site", "."], "event_mentions": [{"id": "21045170_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 14, "end": 15}, "arguments": [{"entity_id": "21045170_9_Ent2", "role": "Treatment", "text": "nicotinic acid", "start": 6, "end": 8}, {"entity_id": "21045170_9_Ent3", "role": "Treatment_Drug", "text": "nicotinic acid", "start": 6, "end": 8}, {"entity_id": "21045170_9_Ent0", "role": "Effect", "text": "exaggerated immune response", "start": 10, "end": 13}, {"entity_id": "21045170_9_Ent1", "role": "Effect", "text": "pain , redness , and swelling at the injection site", "start": 19, "end": 29}]}], "entity_mentions": [{"id": "21045170_9_Ent2", "text": "nicotinic acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21045170_9_Ent3", "text": "nicotinic acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21045170_9_Ent0", "text": "exaggerated immune response", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "21045170_9_Ent1", "text": "pain , redness , and swelling at the injection site", "entity_type": "Entity", "start": 19, "end": 29}], "lang": "en"}
{"doc_id": "2104570_2", "wnd_id": "2104570_2_1", "text": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid , doxorubicin , and mitomycin C.", "tokens": ["Two", "cases", "are", "reported", "of", "patients", "who", "developed", "a", "hematologic", "malignancy", "several", "years", "after", "intravesical", "chemotherapy", "of", "superficial", "bladder", "cancer", "with", "etoglucid", ",", "doxorubicin", ",", "and", "mitomycin", "C."], "event_mentions": [{"id": "2104570_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "2104570_2_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "2104570_2_Ent1", "role": "Effect", "text": "a hematologic malignancy", "start": 8, "end": 11}, {"entity_id": "2104570_2_Ent8", "role": "Treatment_Time_elapsed", "text": "several years after", "start": 11, "end": 14}, {"entity_id": "2104570_2_Ent2", "role": "Treatment", "text": "several years after intravesical chemotherapy", "start": 11, "end": 16}, {"entity_id": "2104570_2_Ent9", "role": "Treatment_Route", "text": "intravesical", "start": 14, "end": 15}, {"entity_id": "2104570_2_Ent7", "role": "Treatment_Disorder", "text": "superficial bladder cancer", "start": 17, "end": 20}, {"entity_id": "2104570_2_Ent3", "role": "Treatment", "text": "with etoglucid , doxorubicin , and mitomycin C.", "start": 20, "end": 28}, {"entity_id": "2104570_2_Ent4", "role": "Treatment_Drug", "text": "etoglucid", "start": 21, "end": 22}, {"entity_id": "2104570_2_Ent12", "role": "Combination_Drug", "text": "etoglucid", "start": 21, "end": 22}, {"entity_id": "2104570_2_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 23, "end": 24}, {"entity_id": "2104570_2_Ent11", "role": "Combination_Drug", "text": "doxorubicin", "start": 23, "end": 24}, {"entity_id": "2104570_2_Ent6", "role": "Treatment_Drug", "text": "mitomycin C.", "start": 26, "end": 28}, {"entity_id": "2104570_2_Ent10", "role": "Combination_Drug", "text": "mitomycin C.", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "2104570_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2104570_2_Ent1", "text": "a hematologic malignancy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2104570_2_Ent8", "text": "several years after", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "2104570_2_Ent2", "text": "several years after intravesical chemotherapy", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "2104570_2_Ent9", "text": "intravesical", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2104570_2_Ent7", "text": "superficial bladder cancer", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "2104570_2_Ent3", "text": "with etoglucid , doxorubicin , and mitomycin C.", "entity_type": "Entity", "start": 20, "end": 28}, {"id": "2104570_2_Ent4", "text": "etoglucid", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2104570_2_Ent12", "text": "etoglucid", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2104570_2_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2104570_2_Ent11", "text": "doxorubicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2104570_2_Ent6", "text": "mitomycin C.", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "2104570_2_Ent10", "text": "mitomycin C.", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "21330680_2", "wnd_id": "21330680_2_1", "text": "The case of a patient taking high - dosage olanzapine who experienced parkinsonism after smoking cessation is reported .", "tokens": ["The", "case", "of", "a", "patient", "taking", "high", "-", "dosage", "olanzapine", "who", "experienced", "parkinsonism", "after", "smoking", "cessation", "is", "reported", "."], "event_mentions": [{"id": "21330680_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 11, "end": 12}, "arguments": [{"entity_id": "21330680_2_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "21330680_2_Ent4", "role": "Treatment_Dosage", "text": "high - dosage", "start": 6, "end": 9}, {"entity_id": "21330680_2_Ent2", "role": "Treatment", "text": "high - dosage olanzapine", "start": 6, "end": 10}, {"entity_id": "21330680_2_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "21330680_2_Ent1", "role": "Effect", "text": "parkinsonism", "start": 12, "end": 13}, {"entity_id": "21330680_2_Ent3", "role": "Treatment", "text": "smoking cessation", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "21330680_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "21330680_2_Ent4", "text": "high - dosage", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "21330680_2_Ent2", "text": "high - dosage olanzapine", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "21330680_2_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21330680_2_Ent1", "text": "parkinsonism", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21330680_2_Ent3", "text": "smoking cessation", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "21350204_12", "wnd_id": "21350204_12_1", "text": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio < 1.7 and may reduce the risk of poor functional outcome .", "tokens": ["The", "results", "from", "the", "present", "study", "suggest", "that", "tissue", "plasminogen", "activator", "treatment", "appears", "to", "be", "safe", "in", "patients", "with", "acute", "ischemic", "stroke", "taking", "warfarin", "with", "an", "international", "normalized", "ratio", "<", "1.7", "and", "may", "reduce", "the", "risk", "of", "poor", "functional", "outcome", "."], "event_mentions": [{"id": "21350204_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "appears", "start": 12, "end": 13}, "arguments": [{"entity_id": "21350204_12_Ent5", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent7", "role": "Combination_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent3", "role": "Treatment", "text": "tissue plasminogen activator treatment", "start": 8, "end": 12}, {"entity_id": "21350204_12_Ent0", "role": "Subject", "text": "patients with acute ischemic stroke", "start": 17, "end": 22}, {"entity_id": "21350204_12_Ent4", "role": "Treatment_Disorder", "text": "acute ischemic stroke", "start": 19, "end": 22}, {"entity_id": "21350204_12_Ent2", "role": "Treatment", "text": "taking warfarin with an international normalized ratio < 1.7", "start": 22, "end": 31}, {"entity_id": "21350204_12_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent8", "role": "Combination_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent1", "role": "Effect", "text": "may reduce the risk of poor functional outcome", "start": 32, "end": 40}]}], "entity_mentions": [{"id": "21350204_12_Ent5", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent7", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent3", "text": "tissue plasminogen activator treatment", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "21350204_12_Ent0", "text": "patients with acute ischemic stroke", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21350204_12_Ent4", "text": "acute ischemic stroke", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "21350204_12_Ent2", "text": "taking warfarin with an international normalized ratio < 1.7", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "21350204_12_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent1", "text": "may reduce the risk of poor functional outcome", "entity_type": "Entity", "start": 32, "end": 40}], "lang": "en"}
{"doc_id": "2140997_2", "wnd_id": "2140997_2_1", "text": "Monitoring of liver function tests should be mandatory in patients receiving high doses of cyproterone acetate ; the drug should be withdrawn immediately if abnormal liver function tests are found .", "tokens": ["Monitoring", "of", "liver", "function", "tests", "should", "be", "mandatory", "in", "patients", "receiving", "high", "doses", "of", "cyproterone", "acetate", ";", "the", "drug", "should", "be", "withdrawn", "immediately", "if", "abnormal", "liver", "function", "tests", "are", "found", "."], "event_mentions": [{"id": "2140997_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "abnormal", "start": 24, "end": 25}, "arguments": [{"entity_id": "2140997_2_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "2140997_2_Ent2", "role": "Treatment", "text": "receiving high doses of cyproterone acetate", "start": 10, "end": 16}, {"entity_id": "2140997_2_Ent4", "role": "Treatment_Dosage", "text": "high doses", "start": 11, "end": 13}, {"entity_id": "2140997_2_Ent3", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 14, "end": 16}, {"entity_id": "2140997_2_Ent1", "role": "Effect", "text": "abnormal liver function", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "2140997_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2140997_2_Ent2", "text": "receiving high doses of cyproterone acetate", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "2140997_2_Ent4", "text": "high doses", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "2140997_2_Ent3", "text": "cyproterone acetate", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "2140997_2_Ent1", "text": "abnormal liver function", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "2144305_1", "wnd_id": "2144305_1_1", "text": "A unique case of a transient , nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported .", "tokens": ["A", "unique", "case", "of", "a", "transient", ",", "nonpigmenting", "fixed", "drug", "eruption", "caused", "by", "the", "radiopaque", "contrast", "medium", "iothalamate", "is", "reported", "."], "event_mentions": [{"id": "2144305_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "2144305_1_Ent0", "role": "Effect", "text": "a transient , nonpigmenting fixed drug eruption", "start": 4, "end": 11}, {"entity_id": "2144305_1_Ent1", "role": "Treatment", "text": "iothalamate", "start": 17, "end": 18}, {"entity_id": "2144305_1_Ent2", "role": "Treatment_Drug", "text": "iothalamate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "2144305_1_Ent0", "text": "a transient , nonpigmenting fixed drug eruption", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "2144305_1_Ent1", "text": "iothalamate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2144305_1_Ent2", "text": "iothalamate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "21448111_5", "wnd_id": "21448111_5_1", "text": "During the second hospitalization it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time , which is very difficult to determine in everyday clinical practice .", "tokens": ["During", "the", "second", "hospitalization", "it", "is", "possible", "that", "antipsychotic", "treatment", "combined", "with", "an", "antidepressant", "caused", "akathisia", "or", "there", "were", "symptoms", "of", "agitated", "depression", "and", "akathisia", "present", "at", "the", "same", "time", ",", "which", "is", "very", "difficult", "to", "determine", "in", "everyday", "clinical", "practice", "."], "event_mentions": [{"id": "21448111_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 14, "end": 15}, "arguments": [{"entity_id": "21448111_5_Ent2", "role": "Treatment_Drug", "text": "antipsychotic", "start": 8, "end": 9}, {"entity_id": "21448111_5_Ent5", "role": "Combination_Drug", "text": "antipsychotic", "start": 8, "end": 9}, {"entity_id": "21448111_5_Ent1", "role": "Treatment", "text": "antipsychotic treatment combined with an antidepressant", "start": 8, "end": 14}, {"entity_id": "21448111_5_Ent3", "role": "Treatment_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "21448111_5_Ent4", "role": "Combination_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "21448111_5_Ent0", "role": "Effect", "text": "akathisia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "21448111_5_Ent2", "text": "antipsychotic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21448111_5_Ent5", "text": "antipsychotic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21448111_5_Ent1", "text": "antipsychotic treatment combined with an antidepressant", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "21448111_5_Ent3", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_5_Ent4", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_5_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "21448111_6", "wnd_id": "21448111_6_1", "text": "We can conclude that in this case , as in many others , akathisia as a possible adverse effect of psychopharmacs was very hard to identify .", "tokens": ["We", "can", "conclude", "that", "in", "this", "case", ",", "as", "in", "many", "others", ",", "akathisia", "as", "a", "possible", "adverse", "effect", "of", "psychopharmacs", "was", "very", "hard", "to", "identify", "."], "event_mentions": [{"id": "21448111_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 17, "end": 19}, "arguments": [{"entity_id": "21448111_6_Ent0", "role": "Subject", "text": "this case", "start": 5, "end": 7}, {"entity_id": "21448111_6_Ent1", "role": "Effect", "text": "akathisia", "start": 13, "end": 14}, {"entity_id": "21448111_6_Ent2", "role": "Treatment", "text": "psychopharmacs", "start": 20, "end": 21}, {"entity_id": "21448111_6_Ent3", "role": "Treatment_Drug", "text": "psychopharmacs", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "21448111_6_Ent0", "text": "this case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "21448111_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_6_Ent2", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_6_Ent3", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "21512888_4", "wnd_id": "21512888_4_1", "text": "Valproic acid also displaces warfarin from the protein binding sites resulting in significant INR changes but this type of drug interaction is less well known .", "tokens": ["Valproic", "acid", "also", "displaces", "warfarin", "from", "the", "protein", "binding", "sites", "resulting", "in", "significant", "INR", "changes", "but", "this", "type", "of", "drug", "interaction", "is", "less", "well", "known", "."], "event_mentions": [{"id": "21512888_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 10, "end": 11}, "arguments": [{"entity_id": "21512888_4_Ent2", "role": "Treatment_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "21512888_4_Ent4", "role": "Combination_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "21512888_4_Ent1", "role": "Treatment", "text": "Valproic acid also displaces warfarin from the protein binding sites", "start": 0, "end": 10}, {"entity_id": "21512888_4_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21512888_4_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21512888_4_Ent0", "role": "Effect", "text": "significant INR changes", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "21512888_4_Ent2", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21512888_4_Ent4", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21512888_4_Ent1", "text": "Valproic acid also displaces warfarin from the protein binding sites", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "21512888_4_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21512888_4_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21512888_4_Ent0", "text": "significant INR changes", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "21512888_7", "wnd_id": "21512888_7_1", "text": "Patient was on warfarin for a prior deep venous thrombosis .", "tokens": ["Patient", "was", "on", "warfarin", "for", "a", "prior", "deep", "venous", "thrombosis", "."], "event_mentions": [{"id": "21512888_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "21512888_7_Ent0", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent1", "role": "Treatment_Disorder", "text": "a prior deep venous thrombosis", "start": 5, "end": 10}]}], "entity_mentions": [{"id": "21512888_7_Ent0", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent1", "text": "a prior deep venous thrombosis", "entity_type": "Entity", "start": 5, "end": 10}], "lang": "en"}
{"doc_id": "21515865_11", "wnd_id": "21515865_11_1", "text": "According to the Drug Interaction Probability Scale , the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use .", "tokens": ["According", "to", "the", "Drug", "Interaction", "Probability", "Scale", ",", "the", "development", "of", "supratherapeutic", "INRs", "was", "probably", "associated", "with", "concomitant", "acetaminophen", "and", "moxifloxacin", "use", "."], "event_mentions": [{"id": "21515865_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "21515865_11_Ent0", "role": "Effect", "text": "development of supratherapeutic INRs", "start": 9, "end": 13}, {"entity_id": "21515865_11_Ent1", "role": "Treatment", "text": "concomitant acetaminophen and moxifloxacin use", "start": 17, "end": 22}, {"entity_id": "21515865_11_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 18, "end": 19}, {"entity_id": "21515865_11_Ent4", "role": "Combination_Drug", "text": "acetaminophen", "start": 18, "end": 19}, {"entity_id": "21515865_11_Ent2", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 20, "end": 21}, {"entity_id": "21515865_11_Ent5", "role": "Combination_Drug", "text": "moxifloxacin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "21515865_11_Ent0", "text": "development of supratherapeutic INRs", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "21515865_11_Ent1", "text": "concomitant acetaminophen and moxifloxacin use", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21515865_11_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21515865_11_Ent4", "text": "acetaminophen", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21515865_11_Ent2", "text": "moxifloxacin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21515865_11_Ent5", "text": "moxifloxacin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "21515865_4", "wnd_id": "21515865_4_1", "text": "On the day before this visit , he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer .", "tokens": ["On", "the", "day", "before", "this", "visit", ",", "he", "had", "received", "the", "third", "of", "six", "serial", "weekly", "BCG", "bladder", "instillations", "for", "the", "treatment", "of", "bladder", "cancer", "."], "event_mentions": [{"id": "21515865_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 9, "end": 10}, "arguments": [{"entity_id": "21515865_4_Ent0", "role": "Subject", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent2", "role": "Subject_Gender", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent3", "role": "Treatment", "text": "the third of six serial weekly BCG bladder instillations", "start": 10, "end": 19}, {"entity_id": "21515865_4_Ent7", "role": "Treatment_Freq", "text": "weekly", "start": 15, "end": 16}, {"entity_id": "21515865_4_Ent6", "role": "Treatment_Drug", "text": "BCG", "start": 16, "end": 17}, {"entity_id": "21515865_4_Ent4", "role": "Treatment_Route", "text": "bladder instillations", "start": 17, "end": 19}, {"entity_id": "21515865_4_Ent1", "role": "Subject", "text": "bladder cancer", "start": 23, "end": 25}, {"entity_id": "21515865_4_Ent5", "role": "Treatment_Disorder", "text": "bladder cancer", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "21515865_4_Ent0", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent2", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent3", "text": "the third of six serial weekly BCG bladder instillations", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "21515865_4_Ent7", "text": "weekly", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21515865_4_Ent6", "text": "BCG", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21515865_4_Ent4", "text": "bladder instillations", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21515865_4_Ent1", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "21515865_4_Ent5", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "2154663_2", "wnd_id": "2154663_2_1", "text": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient .", "tokens": ["Concomitant", "irradiation", "apparently", "enhanced", "the", "skin", "toxicity", "of", "aminoglutethimide", "or", "possibly", "aminoglutethimide", "had", "a", "radiosensitizing", "role", "in", "this", "patient", "."], "event_mentions": [{"id": "2154663_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhanced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2154663_2_Ent2", "role": "Treatment", "text": "Concomitant irradiation", "start": 0, "end": 2}, {"entity_id": "2154663_2_Ent5", "role": "Treatment_Drug", "text": "irradiation", "start": 1, "end": 2}, {"entity_id": "2154663_2_Ent6", "role": "Combination_Drug", "text": "irradiation", "start": 1, "end": 2}, {"entity_id": "2154663_2_Ent1", "role": "Effect", "text": "skin toxicity", "start": 5, "end": 7}, {"entity_id": "2154663_2_Ent3", "role": "Treatment", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent7", "role": "Combination_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent0", "role": "Subject", "text": "this patient", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2154663_2_Ent2", "text": "Concomitant irradiation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2154663_2_Ent5", "text": "irradiation", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2154663_2_Ent6", "text": "irradiation", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2154663_2_Ent1", "text": "skin toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2154663_2_Ent3", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent7", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent0", "text": "this patient", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "21630612_2", "wnd_id": "21630612_2_1", "text": "Myopathy , including rhabdomyolysis , is a well - known , albeit rare complication of statin therapy .", "tokens": ["Myopathy", ",", "including", "rhabdomyolysis", ",", "is", "a", "well", "-", "known", ",", "albeit", "rare", "complication", "of", "statin", "therapy", "."], "event_mentions": [{"id": "21630612_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "21630612_2_Ent0", "role": "Effect", "text": "Myopathy , including rhabdomyolysis", "start": 0, "end": 4}, {"entity_id": "21630612_2_Ent1", "role": "Treatment", "text": "statin", "start": 15, "end": 16}, {"entity_id": "21630612_2_Ent2", "role": "Treatment_Drug", "text": "statin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "21630612_2_Ent0", "text": "Myopathy , including rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21630612_2_Ent1", "text": "statin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_2_Ent2", "text": "statin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "21630612_4", "wnd_id": "21630612_4_1", "text": "We report a case of severe simvastatin - induced rhabdomyolysis triggered by the addition of amiodarone to previously well - tolerated chronic statin therapy .", "tokens": ["We", "report", "a", "case", "of", "severe", "simvastatin", "-", "induced", "rhabdomyolysis", "triggered", "by", "the", "addition", "of", "amiodarone", "to", "previously", "well", "-", "tolerated", "chronic", "statin", "therapy", "."], "event_mentions": [{"id": "21630612_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "21630612_4_Ent1", "role": "Treatment", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent8", "role": "Combination_Drug", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "21630612_4_Ent2", "role": "Treatment", "text": "the addition of amiodarone to previously well - tolerated chronic statin therapy", "start": 12, "end": 24}, {"entity_id": "21630612_4_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 15, "end": 16}, {"entity_id": "21630612_4_Ent7", "role": "Combination_Drug", "text": "amiodarone", "start": 15, "end": 16}, {"entity_id": "21630612_4_Ent6", "role": "Treatment_Time_elapsed", "text": "chronic", "start": 21, "end": 22}, {"entity_id": "21630612_4_Ent5", "role": "Treatment_Drug", "text": "statin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "21630612_4_Ent1", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent8", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21630612_4_Ent2", "text": "the addition of amiodarone to previously well - tolerated chronic statin therapy", "entity_type": "Entity", "start": 12, "end": 24}, {"id": "21630612_4_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_4_Ent7", "text": "amiodarone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_4_Ent6", "text": "chronic", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "21630612_4_Ent5", "text": "statin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "21712512_10", "wnd_id": "21712512_10_1", "text": "Iatrogenic Cushing syndrome has been reported in patients with CF treated concomitantly , and for extended duration , with inhaled corticosteroids and CYP3A4 inhibitors .", "tokens": ["Iatrogenic", "Cushing", "syndrome", "has", "been", "reported", "in", "patients", "with", "CF", "treated", "concomitantly", ",", "and", "for", "extended", "duration", ",", "with", "inhaled", "corticosteroids", "and", "CYP3A4", "inhibitors", "."], "event_mentions": [{"id": "21712512_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 5, "end": 6}, "arguments": [{"entity_id": "21712512_10_Ent2", "role": "Effect", "text": "Iatrogenic Cushing syndrome", "start": 0, "end": 3}, {"entity_id": "21712512_10_Ent0", "role": "Subject", "text": "patients with CF", "start": 7, "end": 10}, {"entity_id": "21712512_10_Ent1", "role": "Subject_Disorder", "text": "CF", "start": 9, "end": 10}, {"entity_id": "21712512_10_Ent4", "role": "Treatment_Route", "text": "inhaled", "start": 19, "end": 20}, {"entity_id": "21712512_10_Ent3", "role": "Treatment", "text": "inhaled corticosteroids and CYP3A4 inhibitors", "start": 19, "end": 24}, {"entity_id": "21712512_10_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 20, "end": 21}, {"entity_id": "21712512_10_Ent7", "role": "Combination_Drug", "text": "corticosteroids", "start": 20, "end": 21}, {"entity_id": "21712512_10_Ent6", "role": "Treatment_Drug", "text": "CYP3A4 inhibitors", "start": 22, "end": 24}, {"entity_id": "21712512_10_Ent8", "role": "Combination_Drug", "text": "CYP3A4 inhibitors", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "21712512_10_Ent2", "text": "Iatrogenic Cushing syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21712512_10_Ent0", "text": "patients with CF", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "21712512_10_Ent1", "text": "CF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21712512_10_Ent4", "text": "inhaled", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "21712512_10_Ent3", "text": "inhaled corticosteroids and CYP3A4 inhibitors", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "21712512_10_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21712512_10_Ent7", "text": "corticosteroids", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21712512_10_Ent6", "text": "CYP3A4 inhibitors", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "21712512_10_Ent8", "text": "CYP3A4 inhibitors", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "21712512_11", "wnd_id": "21712512_11_1", "text": "This case highlights rapid onset of adrenal insufficiency in a patient with CF - related liver disease treated briefly with a moderate CYP3A4 inhibitor .", "tokens": ["This", "case", "highlights", "rapid", "onset", "of", "adrenal", "insufficiency", "in", "a", "patient", "with", "CF", "-", "related", "liver", "disease", "treated", "briefly", "with", "a", "moderate", "CYP3A4", "inhibitor", "."], "event_mentions": [{"id": "21712512_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 4, "end": 5}, "arguments": [{"entity_id": "21712512_11_Ent1", "role": "Effect", "text": "rapid onset of adrenal insufficiency", "start": 3, "end": 8}, {"entity_id": "21712512_11_Ent0", "role": "Subject", "text": "a patient with CF - related liver disease", "start": 9, "end": 17}, {"entity_id": "21712512_11_Ent4", "role": "Treatment_Disorder", "text": "CF - related liver disease", "start": 12, "end": 17}, {"entity_id": "21712512_11_Ent2", "role": "Treatment", "text": "briefly with a moderate CYP3A4 inhibitor", "start": 18, "end": 24}, {"entity_id": "21712512_11_Ent3", "role": "Treatment_Drug", "text": "CYP3A4 inhibitor", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "21712512_11_Ent1", "text": "rapid onset of adrenal insufficiency", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "21712512_11_Ent0", "text": "a patient with CF - related liver disease", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "21712512_11_Ent4", "text": "CF - related liver disease", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "21712512_11_Ent2", "text": "briefly with a moderate CYP3A4 inhibitor", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "21712512_11_Ent3", "text": "CYP3A4 inhibitor", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "21715267_2", "wnd_id": "21715267_2_1", "text": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections .", "tokens": ["Moxifloxacin", "and", "lomefloxacin", "are", "fluoroquinolone", "antibiotics", "used", "in", "treating", "urinary", "and", "respiratory", "tract", "infections", "."], "event_mentions": [{"id": "21715267_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treating", "start": 8, "end": 9}, "arguments": [{"entity_id": "21715267_2_Ent2", "role": "Treatment_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21715267_2_Ent0", "role": "Treatment", "text": "Moxifloxacin and lomefloxacin", "start": 0, "end": 3}, {"entity_id": "21715267_2_Ent3", "role": "Treatment_Drug", "text": "lomefloxacin", "start": 2, "end": 3}, {"entity_id": "21715267_2_Ent1", "role": "Treatment", "text": "fluoroquinolone antibiotics", "start": 4, "end": 6}, {"entity_id": "21715267_2_Ent4", "role": "Treatment_Drug", "text": "fluoroquinolone antibiotics", "start": 4, "end": 6}, {"entity_id": "21715267_2_Ent5", "role": "Treatment_Disorder", "text": "urinary and respiratory tract infections", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "21715267_2_Ent2", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21715267_2_Ent0", "text": "Moxifloxacin and lomefloxacin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21715267_2_Ent3", "text": "lomefloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21715267_2_Ent1", "text": "fluoroquinolone antibiotics", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "21715267_2_Ent4", "text": "fluoroquinolone antibiotics", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "21715267_2_Ent5", "text": "urinary and respiratory tract infections", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "21751542_4", "wnd_id": "21751542_4_1", "text": "Angiotensin converting enzyme blockers and their influence on the endothelial dysfunction , but the risk of hyperpotassemia are showed .", "tokens": ["Angiotensin", "converting", "enzyme", "blockers", "and", "their", "influence", "on", "the", "endothelial", "dysfunction", ",", "but", "the", "risk", "of", "hyperpotassemia", "are", "showed", "."], "event_mentions": [{"id": "21751542_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 18, "end": 19}, "arguments": [{"entity_id": "21751542_4_Ent1", "role": "Treatment", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent2", "role": "Treatment_Drug", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent0", "role": "Effect", "text": "hyperpotassemia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "21751542_4_Ent1", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent2", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent0", "text": "hyperpotassemia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "21751542_5", "wnd_id": "21751542_5_1", "text": "The risk of gastrointestinal bleeding during the treatment with antiagregants and anticoagulants , the risk of bradycardia in beta - blockade , possible interactions with other medications lowering the heart rate are discussed .", "tokens": ["The", "risk", "of", "gastrointestinal", "bleeding", "during", "the", "treatment", "with", "antiagregants", "and", "anticoagulants", ",", "the", "risk", "of", "bradycardia", "in", "beta", "-", "blockade", ",", "possible", "interactions", "with", "other", "medications", "lowering", "the", "heart", "rate", "are", "discussed", "."], "event_mentions": [{"id": "21751542_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 5, "end": 6}, "arguments": [{"entity_id": "21751542_5_Ent0", "role": "Effect", "text": "gastrointestinal bleeding", "start": 3, "end": 5}, {"entity_id": "21751542_5_Ent2", "role": "Treatment_Drug", "text": "antiagregants", "start": 9, "end": 10}, {"entity_id": "21751542_5_Ent4", "role": "Combination_Drug", "text": "antiagregants", "start": 9, "end": 10}, {"entity_id": "21751542_5_Ent1", "role": "Treatment", "text": "antiagregants and anticoagulants", "start": 9, "end": 12}, {"entity_id": "21751542_5_Ent3", "role": "Treatment_Drug", "text": "anticoagulants", "start": 11, "end": 12}, {"entity_id": "21751542_5_Ent5", "role": "Combination_Drug", "text": "anticoagulants", "start": 11, "end": 12}]}, {"id": "21751542_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 17, "end": 18}, "arguments": [{"entity_id": "21751542_5_Ent6", "role": "Effect", "text": "bradycardia", "start": 16, "end": 17}, {"entity_id": "21751542_5_Ent7", "role": "Treatment", "text": "beta - blockade", "start": 18, "end": 21}, {"entity_id": "21751542_5_Ent8", "role": "Treatment_Drug", "text": "beta - blockade", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "21751542_5_Ent0", "text": "gastrointestinal bleeding", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "21751542_5_Ent2", "text": "antiagregants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21751542_5_Ent4", "text": "antiagregants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21751542_5_Ent1", "text": "antiagregants and anticoagulants", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21751542_5_Ent3", "text": "anticoagulants", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751542_5_Ent5", "text": "anticoagulants", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751542_5_Ent6", "text": "bradycardia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21751542_5_Ent7", "text": "beta - blockade", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "21751542_5_Ent8", "text": "beta - blockade", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "21751666_4", "wnd_id": "21751666_4_1", "text": "Post - exposure prophylaxis of H1N1 with oseltamivir was safe , effective and well tolerated to prevent H1N1 influenza A virus infection in newly transplanted renal allograft recipient receiving triple immunosuppression without any interaction with tacrolimus level .", "tokens": ["Post", "-", "exposure", "prophylaxis", "of", "H1N1", "with", "oseltamivir", "was", "safe", ",", "effective", "and", "well", "tolerated", "to", "prevent", "H1N1", "influenza", "A", "virus", "infection", "in", "newly", "transplanted", "renal", "allograft", "recipient", "receiving", "triple", "immunosuppression", "without", "any", "interaction", "with", "tacrolimus", "level", "."], "event_mentions": [{"id": "21751666_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prophylaxis", "start": 3, "end": 4}, "arguments": [{"entity_id": "21751666_4_Ent5", "role": "Treatment_Disorder", "text": "H1N1", "start": 5, "end": 6}, {"entity_id": "21751666_4_Ent3", "role": "Treatment", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_4_Ent6", "role": "Treatment_Drug", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_4_Ent9", "role": "Combination_Drug", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_4_Ent2", "role": "Effect", "text": "safe , effective and well tolerated to prevent H1N1 influenza A virus infection", "start": 9, "end": 22}, {"entity_id": "21751666_4_Ent0", "role": "Subject", "text": "newly transplanted renal allograft recipient", "start": 23, "end": 28}, {"entity_id": "21751666_4_Ent1", "role": "Subject_Disorder", "text": "transplanted renal allograft", "start": 24, "end": 27}, {"entity_id": "21751666_4_Ent4", "role": "Treatment", "text": "without any interaction with tacrolimus level", "start": 31, "end": 37}, {"entity_id": "21751666_4_Ent7", "role": "Treatment_Drug", "text": "tacrolimus", "start": 35, "end": 36}, {"entity_id": "21751666_4_Ent8", "role": "Combination_Drug", "text": "tacrolimus", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "21751666_4_Ent5", "text": "H1N1", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21751666_4_Ent3", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_4_Ent6", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_4_Ent9", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_4_Ent2", "text": "safe , effective and well tolerated to prevent H1N1 influenza A virus infection", "entity_type": "Entity", "start": 9, "end": 22}, {"id": "21751666_4_Ent0", "text": "newly transplanted renal allograft recipient", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "21751666_4_Ent1", "text": "transplanted renal allograft", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "21751666_4_Ent4", "text": "without any interaction with tacrolimus level", "entity_type": "Entity", "start": 31, "end": 37}, {"id": "21751666_4_Ent7", "text": "tacrolimus", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "21751666_4_Ent8", "text": "tacrolimus", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "21751666_5", "wnd_id": "21751666_5_1", "text": "Oseltamivir was effective for post - exposure prophylaxis of H1N1 in close contact .", "tokens": ["Oseltamivir", "was", "effective", "for", "post", "-", "exposure", "prophylaxis", "of", "H1N1", "in", "close", "contact", "."], "event_mentions": [{"id": "21751666_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "post - exposure prophylaxis", "start": 4, "end": 8}, "arguments": [{"entity_id": "21751666_5_Ent0", "role": "Treatment", "text": "Oseltamivir", "start": 0, "end": 1}, {"entity_id": "21751666_5_Ent2", "role": "Treatment_Drug", "text": "Oseltamivir", "start": 0, "end": 1}, {"entity_id": "21751666_5_Ent1", "role": "Treatment_Disorder", "text": "H1N1", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "21751666_5_Ent0", "text": "Oseltamivir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21751666_5_Ent2", "text": "Oseltamivir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21751666_5_Ent1", "text": "H1N1", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "21751692_4", "wnd_id": "21751692_4_1", "text": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low - dose ketamine was added to propofol .", "tokens": ["EA", "signs", "were", "observed", "in", "all", "7", "patients", "in", "association", "with", "propofol", "TIVA", "but", "did", "not", "recur", "in", "any", "of", "123", "subsequent", "anesthetics", "sessions", "during", "which", "low", "-", "dose", "ketamine", "was", "added", "to", "propofol", "."], "event_mentions": [{"id": "21751692_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "21751692_4_Ent2", "role": "Effect", "text": "EA signs", "start": 0, "end": 2}, {"entity_id": "21751692_4_Ent0", "role": "Subject", "text": "all 7 patients", "start": 5, "end": 8}, {"entity_id": "21751692_4_Ent1", "role": "Subject_Population", "text": "7", "start": 6, "end": 7}, {"entity_id": "21751692_4_Ent5", "role": "Treatment_Drug", "text": "propofol", "start": 11, "end": 12}, {"entity_id": "21751692_4_Ent3", "role": "Treatment", "text": "propofol TIVA", "start": 11, "end": 13}, {"entity_id": "21751692_4_Ent8", "role": "Treatment_Route", "text": "TIVA", "start": 12, "end": 13}, {"entity_id": "21751692_4_Ent9", "role": "Treatment_Dosage", "text": "low - dose", "start": 26, "end": 29}, {"entity_id": "21751692_4_Ent4", "role": "Treatment", "text": "low - dose ketamine was added to propofol", "start": 26, "end": 34}, {"entity_id": "21751692_4_Ent6", "role": "Treatment_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent11", "role": "Combination_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent7", "role": "Treatment_Drug", "text": "propofol", "start": 33, "end": 34}, {"entity_id": "21751692_4_Ent10", "role": "Combination_Drug", "text": "propofol", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "21751692_4_Ent2", "text": "EA signs", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21751692_4_Ent0", "text": "all 7 patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "21751692_4_Ent1", "text": "7", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21751692_4_Ent5", "text": "propofol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751692_4_Ent3", "text": "propofol TIVA", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21751692_4_Ent8", "text": "TIVA", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21751692_4_Ent9", "text": "low - dose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "21751692_4_Ent4", "text": "low - dose ketamine was added to propofol", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "21751692_4_Ent6", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent11", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent7", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "21751692_4_Ent10", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "21881031_5", "wnd_id": "21881031_5_1", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 ) were used prior to irinotecan administration in both patients .", "tokens": ["Granisetron", "hydrochloride", "(", "3", "mg", "on", "days", "1", ",", "8", ",", "and", "15", ")", "and", "dexamethasone", "(", "13.2", "mg", "on", "day", "1", "and", "6.6", "mg", "on", "days", "2", ",", "3", ",", "8", ",", "and", "15", ")", "were", "used", "prior", "to", "irinotecan", "administration", "in", "both", "patients", "."], "event_mentions": [{"id": "21881031_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 37, "end": 38}, "arguments": [{"entity_id": "21881031_5_Ent3", "role": "Treatment_Drug", "text": "Granisetron hydrochloride", "start": 0, "end": 2}, {"entity_id": "21881031_5_Ent12", "role": "Combination_Drug", "text": "Granisetron hydrochloride", "start": 0, "end": 2}, {"entity_id": "21881031_5_Ent1", "role": "Treatment", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 )", "start": 0, "end": 36}, {"entity_id": "21881031_5_Ent5", "role": "Treatment_Dosage", "text": "3 mg", "start": 3, "end": 5}, {"entity_id": "21881031_5_Ent9", "role": "Treatment_Freq", "text": "on days 1 , 8 , and 15", "start": 5, "end": 13}, {"entity_id": "21881031_5_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 15, "end": 16}, {"entity_id": "21881031_5_Ent11", "role": "Combination_Drug", "text": "dexamethasone", "start": 15, "end": 16}, {"entity_id": "21881031_5_Ent6", "role": "Treatment_Dosage", "text": "13.2 mg", "start": 17, "end": 19}, {"entity_id": "21881031_5_Ent8", "role": "Treatment_Freq", "text": "on day 1", "start": 19, "end": 22}, {"entity_id": "21881031_5_Ent7", "role": "Treatment_Dosage", "text": "6.6 mg", "start": 23, "end": 25}, {"entity_id": "21881031_5_Ent10", "role": "Treatment_Freq", "text": "on days 2 , 3 , 8 , and 15", "start": 25, "end": 35}, {"entity_id": "21881031_5_Ent2", "role": "Treatment", "text": "irinotecan", "start": 40, "end": 41}, {"entity_id": "21881031_5_Ent0", "role": "Subject", "text": "both patients", "start": 43, "end": 45}]}], "entity_mentions": [{"id": "21881031_5_Ent3", "text": "Granisetron hydrochloride", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21881031_5_Ent12", "text": "Granisetron hydrochloride", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21881031_5_Ent1", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 )", "entity_type": "Entity", "start": 0, "end": 36}, {"id": "21881031_5_Ent5", "text": "3 mg", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "21881031_5_Ent9", "text": "on days 1 , 8 , and 15", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "21881031_5_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21881031_5_Ent11", "text": "dexamethasone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21881031_5_Ent6", "text": "13.2 mg", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21881031_5_Ent8", "text": "on day 1", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "21881031_5_Ent7", "text": "6.6 mg", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "21881031_5_Ent10", "text": "on days 2 , 3 , 8 , and 15", "entity_type": "Entity", "start": 25, "end": 35}, {"id": "21881031_5_Ent2", "text": "irinotecan", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "21881031_5_Ent0", "text": "both patients", "entity_type": "Entity", "start": 43, "end": 45}], "lang": "en"}
{"doc_id": "22010004_9", "wnd_id": "22010004_9_1", "text": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions , there is a potential for synergistic coagulopathy when combined with warfarin therapy .", "tokens": ["Because", "of", "the", "described", "effects", "of", "niacin", "on", "the", "coagulation", "cascade", "and", "the", "possibility", "for", "pharmacokinetic", "interactions", ",", "there", "is", "a", "potential", "for", "synergistic", "coagulopathy", "when", "combined", "with", "warfarin", "therapy", "."], "event_mentions": [{"id": "22010004_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 21, "end": 22}, "arguments": [{"entity_id": "22010004_9_Ent1", "role": "Treatment", "text": "niacin", "start": 6, "end": 7}, {"entity_id": "22010004_9_Ent3", "role": "Treatment_Drug", "text": "niacin", "start": 6, "end": 7}, {"entity_id": "22010004_9_Ent6", "role": "Combination_Drug", "text": "niacin", "start": 6, "end": 7}, {"entity_id": "22010004_9_Ent0", "role": "Effect", "text": "synergistic coagulopathy", "start": 23, "end": 25}, {"entity_id": "22010004_9_Ent2", "role": "Treatment", "text": "combined with warfarin therapy", "start": 26, "end": 30}, {"entity_id": "22010004_9_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 28, "end": 29}, {"entity_id": "22010004_9_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "22010004_9_Ent1", "text": "niacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_9_Ent3", "text": "niacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_9_Ent6", "text": "niacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_9_Ent0", "text": "synergistic coagulopathy", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "22010004_9_Ent2", "text": "combined with warfarin therapy", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "22010004_9_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "22010004_9_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "2234880_1", "wnd_id": "2234880_1_1", "text": "Nitrendipine - induced gingival hyperplasia .", "tokens": ["Nitrendipine", "-", "induced", "gingival", "hyperplasia", "."], "event_mentions": [{"id": "2234880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2234880_1_Ent1", "role": "Treatment", "text": "Nitrendipine", "start": 0, "end": 1}, {"entity_id": "2234880_1_Ent2", "role": "Treatment_Drug", "text": "Nitrendipine", "start": 0, "end": 1}, {"entity_id": "2234880_1_Ent0", "role": "Effect", "text": "gingival hyperplasia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "2234880_1_Ent1", "text": "Nitrendipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2234880_1_Ent2", "text": "Nitrendipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2234880_1_Ent0", "text": "gingival hyperplasia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "22552763_4", "wnd_id": "22552763_4_1", "text": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA .", "tokens": ["We", "assessed", "the", "bleeding", "risk", "in", "patients", "treated", "with", "thromboprophylactic", "dabigatran", "etexilate", ",", "with", "and", "without", "concomitant", "NSAID", "or", "ASA", "."], "event_mentions": [{"id": "22552763_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "22552763_4_Ent1", "role": "Effect", "text": "bleeding", "start": 3, "end": 4}, {"entity_id": "22552763_4_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "22552763_4_Ent2", "role": "Treatment", "text": "thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA", "start": 9, "end": 20}, {"entity_id": "22552763_4_Ent5", "role": "Treatment_Drug", "text": "dabigatran etexilate", "start": 10, "end": 12}, {"entity_id": "22552763_4_Ent6", "role": "Combination_Drug", "text": "dabigatran etexilate", "start": 10, "end": 12}, {"entity_id": "22552763_4_Ent4", "role": "Treatment_Drug", "text": "NSAID", "start": 17, "end": 18}, {"entity_id": "22552763_4_Ent7", "role": "Combination_Drug", "text": "NSAID", "start": 17, "end": 18}, {"entity_id": "22552763_4_Ent3", "role": "Treatment_Drug", "text": "ASA", "start": 19, "end": 20}, {"entity_id": "22552763_4_Ent8", "role": "Combination_Drug", "text": "ASA", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "22552763_4_Ent1", "text": "bleeding", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22552763_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22552763_4_Ent2", "text": "thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "22552763_4_Ent5", "text": "dabigatran etexilate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22552763_4_Ent6", "text": "dabigatran etexilate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22552763_4_Ent4", "text": "NSAID", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22552763_4_Ent7", "text": "NSAID", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22552763_4_Ent3", "text": "ASA", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "22552763_4_Ent8", "text": "ASA", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "22791547_5", "wnd_id": "22791547_5_1", "text": "Although limb dyskinesia after methylphenidate is a commonly reported side effect , to the authors ' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate .", "tokens": ["Although", "limb", "dyskinesia", "after", "methylphenidate", "is", "a", "commonly", "reported", "side", "effect", ",", "to", "the", "authors", "'", "knowledge", "this", "is", "only", "the", "second", "reported", "case", "to", "develop", "both", "orofacial", "and", "limb", "dyskinesia", "in", "the", "acute", "period", "after", "the", "first", "dose", "of", "methylphenidate", "."], "event_mentions": [{"id": "22791547_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 25, "end": 26}, "arguments": [{"entity_id": "22791547_5_Ent3", "role": "Treatment_Drug", "text": "methylphenidate", "start": 4, "end": 5}, {"entity_id": "22791547_5_Ent0", "role": "Subject", "text": "the second reported case", "start": 20, "end": 24}, {"entity_id": "22791547_5_Ent1", "role": "Effect", "text": "orofacial and limb dyskinesia", "start": 27, "end": 31}, {"entity_id": "22791547_5_Ent2", "role": "Treatment", "text": "methylphenidate", "start": 40, "end": 41}, {"entity_id": "22791547_5_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "22791547_5_Ent3", "text": "methylphenidate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22791547_5_Ent0", "text": "the second reported case", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "22791547_5_Ent1", "text": "orofacial and limb dyskinesia", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "22791547_5_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "22791547_5_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "2292051_1", "wnd_id": "2292051_1_1", "text": "Acute coronary events following cisplatin - based chemotherapy .", "tokens": ["Acute", "coronary", "events", "following", "cisplatin", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "2292051_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "2292051_1_Ent0", "role": "Effect", "text": "Acute coronary events", "start": 0, "end": 3}, {"entity_id": "2292051_1_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 4, "end": 5}, {"entity_id": "2292051_1_Ent1", "role": "Treatment", "text": "cisplatin - based chemotherapy", "start": 4, "end": 8}, {"entity_id": "2292051_1_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "2292051_1_Ent0", "text": "Acute coronary events", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2292051_1_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2292051_1_Ent1", "text": "cisplatin - based chemotherapy", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2292051_1_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "2299784_3", "wnd_id": "2299784_3_1", "text": "To our knowledge , this is the first reported case of bromide intoxication due to pyridostigmine bromide administration .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "of", "bromide", "intoxication", "due", "to", "pyridostigmine", "bromide", "administration", "."], "event_mentions": [{"id": "2299784_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 13, "end": 14}, "arguments": [{"entity_id": "2299784_3_Ent1", "role": "Subject_Population", "text": "first", "start": 7, "end": 8}, {"entity_id": "2299784_3_Ent0", "role": "Subject", "text": "first reported case", "start": 7, "end": 10}, {"entity_id": "2299784_3_Ent2", "role": "Effect", "text": "bromide intoxication", "start": 11, "end": 13}, {"entity_id": "2299784_3_Ent3", "role": "Treatment", "text": "pyridostigmine bromide", "start": 15, "end": 17}, {"entity_id": "2299784_3_Ent4", "role": "Treatment_Drug", "text": "pyridostigmine bromide", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "2299784_3_Ent1", "text": "first", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2299784_3_Ent0", "text": "first reported case", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2299784_3_Ent2", "text": "bromide intoxication", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "2299784_3_Ent3", "text": "pyridostigmine bromide", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2299784_3_Ent4", "text": "pyridostigmine bromide", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "23006440_5", "wnd_id": "23006440_5_1", "text": "In this case , 5 - FU increased PHT , which in turn may have increased the PB concentration , suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs , some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT , including frequent monitoring of blood drug concentration .", "tokens": ["In", "this", "case", ",", "5", "-", "FU", "increased", "PHT", ",", "which", "in", "turn", "may", "have", "increased", "the", "PB", "concentration", ",", "suggesting", "that", "when", "fluoropyrimidine", "antitumor", "agents", "are", "administered", "to", "patients", "receiving", "PHT", "in", "combination", "with", "other", "drugs", ",", "some", "measures", "should", "be", "taken", "in", "consideration", "of", "secondary", "effects", "of", "antitumor", "agents", "on", "other", "drugs", "that", "may", "possibly", "interact", "with", "PHT", ",", "including", "frequent", "monitoring", "of", "blood", "drug", "concentration", "."], "event_mentions": [{"id": "23006440_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interact", "start": 57, "end": 58}, "arguments": [{"entity_id": "23006440_5_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "23006440_5_Ent5", "role": "Combination_Drug", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "23006440_5_Ent2", "role": "Treatment", "text": "5 - FU increased PHT , which in turn may have increased the PB concentration", "start": 4, "end": 19}, {"entity_id": "23006440_5_Ent4", "role": "Treatment_Drug", "text": "PHT", "start": 8, "end": 9}, {"entity_id": "23006440_5_Ent6", "role": "Combination_Drug", "text": "PHT", "start": 8, "end": 9}, {"entity_id": "23006440_5_Ent0", "role": "Subject", "text": "patients", "start": 29, "end": 30}, {"entity_id": "23006440_5_Ent1", "role": "Effect", "text": "secondary effects of antitumor agents on other drugs", "start": 46, "end": 54}]}], "entity_mentions": [{"id": "23006440_5_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "23006440_5_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "23006440_5_Ent2", "text": "5 - FU increased PHT , which in turn may have increased the PB concentration", "entity_type": "Entity", "start": 4, "end": 19}, {"id": "23006440_5_Ent4", "text": "PHT", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "23006440_5_Ent6", "text": "PHT", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "23006440_5_Ent0", "text": "patients", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "23006440_5_Ent1", "text": "secondary effects of antitumor agents on other drugs", "entity_type": "Entity", "start": 46, "end": 54}], "lang": "en"}
{"doc_id": "2320800_6", "wnd_id": "2320800_6_1", "text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .", "tokens": ["Ifosfamide", "is", "a", "known", "nephrotoxic", "drug", "with", "demonstrated", "tubulopathies", "."], "event_mentions": [{"id": "2320800_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "2320800_6_Ent1", "role": "Treatment", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent2", "role": "Treatment_Drug", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent0", "role": "Effect", "text": "tubulopathies", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2320800_6_Ent1", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent2", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent0", "text": "tubulopathies", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2327115_1", "wnd_id": "2327115_1_1", "text": "Ciprofloxacin is one drug that has been reported to cause interstitial nephritis .", "tokens": ["Ciprofloxacin", "is", "one", "drug", "that", "has", "been", "reported", "to", "cause", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "2327115_1_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "2327115_1_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "2327115_1_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2327115_1_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2327115_1_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2327115_1_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "2329972_1", "wnd_id": "2329972_1_1", "text": "In a female with acute lymphoblastic leukemia , inadvertent doxorubicin administration intrathecally caused severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus .", "tokens": ["In", "a", "female", "with", "acute", "lymphoblastic", "leukemia", ",", "inadvertent", "doxorubicin", "administration", "intrathecally", "caused", "severe", ",", "life", "-", "threatening", ",", "acute", "encephalopathy", "with", "high", "-", "pressure", "hydrocephalus", "."], "event_mentions": [{"id": "2329972_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 12, "end": 13}, "arguments": [{"entity_id": "2329972_1_Ent1", "role": "Subject_Gender", "text": "female", "start": 2, "end": 3}, {"entity_id": "2329972_1_Ent0", "role": "Subject", "text": "female with acute lymphoblastic leukemia", "start": 2, "end": 7}, {"entity_id": "2329972_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 4, "end": 7}, {"entity_id": "2329972_1_Ent3", "role": "Treatment", "text": "inadvertent doxorubicin administration intrathecally", "start": 8, "end": 12}, {"entity_id": "2329972_1_Ent4", "role": "Treatment_Drug", "text": "doxorubicin", "start": 9, "end": 10}, {"entity_id": "2329972_1_Ent6", "role": "Treatment_Route", "text": "intrathecally", "start": 11, "end": 12}, {"entity_id": "2329972_1_Ent2", "role": "Effect", "text": "severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus", "start": 13, "end": 26}]}], "entity_mentions": [{"id": "2329972_1_Ent1", "text": "female", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2329972_1_Ent0", "text": "female with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "2329972_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2329972_1_Ent3", "text": "inadvertent doxorubicin administration intrathecally", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "2329972_1_Ent4", "text": "doxorubicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2329972_1_Ent6", "text": "intrathecally", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2329972_1_Ent2", "text": "severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus", "entity_type": "Entity", "start": 13, "end": 26}], "lang": "en"}
{"doc_id": "23552010_1", "wnd_id": "23552010_1_1", "text": "Acute angioedema response to topical 5 - fluorouracil therapy .", "tokens": ["Acute", "angioedema", "response", "to", "topical", "5", "-", "fluorouracil", "therapy", "."], "event_mentions": [{"id": "23552010_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 2, "end": 3}, "arguments": [{"entity_id": "23552010_1_Ent0", "role": "Effect", "text": "angioedema", "start": 1, "end": 2}, {"entity_id": "23552010_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "23552010_1_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "23552010_1_Ent0", "text": "angioedema", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "23552010_1_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "23552010_1_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "23552010_2", "wnd_id": "23552010_2_1", "text": "This is a case report involving a patient who was treated with topical 5 - FU cream and subsequently developed a severe case of angioedema .", "tokens": ["This", "is", "a", "case", "report", "involving", "a", "patient", "who", "was", "treated", "with", "topical", "5", "-", "FU", "cream", "and", "subsequently", "developed", "a", "severe", "case", "of", "angioedema", "."], "event_mentions": [{"id": "23552010_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "23552010_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "23552010_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 12, "end": 13}, {"entity_id": "23552010_2_Ent2", "role": "Treatment", "text": "topical 5 - FU cream", "start": 12, "end": 17}, {"entity_id": "23552010_2_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 13, "end": 16}, {"entity_id": "23552010_2_Ent1", "role": "Effect", "text": "a severe case of angioedema", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "23552010_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23552010_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "23552010_2_Ent2", "text": "topical 5 - FU cream", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "23552010_2_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "23552010_2_Ent1", "text": "a severe case of angioedema", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "23624139_2", "wnd_id": "23624139_2_1", "text": "Most of the clinical data on the safety profile of desmopressin ( DDAVP ) , which is an effective treatment for both polyuric conditions and bleeding disorders , originate from studies on the tailoring of drug treatment , whereas few reports exist describing severe side effects secondary to drug - drug interaction .", "tokens": ["Most", "of", "the", "clinical", "data", "on", "the", "safety", "profile", "of", "desmopressin", "(", "DDAVP", ")", ",", "which", "is", "an", "effective", "treatment", "for", "both", "polyuric", "conditions", "and", "bleeding", "disorders", ",", "originate", "from", "studies", "on", "the", "tailoring", "of", "drug", "treatment", ",", "whereas", "few", "reports", "exist", "describing", "severe", "side", "effects", "secondary", "to", "drug", "-", "drug", "interaction", "."], "event_mentions": [{"id": "23624139_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 19, "end": 20}, "arguments": [{"entity_id": "23624139_2_Ent2", "role": "Treatment_Drug", "text": "desmopressin", "start": 10, "end": 11}, {"entity_id": "23624139_2_Ent1", "role": "Treatment", "text": "desmopressin ( DDAVP )", "start": 10, "end": 14}, {"entity_id": "23624139_2_Ent0", "role": "Subject", "text": "both polyuric conditions and bleeding disorders", "start": 21, "end": 27}, {"entity_id": "23624139_2_Ent3", "role": "Treatment_Disorder", "text": "polyuric conditions", "start": 22, "end": 24}, {"entity_id": "23624139_2_Ent4", "role": "Treatment_Disorder", "text": "bleeding disorders", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "23624139_2_Ent2", "text": "desmopressin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23624139_2_Ent1", "text": "desmopressin ( DDAVP )", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "23624139_2_Ent0", "text": "both polyuric conditions and bleeding disorders", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "23624139_2_Ent3", "text": "polyuric conditions", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "23624139_2_Ent4", "text": "bleeding disorders", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "23624139_3", "wnd_id": "23624139_3_1", "text": "We herein describe a case of severe hyponatremia complicated by seizure and coma due to the intake of non - steroidal anti - inflammatory drugs ( NSAIDs ) in a patient on DDAVP replacement therapy for central diabetes insipidus ( DI ) .", "tokens": ["We", "herein", "describe", "a", "case", "of", "severe", "hyponatremia", "complicated", "by", "seizure", "and", "coma", "due", "to", "the", "intake", "of", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "in", "a", "patient", "on", "DDAVP", "replacement", "therapy", "for", "central", "diabetes", "insipidus", "(", "DI", ")", "."], "event_mentions": [{"id": "23624139_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 13, "end": 15}, "arguments": [{"entity_id": "23624139_3_Ent2", "role": "Effect", "text": "severe hyponatremia", "start": 6, "end": 8}, {"entity_id": "23624139_3_Ent3", "role": "Effect", "text": "seizure and coma", "start": 10, "end": 13}, {"entity_id": "23624139_3_Ent4", "role": "Treatment", "text": "intake of non - steroidal anti - inflammatory drugs ( NSAIDs )", "start": 16, "end": 28}, {"entity_id": "23624139_3_Ent6", "role": "Treatment_Drug", "text": "non - steroidal anti - inflammatory drugs", "start": 18, "end": 25}, {"entity_id": "23624139_3_Ent10", "role": "Combination_Drug", "text": "non - steroidal anti - inflammatory drugs", "start": 18, "end": 25}, {"entity_id": "23624139_3_Ent0", "role": "Subject", "text": "a patient", "start": 29, "end": 31}, {"entity_id": "23624139_3_Ent5", "role": "Treatment", "text": "on DDAVP replacement therapy", "start": 31, "end": 35}, {"entity_id": "23624139_3_Ent7", "role": "Treatment_Drug", "text": "DDAVP", "start": 32, "end": 33}, {"entity_id": "23624139_3_Ent9", "role": "Combination_Drug", "text": "DDAVP", "start": 32, "end": 33}, {"entity_id": "23624139_3_Ent1", "role": "Subject", "text": "for central diabetes insipidus ( DI )", "start": 35, "end": 42}, {"entity_id": "23624139_3_Ent8", "role": "Treatment_Disorder", "text": "central diabetes insipidus", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "23624139_3_Ent2", "text": "severe hyponatremia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23624139_3_Ent3", "text": "seizure and coma", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "23624139_3_Ent4", "text": "intake of non - steroidal anti - inflammatory drugs ( NSAIDs )", "entity_type": "Entity", "start": 16, "end": 28}, {"id": "23624139_3_Ent6", "text": "non - steroidal anti - inflammatory drugs", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "23624139_3_Ent10", "text": "non - steroidal anti - inflammatory drugs", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "23624139_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "23624139_3_Ent5", "text": "on DDAVP replacement therapy", "entity_type": "Entity", "start": 31, "end": 35}, {"id": "23624139_3_Ent7", "text": "DDAVP", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "23624139_3_Ent9", "text": "DDAVP", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "23624139_3_Ent1", "text": "for central diabetes insipidus ( DI )", "entity_type": "Entity", "start": 35, "end": 42}, {"id": "23624139_3_Ent8", "text": "central diabetes insipidus", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "2369419_4", "wnd_id": "2369419_4_1", "text": "Upon discontinuation of MTX , her ascites resolved , and her arthritis became more active .", "tokens": ["Upon", "discontinuation", "of", "MTX", ",", "her", "ascites", "resolved", ",", "and", "her", "arthritis", "became", "more", "active", "."], "event_mentions": [{"id": "2369419_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 7, "end": 8}, "arguments": [{"entity_id": "2369419_4_Ent3", "role": "Treatment", "text": "discontinuation of MTX", "start": 1, "end": 4}, {"entity_id": "2369419_4_Ent5", "role": "Treatment_Drug", "text": "MTX", "start": 3, "end": 4}, {"entity_id": "2369419_4_Ent0", "role": "Subject", "text": "her", "start": 5, "end": 6}, {"entity_id": "2369419_4_Ent2", "role": "Subject_Gender", "text": "her", "start": 5, "end": 6}, {"entity_id": "2369419_4_Ent4", "role": "Treatment_Disorder", "text": "ascites", "start": 6, "end": 7}, {"entity_id": "2369419_4_Ent1", "role": "Subject_Disorder", "text": "arthritis", "start": 11, "end": 12}]}, {"id": "2369419_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "active", "start": 14, "end": 15}, "arguments": [{"entity_id": "2369419_4_Ent10", "role": "Treatment", "text": "discontinuation of MTX", "start": 1, "end": 4}, {"entity_id": "2369419_4_Ent12", "role": "Treatment_Drug", "text": "MTX", "start": 3, "end": 4}, {"entity_id": "2369419_4_Ent6", "role": "Subject", "text": "her", "start": 5, "end": 6}, {"entity_id": "2369419_4_Ent8", "role": "Subject_Gender", "text": "her", "start": 5, "end": 6}, {"entity_id": "2369419_4_Ent11", "role": "Treatment_Disorder", "text": "ascites", "start": 6, "end": 7}, {"entity_id": "2369419_4_Ent7", "role": "Subject_Disorder", "text": "arthritis", "start": 11, "end": 12}, {"entity_id": "2369419_4_Ent9", "role": "Effect", "text": "arthritis became more active", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "2369419_4_Ent3", "text": "discontinuation of MTX", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "2369419_4_Ent10", "text": "discontinuation of MTX", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "2369419_4_Ent5", "text": "MTX", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2369419_4_Ent12", "text": "MTX", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2369419_4_Ent0", "text": "her", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2369419_4_Ent2", "text": "her", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2369419_4_Ent6", "text": "her", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2369419_4_Ent8", "text": "her", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2369419_4_Ent4", "text": "ascites", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2369419_4_Ent11", "text": "ascites", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2369419_4_Ent1", "text": "arthritis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2369419_4_Ent7", "text": "arthritis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2369419_4_Ent9", "text": "arthritis became more active", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "2378415_2", "wnd_id": "2378415_2_1", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate .", "tokens": ["A", "patient", "with", "intracranial", "osteosarcoma", "that", "arose", "16", "years", "after", "radiation", "therapy", "for", "hereditary", "retinoblastoma", "developed", "fatal", "cerebral", "edema", "and", "brainstem", "herniation", "after", "she", "received", "a", "single", "dose", "of", "intravenous", "methotrexate", "."], "event_mentions": [{"id": "2378415_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "2378415_2_Ent0", "role": "Subject", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma", "start": 0, "end": 15}, {"entity_id": "2378415_2_Ent4", "role": "Treatment_Disorder", "text": "intracranial osteosarcoma", "start": 3, "end": 5}, {"entity_id": "2378415_2_Ent1", "role": "Subject_Disorder", "text": "hereditary retinoblastoma", "start": 13, "end": 15}, {"entity_id": "2378415_2_Ent2", "role": "Effect", "text": "cerebral edema and brainstem herniation", "start": 17, "end": 22}, {"entity_id": "2378415_2_Ent5", "role": "Treatment_Freq", "text": "a single dose", "start": 25, "end": 28}, {"entity_id": "2378415_2_Ent3", "role": "Treatment", "text": "a single dose of intravenous methotrexate", "start": 25, "end": 31}, {"entity_id": "2378415_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 29, "end": 30}, {"entity_id": "2378415_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "2378415_2_Ent0", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "2378415_2_Ent4", "text": "intracranial osteosarcoma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2378415_2_Ent1", "text": "hereditary retinoblastoma", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "2378415_2_Ent2", "text": "cerebral edema and brainstem herniation", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "2378415_2_Ent5", "text": "a single dose", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "2378415_2_Ent3", "text": "a single dose of intravenous methotrexate", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "2378415_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "2378415_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "23970584_2", "wnd_id": "23970584_2_1", "text": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient .", "tokens": ["This", "case", "report", "describes", "two", "severe", "antiretroviral", "drug", "adverse", "reactions", "that", "occurred", "in", "the", "same", "patient", "."], "event_mentions": [{"id": "23970584_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 11, "end": 12}, "arguments": [{"entity_id": "23970584_2_Ent2", "role": "Treatment", "text": "antiretroviral drug", "start": 6, "end": 8}, {"entity_id": "23970584_2_Ent3", "role": "Treatment_Drug", "text": "antiretroviral drug", "start": 6, "end": 8}, {"entity_id": "23970584_2_Ent1", "role": "Effect", "text": "adverse reactions", "start": 8, "end": 10}, {"entity_id": "23970584_2_Ent0", "role": "Subject", "text": "same patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "23970584_2_Ent2", "text": "antiretroviral drug", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23970584_2_Ent3", "text": "antiretroviral drug", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23970584_2_Ent1", "text": "adverse reactions", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "23970584_2_Ent0", "text": "same patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "23970584_3", "wnd_id": "23970584_3_1", "text": "A 55 - year - old HIV - positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia .", "tokens": ["A", "55", "-", "year", "-", "old", "HIV", "-", "positive", "African", "woman", "received", "a", "single", "epidural", "triamcinolone", "injection", "for", "pain", "relief", "of", "postherpetic", "neuralgia", "."], "event_mentions": [{"id": "23970584_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 11, "end": 12}, "arguments": [{"entity_id": "23970584_3_Ent0", "role": "Subject", "text": "A 55 - year - old HIV - positive African woman", "start": 0, "end": 11}, {"entity_id": "23970584_3_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 1, "end": 6}, {"entity_id": "23970584_3_Ent2", "role": "Subject_Disorder", "text": "HIV", "start": 6, "end": 7}, {"entity_id": "23970584_3_Ent3", "role": "Subject_Race", "text": "African", "start": 9, "end": 10}, {"entity_id": "23970584_3_Ent4", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "23970584_3_Ent5", "role": "Treatment", "text": "a single epidural triamcinolone injection", "start": 12, "end": 17}, {"entity_id": "23970584_3_Ent7", "role": "Treatment_Drug", "text": "triamcinolone", "start": 15, "end": 16}, {"entity_id": "23970584_3_Ent8", "role": "Treatment_Route", "text": "injection", "start": 16, "end": 17}, {"entity_id": "23970584_3_Ent6", "role": "Treatment_Disorder", "text": "pain relief of postherpetic neuralgia", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "23970584_3_Ent0", "text": "A 55 - year - old HIV - positive African woman", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "23970584_3_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "23970584_3_Ent2", "text": "HIV", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23970584_3_Ent3", "text": "African", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "23970584_3_Ent4", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23970584_3_Ent5", "text": "a single epidural triamcinolone injection", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "23970584_3_Ent7", "text": "triamcinolone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23970584_3_Ent8", "text": "injection", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "23970584_3_Ent6", "text": "pain relief of postherpetic neuralgia", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "23970584_8", "wnd_id": "23970584_8_1", "text": "Clinicians should be aware of raltegravir - induced DRESS syndrome as well as the potential for drug - drug interactions due to protease inhibitor - based therapy .", "tokens": ["Clinicians", "should", "be", "aware", "of", "raltegravir", "-", "induced", "DRESS", "syndrome", "as", "well", "as", "the", "potential", "for", "drug", "-", "drug", "interactions", "due", "to", "protease", "inhibitor", "-", "based", "therapy", "."], "event_mentions": [{"id": "23970584_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "23970584_8_Ent1", "role": "Treatment", "text": "raltegravir", "start": 5, "end": 6}, {"entity_id": "23970584_8_Ent2", "role": "Treatment_Drug", "text": "raltegravir", "start": 5, "end": 6}, {"entity_id": "23970584_8_Ent0", "role": "Effect", "text": "DRESS syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "23970584_8_Ent1", "text": "raltegravir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "23970584_8_Ent2", "text": "raltegravir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "23970584_8_Ent0", "text": "DRESS syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "2417800_3", "wnd_id": "2417800_3_1", "text": "Bleomycin pneumonitis potentiated by oxygen administration .", "tokens": ["Bleomycin", "pneumonitis", "potentiated", "by", "oxygen", "administration", "."], "event_mentions": [{"id": "2417800_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 3, "end": 4}, "arguments": [{"entity_id": "2417800_3_Ent0", "role": "Effect", "text": "Bleomycin pneumonitis", "start": 0, "end": 2}, {"entity_id": "2417800_3_Ent2", "role": "Treatment_Drug", "text": "oxygen", "start": 4, "end": 5}, {"entity_id": "2417800_3_Ent1", "role": "Treatment", "text": "oxygen administration", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2417800_3_Ent0", "text": "Bleomycin pneumonitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2417800_3_Ent2", "text": "oxygen", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2417800_3_Ent1", "text": "oxygen administration", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "24318743_14", "wnd_id": "24318743_14_1", "text": "Orally delivered PXD showed no evidence of clinical activity , when combined with weekly AUC2 - carboplatin in PROC .", "tokens": ["Orally", "delivered", "PXD", "showed", "no", "evidence", "of", "clinical", "activity", ",", "when", "combined", "with", "weekly", "AUC2", "-", "carboplatin", "in", "PROC", "."], "event_mentions": [{"id": "24318743_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "clinical activity", "start": 7, "end": 9}, "arguments": [{"entity_id": "24318743_14_Ent3", "role": "Treatment_Route", "text": "Orally", "start": 0, "end": 1}, {"entity_id": "24318743_14_Ent0", "role": "Treatment", "text": "Orally delivered PXD", "start": 0, "end": 3}, {"entity_id": "24318743_14_Ent4", "role": "Treatment_Drug", "text": "PXD", "start": 2, "end": 3}, {"entity_id": "24318743_14_Ent7", "role": "Combination_Drug", "text": "PXD", "start": 2, "end": 3}, {"entity_id": "24318743_14_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 13, "end": 14}, {"entity_id": "24318743_14_Ent1", "role": "Treatment", "text": "weekly AUC2 - carboplatin", "start": 13, "end": 17}, {"entity_id": "24318743_14_Ent5", "role": "Treatment_Drug", "text": "AUC2 - carboplatin", "start": 14, "end": 17}, {"entity_id": "24318743_14_Ent8", "role": "Combination_Drug", "text": "AUC2 - carboplatin", "start": 14, "end": 17}, {"entity_id": "24318743_14_Ent2", "role": "Treatment_Disorder", "text": "PROC", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "24318743_14_Ent3", "text": "Orally", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24318743_14_Ent0", "text": "Orally delivered PXD", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "24318743_14_Ent4", "text": "PXD", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24318743_14_Ent7", "text": "PXD", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24318743_14_Ent6", "text": "weekly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "24318743_14_Ent1", "text": "weekly AUC2 - carboplatin", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "24318743_14_Ent5", "text": "AUC2 - carboplatin", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "24318743_14_Ent8", "text": "AUC2 - carboplatin", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "24318743_14_Ent2", "text": "PROC", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2442958_2", "wnd_id": "2442958_2_1", "text": "This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol ( DES ) therapy for prostatic cancer .", "tokens": ["This", "is", "a", "unique", "autopsy", "case", "of", "hepatocellular", "carcinoma", "closely", "related", "to", "diethylstilbestrol", "(", "DES", ")", "therapy", "for", "prostatic", "cancer", "."], "event_mentions": [{"id": "2442958_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "2442958_2_Ent0", "role": "Subject", "text": "a unique autopsy case", "start": 2, "end": 6}, {"entity_id": "2442958_2_Ent1", "role": "Effect", "text": "hepatocellular carcinoma", "start": 7, "end": 9}, {"entity_id": "2442958_2_Ent4", "role": "Treatment_Drug", "text": "diethylstilbestrol", "start": 12, "end": 13}, {"entity_id": "2442958_2_Ent2", "role": "Treatment", "text": "diethylstilbestrol ( DES )", "start": 12, "end": 16}, {"entity_id": "2442958_2_Ent3", "role": "Treatment_Disorder", "text": "prostatic cancer", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "2442958_2_Ent0", "text": "a unique autopsy case", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "2442958_2_Ent1", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2442958_2_Ent4", "text": "diethylstilbestrol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2442958_2_Ent2", "text": "diethylstilbestrol ( DES )", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "2442958_2_Ent3", "text": "prostatic cancer", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "2461837_2", "wnd_id": "2461837_2_1", "text": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome ( AIDS ) .", "tokens": ["We", "report", "a", "case", "of", "hyperpigmentation", "due", "to", "bleomycin", "treatment", "in", "a", "patient", "with", "acquired", "immune", "deficiency", "syndrome", "(", "AIDS", ")", "."], "event_mentions": [{"id": "2461837_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "2461837_2_Ent1", "role": "Effect", "text": "hyperpigmentation", "start": 5, "end": 6}, {"entity_id": "2461837_2_Ent2", "role": "Treatment", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "2461837_2_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "2461837_2_Ent0", "role": "Subject", "text": "a patient with acquired immune deficiency syndrome ( AIDS )", "start": 11, "end": 21}, {"entity_id": "2461837_2_Ent4", "role": "Treatment_Disorder", "text": "acquired immune deficiency syndrome", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "2461837_2_Ent1", "text": "hyperpigmentation", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2461837_2_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2461837_2_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2461837_2_Ent0", "text": "a patient with acquired immune deficiency syndrome ( AIDS )", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "2461837_2_Ent4", "text": "acquired immune deficiency syndrome", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "24661191_4", "wnd_id": "24661191_4_1", "text": "We report a case of a 29 - year - old liver transplant patient who suffered liver injury most likely induced by drug interaction between capecitabine and warfarin .", "tokens": ["We", "report", "a", "case", "of", "a", "29", "-", "year", "-", "old", "liver", "transplant", "patient", "who", "suffered", "liver", "injury", "most", "likely", "induced", "by", "drug", "interaction", "between", "capecitabine", "and", "warfarin", "."], "event_mentions": [{"id": "24661191_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "24661191_4_Ent0", "role": "Subject", "text": "a 29 - year - old liver transplant patient", "start": 5, "end": 14}, {"entity_id": "24661191_4_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 6, "end": 11}, {"entity_id": "24661191_4_Ent2", "role": "Subject_Disorder", "text": "liver transplant", "start": 11, "end": 13}, {"entity_id": "24661191_4_Ent3", "role": "Effect", "text": "liver injury", "start": 16, "end": 18}, {"entity_id": "24661191_4_Ent4", "role": "Treatment", "text": "drug interaction between capecitabine and warfarin", "start": 22, "end": 28}, {"entity_id": "24661191_4_Ent5", "role": "Treatment_Drug", "text": "capecitabine", "start": 25, "end": 26}, {"entity_id": "24661191_4_Ent7", "role": "Combination_Drug", "text": "capecitabine", "start": 25, "end": 26}, {"entity_id": "24661191_4_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 27, "end": 28}, {"entity_id": "24661191_4_Ent8", "role": "Combination_Drug", "text": "warfarin", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "24661191_4_Ent0", "text": "a 29 - year - old liver transplant patient", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "24661191_4_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "24661191_4_Ent2", "text": "liver transplant", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "24661191_4_Ent3", "text": "liver injury", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "24661191_4_Ent4", "text": "drug interaction between capecitabine and warfarin", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "24661191_4_Ent5", "text": "capecitabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "24661191_4_Ent7", "text": "capecitabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "24661191_4_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24661191_4_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "24679099_8", "wnd_id": "24679099_8_1", "text": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide .", "tokens": ["We", "conclude", "that", "the", "observed", "toxicity", "with", "jaundice", "was", "probably", "caused", "by", "an", "interaction", "of", "this", "popular", "Chinese", "formula", "and", "temozolomide", "."], "event_mentions": [{"id": "24679099_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 10, "end": 11}, "arguments": [{"entity_id": "24679099_8_Ent0", "role": "Effect", "text": "toxicity with jaundice", "start": 5, "end": 8}, {"entity_id": "24679099_8_Ent1", "role": "Treatment", "text": "temozolomide", "start": 20, "end": 21}, {"entity_id": "24679099_8_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "24679099_8_Ent0", "text": "toxicity with jaundice", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "24679099_8_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "24679099_8_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "24755135_3", "wnd_id": "24755135_3_1", "text": "Study 202 was an open - label , add - on study in patients with partial or generalized epilepsy treated with valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy .", "tokens": ["Study", "202", "was", "an", "open", "-", "label", ",", "add", "-", "on", "study", "in", "patients", "with", "partial", "or", "generalized", "epilepsy", "treated", "with", "valproic", "acid", "(", "VPA", ")", ",", "carbamazepine", "(", "CBZ", ")", ",", "phenytoin", "(", "PHT", ")", ",", "or", "topiramate", "(", "TPM", ")", "as", "monotherapy", "."], "event_mentions": [{"id": "24755135_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 19, "end": 20}, "arguments": [{"entity_id": "24755135_3_Ent0", "role": "Subject", "text": "patients with partial or generalized epilepsy", "start": 13, "end": 19}, {"entity_id": "24755135_3_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 21, "end": 23}, {"entity_id": "24755135_3_Ent6", "role": "Combination_Drug", "text": "valproic acid", "start": 21, "end": 23}, {"entity_id": "24755135_3_Ent1", "role": "Treatment", "text": "valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy", "start": 21, "end": 44}, {"entity_id": "24755135_3_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 27, "end": 28}, {"entity_id": "24755135_3_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 27, "end": 28}, {"entity_id": "24755135_3_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 32, "end": 33}, {"entity_id": "24755135_3_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 32, "end": 33}, {"entity_id": "24755135_3_Ent5", "role": "Treatment_Drug", "text": "topiramate", "start": 38, "end": 39}, {"entity_id": "24755135_3_Ent9", "role": "Combination_Drug", "text": "topiramate", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "24755135_3_Ent0", "text": "patients with partial or generalized epilepsy", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "24755135_3_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "24755135_3_Ent6", "text": "valproic acid", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "24755135_3_Ent1", "text": "valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy", "entity_type": "Entity", "start": 21, "end": 44}, {"id": "24755135_3_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24755135_3_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24755135_3_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "24755135_3_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "24755135_3_Ent5", "text": "topiramate", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "24755135_3_Ent9", "text": "topiramate", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "24791374_1", "wnd_id": "24791374_1_1", "text": "Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine : a case of severe drug interaction .", "tokens": ["Propafenone", "associated", "severe", "central", "nervous", "system", "and", "cardiovascular", "toxicity", "due", "to", "mirtazapine", ":", "a", "case", "of", "severe", "drug", "interaction", "."], "event_mentions": [{"id": "24791374_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 9, "end": 11}, "arguments": [{"entity_id": "24791374_1_Ent1", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_1_Ent4", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_1_Ent5", "role": "Combination_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_1_Ent0", "role": "Effect", "text": "central nervous system and cardiovascular toxicity", "start": 3, "end": 9}, {"entity_id": "24791374_1_Ent2", "role": "Treatment", "text": "mirtazapine", "start": 11, "end": 12}, {"entity_id": "24791374_1_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 11, "end": 12}, {"entity_id": "24791374_1_Ent6", "role": "Combination_Drug", "text": "mirtazapine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "24791374_1_Ent1", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_1_Ent4", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_1_Ent5", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_1_Ent0", "text": "central nervous system and cardiovascular toxicity", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "24791374_1_Ent2", "text": "mirtazapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24791374_1_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24791374_1_Ent6", "text": "mirtazapine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "24791374_6", "wnd_id": "24791374_6_1", "text": "Propafenone is an established class IC antiarrhythmic drug commonly used in the treatment of atrial fibrillation .", "tokens": ["Propafenone", "is", "an", "established", "class", "IC", "antiarrhythmic", "drug", "commonly", "used", "in", "the", "treatment", "of", "atrial", "fibrillation", "."], "event_mentions": [{"id": "24791374_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 12, "end": 13}, "arguments": [{"entity_id": "24791374_6_Ent0", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_6_Ent2", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_6_Ent1", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "24791374_6_Ent0", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_6_Ent2", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_6_Ent1", "text": "atrial fibrillation", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "2523364_1", "wnd_id": "2523364_1_1", "text": "Morphea after bromocriptine therapy .", "tokens": ["Morphea", "after", "bromocriptine", "therapy", "."], "event_mentions": [{"id": "2523364_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "2523364_1_Ent0", "role": "Effect", "text": "Morphea", "start": 0, "end": 1}, {"entity_id": "2523364_1_Ent2", "role": "Treatment_Drug", "text": "bromocriptine", "start": 2, "end": 3}, {"entity_id": "2523364_1_Ent1", "role": "Treatment", "text": "bromocriptine therapy", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "2523364_1_Ent0", "text": "Morphea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2523364_1_Ent2", "text": "bromocriptine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2523364_1_Ent1", "text": "bromocriptine therapy", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "25407257_4", "wnd_id": "25407257_4_1", "text": "A 6 - year - old boy ( weight : 16 kg , at the start of treatment ) began sodium valproate ( valproate syrup 5 % ) treatment for epilepsy in February 2012 .", "tokens": ["A", "6", "-", "year", "-", "old", "boy", "(", "weight", ":", "16", "kg", ",", "at", "the", "start", "of", "treatment", ")", "began", "sodium", "valproate", "(", "valproate", "syrup", "5", "%", ")", "treatment", "for", "epilepsy", "in", "February", "2012", "."], "event_mentions": [{"id": "25407257_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 28, "end": 29}, "arguments": [{"entity_id": "25407257_4_Ent0", "role": "Subject", "text": "A 6 - year - old boy ( weight : 16 kg , at the start of treatment )", "start": 0, "end": 19}, {"entity_id": "25407257_4_Ent1", "role": "Subject_Age", "text": "6 - year - old", "start": 1, "end": 6}, {"entity_id": "25407257_4_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "25407257_4_Ent5", "role": "Treatment_Drug", "text": "sodium valproate", "start": 20, "end": 22}, {"entity_id": "25407257_4_Ent3", "role": "Treatment", "text": "sodium valproate ( valproate syrup 5 % )", "start": 20, "end": 28}, {"entity_id": "25407257_4_Ent4", "role": "Treatment_Disorder", "text": "epilepsy", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "25407257_4_Ent0", "text": "A 6 - year - old boy ( weight : 16 kg , at the start of treatment )", "entity_type": "Entity", "start": 0, "end": 19}, {"id": "25407257_4_Ent1", "text": "6 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "25407257_4_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25407257_4_Ent5", "text": "sodium valproate", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "25407257_4_Ent3", "text": "sodium valproate ( valproate syrup 5 % )", "entity_type": "Entity", "start": 20, "end": 28}, {"id": "25407257_4_Ent4", "text": "epilepsy", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "25538343_2", "wnd_id": "25538343_2_1", "text": "Hyponatremia is a known adverse effect of duloxetine , and it can lead to potentially life - threatening complications .", "tokens": ["Hyponatremia", "is", "a", "known", "adverse", "effect", "of", "duloxetine", ",", "and", "it", "can", "lead", "to", "potentially", "life", "-", "threatening", "complications", "."], "event_mentions": [{"id": "25538343_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 4, "end": 5}, "arguments": [{"entity_id": "25538343_2_Ent0", "role": "Effect", "text": "Hyponatremia", "start": 0, "end": 1}, {"entity_id": "25538343_2_Ent2", "role": "Treatment", "text": "duloxetine", "start": 7, "end": 8}, {"entity_id": "25538343_2_Ent3", "role": "Treatment_Drug", "text": "duloxetine", "start": 7, "end": 8}, {"entity_id": "25538343_2_Ent1", "role": "Effect", "text": "potentially life - threatening complications", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "25538343_2_Ent0", "text": "Hyponatremia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_2_Ent2", "text": "duloxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25538343_2_Ent3", "text": "duloxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25538343_2_Ent1", "text": "potentially life - threatening complications", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "25540831_7", "wnd_id": "25540831_7_1", "text": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics .", "tokens": ["Most", "physicians", "are", "aware", "of", "serotonin", "syndrome", "secondary", "to", "antidepressants", "but", "do", "not", "think", "about", "other", "classes", "of", "medications", "such", "as", "analgesics", "."], "event_mentions": [{"id": "25540831_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "25540831_7_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "25540831_7_Ent1", "role": "Treatment", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent2", "role": "Treatment_Drug", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent3", "role": "Treatment_Drug", "text": "analgesics", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "25540831_7_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "25540831_7_Ent1", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent2", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent3", "text": "analgesics", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "25671244_13", "wnd_id": "25671244_13_1", "text": "Severe serotonin toxicity may result from metaxalone abuse in individuals using a selective serotonin reuptake inhibitor therapeutically .", "tokens": ["Severe", "serotonin", "toxicity", "may", "result", "from", "metaxalone", "abuse", "in", "individuals", "using", "a", "selective", "serotonin", "reuptake", "inhibitor", "therapeutically", "."], "event_mentions": [{"id": "25671244_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 4, "end": 5}, "arguments": [{"entity_id": "25671244_13_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 1, "end": 3}, {"entity_id": "25671244_13_Ent3", "role": "Treatment_Drug", "text": "metaxalone", "start": 6, "end": 7}, {"entity_id": "25671244_13_Ent6", "role": "Combination_Drug", "text": "metaxalone", "start": 6, "end": 7}, {"entity_id": "25671244_13_Ent1", "role": "Treatment", "text": "metaxalone abuse", "start": 6, "end": 8}, {"entity_id": "25671244_13_Ent5", "role": "Treatment_Dosage", "text": "abuse", "start": 7, "end": 8}, {"entity_id": "25671244_13_Ent2", "role": "Treatment", "text": "using a selective serotonin reuptake inhibitor therapeutically", "start": 10, "end": 17}, {"entity_id": "25671244_13_Ent4", "role": "Treatment_Drug", "text": "selective serotonin reuptake inhibitor", "start": 12, "end": 16}, {"entity_id": "25671244_13_Ent7", "role": "Combination_Drug", "text": "selective serotonin reuptake inhibitor", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "25671244_13_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "25671244_13_Ent3", "text": "metaxalone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25671244_13_Ent6", "text": "metaxalone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25671244_13_Ent1", "text": "metaxalone abuse", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "25671244_13_Ent5", "text": "abuse", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25671244_13_Ent2", "text": "using a selective serotonin reuptake inhibitor therapeutically", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "25671244_13_Ent4", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "25671244_13_Ent7", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "25671244_2", "wnd_id": "25671244_2_1", "text": "Metaxalone has only recently been associated with serotonin syndrome .", "tokens": ["Metaxalone", "has", "only", "recently", "been", "associated", "with", "serotonin", "syndrome", "."], "event_mentions": [{"id": "25671244_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "25671244_2_Ent1", "role": "Treatment", "text": "Metaxalone", "start": 0, "end": 1}, {"entity_id": "25671244_2_Ent2", "role": "Treatment_Drug", "text": "Metaxalone", "start": 0, "end": 1}, {"entity_id": "25671244_2_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "25671244_2_Ent1", "text": "Metaxalone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25671244_2_Ent2", "text": "Metaxalone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25671244_2_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "2621382_3", "wnd_id": "2621382_3_1", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine , showed discoloration of nail plate , subungual hyperkeratosis and onycholysis .", "tokens": ["Two", "cases", "of", "lepromatous", "leprosy", "with", "erythema", "nodosum", "leprosum", "who", "were", "on", "high", "doses", "of", "clofazimine", ",", "showed", "discoloration", "of", "nail", "plate", ",", "subungual", "hyperkeratosis", "and", "onycholysis", "."], "event_mentions": [{"id": "2621382_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 17, "end": 18}, "arguments": [{"entity_id": "2621382_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2621382_3_Ent0", "role": "Subject", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum", "start": 0, "end": 9}, {"entity_id": "2621382_3_Ent4", "role": "Treatment_Disorder", "text": "lepromatous leprosy with erythema nodosum leprosum", "start": 3, "end": 9}, {"entity_id": "2621382_3_Ent6", "role": "Treatment_Dosage", "text": "high doses", "start": 12, "end": 14}, {"entity_id": "2621382_3_Ent3", "role": "Treatment", "text": "high doses of clofazimine", "start": 12, "end": 16}, {"entity_id": "2621382_3_Ent5", "role": "Treatment_Drug", "text": "clofazimine", "start": 15, "end": 16}, {"entity_id": "2621382_3_Ent2", "role": "Effect", "text": "discoloration of nail plate , subungual hyperkeratosis and onycholysis", "start": 18, "end": 27}]}], "entity_mentions": [{"id": "2621382_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2621382_3_Ent0", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "2621382_3_Ent4", "text": "lepromatous leprosy with erythema nodosum leprosum", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "2621382_3_Ent6", "text": "high doses", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2621382_3_Ent3", "text": "high doses of clofazimine", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "2621382_3_Ent5", "text": "clofazimine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2621382_3_Ent2", "text": "discoloration of nail plate , subungual hyperkeratosis and onycholysis", "entity_type": "Entity", "start": 18, "end": 27}], "lang": "en"}
{"doc_id": "2663536_1", "wnd_id": "2663536_1_1", "text": "Development of persistent late onset asthma following treatment with captopril .", "tokens": ["Development", "of", "persistent", "late", "onset", "asthma", "following", "treatment", "with", "captopril", "."], "event_mentions": [{"id": "2663536_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "2663536_1_Ent0", "role": "Effect", "text": "persistent late onset asthma", "start": 2, "end": 6}, {"entity_id": "2663536_1_Ent1", "role": "Treatment", "text": "captopril", "start": 9, "end": 10}, {"entity_id": "2663536_1_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2663536_1_Ent0", "text": "persistent late onset asthma", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "2663536_1_Ent1", "text": "captopril", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2663536_1_Ent2", "text": "captopril", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2669373_1", "wnd_id": "2669373_1_1", "text": "A case report of a patient with probable cisplatin and bleomycin - induced TMA is presented .", "tokens": ["A", "case", "report", "of", "a", "patient", "with", "probable", "cisplatin", "and", "bleomycin", "-", "induced", "TMA", "is", "presented", "."], "event_mentions": [{"id": "2669373_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "2669373_1_Ent0", "role": "Subject", "text": "a patient with probable cisplatin", "start": 4, "end": 9}, {"entity_id": "2669373_1_Ent4", "role": "Treatment_Disorder", "text": "probable cisplatin", "start": 7, "end": 9}, {"entity_id": "2669373_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "2669373_1_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "2669373_1_Ent1", "role": "Effect", "text": "TMA", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "2669373_1_Ent0", "text": "a patient with probable cisplatin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "2669373_1_Ent4", "text": "probable cisplatin", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2669373_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2669373_1_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2669373_1_Ent1", "text": "TMA", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2719905_1", "wnd_id": "2719905_1_1", "text": "Long lasting respiratory depression induced by morphine - 6 - glucuronide ?", "tokens": ["Long", "lasting", "respiratory", "depression", "induced", "by", "morphine", "-", "6", "-", "glucuronide", "?"], "event_mentions": [{"id": "2719905_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "2719905_1_Ent0", "role": "Effect", "text": "Long lasting respiratory depression", "start": 0, "end": 4}, {"entity_id": "2719905_1_Ent1", "role": "Treatment", "text": "morphine - 6 - glucuronide", "start": 6, "end": 11}, {"entity_id": "2719905_1_Ent2", "role": "Treatment_Drug", "text": "morphine - 6 - glucuronide", "start": 6, "end": 11}]}], "entity_mentions": [{"id": "2719905_1_Ent0", "text": "Long lasting respiratory depression", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2719905_1_Ent1", "text": "morphine - 6 - glucuronide", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "2719905_1_Ent2", "text": "morphine - 6 - glucuronide", "entity_type": "Entity", "start": 6, "end": 11}], "lang": "en"}
{"doc_id": "2728526_4", "wnd_id": "2728526_4_1", "text": "This article reports the occurrence of rifampin - associated thrombocytopenia in an indigent patient after a four - month lapse in therapy for pulmonary tuberculosis .", "tokens": ["This", "article", "reports", "the", "occurrence", "of", "rifampin", "-", "associated", "thrombocytopenia", "in", "an", "indigent", "patient", "after", "a", "four", "-", "month", "lapse", "in", "therapy", "for", "pulmonary", "tuberculosis", "."], "event_mentions": [{"id": "2728526_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "2728526_4_Ent2", "role": "Treatment", "text": "rifampin", "start": 6, "end": 7}, {"entity_id": "2728526_4_Ent4", "role": "Treatment_Drug", "text": "rifampin", "start": 6, "end": 7}, {"entity_id": "2728526_4_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 9, "end": 10}, {"entity_id": "2728526_4_Ent0", "role": "Subject", "text": "an indigent patient", "start": 11, "end": 14}, {"entity_id": "2728526_4_Ent3", "role": "Treatment", "text": "after a four - month lapse in therapy for pulmonary tuberculosis", "start": 14, "end": 25}, {"entity_id": "2728526_4_Ent5", "role": "Treatment_Time_elapsed", "text": "four - month", "start": 16, "end": 19}, {"entity_id": "2728526_4_Ent6", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "2728526_4_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2728526_4_Ent4", "text": "rifampin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2728526_4_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2728526_4_Ent0", "text": "an indigent patient", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "2728526_4_Ent3", "text": "after a four - month lapse in therapy for pulmonary tuberculosis", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "2728526_4_Ent5", "text": "four - month", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2728526_4_Ent6", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "2738729_1", "wnd_id": "2738729_1_1", "text": "We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy .", "tokens": ["We", "present", "the", "first", "case", "of", "WES", "in", "an", "infant", "born", "to", "a", "mother", "taking", "haloperidol", "during", "her", "pregnancy", "."], "event_mentions": [{"id": "2738729_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 4, "end": 5}, "arguments": [{"entity_id": "2738729_1_Ent2", "role": "Effect", "text": "WES", "start": 6, "end": 7}, {"entity_id": "2738729_1_Ent0", "role": "Subject", "text": "an infant born to a mother", "start": 8, "end": 14}, {"entity_id": "2738729_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 9, "end": 10}, {"entity_id": "2738729_1_Ent3", "role": "Treatment", "text": "haloperidol", "start": 15, "end": 16}, {"entity_id": "2738729_1_Ent4", "role": "Treatment_Drug", "text": "haloperidol", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2738729_1_Ent2", "text": "WES", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2738729_1_Ent0", "text": "an infant born to a mother", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "2738729_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2738729_1_Ent3", "text": "haloperidol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2738729_1_Ent4", "text": "haloperidol", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2738729_2", "wnd_id": "2738729_2_1", "text": "Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy .", "tokens": ["Withdrawal", "emergent", "syndrome", "in", "an", "infant", "associated", "with", "maternal", "haloperidol", "therapy", "."], "event_mentions": [{"id": "2738729_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "2738729_2_Ent2", "role": "Effect", "text": "Withdrawal emergent syndrome", "start": 0, "end": 3}, {"entity_id": "2738729_2_Ent0", "role": "Subject", "text": "an infant", "start": 4, "end": 6}, {"entity_id": "2738729_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 5, "end": 6}, {"entity_id": "2738729_2_Ent5", "role": "Treatment_Route", "text": "maternal", "start": 8, "end": 9}, {"entity_id": "2738729_2_Ent3", "role": "Treatment", "text": "maternal haloperidol therapy", "start": 8, "end": 11}, {"entity_id": "2738729_2_Ent4", "role": "Treatment_Drug", "text": "haloperidol", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2738729_2_Ent2", "text": "Withdrawal emergent syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2738729_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2738729_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2738729_2_Ent5", "text": "maternal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2738729_2_Ent3", "text": "maternal haloperidol therapy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2738729_2_Ent4", "text": "haloperidol", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2768785_1", "wnd_id": "2768785_1_1", "text": "Intravenous cytarabine and methotrexate appear to act synergistically to enhance the potential for central nervous system toxicity .", "tokens": ["Intravenous", "cytarabine", "and", "methotrexate", "appear", "to", "act", "synergistically", "to", "enhance", "the", "potential", "for", "central", "nervous", "system", "toxicity", "."], "event_mentions": [{"id": "2768785_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhance", "start": 9, "end": 10}, "arguments": [{"entity_id": "2768785_1_Ent4", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "2768785_1_Ent1", "role": "Treatment", "text": "Intravenous cytarabine and methotrexate", "start": 0, "end": 4}, {"entity_id": "2768785_1_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 1, "end": 2}, {"entity_id": "2768785_1_Ent6", "role": "Combination_Drug", "text": "cytarabine", "start": 1, "end": 2}, {"entity_id": "2768785_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "2768785_1_Ent5", "role": "Combination_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "2768785_1_Ent0", "role": "Effect", "text": "central nervous system toxicity", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "2768785_1_Ent4", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2768785_1_Ent1", "text": "Intravenous cytarabine and methotrexate", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2768785_1_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2768785_1_Ent6", "text": "cytarabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2768785_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2768785_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2768785_1_Ent0", "text": "central nervous system toxicity", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "2862137_2", "wnd_id": "2862137_2_1", "text": "Alprazolam withdrawal delirium unresponsive to diazepam : case report .", "tokens": ["Alprazolam", "withdrawal", "delirium", "unresponsive", "to", "diazepam", ":", "case", "report", "."], "event_mentions": [{"id": "2862137_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "2862137_2_Ent1", "role": "Treatment_Disorder", "text": "Alprazolam withdrawal delirium", "start": 0, "end": 3}, {"entity_id": "2862137_2_Ent0", "role": "Treatment", "text": "diazepam", "start": 5, "end": 6}, {"entity_id": "2862137_2_Ent2", "role": "Treatment_Drug", "text": "diazepam", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2862137_2_Ent1", "text": "Alprazolam withdrawal delirium", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2862137_2_Ent0", "text": "diazepam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2862137_2_Ent2", "text": "diazepam", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2875665_1", "wnd_id": "2875665_1_1", "text": "Exacerbation of schizophrenia associated with amantadine .", "tokens": ["Exacerbation", "of", "schizophrenia", "associated", "with", "amantadine", "."], "event_mentions": [{"id": "2875665_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2875665_1_Ent0", "role": "Effect", "text": "Exacerbation of schizophrenia", "start": 0, "end": 3}, {"entity_id": "2875665_1_Ent1", "role": "Treatment", "text": "amantadine", "start": 5, "end": 6}, {"entity_id": "2875665_1_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2875665_1_Ent0", "text": "Exacerbation of schizophrenia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2875665_1_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2875665_1_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2894766_3", "wnd_id": "2894766_3_1", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .", "tokens": ["Pneumonitis", ",", "bilateral", "pleural", "effusions", ",", "echocardiographic", "evidence", "of", "cardiac", "tamponade", ",", "and", "positive", "autoantibodies", "developed", "in", "a", "43", "-", "year", "-", "old", "man", ",", "who", "was", "receiving", "long", "-", "term", "sulfasalazine", "therapy", "for", "chronic", "ulcerative", "colitis", "."], "event_mentions": [{"id": "2894766_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "2894766_3_Ent3", "role": "Effect", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies", "start": 0, "end": 15}, {"entity_id": "2894766_3_Ent0", "role": "Subject", "text": "a 43 - year - old man", "start": 17, "end": 24}, {"entity_id": "2894766_3_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 18, "end": 23}, {"entity_id": "2894766_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 23, "end": 24}, {"entity_id": "2894766_3_Ent4", "role": "Treatment", "text": "long - term sulfasalazine", "start": 28, "end": 32}, {"entity_id": "2894766_3_Ent6", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 31, "end": 32}, {"entity_id": "2894766_3_Ent5", "role": "Treatment_Disorder", "text": "chronic ulcerative colitis", "start": 34, "end": 37}]}], "entity_mentions": [{"id": "2894766_3_Ent3", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "2894766_3_Ent0", "text": "a 43 - year - old man", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "2894766_3_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "2894766_3_Ent2", "text": "man", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2894766_3_Ent4", "text": "long - term sulfasalazine", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "2894766_3_Ent6", "text": "sulfasalazine", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "2894766_3_Ent5", "text": "chronic ulcerative colitis", "entity_type": "Entity", "start": 34, "end": 37}], "lang": "en"}
{"doc_id": "2931445_3", "wnd_id": "2931445_3_1", "text": "L - T4 stimulated lymphocyte transformation in this patient .", "tokens": ["L", "-", "T4", "stimulated", "lymphocyte", "transformation", "in", "this", "patient", "."], "event_mentions": [{"id": "2931445_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "stimulated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2931445_3_Ent2", "role": "Treatment", "text": "L - T4", "start": 0, "end": 3}, {"entity_id": "2931445_3_Ent3", "role": "Treatment_Drug", "text": "L - T4", "start": 0, "end": 3}, {"entity_id": "2931445_3_Ent1", "role": "Effect", "text": "lymphocyte transformation", "start": 4, "end": 6}, {"entity_id": "2931445_3_Ent0", "role": "Subject", "text": "this patient", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "2931445_3_Ent2", "text": "L - T4", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_3_Ent3", "text": "L - T4", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_3_Ent1", "text": "lymphocyte transformation", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2931445_3_Ent0", "text": "this patient", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "2937155_2", "wnd_id": "2937155_2_1", "text": "The possible development of a drug - induced vasculitis or lupus - like syndrome should be added to the list of rare toxic effects of vancomycin .", "tokens": ["The", "possible", "development", "of", "a", "drug", "-", "induced", "vasculitis", "or", "lupus", "-", "like", "syndrome", "should", "be", "added", "to", "the", "list", "of", "rare", "toxic", "effects", "of", "vancomycin", "."], "event_mentions": [{"id": "2937155_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 2, "end": 3}, "arguments": [{"entity_id": "2937155_2_Ent0", "role": "Effect", "text": "drug - induced vasculitis or lupus - like syndrome", "start": 5, "end": 14}, {"entity_id": "2937155_2_Ent1", "role": "Treatment", "text": "vancomycin", "start": 25, "end": 26}, {"entity_id": "2937155_2_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "2937155_2_Ent0", "text": "drug - induced vasculitis or lupus - like syndrome", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "2937155_2_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "2937155_2_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "2937155_3", "wnd_id": "2937155_3_1", "text": "Vancomycin - induced vasculitis .", "tokens": ["Vancomycin", "-", "induced", "vasculitis", "."], "event_mentions": [{"id": "2937155_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2937155_3_Ent1", "role": "Treatment", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "2937155_3_Ent2", "role": "Treatment_Drug", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "2937155_3_Ent0", "role": "Effect", "text": "vasculitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2937155_3_Ent1", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2937155_3_Ent2", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2937155_3_Ent0", "text": "vasculitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2956288_3", "wnd_id": "2956288_3_1", "text": "Optic neuropathy in ethambutol - treated renal tuberculosis .", "tokens": ["Optic", "neuropathy", "in", "ethambutol", "-", "treated", "renal", "tuberculosis", "."], "event_mentions": [{"id": "2956288_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "2956288_3_Ent0", "role": "Effect", "text": "Optic neuropathy", "start": 0, "end": 2}, {"entity_id": "2956288_3_Ent1", "role": "Treatment", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "2956288_3_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "2956288_3_Ent3", "role": "Treatment_Disorder", "text": "renal tuberculosis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "2956288_3_Ent0", "text": "Optic neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2956288_3_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2956288_3_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2956288_3_Ent3", "text": "renal tuberculosis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "3003260_3", "wnd_id": "3003260_3_1", "text": "Recent reports have shown that Decadron ( dexamethasone ; Merck Sharp & Dohme , West Point , Pa ) has a significant antiemetic effect on cisplatin - induced vomiting .", "tokens": ["Recent", "reports", "have", "shown", "that", "Decadron", "(", "dexamethasone", ";", "Merck", "Sharp", "&", "Dohme", ",", "West", "Point", ",", "Pa", ")", "has", "a", "significant", "antiemetic", "effect", "on", "cisplatin", "-", "induced", "vomiting", "."], "event_mentions": [{"id": "3003260_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "antiemetic", "start": 22, "end": 23}, "arguments": [{"entity_id": "3003260_3_Ent0", "role": "Treatment", "text": "Decadron", "start": 5, "end": 6}, {"entity_id": "3003260_3_Ent2", "role": "Treatment_Drug", "text": "Decadron", "start": 5, "end": 6}, {"entity_id": "3003260_3_Ent1", "role": "Treatment_Disorder", "text": "cisplatin - induced vomiting", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "3003260_3_Ent0", "text": "Decadron", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3003260_3_Ent2", "text": "Decadron", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3003260_3_Ent1", "text": "cisplatin - induced vomiting", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "3067748_1", "wnd_id": "3067748_1_1", "text": "Adrenaline dacryolith : detection by ultrasound examination of the nasolacrimal duct .", "tokens": ["Adrenaline", "dacryolith", ":", "detection", "by", "ultrasound", "examination", "of", "the", "nasolacrimal", "duct", "."], "event_mentions": [{"id": "3067748_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Adrenaline dacryolith", "start": 0, "end": 2}, "arguments": [{"entity_id": "3067748_1_Ent1", "role": "Treatment", "text": "Adrenaline", "start": 0, "end": 1}, {"entity_id": "3067748_1_Ent2", "role": "Treatment_Drug", "text": "Adrenaline", "start": 0, "end": 1}, {"entity_id": "3067748_1_Ent0", "role": "Effect", "text": "dacryolith", "start": 1, "end": 2}, {"entity_id": "3067748_1_Ent3", "role": "Treatment_Route", "text": "nasolacrimal duct", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3067748_1_Ent1", "text": "Adrenaline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3067748_1_Ent2", "text": "Adrenaline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3067748_1_Ent0", "text": "dacryolith", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3067748_1_Ent3", "text": "nasolacrimal duct", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3115809_3", "wnd_id": "3115809_3_1", "text": "Isoniazid and ethambutol as a cause of optic neuropathy .", "tokens": ["Isoniazid", "and", "ethambutol", "as", "a", "cause", "of", "optic", "neuropathy", "."], "event_mentions": [{"id": "3115809_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "3115809_3_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "3115809_3_Ent4", "role": "Combination_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "3115809_3_Ent1", "role": "Treatment", "text": "Isoniazid and ethambutol", "start": 0, "end": 3}, {"entity_id": "3115809_3_Ent3", "role": "Treatment_Drug", "text": "ethambutol", "start": 2, "end": 3}, {"entity_id": "3115809_3_Ent5", "role": "Combination_Drug", "text": "ethambutol", "start": 2, "end": 3}, {"entity_id": "3115809_3_Ent0", "role": "Effect", "text": "optic neuropathy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "3115809_3_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3115809_3_Ent4", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3115809_3_Ent1", "text": "Isoniazid and ethambutol", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3115809_3_Ent3", "text": "ethambutol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3115809_3_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3115809_3_Ent0", "text": "optic neuropathy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "3136101_1", "wnd_id": "3136101_1_1", "text": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms .", "tokens": ["Hyperkalemia", "as", "a", "late", "side", "effect", "of", "prolonged", "adrenocorticotropic", "hormone", "therapy", "for", "infantile", "spasms", "."], "event_mentions": [{"id": "3136101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 6, "end": 7}, "arguments": [{"entity_id": "3136101_1_Ent2", "role": "Effect", "text": "Hyperkalemia", "start": 0, "end": 1}, {"entity_id": "3136101_1_Ent3", "role": "Treatment", "text": "adrenocorticotropic hormone", "start": 8, "end": 10}, {"entity_id": "3136101_1_Ent5", "role": "Treatment_Drug", "text": "adrenocorticotropic hormone", "start": 8, "end": 10}, {"entity_id": "3136101_1_Ent1", "role": "Subject_Age", "text": "infantile", "start": 12, "end": 13}, {"entity_id": "3136101_1_Ent0", "role": "Subject", "text": "infantile spasms", "start": 12, "end": 14}, {"entity_id": "3136101_1_Ent4", "role": "Treatment_Disorder", "text": "infantile spasms", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3136101_1_Ent2", "text": "Hyperkalemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3136101_1_Ent3", "text": "adrenocorticotropic hormone", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3136101_1_Ent5", "text": "adrenocorticotropic hormone", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3136101_1_Ent1", "text": "infantile", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3136101_1_Ent0", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "3136101_1_Ent4", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3136101_3", "wnd_id": "3136101_3_1", "text": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia .", "tokens": ["We", "wish", "to", "call", "for", "cautious", "approach", "at", "time", "of", "cessation", "of", "prolonged", "ACTH", "therapy", "because", "of", "possible", "unexpected", "and", "only", "partially", "understood", "hazardous", "side", "effects", "such", "as", "hyperkalemia", "."], "event_mentions": [{"id": "3136101_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 9, "end": 10}, "arguments": [{"entity_id": "3136101_3_Ent1", "role": "Treatment", "text": "cessation of prolonged ACTH", "start": 10, "end": 14}, {"entity_id": "3136101_3_Ent2", "role": "Treatment_Drug", "text": "ACTH", "start": 13, "end": 14}, {"entity_id": "3136101_3_Ent0", "role": "Effect", "text": "hyperkalemia", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "3136101_3_Ent1", "text": "cessation of prolonged ACTH", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "3136101_3_Ent2", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3136101_3_Ent0", "text": "hyperkalemia", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "3143551_5", "wnd_id": "3143551_5_1", "text": "Hepatopathy subsided after the cessation of carbamazepine and lynestrenol .", "tokens": ["Hepatopathy", "subsided", "after", "the", "cessation", "of", "carbamazepine", "and", "lynestrenol", "."], "event_mentions": [{"id": "3143551_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "3143551_5_Ent0", "role": "Effect", "text": "Hepatopathy subsided", "start": 0, "end": 2}, {"entity_id": "3143551_5_Ent3", "role": "Treatment_Dosage", "text": "cessation", "start": 4, "end": 5}, {"entity_id": "3143551_5_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent2", "role": "Treatment", "text": "lynestrenol", "start": 8, "end": 9}, {"entity_id": "3143551_5_Ent5", "role": "Treatment_Drug", "text": "lynestrenol", "start": 8, "end": 9}, {"entity_id": "3143551_5_Ent6", "role": "Combination_Drug", "text": "lynestrenol", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3143551_5_Ent0", "text": "Hepatopathy subsided", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3143551_5_Ent3", "text": "cessation", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3143551_5_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent2", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3143551_5_Ent5", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3143551_5_Ent6", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3156465_2", "wnd_id": "3156465_2_1", "text": "Isotretinoin teratogenicity .", "tokens": ["Isotretinoin", "teratogenicity", "."], "event_mentions": [{"id": "3156465_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Isotretinoin teratogenicity", "start": 0, "end": 2}, "arguments": [{"entity_id": "3156465_2_Ent1", "role": "Treatment", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_2_Ent2", "role": "Treatment_Drug", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_2_Ent0", "role": "Effect", "text": "teratogenicity", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "3156465_2_Ent1", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_2_Ent2", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_2_Ent0", "text": "teratogenicity", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "3159106_3", "wnd_id": "3159106_3_1", "text": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction .", "tokens": ["The", "allopurinol", "hypersensitivity", "syndrome", "is", "a", "rare", "adverse", "drug", "reaction", "."], "event_mentions": [{"id": "3159106_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 7, "end": 8}, "arguments": [{"entity_id": "3159106_3_Ent1", "role": "Treatment", "text": "allopurinol", "start": 1, "end": 2}, {"entity_id": "3159106_3_Ent2", "role": "Treatment_Drug", "text": "allopurinol", "start": 1, "end": 2}, {"entity_id": "3159106_3_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "3159106_3_Ent1", "text": "allopurinol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3159106_3_Ent2", "text": "allopurinol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3159106_3_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "3171334_3", "wnd_id": "3171334_3_1", "text": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma .", "tokens": ["Severe", "visual", "loss", "after", "a", "single", "dose", "of", "vincristine", "in", "a", "patient", "with", "spinal", "cord", "astrocytoma", "."], "event_mentions": [{"id": "3171334_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "3171334_3_Ent1", "role": "Effect", "text": "Severe visual loss", "start": 0, "end": 3}, {"entity_id": "3171334_3_Ent5", "role": "Treatment_Freq", "text": "a single dose", "start": 4, "end": 7}, {"entity_id": "3171334_3_Ent2", "role": "Treatment", "text": "a single dose of vincristine", "start": 4, "end": 9}, {"entity_id": "3171334_3_Ent4", "role": "Treatment_Drug", "text": "vincristine", "start": 8, "end": 9}, {"entity_id": "3171334_3_Ent0", "role": "Subject", "text": "a patient with spinal cord astrocytoma", "start": 10, "end": 16}, {"entity_id": "3171334_3_Ent3", "role": "Treatment_Disorder", "text": "spinal cord astrocytoma", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "3171334_3_Ent1", "text": "Severe visual loss", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3171334_3_Ent5", "text": "a single dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "3171334_3_Ent2", "text": "a single dose of vincristine", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "3171334_3_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3171334_3_Ent0", "text": "a patient with spinal cord astrocytoma", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3171334_3_Ent3", "text": "spinal cord astrocytoma", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "3174043_1", "wnd_id": "3174043_1_1", "text": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67 % of patients taking high doses of the drug .", "tokens": ["Niacin", "causes", "a", "reversible", "toxic", "cystoid", "maculopathy", "that", "occurs", "in", "approximately", "0.67", "%", "of", "patients", "taking", "high", "doses", "of", "the", "drug", "."], "event_mentions": [{"id": "3174043_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 1, "end": 2}, "arguments": [{"entity_id": "3174043_1_Ent3", "role": "Treatment", "text": "Niacin", "start": 0, "end": 1}, {"entity_id": "3174043_1_Ent5", "role": "Treatment_Drug", "text": "Niacin", "start": 0, "end": 1}, {"entity_id": "3174043_1_Ent2", "role": "Effect", "text": "reversible toxic cystoid maculopathy", "start": 3, "end": 7}, {"entity_id": "3174043_1_Ent0", "role": "Subject", "text": "approximately 0.67 % of patients", "start": 10, "end": 15}, {"entity_id": "3174043_1_Ent1", "role": "Subject_Population", "text": "0.67 %", "start": 11, "end": 13}, {"entity_id": "3174043_1_Ent4", "role": "Treatment", "text": "high doses", "start": 16, "end": 18}, {"entity_id": "3174043_1_Ent6", "role": "Treatment_Dosage", "text": "high doses", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "3174043_1_Ent3", "text": "Niacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3174043_1_Ent5", "text": "Niacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3174043_1_Ent2", "text": "reversible toxic cystoid maculopathy", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "3174043_1_Ent0", "text": "approximately 0.67 % of patients", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "3174043_1_Ent1", "text": "0.67 %", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3174043_1_Ent4", "text": "high doses", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "3174043_1_Ent6", "text": "high doses", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "3195622_3", "wnd_id": "3195622_3_1", "text": "Case report : dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider .", "tokens": ["Case", "report", ":", "dapsone", "hypersensitivity", "syndrome", "associated", "with", "treatment", "of", "the", "bite", "of", "a", "brown", "recluse", "spider", "."], "event_mentions": [{"id": "3195622_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "3195622_3_Ent1", "role": "Treatment", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3195622_3_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3301251_1", "wnd_id": "3301251_1_1", "text": "A case of a 21 - year - old woman who had developed mild hepatotoxicity while receiving choline magnesium trisalicylate therapy is described .", "tokens": ["A", "case", "of", "a", "21", "-", "year", "-", "old", "woman", "who", "had", "developed", "mild", "hepatotoxicity", "while", "receiving", "choline", "magnesium", "trisalicylate", "therapy", "is", "described", "."], "event_mentions": [{"id": "3301251_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 16, "end": 17}, "arguments": [{"entity_id": "3301251_1_Ent0", "role": "Subject", "text": "a 21 - year - old woman", "start": 3, "end": 10}, {"entity_id": "3301251_1_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 4, "end": 9}, {"entity_id": "3301251_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "3301251_1_Ent3", "role": "Effect", "text": "mild hepatotoxicity", "start": 13, "end": 15}, {"entity_id": "3301251_1_Ent4", "role": "Treatment", "text": "choline magnesium trisalicylate", "start": 17, "end": 20}, {"entity_id": "3301251_1_Ent5", "role": "Treatment_Drug", "text": "choline magnesium trisalicylate", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "3301251_1_Ent0", "text": "a 21 - year - old woman", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "3301251_1_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "3301251_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3301251_1_Ent3", "text": "mild hepatotoxicity", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "3301251_1_Ent4", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3301251_1_Ent5", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "3359700_1", "wnd_id": "3359700_1_1", "text": "After a six - week course of low - dose cyclosporine A , she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels .", "tokens": ["After", "a", "six", "-", "week", "course", "of", "low", "-", "dose", "cyclosporine", "A", ",", "she", "developed", "a", "severe", "but", "reversible", "loss", "of", "glomerular", "filtration", "rate", "and", "effective", "renal", "plasma", "flow", "despite", "of", "low", "cyclosporine", "A", "plasma", "levels", "."], "event_mentions": [{"id": "3359700_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "3359700_1_Ent1", "role": "Treatment", "text": "After a six - week course of low - dose cyclosporine A", "start": 0, "end": 12}, {"entity_id": "3359700_1_Ent4", "role": "Treatment_Time_elapsed", "text": "six - week course", "start": 2, "end": 6}, {"entity_id": "3359700_1_Ent2", "role": "Treatment_Dosage", "text": "low - dose", "start": 7, "end": 10}, {"entity_id": "3359700_1_Ent3", "role": "Treatment_Drug", "text": "cyclosporine A", "start": 10, "end": 12}, {"entity_id": "3359700_1_Ent0", "role": "Effect", "text": "loss of glomerular filtration rate and effective renal plasma flow", "start": 19, "end": 29}]}], "entity_mentions": [{"id": "3359700_1_Ent1", "text": "After a six - week course of low - dose cyclosporine A", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "3359700_1_Ent4", "text": "six - week course", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "3359700_1_Ent2", "text": "low - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3359700_1_Ent3", "text": "cyclosporine A", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3359700_1_Ent0", "text": "loss of glomerular filtration rate and effective renal plasma flow", "entity_type": "Entity", "start": 19, "end": 29}], "lang": "en"}
{"doc_id": "3400849_1", "wnd_id": "3400849_1_1", "text": "Myoclonic spasms following intrathecal morphine .", "tokens": ["Myoclonic", "spasms", "following", "intrathecal", "morphine", "."], "event_mentions": [{"id": "3400849_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3400849_1_Ent0", "role": "Effect", "text": "Myoclonic spasms", "start": 0, "end": 2}, {"entity_id": "3400849_1_Ent1", "role": "Treatment", "text": "intrathecal morphine", "start": 3, "end": 5}, {"entity_id": "3400849_1_Ent2", "role": "Treatment_Drug", "text": "morphine .", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3400849_1_Ent0", "text": "Myoclonic spasms", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3400849_1_Ent1", "text": "intrathecal morphine", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3400849_1_Ent2", "text": "morphine .", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3438585_3", "wnd_id": "3438585_3_1", "text": "We describe a patient with rheumatoid arthritis treated with gold salts , who developed bilateral interstitial pulmonary abnormalities and showed a dramatic response on corticosteroid therapy .", "tokens": ["We", "describe", "a", "patient", "with", "rheumatoid", "arthritis", "treated", "with", "gold", "salts", ",", "who", "developed", "bilateral", "interstitial", "pulmonary", "abnormalities", "and", "showed", "a", "dramatic", "response", "on", "corticosteroid", "therapy", "."], "event_mentions": [{"id": "3438585_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 7, "end": 9}, "arguments": [{"entity_id": "3438585_3_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 2, "end": 7}, {"entity_id": "3438585_3_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}, {"entity_id": "3438585_3_Ent2", "role": "Treatment", "text": "gold salts", "start": 9, "end": 11}, {"entity_id": "3438585_3_Ent3", "role": "Treatment_Drug", "text": "gold salts", "start": 9, "end": 11}, {"entity_id": "3438585_3_Ent1", "role": "Effect", "text": "bilateral interstitial pulmonary abnormalities", "start": 14, "end": 18}, {"entity_id": "3438585_3_Ent4", "role": "Treatment_Drug", "text": "corticosteroid", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "3438585_3_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "3438585_3_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3438585_3_Ent2", "text": "gold salts", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3438585_3_Ent3", "text": "gold salts", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3438585_3_Ent1", "text": "bilateral interstitial pulmonary abnormalities", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "3438585_3_Ent4", "text": "corticosteroid", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "3438585_5", "wnd_id": "3438585_5_1", "text": "Corticosteroid therapy was continued for 8 months since there was still improvement of pulmonary function studies .", "tokens": ["Corticosteroid", "therapy", "was", "continued", "for", "8", "months", "since", "there", "was", "still", "improvement", "of", "pulmonary", "function", "studies", "."], "event_mentions": [{"id": "3438585_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improvement", "start": 11, "end": 12}, "arguments": [{"entity_id": "3438585_5_Ent0", "role": "Treatment", "text": "Corticosteroid", "start": 0, "end": 1}, {"entity_id": "3438585_5_Ent3", "role": "Treatment_Drug", "text": "Corticosteroid", "start": 0, "end": 1}, {"entity_id": "3438585_5_Ent1", "role": "Treatment", "text": "for 8 months", "start": 4, "end": 7}, {"entity_id": "3438585_5_Ent4", "role": "Treatment_Duration", "text": "for 8 months", "start": 4, "end": 7}, {"entity_id": "3438585_5_Ent2", "role": "Treatment_Disorder", "text": "pulmonary function", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "3438585_5_Ent0", "text": "Corticosteroid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3438585_5_Ent3", "text": "Corticosteroid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3438585_5_Ent1", "text": "for 8 months", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "3438585_5_Ent4", "text": "for 8 months", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "3438585_5_Ent2", "text": "pulmonary function", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "3470173_5", "wnd_id": "3470173_5_1", "text": "This case report illustrates the neurotoxicity unique to HDARAC .", "tokens": ["This", "case", "report", "illustrates", "the", "neurotoxicity", "unique", "to", "HDARAC", "."], "event_mentions": [{"id": "3470173_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 7, "end": 8}, "arguments": [{"entity_id": "3470173_5_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "3470173_5_Ent1", "role": "Effect", "text": "neurotoxicity unique", "start": 5, "end": 7}, {"entity_id": "3470173_5_Ent2", "role": "Treatment", "text": "HDARAC", "start": 8, "end": 9}, {"entity_id": "3470173_5_Ent3", "role": "Treatment_Drug", "text": "HDARAC", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3470173_5_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3470173_5_Ent1", "text": "neurotoxicity unique", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3470173_5_Ent2", "text": "HDARAC", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3470173_5_Ent3", "text": "HDARAC", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3513544_3", "wnd_id": "3513544_3_1", "text": "With the increasing use of Cyclosporine A in transplant patients , the incidence of herpes esophagitis may increase .", "tokens": ["With", "the", "increasing", "use", "of", "Cyclosporine", "A", "in", "transplant", "patients", ",", "the", "incidence", "of", "herpes", "esophagitis", "may", "increase", "."], "event_mentions": [{"id": "3513544_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incidence", "start": 12, "end": 13}, "arguments": [{"entity_id": "3513544_3_Ent3", "role": "Treatment", "text": "Cyclosporine A", "start": 5, "end": 7}, {"entity_id": "3513544_3_Ent4", "role": "Treatment_Drug", "text": "Cyclosporine A", "start": 5, "end": 7}, {"entity_id": "3513544_3_Ent1", "role": "Subject_Disorder", "text": "transplant", "start": 8, "end": 9}, {"entity_id": "3513544_3_Ent0", "role": "Subject", "text": "transplant patients", "start": 8, "end": 10}, {"entity_id": "3513544_3_Ent2", "role": "Effect", "text": "herpes esophagitis may increase .", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "3513544_3_Ent3", "text": "Cyclosporine A", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3513544_3_Ent4", "text": "Cyclosporine A", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3513544_3_Ent1", "text": "transplant", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3513544_3_Ent0", "text": "transplant patients", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3513544_3_Ent2", "text": "herpes esophagitis may increase .", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "3542612_1", "wnd_id": "3542612_1_1", "text": "Captopril - induced lichen planus pemphigoides with pemphigus - like features .", "tokens": ["Captopril", "-", "induced", "lichen", "planus", "pemphigoides", "with", "pemphigus", "-", "like", "features", "."], "event_mentions": [{"id": "3542612_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3542612_1_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3542612_1_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3542612_1_Ent0", "role": "Effect", "text": "lichen planus pemphigoides", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3542612_1_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3542612_1_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3542612_1_Ent0", "text": "lichen planus pemphigoides", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3586163_3", "wnd_id": "3586163_3_1", "text": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin 's lymphoma .", "tokens": ["We", "report", "an", "unusual", "case", "of", "simultaneous", "transitional", "cell", "carcinoma", "of", "the", "renal", "pelvis", "and", "distal", "ureter", "without", "transitional", "cell", "carcinoma", "of", "the", "bladder", "occurring", "after", "chronic", "cyclophosphamide", "therapy", "for", "nonHodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "3586163_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 25, "end": 26}, "arguments": [{"entity_id": "3586163_3_Ent0", "role": "Effect", "text": "simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder", "start": 6, "end": 24}, {"entity_id": "3586163_3_Ent4", "role": "Treatment_Duration", "text": "chronic", "start": 26, "end": 27}, {"entity_id": "3586163_3_Ent1", "role": "Treatment", "text": "chronic cyclophosphamide therapy", "start": 26, "end": 29}, {"entity_id": "3586163_3_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}, {"entity_id": "3586163_3_Ent3", "role": "Treatment_Disorder", "text": "nonHodgkin 's lymphoma", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "3586163_3_Ent0", "text": "simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder", "entity_type": "Entity", "start": 6, "end": 24}, {"id": "3586163_3_Ent4", "text": "chronic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3586163_3_Ent1", "text": "chronic cyclophosphamide therapy", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "3586163_3_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "3586163_3_Ent3", "text": "nonHodgkin 's lymphoma", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "3620420_1", "wnd_id": "3620420_1_1", "text": "Cyclosporin therapy in Mooren 's ulcer .", "tokens": ["Cyclosporin", "therapy", "in", "Mooren", "'s", "ulcer", "."], "event_mentions": [{"id": "3620420_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 1, "end": 2}, "arguments": [{"entity_id": "3620420_1_Ent0", "role": "Treatment", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_1_Ent2", "role": "Treatment_Drug", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_1_Ent1", "role": "Treatment_Disorder", "text": "Mooren 's ulcer", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3620420_1_Ent0", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_1_Ent2", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_1_Ent1", "text": "Mooren 's ulcer", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3620420_6", "wnd_id": "3620420_6_1", "text": "Cyclosporin side effects included hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "tokens": ["Cyclosporin", "side", "effects", "included", "hirsutism", ",", "hypertension", ",", "increased", "blood", "levels", "of", "urea", "and", "creatinine", ",", "and", "abnormalities", "in", "liver", "function", "tests", "."], "event_mentions": [{"id": "3620420_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 1, "end": 3}, "arguments": [{"entity_id": "3620420_6_Ent1", "role": "Treatment", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_6_Ent2", "role": "Treatment_Drug", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_6_Ent0", "role": "Effect", "text": "hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "start": 4, "end": 23}]}], "entity_mentions": [{"id": "3620420_6_Ent1", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_6_Ent2", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_6_Ent0", "text": "hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "entity_type": "Entity", "start": 4, "end": 23}], "lang": "en"}
{"doc_id": "3677571_15", "wnd_id": "3677571_15_1", "text": "The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms , particularly fever , rash , and lymphadenopathy .", "tokens": ["The", "possibility", "of", "phenytoin", "hypersensitivity", "reactions", "should", "be", "considered", "when", "patients", "receiving", "phenytoin", "have", "unusual", "symptoms", ",", "particularly", "fever", ",", "rash", ",", "and", "lymphadenopathy", "."], "event_mentions": [{"id": "3677571_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 11, "end": 12}, "arguments": [{"entity_id": "3677571_15_Ent0", "role": "Effect", "text": "phenytoin hypersensitivity", "start": 3, "end": 5}, {"entity_id": "3677571_15_Ent2", "role": "Treatment", "text": "phenytoin", "start": 12, "end": 13}, {"entity_id": "3677571_15_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 12, "end": 13}, {"entity_id": "3677571_15_Ent1", "role": "Effect", "text": "fever , rash , and lymphadenopathy", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "3677571_15_Ent0", "text": "phenytoin hypersensitivity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3677571_15_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3677571_15_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3677571_15_Ent1", "text": "fever , rash , and lymphadenopathy", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "369675_1", "wnd_id": "369675_1_1", "text": "Five and one - half years after the diagnosis of myeloma , while in remission on cyclophosphamide therapy , the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma .", "tokens": ["Five", "and", "one", "-", "half", "years", "after", "the", "diagnosis", "of", "myeloma", ",", "while", "in", "remission", "on", "cyclophosphamide", "therapy", ",", "the", "patient", "experienced", "severe", "abdominal", "right", "lower", "quadrant", "pain", "due", "to", "a", "large", "cecal", "lymphoma", "."], "event_mentions": [{"id": "369675_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 21, "end": 22}, "arguments": [{"entity_id": "369675_1_Ent0", "role": "Subject", "text": "diagnosis of myeloma", "start": 8, "end": 11}, {"entity_id": "369675_1_Ent6", "role": "Treatment_Disorder", "text": "myeloma", "start": 10, "end": 11}, {"entity_id": "369675_1_Ent5", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 16, "end": 17}, {"entity_id": "369675_1_Ent4", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 16, "end": 18}, {"entity_id": "369675_1_Ent1", "role": "Subject", "text": "patient", "start": 20, "end": 21}, {"entity_id": "369675_1_Ent2", "role": "Effect", "text": "severe abdominal right lower quadrant pain", "start": 22, "end": 28}, {"entity_id": "369675_1_Ent3", "role": "Effect", "text": "large cecal lymphoma", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "369675_1_Ent0", "text": "diagnosis of myeloma", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "369675_1_Ent6", "text": "myeloma", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "369675_1_Ent5", "text": "cyclophosphamide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "369675_1_Ent4", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "369675_1_Ent1", "text": "patient", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "369675_1_Ent2", "text": "severe abdominal right lower quadrant pain", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "369675_1_Ent3", "text": "large cecal lymphoma", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "3720318_1", "wnd_id": "3720318_1_1", "text": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono - octanoin .", "tokens": ["Noncardiogenic", "pulmonary", "edema", "during", "intrabiliary", "infusion", "of", "mono", "-", "octanoin", "."], "event_mentions": [{"id": "3720318_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "3720318_1_Ent0", "role": "Effect", "text": "Noncardiogenic pulmonary edema", "start": 0, "end": 3}, {"entity_id": "3720318_1_Ent2", "role": "Treatment_Route", "text": "intrabiliary infusion", "start": 4, "end": 6}, {"entity_id": "3720318_1_Ent1", "role": "Treatment", "text": "intrabiliary infusion of mono - octanoin", "start": 4, "end": 10}, {"entity_id": "3720318_1_Ent3", "role": "Treatment_Drug", "text": "mono - octanoin", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "3720318_1_Ent0", "text": "Noncardiogenic pulmonary edema", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3720318_1_Ent2", "text": "intrabiliary infusion", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3720318_1_Ent1", "text": "intrabiliary infusion of mono - octanoin", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "3720318_1_Ent3", "text": "mono - octanoin", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "3732375_1", "wnd_id": "3732375_1_1", "text": "Theophylline intoxication following viloxazine induced decrease in clearance .", "tokens": ["Theophylline", "intoxication", "following", "viloxazine", "induced", "decrease", "in", "clearance", "."], "event_mentions": [{"id": "3732375_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3732375_1_Ent3", "role": "Treatment_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent5", "role": "Combination_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent0", "role": "Effect", "text": "Theophylline intoxication", "start": 0, "end": 2}, {"entity_id": "3732375_1_Ent1", "role": "Treatment", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent2", "role": "Treatment_Drug", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent4", "role": "Combination_Drug", "text": "viloxazine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3732375_1_Ent3", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent5", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent0", "text": "Theophylline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3732375_1_Ent1", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent2", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent4", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3753891_1", "wnd_id": "3753891_1_1", "text": "Acute myocardial necrosis during administration of amsacrine .", "tokens": ["Acute", "myocardial", "necrosis", "during", "administration", "of", "amsacrine", "."], "event_mentions": [{"id": "3753891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "3753891_1_Ent0", "role": "Effect", "text": "Acute myocardial necrosis", "start": 0, "end": 3}, {"entity_id": "3753891_1_Ent1", "role": "Treatment", "text": "amsacrine", "start": 6, "end": 7}, {"entity_id": "3753891_1_Ent2", "role": "Treatment_Drug", "text": "amsacrine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3753891_1_Ent0", "text": "Acute myocardial necrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3753891_1_Ent1", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3753891_1_Ent2", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3767790_2", "wnd_id": "3767790_2_1", "text": "Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation .", "tokens": ["Two", "patients", "who", "were", "receiving", "Tolazoline", "by", "infusion", "developed", "duodenal", "ulceration", "and", "subsequent", "intestinal", "perforation", "."], "event_mentions": [{"id": "3767790_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "3767790_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "3767790_2_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "3767790_2_Ent3", "role": "Treatment", "text": "receiving Tolazoline by infusion", "start": 4, "end": 8}, {"entity_id": "3767790_2_Ent4", "role": "Treatment_Drug", "text": "Tolazoline", "start": 5, "end": 6}, {"entity_id": "3767790_2_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 7, "end": 8}, {"entity_id": "3767790_2_Ent2", "role": "Effect", "text": "duodenal ulceration and subsequent intestinal perforation", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "3767790_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3767790_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3767790_2_Ent3", "text": "receiving Tolazoline by infusion", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3767790_2_Ent4", "text": "Tolazoline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3767790_2_Ent5", "text": "infusion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3767790_2_Ent2", "text": "duodenal ulceration and subsequent intestinal perforation", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "3892171_1", "wnd_id": "3892171_1_1", "text": "Protamine - induced fatal anaphylaxis .", "tokens": ["Protamine", "-", "induced", "fatal", "anaphylaxis", "."], "event_mentions": [{"id": "3892171_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3892171_1_Ent1", "role": "Treatment", "text": "Protamine", "start": 0, "end": 1}, {"entity_id": "3892171_1_Ent2", "role": "Treatment_Drug", "text": "Protamine", "start": 0, "end": 1}, {"entity_id": "3892171_1_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3892171_1_Ent1", "text": "Protamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3892171_1_Ent2", "text": "Protamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3892171_1_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3947272_2", "wnd_id": "3947272_2_1", "text": "Ampicillin may aggravate clinical and experimental myasthenia gravis .", "tokens": ["Ampicillin", "may", "aggravate", "clinical", "and", "experimental", "myasthenia", "gravis", "."], "event_mentions": [{"id": "3947272_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aggravate", "start": 2, "end": 3}, "arguments": [{"entity_id": "3947272_2_Ent1", "role": "Treatment", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "3947272_2_Ent2", "role": "Treatment_Drug", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "3947272_2_Ent0", "role": "Effect", "text": "myasthenia gravis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "3947272_2_Ent1", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_2_Ent2", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_2_Ent0", "text": "myasthenia gravis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "3954165_2", "wnd_id": "3954165_2_1", "text": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer .", "tokens": ["We", "presented", "a", "patient", "with", "status", "asthmaticus", "treated", "with", "a", "combination", "of", "theophylline", "and", "prednisone", "who", "developed", "a", "perforated", "gastric", "ulcer", "."], "event_mentions": [{"id": "3954165_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "3954165_2_Ent0", "role": "Subject", "text": "a patient with status asthmaticus", "start": 2, "end": 7}, {"entity_id": "3954165_2_Ent5", "role": "Treatment_Disorder", "text": "status asthmaticus", "start": 5, "end": 7}, {"entity_id": "3954165_2_Ent3", "role": "Treatment_Drug", "text": "theophylline", "start": 12, "end": 13}, {"entity_id": "3954165_2_Ent6", "role": "Combination_Drug", "text": "theophylline", "start": 12, "end": 13}, {"entity_id": "3954165_2_Ent2", "role": "Treatment", "text": "theophylline and prednisone", "start": 12, "end": 15}, {"entity_id": "3954165_2_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 14, "end": 15}, {"entity_id": "3954165_2_Ent7", "role": "Combination_Drug", "text": "prednisone", "start": 14, "end": 15}, {"entity_id": "3954165_2_Ent1", "role": "Effect", "text": "perforated gastric ulcer", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "3954165_2_Ent0", "text": "a patient with status asthmaticus", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "3954165_2_Ent5", "text": "status asthmaticus", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3954165_2_Ent3", "text": "theophylline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3954165_2_Ent6", "text": "theophylline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3954165_2_Ent2", "text": "theophylline and prednisone", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "3954165_2_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3954165_2_Ent7", "text": "prednisone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3954165_2_Ent1", "text": "perforated gastric ulcer", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "3967572_5", "wnd_id": "3967572_5_1", "text": "With combined use , clinicians should be aware , when phenytoin is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations .", "tokens": ["With", "combined", "use", ",", "clinicians", "should", "be", "aware", ",", "when", "phenytoin", "is", "added", ",", "of", "the", "potential", "for", "reexacerbation", "of", "pulmonary", "symptomatology", "due", "to", "lowered", "serum", "theophylline", "concentrations", "."], "event_mentions": [{"id": "3967572_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 22, "end": 23}, "arguments": [{"entity_id": "3967572_5_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 10, "end": 11}, {"entity_id": "3967572_5_Ent5", "role": "Combination_Drug", "text": "phenytoin", "start": 10, "end": 11}, {"entity_id": "3967572_5_Ent1", "role": "Treatment", "text": "phenytoin is added", "start": 10, "end": 13}, {"entity_id": "3967572_5_Ent0", "role": "Effect", "text": "reexacerbation of pulmonary symptomatology", "start": 18, "end": 22}, {"entity_id": "3967572_5_Ent2", "role": "Treatment", "text": "theophylline", "start": 26, "end": 27}, {"entity_id": "3967572_5_Ent4", "role": "Treatment_Drug", "text": "theophylline", "start": 26, "end": 27}, {"entity_id": "3967572_5_Ent6", "role": "Combination_Drug", "text": "theophylline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3967572_5_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3967572_5_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3967572_5_Ent1", "text": "phenytoin is added", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3967572_5_Ent0", "text": "reexacerbation of pulmonary symptomatology", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "3967572_5_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3967572_5_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3967572_5_Ent6", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3969689_4", "wnd_id": "3969689_4_1", "text": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine .", "tokens": ["Careful", "observations", "on", "hepatotoxicity", "are", "suggested", "when", "acetaminophen", "is", "prescribed", "with", "caffeine", "."], "event_mentions": [{"id": "3969689_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "3969689_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}, {"entity_id": "3969689_4_Ent1", "role": "Treatment", "text": "acetaminophen", "start": 7, "end": 8}, {"entity_id": "3969689_4_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 7, "end": 8}, {"entity_id": "3969689_4_Ent2", "role": "Treatment", "text": "caffeine", "start": 11, "end": 12}, {"entity_id": "3969689_4_Ent4", "role": "Treatment_Drug", "text": "caffeine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3969689_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3969689_4_Ent1", "text": "acetaminophen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3969689_4_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3969689_4_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3969689_4_Ent4", "text": "caffeine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3997294_1", "wnd_id": "3997294_1_1", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .", "tokens": ["Pneumonitis", "with", "pleural", "and", "pericardial", "effusion", "and", "neuropathy", "during", "amiodarone", "therapy", "."], "event_mentions": [{"id": "3997294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "3997294_1_Ent0", "role": "Effect", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "start": 0, "end": 8}, {"entity_id": "3997294_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 9, "end": 10}, {"entity_id": "3997294_1_Ent1", "role": "Treatment", "text": "amiodarone therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3997294_1_Ent0", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3997294_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3997294_1_Ent1", "text": "amiodarone therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "4004433_1", "wnd_id": "4004433_1_1", "text": "Heparin - induced hyperkalemia .", "tokens": ["Heparin", "-", "induced", "hyperkalemia", "."], "event_mentions": [{"id": "4004433_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4004433_1_Ent1", "role": "Treatment", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "4004433_1_Ent2", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "4004433_1_Ent0", "role": "Effect", "text": "hyperkalemia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "4004433_1_Ent1", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4004433_1_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4004433_1_Ent0", "text": "hyperkalemia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "4014301_1", "wnd_id": "4014301_1_1", "text": "Insulin - induced cardiac failure .", "tokens": ["Insulin", "-", "induced", "cardiac", "failure", "."], "event_mentions": [{"id": "4014301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4014301_1_Ent1", "role": "Treatment", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "4014301_1_Ent2", "role": "Treatment_Drug", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "4014301_1_Ent0", "role": "Effect", "text": "cardiac failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "4014301_1_Ent1", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4014301_1_Ent2", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4014301_1_Ent0", "text": "cardiac failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "4018433_2", "wnd_id": "4018433_2_1", "text": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia .", "tokens": ["Administration", "of", "pyridoxine", "to", "an", "infant", "after", "a", "long", "period", "of", "convulsions", "was", "followed", "by", "acute", "hypotonia", "."], "event_mentions": [{"id": "4018433_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 13, "end": 14}, "arguments": [{"entity_id": "4018433_2_Ent3", "role": "Treatment", "text": "pyridoxine", "start": 2, "end": 3}, {"entity_id": "4018433_2_Ent4", "role": "Treatment_Drug", "text": "pyridoxine", "start": 2, "end": 3}, {"entity_id": "4018433_2_Ent0", "role": "Subject", "text": "an infant", "start": 4, "end": 6}, {"entity_id": "4018433_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 5, "end": 6}, {"entity_id": "4018433_2_Ent5", "role": "Treatment_Disorder", "text": "convulsions", "start": 11, "end": 12}, {"entity_id": "4018433_2_Ent2", "role": "Effect", "text": "acute hypotonia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "4018433_2_Ent3", "text": "pyridoxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4018433_2_Ent4", "text": "pyridoxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4018433_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "4018433_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4018433_2_Ent5", "text": "convulsions", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4018433_2_Ent2", "text": "acute hypotonia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "4054170_1", "wnd_id": "4054170_1_1", "text": "According to the literature , chlorambucil central nervous toxicity is found almost exclusively in childhood nephrotic syndrome .", "tokens": ["According", "to", "the", "literature", ",", "chlorambucil", "central", "nervous", "toxicity", "is", "found", "almost", "exclusively", "in", "childhood", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "4054170_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "found", "start": 10, "end": 11}, "arguments": [{"entity_id": "4054170_1_Ent4", "role": "Treatment", "text": "chlorambucil", "start": 5, "end": 6}, {"entity_id": "4054170_1_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 5, "end": 6}, {"entity_id": "4054170_1_Ent3", "role": "Effect", "text": "central nervous toxicity", "start": 6, "end": 9}, {"entity_id": "4054170_1_Ent1", "role": "Subject_Age", "text": "childhood", "start": 14, "end": 15}, {"entity_id": "4054170_1_Ent0", "role": "Subject", "text": "childhood nephrotic syndrome", "start": 14, "end": 17}, {"entity_id": "4054170_1_Ent2", "role": "Subject_Disorder", "text": "nephrotic syndrome", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "4054170_1_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4054170_1_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4054170_1_Ent3", "text": "central nervous toxicity", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "4054170_1_Ent1", "text": "childhood", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "4054170_1_Ent0", "text": "childhood nephrotic syndrome", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "4054170_1_Ent2", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "4063627_1", "wnd_id": "4063627_1_1", "text": "A 35 - year - old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac .", "tokens": ["A", "35", "-", "year", "-", "old", "man", "with", "seropositive", "rheumatoid", "arthritis", "developed", "selective", "IgA", "deficiency", "during", "treatment", "with", "fenclofenac", "."], "event_mentions": [{"id": "4063627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "4063627_1_Ent0", "role": "Subject", "text": "A 35 - year - old man with seropositive rheumatoid arthritis", "start": 0, "end": 11}, {"entity_id": "4063627_1_Ent1", "role": "Subject_Age", "text": "35 - year - old", "start": 1, "end": 6}, {"entity_id": "4063627_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "4063627_1_Ent6", "role": "Treatment_Disorder", "text": "seropositive rheumatoid arthritis", "start": 8, "end": 11}, {"entity_id": "4063627_1_Ent3", "role": "Effect", "text": "selective IgA deficiency", "start": 12, "end": 15}, {"entity_id": "4063627_1_Ent4", "role": "Treatment", "text": "fenclofenac", "start": 18, "end": 19}, {"entity_id": "4063627_1_Ent5", "role": "Treatment_Drug", "text": "fenclofenac", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "4063627_1_Ent0", "text": "A 35 - year - old man with seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "4063627_1_Ent1", "text": "35 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "4063627_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4063627_1_Ent6", "text": "seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "4063627_1_Ent3", "text": "selective IgA deficiency", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "4063627_1_Ent4", "text": "fenclofenac", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "4063627_1_Ent5", "text": "fenclofenac", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "4075534_2", "wnd_id": "4075534_2_1", "text": "Spindle coma in benzodiazepine toxicity : case report .", "tokens": ["Spindle", "coma", "in", "benzodiazepine", "toxicity", ":", "case", "report", "."], "event_mentions": [{"id": "4075534_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "4075534_2_Ent0", "role": "Effect", "text": "Spindle coma", "start": 0, "end": 2}, {"entity_id": "4075534_2_Ent1", "role": "Treatment", "text": "benzodiazepine", "start": 3, "end": 4}, {"entity_id": "4075534_2_Ent2", "role": "Treatment_Drug", "text": "benzodiazepine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "4075534_2_Ent0", "text": "Spindle coma", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4075534_2_Ent1", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "4075534_2_Ent2", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "4082283_3", "wnd_id": "4082283_3_1", "text": "The following is a report of 2 cases of rifampicin - induced renal insufficiency .", "tokens": ["The", "following", "is", "a", "report", "of", "2", "cases", "of", "rifampicin", "-", "induced", "renal", "insufficiency", "."], "event_mentions": [{"id": "4082283_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "4082283_3_Ent1", "role": "Treatment", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_3_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_3_Ent0", "role": "Effect", "text": "renal insufficiency", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "4082283_3_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_3_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_3_Ent0", "text": "renal insufficiency", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "440873_3", "wnd_id": "440873_3_1", "text": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia .", "tokens": ["The", "currently", "available", "clinical", "and", "neuropharmacologic", "data", "suggest", "that", "carbamazepine", "may", "be", "an", "antagonist", "of", "dopamine", "and", "that", "this", "property", "is", "responsible", "for", "the", "production", "of", "dystonia", "."], "event_mentions": [{"id": "440873_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 21, "end": 22}, "arguments": [{"entity_id": "440873_3_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 9, "end": 10}, {"entity_id": "440873_3_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 9, "end": 10}, {"entity_id": "440873_3_Ent0", "role": "Effect", "text": "dystonia", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "440873_3_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "440873_3_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "440873_3_Ent0", "text": "dystonia", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "489527_1", "wnd_id": "489527_1_1", "text": "Renal damage associated with long term use of lithium carbonate .", "tokens": ["Renal", "damage", "associated", "with", "long", "term", "use", "of", "lithium", "carbonate", "."], "event_mentions": [{"id": "489527_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "489527_1_Ent0", "role": "Effect", "text": "Renal damage", "start": 0, "end": 2}, {"entity_id": "489527_1_Ent1", "role": "Treatment", "text": "lithium carbonate", "start": 8, "end": 10}, {"entity_id": "489527_1_Ent2", "role": "Treatment_Drug", "text": "lithium carbonate .", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "489527_1_Ent0", "text": "Renal damage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "489527_1_Ent1", "text": "lithium carbonate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "489527_1_Ent2", "text": "lithium carbonate .", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "489527_2", "wnd_id": "489527_2_1", "text": "The authors report 2 cases of renal damage associated with lithium carbonate treatment .", "tokens": ["The", "authors", "report", "2", "cases", "of", "renal", "damage", "associated", "with", "lithium", "carbonate", "treatment", "."], "event_mentions": [{"id": "489527_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "489527_2_Ent1", "role": "Subject_Population", "text": "2", "start": 3, "end": 4}, {"entity_id": "489527_2_Ent0", "role": "Subject", "text": "2 cases", "start": 3, "end": 5}, {"entity_id": "489527_2_Ent2", "role": "Effect", "text": "renal damage", "start": 6, "end": 8}, {"entity_id": "489527_2_Ent4", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 10, "end": 12}, {"entity_id": "489527_2_Ent3", "role": "Treatment", "text": "lithium carbonate treatment", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "489527_2_Ent1", "text": "2", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "489527_2_Ent0", "text": "2 cases", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "489527_2_Ent2", "text": "renal damage", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "489527_2_Ent4", "text": "lithium carbonate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "489527_2_Ent3", "text": "lithium carbonate treatment", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "507889_1", "wnd_id": "507889_1_1", "text": "In two patients with mycosis fungoides , a squamous cell carcinoma developed during therapy with psoralens plus long - wave ultraviolet radiation ( PUVA ) .", "tokens": ["In", "two", "patients", "with", "mycosis", "fungoides", ",", "a", "squamous", "cell", "carcinoma", "developed", "during", "therapy", "with", "psoralens", "plus", "long", "-", "wave", "ultraviolet", "radiation", "(", "PUVA", ")", "."], "event_mentions": [{"id": "507889_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "507889_1_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "507889_1_Ent0", "role": "Subject", "text": "two patients with mycosis fungoides", "start": 1, "end": 6}, {"entity_id": "507889_1_Ent4", "role": "Treatment_Disorder", "text": "mycosis fungoides", "start": 4, "end": 6}, {"entity_id": "507889_1_Ent2", "role": "Effect", "text": "squamous cell carcinoma", "start": 8, "end": 11}, {"entity_id": "507889_1_Ent5", "role": "Treatment_Drug", "text": "psoralens", "start": 15, "end": 16}, {"entity_id": "507889_1_Ent3", "role": "Treatment", "text": "psoralens plus long - wave ultraviolet radiation ( PUVA )", "start": 15, "end": 25}]}], "entity_mentions": [{"id": "507889_1_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "507889_1_Ent0", "text": "two patients with mycosis fungoides", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "507889_1_Ent4", "text": "mycosis fungoides", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "507889_1_Ent2", "text": "squamous cell carcinoma", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "507889_1_Ent5", "text": "psoralens", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "507889_1_Ent3", "text": "psoralens plus long - wave ultraviolet radiation ( PUVA )", "entity_type": "Entity", "start": 15, "end": 25}], "lang": "en"}
{"doc_id": "556126_1", "wnd_id": "556126_1_1", "text": "An infertile patient with amenorrhea - galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment .", "tokens": ["An", "infertile", "patient", "with", "amenorrhea", "-", "galactorrhea", "syndrome", "lost", "vision", "during", "a", "pregnancy", "occurring", "after", "Bromocryptine", "treatment", "."], "event_mentions": [{"id": "556126_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "556126_1_Ent0", "role": "Subject", "text": "An infertile patient with amenorrhea - galactorrhea syndrome", "start": 0, "end": 8}, {"entity_id": "556126_1_Ent1", "role": "Subject_Disorder", "text": "infertile", "start": 1, "end": 2}, {"entity_id": "556126_1_Ent5", "role": "Treatment_Disorder", "text": "amenorrhea - galactorrhea syndrome", "start": 4, "end": 8}, {"entity_id": "556126_1_Ent2", "role": "Effect", "text": "lost vision", "start": 8, "end": 10}, {"entity_id": "556126_1_Ent3", "role": "Treatment", "text": "Bromocryptine", "start": 15, "end": 16}, {"entity_id": "556126_1_Ent4", "role": "Treatment_Drug", "text": "Bromocryptine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "556126_1_Ent0", "text": "An infertile patient with amenorrhea - galactorrhea syndrome", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "556126_1_Ent1", "text": "infertile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "556126_1_Ent5", "text": "amenorrhea - galactorrhea syndrome", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "556126_1_Ent2", "text": "lost vision", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "556126_1_Ent3", "text": "Bromocryptine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "556126_1_Ent4", "text": "Bromocryptine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "573779_3", "wnd_id": "573779_3_1", "text": "A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant , amoxapine .", "tokens": ["A", "young", "woman", "developed", "galactorrhea", "during", "treatment", "with", "a", "new", "dibenzoxazepine", "antidepressant", ",", "amoxapine", "."], "event_mentions": [{"id": "573779_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "573779_3_Ent0", "role": "Subject", "text": "A young woman", "start": 0, "end": 3}, {"entity_id": "573779_3_Ent1", "role": "Subject_Age", "text": "young", "start": 1, "end": 2}, {"entity_id": "573779_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 2, "end": 3}, {"entity_id": "573779_3_Ent3", "role": "Effect", "text": "galactorrhea", "start": 4, "end": 5}, {"entity_id": "573779_3_Ent4", "role": "Treatment", "text": "during treatment with a new dibenzoxazepine antidepressant , amoxapine", "start": 5, "end": 14}, {"entity_id": "573779_3_Ent5", "role": "Treatment_Drug", "text": "amoxapine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "573779_3_Ent0", "text": "A young woman", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "573779_3_Ent1", "text": "young", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "573779_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "573779_3_Ent3", "text": "galactorrhea", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "573779_3_Ent4", "text": "during treatment with a new dibenzoxazepine antidepressant , amoxapine", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "573779_3_Ent5", "text": "amoxapine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "576675_1", "wnd_id": "576675_1_1", "text": "A 15 - kg weight gain developed in a patient during the third week of ibuprofen therapy .", "tokens": ["A", "15", "-", "kg", "weight", "gain", "developed", "in", "a", "patient", "during", "the", "third", "week", "of", "ibuprofen", "therapy", "."], "event_mentions": [{"id": "576675_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "576675_1_Ent1", "role": "Effect", "text": "A 15 - kg weight gain", "start": 0, "end": 6}, {"entity_id": "576675_1_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "576675_1_Ent4", "role": "Treatment_Time_elapsed", "text": "the third week", "start": 11, "end": 14}, {"entity_id": "576675_1_Ent2", "role": "Treatment", "text": "ibuprofen", "start": 15, "end": 16}, {"entity_id": "576675_1_Ent3", "role": "Treatment_Drug", "text": "ibuprofen", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "576675_1_Ent1", "text": "A 15 - kg weight gain", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "576675_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "576675_1_Ent4", "text": "the third week", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "576675_1_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "576675_1_Ent3", "text": "ibuprofen", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "578255_1", "wnd_id": "578255_1_1", "text": "Allopurinol - associated hand and foot deformities in chronic tophaceous gout .", "tokens": ["Allopurinol", "-", "associated", "hand", "and", "foot", "deformities", "in", "chronic", "tophaceous", "gout", "."], "event_mentions": [{"id": "578255_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "578255_1_Ent1", "role": "Treatment", "text": "Allopurinol", "start": 0, "end": 1}, {"entity_id": "578255_1_Ent2", "role": "Treatment_Drug", "text": "Allopurinol", "start": 0, "end": 1}, {"entity_id": "578255_1_Ent0", "role": "Effect", "text": "hand and foot deformities", "start": 3, "end": 7}, {"entity_id": "578255_1_Ent3", "role": "Treatment_Disorder", "text": "chronic tophaceous gout", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "578255_1_Ent1", "text": "Allopurinol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "578255_1_Ent2", "text": "Allopurinol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "578255_1_Ent0", "text": "hand and foot deformities", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "578255_1_Ent3", "text": "chronic tophaceous gout", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "578255_2", "wnd_id": "578255_2_1", "text": "Telescoped digits of the hands and feet developed in a 69 - year - old male with severe chronic tophaceous gout during allopurinol treatment .", "tokens": ["Telescoped", "digits", "of", "the", "hands", "and", "feet", "developed", "in", "a", "69", "-", "year", "-", "old", "male", "with", "severe", "chronic", "tophaceous", "gout", "during", "allopurinol", "treatment", "."], "event_mentions": [{"id": "578255_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "578255_2_Ent3", "role": "Effect", "text": "Telescoped digits of the hands and feet", "start": 0, "end": 7}, {"entity_id": "578255_2_Ent0", "role": "Subject", "text": "a 69 - year - old male with severe chronic tophaceous gout", "start": 9, "end": 21}, {"entity_id": "578255_2_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 10, "end": 15}, {"entity_id": "578255_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 15, "end": 16}, {"entity_id": "578255_2_Ent5", "role": "Treatment_Disorder", "text": "severe chronic tophaceous gout", "start": 17, "end": 21}, {"entity_id": "578255_2_Ent6", "role": "Treatment_Drug", "text": "allopurinol", "start": 22, "end": 23}, {"entity_id": "578255_2_Ent4", "role": "Treatment", "text": "allopurinol treatment", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "578255_2_Ent3", "text": "Telescoped digits of the hands and feet", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "578255_2_Ent0", "text": "a 69 - year - old male with severe chronic tophaceous gout", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "578255_2_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "578255_2_Ent2", "text": "male", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "578255_2_Ent5", "text": "severe chronic tophaceous gout", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "578255_2_Ent6", "text": "allopurinol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "578255_2_Ent4", "text": "allopurinol treatment", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "6093724_3", "wnd_id": "6093724_3_1", "text": "To our knowledge , we describe the first reported case of isolated paresthesia and peripheral neuropathy , without systemic involvement , secondary to sulindac administration .", "tokens": ["To", "our", "knowledge", ",", "we", "describe", "the", "first", "reported", "case", "of", "isolated", "paresthesia", "and", "peripheral", "neuropathy", ",", "without", "systemic", "involvement", ",", "secondary", "to", "sulindac", "administration", "."], "event_mentions": [{"id": "6093724_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 21, "end": 22}, "arguments": [{"entity_id": "6093724_3_Ent0", "role": "Effect", "text": "isolated paresthesia and peripheral neuropathy", "start": 11, "end": 16}, {"entity_id": "6093724_3_Ent2", "role": "Treatment_Drug", "text": "sulindac", "start": 23, "end": 24}, {"entity_id": "6093724_3_Ent1", "role": "Treatment", "text": "sulindac administration", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "6093724_3_Ent0", "text": "isolated paresthesia and peripheral neuropathy", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "6093724_3_Ent2", "text": "sulindac", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "6093724_3_Ent1", "text": "sulindac administration", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "6113770_1", "wnd_id": "6113770_1_1", "text": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia , severe rigidity , mutism , and development of irreversible tardive dyskinesia .", "tokens": ["The", "authors", "describe", "a", "case", "of", "combined", "lithium", "and", "haloperidol", "toxicity", "characterized", "by", "hyperpyrexia", ",", "severe", "rigidity", ",", "mutism", ",", "and", "development", "of", "irreversible", "tardive", "dyskinesia", "."], "event_mentions": [{"id": "6113770_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 10, "end": 11}, "arguments": [{"entity_id": "6113770_1_Ent1", "role": "Treatment", "text": "combined lithium and haloperidol", "start": 6, "end": 10}, {"entity_id": "6113770_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "6113770_1_Ent4", "role": "Combination_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "6113770_1_Ent3", "role": "Treatment_Drug", "text": "haloperidol", "start": 9, "end": 10}, {"entity_id": "6113770_1_Ent5", "role": "Combination_Drug", "text": "haloperidol", "start": 9, "end": 10}, {"entity_id": "6113770_1_Ent0", "role": "Effect", "text": "hyperpyrexia , severe rigidity , mutism , and development of irreversible tardive dyskinesia", "start": 13, "end": 26}]}], "entity_mentions": [{"id": "6113770_1_Ent1", "text": "combined lithium and haloperidol", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "6113770_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6113770_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6113770_1_Ent3", "text": "haloperidol", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6113770_1_Ent5", "text": "haloperidol", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6113770_1_Ent0", "text": "hyperpyrexia , severe rigidity , mutism , and development of irreversible tardive dyskinesia", "entity_type": "Entity", "start": 13, "end": 26}], "lang": "en"}
{"doc_id": "6113770_2", "wnd_id": "6113770_2_1", "text": "The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines , primarily thioridazine .", "tokens": ["The", "authors", "postulate", "that", "two", "types", "of", "combined", "lithium", "-", "neuroleptic", "toxicity", "occur", ":", "a", "neuroleptic", "malignant", "extrapyramidal", "syndrome", "and", "a", "lithium", "toxicity", "that", "occurs", "in", "combination", "with", "phenothiazines", ",", "primarily", "thioridazine", "."], "event_mentions": [{"id": "6113770_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 12, "end": 13}, "arguments": [{"entity_id": "6113770_2_Ent1", "role": "Treatment", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "6113770_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "6113770_2_Ent0", "role": "Effect", "text": "neuroleptic toxicity", "start": 10, "end": 12}]}, {"id": "6113770_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 24, "end": 25}, "arguments": [{"entity_id": "6113770_2_Ent3", "role": "Effect", "text": "a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity", "start": 14, "end": 23}, {"entity_id": "6113770_2_Ent4", "role": "Treatment", "text": "lithium", "start": 21, "end": 22}, {"entity_id": "6113770_2_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 21, "end": 22}, {"entity_id": "6113770_2_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 21, "end": 22}, {"entity_id": "6113770_2_Ent5", "role": "Treatment", "text": "in combination with phenothiazines , primarily thioridazine", "start": 25, "end": 32}, {"entity_id": "6113770_2_Ent7", "role": "Treatment_Drug", "text": "phenothiazines", "start": 28, "end": 29}, {"entity_id": "6113770_2_Ent9", "role": "Combination_Drug", "text": "phenothiazines", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "6113770_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6113770_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6113770_2_Ent0", "text": "neuroleptic toxicity", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "6113770_2_Ent3", "text": "a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "6113770_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6113770_2_Ent6", "text": "lithium", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6113770_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6113770_2_Ent5", "text": "in combination with phenothiazines , primarily thioridazine", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "6113770_2_Ent7", "text": "phenothiazines", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "6113770_2_Ent9", "text": "phenothiazines", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "6149250_5", "wnd_id": "6149250_5_1", "text": "Both patients developed severe complications when treated with aminoglutethimide as a cancer hormonal therapy .", "tokens": ["Both", "patients", "developed", "severe", "complications", "when", "treated", "with", "aminoglutethimide", "as", "a", "cancer", "hormonal", "therapy", "."], "event_mentions": [{"id": "6149250_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6149250_5_Ent0", "role": "Subject", "text": "Both patients", "start": 0, "end": 2}, {"entity_id": "6149250_5_Ent1", "role": "Effect", "text": "severe complications", "start": 3, "end": 5}, {"entity_id": "6149250_5_Ent2", "role": "Treatment", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "6149250_5_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "6149250_5_Ent3", "role": "Treatment_Disorder", "text": "cancer", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6149250_5_Ent0", "text": "Both patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6149250_5_Ent1", "text": "severe complications", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6149250_5_Ent2", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6149250_5_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6149250_5_Ent3", "text": "cancer", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6159523_7", "wnd_id": "6159523_7_1", "text": "Preliminary results suggest that the higher concentrations of dextrose induce increased histamine release from blood cells , and that this phenomenon is more marked in diabetic , and particularly diabetic - allergic , individuals .", "tokens": ["Preliminary", "results", "suggest", "that", "the", "higher", "concentrations", "of", "dextrose", "induce", "increased", "histamine", "release", "from", "blood", "cells", ",", "and", "that", "this", "phenomenon", "is", "more", "marked", "in", "diabetic", ",", "and", "particularly", "diabetic", "-", "allergic", ",", "individuals", "."], "event_mentions": [{"id": "6159523_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 9, "end": 10}, "arguments": [{"entity_id": "6159523_7_Ent6", "role": "Treatment_Dosage", "text": "higher concentrations", "start": 5, "end": 7}, {"entity_id": "6159523_7_Ent4", "role": "Treatment", "text": "higher concentrations of dextrose", "start": 5, "end": 9}, {"entity_id": "6159523_7_Ent5", "role": "Treatment_Drug", "text": "dextrose", "start": 8, "end": 9}, {"entity_id": "6159523_7_Ent3", "role": "Effect", "text": "increased histamine release from blood cells", "start": 10, "end": 16}, {"entity_id": "6159523_7_Ent1", "role": "Subject_Disorder", "text": "diabetic", "start": 25, "end": 26}, {"entity_id": "6159523_7_Ent0", "role": "Subject", "text": "diabetic , and particularly diabetic - allergic , individuals", "start": 25, "end": 34}, {"entity_id": "6159523_7_Ent2", "role": "Subject_Disorder", "text": "diabetic - allergic", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "6159523_7_Ent6", "text": "higher concentrations", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6159523_7_Ent4", "text": "higher concentrations of dextrose", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "6159523_7_Ent5", "text": "dextrose", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6159523_7_Ent3", "text": "increased histamine release from blood cells", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "6159523_7_Ent1", "text": "diabetic", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6159523_7_Ent0", "text": "diabetic , and particularly diabetic - allergic , individuals", "entity_type": "Entity", "start": 25, "end": 34}, {"id": "6159523_7_Ent2", "text": "diabetic - allergic", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "6199475_1", "wnd_id": "6199475_1_1", "text": "A 36 - year - old man being treated with cisplatinum , vinblastine , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia , encephalopathy , and a partial nondominant parietal lobe syndrome .", "tokens": ["A", "36", "-", "year", "-", "old", "man", "being", "treated", "with", "cisplatinum", ",", "vinblastine", ",", "and", "bleomycin", "for", "testicular", "carcinoma", "developed", "a", "dense", "left", "homonymous", "hemianopsia", ",", "encephalopathy", ",", "and", "a", "partial", "nondominant", "parietal", "lobe", "syndrome", "."], "event_mentions": [{"id": "6199475_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "6199475_1_Ent0", "role": "Subject", "text": "A 36 - year - old man", "start": 0, "end": 7}, {"entity_id": "6199475_1_Ent2", "role": "Subject_Age", "text": "36 - year - old", "start": 1, "end": 6}, {"entity_id": "6199475_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "6199475_1_Ent7", "role": "Treatment_Drug", "text": "cisplatinum", "start": 10, "end": 11}, {"entity_id": "6199475_1_Ent10", "role": "Combination_Drug", "text": "cisplatinum", "start": 10, "end": 11}, {"entity_id": "6199475_1_Ent5", "role": "Treatment", "text": "cisplatinum , vinblastine , and bleomycin", "start": 10, "end": 16}, {"entity_id": "6199475_1_Ent8", "role": "Treatment_Drug", "text": "vinblastine", "start": 12, "end": 13}, {"entity_id": "6199475_1_Ent11", "role": "Combination_Drug", "text": "vinblastine", "start": 12, "end": 13}, {"entity_id": "6199475_1_Ent9", "role": "Treatment_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "6199475_1_Ent12", "role": "Combination_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "6199475_1_Ent1", "role": "Subject", "text": "testicular carcinoma", "start": 17, "end": 19}, {"entity_id": "6199475_1_Ent6", "role": "Treatment_Disorder", "text": "testicular carcinoma", "start": 17, "end": 19}, {"entity_id": "6199475_1_Ent4", "role": "Effect", "text": "dense left homonymous hemianopsia , encephalopathy , and a partial nondominant parietal lobe syndrome", "start": 21, "end": 35}]}], "entity_mentions": [{"id": "6199475_1_Ent0", "text": "A 36 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6199475_1_Ent2", "text": "36 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6199475_1_Ent3", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6199475_1_Ent7", "text": "cisplatinum", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6199475_1_Ent10", "text": "cisplatinum", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6199475_1_Ent5", "text": "cisplatinum , vinblastine , and bleomycin", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "6199475_1_Ent8", "text": "vinblastine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6199475_1_Ent11", "text": "vinblastine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6199475_1_Ent9", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6199475_1_Ent12", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6199475_1_Ent1", "text": "testicular carcinoma", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "6199475_1_Ent6", "text": "testicular carcinoma", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "6199475_1_Ent4", "text": "dense left homonymous hemianopsia , encephalopathy , and a partial nondominant parietal lobe syndrome", "entity_type": "Entity", "start": 21, "end": 35}], "lang": "en"}
{"doc_id": "6245286_2", "wnd_id": "6245286_2_1", "text": "In three of these patients the infection was clinically unsuspected ; in the fourth , cutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days .", "tokens": ["In", "three", "of", "these", "patients", "the", "infection", "was", "clinically", "unsuspected", ";", "in", "the", "fourth", ",", "cutaneous", "herpes", "zoster", "developed", "after", "administration", "of", "300", "mg", "of", "cytarabine", "daily", "for", "the", "preceding", "five", "days", "."], "event_mentions": [{"id": "6245286_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6245286_2_Ent1", "role": "Subject_Population", "text": "three", "start": 1, "end": 2}, {"entity_id": "6245286_2_Ent0", "role": "Subject", "text": "three of these patients", "start": 1, "end": 5}, {"entity_id": "6245286_2_Ent2", "role": "Effect", "text": "cutaneous herpes zoster", "start": 15, "end": 18}, {"entity_id": "6245286_2_Ent4", "role": "Treatment_Dosage", "text": "300 mg", "start": 22, "end": 24}, {"entity_id": "6245286_2_Ent3", "role": "Treatment", "text": "300 mg of cytarabine daily for the preceding five days", "start": 22, "end": 32}, {"entity_id": "6245286_2_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 25, "end": 26}, {"entity_id": "6245286_2_Ent6", "role": "Treatment_Freq", "text": "daily", "start": 26, "end": 27}, {"entity_id": "6245286_2_Ent7", "role": "Treatment_Duration", "text": "preceding five days", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "6245286_2_Ent1", "text": "three", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6245286_2_Ent0", "text": "three of these patients", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6245286_2_Ent2", "text": "cutaneous herpes zoster", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "6245286_2_Ent4", "text": "300 mg", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "6245286_2_Ent3", "text": "300 mg of cytarabine daily for the preceding five days", "entity_type": "Entity", "start": 22, "end": 32}, {"id": "6245286_2_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6245286_2_Ent6", "text": "daily", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "6245286_2_Ent7", "text": "preceding five days", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "6245286_3", "wnd_id": "6245286_3_1", "text": "Visceral herpesvirus infections in leukemic patients receiving cytarabine .", "tokens": ["Visceral", "herpesvirus", "infections", "in", "leukemic", "patients", "receiving", "cytarabine", "."], "event_mentions": [{"id": "6245286_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "6245286_3_Ent1", "role": "Effect", "text": "Visceral herpesvirus infections", "start": 0, "end": 3}, {"entity_id": "6245286_3_Ent4", "role": "Treatment_Disorder", "text": "leukemic", "start": 4, "end": 5}, {"entity_id": "6245286_3_Ent0", "role": "Subject", "text": "leukemic patients", "start": 4, "end": 6}, {"entity_id": "6245286_3_Ent2", "role": "Treatment", "text": "cytarabine", "start": 7, "end": 8}, {"entity_id": "6245286_3_Ent3", "role": "Treatment_Drug", "text": "cytarabine .", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6245286_3_Ent1", "text": "Visceral herpesvirus infections", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6245286_3_Ent4", "text": "leukemic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6245286_3_Ent0", "text": "leukemic patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "6245286_3_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6245286_3_Ent3", "text": "cytarabine .", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6292681_1", "wnd_id": "6292681_1_1", "text": "Severe neurotoxicity with methyl G : CALGB experience .", "tokens": ["Severe", "neurotoxicity", "with", "methyl", "G", ":", "CALGB", "experience", "."], "event_mentions": [{"id": "6292681_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "6292681_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}, {"entity_id": "6292681_1_Ent1", "role": "Treatment", "text": "methyl G", "start": 3, "end": 5}, {"entity_id": "6292681_1_Ent2", "role": "Treatment_Drug", "text": "methyl G", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "6292681_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6292681_1_Ent1", "text": "methyl G", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6292681_1_Ent2", "text": "methyl G", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "6311654_5", "wnd_id": "6311654_5_1", "text": "There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma .", "tokens": ["There", "was", "a", "good", "correlation", "between", "the", "total", "dose", "of", "ACTH", "and", "the", "percentage", "decrease", "of", "brain", "parenchyma", "."], "event_mentions": [{"id": "6311654_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "correlation", "start": 4, "end": 5}, "arguments": [{"entity_id": "6311654_5_Ent1", "role": "Treatment", "text": "total dose of ACTH", "start": 7, "end": 11}, {"entity_id": "6311654_5_Ent2", "role": "Treatment_Drug", "text": "ACTH", "start": 10, "end": 11}, {"entity_id": "6311654_5_Ent0", "role": "Effect", "text": "percentage decrease of brain parenchyma", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "6311654_5_Ent1", "text": "total dose of ACTH", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "6311654_5_Ent2", "text": "ACTH", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6311654_5_Ent0", "text": "percentage decrease of brain parenchyma", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "6340463_4", "wnd_id": "6340463_4_1", "text": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long - term prednisone for graft - versus - host disease .", "tokens": ["Patients", "from", "endemic", "areas", "referred", "to", "transplant", "centers", "may", "be", "at", "high", "risk", "for", "disseminated", "histoplasmosis", "when", "treated", "with", "long", "-", "term", "prednisone", "for", "graft", "-", "versus", "-", "host", "disease", "."], "event_mentions": [{"id": "6340463_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 18, "end": 19}, "arguments": [{"entity_id": "6340463_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "6340463_4_Ent1", "role": "Effect", "text": "disseminated histoplasmosis", "start": 14, "end": 16}, {"entity_id": "6340463_4_Ent2", "role": "Treatment", "text": "long - term prednisone", "start": 19, "end": 23}, {"entity_id": "6340463_4_Ent3", "role": "Treatment_Drug", "text": "prednisone", "start": 22, "end": 23}, {"entity_id": "6340463_4_Ent4", "role": "Treatment_Disorder", "text": "graft - versus - host disease .", "start": 24, "end": 31}]}], "entity_mentions": [{"id": "6340463_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6340463_4_Ent1", "text": "disseminated histoplasmosis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6340463_4_Ent2", "text": "long - term prednisone", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "6340463_4_Ent3", "text": "prednisone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6340463_4_Ent4", "text": "graft - versus - host disease .", "entity_type": "Entity", "start": 24, "end": 31}], "lang": "en"}
{"doc_id": "6401771_1", "wnd_id": "6401771_1_1", "text": "Haemolytic - uraemic syndrome complicating long - term mitomycin C and 5 - fluorouracil therapy for gastric carcinoma .", "tokens": ["Haemolytic", "-", "uraemic", "syndrome", "complicating", "long", "-", "term", "mitomycin", "C", "and", "5", "-", "fluorouracil", "therapy", "for", "gastric", "carcinoma", "."], "event_mentions": [{"id": "6401771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 4, "end": 5}, "arguments": [{"entity_id": "6401771_1_Ent0", "role": "Effect", "text": "Haemolytic - uraemic syndrome", "start": 0, "end": 4}, {"entity_id": "6401771_1_Ent1", "role": "Treatment", "text": "long - term mitomycin C and 5 - fluorouracil therapy", "start": 5, "end": 15}, {"entity_id": "6401771_1_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 8, "end": 10}, {"entity_id": "6401771_1_Ent5", "role": "Combination_Drug", "text": "mitomycin C", "start": 8, "end": 10}, {"entity_id": "6401771_1_Ent4", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 11, "end": 14}, {"entity_id": "6401771_1_Ent6", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 11, "end": 14}, {"entity_id": "6401771_1_Ent2", "role": "Treatment_Disorder", "text": "gastric carcinoma", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "6401771_1_Ent0", "text": "Haemolytic - uraemic syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6401771_1_Ent1", "text": "long - term mitomycin C and 5 - fluorouracil therapy", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "6401771_1_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "6401771_1_Ent5", "text": "mitomycin C", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "6401771_1_Ent4", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "6401771_1_Ent6", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "6401771_1_Ent2", "text": "gastric carcinoma", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "640344_2", "wnd_id": "640344_2_1", "text": "Severe histological osteomalacia developed in a woman with Crohn 's disease 2 years after ileal resection and the start of cholestyramine therapy .", "tokens": ["Severe", "histological", "osteomalacia", "developed", "in", "a", "woman", "with", "Crohn", "'s", "disease", "2", "years", "after", "ileal", "resection", "and", "the", "start", "of", "cholestyramine", "therapy", "."], "event_mentions": [{"id": "640344_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "640344_2_Ent2", "role": "Effect", "text": "histological osteomalacia", "start": 1, "end": 3}, {"entity_id": "640344_2_Ent0", "role": "Subject", "text": "a woman with Crohn 's disease", "start": 5, "end": 11}, {"entity_id": "640344_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "640344_2_Ent6", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}, {"entity_id": "640344_2_Ent3", "role": "Treatment", "text": "2 years after ileal resection and the start of cholestyramine", "start": 11, "end": 21}, {"entity_id": "640344_2_Ent5", "role": "Treatment_Time_elapsed", "text": "start", "start": 18, "end": 19}, {"entity_id": "640344_2_Ent4", "role": "Treatment_Drug", "text": "cholestyramine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "640344_2_Ent2", "text": "histological osteomalacia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "640344_2_Ent0", "text": "a woman with Crohn 's disease", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "640344_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "640344_2_Ent6", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "640344_2_Ent3", "text": "2 years after ileal resection and the start of cholestyramine", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "640344_2_Ent5", "text": "start", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "640344_2_Ent4", "text": "cholestyramine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "6408978_1", "wnd_id": "6408978_1_1", "text": "Intravenous diazepam exacerbated the seizures .", "tokens": ["Intravenous", "diazepam", "exacerbated", "the", "seizures", "."], "event_mentions": [{"id": "6408978_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6408978_1_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "6408978_1_Ent1", "role": "Treatment", "text": "Intravenous diazepam", "start": 0, "end": 2}, {"entity_id": "6408978_1_Ent3", "role": "Treatment_Drug", "text": "diazepam", "start": 1, "end": 2}, {"entity_id": "6408978_1_Ent0", "role": "Effect", "text": "seizures", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6408978_1_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6408978_1_Ent1", "text": "Intravenous diazepam", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6408978_1_Ent3", "text": "diazepam", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6408978_1_Ent0", "text": "seizures", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6414095_5", "wnd_id": "6414095_5_1", "text": "A possible mechanism for focal neurological deficit in brain - damaged patients on phenytoin therapy is discussed .", "tokens": ["A", "possible", "mechanism", "for", "focal", "neurological", "deficit", "in", "brain", "-", "damaged", "patients", "on", "phenytoin", "therapy", "is", "discussed", "."], "event_mentions": [{"id": "6414095_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mechanism", "start": 2, "end": 3}, "arguments": [{"entity_id": "6414095_5_Ent1", "role": "Effect", "text": "focal neurological deficit", "start": 4, "end": 7}, {"entity_id": "6414095_5_Ent4", "role": "Treatment_Disorder", "text": "brain - damaged", "start": 8, "end": 11}, {"entity_id": "6414095_5_Ent0", "role": "Subject", "text": "brain - damaged patients", "start": 8, "end": 12}, {"entity_id": "6414095_5_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 13, "end": 14}, {"entity_id": "6414095_5_Ent2", "role": "Treatment", "text": "phenytoin therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "6414095_5_Ent1", "text": "focal neurological deficit", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "6414095_5_Ent4", "text": "brain - damaged", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6414095_5_Ent0", "text": "brain - damaged patients", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "6414095_5_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6414095_5_Ent2", "text": "phenytoin therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "6427463_2", "wnd_id": "6427463_2_1", "text": "Vasomotor reactions after gold sodium thiomalate are well recognized .", "tokens": ["Vasomotor", "reactions", "after", "gold", "sodium", "thiomalate", "are", "well", "recognized", "."], "event_mentions": [{"id": "6427463_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "6427463_2_Ent0", "role": "Effect", "text": "Vasomotor reactions", "start": 0, "end": 2}, {"entity_id": "6427463_2_Ent1", "role": "Treatment", "text": "gold sodium thiomalate", "start": 3, "end": 6}, {"entity_id": "6427463_2_Ent2", "role": "Treatment_Drug", "text": "gold sodium thiomalate", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "6427463_2_Ent0", "text": "Vasomotor reactions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6427463_2_Ent1", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6427463_2_Ent2", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "6440806_1", "wnd_id": "6440806_1_1", "text": "A 52 - year - old , white female developed low - grade fever , cough , and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis .", "tokens": ["A", "52", "-", "year", "-", "old", ",", "white", "female", "developed", "low", "-", "grade", "fever", ",", "cough", ",", "and", "dyspnea", "after", "8", "weeks", "treatment", "with", "sodium", "aurothiomalate", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6440806_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "6440806_1_Ent0", "role": "Subject", "text": "A 52 - year - old", "start": 0, "end": 6}, {"entity_id": "6440806_1_Ent2", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "6440806_1_Ent3", "role": "Subject_Race", "text": "white", "start": 7, "end": 8}, {"entity_id": "6440806_1_Ent1", "role": "Subject", "text": "white female", "start": 7, "end": 9}, {"entity_id": "6440806_1_Ent4", "role": "Subject_Gender", "text": "female", "start": 8, "end": 9}, {"entity_id": "6440806_1_Ent5", "role": "Effect", "text": "low - grade fever , cough , and dyspnea", "start": 10, "end": 19}, {"entity_id": "6440806_1_Ent7", "role": "Treatment_Time_elapsed", "text": "8 weeks", "start": 20, "end": 22}, {"entity_id": "6440806_1_Ent6", "role": "Treatment", "text": "sodium aurothiomalate", "start": 24, "end": 26}, {"entity_id": "6440806_1_Ent8", "role": "Treatment_Drug", "text": "sodium aurothiomalate", "start": 24, "end": 26}, {"entity_id": "6440806_1_Ent9", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "6440806_1_Ent0", "text": "A 52 - year - old", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6440806_1_Ent2", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6440806_1_Ent3", "text": "white", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6440806_1_Ent1", "text": "white female", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6440806_1_Ent4", "text": "female", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6440806_1_Ent5", "text": "low - grade fever , cough , and dyspnea", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "6440806_1_Ent7", "text": "8 weeks", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "6440806_1_Ent6", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "6440806_1_Ent8", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "6440806_1_Ent9", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "6453500_1", "wnd_id": "6453500_1_1", "text": "A reversible toxic liver damage was observed in a non - alcoholic woman treated with disulfiram .", "tokens": ["A", "reversible", "toxic", "liver", "damage", "was", "observed", "in", "a", "non", "-", "alcoholic", "woman", "treated", "with", "disulfiram", "."], "event_mentions": [{"id": "6453500_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "damage", "start": 4, "end": 5}, "arguments": [{"entity_id": "6453500_1_Ent3", "role": "Effect", "text": "reversible toxic liver damage", "start": 1, "end": 5}, {"entity_id": "6453500_1_Ent0", "role": "Subject", "text": "a non - alcoholic woman", "start": 8, "end": 13}, {"entity_id": "6453500_1_Ent1", "role": "Subject_Disorder", "text": "non - alcoholic", "start": 9, "end": 12}, {"entity_id": "6453500_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "6453500_1_Ent4", "role": "Treatment", "text": "disulfiram", "start": 15, "end": 16}, {"entity_id": "6453500_1_Ent5", "role": "Treatment_Drug", "text": "disulfiram", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6453500_1_Ent3", "text": "reversible toxic liver damage", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6453500_1_Ent0", "text": "a non - alcoholic woman", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6453500_1_Ent1", "text": "non - alcoholic", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6453500_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6453500_1_Ent4", "text": "disulfiram", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6453500_1_Ent5", "text": "disulfiram", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6460590_1", "wnd_id": "6460590_1_1", "text": "One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol .", "tokens": ["One", "type", "of", "SMON", "is", "associated", "with", "acrodermatitis", "enteropathica", "which", "has", "a", "very", "high", "frequency", "of", "occurrence", "in", "association", "with", "administration", "of", "clioquinol", "."], "event_mentions": [{"id": "6460590_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 18, "end": 19}, "arguments": [{"entity_id": "6460590_1_Ent0", "role": "Effect", "text": "SMON", "start": 3, "end": 4}, {"entity_id": "6460590_1_Ent1", "role": "Effect", "text": "acrodermatitis enteropathica", "start": 7, "end": 9}, {"entity_id": "6460590_1_Ent2", "role": "Treatment", "text": "clioquinol", "start": 22, "end": 23}, {"entity_id": "6460590_1_Ent3", "role": "Treatment_Drug", "text": "clioquinol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "6460590_1_Ent0", "text": "SMON", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6460590_1_Ent1", "text": "acrodermatitis enteropathica", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6460590_1_Ent2", "text": "clioquinol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6460590_1_Ent3", "text": "clioquinol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "647693_3", "wnd_id": "647693_3_1", "text": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described .", "tokens": ["These", "findings", "suggest", "that", "the", "corneal", "and", "retinal", "changes", "are", "the", "result", "of", "a", "toxic", "effect", "of", "tamoxifen", "when", "used", "in", "the", "doses", "and", "duration", "described", "."], "event_mentions": [{"id": "647693_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 11, "end": 12}, "arguments": [{"entity_id": "647693_3_Ent0", "role": "Effect", "text": "corneal and retinal changes", "start": 5, "end": 9}, {"entity_id": "647693_3_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "647693_3_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "647693_3_Ent0", "text": "corneal and retinal changes", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "647693_3_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "647693_3_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6484655_3", "wnd_id": "6484655_3_1", "text": "Two patients had ampicillin - associated seizures .", "tokens": ["Two", "patients", "had", "ampicillin", "-", "associated", "seizures", "."], "event_mentions": [{"id": "6484655_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6484655_3_Ent1", "role": "Treatment", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "6484655_3_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "6484655_3_Ent0", "role": "Effect", "text": "seizures", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6484655_3_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6484655_3_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6484655_3_Ent0", "text": "seizures", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6498095_3", "wnd_id": "6498095_3_1", "text": "Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy .", "tokens": ["Pemphigus", "foliaceus", "was", "seen", "in", "a", "patient", "with", "pulmonary", "tuberculosis", "during", "rifampicin", "therapy", "."], "event_mentions": [{"id": "6498095_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 3, "end": 4}, "arguments": [{"entity_id": "6498095_3_Ent1", "role": "Effect", "text": "Pemphigus foliaceus", "start": 0, "end": 2}, {"entity_id": "6498095_3_Ent0", "role": "Subject", "text": "a patient with pulmonary tuberculosis", "start": 5, "end": 10}, {"entity_id": "6498095_3_Ent3", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 8, "end": 10}, {"entity_id": "6498095_3_Ent2", "role": "Treatment", "text": "rifampicin", "start": 11, "end": 12}, {"entity_id": "6498095_3_Ent4", "role": "Treatment_Drug", "text": "rifampicin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6498095_3_Ent1", "text": "Pemphigus foliaceus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6498095_3_Ent0", "text": "a patient with pulmonary tuberculosis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "6498095_3_Ent3", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "6498095_3_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6498095_3_Ent4", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6519218_1", "wnd_id": "6519218_1_1", "text": "In a 61 - year - old man receiving chronic low - dosage amiodarone an interstitial pneumopathy was observed .", "tokens": ["In", "a", "61", "-", "year", "-", "old", "man", "receiving", "chronic", "low", "-", "dosage", "amiodarone", "an", "interstitial", "pneumopathy", "was", "observed", "."], "event_mentions": [{"id": "6519218_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6519218_1_Ent0", "role": "Subject", "text": "a 61 - year - old man", "start": 1, "end": 8}, {"entity_id": "6519218_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 2, "end": 7}, {"entity_id": "6519218_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "6519218_1_Ent4", "role": "Treatment", "text": "chronic low - dosage amiodarone", "start": 9, "end": 14}, {"entity_id": "6519218_1_Ent6", "role": "Treatment_Dosage", "text": "low - dosage", "start": 10, "end": 13}, {"entity_id": "6519218_1_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "6519218_1_Ent3", "role": "Effect", "text": "interstitial pneumopathy", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "6519218_1_Ent0", "text": "a 61 - year - old man", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "6519218_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "6519218_1_Ent2", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6519218_1_Ent4", "text": "chronic low - dosage amiodarone", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "6519218_1_Ent6", "text": "low - dosage", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6519218_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6519218_1_Ent3", "text": "interstitial pneumopathy", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "6529939_3", "wnd_id": "6529939_3_1", "text": "The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S - A block was seen .", "tokens": ["The", "abnormal", "rhythm", "disappeared", "with", "the", "withdrawal", "of", "propranolol", "and", "when", "the", "drug", "was", "restarted", "a", "2/1", "S", "-", "A", "block", "was", "seen", "."], "event_mentions": [{"id": "6529939_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 22, "end": 23}, "arguments": [{"entity_id": "6529939_3_Ent1", "role": "Treatment", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "6529939_3_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "6529939_3_Ent0", "role": "Effect", "text": "2/1 S - A block", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "6529939_3_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6529939_3_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6529939_3_Ent0", "text": "2/1 S - A block", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "6540393_2", "wnd_id": "6540393_2_1", "text": "Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis .", "tokens": ["Anaphylactoid", "reaction", "to", "methylprednisolone", "pulsed", "therapy", "for", "multiple", "sclerosis", "."], "event_mentions": [{"id": "6540393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "6540393_2_Ent0", "role": "Effect", "text": "Anaphylactoid reaction", "start": 0, "end": 2}, {"entity_id": "6540393_2_Ent3", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 3, "end": 4}, {"entity_id": "6540393_2_Ent1", "role": "Treatment", "text": "methylprednisolone pulsed therapy", "start": 3, "end": 6}, {"entity_id": "6540393_2_Ent2", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6540393_2_Ent0", "text": "Anaphylactoid reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6540393_2_Ent3", "text": "methylprednisolone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6540393_2_Ent1", "text": "methylprednisolone pulsed therapy", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6540393_2_Ent2", "text": "multiple sclerosis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6578007_2", "wnd_id": "6578007_2_1", "text": "We report a 59 - year - old patient with chronic myeloid leukemia , who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan .", "tokens": ["We", "report", "a", "59", "-", "year", "-", "old", "patient", "with", "chronic", "myeloid", "leukemia", ",", "who", "developed", "severe", "interstitial", "lung", "fibrosis", "after", "short", "term", "and", "sequential", "treatment", "with", "melphalan", "and", "busulfan", "."], "event_mentions": [{"id": "6578007_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "6578007_2_Ent0", "role": "Subject", "text": "a 59 - year - old patient with chronic myeloid leukemia", "start": 2, "end": 13}, {"entity_id": "6578007_2_Ent1", "role": "Subject_Age", "text": "59 - year - old", "start": 3, "end": 8}, {"entity_id": "6578007_2_Ent4", "role": "Treatment_Disorder", "text": "chronic myeloid leukemia", "start": 10, "end": 13}, {"entity_id": "6578007_2_Ent2", "role": "Effect", "text": "interstitial lung fibrosis", "start": 17, "end": 20}, {"entity_id": "6578007_2_Ent5", "role": "Treatment_Time_elapsed", "text": "short term", "start": 21, "end": 23}, {"entity_id": "6578007_2_Ent3", "role": "Treatment", "text": "short term and sequential treatment with melphalan and busulfan", "start": 21, "end": 30}, {"entity_id": "6578007_2_Ent6", "role": "Treatment_Drug", "text": "melphalan", "start": 27, "end": 28}, {"entity_id": "6578007_2_Ent8", "role": "Combination_Drug", "text": "melphalan", "start": 27, "end": 28}, {"entity_id": "6578007_2_Ent7", "role": "Treatment_Drug", "text": "busulfan", "start": 29, "end": 30}, {"entity_id": "6578007_2_Ent9", "role": "Combination_Drug", "text": "busulfan", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "6578007_2_Ent0", "text": "a 59 - year - old patient with chronic myeloid leukemia", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "6578007_2_Ent1", "text": "59 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6578007_2_Ent4", "text": "chronic myeloid leukemia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6578007_2_Ent2", "text": "interstitial lung fibrosis", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "6578007_2_Ent5", "text": "short term", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "6578007_2_Ent3", "text": "short term and sequential treatment with melphalan and busulfan", "entity_type": "Entity", "start": 21, "end": 30}, {"id": "6578007_2_Ent6", "text": "melphalan", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "6578007_2_Ent8", "text": "melphalan", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "6578007_2_Ent7", "text": "busulfan", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "6578007_2_Ent9", "text": "busulfan", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "6597713_2", "wnd_id": "6597713_2_1", "text": "Cholestyramine induced hyperchloremic metabolic acidosis .", "tokens": ["Cholestyramine", "induced", "hyperchloremic", "metabolic", "acidosis", "."], "event_mentions": [{"id": "6597713_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "6597713_2_Ent1", "role": "Treatment", "text": "Cholestyramine", "start": 0, "end": 1}, {"entity_id": "6597713_2_Ent2", "role": "Treatment_Drug", "text": "Cholestyramine", "start": 0, "end": 1}, {"entity_id": "6597713_2_Ent0", "role": "Effect", "text": "hyperchloremic metabolic acidosis .", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "6597713_2_Ent1", "text": "Cholestyramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6597713_2_Ent2", "text": "Cholestyramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6597713_2_Ent0", "text": "hyperchloremic metabolic acidosis .", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "6608139_1", "wnd_id": "6608139_1_1", "text": "Although myelosuppression is mild , immunosuppression and superinfection are potential hazards of treatment with DCF .", "tokens": ["Although", "myelosuppression", "is", "mild", ",", "immunosuppression", "and", "superinfection", "are", "potential", "hazards", "of", "treatment", "with", "DCF", "."], "event_mentions": [{"id": "6608139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hazards", "start": 10, "end": 11}, "arguments": [{"entity_id": "6608139_1_Ent0", "role": "Effect", "text": "myelosuppression", "start": 1, "end": 2}, {"entity_id": "6608139_1_Ent1", "role": "Effect", "text": "immunosuppression and superinfection", "start": 5, "end": 8}, {"entity_id": "6608139_1_Ent2", "role": "Treatment", "text": "DCF", "start": 14, "end": 15}, {"entity_id": "6608139_1_Ent3", "role": "Treatment_Drug", "text": "DCF", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6608139_1_Ent0", "text": "myelosuppression", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6608139_1_Ent1", "text": "immunosuppression and superinfection", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6608139_1_Ent2", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6608139_1_Ent3", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6614033_1", "wnd_id": "6614033_1_1", "text": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity .", "tokens": ["A", "major", "limitation", "in", "the", "use", "of", "amphotericin", "B", "is", "its", "potential", "to", "cause", "nephrotoxicity", "."], "event_mentions": [{"id": "6614033_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "6614033_1_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6614033_1_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6671350_3", "wnd_id": "6671350_3_1", "text": "Moxalactam is more likely to be associated with platelet dysfunction .", "tokens": ["Moxalactam", "is", "more", "likely", "to", "be", "associated", "with", "platelet", "dysfunction", "."], "event_mentions": [{"id": "6671350_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "6671350_3_Ent1", "role": "Treatment", "text": "Moxalactam", "start": 0, "end": 1}, {"entity_id": "6671350_3_Ent2", "role": "Treatment_Drug", "text": "Moxalactam", "start": 0, "end": 1}, {"entity_id": "6671350_3_Ent0", "role": "Effect", "text": "platelet dysfunction", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "6671350_3_Ent1", "text": "Moxalactam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_3_Ent2", "text": "Moxalactam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_3_Ent0", "text": "platelet dysfunction", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "6683487_1", "wnd_id": "6683487_1_1", "text": "Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis .", "tokens": ["Thrombotic", "thrombocytopenic", "purpura", "during", "penicillamine", "therapy", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6683487_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "6683487_1_Ent0", "role": "Effect", "text": "Thrombotic thrombocytopenic purpura", "start": 0, "end": 3}, {"entity_id": "6683487_1_Ent1", "role": "Treatment", "text": "penicillamine", "start": 4, "end": 5}, {"entity_id": "6683487_1_Ent3", "role": "Treatment_Drug", "text": "penicillamine", "start": 4, "end": 5}, {"entity_id": "6683487_1_Ent2", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6683487_1_Ent0", "text": "Thrombotic thrombocytopenic purpura", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6683487_1_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6683487_1_Ent3", "text": "penicillamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6683487_1_Ent2", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6693840_2", "wnd_id": "6693840_2_1", "text": "Gynecomastia associated with theophylline .", "tokens": ["Gynecomastia", "associated", "with", "theophylline", "."], "event_mentions": [{"id": "6693840_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "6693840_2_Ent0", "role": "Effect", "text": "Gynecomastia", "start": 0, "end": 1}, {"entity_id": "6693840_2_Ent1", "role": "Treatment", "text": "theophylline", "start": 3, "end": 4}, {"entity_id": "6693840_2_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "6693840_2_Ent0", "text": "Gynecomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6693840_2_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6693840_2_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "6693840_4", "wnd_id": "6693840_4_1", "text": "The gynecomastia regressed when the theophylline was discontinued .", "tokens": ["The", "gynecomastia", "regressed", "when", "the", "theophylline", "was", "discontinued", "."], "event_mentions": [{"id": "6693840_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinued", "start": 7, "end": 8}, "arguments": [{"entity_id": "6693840_4_Ent0", "role": "Effect", "text": "gynecomastia", "start": 1, "end": 2}, {"entity_id": "6693840_4_Ent1", "role": "Treatment", "text": "theophylline", "start": 5, "end": 6}, {"entity_id": "6693840_4_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6693840_4_Ent0", "text": "gynecomastia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6693840_4_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6693840_4_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6721543_1", "wnd_id": "6721543_1_1", "text": "Drug - induced psychosis resulted from the administration of quinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus .", "tokens": ["Drug", "-", "induced", "psychosis", "resulted", "from", "the", "administration", "of", "quinacrine", "hydrochloride", "at", "a", "dosage", "of", "100", "mg", "twice", "daily", "for", "the", "treatment", "of", "discoid", "lupus", "."], "event_mentions": [{"id": "6721543_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6721543_1_Ent0", "role": "Effect", "text": "psychosis resulted", "start": 3, "end": 5}, {"entity_id": "6721543_1_Ent1", "role": "Treatment", "text": "administration of quinacrine hydrochloride at a dosage of 100 mg twice daily", "start": 7, "end": 19}, {"entity_id": "6721543_1_Ent5", "role": "Treatment_Drug", "text": "quinacrine hydrochloride", "start": 9, "end": 11}, {"entity_id": "6721543_1_Ent2", "role": "Treatment_Dosage", "text": "100 mg", "start": 15, "end": 17}, {"entity_id": "6721543_1_Ent3", "role": "Treatment_Freq", "text": "twice daily", "start": 17, "end": 19}, {"entity_id": "6721543_1_Ent4", "role": "Treatment_Disorder", "text": "discoid lupus", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "6721543_1_Ent0", "text": "psychosis resulted", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6721543_1_Ent1", "text": "administration of quinacrine hydrochloride at a dosage of 100 mg twice daily", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "6721543_1_Ent5", "text": "quinacrine hydrochloride", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "6721543_1_Ent2", "text": "100 mg", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6721543_1_Ent3", "text": "twice daily", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "6721543_1_Ent4", "text": "discoid lupus", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "6725214_1", "wnd_id": "6725214_1_1", "text": "A case of priapism associated with trazodone is described .", "tokens": ["A", "case", "of", "priapism", "associated", "with", "trazodone", "is", "described", "."], "event_mentions": [{"id": "6725214_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6725214_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "6725214_1_Ent1", "role": "Effect", "text": "priapism", "start": 3, "end": 4}, {"entity_id": "6725214_1_Ent2", "role": "Treatment", "text": "trazodone", "start": 6, "end": 7}, {"entity_id": "6725214_1_Ent3", "role": "Treatment_Drug", "text": "trazodone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6725214_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6725214_1_Ent1", "text": "priapism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6725214_1_Ent2", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6725214_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6731466_6", "wnd_id": "6731466_6_1", "text": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti - inflammatory agents , especially zomepirac .", "tokens": ["This", "observation", "adds", "another", "dimension", "to", "the", "previously", "reported", "renal", "complications", "of", "nonsteroidal", "anti", "-", "inflammatory", "agents", ",", "especially", "zomepirac", "."], "event_mentions": [{"id": "6731466_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 8, "end": 9}, "arguments": [{"entity_id": "6731466_6_Ent0", "role": "Effect", "text": "renal complications", "start": 9, "end": 11}, {"entity_id": "6731466_6_Ent2", "role": "Treatment_Drug", "text": "nonsteroidal anti - inflammatory", "start": 12, "end": 16}, {"entity_id": "6731466_6_Ent1", "role": "Treatment", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "start": 12, "end": 20}, {"entity_id": "6731466_6_Ent3", "role": "Treatment_Drug", "text": "zomepirac", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "6731466_6_Ent0", "text": "renal complications", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "6731466_6_Ent2", "text": "nonsteroidal anti - inflammatory", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6731466_6_Ent1", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "6731466_6_Ent3", "text": "zomepirac", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "6733633_2", "wnd_id": "6733633_2_1", "text": "Cimetidine is a rare cause of drug - induced fever .", "tokens": ["Cimetidine", "is", "a", "rare", "cause", "of", "drug", "-", "induced", "fever", "."], "event_mentions": [{"id": "6733633_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "6733633_2_Ent1", "role": "Treatment", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_2_Ent2", "role": "Treatment_Drug", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_2_Ent0", "role": "Effect", "text": "fever", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6733633_2_Ent1", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_2_Ent2", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_2_Ent0", "text": "fever", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6826112_2", "wnd_id": "6826112_2_1", "text": "Thirty patients with hepatic reactions to cyclofenil , a non - steroidal drug with a stimulating effect on ovulation , are reviewed .", "tokens": ["Thirty", "patients", "with", "hepatic", "reactions", "to", "cyclofenil", ",", "a", "non", "-", "steroidal", "drug", "with", "a", "stimulating", "effect", "on", "ovulation", ",", "are", "reviewed", "."], "event_mentions": [{"id": "6826112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 4, "end": 5}, "arguments": [{"entity_id": "6826112_2_Ent1", "role": "Subject_Population", "text": "Thirty", "start": 0, "end": 1}, {"entity_id": "6826112_2_Ent0", "role": "Subject", "text": "Thirty patients", "start": 0, "end": 2}, {"entity_id": "6826112_2_Ent2", "role": "Effect", "text": "hepatic", "start": 3, "end": 4}, {"entity_id": "6826112_2_Ent3", "role": "Treatment", "text": "cyclofenil", "start": 6, "end": 7}, {"entity_id": "6826112_2_Ent4", "role": "Treatment_Drug", "text": "cyclofenil", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6826112_2_Ent1", "text": "Thirty", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6826112_2_Ent0", "text": "Thirty patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6826112_2_Ent2", "text": "hepatic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6826112_2_Ent3", "text": "cyclofenil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6826112_2_Ent4", "text": "cyclofenil", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6833205_1", "wnd_id": "6833205_1_1", "text": "A case of SIADH associated with desipramine treatment in an elderly depressed woman is described .", "tokens": ["A", "case", "of", "SIADH", "associated", "with", "desipramine", "treatment", "in", "an", "elderly", "depressed", "woman", "is", "described", "."], "event_mentions": [{"id": "6833205_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6833205_1_Ent3", "role": "Effect", "text": "SIADH", "start": 3, "end": 4}, {"entity_id": "6833205_1_Ent6", "role": "Treatment_Drug", "text": "desipramine", "start": 6, "end": 7}, {"entity_id": "6833205_1_Ent4", "role": "Treatment", "text": "desipramine treatment", "start": 6, "end": 8}, {"entity_id": "6833205_1_Ent0", "role": "Subject", "text": "an elderly depressed woman", "start": 9, "end": 13}, {"entity_id": "6833205_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 10, "end": 11}, {"entity_id": "6833205_1_Ent5", "role": "Treatment_Disorder", "text": "depressed", "start": 11, "end": 12}, {"entity_id": "6833205_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "6833205_1_Ent3", "text": "SIADH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6833205_1_Ent6", "text": "desipramine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6833205_1_Ent4", "text": "desipramine treatment", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "6833205_1_Ent0", "text": "an elderly depressed woman", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "6833205_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6833205_1_Ent5", "text": "depressed", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6833205_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "6854698_1", "wnd_id": "6854698_1_1", "text": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction .", "tokens": ["When", "tuberculosis", "patients", "on", "isoniazid", "eat", "certain", "varieties", "of", "fish", "they", "may", "develop", "a", "histamine", "reaction", "."], "event_mentions": [{"id": "6854698_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 12, "end": 13}, "arguments": [{"entity_id": "6854698_1_Ent4", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 1, "end": 2}, {"entity_id": "6854698_1_Ent0", "role": "Subject", "text": "tuberculosis patients", "start": 1, "end": 3}, {"entity_id": "6854698_1_Ent2", "role": "Treatment", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "6854698_1_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "6854698_1_Ent1", "role": "Effect", "text": "histamine reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "6854698_1_Ent4", "text": "tuberculosis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6854698_1_Ent0", "text": "tuberculosis patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6854698_1_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6854698_1_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6854698_1_Ent1", "text": "histamine reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "6860059_2", "wnd_id": "6860059_2_1", "text": "We report a case of fatal fulminant hepatitis caused by the use of disulfiram in a man with previously normal hepatocellular function .", "tokens": ["We", "report", "a", "case", "of", "fatal", "fulminant", "hepatitis", "caused", "by", "the", "use", "of", "disulfiram", "in", "a", "man", "with", "previously", "normal", "hepatocellular", "function", "."], "event_mentions": [{"id": "6860059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "6860059_2_Ent2", "role": "Effect", "text": "fatal fulminant hepatitis", "start": 5, "end": 8}, {"entity_id": "6860059_2_Ent3", "role": "Treatment", "text": "disulfiram", "start": 13, "end": 14}, {"entity_id": "6860059_2_Ent4", "role": "Treatment_Drug", "text": "disulfiram", "start": 13, "end": 14}, {"entity_id": "6860059_2_Ent0", "role": "Subject", "text": "a man", "start": 15, "end": 17}, {"entity_id": "6860059_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "6860059_2_Ent2", "text": "fatal fulminant hepatitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6860059_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6860059_2_Ent4", "text": "disulfiram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6860059_2_Ent0", "text": "a man", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6860059_2_Ent1", "text": "man", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "6873616_1", "wnd_id": "6873616_1_1", "text": "A 55 - yr - old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy .", "tokens": ["A", "55", "-", "yr", "-", "old", "man", "developed", "prolonged", "jaundice", "and", "sicca", "complex", "after", "a", "course", "of", "thiabendazole", "therapy", "."], "event_mentions": [{"id": "6873616_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "6873616_1_Ent0", "role": "Subject", "text": "A 55 - yr - old man", "start": 0, "end": 7}, {"entity_id": "6873616_1_Ent1", "role": "Subject_Age", "text": "55 - yr - old", "start": 1, "end": 6}, {"entity_id": "6873616_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "6873616_1_Ent3", "role": "Effect", "text": "prolonged jaundice and sicca complex", "start": 8, "end": 13}, {"entity_id": "6873616_1_Ent4", "role": "Treatment", "text": "a course of thiabendazole", "start": 14, "end": 18}, {"entity_id": "6873616_1_Ent5", "role": "Treatment_Drug", "text": "thiabendazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "6873616_1_Ent0", "text": "A 55 - yr - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6873616_1_Ent1", "text": "55 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6873616_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6873616_1_Ent3", "text": "prolonged jaundice and sicca complex", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6873616_1_Ent4", "text": "a course of thiabendazole", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "6873616_1_Ent5", "text": "thiabendazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "7019786_3", "wnd_id": "7019786_3_1", "text": "Two elderly women suffered an acute deterioration of renal function after treatment with cefoxitin sodium .", "tokens": ["Two", "elderly", "women", "suffered", "an", "acute", "deterioration", "of", "renal", "function", "after", "treatment", "with", "cefoxitin", "sodium", "."], "event_mentions": [{"id": "7019786_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "7019786_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7019786_3_Ent0", "role": "Subject", "text": "Two elderly women", "start": 0, "end": 3}, {"entity_id": "7019786_3_Ent2", "role": "Subject_Age", "text": "elderly", "start": 1, "end": 2}, {"entity_id": "7019786_3_Ent3", "role": "Subject_Gender", "text": "women", "start": 2, "end": 3}, {"entity_id": "7019786_3_Ent4", "role": "Effect", "text": "acute deterioration of renal function", "start": 5, "end": 10}, {"entity_id": "7019786_3_Ent5", "role": "Treatment", "text": "treatment with cefoxitin sodium", "start": 11, "end": 15}, {"entity_id": "7019786_3_Ent6", "role": "Treatment_Drug", "text": "cefoxitin sodium", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7019786_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7019786_3_Ent0", "text": "Two elderly women", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7019786_3_Ent2", "text": "elderly", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7019786_3_Ent3", "text": "women", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7019786_3_Ent4", "text": "acute deterioration of renal function", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "7019786_3_Ent5", "text": "treatment with cefoxitin sodium", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7019786_3_Ent6", "text": "cefoxitin sodium", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7035691_3", "wnd_id": "7035691_3_1", "text": "Although inhibition of the angiotensin - converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure , care should be taken when captopril is administered initially to a patient with decreased renal function , under the conditions of sodium and water depletion .", "tokens": ["Although", "inhibition", "of", "the", "angiotensin", "-", "converting", "enzyme", "is", "considered", "to", "be", "efficient", "treatment", "for", "hypertension", "associated", "with", "chronic", "renal", "failure", ",", "care", "should", "be", "taken", "when", "captopril", "is", "administered", "initially", "to", "a", "patient", "with", "decreased", "renal", "function", ",", "under", "the", "conditions", "of", "sodium", "and", "water", "depletion", "."], "event_mentions": [{"id": "7035691_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "7035691_3_Ent3", "role": "Treatment_Disorder", "text": "hypertension associated with chronic renal failure", "start": 15, "end": 21}, {"entity_id": "7035691_3_Ent2", "role": "Treatment", "text": "captopril", "start": 27, "end": 28}, {"entity_id": "7035691_3_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 27, "end": 28}, {"entity_id": "7035691_3_Ent0", "role": "Subject", "text": "a patient with decreased renal function", "start": 32, "end": 38}, {"entity_id": "7035691_3_Ent1", "role": "Subject_Disorder", "text": "decreased renal function", "start": 35, "end": 38}]}], "entity_mentions": [{"id": "7035691_3_Ent3", "text": "hypertension associated with chronic renal failure", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "7035691_3_Ent2", "text": "captopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7035691_3_Ent4", "text": "captopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7035691_3_Ent0", "text": "a patient with decreased renal function", "entity_type": "Entity", "start": 32, "end": 38}, {"id": "7035691_3_Ent1", "text": "decreased renal function", "entity_type": "Entity", "start": 35, "end": 38}], "lang": "en"}
{"doc_id": "7081289_2", "wnd_id": "7081289_2_1", "text": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed .", "tokens": ["The", "case", "of", "an", "adult", "who", "developed", "both", "hepatic", "dysfunction", "and", "an", "impaired", "macrophage", "migration", "after", "exposure", "to", "cimetidine", "is", "discussed", "."], "event_mentions": [{"id": "7081289_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "7081289_2_Ent0", "role": "Subject", "text": "an adult", "start": 3, "end": 5}, {"entity_id": "7081289_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 4, "end": 5}, {"entity_id": "7081289_2_Ent2", "role": "Effect", "text": "hepatic dysfunction and an impaired macrophage migration", "start": 8, "end": 15}, {"entity_id": "7081289_2_Ent4", "role": "Treatment_Drug", "text": "cimetidine", "start": 18, "end": 19}, {"entity_id": "7081289_2_Ent3", "role": "Treatment", "text": "cimetidine is discussed", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "7081289_2_Ent0", "text": "an adult", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7081289_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7081289_2_Ent2", "text": "hepatic dysfunction and an impaired macrophage migration", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "7081289_2_Ent4", "text": "cimetidine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7081289_2_Ent3", "text": "cimetidine is discussed", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "7139589_1", "wnd_id": "7139589_1_1", "text": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L - asparaginase .", "tokens": ["An", "adolescent", "male", "developed", "acute", "pancreatitis", "and", "pseudocyst", "of", "the", "pancreas", "16", "weeks", "after", "cessation", "of", "intramuscular", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "7139589_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "7139589_1_Ent0", "role": "Subject", "text": "An adolescent male", "start": 0, "end": 3}, {"entity_id": "7139589_1_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 1, "end": 2}, {"entity_id": "7139589_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 2, "end": 3}, {"entity_id": "7139589_1_Ent3", "role": "Effect", "text": "acute pancreatitis and pseudocyst of the pancreas", "start": 4, "end": 11}, {"entity_id": "7139589_1_Ent7", "role": "Treatment_Time_elapsed", "text": "16 weeks", "start": 11, "end": 13}, {"entity_id": "7139589_1_Ent4", "role": "Treatment", "text": "cessation of intramuscular L - asparaginase", "start": 14, "end": 20}, {"entity_id": "7139589_1_Ent6", "role": "Treatment_Route", "text": "intramuscular", "start": 16, "end": 17}, {"entity_id": "7139589_1_Ent5", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "7139589_1_Ent0", "text": "An adolescent male", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_1_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7139589_1_Ent2", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7139589_1_Ent3", "text": "acute pancreatitis and pseudocyst of the pancreas", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "7139589_1_Ent7", "text": "16 weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "7139589_1_Ent4", "text": "cessation of intramuscular L - asparaginase", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "7139589_1_Ent6", "text": "intramuscular", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7139589_1_Ent5", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "7139589_3", "wnd_id": "7139589_3_1", "text": "L - asparaginase - induced pancreatitis has been reported during or closely following administration of the drug .", "tokens": ["L", "-", "asparaginase", "-", "induced", "pancreatitis", "has", "been", "reported", "during", "or", "closely", "following", "administration", "of", "the", "drug", "."], "event_mentions": [{"id": "7139589_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7139589_3_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent0", "role": "Effect", "text": "pancreatitis", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "7139589_3_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7212107_1", "wnd_id": "7212107_1_1", "text": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible .", "tokens": ["Secondary", "hyperparathyroidism", "in", "certain", "patients", "with", "lithium", "nephrotoxicity", "is", "also", "possible", "."], "event_mentions": [{"id": "7212107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "7212107_1_Ent2", "role": "Effect", "text": "Secondary hyperparathyroidism", "start": 0, "end": 2}, {"entity_id": "7212107_1_Ent0", "role": "Subject", "text": "certain patients", "start": 3, "end": 5}, {"entity_id": "7212107_1_Ent3", "role": "Treatment", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7212107_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7212107_1_Ent1", "role": "Effect", "text": "nephrotoxicity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7212107_1_Ent2", "text": "Secondary hyperparathyroidism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7212107_1_Ent0", "text": "certain patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7212107_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7212107_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7212107_1_Ent1", "text": "nephrotoxicity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7226916_2", "wnd_id": "7226916_2_1", "text": "Disopyramide - induced heart block .", "tokens": ["Disopyramide", "-", "induced", "heart", "block", "."], "event_mentions": [{"id": "7226916_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7226916_2_Ent1", "role": "Treatment", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "7226916_2_Ent2", "role": "Treatment_Drug", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "7226916_2_Ent0", "role": "Effect", "text": "heart block", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "7226916_2_Ent1", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7226916_2_Ent2", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7226916_2_Ent0", "text": "heart block", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "7351000_4", "wnd_id": "7351000_4_1", "text": "The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan .", "tokens": ["The", "probability", "of", "developing", "acute", "leukemia", "in", "this", "study", "was", "not", "significantly", "correlated", "to", "the", "total", "cumulative", "dosage", "of", "Treosulfan", "."], "event_mentions": [{"id": "7351000_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 3, "end": 4}, "arguments": [{"entity_id": "7351000_4_Ent0", "role": "Effect", "text": "acute leukemia", "start": 4, "end": 6}, {"entity_id": "7351000_4_Ent1", "role": "Treatment", "text": "the total cumulative dosage of Treosulfan", "start": 14, "end": 20}, {"entity_id": "7351000_4_Ent2", "role": "Treatment_Drug", "text": "Treosulfan", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "7351000_4_Ent0", "text": "acute leukemia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7351000_4_Ent1", "text": "the total cumulative dosage of Treosulfan", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "7351000_4_Ent2", "text": "Treosulfan", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "7362333_1", "wnd_id": "7362333_1_1", "text": "Propranolol : an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass .", "tokens": ["Propranolol", ":", "an", "unrecognized", "cause", "of", "central", "nervous", "system", "dysfunction", "in", "patients", "undergoing", "cardiopulmonary", "bypass", "."], "event_mentions": [{"id": "7362333_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "7362333_1_Ent3", "role": "Treatment", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent4", "role": "Treatment_Drug", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent2", "role": "Effect", "text": "central nervous system dysfunction", "start": 6, "end": 10}, {"entity_id": "7362333_1_Ent0", "role": "Subject", "text": "patients undergoing cardiopulmonary bypass", "start": 11, "end": 15}, {"entity_id": "7362333_1_Ent1", "role": "Subject_Disorder", "text": "cardiopulmonary bypass", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7362333_1_Ent3", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent4", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent2", "text": "central nervous system dysfunction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7362333_1_Ent0", "text": "patients undergoing cardiopulmonary bypass", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7362333_1_Ent1", "text": "cardiopulmonary bypass", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "736591_2", "wnd_id": "736591_2_1", "text": "Progressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of methotrexate for 18 years .", "tokens": ["Progressive", "interstitial", "fibrosis", "with", "roentgenographic", "honeycombing", "developed", "in", "the", "case", "of", "a", "psoriatic", "patient", "who", "had", "been", "on", "a", "regimen", "of", "methotrexate", "for", "18", "years", "."], "event_mentions": [{"id": "736591_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "736591_2_Ent1", "role": "Effect", "text": "Progressive interstitial fibrosis with roentgenographic honeycombing", "start": 0, "end": 6}, {"entity_id": "736591_2_Ent0", "role": "Subject", "text": "a psoriatic patient", "start": 11, "end": 14}, {"entity_id": "736591_2_Ent5", "role": "Treatment_Disorder", "text": "psoriatic", "start": 12, "end": 13}, {"entity_id": "736591_2_Ent2", "role": "Treatment", "text": "a regimen of methotrexate for 18 years", "start": 18, "end": 25}, {"entity_id": "736591_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 21, "end": 22}, {"entity_id": "736591_2_Ent4", "role": "Treatment_Duration", "text": "18 years", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "736591_2_Ent1", "text": "Progressive interstitial fibrosis with roentgenographic honeycombing", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "736591_2_Ent0", "text": "a psoriatic patient", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "736591_2_Ent5", "text": "psoriatic", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "736591_2_Ent2", "text": "a regimen of methotrexate for 18 years", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "736591_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "736591_2_Ent4", "text": "18 years", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "7369302_1", "wnd_id": "7369302_1_1", "text": "Abnormalities of the pupil and visual - evoked potential in quinine amblyopia .", "tokens": ["Abnormalities", "of", "the", "pupil", "and", "visual", "-", "evoked", "potential", "in", "quinine", "amblyopia", "."], "event_mentions": [{"id": "7369302_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "7369302_1_Ent1", "role": "Effect", "text": "Abnormalities of the pupil and visual - evoked potential", "start": 0, "end": 9}, {"entity_id": "7369302_1_Ent2", "role": "Treatment", "text": "quinine", "start": 10, "end": 11}, {"entity_id": "7369302_1_Ent3", "role": "Treatment_Drug", "text": "quinine", "start": 10, "end": 11}, {"entity_id": "7369302_1_Ent0", "role": "Effect", "text": "amblyopia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7369302_1_Ent1", "text": "Abnormalities of the pupil and visual - evoked potential", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "7369302_1_Ent2", "text": "quinine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7369302_1_Ent3", "text": "quinine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7369302_1_Ent0", "text": "amblyopia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7369302_2", "wnd_id": "7369302_2_1", "text": "A transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials in quinine toxicity , to our knowledge , have not been previously reported .", "tokens": ["A", "transient", "tonic", "pupillary", "response", ",", "denervation", "supersensitivity", ",", "and", "abnormal", "visual", "-", "evoked", "potentials", "in", "quinine", "toxicity", ",", "to", "our", "knowledge", ",", "have", "not", "been", "previously", "reported", "."], "event_mentions": [{"id": "7369302_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 27, "end": 28}, "arguments": [{"entity_id": "7369302_2_Ent0", "role": "Effect", "text": "transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials", "start": 1, "end": 15}, {"entity_id": "7369302_2_Ent1", "role": "Treatment", "text": "quinine", "start": 16, "end": 17}, {"entity_id": "7369302_2_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7369302_2_Ent0", "text": "transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials", "entity_type": "Entity", "start": 1, "end": 15}, {"id": "7369302_2_Ent1", "text": "quinine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7369302_2_Ent2", "text": "quinine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7387219_3", "wnd_id": "7387219_3_1", "text": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D - penicillamine .", "tokens": ["Two", "patients", "with", "rheumatoid", "arthritis", "developed", "evidence", "of", "hepatotoxicity", "while", "receiving", "D", "-", "penicillamine", "."], "event_mentions": [{"id": "7387219_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "7387219_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7387219_3_Ent0", "role": "Subject", "text": "Two patients with rheumatoid arthritis", "start": 0, "end": 5}, {"entity_id": "7387219_3_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 3, "end": 5}, {"entity_id": "7387219_3_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}, {"entity_id": "7387219_3_Ent3", "role": "Treatment", "text": "D - penicillamine", "start": 11, "end": 14}, {"entity_id": "7387219_3_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7387219_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7387219_3_Ent0", "text": "Two patients with rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7387219_3_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7387219_3_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7387219_3_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7387219_3_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7393795_4", "wnd_id": "7393795_4_1", "text": "The introduction of para - aminosalicylic acid ( PAS ) led to hypoglycaemic coma .", "tokens": ["The", "introduction", "of", "para", "-", "aminosalicylic", "acid", "(", "PAS", ")", "led", "to", "hypoglycaemic", "coma", "."], "event_mentions": [{"id": "7393795_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led to", "start": 10, "end": 12}, "arguments": [{"entity_id": "7393795_4_Ent1", "role": "Treatment", "text": "The introduction of para - aminosalicylic acid ( PAS )", "start": 0, "end": 10}, {"entity_id": "7393795_4_Ent2", "role": "Treatment_Drug", "text": "para - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "7393795_4_Ent0", "role": "Effect", "text": "hypoglycaemic coma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "7393795_4_Ent1", "text": "The introduction of para - aminosalicylic acid ( PAS )", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "7393795_4_Ent2", "text": "para - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7393795_4_Ent0", "text": "hypoglycaemic coma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "7397053_1", "wnd_id": "7397053_1_1", "text": "A patient developed papilloedema and hepatic dysfunction while being treated with perhexiline maleate .", "tokens": ["A", "patient", "developed", "papilloedema", "and", "hepatic", "dysfunction", "while", "being", "treated", "with", "perhexiline", "maleate", "."], "event_mentions": [{"id": "7397053_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 7, "end": 8}, "arguments": [{"entity_id": "7397053_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "7397053_1_Ent1", "role": "Effect", "text": "papilloedema and hepatic dysfunction", "start": 3, "end": 7}, {"entity_id": "7397053_1_Ent2", "role": "Treatment", "text": "perhexiline maleate", "start": 11, "end": 13}, {"entity_id": "7397053_1_Ent3", "role": "Treatment_Drug", "text": "perhexiline maleate", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "7397053_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7397053_1_Ent1", "text": "papilloedema and hepatic dysfunction", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7397053_1_Ent2", "text": "perhexiline maleate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "7397053_1_Ent3", "text": "perhexiline maleate", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "7416268_1", "wnd_id": "7416268_1_1", "text": "Disulfiram encephalopathy as a cause of the catatonia syndrome .", "tokens": ["Disulfiram", "encephalopathy", "as", "a", "cause", "of", "the", "catatonia", "syndrome", "."], "event_mentions": [{"id": "7416268_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "7416268_1_Ent2", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "7416268_1_Ent3", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "7416268_1_Ent1", "role": "Effect", "text": "encephalopathy", "start": 1, "end": 2}, {"entity_id": "7416268_1_Ent0", "role": "Effect", "text": "catatonia syndrome", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7416268_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7416268_1_Ent3", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7416268_1_Ent1", "text": "encephalopathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7416268_1_Ent0", "text": "catatonia syndrome", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7416268_2", "wnd_id": "7416268_2_1", "text": "The authors describe a case of the catatonia syndrome associated with disulfiram therapy .", "tokens": ["The", "authors", "describe", "a", "case", "of", "the", "catatonia", "syndrome", "associated", "with", "disulfiram", "therapy", "."], "event_mentions": [{"id": "7416268_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "7416268_2_Ent0", "role": "Effect", "text": "catatonia syndrome", "start": 7, "end": 9}, {"entity_id": "7416268_2_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 11, "end": 12}, {"entity_id": "7416268_2_Ent1", "role": "Treatment", "text": "disulfiram therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "7416268_2_Ent0", "text": "catatonia syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7416268_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7416268_2_Ent1", "text": "disulfiram therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "7439122_2", "wnd_id": "7439122_2_1", "text": "However , we have recently had four cases of clofibrate - induced myopathy in patients with diabetes insipidus due to hypothalamic lesions .", "tokens": ["However", ",", "we", "have", "recently", "had", "four", "cases", "of", "clofibrate", "-", "induced", "myopathy", "in", "patients", "with", "diabetes", "insipidus", "due", "to", "hypothalamic", "lesions", "."], "event_mentions": [{"id": "7439122_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "7439122_2_Ent2", "role": "Subject_Population", "text": "four", "start": 6, "end": 7}, {"entity_id": "7439122_2_Ent0", "role": "Subject", "text": "four cases", "start": 6, "end": 8}, {"entity_id": "7439122_2_Ent4", "role": "Treatment", "text": "clofibrate", "start": 9, "end": 10}, {"entity_id": "7439122_2_Ent5", "role": "Treatment_Drug", "text": "clofibrate", "start": 9, "end": 10}, {"entity_id": "7439122_2_Ent3", "role": "Effect", "text": "myopathy", "start": 12, "end": 13}, {"entity_id": "7439122_2_Ent6", "role": "Treatment_Disorder", "text": "diabetes insipidus", "start": 16, "end": 18}, {"entity_id": "7439122_2_Ent1", "role": "Subject", "text": "diabetes insipidus due to hypothalamic lesions", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "7439122_2_Ent2", "text": "four", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7439122_2_Ent0", "text": "four cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7439122_2_Ent4", "text": "clofibrate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7439122_2_Ent5", "text": "clofibrate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7439122_2_Ent3", "text": "myopathy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7439122_2_Ent6", "text": "diabetes insipidus", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7439122_2_Ent1", "text": "diabetes insipidus due to hypothalamic lesions", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "7468565_4", "wnd_id": "7468565_4_1", "text": "The patient 's clinical presentation , histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis .", "tokens": ["The", "patient", "'s", "clinical", "presentation", ",", "histologic", "features", "on", "liver", "biopsy", "and", "favorable", "course", "after", "stopping", "the", "drug", "suggest", "that", "barbiturates", "can", "be", "added", "to", "the", "list", "of", "agents", "which", "can", "cause", "submassive", "hepatic", "necrosis", "."], "event_mentions": [{"id": "7468565_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 31, "end": 32}, "arguments": [{"entity_id": "7468565_4_Ent1", "role": "Treatment", "text": "barbiturates", "start": 20, "end": 21}, {"entity_id": "7468565_4_Ent2", "role": "Treatment_Drug", "text": "barbiturates", "start": 20, "end": 21}, {"entity_id": "7468565_4_Ent0", "role": "Effect", "text": "submassive hepatic necrosis", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "7468565_4_Ent1", "text": "barbiturates", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "7468565_4_Ent2", "text": "barbiturates", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "7468565_4_Ent0", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "748238_2", "wnd_id": "748238_2_1", "text": "The development of an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( DILANTIN ) therapy for 20 years is reported .", "tokens": ["The", "development", "of", "an", "IgG", "lambda", "-", "type", "monoclonal", "gammopathy", "and", "subsequent", "multiple", "myeloma", "in", "an", "epilepsy", "patient", "on", "diphenylhydantoin", "(", "DILANTIN", ")", "therapy", "for", "20", "years", "is", "reported", "."], "event_mentions": [{"id": "748238_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "748238_2_Ent1", "role": "Effect", "text": "an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma", "start": 3, "end": 14}, {"entity_id": "748238_2_Ent0", "role": "Subject", "text": "an epilepsy patient", "start": 15, "end": 18}, {"entity_id": "748238_2_Ent3", "role": "Treatment_Disorder", "text": "epilepsy", "start": 16, "end": 17}, {"entity_id": "748238_2_Ent4", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 19, "end": 20}, {"entity_id": "748238_2_Ent2", "role": "Treatment", "text": "diphenylhydantoin ( DILANTIN ) therapy for 20 years", "start": 19, "end": 27}, {"entity_id": "748238_2_Ent5", "role": "Treatment_Duration", "text": "for 20 years", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "748238_2_Ent1", "text": "an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "748238_2_Ent0", "text": "an epilepsy patient", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "748238_2_Ent3", "text": "epilepsy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "748238_2_Ent4", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "748238_2_Ent2", "text": "diphenylhydantoin ( DILANTIN ) therapy for 20 years", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "748238_2_Ent5", "text": "for 20 years", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "7485371_4", "wnd_id": "7485371_4_1", "text": "Vortex keratopathy associated with atovaquone .", "tokens": ["Vortex", "keratopathy", "associated", "with", "atovaquone", "."], "event_mentions": [{"id": "7485371_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "7485371_4_Ent0", "role": "Effect", "text": "Vortex keratopathy", "start": 0, "end": 2}, {"entity_id": "7485371_4_Ent1", "role": "Treatment", "text": "atovaquone", "start": 4, "end": 5}, {"entity_id": "7485371_4_Ent2", "role": "Treatment_Drug", "text": "atovaquone", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7485371_4_Ent0", "text": "Vortex keratopathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7485371_4_Ent1", "text": "atovaquone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7485371_4_Ent2", "text": "atovaquone", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7496198_9", "wnd_id": "7496198_9_1", "text": "Among the risk factors studied , two appear to increase the risk of ARE : the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients .", "tokens": ["Among", "the", "risk", "factors", "studied", ",", "two", "appear", "to", "increase", "the", "risk", "of", "ARE", ":", "the", "prescription", "of", "thiabendazole", "to", "treat", "strongyloidiasis", "during", "the", "melarsoprol", "cure", "and", "the", "bad", "general", "clinical", "conditions", "of", "patients", "."], "event_mentions": [{"id": "7496198_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear to", "start": 7, "end": 9}, "arguments": [{"entity_id": "7496198_9_Ent0", "role": "Effect", "text": "increase the risk of ARE", "start": 9, "end": 14}, {"entity_id": "7496198_9_Ent1", "role": "Treatment", "text": "prescription of thiabendazole", "start": 16, "end": 19}, {"entity_id": "7496198_9_Ent3", "role": "Treatment_Drug", "text": "thiabendazole", "start": 18, "end": 19}, {"entity_id": "7496198_9_Ent5", "role": "Treatment_Disorder", "text": "strongyloidiasis", "start": 21, "end": 22}, {"entity_id": "7496198_9_Ent2", "role": "Treatment", "text": "during the melarsoprol cure", "start": 22, "end": 26}, {"entity_id": "7496198_9_Ent4", "role": "Treatment_Drug", "text": "melarsoprol", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "7496198_9_Ent0", "text": "increase the risk of ARE", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "7496198_9_Ent1", "text": "prescription of thiabendazole", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "7496198_9_Ent3", "text": "thiabendazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7496198_9_Ent5", "text": "strongyloidiasis", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7496198_9_Ent2", "text": "during the melarsoprol cure", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "7496198_9_Ent4", "text": "melarsoprol", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "7519913_1", "wnd_id": "7519913_1_1", "text": "However , there remain questions concerning whether these drugs , especially methimazole ( MMI ) , may be associated with aplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use .", "tokens": ["However", ",", "there", "remain", "questions", "concerning", "whether", "these", "drugs", ",", "especially", "methimazole", "(", "MMI", ")", ",", "may", "be", "associated", "with", "aplasia", "cutis", "congenita", "(", "ACC", ")", "and", "how", "best", "to", "avoid", "impairment", "of", "fetal", "thyroid", "function", "during", "their", "use", "."], "event_mentions": [{"id": "7519913_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "7519913_1_Ent1", "role": "Treatment", "text": "methimazole", "start": 11, "end": 12}, {"entity_id": "7519913_1_Ent2", "role": "Treatment_Drug", "text": "methimazole ( MMI )", "start": 11, "end": 15}, {"entity_id": "7519913_1_Ent0", "role": "Effect", "text": "aplasia cutis congenita", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "7519913_1_Ent1", "text": "methimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7519913_1_Ent2", "text": "methimazole ( MMI )", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7519913_1_Ent0", "text": "aplasia cutis congenita", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "7538828_8", "wnd_id": "7538828_8_1", "text": "Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life - threatening bone marrow aplasia .", "tokens": ["Development", "of", "an", "extensive", "skin", "rash", "following", "a", "single", "dose", "of", "MTX", "may", "be", "an", "early", "warning", "sign", "for", "life", "-", "threatening", "bone", "marrow", "aplasia", "."], "event_mentions": [{"id": "7538828_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "7538828_8_Ent0", "role": "Effect", "text": "extensive skin rash", "start": 3, "end": 6}, {"entity_id": "7538828_8_Ent1", "role": "Treatment", "text": "MTX", "start": 11, "end": 12}, {"entity_id": "7538828_8_Ent2", "role": "Treatment_Drug", "text": "MTX", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7538828_8_Ent0", "text": "extensive skin rash", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7538828_8_Ent1", "text": "MTX", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7538828_8_Ent2", "text": "MTX", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7582710_2", "wnd_id": "7582710_2_1", "text": "The first patient developed mild nitritoid symptoms and pain in a band - like distribution , corresponding to T10 - T12 dermatomes , shortly after gold sodium thiomalate ( GSTM ) injection .", "tokens": ["The", "first", "patient", "developed", "mild", "nitritoid", "symptoms", "and", "pain", "in", "a", "band", "-", "like", "distribution", ",", "corresponding", "to", "T10", "-", "T12", "dermatomes", ",", "shortly", "after", "gold", "sodium", "thiomalate", "(", "GSTM", ")", "injection", "."], "event_mentions": [{"id": "7582710_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "7582710_2_Ent0", "role": "Subject", "text": "The first patient", "start": 0, "end": 3}, {"entity_id": "7582710_2_Ent1", "role": "Effect", "text": "mild nitritoid symptoms and pain in a band - like distribution", "start": 4, "end": 15}, {"entity_id": "7582710_2_Ent3", "role": "Treatment_Drug", "text": "gold sodium thiomalate", "start": 25, "end": 28}, {"entity_id": "7582710_2_Ent2", "role": "Treatment", "text": "gold sodium thiomalate ( GSTM ) injection", "start": 25, "end": 32}, {"entity_id": "7582710_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "7582710_2_Ent0", "text": "The first patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7582710_2_Ent1", "text": "mild nitritoid symptoms and pain in a band - like distribution", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "7582710_2_Ent3", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7582710_2_Ent2", "text": "gold sodium thiomalate ( GSTM ) injection", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "7582710_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "7594371_3", "wnd_id": "7594371_3_1", "text": "We recommend the cautious use of ketorolac in patients with underlying illnesses where NSAID - induced ototoxicity could result in adverse otologic consequences .", "tokens": ["We", "recommend", "the", "cautious", "use", "of", "ketorolac", "in", "patients", "with", "underlying", "illnesses", "where", "NSAID", "-", "induced", "ototoxicity", "could", "result", "in", "adverse", "otologic", "consequences", "."], "event_mentions": [{"id": "7594371_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "where", "start": 12, "end": 13}, "arguments": [{"entity_id": "7594371_3_Ent3", "role": "Treatment", "text": "ketorolac", "start": 6, "end": 7}, {"entity_id": "7594371_3_Ent4", "role": "Treatment_Drug", "text": "ketorolac", "start": 6, "end": 7}, {"entity_id": "7594371_3_Ent0", "role": "Subject", "text": "patients with underlying illnesses", "start": 8, "end": 12}, {"entity_id": "7594371_3_Ent1", "role": "Subject_Disorder", "text": "underlying illnesses", "start": 10, "end": 12}, {"entity_id": "7594371_3_Ent2", "role": "Effect", "text": "NSAID - induced ototoxicity could result in adverse otologic consequences", "start": 13, "end": 23}]}], "entity_mentions": [{"id": "7594371_3_Ent3", "text": "ketorolac", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7594371_3_Ent4", "text": "ketorolac", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7594371_3_Ent0", "text": "patients with underlying illnesses", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7594371_3_Ent1", "text": "underlying illnesses", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7594371_3_Ent2", "text": "NSAID - induced ototoxicity could result in adverse otologic consequences", "entity_type": "Entity", "start": 13, "end": 23}], "lang": "en"}
{"doc_id": "7594371_4", "wnd_id": "7594371_4_1", "text": "We report the case of a 20 - year - old female with polyarteritis nodosa ( PAN ) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac .", "tokens": ["We", "report", "the", "case", "of", "a", "20", "-", "year", "-", "old", "female", "with", "polyarteritis", "nodosa", "(", "PAN", ")", "who", "developed", "bilateral", "sensorineural", "hearing", "loss", "25", "minutes", "after", "receiving", "30", "mg", "of", "intravenous", "ketoralac", "."], "event_mentions": [{"id": "7594371_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "7594371_4_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "7594371_4_Ent0", "role": "Subject", "text": "20 - year - old female with polyarteritis nodosa ( PAN )", "start": 6, "end": 18}, {"entity_id": "7594371_4_Ent2", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "7594371_4_Ent5", "role": "Treatment_Disorder", "text": "polyarteritis nodosa", "start": 13, "end": 15}, {"entity_id": "7594371_4_Ent3", "role": "Effect", "text": "bilateral sensorineural hearing loss", "start": 20, "end": 24}, {"entity_id": "7594371_4_Ent6", "role": "Treatment_Time_elapsed", "text": "25 minutes after", "start": 24, "end": 27}, {"entity_id": "7594371_4_Ent7", "role": "Treatment_Dosage", "text": "30 mg", "start": 28, "end": 30}, {"entity_id": "7594371_4_Ent4", "role": "Treatment", "text": "30 mg of intravenous ketoralac", "start": 28, "end": 33}, {"entity_id": "7594371_4_Ent8", "role": "Treatment_Route", "text": "intravenous", "start": 31, "end": 32}, {"entity_id": "7594371_4_Ent9", "role": "Treatment_Drug", "text": "ketoralac", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "7594371_4_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "7594371_4_Ent0", "text": "20 - year - old female with polyarteritis nodosa ( PAN )", "entity_type": "Entity", "start": 6, "end": 18}, {"id": "7594371_4_Ent2", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7594371_4_Ent5", "text": "polyarteritis nodosa", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "7594371_4_Ent3", "text": "bilateral sensorineural hearing loss", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "7594371_4_Ent6", "text": "25 minutes after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "7594371_4_Ent7", "text": "30 mg", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "7594371_4_Ent4", "text": "30 mg of intravenous ketoralac", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "7594371_4_Ent8", "text": "intravenous", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "7594371_4_Ent9", "text": "ketoralac", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "7606071_1", "wnd_id": "7606071_1_1", "text": "Anaphylactoid reactions with intraperitoneal cisplatin .", "tokens": ["Anaphylactoid", "reactions", "with", "intraperitoneal", "cisplatin", "."], "event_mentions": [{"id": "7606071_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "7606071_1_Ent0", "role": "Effect", "text": "Anaphylactoid reactions", "start": 0, "end": 2}, {"entity_id": "7606071_1_Ent2", "role": "Treatment_Route", "text": "intraperitoneal", "start": 3, "end": 4}, {"entity_id": "7606071_1_Ent1", "role": "Treatment", "text": "intraperitoneal cisplatin", "start": 3, "end": 5}, {"entity_id": "7606071_1_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7606071_1_Ent0", "text": "Anaphylactoid reactions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7606071_1_Ent2", "text": "intraperitoneal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7606071_1_Ent1", "text": "intraperitoneal cisplatin", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7606071_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7606071_4", "wnd_id": "7606071_4_1", "text": "DISCUSSION : Anaphylactoid reactions have been described previously with cisplatin administration .", "tokens": ["DISCUSSION", ":", "Anaphylactoid", "reactions", "have", "been", "described", "previously", "with", "cisplatin", "administration", "."], "event_mentions": [{"id": "7606071_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "7606071_4_Ent0", "role": "Effect", "text": "Anaphylactoid reactions", "start": 2, "end": 4}, {"entity_id": "7606071_4_Ent1", "role": "Treatment", "text": "cisplatin", "start": 9, "end": 10}, {"entity_id": "7606071_4_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7606071_4_Ent0", "text": "Anaphylactoid reactions", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7606071_4_Ent1", "text": "cisplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7606071_4_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7632529_1", "wnd_id": "7632529_1_1", "text": "A 9 - year - old boy developed acute renal failure following intravenous acyclovir ( 30 mg / kg per day ) administered for 6 days to treat herpetic encephalitis .", "tokens": ["A", "9", "-", "year", "-", "old", "boy", "developed", "acute", "renal", "failure", "following", "intravenous", "acyclovir", "(", "30", "mg", "/", "kg", "per", "day", ")", "administered", "for", "6", "days", "to", "treat", "herpetic", "encephalitis", "."], "event_mentions": [{"id": "7632529_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "7632529_1_Ent0", "role": "Subject", "text": "A 9 - year - old boy", "start": 0, "end": 7}, {"entity_id": "7632529_1_Ent1", "role": "Subject_Age", "text": "9 - year - old", "start": 1, "end": 6}, {"entity_id": "7632529_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "7632529_1_Ent3", "role": "Effect", "text": "acute renal failure", "start": 8, "end": 11}, {"entity_id": "7632529_1_Ent4", "role": "Treatment", "text": "intravenous acyclovir", "start": 12, "end": 14}, {"entity_id": "7632529_1_Ent6", "role": "Treatment_Drug", "text": "intravenous acyclovir", "start": 12, "end": 14}, {"entity_id": "7632529_1_Ent7", "role": "Treatment_Dosage", "text": "30 mg / kg", "start": 15, "end": 19}, {"entity_id": "7632529_1_Ent8", "role": "Treatment_Freq", "text": "per day", "start": 19, "end": 21}, {"entity_id": "7632529_1_Ent9", "role": "Treatment_Duration", "text": "6 days", "start": 24, "end": 26}, {"entity_id": "7632529_1_Ent5", "role": "Treatment_Disorder", "text": "herpetic encephalitis", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "7632529_1_Ent0", "text": "A 9 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7632529_1_Ent1", "text": "9 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7632529_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7632529_1_Ent3", "text": "acute renal failure", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7632529_1_Ent4", "text": "intravenous acyclovir", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7632529_1_Ent6", "text": "intravenous acyclovir", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7632529_1_Ent7", "text": "30 mg / kg", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "7632529_1_Ent8", "text": "per day", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "7632529_1_Ent9", "text": "6 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "7632529_1_Ent5", "text": "herpetic encephalitis", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "7653281_8", "wnd_id": "7653281_8_1", "text": "These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde ; they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage .", "tokens": ["These", "results", "suggest", "that", "the", "hepatoxicity", "of", "ethanol", "in", "alcoholic", "beverages", "is", "enhanced", "by", "interaction", "with", "its", "congeners", "and", "acetaldehyde", ";", "they", "also", "suggest", "that", "alcoholic", "beverages", "are", "not", "equivalent", "in", "their", "potential", "to", "cause", "liver", "damage", "."], "event_mentions": [{"id": "7653281_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhanced", "start": 12, "end": 13}, "arguments": [{"entity_id": "7653281_8_Ent0", "role": "Effect", "text": "hepatoxicity", "start": 5, "end": 6}, {"entity_id": "7653281_8_Ent1", "role": "Treatment", "text": "alcoholic", "start": 9, "end": 10}, {"entity_id": "7653281_8_Ent2", "role": "Treatment_Drug", "text": "alcoholic", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7653281_8_Ent0", "text": "hepatoxicity", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7653281_8_Ent1", "text": "alcoholic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7653281_8_Ent2", "text": "alcoholic", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7655130_1", "wnd_id": "7655130_1_1", "text": "CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .", "tokens": ["CASE", "SUMMARIES", ":", "Two", "patients", "with", "stable", "hypothyroidism", "experienced", "symptoms", "of", "hypothyroidism", "with", "increased", "serum", "thyroid", "-", "stimulating", "hormone", "(", "TSH", ")", "concentrations", "after", "switching", "from", "1", "levothyroxine", "product", "to", "another", "."], "event_mentions": [{"id": "7655130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "7655130_1_Ent1", "role": "Subject_Population", "text": "Two", "start": 3, "end": 4}, {"entity_id": "7655130_1_Ent0", "role": "Subject", "text": "Two patients with stable hypothyroidism", "start": 3, "end": 8}, {"entity_id": "7655130_1_Ent4", "role": "Treatment_Disorder", "text": "stable hypothyroidism", "start": 6, "end": 8}, {"entity_id": "7655130_1_Ent2", "role": "Effect", "text": "hypothyroidism with increased serum thyroid - stimulating hormone", "start": 11, "end": 19}, {"entity_id": "7655130_1_Ent3", "role": "Treatment", "text": "switching from 1 levothyroxine product to another", "start": 24, "end": 31}, {"entity_id": "7655130_1_Ent5", "role": "Treatment_Drug", "text": "levothyroxine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7655130_1_Ent1", "text": "Two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7655130_1_Ent0", "text": "Two patients with stable hypothyroidism", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7655130_1_Ent4", "text": "stable hypothyroidism", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7655130_1_Ent2", "text": "hypothyroidism with increased serum thyroid - stimulating hormone", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "7655130_1_Ent3", "text": "switching from 1 levothyroxine product to another", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "7655130_1_Ent5", "text": "levothyroxine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7663030_1", "wnd_id": "7663030_1_1", "text": "Probable propafenone - induced transient global amnesia .", "tokens": ["Probable", "propafenone", "-", "induced", "transient", "global", "amnesia", "."], "event_mentions": [{"id": "7663030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7663030_1_Ent1", "role": "Treatment", "text": "propafenone", "start": 1, "end": 2}, {"entity_id": "7663030_1_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 1, "end": 2}, {"entity_id": "7663030_1_Ent0", "role": "Effect", "text": "transient global amnesia", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "7663030_1_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7663030_1_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7663030_1_Ent0", "text": "transient global amnesia", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "7663030_14", "wnd_id": "7663030_14_1", "text": "Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .", "tokens": ["Comparable", "adverse", "effects", ",", "such", "as", "disorientation", "and", "temporary", "amnesia", ",", "have", "been", "reported", "in", "patients", "in", "the", "analogous", "agent", ",", "propranolol", "."], "event_mentions": [{"id": "7663030_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "been reported", "start": 12, "end": 14}, "arguments": [{"entity_id": "7663030_14_Ent1", "role": "Effect", "text": "disorientation and temporary amnesia", "start": 6, "end": 10}, {"entity_id": "7663030_14_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}, {"entity_id": "7663030_14_Ent2", "role": "Treatment", "text": "propranolol", "start": 21, "end": 22}, {"entity_id": "7663030_14_Ent3", "role": "Treatment_Drug", "text": "propranolol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "7663030_14_Ent1", "text": "disorientation and temporary amnesia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7663030_14_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7663030_14_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7663030_14_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "7673653_1", "wnd_id": "7673653_1_1", "text": "Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .", "tokens": ["Beneficial", "effect", "of", "low", "-", "dose", "mianserin", "on", "fluvoxamine", "-", "induced", "akathisia", "in", "an", "obsessive", "-", "compulsive", "patient", "."], "event_mentions": [{"id": "7673653_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Beneficial", "start": 0, "end": 1}, "arguments": [{"entity_id": "7673653_1_Ent8", "role": "Treatment_Dosage", "text": "low - dose", "start": 3, "end": 6}, {"entity_id": "7673653_1_Ent6", "role": "Treatment", "text": "low - dose mianserin", "start": 3, "end": 7}, {"entity_id": "7673653_1_Ent9", "role": "Treatment_Drug", "text": "mianserin", "start": 6, "end": 7}, {"entity_id": "7673653_1_Ent7", "role": "Treatment_Disorder", "text": "fluvoxamine - induced akathisia", "start": 8, "end": 12}, {"entity_id": "7673653_1_Ent5", "role": "Subject", "text": "obsessive - compulsive patient", "start": 14, "end": 18}]}, {"id": "7673653_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "7673653_1_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 8, "end": 9}, {"entity_id": "7673653_1_Ent4", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 8, "end": 9}, {"entity_id": "7673653_1_Ent1", "role": "Effect", "text": "akathisia", "start": 11, "end": 12}, {"entity_id": "7673653_1_Ent3", "role": "Treatment_Disorder", "text": "obsessive - compulsive", "start": 14, "end": 17}, {"entity_id": "7673653_1_Ent0", "role": "Subject", "text": "obsessive - compulsive patient", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "7673653_1_Ent8", "text": "low - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7673653_1_Ent6", "text": "low - dose mianserin", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7673653_1_Ent9", "text": "mianserin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7673653_1_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7673653_1_Ent4", "text": "fluvoxamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7673653_1_Ent7", "text": "fluvoxamine - induced akathisia", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7673653_1_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7673653_1_Ent3", "text": "obsessive - compulsive", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7673653_1_Ent0", "text": "obsessive - compulsive patient", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "7673653_1_Ent5", "text": "obsessive - compulsive patient", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "7673653_3", "wnd_id": "7673653_3_1", "text": "However , the occurrence and management of akathisia induced by fluvoxamine have not been described .", "tokens": ["However", ",", "the", "occurrence", "and", "management", "of", "akathisia", "induced", "by", "fluvoxamine", "have", "not", "been", "described", "."], "event_mentions": [{"id": "7673653_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "7673653_3_Ent0", "role": "Effect", "text": "akathisia", "start": 7, "end": 8}, {"entity_id": "7673653_3_Ent1", "role": "Treatment", "text": "fluvoxamine", "start": 10, "end": 11}, {"entity_id": "7673653_3_Ent2", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "7673653_3_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7673653_3_Ent1", "text": "fluvoxamine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7673653_3_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "7679525_2", "wnd_id": "7679525_2_1", "text": "A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .", "tokens": ["A", "42", "year", "old", "man", ",", "treated", "for", "testicular", "carcinoma", "with", "combination", "chemotherapy", "that", "included", "bleomycin", ",", "developed", "life", "threatening", "interstitial", "pneumonitis", "."], "event_mentions": [{"id": "7679525_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "7679525_2_Ent1", "role": "Subject_Age", "text": "42 year old", "start": 1, "end": 4}, {"entity_id": "7679525_2_Ent0", "role": "Subject", "text": "42 year old man", "start": 1, "end": 5}, {"entity_id": "7679525_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 4, "end": 5}, {"entity_id": "7679525_2_Ent5", "role": "Treatment_Disorder", "text": "testicular carcinoma", "start": 8, "end": 10}, {"entity_id": "7679525_2_Ent4", "role": "Treatment", "text": "combination chemotherapy that included bleomycin ,", "start": 11, "end": 17}, {"entity_id": "7679525_2_Ent6", "role": "Treatment_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "7679525_2_Ent3", "role": "Effect", "text": "interstitial pneumonitis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "7679525_2_Ent1", "text": "42 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "7679525_2_Ent0", "text": "42 year old man", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "7679525_2_Ent2", "text": "man", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7679525_2_Ent5", "text": "testicular carcinoma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7679525_2_Ent4", "text": "combination chemotherapy that included bleomycin ,", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "7679525_2_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7679525_2_Ent3", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "7696938_2", "wnd_id": "7696938_2_1", "text": "Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .", "tokens": ["Correction", "of", "serum", "electrolyte", "imbalance", "prevents", "cardiac", "arrhythmia", "during", "amphotericin", "B", "administration", "."], "event_mentions": [{"id": "7696938_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "7696938_2_Ent0", "role": "Effect", "text": "cardiac arrhythmia", "start": 6, "end": 8}, {"entity_id": "7696938_2_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 9, "end": 11}, {"entity_id": "7696938_2_Ent1", "role": "Treatment", "text": "amphotericin B administration", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "7696938_2_Ent0", "text": "cardiac arrhythmia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7696938_2_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7696938_2_Ent1", "text": "amphotericin B administration", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "7718983_5", "wnd_id": "7718983_5_1", "text": "We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .", "tokens": ["We", "report", "a", "case", "of", "Graves", "'", "hyperthyroidism", "induced", "by", "long", "-", "term", "interferon", "(", "IFN", ")", "therapy", "."], "event_mentions": [{"id": "7718983_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "7718983_5_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "7718983_5_Ent1", "role": "Effect", "text": "Graves ' hyperthyroidism", "start": 5, "end": 8}, {"entity_id": "7718983_5_Ent3", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "7718983_5_Ent2", "role": "Treatment", "text": "long - term interferon ( IFN ) therapy", "start": 10, "end": 18}, {"entity_id": "7718983_5_Ent4", "role": "Treatment_Drug", "text": "interferon", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7718983_5_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7718983_5_Ent1", "text": "Graves ' hyperthyroidism", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7718983_5_Ent3", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "7718983_5_Ent2", "text": "long - term interferon ( IFN ) therapy", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "7718983_5_Ent4", "text": "interferon", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7752014_1", "wnd_id": "7752014_1_1", "text": "Furosemide - associated fever .", "tokens": ["Furosemide", "-", "associated", "fever", "."], "event_mentions": [{"id": "7752014_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7752014_1_Ent1", "role": "Treatment", "text": "Furosemide", "start": 0, "end": 1}, {"entity_id": "7752014_1_Ent2", "role": "Treatment_Drug", "text": "Furosemide", "start": 0, "end": 1}, {"entity_id": "7752014_1_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "7752014_1_Ent1", "text": "Furosemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_1_Ent2", "text": "Furosemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "7776854_2", "wnd_id": "7776854_2_1", "text": "Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .", "tokens": ["Severe", "hepatotoxicity", "related", "to", "benzarone", ":", "a", "report", "of", "three", "cases", "with", "two", "fatalities", "."], "event_mentions": [{"id": "7776854_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "7776854_2_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 1, "end": 2}, {"entity_id": "7776854_2_Ent3", "role": "Treatment", "text": "benzarone", "start": 4, "end": 5}, {"entity_id": "7776854_2_Ent4", "role": "Treatment_Drug", "text": "benzarone", "start": 4, "end": 5}, {"entity_id": "7776854_2_Ent1", "role": "Subject_Population", "text": "three", "start": 9, "end": 10}, {"entity_id": "7776854_2_Ent0", "role": "Subject", "text": "three cases", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "7776854_2_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7776854_2_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7776854_2_Ent4", "text": "benzarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7776854_2_Ent1", "text": "three", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7776854_2_Ent0", "text": "three cases", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "7779233_1", "wnd_id": "7779233_1_1", "text": "Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .", "tokens": ["Case", "study", ":", "a", "modified", "topical", "treatment", "regimen", "for", "sodium", "warfarin", "-", "induced", "necrotizing", "fasciitis", "."], "event_mentions": [{"id": "7779233_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "7779233_1_Ent1", "role": "Treatment", "text": "sodium warfarin", "start": 9, "end": 11}, {"entity_id": "7779233_1_Ent2", "role": "Treatment_Drug", "text": "sodium warfarin", "start": 9, "end": 11}, {"entity_id": "7779233_1_Ent0", "role": "Effect", "text": "necrotizing fasciitis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7779233_1_Ent1", "text": "sodium warfarin", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7779233_1_Ent2", "text": "sodium warfarin", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7779233_1_Ent0", "text": "necrotizing fasciitis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7783891_2", "wnd_id": "7783891_2_1", "text": "Cardiac arrest following use of sumatriptan .", "tokens": ["Cardiac", "arrest", "following", "use", "of", "sumatriptan", "."], "event_mentions": [{"id": "7783891_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "7783891_2_Ent0", "role": "Effect", "text": "Cardiac arrest", "start": 0, "end": 2}, {"entity_id": "7783891_2_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 5, "end": 6}, {"entity_id": "7783891_2_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "7783891_2_Ent0", "text": "Cardiac arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7783891_2_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7783891_2_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7797283_2", "wnd_id": "7797283_2_1", "text": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .", "tokens": ["Esophageal", "candidiasis", "was", "diagnosed", "at", "endoscopy", "in", "two", "patients", "receiving", "omeprazole", "therapy", "."], "event_mentions": [{"id": "7797283_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "7797283_2_Ent2", "role": "Effect", "text": "Esophageal candidiasis", "start": 0, "end": 2}, {"entity_id": "7797283_2_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "7797283_2_Ent0", "role": "Subject", "text": "two patients", "start": 7, "end": 9}, {"entity_id": "7797283_2_Ent4", "role": "Treatment_Drug", "text": "omeprazole", "start": 10, "end": 11}, {"entity_id": "7797283_2_Ent3", "role": "Treatment", "text": "omeprazole therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7797283_2_Ent2", "text": "Esophageal candidiasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7797283_2_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7797283_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7797283_2_Ent4", "text": "omeprazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7797283_2_Ent3", "text": "omeprazole therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7835785_1", "wnd_id": "7835785_1_1", "text": "Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .", "tokens": ["Ovarian", "endometrioid", "carcinoma", "and", "endometriosis", "developing", "in", "a", "postmenopausal", "breast", "cancer", "patient", "during", "tamoxifen", "therapy", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "7835785_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "7835785_1_Ent2", "role": "Effect", "text": "Ovarian endometrioid carcinoma and endometriosis", "start": 0, "end": 5}, {"entity_id": "7835785_1_Ent0", "role": "Subject", "text": "a postmenopausal breast cancer patient", "start": 7, "end": 12}, {"entity_id": "7835785_1_Ent1", "role": "Subject_Disorder", "text": "postmenopausal", "start": 8, "end": 9}, {"entity_id": "7835785_1_Ent5", "role": "Treatment_Disorder", "text": "breast cancer", "start": 9, "end": 11}, {"entity_id": "7835785_1_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 13, "end": 14}, {"entity_id": "7835785_1_Ent3", "role": "Treatment", "text": "tamoxifen therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7835785_1_Ent2", "text": "Ovarian endometrioid carcinoma and endometriosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7835785_1_Ent0", "text": "a postmenopausal breast cancer patient", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7835785_1_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7835785_1_Ent5", "text": "breast cancer", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7835785_1_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7835785_1_Ent3", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7835785_2", "wnd_id": "7835785_2_1", "text": "The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .", "tokens": ["The", "association", "with", "prolonged", "unopposed", "estrogen", "-", "like", "stimulation", "with", "tamoxifen", "as", "a", "possible", "factor", "in", "the", "development", "of", "ovarian", "endometrioid", "carcinoma", "is", "discussed", "."], "event_mentions": [{"id": "7835785_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "7835785_2_Ent2", "role": "Treatment_Duration", "text": "prolonged", "start": 3, "end": 4}, {"entity_id": "7835785_2_Ent1", "role": "Treatment", "text": "prolonged unopposed estrogen - like stimulation with tamoxifen", "start": 3, "end": 11}, {"entity_id": "7835785_2_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 10, "end": 11}, {"entity_id": "7835785_2_Ent0", "role": "Effect", "text": "development of ovarian endometrioid carcinoma", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "7835785_2_Ent2", "text": "prolonged", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7835785_2_Ent1", "text": "prolonged unopposed estrogen - like stimulation with tamoxifen", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "7835785_2_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7835785_2_Ent0", "text": "development of ovarian endometrioid carcinoma", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "7887138_2", "wnd_id": "7887138_2_1", "text": "INTRODUCTION - The aim of this case report is to present a 15 - year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .", "tokens": ["INTRODUCTION", "-", "The", "aim", "of", "this", "case", "report", "is", "to", "present", "a", "15", "-", "year", "follow", "-", "up", "of", "a", "patient", "with", "phenytoin", "(", "PHT", ")", "intoxication", "with", "unilateral", "gingival", "hyperplasia", "(", "GH", ")", "."], "event_mentions": [{"id": "7887138_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 26, "end": 27}, "arguments": [{"entity_id": "7887138_2_Ent0", "role": "Subject", "text": "a patient", "start": 19, "end": 21}, {"entity_id": "7887138_2_Ent2", "role": "Treatment", "text": "phenytoin", "start": 22, "end": 23}, {"entity_id": "7887138_2_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 22, "end": 23}, {"entity_id": "7887138_2_Ent1", "role": "Effect", "text": "phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH )", "start": 22, "end": 34}]}], "entity_mentions": [{"id": "7887138_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "7887138_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7887138_2_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7887138_2_Ent1", "text": "phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH )", "entity_type": "Entity", "start": 22, "end": 34}], "lang": "en"}
{"doc_id": "7907218_1", "wnd_id": "7907218_1_1", "text": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .", "tokens": ["Two", "patients", "with", "extrapyramidal", "side", "effects", "after", "the", "use", "of", "fluphenazine", "decanoate", "were", "evaluated", "by", "means", "of", "IBZM", "-", "SPECT", "."], "event_mentions": [{"id": "7907218_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "7907218_1_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7907218_1_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "7907218_1_Ent2", "role": "Effect", "text": "extrapyramidal side effects", "start": 3, "end": 6}, {"entity_id": "7907218_1_Ent3", "role": "Treatment", "text": "fluphenazine decanoate", "start": 10, "end": 12}, {"entity_id": "7907218_1_Ent4", "role": "Treatment_Drug", "text": "fluphenazine decanoate", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7907218_1_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7907218_1_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7907218_1_Ent2", "text": "extrapyramidal side effects", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7907218_1_Ent3", "text": "fluphenazine decanoate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7907218_1_Ent4", "text": "fluphenazine decanoate", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7914463_1", "wnd_id": "7914463_1_1", "text": "Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .", "tokens": ["Flumazenil", "reversal", "of", "benzodiazepine", "-", "induced", "sedation", "for", "a", "patient", "with", "severe", "pre", "-", "ECT", "anxiety", "."], "event_mentions": [{"id": "7914463_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversal", "start": 1, "end": 2}, "arguments": [{"entity_id": "7914463_1_Ent7", "role": "Treatment", "text": "Flumazenil", "start": 0, "end": 1}, {"entity_id": "7914463_1_Ent9", "role": "Treatment_Drug", "text": "Flumazenil", "start": 0, "end": 1}, {"entity_id": "7914463_1_Ent8", "role": "Treatment_Disorder", "text": "benzodiazepine - induced sedation", "start": 3, "end": 7}, {"entity_id": "7914463_1_Ent5", "role": "Subject", "text": "a patient with severe pre - ECT anxiety", "start": 8, "end": 16}, {"entity_id": "7914463_1_Ent6", "role": "Subject_Disorder", "text": "severe pre - ECT anxiety", "start": 11, "end": 16}]}, {"id": "7914463_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7914463_1_Ent3", "role": "Treatment", "text": "benzodiazepine", "start": 3, "end": 4}, {"entity_id": "7914463_1_Ent4", "role": "Treatment_Drug", "text": "benzodiazepine", "start": 3, "end": 4}, {"entity_id": "7914463_1_Ent2", "role": "Effect", "text": "sedation", "start": 6, "end": 7}, {"entity_id": "7914463_1_Ent0", "role": "Subject", "text": "a patient with severe pre - ECT anxiety", "start": 8, "end": 16}, {"entity_id": "7914463_1_Ent1", "role": "Subject_Disorder", "text": "severe pre - ECT anxiety", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "7914463_1_Ent7", "text": "Flumazenil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7914463_1_Ent9", "text": "Flumazenil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7914463_1_Ent3", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7914463_1_Ent4", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7914463_1_Ent8", "text": "benzodiazepine - induced sedation", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7914463_1_Ent2", "text": "sedation", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7914463_1_Ent0", "text": "a patient with severe pre - ECT anxiety", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "7914463_1_Ent5", "text": "a patient with severe pre - ECT anxiety", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "7914463_1_Ent1", "text": "severe pre - ECT anxiety", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7914463_1_Ent6", "text": "severe pre - ECT anxiety", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "7919557_4", "wnd_id": "7919557_4_1", "text": "The cough continued for the duration of therapy with quinapril .", "tokens": ["The", "cough", "continued", "for", "the", "duration", "of", "therapy", "with", "quinapril", "."], "event_mentions": [{"id": "7919557_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "continued", "start": 2, "end": 3}, "arguments": [{"entity_id": "7919557_4_Ent0", "role": "Effect", "text": "cough", "start": 1, "end": 2}, {"entity_id": "7919557_4_Ent1", "role": "Treatment", "text": "quinapril", "start": 9, "end": 10}, {"entity_id": "7919557_4_Ent2", "role": "Treatment_Drug", "text": "quinapril", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7919557_4_Ent0", "text": "cough", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7919557_4_Ent1", "text": "quinapril", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7919557_4_Ent2", "text": "quinapril", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7937287_8", "wnd_id": "7937287_8_1", "text": "In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .", "tokens": ["In", "our", "patient", ",", "DIAN", "possibly", "was", "related", "to", "cefuroxime", ",", "but", "the", "patient", "did", "not", "experience", "associated", "allergic", "symptoms", "."], "event_mentions": [{"id": "7937287_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 7, "end": 9}, "arguments": [{"entity_id": "7937287_8_Ent0", "role": "Subject", "text": "our patient", "start": 1, "end": 3}, {"entity_id": "7937287_8_Ent1", "role": "Effect", "text": "DIAN", "start": 4, "end": 5}, {"entity_id": "7937287_8_Ent2", "role": "Treatment", "text": "cefuroxime", "start": 9, "end": 10}, {"entity_id": "7937287_8_Ent3", "role": "Treatment_Drug", "text": "cefuroxime", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7937287_8_Ent0", "text": "our patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "7937287_8_Ent1", "text": "DIAN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7937287_8_Ent2", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7937287_8_Ent3", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7949255_3", "wnd_id": "7949255_3_1", "text": "Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .", "tokens": ["Transient", "neurological", "disturbances", "induced", "by", "the", "chemotherapy", "of", "high", "-", "dose", "methotrexate", "for", "osteogenic", "sarcoma", "."], "event_mentions": [{"id": "7949255_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7949255_3_Ent0", "role": "Effect", "text": "Transient neurological disturbances", "start": 0, "end": 3}, {"entity_id": "7949255_3_Ent1", "role": "Treatment", "text": "the chemotherapy of high - dose methotrexate", "start": 5, "end": 12}, {"entity_id": "7949255_3_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 8, "end": 11}, {"entity_id": "7949255_3_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 11, "end": 12}, {"entity_id": "7949255_3_Ent4", "role": "Treatment_Disorder", "text": "osteogenic sarcoma", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7949255_3_Ent0", "text": "Transient neurological disturbances", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7949255_3_Ent1", "text": "the chemotherapy of high - dose methotrexate", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "7949255_3_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7949255_3_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7949255_3_Ent4", "text": "osteogenic sarcoma", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7962394_1", "wnd_id": "7962394_1_1", "text": "Acute pancreatitis associated with danazol treatment for endometriosis .", "tokens": ["Acute", "pancreatitis", "associated", "with", "danazol", "treatment", "for", "endometriosis", "."], "event_mentions": [{"id": "7962394_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7962394_1_Ent0", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "7962394_1_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 4, "end": 5}, {"entity_id": "7962394_1_Ent1", "role": "Treatment", "text": "danazol treatment", "start": 4, "end": 6}, {"entity_id": "7962394_1_Ent3", "role": "Treatment_Disorder", "text": "endometriosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7962394_1_Ent0", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7962394_1_Ent2", "text": "danazol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7962394_1_Ent1", "text": "danazol treatment", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7962394_1_Ent3", "text": "endometriosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7962394_2", "wnd_id": "7962394_2_1", "text": "Additionally , danazol produces hepatocellular damage in approximately 10 % of women .", "tokens": ["Additionally", ",", "danazol", "produces", "hepatocellular", "damage", "in", "approximately", "10", "%", "of", "women", "."], "event_mentions": [{"id": "7962394_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produces", "start": 3, "end": 4}, "arguments": [{"entity_id": "7962394_2_Ent4", "role": "Treatment", "text": "danazol", "start": 2, "end": 3}, {"entity_id": "7962394_2_Ent5", "role": "Treatment_Drug", "text": "danazol", "start": 2, "end": 3}, {"entity_id": "7962394_2_Ent3", "role": "Effect", "text": "hepatocellular damage", "start": 4, "end": 6}, {"entity_id": "7962394_2_Ent1", "role": "Subject_Population", "text": "10 %", "start": 8, "end": 10}, {"entity_id": "7962394_2_Ent0", "role": "Subject", "text": "10 % of women", "start": 8, "end": 12}, {"entity_id": "7962394_2_Ent2", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7962394_2_Ent4", "text": "danazol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7962394_2_Ent5", "text": "danazol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7962394_2_Ent3", "text": "hepatocellular damage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7962394_2_Ent1", "text": "10 %", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7962394_2_Ent0", "text": "10 % of women", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7962394_2_Ent2", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7973922_1", "wnd_id": "7973922_1_1", "text": "Acyclovir neurotoxicity : clinical experience and review of the literature .", "tokens": ["Acyclovir", "neurotoxicity", ":", "clinical", "experience", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "7973922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experience", "start": 4, "end": 5}, "arguments": [{"entity_id": "7973922_1_Ent1", "role": "Treatment", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent2", "role": "Treatment_Drug", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "7973922_1_Ent1", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent2", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "7978578_1", "wnd_id": "7978578_1_1", "text": "Response of a promethazine - induced coma to flumazenil .", "tokens": ["Response", "of", "a", "promethazine", "-", "induced", "coma", "to", "flumazenil", "."], "event_mentions": [{"id": "7978578_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Response", "start": 0, "end": 1}, "arguments": [{"entity_id": "7978578_1_Ent4", "role": "Treatment_Disorder", "text": "promethazine - induced coma", "start": 3, "end": 7}, {"entity_id": "7978578_1_Ent3", "role": "Treatment", "text": "flumazenil", "start": 8, "end": 9}, {"entity_id": "7978578_1_Ent5", "role": "Treatment_Drug", "text": "flumazenil", "start": 8, "end": 9}]}, {"id": "7978578_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7978578_1_Ent1", "role": "Treatment", "text": "promethazine", "start": 3, "end": 4}, {"entity_id": "7978578_1_Ent2", "role": "Treatment_Drug", "text": "promethazine", "start": 3, "end": 4}, {"entity_id": "7978578_1_Ent0", "role": "Effect", "text": "coma", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7978578_1_Ent1", "text": "promethazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7978578_1_Ent2", "text": "promethazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7978578_1_Ent4", "text": "promethazine - induced coma", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7978578_1_Ent0", "text": "coma", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7978578_1_Ent3", "text": "flumazenil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7978578_1_Ent5", "text": "flumazenil", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7995508_2", "wnd_id": "7995508_2_1", "text": "We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .", "tokens": ["We", "report", "a", "cae", "of", "paranoid", "psychosis", "following", "use", "of", "a", "decongestant", "containing", "PPA", "and", "summarize", "the", "case", "report", "literature", "of", "psychiatric", "adverse", "effects", "to", "PPA", "in", "which", "doses", "were", "known", "and", "stated", "to", "be", "within", "recommended", "guidelines", "."], "event_mentions": [{"id": "7995508_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "7995508_2_Ent0", "role": "Subject", "text": "a cae", "start": 2, "end": 4}, {"entity_id": "7995508_2_Ent1", "role": "Effect", "text": "paranoid psychosis", "start": 5, "end": 7}, {"entity_id": "7995508_2_Ent2", "role": "Treatment", "text": "decongestant containing PPA", "start": 11, "end": 14}, {"entity_id": "7995508_2_Ent3", "role": "Treatment_Drug", "text": "PPA", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7995508_2_Ent0", "text": "a cae", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7995508_2_Ent1", "text": "paranoid psychosis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7995508_2_Ent2", "text": "decongestant containing PPA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7995508_2_Ent3", "text": "PPA", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8038468_1", "wnd_id": "8038468_1_1", "text": "CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5 - FU to a previous regimen of warfarin alone .", "tokens": ["CONCLUSIONS", ":", "This", "case", "describes", "the", "clinically", "significant", "increase", "of", "INR", "in", "an", "elderly", "patient", "after", "adding", "a", "chemotherapy", "regimen", "of", "levamisole", "and", "5", "-", "FU", "to", "a", "previous", "regimen", "of", "warfarin", "alone", "."], "event_mentions": [{"id": "8038468_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 11, "end": 12}, "arguments": [{"entity_id": "8038468_1_Ent2", "role": "Effect", "text": "increase of INR", "start": 8, "end": 11}, {"entity_id": "8038468_1_Ent0", "role": "Subject", "text": "an elderly patient", "start": 12, "end": 15}, {"entity_id": "8038468_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "8038468_1_Ent5", "role": "Treatment_Drug", "text": "levamisole", "start": 21, "end": 22}, {"entity_id": "8038468_1_Ent8", "role": "Combination_Drug", "text": "levamisole", "start": 21, "end": 22}, {"entity_id": "8038468_1_Ent3", "role": "Treatment", "text": "levamisole and 5 - FU", "start": 21, "end": 26}, {"entity_id": "8038468_1_Ent6", "role": "Treatment_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_1_Ent9", "role": "Combination_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_1_Ent4", "role": "Treatment", "text": "warfarin", "start": 31, "end": 32}, {"entity_id": "8038468_1_Ent7", "role": "Treatment_Drug", "text": "warfarin", "start": 31, "end": 32}, {"entity_id": "8038468_1_Ent10", "role": "Combination_Drug", "text": "warfarin", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "8038468_1_Ent2", "text": "increase of INR", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8038468_1_Ent0", "text": "an elderly patient", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "8038468_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8038468_1_Ent5", "text": "levamisole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8038468_1_Ent8", "text": "levamisole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8038468_1_Ent3", "text": "levamisole and 5 - FU", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "8038468_1_Ent6", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_1_Ent9", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "8038468_1_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "8038468_1_Ent10", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "8038468_2", "wnd_id": "8038468_2_1", "text": "However , prolongation of 5 - FU half - life and an increase in INR have been reported with the concurrent use of 5 - FU and warfarin .", "tokens": ["However", ",", "prolongation", "of", "5", "-", "FU", "half", "-", "life", "and", "an", "increase", "in", "INR", "have", "been", "reported", "with", "the", "concurrent", "use", "of", "5", "-", "FU", "and", "warfarin", "."], "event_mentions": [{"id": "8038468_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 17, "end": 18}, "arguments": [{"entity_id": "8038468_2_Ent0", "role": "Effect", "text": "prolongation of 5 - FU half - life and an increase in INR", "start": 2, "end": 15}, {"entity_id": "8038468_2_Ent1", "role": "Treatment", "text": "the concurrent use of 5 - FU and warfarin", "start": 19, "end": 28}, {"entity_id": "8038468_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_2_Ent4", "role": "Combination_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 27, "end": 28}, {"entity_id": "8038468_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "8038468_2_Ent0", "text": "prolongation of 5 - FU half - life and an increase in INR", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "8038468_2_Ent1", "text": "the concurrent use of 5 - FU and warfarin", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "8038468_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_2_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8038468_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "8071504_1", "wnd_id": "8071504_1_1", "text": "Toxic optic neuropathy associated with ethambutol : implications for current therapy .", "tokens": ["Toxic", "optic", "neuropathy", "associated", "with", "ethambutol", ":", "implications", "for", "current", "therapy", "."], "event_mentions": [{"id": "8071504_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "8071504_1_Ent0", "role": "Effect", "text": "Toxic optic neuropathy", "start": 0, "end": 3}, {"entity_id": "8071504_1_Ent1", "role": "Treatment", "text": "ethambutol", "start": 5, "end": 6}, {"entity_id": "8071504_1_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "8071504_1_Ent0", "text": "Toxic optic neuropathy", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8071504_1_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8071504_1_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "8071504_5", "wnd_id": "8071504_5_1", "text": "METHODS : A patient who developed dramatic , permanent vision loss after a 9 - month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .", "tokens": ["METHODS", ":", "A", "patient", "who", "developed", "dramatic", ",", "permanent", "vision", "loss", "after", "a", "9", "-", "month", "course", "of", "treatment", "with", "ethambutol", "and", "isoniazid", "for", "pulmonary", "tuberculosis", "is", "presented", "."], "event_mentions": [{"id": "8071504_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8071504_5_Ent0", "role": "Subject", "text": "A patient", "start": 2, "end": 4}, {"entity_id": "8071504_5_Ent1", "role": "Effect", "text": "permanent vision loss", "start": 8, "end": 11}, {"entity_id": "8071504_5_Ent4", "role": "Treatment_Time_elapsed", "text": "9 - month", "start": 13, "end": 16}, {"entity_id": "8071504_5_Ent2", "role": "Treatment", "text": "9 - month course of treatment with ethambutol and isoniazid", "start": 13, "end": 23}, {"entity_id": "8071504_5_Ent5", "role": "Treatment_Drug", "text": "ethambutol", "start": 20, "end": 21}, {"entity_id": "8071504_5_Ent7", "role": "Combination_Drug", "text": "ethambutol", "start": 20, "end": 21}, {"entity_id": "8071504_5_Ent6", "role": "Treatment_Drug", "text": "isoniazid", "start": 22, "end": 23}, {"entity_id": "8071504_5_Ent8", "role": "Combination_Drug", "text": "isoniazid", "start": 22, "end": 23}, {"entity_id": "8071504_5_Ent3", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "8071504_5_Ent0", "text": "A patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8071504_5_Ent1", "text": "permanent vision loss", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8071504_5_Ent4", "text": "9 - month", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "8071504_5_Ent2", "text": "9 - month course of treatment with ethambutol and isoniazid", "entity_type": "Entity", "start": 13, "end": 23}, {"id": "8071504_5_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8071504_5_Ent7", "text": "ethambutol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8071504_5_Ent6", "text": "isoniazid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8071504_5_Ent8", "text": "isoniazid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8071504_5_Ent3", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "8098286_2", "wnd_id": "8098286_2_1", "text": "Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .", "tokens": ["Inadvertent", "subsequent", "rechallenge", "with", "celiprolol", "led", "to", "recurrence", "of", "the", "pneumonitis", ",", "10", "weeks", "after", "drug", "readministration", "."], "event_mentions": [{"id": "8098286_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led to", "start": 5, "end": 7}, "arguments": [{"entity_id": "8098286_2_Ent1", "role": "Treatment", "text": "Inadvertent subsequent rechallenge with celiprolol", "start": 0, "end": 5}, {"entity_id": "8098286_2_Ent3", "role": "Treatment_Drug", "text": "celiprolol", "start": 4, "end": 5}, {"entity_id": "8098286_2_Ent0", "role": "Effect", "text": "recurrence of the pneumonitis", "start": 7, "end": 11}, {"entity_id": "8098286_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 weeks", "start": 12, "end": 14}, {"entity_id": "8098286_2_Ent2", "role": "Treatment", "text": "10 weeks after drug readministration", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "8098286_2_Ent1", "text": "Inadvertent subsequent rechallenge with celiprolol", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8098286_2_Ent3", "text": "celiprolol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8098286_2_Ent0", "text": "recurrence of the pneumonitis", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8098286_2_Ent4", "text": "10 weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8098286_2_Ent2", "text": "10 weeks after drug readministration", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "8098286_3", "wnd_id": "8098286_3_1", "text": "We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .", "tokens": ["We", "report", "on", "a", "patient", "who", "developed", "hypersensitivity", "pneumonitis", "during", "treatment", "with", "the", "beta", "-", "blocker", ",", "celiprolol", "."], "event_mentions": [{"id": "8098286_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "8098286_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "8098286_3_Ent1", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 7, "end": 9}, {"entity_id": "8098286_3_Ent2", "role": "Treatment", "text": "celiprolol", "start": 17, "end": 18}, {"entity_id": "8098286_3_Ent3", "role": "Treatment_Drug", "text": "celiprolol", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8098286_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8098286_3_Ent1", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8098286_3_Ent2", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8098286_3_Ent3", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8104147_2", "wnd_id": "8104147_2_1", "text": "Reversible leukopenia was documented in an 81 - year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .", "tokens": ["Reversible", "leukopenia", "was", "documented", "in", "an", "81", "-", "year", "-", "old", "woman", "treated", "with", "adjunctive", "ibopamine", "100", "mg", "t.i.d", ".", "for", "chronic", "congestive", "heart", "failure", "."], "event_mentions": [{"id": "8104147_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "documented", "start": 3, "end": 4}, "arguments": [{"entity_id": "8104147_2_Ent3", "role": "Effect", "text": "Reversible leukopenia", "start": 0, "end": 2}, {"entity_id": "8104147_2_Ent0", "role": "Subject", "text": "an 81 - year - old woman", "start": 5, "end": 12}, {"entity_id": "8104147_2_Ent1", "role": "Subject_Age", "text": "81 - year - old", "start": 6, "end": 11}, {"entity_id": "8104147_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "8104147_2_Ent4", "role": "Treatment", "text": "adjunctive ibopamine 100 mg t.i.d .", "start": 14, "end": 20}, {"entity_id": "8104147_2_Ent6", "role": "Treatment_Drug", "text": "ibopamine", "start": 15, "end": 16}, {"entity_id": "8104147_2_Ent7", "role": "Treatment_Dosage", "text": "100 mg", "start": 16, "end": 18}, {"entity_id": "8104147_2_Ent5", "role": "Treatment_Disorder", "text": "chronic congestive heart failure", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "8104147_2_Ent3", "text": "Reversible leukopenia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8104147_2_Ent0", "text": "an 81 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8104147_2_Ent1", "text": "81 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8104147_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8104147_2_Ent4", "text": "adjunctive ibopamine 100 mg t.i.d .", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "8104147_2_Ent6", "text": "ibopamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8104147_2_Ent7", "text": "100 mg", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "8104147_2_Ent5", "text": "chronic congestive heart failure", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "812008_2", "wnd_id": "812008_2_1", "text": "Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .", "tokens": ["Significant", "clinical", "improvement", "of", "the", "porphyria", "followed", "withdrawal", "of", "the", "diphenylhydantoin", "."], "event_mentions": [{"id": "812008_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improvement", "start": 2, "end": 3}, "arguments": [{"entity_id": "812008_2_Ent1", "role": "Treatment_Disorder", "text": "porphyria", "start": 5, "end": 6}, {"entity_id": "812008_2_Ent0", "role": "Treatment", "text": "withdrawal of the diphenylhydantoin", "start": 7, "end": 11}, {"entity_id": "812008_2_Ent2", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "812008_2_Ent1", "text": "porphyria", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "812008_2_Ent0", "text": "withdrawal of the diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "812008_2_Ent2", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8124920_2", "wnd_id": "8124920_2_1", "text": "In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .", "tokens": ["In", "a", "patient", "suffering", "from", "rheumatoid", "arthritis", ",", "we", "report", "the", "first", "simultaneous", "occurrence", "of", "two", "side", "effects", "of", "low", "-", "dose", "methotrexate", ":", "an", "acute", "megaloblastic", "anaemia", "and", "a", "pneumonitis", "."], "event_mentions": [{"id": "8124920_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "an", "start": 24, "end": 25}, "arguments": [{"entity_id": "8124920_2_Ent0", "role": "Subject", "text": "patient suffering from rheumatoid arthritis", "start": 2, "end": 7}, {"entity_id": "8124920_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}, {"entity_id": "8124920_2_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 19, "end": 22}, {"entity_id": "8124920_2_Ent2", "role": "Treatment", "text": "low - dose methotrexate", "start": 19, "end": 23}, {"entity_id": "8124920_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "8124920_2_Ent1", "role": "Effect", "text": "acute megaloblastic anaemia and a pneumonitis", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "8124920_2_Ent0", "text": "patient suffering from rheumatoid arthritis", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "8124920_2_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8124920_2_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "8124920_2_Ent2", "text": "low - dose methotrexate", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "8124920_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8124920_2_Ent1", "text": "acute megaloblastic anaemia and a pneumonitis", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "8140860_3", "wnd_id": "8140860_3_1", "text": "Seven days after the introduction of amoxycillin ( 500 mg/8 h ) for a probable respiratory infection , the patient developed spontaneous bruising , with an INR of 7.1 .", "tokens": ["Seven", "days", "after", "the", "introduction", "of", "amoxycillin", "(", "500", "mg/8", "h", ")", "for", "a", "probable", "respiratory", "infection", ",", "the", "patient", "developed", "spontaneous", "bruising", ",", "with", "an", "INR", "of", "7.1", "."], "event_mentions": [{"id": "8140860_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "8140860_3_Ent4", "role": "Treatment_Time_elapsed", "text": "Seven days after", "start": 0, "end": 3}, {"entity_id": "8140860_3_Ent2", "role": "Treatment", "text": "Seven days after the introduction of amoxycillin ( 500 mg/8 h )", "start": 0, "end": 12}, {"entity_id": "8140860_3_Ent5", "role": "Treatment_Drug", "text": "amoxycillin", "start": 6, "end": 7}, {"entity_id": "8140860_3_Ent6", "role": "Treatment_Dosage", "text": "500 mg/8 h", "start": 8, "end": 11}, {"entity_id": "8140860_3_Ent3", "role": "Treatment_Disorder", "text": "a probable respiratory infection", "start": 13, "end": 17}, {"entity_id": "8140860_3_Ent0", "role": "Subject", "text": "the patient", "start": 18, "end": 20}, {"entity_id": "8140860_3_Ent1", "role": "Effect", "text": "spontaneous bruising , with an INR of 7.1", "start": 21, "end": 29}]}], "entity_mentions": [{"id": "8140860_3_Ent4", "text": "Seven days after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8140860_3_Ent2", "text": "Seven days after the introduction of amoxycillin ( 500 mg/8 h )", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "8140860_3_Ent5", "text": "amoxycillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8140860_3_Ent6", "text": "500 mg/8 h", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8140860_3_Ent3", "text": "a probable respiratory infection", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "8140860_3_Ent0", "text": "the patient", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8140860_3_Ent1", "text": "spontaneous bruising , with an INR of 7.1", "entity_type": "Entity", "start": 21, "end": 29}], "lang": "en"}
{"doc_id": "8149366_1", "wnd_id": "8149366_1_1", "text": "In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .", "tokens": ["In", "two", "patients", ",", "apomorphine", "remained", "effective", "in", "the", "morning", ",", "but", "increased", "the", "intensity", "of", "the", "dyskinesias", "in", "the", "afternoon", "."], "event_mentions": [{"id": "8149366_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 12, "end": 13}, "arguments": [{"entity_id": "8149366_1_Ent0", "role": "Subject", "text": "In two patients", "start": 0, "end": 3}, {"entity_id": "8149366_1_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "8149366_1_Ent3", "role": "Treatment", "text": "apomorphine", "start": 4, "end": 5}, {"entity_id": "8149366_1_Ent4", "role": "Treatment_Drug", "text": "apomorphine", "start": 4, "end": 5}, {"entity_id": "8149366_1_Ent2", "role": "Effect", "text": "intensity of the dyskinesias in the afternoon", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "8149366_1_Ent0", "text": "In two patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8149366_1_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8149366_1_Ent3", "text": "apomorphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8149366_1_Ent4", "text": "apomorphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8149366_1_Ent2", "text": "intensity of the dyskinesias in the afternoon", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "8151270_1", "wnd_id": "8151270_1_1", "text": "Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .", "tokens": ["Fulminant", "hepatitis", "with", "severe", "lactate", "acidosis", "in", "HIV", "-", "infected", "patients", "on", "didanosine", "therapy", "."], "event_mentions": [{"id": "8151270_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 11, "end": 12}, "arguments": [{"entity_id": "8151270_1_Ent1", "role": "Effect", "text": "Fulminant hepatitis with severe lactate acidosis", "start": 0, "end": 6}, {"entity_id": "8151270_1_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 7, "end": 8}, {"entity_id": "8151270_1_Ent0", "role": "Subject", "text": "HIV - infected patients", "start": 7, "end": 11}, {"entity_id": "8151270_1_Ent2", "role": "Treatment", "text": "didanosine", "start": 12, "end": 13}, {"entity_id": "8151270_1_Ent4", "role": "Treatment_Drug", "text": "didanosine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8151270_1_Ent1", "text": "Fulminant hepatitis with severe lactate acidosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "8151270_1_Ent3", "text": "HIV", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8151270_1_Ent0", "text": "HIV - infected patients", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8151270_1_Ent2", "text": "didanosine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8151270_1_Ent4", "text": "didanosine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8151270_3", "wnd_id": "8151270_3_1", "text": "We report two cases of fulminant hepatic failure in HIV - 1 - infected patients treated with didanosine ( ddI ) .", "tokens": ["We", "report", "two", "cases", "of", "fulminant", "hepatic", "failure", "in", "HIV", "-", "1", "-", "infected", "patients", "treated", "with", "didanosine", "(", "ddI", ")", "."], "event_mentions": [{"id": "8151270_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 4, "end": 5}, "arguments": [{"entity_id": "8151270_3_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 5, "end": 8}, {"entity_id": "8151270_3_Ent4", "role": "Treatment_Disorder", "text": "HIV - 1", "start": 9, "end": 12}, {"entity_id": "8151270_3_Ent0", "role": "Subject", "text": "HIV - 1 - infected patients", "start": 9, "end": 15}, {"entity_id": "8151270_3_Ent3", "role": "Treatment_Drug", "text": "didanosine", "start": 17, "end": 18}, {"entity_id": "8151270_3_Ent2", "role": "Treatment", "text": "didanosine ( ddI )", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "8151270_3_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8151270_3_Ent4", "text": "HIV - 1", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8151270_3_Ent0", "text": "HIV - 1 - infected patients", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "8151270_3_Ent3", "text": "didanosine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8151270_3_Ent2", "text": "didanosine ( ddI )", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "8175330_1", "wnd_id": "8175330_1_1", "text": "Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .", "tokens": ["Sodium", "valproate", "and", "carbamazepine", ",", "antiepileptic", "drugs", "that", "are", "associated", "with", "a", "relatively", "low", "rate", "of", "adverse", "cutaneous", "reactions", ",", "should", "be", "added", "to", "the", "growing", "list", "of", "drugs", "that", "produce", "psoriasiform", "eruptions", "."], "event_mentions": [{"id": "8175330_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 9, "end": 11}, "arguments": [{"entity_id": "8175330_1_Ent3", "role": "Treatment_Drug", "text": "Sodium valproate", "start": 0, "end": 2}, {"entity_id": "8175330_1_Ent1", "role": "Treatment", "text": "Sodium valproate and carbamazepine", "start": 0, "end": 4}, {"entity_id": "8175330_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 3, "end": 4}, {"entity_id": "8175330_1_Ent0", "role": "Effect", "text": "adverse cutaneous reactions", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "8175330_1_Ent3", "text": "Sodium valproate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8175330_1_Ent1", "text": "Sodium valproate and carbamazepine", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8175330_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8175330_1_Ent0", "text": "adverse cutaneous reactions", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "8175330_2", "wnd_id": "8175330_2_1", "text": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .", "tokens": ["We", "present", "findings", "from", "three", "patients", "who", "experienced", "a", "psoriasiform", "eruption", "apparently", "due", "to", "the", "antiepileptic", "agents", "sodium", "valproate", "and", "carbamazepine", "."], "event_mentions": [{"id": "8175330_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "8175330_2_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "8175330_2_Ent0", "role": "Subject", "text": "three patients", "start": 4, "end": 6}, {"entity_id": "8175330_2_Ent2", "role": "Effect", "text": "psoriasiform eruption", "start": 9, "end": 11}, {"entity_id": "8175330_2_Ent3", "role": "Treatment", "text": "antiepileptic agents sodium valproate and carbamazepine", "start": 15, "end": 21}, {"entity_id": "8175330_2_Ent4", "role": "Treatment_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent6", "role": "Combination_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "8175330_2_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8175330_2_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8175330_2_Ent0", "text": "three patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8175330_2_Ent2", "text": "psoriasiform eruption", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8175330_2_Ent3", "text": "antiepileptic agents sodium valproate and carbamazepine", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "8175330_2_Ent4", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent6", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8175330_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8244201_3", "wnd_id": "8244201_3_1", "text": "Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .", "tokens": ["Hyperkalaemia", "with", "renal", "tubular", "dysfunction", "by", "sulfamethoxazole", "-", "trimethoprim", "for", "Pneumocystis", "carinii", "pneumonia", "in", "patients", "with", "lymphoid", "malignancy", "."], "event_mentions": [{"id": "8244201_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "8244201_3_Ent2", "role": "Effect", "text": "Hyperkalaemia with renal tubular dysfunction", "start": 0, "end": 5}, {"entity_id": "8244201_3_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole - trimethoprim", "start": 6, "end": 9}, {"entity_id": "8244201_3_Ent3", "role": "Treatment", "text": "sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia", "start": 6, "end": 13}, {"entity_id": "8244201_3_Ent4", "role": "Treatment_Disorder", "text": "Pneumocystis carinii pneumonia", "start": 10, "end": 13}, {"entity_id": "8244201_3_Ent0", "role": "Subject", "text": "patients with lymphoid malignancy", "start": 14, "end": 18}, {"entity_id": "8244201_3_Ent1", "role": "Subject_Disorder", "text": "lymphoid malignancy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "8244201_3_Ent2", "text": "Hyperkalaemia with renal tubular dysfunction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_3_Ent5", "text": "sulfamethoxazole - trimethoprim", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8244201_3_Ent3", "text": "sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "8244201_3_Ent4", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8244201_3_Ent0", "text": "patients with lymphoid malignancy", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8244201_3_Ent1", "text": "lymphoid malignancy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "8305778_6", "wnd_id": "8305778_6_1", "text": "Amiodarone is a Class III antiarrhythmic with an adverse - effect profile involving many different organ systems .", "tokens": ["Amiodarone", "is", "a", "Class", "III", "antiarrhythmic", "with", "an", "adverse", "-", "effect", "profile", "involving", "many", "different", "organ", "systems", "."], "event_mentions": [{"id": "8305778_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse - effect", "start": 8, "end": 11}, "arguments": [{"entity_id": "8305778_6_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "8305778_6_Ent0", "role": "Effect", "text": "an adverse - effect profile involving many different organ systems", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "8305778_6_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8305778_6_Ent0", "text": "an adverse - effect profile involving many different organ systems", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "8308951_1", "wnd_id": "8308951_1_1", "text": "Cutaneous exposure to warfarin - like anticoagulant causing an intracerebral hemorrhage : a case report .", "tokens": ["Cutaneous", "exposure", "to", "warfarin", "-", "like", "anticoagulant", "causing", "an", "intracerebral", "hemorrhage", ":", "a", "case", "report", "."], "event_mentions": [{"id": "8308951_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 7, "end": 8}, "arguments": [{"entity_id": "8308951_1_Ent2", "role": "Treatment", "text": "Cutaneous exposure to warfarin - like anticoagulant", "start": 0, "end": 7}, {"entity_id": "8308951_1_Ent3", "role": "Treatment_Drug", "text": "warfarin - like anticoagulant", "start": 3, "end": 7}, {"entity_id": "8308951_1_Ent1", "role": "Effect", "text": "an intracerebral hemorrhage", "start": 8, "end": 11}, {"entity_id": "8308951_1_Ent0", "role": "Subject", "text": "a case", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "8308951_1_Ent2", "text": "Cutaneous exposure to warfarin - like anticoagulant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8308951_1_Ent3", "text": "warfarin - like anticoagulant", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8308951_1_Ent1", "text": "an intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8308951_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "8313300_6", "wnd_id": "8313300_6_1", "text": "A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .", "tokens": ["A", "severe", "form", "of", "exophthalmos", "resulting", "from", "lithium", "therapy", "has", "not", "been", "described", "in", "the", "literature", "."], "event_mentions": [{"id": "8313300_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 5, "end": 6}, "arguments": [{"entity_id": "8313300_6_Ent0", "role": "Effect", "text": "exophthalmos", "start": 4, "end": 5}, {"entity_id": "8313300_6_Ent1", "role": "Treatment", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "8313300_6_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "8313300_6_Ent0", "text": "exophthalmos", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8313300_6_Ent1", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8313300_6_Ent2", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "8313300_7", "wnd_id": "8313300_7_1", "text": "Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .", "tokens": ["Lithium", "therapy", "was", "discontinued", "because", "of", "poor", "compliance", "to", "the", "medication", "and", "intolerable", "polyuria", "."], "event_mentions": [{"id": "8313300_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 4, "end": 5}, "arguments": [{"entity_id": "8313300_7_Ent1", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8313300_7_Ent0", "role": "Effect", "text": "polyuria", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8313300_7_Ent1", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8313300_7_Ent0", "text": "polyuria", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8316494_1", "wnd_id": "8316494_1_1", "text": "Severe abdominal pain in low dosage clofazimine .", "tokens": ["Severe", "abdominal", "pain", "in", "low", "dosage", "clofazimine", "."], "event_mentions": [{"id": "8316494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "8316494_1_Ent0", "role": "Effect", "text": "abdominal pain", "start": 1, "end": 3}, {"entity_id": "8316494_1_Ent3", "role": "Treatment_Dosage", "text": "low dosage", "start": 4, "end": 6}, {"entity_id": "8316494_1_Ent1", "role": "Treatment", "text": "low dosage clofazimine", "start": 4, "end": 7}, {"entity_id": "8316494_1_Ent2", "role": "Treatment_Drug", "text": "clofazimine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8316494_1_Ent0", "text": "abdominal pain", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8316494_1_Ent3", "text": "low dosage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8316494_1_Ent1", "text": "low dosage clofazimine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8316494_1_Ent2", "text": "clofazimine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8329789_8", "wnd_id": "8329789_8_1", "text": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias .", "tokens": ["Evaluation", "of", "the", "literature", "provides", "substantial", "evidence", "for", "the", "use", "of", "hydrocortisone", "in", "prevention", "of", "cardiac", "arrhythmias", "."], "event_mentions": [{"id": "8329789_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevention", "start": 13, "end": 14}, "arguments": [{"entity_id": "8329789_8_Ent0", "role": "Treatment", "text": "hydrocortisone", "start": 11, "end": 12}, {"entity_id": "8329789_8_Ent1", "role": "Treatment_Drug", "text": "hydrocortisone", "start": 11, "end": 12}, {"entity_id": "8329789_8_Ent2", "role": "Treatment_Disorder", "text": "cardiac arrhythmias", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8329789_8_Ent0", "text": "hydrocortisone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8329789_8_Ent1", "text": "hydrocortisone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8329789_8_Ent2", "text": "cardiac arrhythmias", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8329789_9", "wnd_id": "8329789_9_1", "text": "CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .", "tokens": ["CONCLUSIONS", ":", "Amphotericin", "B", "overdose", "can", "be", "fatal", "in", "children", "and", "infants", "."], "event_mentions": [{"id": "8329789_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 6, "end": 7}, "arguments": [{"entity_id": "8329789_9_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 2, "end": 4}, {"entity_id": "8329789_9_Ent3", "role": "Treatment", "text": "Amphotericin B overdose", "start": 2, "end": 5}, {"entity_id": "8329789_9_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "8329789_9_Ent1", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "8329789_9_Ent0", "role": "Subject", "text": "children and infants", "start": 9, "end": 12}, {"entity_id": "8329789_9_Ent2", "role": "Subject_Age", "text": "infants", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8329789_9_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8329789_9_Ent3", "text": "Amphotericin B overdose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8329789_9_Ent5", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8329789_9_Ent1", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8329789_9_Ent0", "text": "children and infants", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_9_Ent2", "text": "infants", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8375752_1", "wnd_id": "8375752_1_1", "text": "Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : \" the retinoic acid syndrome \" .", "tokens": ["Although", "retinoic", "acid", "is", "well", "tolerated", "by", "the", "majority", "of", "patients", "with", "this", "disease", ",", "a", "potentially", "fatal", "complication", "of", "this", "kind", "of", "treatment", "has", "been", "reported", ":", "\"", "the", "retinoic", "acid", "syndrome", "\"", "."], "event_mentions": [{"id": "8375752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 18, "end": 19}, "arguments": [{"entity_id": "8375752_1_Ent1", "role": "Treatment", "text": "retinoic acid", "start": 1, "end": 3}, {"entity_id": "8375752_1_Ent2", "role": "Treatment_Drug", "text": "retinoic acid", "start": 1, "end": 3}, {"entity_id": "8375752_1_Ent0", "role": "Effect", "text": "fatal complication", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "8375752_1_Ent1", "text": "retinoic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8375752_1_Ent2", "text": "retinoic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8375752_1_Ent0", "text": "fatal complication", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "8396491_1", "wnd_id": "8396491_1_1", "text": "Interference with the cortisol axis by the microtubule antagonist , CPH82 .", "tokens": ["Interference", "with", "the", "cortisol", "axis", "by", "the", "microtubule", "antagonist", ",", "CPH82", "."], "event_mentions": [{"id": "8396491_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "8396491_1_Ent0", "role": "Effect", "text": "Interference with the cortisol axis", "start": 0, "end": 5}, {"entity_id": "8396491_1_Ent1", "role": "Treatment", "text": "CPH82", "start": 10, "end": 11}, {"entity_id": "8396491_1_Ent2", "role": "Treatment_Drug", "text": "CPH82", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8396491_1_Ent0", "text": "Interference with the cortisol axis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8396491_1_Ent1", "text": "CPH82", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8396491_1_Ent2", "text": "CPH82", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8438851_4", "wnd_id": "8438851_4_1", "text": "These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .", "tokens": ["These", "multiple", "overlapping", "factors", "probably", "lead", "to", "rhabdomyolysis", "in", "a", "minority", "of", "patients", "receiving", "vasopressin", "infusion", "."], "event_mentions": [{"id": "8438851_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 5, "end": 6}, "arguments": [{"entity_id": "8438851_4_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 7, "end": 8}, {"entity_id": "8438851_4_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "8438851_4_Ent2", "role": "Treatment", "text": "vasopressin", "start": 14, "end": 15}, {"entity_id": "8438851_4_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 14, "end": 15}, {"entity_id": "8438851_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8438851_4_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8438851_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8438851_4_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8438851_4_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8438851_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "847572_2", "wnd_id": "847572_2_1", "text": "The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .", "tokens": ["The", "biochemistry", "of", "paracetamol", "hepatotoxicity", "is", "outlined", "and", "the", "increased", "susceptibility", "of", "alcoholic", "patients", "to", "the", "hepatotoxic", "effects", "of", "paracetamol", "is", "remarked", "upon", "."], "event_mentions": [{"id": "847572_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "remarked", "start": 21, "end": 22}, "arguments": [{"entity_id": "847572_2_Ent0", "role": "Subject", "text": "alcoholic patients", "start": 12, "end": 14}, {"entity_id": "847572_2_Ent1", "role": "Effect", "text": "hepatotoxic effects", "start": 16, "end": 18}, {"entity_id": "847572_2_Ent2", "role": "Treatment", "text": "paracetamol", "start": 19, "end": 20}, {"entity_id": "847572_2_Ent3", "role": "Treatment_Drug", "text": "paracetamol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "847572_2_Ent0", "text": "alcoholic patients", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "847572_2_Ent1", "text": "hepatotoxic effects", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "847572_2_Ent2", "text": "paracetamol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "847572_2_Ent3", "text": "paracetamol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "847572_3", "wnd_id": "847572_3_1", "text": "Two fatal cases of poisoning by paracetamol are described .", "tokens": ["Two", "fatal", "cases", "of", "poisoning", "by", "paracetamol", "are", "described", "."], "event_mentions": [{"id": "847572_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "847572_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "847572_3_Ent0", "role": "Subject", "text": "Two fatal cases", "start": 0, "end": 3}, {"entity_id": "847572_3_Ent2", "role": "Effect", "text": "poisoning", "start": 4, "end": 5}, {"entity_id": "847572_3_Ent3", "role": "Treatment", "text": "paracetamol", "start": 6, "end": 7}, {"entity_id": "847572_3_Ent4", "role": "Treatment_Drug", "text": "paracetamol", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "847572_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "847572_3_Ent0", "text": "Two fatal cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "847572_3_Ent2", "text": "poisoning", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "847572_3_Ent3", "text": "paracetamol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "847572_3_Ent4", "text": "paracetamol", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8530331_6", "wnd_id": "8530331_6_1", "text": "Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .", "tokens": ["Two", "of", "the", "five", "patients", "who", "worsened", "motorically", "also", "developed", "encephalopathy", "during", "risperidone", "treatment", ";", "the", "encephalopathy", "resolved", "when", "the", "patients", "were", "switched", "to", "clozapine", "treatment", "."], "event_mentions": [{"id": "8530331_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "8530331_6_Ent1", "role": "Subject_Population", "text": "Two of the five", "start": 0, "end": 4}, {"entity_id": "8530331_6_Ent0", "role": "Subject", "text": "Two of the five patients who worsened motorically", "start": 0, "end": 8}, {"entity_id": "8530331_6_Ent2", "role": "Subject_Disorder", "text": "worsened motorically", "start": 6, "end": 8}, {"entity_id": "8530331_6_Ent3", "role": "Effect", "text": "encephalopathy", "start": 10, "end": 11}, {"entity_id": "8530331_6_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 12, "end": 13}, {"entity_id": "8530331_6_Ent4", "role": "Treatment", "text": "risperidone treatment", "start": 12, "end": 14}]}, {"id": "8530331_6_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 17, "end": 18}, "arguments": [{"entity_id": "8530331_6_Ent7", "role": "Subject_Population", "text": "Two of the five", "start": 0, "end": 4}, {"entity_id": "8530331_6_Ent6", "role": "Subject", "text": "Two of the five patients who worsened motorically", "start": 0, "end": 8}, {"entity_id": "8530331_6_Ent8", "role": "Subject_Disorder", "text": "worsened motorically", "start": 6, "end": 8}, {"entity_id": "8530331_6_Ent10", "role": "Treatment_Disorder", "text": "encephalopathy", "start": 16, "end": 17}, {"entity_id": "8530331_6_Ent9", "role": "Treatment", "text": "switched to clozapine treatment", "start": 22, "end": 26}, {"entity_id": "8530331_6_Ent11", "role": "Treatment_Drug", "text": "clozapine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "8530331_6_Ent1", "text": "Two of the five", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8530331_6_Ent7", "text": "Two of the five", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8530331_6_Ent0", "text": "Two of the five patients who worsened motorically", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8530331_6_Ent6", "text": "Two of the five patients who worsened motorically", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8530331_6_Ent2", "text": "worsened motorically", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8530331_6_Ent8", "text": "worsened motorically", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8530331_6_Ent3", "text": "encephalopathy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8530331_6_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8530331_6_Ent4", "text": "risperidone treatment", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8530331_6_Ent10", "text": "encephalopathy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8530331_6_Ent9", "text": "switched to clozapine treatment", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "8530331_6_Ent11", "text": "clozapine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "8589490_1", "wnd_id": "8589490_1_1", "text": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki - 1) - positive anaplastic large - cell lymphoma .", "tokens": ["Supravenous", "hyperpigmentation", "in", "association", "with", "CHOP", "chemotherapy", "of", "a", "CD30", "(", "Ki", "-", "1)", "-", "positive", "anaplastic", "large", "-", "cell", "lymphoma", "."], "event_mentions": [{"id": "8589490_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 3, "end": 4}, "arguments": [{"entity_id": "8589490_1_Ent0", "role": "Effect", "text": "Supravenous hyperpigmentation", "start": 0, "end": 2}, {"entity_id": "8589490_1_Ent3", "role": "Treatment_Drug", "text": "CHOP", "start": 5, "end": 6}, {"entity_id": "8589490_1_Ent1", "role": "Treatment", "text": "CHOP chemotherapy", "start": 5, "end": 7}, {"entity_id": "8589490_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "8589490_1_Ent2", "role": "Treatment_Disorder", "text": "a CD30 ( Ki - 1) - positive anaplastic large - cell lymphoma", "start": 8, "end": 21}]}], "entity_mentions": [{"id": "8589490_1_Ent0", "text": "Supravenous hyperpigmentation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8589490_1_Ent3", "text": "CHOP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8589490_1_Ent1", "text": "CHOP chemotherapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8589490_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8589490_1_Ent2", "text": "a CD30 ( Ki - 1) - positive anaplastic large - cell lymphoma", "entity_type": "Entity", "start": 8, "end": 21}], "lang": "en"}
{"doc_id": "8597009_1", "wnd_id": "8597009_1_1", "text": "Phenytoin toxicity due to concomitant antituberculosis therapy .", "tokens": ["Phenytoin", "toxicity", "due", "to", "concomitant", "antituberculosis", "therapy", "."], "event_mentions": [{"id": "8597009_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "8597009_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "8597009_1_Ent5", "role": "Combination_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "8597009_1_Ent0", "role": "Effect", "text": "Phenytoin toxicity", "start": 0, "end": 2}, {"entity_id": "8597009_1_Ent1", "role": "Treatment", "text": "concomitant antituberculosis therapy .", "start": 4, "end": 8}, {"entity_id": "8597009_1_Ent3", "role": "Treatment_Drug", "text": "antituberculosis", "start": 5, "end": 6}, {"entity_id": "8597009_1_Ent4", "role": "Combination_Drug", "text": "antituberculosis", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "8597009_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8597009_1_Ent5", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8597009_1_Ent0", "text": "Phenytoin toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8597009_1_Ent1", "text": "concomitant antituberculosis therapy .", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8597009_1_Ent3", "text": "antituberculosis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8597009_1_Ent4", "text": "antituberculosis", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "8597009_3", "wnd_id": "8597009_3_1", "text": "Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .", "tokens": ["Slow", "acetylators", ",", "who", "comprise", "roughly", "50", "%", "of", "the", "South", "African", "population", ",", "are", "likely", "to", "develop", "clinical", "and", "biochemical", "features", "of", "phenytoin", "toxicity", "when", "this", "drug", "is", "given", "together", "with", "antituberculosis", "therapy", "."], "event_mentions": [{"id": "8597009_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 17, "end": 18}, "arguments": [{"entity_id": "8597009_3_Ent0", "role": "Subject", "text": "Slow acetylators", "start": 0, "end": 2}, {"entity_id": "8597009_3_Ent1", "role": "Subject_Disorder", "text": "Slow acetylators", "start": 0, "end": 2}, {"entity_id": "8597009_3_Ent2", "role": "Effect", "text": "clinical and biochemical features of phenytoin toxicity", "start": 18, "end": 25}, {"entity_id": "8597009_3_Ent3", "role": "Treatment", "text": "phenytoin", "start": 23, "end": 24}, {"entity_id": "8597009_3_Ent6", "role": "Treatment_Drug", "text": "phenytoin", "start": 23, "end": 24}, {"entity_id": "8597009_3_Ent7", "role": "Combination_Drug", "text": "phenytoin", "start": 23, "end": 24}, {"entity_id": "8597009_3_Ent4", "role": "Treatment", "text": "together with antituberculosis", "start": 30, "end": 33}, {"entity_id": "8597009_3_Ent5", "role": "Treatment_Drug", "text": "antituberculosis", "start": 32, "end": 33}, {"entity_id": "8597009_3_Ent8", "role": "Combination_Drug", "text": "antituberculosis", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "8597009_3_Ent0", "text": "Slow acetylators", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8597009_3_Ent1", "text": "Slow acetylators", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8597009_3_Ent2", "text": "clinical and biochemical features of phenytoin toxicity", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "8597009_3_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8597009_3_Ent6", "text": "phenytoin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8597009_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8597009_3_Ent4", "text": "together with antituberculosis", "entity_type": "Entity", "start": 30, "end": 33}, {"id": "8597009_3_Ent5", "text": "antituberculosis", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "8597009_3_Ent8", "text": "antituberculosis", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "8597009_4", "wnd_id": "8597009_4_1", "text": "The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .", "tokens": ["The", "wide", "use", "of", "phenytoin", "during", "the", "recent", "tuberculosis", "epidemic", "makes", "it", "imperative", "to", "suspect", "this", "drug", "interaction", "in", "patients", "exhibiting", "clinical", "features", "that", "might", "be", "related", "to", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "8597009_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspect", "start": 14, "end": 15}, "arguments": [{"entity_id": "8597009_4_Ent2", "role": "Treatment", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent3", "role": "Treatment_Duration", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "8597009_4_Ent0", "role": "Subject", "text": "patients", "start": 19, "end": 20}, {"entity_id": "8597009_4_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "8597009_4_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8597009_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8597009_4_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "8604715_2", "wnd_id": "8604715_2_1", "text": "No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .", "tokens": ["No", "cases", "of", "renal", "acidosis", ",", "and", "only", "one", "case", "of", "nephrogenic", "diabetes", "insipidus", ",", "has", "been", "previously", "reported", "as", "a", "complication", "of", "foscarnet", "treatment", "."], "event_mentions": [{"id": "8604715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 18, "end": 19}, "arguments": [{"entity_id": "8604715_2_Ent0", "role": "Effect", "text": "nephrogenic diabetes insipidus", "start": 11, "end": 14}, {"entity_id": "8604715_2_Ent2", "role": "Treatment_Drug", "text": "foscarnet", "start": 23, "end": 24}, {"entity_id": "8604715_2_Ent1", "role": "Treatment", "text": "foscarnet treatment", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8604715_2_Ent0", "text": "nephrogenic diabetes insipidus", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8604715_2_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8604715_2_Ent1", "text": "foscarnet treatment", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8627446_1", "wnd_id": "8627446_1_1", "text": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .", "tokens": ["Accelerated", "nodulosis", "during", "methotrexate", "therapy", "for", "juvenile", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "8627446_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "8627446_1_Ent0", "role": "Effect", "text": "Accelerated nodulosis", "start": 0, "end": 2}, {"entity_id": "8627446_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent3", "role": "Treatment_Disorder", "text": "juvenile rheumatoid arthritis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "8627446_1_Ent0", "text": "Accelerated nodulosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8627446_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent3", "text": "juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "8627446_4", "wnd_id": "8627446_4_1", "text": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .", "tokens": ["The", "nodules", "regressed", "after", "withdrawal", "of", "methotrexate", "therapy", "in", "one", "patient", "and", "were", "arrested", "with", "the", "addition", "of", "hydroxychloroquine", "in", "the", "other", "."], "event_mentions": [{"id": "8627446_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "8627446_4_Ent4", "role": "Treatment_Disorder", "text": "nodules", "start": 1, "end": 2}, {"entity_id": "8627446_4_Ent2", "role": "Effect", "text": "regressed", "start": 2, "end": 3}, {"entity_id": "8627446_4_Ent3", "role": "Treatment", "text": "withdrawal of methotrexate therapy", "start": 4, "end": 8}, {"entity_id": "8627446_4_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "8627446_4_Ent1", "role": "Subject_Population", "text": "one", "start": 9, "end": 10}, {"entity_id": "8627446_4_Ent0", "role": "Subject", "text": "one patient", "start": 9, "end": 11}]}, {"id": "8627446_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "with", "start": 14, "end": 15}, "arguments": [{"entity_id": "8627446_4_Ent11", "role": "Treatment_Disorder", "text": "nodules", "start": 1, "end": 2}, {"entity_id": "8627446_4_Ent8", "role": "Subject_Population", "text": "one", "start": 9, "end": 10}, {"entity_id": "8627446_4_Ent6", "role": "Subject", "text": "one patient", "start": 9, "end": 11}, {"entity_id": "8627446_4_Ent9", "role": "Effect", "text": "arrested", "start": 13, "end": 14}, {"entity_id": "8627446_4_Ent10", "role": "Treatment", "text": "the addition of hydroxychloroquine", "start": 15, "end": 19}, {"entity_id": "8627446_4_Ent12", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 18, "end": 19}, {"entity_id": "8627446_4_Ent7", "role": "Subject", "text": "the other", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "8627446_4_Ent4", "text": "nodules", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8627446_4_Ent11", "text": "nodules", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8627446_4_Ent2", "text": "regressed", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8627446_4_Ent3", "text": "withdrawal of methotrexate therapy", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8627446_4_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8627446_4_Ent1", "text": "one", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8627446_4_Ent8", "text": "one", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8627446_4_Ent0", "text": "one patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8627446_4_Ent6", "text": "one patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8627446_4_Ent9", "text": "arrested", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8627446_4_Ent10", "text": "the addition of hydroxychloroquine", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "8627446_4_Ent12", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8627446_4_Ent7", "text": "the other", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8636829_1", "wnd_id": "8636829_1_1", "text": "A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .", "tokens": ["A", "macrophage", "activation", "syndrome", ",", "possibly", "related", "to", "methotrexate", "toxicity", ",", "developed", "in", "a", "boy", "with", "systemic", "juvenile", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "8636829_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "8636829_1_Ent2", "role": "Effect", "text": "macrophage activation syndrome", "start": 1, "end": 4}, {"entity_id": "8636829_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 8, "end": 9}, {"entity_id": "8636829_1_Ent3", "role": "Treatment", "text": "methotrexate toxicity", "start": 8, "end": 10}, {"entity_id": "8636829_1_Ent0", "role": "Subject", "text": "a boy with systemic juvenile rheumatoid arthritis", "start": 13, "end": 20}, {"entity_id": "8636829_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 14, "end": 15}, {"entity_id": "8636829_1_Ent5", "role": "Treatment_Disorder", "text": "systemic juvenile rheumatoid arthritis", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "8636829_1_Ent2", "text": "macrophage activation syndrome", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "8636829_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8636829_1_Ent3", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8636829_1_Ent0", "text": "a boy with systemic juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "8636829_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8636829_1_Ent5", "text": "systemic juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "8638872_1", "wnd_id": "8638872_1_1", "text": "Jaundice induced by streptokinase .", "tokens": ["Jaundice", "induced", "by", "streptokinase", "."], "event_mentions": [{"id": "8638872_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "8638872_1_Ent0", "role": "Effect", "text": "Jaundice", "start": 0, "end": 1}, {"entity_id": "8638872_1_Ent1", "role": "Treatment", "text": "streptokinase", "start": 3, "end": 4}, {"entity_id": "8638872_1_Ent2", "role": "Treatment_Drug", "text": "streptokinase", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8638872_1_Ent0", "text": "Jaundice", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8638872_1_Ent1", "text": "streptokinase", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8638872_1_Ent2", "text": "streptokinase", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8638872_2", "wnd_id": "8638872_2_1", "text": "Only a few reports of overt jaundice are associated with streptokinase .", "tokens": ["Only", "a", "few", "reports", "of", "overt", "jaundice", "are", "associated", "with", "streptokinase", "."], "event_mentions": [{"id": "8638872_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "8638872_2_Ent0", "role": "Effect", "text": "overt jaundice", "start": 5, "end": 7}, {"entity_id": "8638872_2_Ent1", "role": "Treatment", "text": "streptokinase", "start": 10, "end": 11}, {"entity_id": "8638872_2_Ent2", "role": "Treatment_Drug", "text": "streptokinase", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8638872_2_Ent0", "text": "overt jaundice", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8638872_2_Ent1", "text": "streptokinase", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8638872_2_Ent2", "text": "streptokinase", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8641617_2", "wnd_id": "8641617_2_1", "text": "Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .", "tokens": ["Based", "on", "our", "findings", ",", "it", "is", "thus", "concluded", "that", "cisplatin", "may", "cause", "C.", "difficile", "colitis", "."], "event_mentions": [{"id": "8641617_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 12, "end": 13}, "arguments": [{"entity_id": "8641617_2_Ent1", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "8641617_2_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "8641617_2_Ent0", "role": "Effect", "text": "C. difficile colitis", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "8641617_2_Ent1", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8641617_2_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8641617_2_Ent0", "text": "C. difficile colitis", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "8641617_4", "wnd_id": "8641617_4_1", "text": "Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .", "tokens": ["Clostridium", "difficile", "colitis", "associated", "with", "cisplatin", "-", "based", "chemotherapy", "in", "ovarian", "cancer", "patients", "."], "event_mentions": [{"id": "8641617_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "8641617_4_Ent1", "role": "Effect", "text": "Clostridium difficile colitis", "start": 0, "end": 3}, {"entity_id": "8641617_4_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 5, "end": 6}, {"entity_id": "8641617_4_Ent2", "role": "Treatment", "text": "cisplatin - based chemotherapy", "start": 5, "end": 9}, {"entity_id": "8641617_4_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 8, "end": 9}, {"entity_id": "8641617_4_Ent4", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 10, "end": 12}, {"entity_id": "8641617_4_Ent0", "role": "Subject", "text": "ovarian cancer patients .", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "8641617_4_Ent1", "text": "Clostridium difficile colitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8641617_4_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8641617_4_Ent2", "text": "cisplatin - based chemotherapy", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8641617_4_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8641617_4_Ent4", "text": "ovarian cancer", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8641617_4_Ent0", "text": "ovarian cancer patients .", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "8641617_5", "wnd_id": "8641617_5_1", "text": "Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .", "tokens": ["Severe", "C.", "difficile", "colitis", "occurred", "in", "2", "patients", "(", "6.1", "%", ")", "after", "receiving", "cisplatin", "-", "based", "combination", "chemotherapy", "for", "ovarian", "malignancies", "."], "event_mentions": [{"id": "8641617_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 4, "end": 5}, "arguments": [{"entity_id": "8641617_5_Ent3", "role": "Effect", "text": "Severe C. difficile colitis", "start": 0, "end": 4}, {"entity_id": "8641617_5_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "8641617_5_Ent0", "role": "Subject", "text": "2 patients ( 6.1 % )", "start": 6, "end": 12}, {"entity_id": "8641617_5_Ent2", "role": "Subject_Population", "text": "( 6.1 % )", "start": 8, "end": 12}, {"entity_id": "8641617_5_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 14, "end": 15}, {"entity_id": "8641617_5_Ent4", "role": "Treatment", "text": "cisplatin - based combination chemotherapy", "start": 14, "end": 19}, {"entity_id": "8641617_5_Ent7", "role": "Treatment_Route", "text": "chemotherapy", "start": 18, "end": 19}, {"entity_id": "8641617_5_Ent6", "role": "Treatment_Disorder", "text": "ovarian malignancies", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "8641617_5_Ent3", "text": "Severe C. difficile colitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8641617_5_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8641617_5_Ent0", "text": "2 patients ( 6.1 % )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "8641617_5_Ent2", "text": "( 6.1 % )", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "8641617_5_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8641617_5_Ent4", "text": "cisplatin - based combination chemotherapy", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "8641617_5_Ent7", "text": "chemotherapy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8641617_5_Ent6", "text": "ovarian malignancies", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8645078_4", "wnd_id": "8645078_4_1", "text": "Patients treated with captopril who develop \" atypical cholangitis \" should be suspected of having captopril - associated liver damage .", "tokens": ["Patients", "treated", "with", "captopril", "who", "develop", "\"", "atypical", "cholangitis", "\"", "should", "be", "suspected", "of", "having", "captopril", "-", "associated", "liver", "damage", "."], "event_mentions": [{"id": "8645078_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "8645078_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "8645078_4_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 3, "end": 4}, {"entity_id": "8645078_4_Ent1", "role": "Effect", "text": "atypical cholangitis", "start": 7, "end": 9}, {"entity_id": "8645078_4_Ent3", "role": "Treatment", "text": "captopril", "start": 15, "end": 16}, {"entity_id": "8645078_4_Ent5", "role": "Treatment_Drug", "text": "captopril", "start": 15, "end": 16}, {"entity_id": "8645078_4_Ent2", "role": "Effect", "text": "liver damage", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "8645078_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_4_Ent4", "text": "captopril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8645078_4_Ent1", "text": "atypical cholangitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8645078_4_Ent3", "text": "captopril", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8645078_4_Ent5", "text": "captopril", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8645078_4_Ent2", "text": "liver damage", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "8651254_2", "wnd_id": "8651254_2_1", "text": "It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .", "tokens": ["It", "should", "be", "emphasized", "that", "the", "recurrence", "of", "nephrotic", "syndrome", "was", "observed", "after", "the", "following", "chemotherapy", ",", "including", "M", "-", "CSF", ",", "whereas", "the", "bone", "marrow", "still", "remained", "completely", "remitted", "."], "event_mentions": [{"id": "8651254_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "8651254_2_Ent0", "role": "Effect", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "8651254_2_Ent2", "role": "Treatment", "text": "chemotherapy , including M - CSF", "start": 15, "end": 21}, {"entity_id": "8651254_2_Ent3", "role": "Treatment_Drug", "text": "M - CSF", "start": 18, "end": 21}, {"entity_id": "8651254_2_Ent1", "role": "Effect", "text": "the bone marrow still remained completely remitted", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "8651254_2_Ent0", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8651254_2_Ent2", "text": "chemotherapy , including M - CSF", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "8651254_2_Ent3", "text": "M - CSF", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8651254_2_Ent1", "text": "the bone marrow still remained completely remitted", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "8651254_3", "wnd_id": "8651254_3_1", "text": "The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .", "tokens": ["The", "possibility", "can", "be", "raised", "that", "M", "-", "CSF", "accelerated", "the", "underlying", "renal", "disease", "in", "this", "case", "through", "enhancing", "macrophage", "accumulation", "into", "the", "glomerulus", ",", "leading", "to", "the", "development", "of", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "8651254_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 9, "end": 10}, "arguments": [{"entity_id": "8651254_3_Ent1", "role": "Treatment", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent2", "role": "Treatment_Drug", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent0", "role": "Effect", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "start": 11, "end": 32}]}], "entity_mentions": [{"id": "8651254_3_Ent1", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent2", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent0", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 32}], "lang": "en"}
{"doc_id": "8656412_1", "wnd_id": "8656412_1_1", "text": "On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .", "tokens": ["On", "the", "fifth", "day", "of", "tocolysis", "with", "magnesium", "sulfate", ",", "nifedipine", ",", "terbutaline", "and", "betamethasone", ",", "edema", "developed", "in", "both", "labia", "."], "event_mentions": [{"id": "8656412_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "8656412_1_Ent2", "role": "Treatment", "text": "On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone", "start": 0, "end": 15}, {"entity_id": "8656412_1_Ent3", "role": "Treatment_Duration", "text": "the fifth day", "start": 1, "end": 4}, {"entity_id": "8656412_1_Ent4", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 7, "end": 9}, {"entity_id": "8656412_1_Ent8", "role": "Combination_Drug", "text": "magnesium sulfate", "start": 7, "end": 9}, {"entity_id": "8656412_1_Ent5", "role": "Treatment_Drug", "text": "nifedipine", "start": 10, "end": 11}, {"entity_id": "8656412_1_Ent9", "role": "Combination_Drug", "text": "nifedipine", "start": 10, "end": 11}, {"entity_id": "8656412_1_Ent6", "role": "Treatment_Drug", "text": "terbutaline", "start": 12, "end": 13}, {"entity_id": "8656412_1_Ent10", "role": "Combination_Drug", "text": "terbutaline", "start": 12, "end": 13}, {"entity_id": "8656412_1_Ent7", "role": "Treatment_Drug", "text": "betamethasone", "start": 14, "end": 15}, {"entity_id": "8656412_1_Ent11", "role": "Combination_Drug", "text": "betamethasone", "start": 14, "end": 15}, {"entity_id": "8656412_1_Ent0", "role": "Effect", "text": "edema", "start": 16, "end": 17}, {"entity_id": "8656412_1_Ent1", "role": "Effect", "text": "in both labia", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "8656412_1_Ent2", "text": "On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "8656412_1_Ent3", "text": "the fifth day", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "8656412_1_Ent4", "text": "magnesium sulfate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8656412_1_Ent8", "text": "magnesium sulfate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8656412_1_Ent5", "text": "nifedipine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8656412_1_Ent9", "text": "nifedipine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8656412_1_Ent6", "text": "terbutaline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8656412_1_Ent10", "text": "terbutaline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8656412_1_Ent7", "text": "betamethasone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8656412_1_Ent11", "text": "betamethasone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8656412_1_Ent0", "text": "edema", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8656412_1_Ent1", "text": "in both labia", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "8667442_2", "wnd_id": "8667442_2_1", "text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .", "tokens": ["This", "article", "presents", "a", "patient", "with", "hypoparathyroidism", "who", "was", "treated", "with", "calcium", "carbonate", "and", "calcitriol", "resulting", "in", "two", "admissions", "to", "the", "hospital", "for", "milk", "-", "alkali", "syndrome", "."], "event_mentions": [{"id": "8667442_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 15, "end": 16}, "arguments": [{"entity_id": "8667442_2_Ent0", "role": "Subject", "text": "a patient with hypoparathyroidism", "start": 3, "end": 7}, {"entity_id": "8667442_2_Ent3", "role": "Treatment_Disorder", "text": "hypoparathyroidism", "start": 6, "end": 7}, {"entity_id": "8667442_2_Ent4", "role": "Treatment_Drug", "text": "calcium carbonate", "start": 11, "end": 13}, {"entity_id": "8667442_2_Ent6", "role": "Combination_Drug", "text": "calcium carbonate", "start": 11, "end": 13}, {"entity_id": "8667442_2_Ent2", "role": "Treatment", "text": "calcium carbonate and calcitriol", "start": 11, "end": 15}, {"entity_id": "8667442_2_Ent5", "role": "Treatment_Drug", "text": "calcitriol", "start": 14, "end": 15}, {"entity_id": "8667442_2_Ent7", "role": "Combination_Drug", "text": "calcitriol", "start": 14, "end": 15}, {"entity_id": "8667442_2_Ent1", "role": "Effect", "text": "two admissions to the hospital for milk - alkali syndrome", "start": 17, "end": 27}]}], "entity_mentions": [{"id": "8667442_2_Ent0", "text": "a patient with hypoparathyroidism", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8667442_2_Ent3", "text": "hypoparathyroidism", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8667442_2_Ent4", "text": "calcium carbonate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8667442_2_Ent6", "text": "calcium carbonate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8667442_2_Ent2", "text": "calcium carbonate and calcitriol", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "8667442_2_Ent5", "text": "calcitriol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8667442_2_Ent7", "text": "calcitriol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8667442_2_Ent1", "text": "two admissions to the hospital for milk - alkali syndrome", "entity_type": "Entity", "start": 17, "end": 27}], "lang": "en"}
{"doc_id": "8672829_6", "wnd_id": "8672829_6_1", "text": "This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .", "tokens": ["This", "represents", "the", "first", "report", "of", "nonconvulsive", "status", "epilepticus", "induced", "by", "ifosfamide", "."], "event_mentions": [{"id": "8672829_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8672829_6_Ent0", "role": "Effect", "text": "nonconvulsive status epilepticus", "start": 6, "end": 9}, {"entity_id": "8672829_6_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "8672829_6_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8672829_6_Ent0", "text": "nonconvulsive status epilepticus", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8672829_6_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8672829_6_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8678015_3", "wnd_id": "8678015_3_1", "text": "While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .", "tokens": ["While", "undergoing", "treatment", "with", "albendazole", ",", "he", "developed", "worsening", "diarrhea", "with", "abdominal", "pain", "and", "fever", "."], "event_mentions": [{"id": "8678015_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "8678015_3_Ent3", "role": "Treatment", "text": "albendazole", "start": 4, "end": 5}, {"entity_id": "8678015_3_Ent4", "role": "Treatment_Drug", "text": "albendazole", "start": 4, "end": 5}, {"entity_id": "8678015_3_Ent0", "role": "Subject", "text": "he", "start": 6, "end": 7}, {"entity_id": "8678015_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 6, "end": 7}, {"entity_id": "8678015_3_Ent2", "role": "Effect", "text": "worsening diarrhea with abdominal pain and fever", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "8678015_3_Ent3", "text": "albendazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8678015_3_Ent4", "text": "albendazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8678015_3_Ent0", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_3_Ent1", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_3_Ent2", "text": "worsening diarrhea with abdominal pain and fever", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "868978_2", "wnd_id": "868978_2_1", "text": "The ocular motor disturbances are probably an expression of regional 5 - FU neurotoxicity primarily affecting the brain stem .", "tokens": ["The", "ocular", "motor", "disturbances", "are", "probably", "an", "expression", "of", "regional", "5", "-", "FU", "neurotoxicity", "primarily", "affecting", "the", "brain", "stem", "."], "event_mentions": [{"id": "868978_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "expression", "start": 7, "end": 8}, "arguments": [{"entity_id": "868978_2_Ent0", "role": "Effect", "text": "The ocular motor disturbances", "start": 0, "end": 4}, {"entity_id": "868978_2_Ent2", "role": "Treatment", "text": "5 - FU", "start": 10, "end": 13}, {"entity_id": "868978_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 10, "end": 13}, {"entity_id": "868978_2_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "868978_2_Ent0", "text": "The ocular motor disturbances", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "868978_2_Ent2", "text": "5 - FU", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "868978_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "868978_2_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8691927_4", "wnd_id": "8691927_4_1", "text": "INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .", "tokens": ["INTERPRETATION", ":", "When", "high", "doses", "of", "fluticasone", "propionate", "are", "used", ",", "growth", "may", "be", "retarded", "and", "adrenal", "suppression", "may", "occur", "."], "event_mentions": [{"id": "8691927_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 19, "end": 20}, "arguments": [{"entity_id": "8691927_4_Ent2", "role": "Treatment_Dosage", "text": "high doses", "start": 3, "end": 5}, {"entity_id": "8691927_4_Ent1", "role": "Treatment", "text": "high doses of fluticasone propionate", "start": 3, "end": 8}, {"entity_id": "8691927_4_Ent3", "role": "Treatment_Drug", "text": "fluticasone propionate", "start": 6, "end": 8}, {"entity_id": "8691927_4_Ent0", "role": "Effect", "text": "growth may be retarded and adrenal suppression", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "8691927_4_Ent2", "text": "high doses", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8691927_4_Ent1", "text": "high doses of fluticasone propionate", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "8691927_4_Ent3", "text": "fluticasone propionate", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8691927_4_Ent0", "text": "growth may be retarded and adrenal suppression", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "8696525_1", "wnd_id": "8696525_1_1", "text": "Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .", "tokens": ["Metipranolol", "associated", "granulomatous", "anterior", "uveitis", ":", "not", "so", "uncommon", "as", "thought", "."], "event_mentions": [{"id": "8696525_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "8696525_1_Ent1", "role": "Treatment", "text": "Metipranolol", "start": 0, "end": 1}, {"entity_id": "8696525_1_Ent2", "role": "Treatment_Drug", "text": "Metipranolol", "start": 0, "end": 1}, {"entity_id": "8696525_1_Ent0", "role": "Effect", "text": "granulomatous anterior uveitis", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "8696525_1_Ent1", "text": "Metipranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8696525_1_Ent2", "text": "Metipranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8696525_1_Ent0", "text": "granulomatous anterior uveitis", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "8700794_3", "wnd_id": "8700794_3_1", "text": "When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .", "tokens": ["When", "vague", "symptoms", "develop", "during", "desmopressin", "therapy", ",", "hyponatremia", "must", "be", "considered", "as", "part", "of", "the", "differential", "diagnosis", "."], "event_mentions": [{"id": "8700794_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "8700794_3_Ent0", "role": "Effect", "text": "vague symptoms", "start": 1, "end": 3}, {"entity_id": "8700794_3_Ent2", "role": "Treatment", "text": "desmopressin", "start": 5, "end": 6}, {"entity_id": "8700794_3_Ent3", "role": "Treatment_Drug", "text": "desmopressin", "start": 5, "end": 6}, {"entity_id": "8700794_3_Ent1", "role": "Effect", "text": "hyponatremia", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8700794_3_Ent0", "text": "vague symptoms", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8700794_3_Ent2", "text": "desmopressin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8700794_3_Ent3", "text": "desmopressin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8700794_3_Ent1", "text": "hyponatremia", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8700794_4", "wnd_id": "8700794_4_1", "text": "Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .", "tokens": ["Within", "24", "hours", "of", "fluid", "restriction", "and", "cessation", "of", "desmopressin", ",", "her", "symptoms", "and", "hyponatremia", "resolved", "."], "event_mentions": [{"id": "8700794_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 15, "end": 16}, "arguments": [{"entity_id": "8700794_4_Ent4", "role": "Treatment_Duration", "text": "24 hours", "start": 1, "end": 3}, {"entity_id": "8700794_4_Ent3", "role": "Treatment", "text": "24 hours of fluid restriction and cessation of desmopressin", "start": 1, "end": 10}, {"entity_id": "8700794_4_Ent5", "role": "Treatment_Drug", "text": "desmopressin", "start": 9, "end": 10}, {"entity_id": "8700794_4_Ent0", "role": "Subject", "text": "her", "start": 11, "end": 12}, {"entity_id": "8700794_4_Ent1", "role": "Subject_Gender", "text": "her", "start": 11, "end": 12}, {"entity_id": "8700794_4_Ent2", "role": "Effect", "text": "symptoms and hyponatremia", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8700794_4_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8700794_4_Ent3", "text": "24 hours of fluid restriction and cessation of desmopressin", "entity_type": "Entity", "start": 1, "end": 10}, {"id": "8700794_4_Ent5", "text": "desmopressin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8700794_4_Ent0", "text": "her", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8700794_4_Ent1", "text": "her", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8700794_4_Ent2", "text": "symptoms and hyponatremia", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8730143_3", "wnd_id": "8730143_3_1", "text": "We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .", "tokens": ["We", "describe", "2", "patients", "with", "cutaneous", "lupus", "erythematosus", "who", "developed", "severe", "dapsone", "reaction", "after", "low", "dose", "therapy", ",", "with", "a", "fatal", "outcome", "in", "one", "."], "event_mentions": [{"id": "8730143_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "8730143_3_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "8730143_3_Ent0", "role": "Subject", "text": "2 patients with cutaneous lupus erythematosus", "start": 2, "end": 8}, {"entity_id": "8730143_3_Ent5", "role": "Treatment_Disorder", "text": "cutaneous lupus erythematosus", "start": 5, "end": 8}, {"entity_id": "8730143_3_Ent2", "role": "Effect", "text": "severe dapsone reaction", "start": 10, "end": 13}, {"entity_id": "8730143_3_Ent7", "role": "Treatment_Drug", "text": "dapsone", "start": 11, "end": 12}, {"entity_id": "8730143_3_Ent6", "role": "Treatment_Dosage", "text": "low dose", "start": 14, "end": 16}, {"entity_id": "8730143_3_Ent4", "role": "Treatment", "text": "low dose therapy", "start": 14, "end": 17}, {"entity_id": "8730143_3_Ent3", "role": "Effect", "text": "with a fatal outcome in one", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "8730143_3_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8730143_3_Ent0", "text": "2 patients with cutaneous lupus erythematosus", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "8730143_3_Ent5", "text": "cutaneous lupus erythematosus", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8730143_3_Ent2", "text": "severe dapsone reaction", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8730143_3_Ent7", "text": "dapsone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8730143_3_Ent6", "text": "low dose", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8730143_3_Ent4", "text": "low dose therapy", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8730143_3_Ent3", "text": "with a fatal outcome in one", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "8739289_2", "wnd_id": "8739289_2_1", "text": "Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .", "tokens": ["Nephrogenic", "diabetes", "insipidus", "(", "NDI", ")", "is", "a", "well", "-", "documented", "complication", "of", "lithium", "use", "."], "event_mentions": [{"id": "8739289_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "8739289_2_Ent0", "role": "Effect", "text": "Nephrogenic diabetes insipidus ( NDI )", "start": 0, "end": 6}, {"entity_id": "8739289_2_Ent1", "role": "Treatment", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8739289_2_Ent0", "text": "Nephrogenic diabetes insipidus ( NDI )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "8739289_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8749646_1", "wnd_id": "8749646_1_1", "text": "Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .", "tokens": ["Improved", "awareness", "of", "and", "further", "investigation", "into", "the", "neurotoxic", "effects", "of", "ofloxacin", "may", "enhance", "its", "safe", "use", "."], "event_mentions": [{"id": "8749646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 10, "end": 11}, "arguments": [{"entity_id": "8749646_1_Ent0", "role": "Effect", "text": "neurotoxic effects", "start": 8, "end": 10}, {"entity_id": "8749646_1_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 11, "end": 12}, {"entity_id": "8749646_1_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8749646_1_Ent0", "text": "neurotoxic effects", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8749646_1_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8749646_1_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8749646_2", "wnd_id": "8749646_2_1", "text": "Seizures associated with ofloxacin therapy .", "tokens": ["Seizures", "associated", "with", "ofloxacin", "therapy", "."], "event_mentions": [{"id": "8749646_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "8749646_2_Ent0", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "8749646_2_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 3, "end": 4}, {"entity_id": "8749646_2_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8749646_2_Ent0", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8749646_2_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8749646_2_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "879939_2", "wnd_id": "879939_2_1", "text": "Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .", "tokens": ["Severe", "osteomalacia", "was", "present", "in", "two", "epileptic", "patients", "who", "were", "under", "long", "-", "term", "treatment", "with", "congeners", "of", "phenytoin", ",", "phenobarbital", ",", "and", "acetazolamide", "."], "event_mentions": [{"id": "879939_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 3, "end": 4}, "arguments": [{"entity_id": "879939_2_Ent2", "role": "Effect", "text": "osteomalacia", "start": 1, "end": 2}, {"entity_id": "879939_2_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "879939_2_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 5, "end": 8}, {"entity_id": "879939_2_Ent4", "role": "Treatment_Disorder", "text": "epileptic", "start": 6, "end": 7}, {"entity_id": "879939_2_Ent3", "role": "Treatment", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "start": 11, "end": 24}, {"entity_id": "879939_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent9", "role": "Combination_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent7", "role": "Treatment_Drug", "text": "acetazolamide", "start": 23, "end": 24}, {"entity_id": "879939_2_Ent10", "role": "Combination_Drug", "text": "acetazolamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "879939_2_Ent2", "text": "osteomalacia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "879939_2_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "879939_2_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "879939_2_Ent4", "text": "epileptic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "879939_2_Ent3", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "879939_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent9", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent7", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "879939_2_Ent10", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "8816294_1", "wnd_id": "8816294_1_1", "text": "The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .", "tokens": ["The", "delayed", "encephalopathy", "developed", "9", "and", "22", "months", "respectively", "after", "the", "first", "dose", "of", "intrathecal", "methotrexate", "."], "event_mentions": [{"id": "8816294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "8816294_1_Ent0", "role": "Effect", "text": "delayed encephalopathy", "start": 1, "end": 3}, {"entity_id": "8816294_1_Ent2", "role": "Treatment_Time_elapsed", "text": "9 and 22 months", "start": 4, "end": 8}, {"entity_id": "8816294_1_Ent4", "role": "Treatment_Route", "text": "intrathecal", "start": 14, "end": 15}, {"entity_id": "8816294_1_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 14, "end": 16}, {"entity_id": "8816294_1_Ent3", "role": "Treatment_Dosage", "text": "methotrexate", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8816294_1_Ent0", "text": "delayed encephalopathy", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8816294_1_Ent2", "text": "9 and 22 months", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8816294_1_Ent4", "text": "intrathecal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8816294_1_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8816294_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8828999_1", "wnd_id": "8828999_1_1", "text": "a 67 - year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .", "tokens": ["a", "67", "-", "year", "-", "old", "man", "with", "bipolar", "disorder", "developed", "a", "Creutzfeldt", "-", "Jakob", "like", "syndrome", "during", "lithium", "carbonate", "treatment", "."], "event_mentions": [{"id": "8828999_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 17, "end": 18}, "arguments": [{"entity_id": "8828999_1_Ent0", "role": "Subject", "text": "a 67 - year - old man with bipolar disorder", "start": 0, "end": 10}, {"entity_id": "8828999_1_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 1, "end": 6}, {"entity_id": "8828999_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "8828999_1_Ent6", "role": "Treatment_Disorder", "text": "bipolar disorder", "start": 8, "end": 10}, {"entity_id": "8828999_1_Ent3", "role": "Effect", "text": "Creutzfeldt - Jakob like syndrome", "start": 12, "end": 17}, {"entity_id": "8828999_1_Ent4", "role": "Treatment", "text": "lithium carbonate", "start": 18, "end": 20}, {"entity_id": "8828999_1_Ent5", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "8828999_1_Ent0", "text": "a 67 - year - old man with bipolar disorder", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "8828999_1_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8828999_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8828999_1_Ent6", "text": "bipolar disorder", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8828999_1_Ent3", "text": "Creutzfeldt - Jakob like syndrome", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8828999_1_Ent4", "text": "lithium carbonate", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8828999_1_Ent5", "text": "lithium carbonate", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "8828999_2", "wnd_id": "8828999_2_1", "text": "Lithium - induced Creutzfeldt - Jakob syndrome .", "tokens": ["Lithium", "-", "induced", "Creutzfeldt", "-", "Jakob", "syndrome", "."], "event_mentions": [{"id": "8828999_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8828999_2_Ent1", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_2_Ent2", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_2_Ent0", "role": "Effect", "text": "Creutzfeldt - Jakob syndrome", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "8828999_2_Ent1", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_2_Ent2", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_2_Ent0", "text": "Creutzfeldt - Jakob syndrome", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "8828999_3", "wnd_id": "8828999_3_1", "text": "Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .", "tokens": ["Lithium", "neurotoxicity", "should", "be", "considered", "in", "Creutzfeldt", "-", "Jakob", "disease", "differential", "diagnosis", ",", "serial", "electroencephalograms", "being", "the", "most", "valuable", "."], "event_mentions": [{"id": "8828999_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 4, "end": 5}, "arguments": [{"entity_id": "8828999_3_Ent1", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_3_Ent3", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_3_Ent0", "role": "Effect", "text": "Lithium neurotoxicity", "start": 0, "end": 2}, {"entity_id": "8828999_3_Ent2", "role": "Treatment_Disorder", "text": "Creutzfeldt - Jakob disease", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "8828999_3_Ent1", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_3_Ent3", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_3_Ent0", "text": "Lithium neurotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8828999_3_Ent2", "text": "Creutzfeldt - Jakob disease", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "8850251_5", "wnd_id": "8850251_5_1", "text": "Two cases of mequitazine - induced photosensitivity reactions .", "tokens": ["Two", "cases", "of", "mequitazine", "-", "induced", "photosensitivity", "reactions", "."], "event_mentions": [{"id": "8850251_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "8850251_5_Ent1", "role": "Treatment", "text": "mequitazine", "start": 3, "end": 4}, {"entity_id": "8850251_5_Ent2", "role": "Treatment_Drug", "text": "mequitazine", "start": 3, "end": 4}, {"entity_id": "8850251_5_Ent0", "role": "Effect", "text": "photosensitivity reactions", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "8850251_5_Ent1", "text": "mequitazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8850251_5_Ent2", "text": "mequitazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8850251_5_Ent0", "text": "photosensitivity reactions", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "8862924_2", "wnd_id": "8862924_2_1", "text": "Methamphetamine 's extensive physiologic effects , inconsistent street purity , and multiple routes of administration offer many possibilities for injury to the cornea .", "tokens": ["Methamphetamine", "'s", "extensive", "physiologic", "effects", ",", "inconsistent", "street", "purity", ",", "and", "multiple", "routes", "of", "administration", "offer", "many", "possibilities", "for", "injury", "to", "the", "cornea", "."], "event_mentions": [{"id": "8862924_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "offer", "start": 15, "end": 16}, "arguments": [{"entity_id": "8862924_2_Ent0", "role": "Treatment", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent2", "role": "Treatment_Drug", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent1", "role": "Treatment_Disorder", "text": "injury to the cornea", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "8862924_2_Ent0", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent2", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent1", "text": "injury to the cornea", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "8862924_5", "wnd_id": "8862924_5_1", "text": "We report four cases of severe corneal ulceration in methamphetamine abusers .", "tokens": ["We", "report", "four", "cases", "of", "severe", "corneal", "ulceration", "in", "methamphetamine", "abusers", "."], "event_mentions": [{"id": "8862924_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "8862924_5_Ent1", "role": "Subject_Population", "text": "four", "start": 2, "end": 3}, {"entity_id": "8862924_5_Ent0", "role": "Subject", "text": "four cases", "start": 2, "end": 4}, {"entity_id": "8862924_5_Ent2", "role": "Effect", "text": "corneal ulceration", "start": 6, "end": 8}, {"entity_id": "8862924_5_Ent3", "role": "Treatment", "text": "methamphetamine", "start": 9, "end": 10}, {"entity_id": "8862924_5_Ent4", "role": "Treatment_Drug", "text": "methamphetamine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8862924_5_Ent1", "text": "four", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8862924_5_Ent0", "text": "four cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8862924_5_Ent2", "text": "corneal ulceration", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8862924_5_Ent3", "text": "methamphetamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8862924_5_Ent4", "text": "methamphetamine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8880251_3", "wnd_id": "8880251_3_1", "text": "This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger MH .", "tokens": ["This", "case", "supports", "the", "assessment", "that", "MH", "and", "diabetes", "are", "associated", "diseases", "and", "that", "cresol", "could", "possibly", "trigger", "MH", "."], "event_mentions": [{"id": "8880251_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 17, "end": 18}, "arguments": [{"entity_id": "8880251_3_Ent1", "role": "Treatment", "text": "cresol", "start": 14, "end": 15}, {"entity_id": "8880251_3_Ent2", "role": "Treatment_Drug", "text": "cresol", "start": 14, "end": 15}, {"entity_id": "8880251_3_Ent0", "role": "Effect", "text": "MH", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8880251_3_Ent1", "text": "cresol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8880251_3_Ent2", "text": "cresol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8880251_3_Ent0", "text": "MH", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "889156_1", "wnd_id": "889156_1_1", "text": "The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction .", "tokens": ["The", "use", "of", "beclomethasone", "diproprionate", "inhaler", "complicated", "by", "the", "development", "of", "an", "eosinophilic", "pneumonia", "reaction", "."], "event_mentions": [{"id": "889156_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "889156_1_Ent3", "role": "Treatment_Drug", "text": "beclomethasone diproprionate", "start": 3, "end": 5}, {"entity_id": "889156_1_Ent1", "role": "Treatment", "text": "beclomethasone diproprionate inhaler", "start": 3, "end": 6}, {"entity_id": "889156_1_Ent2", "role": "Treatment_Route", "text": "inhaler", "start": 5, "end": 6}, {"entity_id": "889156_1_Ent0", "role": "Effect", "text": "eosinophilic pneumonia reaction", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "889156_1_Ent3", "text": "beclomethasone diproprionate", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "889156_1_Ent1", "text": "beclomethasone diproprionate inhaler", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "889156_1_Ent2", "text": "inhaler", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "889156_1_Ent0", "text": "eosinophilic pneumonia reaction", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "889156_7", "wnd_id": "889156_7_1", "text": "While a lower systemic steroid dosage may have been the provoking factor , we feel that an adverse reaction to oleic acid , a dispersing agent in the aerosol freon vehicle , is a strong possibility .", "tokens": ["While", "a", "lower", "systemic", "steroid", "dosage", "may", "have", "been", "the", "provoking", "factor", ",", "we", "feel", "that", "an", "adverse", "reaction", "to", "oleic", "acid", ",", "a", "dispersing", "agent", "in", "the", "aerosol", "freon", "vehicle", ",", "is", "a", "strong", "possibility", "."], "event_mentions": [{"id": "889156_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 19, "end": 20}, "arguments": [{"entity_id": "889156_7_Ent0", "role": "Effect", "text": "adverse reaction", "start": 17, "end": 19}, {"entity_id": "889156_7_Ent1", "role": "Treatment", "text": "oleic acid", "start": 20, "end": 22}, {"entity_id": "889156_7_Ent2", "role": "Treatment_Drug", "text": "oleic acid", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "889156_7_Ent0", "text": "adverse reaction", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "889156_7_Ent1", "text": "oleic acid", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "889156_7_Ent2", "text": "oleic acid", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8903300_1", "wnd_id": "8903300_1_1", "text": "She had just finished a 3 - week course of intravenous tobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of tetany .", "tokens": ["She", "had", "just", "finished", "a", "3", "-", "week", "course", "of", "intravenous", "tobramycin", "for", "bronchiectasis", "and", "had", "an", "elevated", "serum", "tobramycin", "trough", "level", "1", "week", "before", "the", "onset", "of", "tetany", "."], "event_mentions": [{"id": "8903300_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 15, "end": 16}, "arguments": [{"entity_id": "8903300_1_Ent1", "role": "Treatment", "text": "a 3 - week course of intravenous tobramycin", "start": 4, "end": 12}, {"entity_id": "8903300_1_Ent3", "role": "Treatment_Duration", "text": "3 - week course", "start": 5, "end": 9}, {"entity_id": "8903300_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 10, "end": 11}, {"entity_id": "8903300_1_Ent2", "role": "Treatment_Drug", "text": "tobramycin", "start": 11, "end": 12}, {"entity_id": "8903300_1_Ent5", "role": "Treatment_Disorder", "text": "bronchiectasis", "start": 13, "end": 14}, {"entity_id": "8903300_1_Ent0", "role": "Effect", "text": "elevated serum tobramycin trough level 1 week before the onset of tetany", "start": 17, "end": 29}]}], "entity_mentions": [{"id": "8903300_1_Ent1", "text": "a 3 - week course of intravenous tobramycin", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "8903300_1_Ent3", "text": "3 - week course", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8903300_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8903300_1_Ent2", "text": "tobramycin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8903300_1_Ent5", "text": "bronchiectasis", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8903300_1_Ent0", "text": "elevated serum tobramycin trough level 1 week before the onset of tetany", "entity_type": "Entity", "start": 17, "end": 29}], "lang": "en"}
{"doc_id": "8908396_1", "wnd_id": "8908396_1_1", "text": "CONCLUSIONS : In our reported case , a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone .", "tokens": ["CONCLUSIONS", ":", "In", "our", "reported", "case", ",", "a", "local", "hyperproduction", "of", "TNF", "-", "alpha", "from", "macrophages", "that", "was", "induced", "by", "the", "injected", "insulin", "could", "explain", "the", "dedifferentiation", "of", "the", "adipocytes", "of", "the", "subcutaneous", "tissue", "and", "the", "reversion", "that", "was", "induced", "by", "the", "local", "injection", "of", "dexamethasone", "."], "event_mentions": [{"id": "8908396_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "8908396_1_Ent0", "role": "Subject", "text": "reported case", "start": 4, "end": 6}, {"entity_id": "8908396_1_Ent1", "role": "Effect", "text": "local hyperproduction of TNF - alpha from macrophages", "start": 8, "end": 16}, {"entity_id": "8908396_1_Ent4", "role": "Treatment_Route", "text": "injected", "start": 21, "end": 22}, {"entity_id": "8908396_1_Ent3", "role": "Treatment", "text": "injected insulin", "start": 21, "end": 23}, {"entity_id": "8908396_1_Ent5", "role": "Treatment_Drug", "text": "insulin", "start": 22, "end": 23}, {"entity_id": "8908396_1_Ent2", "role": "Effect", "text": "dedifferentiation of the adipocytes of the subcutaneous tissue", "start": 26, "end": 34}]}], "entity_mentions": [{"id": "8908396_1_Ent0", "text": "reported case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8908396_1_Ent1", "text": "local hyperproduction of TNF - alpha from macrophages", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "8908396_1_Ent4", "text": "injected", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8908396_1_Ent3", "text": "injected insulin", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8908396_1_Ent5", "text": "insulin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8908396_1_Ent2", "text": "dedifferentiation of the adipocytes of the subcutaneous tissue", "entity_type": "Entity", "start": 26, "end": 34}], "lang": "en"}
{"doc_id": "8908396_3", "wnd_id": "8908396_3_1", "text": "OBJECTIVE : To test the hypothesis that tumor necrosis factor ( TNF) - alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin - induced lipoatrophies of a diabetic patient who presented extensive lesions .", "tokens": ["OBJECTIVE", ":", "To", "test", "the", "hypothesis", "that", "tumor", "necrosis", "factor", "(", "TNF)", "-", "alpha", "may", "mediate", "the", "loss", "and", "the", "dedifferentiation", "of", "subcutaneous", "fat", "tissue", "in", "the", "insulin", "-", "induced", "lipoatrophies", "of", "a", "diabetic", "patient", "who", "presented", "extensive", "lesions", "."], "event_mentions": [{"id": "8908396_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 29, "end": 30}, "arguments": [{"entity_id": "8908396_3_Ent1", "role": "Treatment", "text": "insulin", "start": 27, "end": 28}, {"entity_id": "8908396_3_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 27, "end": 28}, {"entity_id": "8908396_3_Ent0", "role": "Effect", "text": "lipoatrophies", "start": 30, "end": 31}, {"entity_id": "8908396_3_Ent3", "role": "Treatment_Disorder", "text": "diabetic", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "8908396_3_Ent1", "text": "insulin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8908396_3_Ent2", "text": "insulin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8908396_3_Ent0", "text": "lipoatrophies", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "8908396_3_Ent3", "text": "diabetic", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "8912599_6", "wnd_id": "8912599_6_1", "text": "Erosion of psoriatic plaques : an early sign of methotrexate toxicity .", "tokens": ["Erosion", "of", "psoriatic", "plaques", ":", "an", "early", "sign", "of", "methotrexate", "toxicity", "."], "event_mentions": [{"id": "8912599_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "8912599_6_Ent0", "role": "Effect", "text": "Erosion of psoriatic plaques", "start": 0, "end": 4}, {"entity_id": "8912599_6_Ent1", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "8912599_6_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8912599_6_Ent0", "text": "Erosion of psoriatic plaques", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8912599_6_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8912599_6_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8912599_8", "wnd_id": "8912599_8_1", "text": "Well - known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration .", "tokens": ["Well", "-", "known", "signs", "of", "methotrexate", "toxicity", "include", "bone", "marrow", "suppression", "and", "oral", "and", "gastrointestinal", "ulceration", "."], "event_mentions": [{"id": "8912599_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "signs", "start": 3, "end": 4}, "arguments": [{"entity_id": "8912599_8_Ent1", "role": "Treatment", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "8912599_8_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "8912599_8_Ent0", "role": "Effect", "text": "bone marrow suppression and oral and gastrointestinal ulceration", "start": 8, "end": 16}]}], "entity_mentions": [{"id": "8912599_8_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8912599_8_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8912599_8_Ent0", "text": "bone marrow suppression and oral and gastrointestinal ulceration", "entity_type": "Entity", "start": 8, "end": 16}], "lang": "en"}
{"doc_id": "8921647_1", "wnd_id": "8921647_1_1", "text": "After treatment with cimetidine , there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values .", "tokens": ["After", "treatment", "with", "cimetidine", ",", "there", "was", "a", "rapid", "deterioration", "with", "decreased", "oxygen", "saturation", "and", "arterial", "PO2", "values", "."], "event_mentions": [{"id": "8921647_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "was", "start": 6, "end": 7}, "arguments": [{"entity_id": "8921647_1_Ent1", "role": "Treatment", "text": "cimetidine", "start": 3, "end": 4}, {"entity_id": "8921647_1_Ent2", "role": "Treatment_Drug", "text": "cimetidine", "start": 3, "end": 4}, {"entity_id": "8921647_1_Ent0", "role": "Effect", "text": "a rapid deterioration with decreased oxygen saturation and arterial PO2 values", "start": 7, "end": 18}]}], "entity_mentions": [{"id": "8921647_1_Ent1", "text": "cimetidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8921647_1_Ent2", "text": "cimetidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8921647_1_Ent0", "text": "a rapid deterioration with decreased oxygen saturation and arterial PO2 values", "entity_type": "Entity", "start": 7, "end": 18}], "lang": "en"}
{"doc_id": "8926752_1", "wnd_id": "8926752_1_1", "text": "Zolpidem ( Ambien ) , a relatively new nonbenzodiazepine sedative - hypnotic , was involved in the death of a 39 - year - old obese male who was being treated for depression and insomnia .", "tokens": ["Zolpidem", "(", "Ambien", ")", ",", "a", "relatively", "new", "nonbenzodiazepine", "sedative", "-", "hypnotic", ",", "was", "involved", "in", "the", "death", "of", "a", "39", "-", "year", "-", "old", "obese", "male", "who", "was", "being", "treated", "for", "depression", "and", "insomnia", "."], "event_mentions": [{"id": "8926752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involved", "start": 14, "end": 15}, "arguments": [{"entity_id": "8926752_1_Ent7", "role": "Treatment_Drug", "text": "Zolpidem", "start": 0, "end": 1}, {"entity_id": "8926752_1_Ent5", "role": "Treatment", "text": "Zolpidem ( Ambien )", "start": 0, "end": 4}, {"entity_id": "8926752_1_Ent4", "role": "Effect", "text": "death", "start": 17, "end": 18}, {"entity_id": "8926752_1_Ent0", "role": "Subject", "text": "a 39 - year - old obese male", "start": 19, "end": 27}, {"entity_id": "8926752_1_Ent1", "role": "Subject_Age", "text": "39 - year - old", "start": 20, "end": 25}, {"entity_id": "8926752_1_Ent2", "role": "Subject_Disorder", "text": "obese", "start": 25, "end": 26}, {"entity_id": "8926752_1_Ent3", "role": "Subject_Gender", "text": "male", "start": 26, "end": 27}, {"entity_id": "8926752_1_Ent6", "role": "Treatment_Disorder", "text": "depression and insomnia", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "8926752_1_Ent7", "text": "Zolpidem", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8926752_1_Ent5", "text": "Zolpidem ( Ambien )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8926752_1_Ent4", "text": "death", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8926752_1_Ent0", "text": "a 39 - year - old obese male", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "8926752_1_Ent1", "text": "39 - year - old", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "8926752_1_Ent2", "text": "obese", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "8926752_1_Ent3", "text": "male", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "8926752_1_Ent6", "text": "depression and insomnia", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "8949576_1", "wnd_id": "8949576_1_1", "text": "A potential role for renal and hepatic impairment in the observed protracted course of amiodarone - induced thyrotoxicosis is suggested .", "tokens": ["A", "potential", "role", "for", "renal", "and", "hepatic", "impairment", "in", "the", "observed", "protracted", "course", "of", "amiodarone", "-", "induced", "thyrotoxicosis", "is", "suggested", "."], "event_mentions": [{"id": "8949576_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "8949576_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent0", "role": "Effect", "text": "thyrotoxicosis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8949576_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent0", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8949576_2", "wnd_id": "8949576_2_1", "text": "Failure of plasmapheresis , corticosteroids and thionamides to ameliorate a case of protracted amiodarone - induced thyroiditis .", "tokens": ["Failure", "of", "plasmapheresis", ",", "corticosteroids", "and", "thionamides", "to", "ameliorate", "a", "case", "of", "protracted", "amiodarone", "-", "induced", "thyroiditis", "."], "event_mentions": [{"id": "8949576_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorate", "start": 8, "end": 9}, "arguments": [{"entity_id": "8949576_2_Ent3", "role": "Treatment", "text": "plasmapheresis , corticosteroids and thionamides", "start": 2, "end": 7}, {"entity_id": "8949576_2_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 4, "end": 5}, {"entity_id": "8949576_2_Ent6", "role": "Treatment_Drug", "text": "thionamides", "start": 6, "end": 7}, {"entity_id": "8949576_2_Ent4", "role": "Treatment_Disorder", "text": "amiodarone - induced thyroiditis", "start": 13, "end": 17}]}, {"id": "8949576_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "8949576_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "8949576_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "8949576_2_Ent0", "role": "Effect", "text": "thyroiditis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "8949576_2_Ent3", "text": "plasmapheresis , corticosteroids and thionamides", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "8949576_2_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8949576_2_Ent6", "text": "thionamides", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8949576_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8949576_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8949576_2_Ent4", "text": "amiodarone - induced thyroiditis", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "8949576_2_Ent0", "text": "thyroiditis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "8979664_1", "wnd_id": "8979664_1_1", "text": "METHODS / RESULTS : This paper presents a new case of rifabutin uveitis and a review of the various published reports to date .", "tokens": ["METHODS", "/", "RESULTS", ":", "This", "paper", "presents", "a", "new", "case", "of", "rifabutin", "uveitis", "and", "a", "review", "of", "the", "various", "published", "reports", "to", "date", "."], "event_mentions": [{"id": "8979664_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presents", "start": 6, "end": 7}, "arguments": [{"entity_id": "8979664_1_Ent0", "role": "Subject", "text": "new case", "start": 8, "end": 10}, {"entity_id": "8979664_1_Ent2", "role": "Treatment", "text": "rifabutin", "start": 11, "end": 12}, {"entity_id": "8979664_1_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 11, "end": 12}, {"entity_id": "8979664_1_Ent1", "role": "Effect", "text": "uveitis", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8979664_1_Ent0", "text": "new case", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8979664_1_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8979664_1_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8979664_1_Ent1", "text": "uveitis", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8996514_1", "wnd_id": "8996514_1_1", "text": "CASE DESCRIPTION : A 59 - year - old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy .", "tokens": ["CASE", "DESCRIPTION", ":", "A", "59", "-", "year", "-", "old", "man", "with", "known", "neurocysticercosis", "developed", "a", "large", "cerebral", "infarction", "during", "praziquantel", "therapy", "."], "event_mentions": [{"id": "8996514_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "8996514_1_Ent0", "role": "Subject", "text": "A 59 - year - old man with known neurocysticercosis", "start": 3, "end": 13}, {"entity_id": "8996514_1_Ent1", "role": "Subject_Age", "text": "59 - year - old", "start": 4, "end": 9}, {"entity_id": "8996514_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "8996514_1_Ent5", "role": "Treatment_Disorder", "text": "neurocysticercosis", "start": 12, "end": 13}, {"entity_id": "8996514_1_Ent3", "role": "Effect", "text": "a large cerebral infarction", "start": 14, "end": 18}, {"entity_id": "8996514_1_Ent4", "role": "Treatment", "text": "during praziquantel therapy", "start": 18, "end": 21}, {"entity_id": "8996514_1_Ent6", "role": "Treatment_Drug", "text": "praziquantel", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "8996514_1_Ent0", "text": "A 59 - year - old man with known neurocysticercosis", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "8996514_1_Ent1", "text": "59 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "8996514_1_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8996514_1_Ent5", "text": "neurocysticercosis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8996514_1_Ent3", "text": "a large cerebral infarction", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8996514_1_Ent4", "text": "during praziquantel therapy", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8996514_1_Ent6", "text": "praziquantel", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9007910_2", "wnd_id": "9007910_2_1", "text": "PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency , which predisposes patients with cancer to potentially lethal adverse reactions following 5 - fluorouracil ( 5 - FU) - based chemotherapy .", "tokens": ["PURPOSE", "/", "OBJECTIVES", ":", "To", "describe", "the", "pharmacogenetic", "syndrome", "of", "dihydropyrimidine", "dehydrogenase", "(", "DPD", ")", "deficiency", ",", "which", "predisposes", "patients", "with", "cancer", "to", "potentially", "lethal", "adverse", "reactions", "following", "5", "-", "fluorouracil", "(", "5", "-", "FU)", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "9007910_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "predisposes", "start": 18, "end": 19}, "arguments": [{"entity_id": "9007910_2_Ent0", "role": "Subject", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "start": 10, "end": 16}, {"entity_id": "9007910_2_Ent1", "role": "Subject_Disorder", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "start": 10, "end": 16}, {"entity_id": "9007910_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 21, "end": 22}, {"entity_id": "9007910_2_Ent2", "role": "Effect", "text": "lethal adverse reactions", "start": 24, "end": 27}, {"entity_id": "9007910_2_Ent5", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 28, "end": 31}, {"entity_id": "9007910_2_Ent3", "role": "Treatment", "text": "5 - fluorouracil ( 5 - FU) - based chemotherapy", "start": 28, "end": 38}, {"entity_id": "9007910_2_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "9007910_2_Ent0", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9007910_2_Ent1", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9007910_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9007910_2_Ent2", "text": "lethal adverse reactions", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "9007910_2_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "9007910_2_Ent3", "text": "5 - fluorouracil ( 5 - FU) - based chemotherapy", "entity_type": "Entity", "start": 28, "end": 38}, {"id": "9007910_2_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "9039216_2", "wnd_id": "9039216_2_1", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis : a severe adverse reaction to minocycline .", "tokens": ["Fever", ",", "lymphadenopathy", ",", "eosinophilia", ",", "lymphocytosis", ",", "hepatitis", ",", "and", "dermatitis", ":", "a", "severe", "adverse", "reaction", "to", "minocycline", "."], "event_mentions": [{"id": "9039216_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 15, "end": 17}, "arguments": [{"entity_id": "9039216_2_Ent0", "role": "Effect", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis", "start": 0, "end": 12}, {"entity_id": "9039216_2_Ent1", "role": "Treatment", "text": "minocycline", "start": 18, "end": 19}, {"entity_id": "9039216_2_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9039216_2_Ent0", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9039216_2_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9039216_2_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9100429_1", "wnd_id": "9100429_1_1", "text": "Case study : adverse response to clonidine .", "tokens": ["Case", "study", ":", "adverse", "response", "to", "clonidine", "."], "event_mentions": [{"id": "9100429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "9100429_1_Ent0", "role": "Effect", "text": "adverse response", "start": 3, "end": 5}, {"entity_id": "9100429_1_Ent1", "role": "Treatment", "text": "clonidine", "start": 6, "end": 7}, {"entity_id": "9100429_1_Ent2", "role": "Treatment_Drug", "text": "clonidine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9100429_1_Ent0", "text": "adverse response", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9100429_1_Ent1", "text": "clonidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9100429_1_Ent2", "text": "clonidine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "910864_1", "wnd_id": "910864_1_1", "text": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide .", "tokens": ["In", "one", "instance", "a", "systemic", "hypoglycemic", "reaction", "resulting", "in", "head", "trauma", "and", "confusion", "ended", "in", "an", "emegency", "hospital", "admission", "following", "the", "substitution", "of", "acetohexamide", "for", "acetazolamide", "."], "event_mentions": [{"id": "910864_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 19, "end": 20}, "arguments": [{"entity_id": "910864_1_Ent0", "role": "Effect", "text": "systemic hypoglycemic reaction resulting in head trauma and confusion", "start": 4, "end": 13}, {"entity_id": "910864_1_Ent1", "role": "Treatment", "text": "acetohexamide", "start": 23, "end": 24}, {"entity_id": "910864_1_Ent2", "role": "Treatment_Drug", "text": "acetohexamide", "start": 23, "end": 24}, {"entity_id": "910864_1_Ent3", "role": "Treatment_Drug", "text": "acetazolamide", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "910864_1_Ent0", "text": "systemic hypoglycemic reaction resulting in head trauma and confusion", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "910864_1_Ent1", "text": "acetohexamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "910864_1_Ent2", "text": "acetohexamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "910864_1_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9111724_1", "wnd_id": "9111724_1_1", "text": "Discontinuation of the itraconazole caused resolution of the drug eruption .", "tokens": ["Discontinuation", "of", "the", "itraconazole", "caused", "resolution", "of", "the", "drug", "eruption", "."], "event_mentions": [{"id": "9111724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "9111724_1_Ent1", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "9111724_1_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "9111724_1_Ent0", "role": "Effect", "text": "drug eruption", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9111724_1_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9111724_1_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9111724_1_Ent0", "text": "drug eruption", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9128433_1", "wnd_id": "9128433_1_1", "text": "Its overall toxicity is considerably less compared to standard induction chemotherapy ; however , it is associated with a high incidence of a potentially fatal symptom complex referred to as \" retinoic acid syndrome . \" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis .", "tokens": ["Its", "overall", "toxicity", "is", "considerably", "less", "compared", "to", "standard", "induction", "chemotherapy", ";", "however", ",", "it", "is", "associated", "with", "a", "high", "incidence", "of", "a", "potentially", "fatal", "symptom", "complex", "referred", "to", "as", "\"", "retinoic", "acid", "syndrome", ".", "\"", "This", "report", "describes", "a", "patient", "with", "APL", "who", "developed", "the", "syndrome", "a", "few", "weeks", "after", "initiating", "induction", "therapy", "with", "ATRA", "despite", "being", "treated", "for", "hyperleukocytosis", "."], "event_mentions": [{"id": "9128433_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 44, "end": 45}, "arguments": [{"entity_id": "9128433_1_Ent1", "role": "Effect", "text": "symptom complex referred to as \" retinoic acid syndrome . \"", "start": 25, "end": 36}, {"entity_id": "9128433_1_Ent0", "role": "Subject", "text": "a patient with APL", "start": 39, "end": 43}, {"entity_id": "9128433_1_Ent5", "role": "Treatment_Disorder", "text": "APL", "start": 42, "end": 43}, {"entity_id": "9128433_1_Ent4", "role": "Treatment_Time_elapsed", "text": "a few weeks", "start": 47, "end": 50}, {"entity_id": "9128433_1_Ent2", "role": "Treatment", "text": "a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis", "start": 47, "end": 61}, {"entity_id": "9128433_1_Ent3", "role": "Treatment_Drug", "text": "ATRA", "start": 55, "end": 56}]}], "entity_mentions": [{"id": "9128433_1_Ent1", "text": "symptom complex referred to as \" retinoic acid syndrome . \"", "entity_type": "Entity", "start": 25, "end": 36}, {"id": "9128433_1_Ent0", "text": "a patient with APL", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "9128433_1_Ent5", "text": "APL", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "9128433_1_Ent4", "text": "a few weeks", "entity_type": "Entity", "start": 47, "end": 50}, {"id": "9128433_1_Ent2", "text": "a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis", "entity_type": "Entity", "start": 47, "end": 61}, {"id": "9128433_1_Ent3", "text": "ATRA", "entity_type": "Entity", "start": 55, "end": 56}], "lang": "en"}
{"doc_id": "9149614_1", "wnd_id": "9149614_1_1", "text": "Eleven days after initiation of therapy with amiodarone , the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia .", "tokens": ["Eleven", "days", "after", "initiation", "of", "therapy", "with", "amiodarone", ",", "the", "patient", "experienced", "syncope", "and", "was", "noted", "to", "have", "recurrent", "episodes", "of", "polymorphous", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "9149614_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 11, "end": 12}, "arguments": [{"entity_id": "9149614_1_Ent3", "role": "Treatment_Time_elapsed", "text": "Eleven days after", "start": 0, "end": 3}, {"entity_id": "9149614_1_Ent2", "role": "Treatment", "text": "Eleven days after initiation of therapy with amiodarone", "start": 0, "end": 8}, {"entity_id": "9149614_1_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "9149614_1_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "9149614_1_Ent1", "role": "Effect", "text": "syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia", "start": 12, "end": 24}]}], "entity_mentions": [{"id": "9149614_1_Ent3", "text": "Eleven days after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9149614_1_Ent2", "text": "Eleven days after initiation of therapy with amiodarone", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9149614_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9149614_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9149614_1_Ent1", "text": "syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia", "entity_type": "Entity", "start": 12, "end": 24}], "lang": "en"}
{"doc_id": "9161656_15", "wnd_id": "9161656_15_1", "text": "CONCLUSIONS : Sustained - release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained - release verapamil and were relieved after its discontinuation .", "tokens": ["CONCLUSIONS", ":", "Sustained", "-", "release", "verapamil", "is", "thought", "to", "be", "the", "cause", "of", "the", "asthma", "attack", "in", "this", "patient", "because", "she", "was", "not", "taking", "any", "other", "preparations", ";", "the", "symptoms", "started", "with", "the", "administration", "of", "sustained", "-", "release", "verapamil", "and", "were", "relieved", "after", "its", "discontinuation", "."], "event_mentions": [{"id": "9161656_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "9161656_15_Ent1", "role": "Treatment", "text": "Sustained - release verapamil", "start": 2, "end": 6}, {"entity_id": "9161656_15_Ent2", "role": "Treatment_Drug", "text": "verapamil", "start": 5, "end": 6}, {"entity_id": "9161656_15_Ent0", "role": "Effect", "text": "asthma attack", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "9161656_15_Ent1", "text": "Sustained - release verapamil", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9161656_15_Ent2", "text": "verapamil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9161656_15_Ent0", "text": "asthma attack", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "9169264_1", "wnd_id": "9169264_1_1", "text": "Cephalexin rash in infectious mononucleosis .", "tokens": ["Cephalexin", "rash", "in", "infectious", "mononucleosis", "."], "event_mentions": [{"id": "9169264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "9169264_1_Ent1", "role": "Treatment", "text": "Cephalexin", "start": 0, "end": 1}, {"entity_id": "9169264_1_Ent2", "role": "Treatment_Drug", "text": "Cephalexin", "start": 0, "end": 1}, {"entity_id": "9169264_1_Ent0", "role": "Effect", "text": "Cephalexin rash", "start": 0, "end": 2}, {"entity_id": "9169264_1_Ent3", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9169264_1_Ent1", "text": "Cephalexin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9169264_1_Ent2", "text": "Cephalexin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9169264_1_Ent0", "text": "Cephalexin rash", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9169264_1_Ent3", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9177620_3", "wnd_id": "9177620_3_1", "text": "The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of acute pancreatitis .", "tokens": ["The", "evidence", "of", "high", "plasmatic", "levels", "of", "CBZ", "and", "the", "absence", "of", "other", "aetiologic", "factors", "lead", "the", "authors", "to", "conclude", "that", "the", "overdose", "of", "CBZ", "could", "have", "represented", "the", "precipitating", "of", "the", "episode", "of", "acute", "pancreatitis", "."], "event_mentions": [{"id": "9177620_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitating", "start": 29, "end": 30}, "arguments": [{"entity_id": "9177620_3_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 7, "end": 8}, {"entity_id": "9177620_3_Ent1", "role": "Treatment", "text": "overdose of CBZ", "start": 22, "end": 25}, {"entity_id": "9177620_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 34, "end": 36}]}], "entity_mentions": [{"id": "9177620_3_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9177620_3_Ent1", "text": "overdose of CBZ", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "9177620_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 34, "end": 36}], "lang": "en"}
{"doc_id": "9184269_2", "wnd_id": "9184269_2_1", "text": "Methotrexate - induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis : report of five cases and review of the literature .", "tokens": ["Methotrexate", "-", "induced", "pneumonitis", "in", "patients", "with", "rheumatoid", "arthritis", "and", "psoriatic", "arthritis", ":", "report", "of", "five", "cases", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "9184269_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9184269_2_Ent2", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9184269_2_Ent5", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9184269_2_Ent1", "role": "Effect", "text": "pneumonitis", "start": 3, "end": 4}, {"entity_id": "9184269_2_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis and psoriatic arthritis", "start": 5, "end": 12}, {"entity_id": "9184269_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}, {"entity_id": "9184269_2_Ent4", "role": "Treatment_Disorder", "text": "psoriatic arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "9184269_2_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9184269_2_Ent5", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9184269_2_Ent1", "text": "pneumonitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9184269_2_Ent0", "text": "patients with rheumatoid arthritis and psoriatic arthritis", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "9184269_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9184269_2_Ent4", "text": "psoriatic arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "9184269_3", "wnd_id": "9184269_3_1", "text": "On the other hand , MTX - induced pneumonitis seems to be very rare in psoriatic arthritis ( PsA ) .", "tokens": ["On", "the", "other", "hand", ",", "MTX", "-", "induced", "pneumonitis", "seems", "to", "be", "very", "rare", "in", "psoriatic", "arthritis", "(", "PsA", ")", "."], "event_mentions": [{"id": "9184269_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "9184269_3_Ent1", "role": "Treatment", "text": "MTX", "start": 5, "end": 6}, {"entity_id": "9184269_3_Ent2", "role": "Treatment_Drug", "text": "MTX", "start": 5, "end": 6}, {"entity_id": "9184269_3_Ent0", "role": "Effect", "text": "pneumonitis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9184269_3_Ent1", "text": "MTX", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9184269_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9184269_3_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9220046_3", "wnd_id": "9220046_3_1", "text": "DISCUSSION : Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis , including lovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor .", "tokens": ["DISCUSSION", ":", "Rhabdomyolysis", "is", "a", "clinical", "syndrome", "resulting", "from", "the", "destruction", "of", "skeletal", "muscle", "that", "may", "progress", "to", "renal", "failure", "Several", "drugs", "have", "been", "associated", "with", "rhabdomyolysis", ",", "including", "lovastatin", ",", "a", "hydroxymethylglutaryl", "-", "coenzyme", "A", "reductase", "inhibitor", "."], "event_mentions": [{"id": "9220046_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 24, "end": 25}, "arguments": [{"entity_id": "9220046_3_Ent0", "role": "Effect", "text": "Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure", "start": 2, "end": 20}, {"entity_id": "9220046_3_Ent2", "role": "Treatment_Drug", "text": "lovastatin", "start": 29, "end": 30}, {"entity_id": "9220046_3_Ent1", "role": "Treatment", "text": "lovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor", "start": 29, "end": 38}]}], "entity_mentions": [{"id": "9220046_3_Ent0", "text": "Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure", "entity_type": "Entity", "start": 2, "end": 20}, {"id": "9220046_3_Ent2", "text": "lovastatin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "9220046_3_Ent1", "text": "lovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor", "entity_type": "Entity", "start": 29, "end": 38}], "lang": "en"}
{"doc_id": "9232614_2", "wnd_id": "9232614_2_1", "text": "Tamoxifen is suggested to be carcinogenic both through direct genotoxic and epigenetic mechanisms .", "tokens": ["Tamoxifen", "is", "suggested", "to", "be", "carcinogenic", "both", "through", "direct", "genotoxic", "and", "epigenetic", "mechanisms", "."], "event_mentions": [{"id": "9232614_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suggested", "start": 2, "end": 3}, "arguments": [{"entity_id": "9232614_2_Ent1", "role": "Treatment", "text": "Tamoxifen", "start": 0, "end": 1}, {"entity_id": "9232614_2_Ent2", "role": "Treatment_Drug", "text": "Tamoxifen", "start": 0, "end": 1}, {"entity_id": "9232614_2_Ent0", "role": "Effect", "text": "carcinogenic both through direct genotoxic and epigenetic mechanisms", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "9232614_2_Ent1", "text": "Tamoxifen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9232614_2_Ent2", "text": "Tamoxifen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9232614_2_Ent0", "text": "carcinogenic both through direct genotoxic and epigenetic mechanisms", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "9240497_1", "wnd_id": "9240497_1_1", "text": "Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all - trans retinoic acid .", "tokens": ["Relapse", "in", "the", "external", "auditory", "canal", "of", "acute", "promyelocytic", "leukemia", "after", "treatment", "with", "all", "-", "trans", "retinoic", "acid", "."], "event_mentions": [{"id": "9240497_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "9240497_1_Ent0", "role": "Effect", "text": "Relapse in the external auditory canal of acute promyelocytic leukemia", "start": 0, "end": 10}, {"entity_id": "9240497_1_Ent1", "role": "Treatment", "text": "treatment with all - trans retinoic acid", "start": 11, "end": 18}, {"entity_id": "9240497_1_Ent2", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "9240497_1_Ent0", "text": "Relapse in the external auditory canal of acute promyelocytic leukemia", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "9240497_1_Ent1", "text": "treatment with all - trans retinoic acid", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "9240497_1_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "9247841_1", "wnd_id": "9247841_1_1", "text": "Propylthiouracil - induced cutaneous vasculitis .", "tokens": ["Propylthiouracil", "-", "induced", "cutaneous", "vasculitis", "."], "event_mentions": [{"id": "9247841_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9247841_1_Ent1", "role": "Treatment", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "9247841_1_Ent2", "role": "Treatment_Drug", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "9247841_1_Ent0", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9247841_1_Ent1", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9247841_1_Ent2", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9247841_1_Ent0", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9253492_3", "wnd_id": "9253492_3_1", "text": "Heat stroke - like episode in a child caused by zonisamide .", "tokens": ["Heat", "stroke", "-", "like", "episode", "in", "a", "child", "caused", "by", "zonisamide", "."], "event_mentions": [{"id": "9253492_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "9253492_3_Ent2", "role": "Effect", "text": "Heat stroke - like episode", "start": 0, "end": 5}, {"entity_id": "9253492_3_Ent0", "role": "Subject", "text": "a child", "start": 6, "end": 8}, {"entity_id": "9253492_3_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}, {"entity_id": "9253492_3_Ent3", "role": "Treatment", "text": "zonisamide", "start": 10, "end": 11}, {"entity_id": "9253492_3_Ent4", "role": "Treatment_Drug", "text": "zonisamide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "9253492_3_Ent2", "text": "Heat stroke - like episode", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9253492_3_Ent0", "text": "a child", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9253492_3_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9253492_3_Ent3", "text": "zonisamide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9253492_3_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "9253492_4", "wnd_id": "9253492_4_1", "text": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration .", "tokens": ["The", "oligohidrosis", "caused", "by", "zonisamide", "was", "reversible", "in", "that", "the", "patient", "regained", "the", "ability", "to", "sweat", "within", "2", "weeks", "of", "the", "cessation", "of", "drug", "administration", "."], "event_mentions": [{"id": "9253492_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "of the", "start": 19, "end": 21}, "arguments": [{"entity_id": "9253492_4_Ent2", "role": "Treatment", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "9253492_4_Ent4", "role": "Treatment_Drug", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "9253492_4_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "9253492_4_Ent1", "role": "Effect", "text": "regained the ability to sweat within 2 weeks", "start": 11, "end": 19}, {"entity_id": "9253492_4_Ent6", "role": "Treatment_Time_elapsed", "text": "within 2 weeks", "start": 16, "end": 19}, {"entity_id": "9253492_4_Ent5", "role": "Treatment_Dosage", "text": "cessation", "start": 21, "end": 22}, {"entity_id": "9253492_4_Ent3", "role": "Treatment", "text": "cessation of drug administration", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "9253492_4_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9253492_4_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9253492_4_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9253492_4_Ent1", "text": "regained the ability to sweat within 2 weeks", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "9253492_4_Ent6", "text": "within 2 weeks", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9253492_4_Ent5", "text": "cessation", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9253492_4_Ent3", "text": "cessation of drug administration", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "9302445_1", "wnd_id": "9302445_1_1", "text": "CONCLUSION : We believe this to be the first reported case of rhGH - induced hypercalcemia in an HIV - infected patient .", "tokens": ["CONCLUSION", ":", "We", "believe", "this", "to", "be", "the", "first", "reported", "case", "of", "rhGH", "-", "induced", "hypercalcemia", "in", "an", "HIV", "-", "infected", "patient", "."], "event_mentions": [{"id": "9302445_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9302445_1_Ent2", "role": "Treatment", "text": "rhGH", "start": 12, "end": 13}, {"entity_id": "9302445_1_Ent3", "role": "Treatment_Drug", "text": "rhGH", "start": 12, "end": 13}, {"entity_id": "9302445_1_Ent1", "role": "Effect", "text": "hypercalcemia", "start": 15, "end": 16}, {"entity_id": "9302445_1_Ent0", "role": "Subject", "text": "an HIV - infected patient", "start": 17, "end": 22}, {"entity_id": "9302445_1_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9302445_1_Ent2", "text": "rhGH", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9302445_1_Ent3", "text": "rhGH", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9302445_1_Ent1", "text": "hypercalcemia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9302445_1_Ent0", "text": "an HIV - infected patient", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "9302445_1_Ent4", "text": "HIV", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9302445_2", "wnd_id": "9302445_2_1", "text": "Hypercalcemia in an AIDS patient treated with growth hormone .", "tokens": ["Hypercalcemia", "in", "an", "AIDS", "patient", "treated", "with", "growth", "hormone", "."], "event_mentions": [{"id": "9302445_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "9302445_2_Ent1", "role": "Effect", "text": "Hypercalcemia", "start": 0, "end": 1}, {"entity_id": "9302445_2_Ent0", "role": "Subject", "text": "an AIDS patient", "start": 2, "end": 5}, {"entity_id": "9302445_2_Ent3", "role": "Treatment_Disorder", "text": "AIDS", "start": 3, "end": 4}, {"entity_id": "9302445_2_Ent2", "role": "Treatment", "text": "growth hormone", "start": 7, "end": 9}, {"entity_id": "9302445_2_Ent4", "role": "Treatment_Drug", "text": "growth hormone", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9302445_2_Ent1", "text": "Hypercalcemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9302445_2_Ent0", "text": "an AIDS patient", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9302445_2_Ent3", "text": "AIDS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9302445_2_Ent2", "text": "growth hormone", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9302445_2_Ent4", "text": "growth hormone", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9302445_3", "wnd_id": "9302445_3_1", "text": "The hypercalcemia responded to discontinuation of rhGH and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow - up .", "tokens": ["The", "hypercalcemia", "responded", "to", "discontinuation", "of", "rhGH", "and", "a", "single", "dose", "of", "intravenous", "pamidronate", "disodium", "and", "has", "not", "recurred", "in", "8", "months", "of", "follow", "-", "up", "."], "event_mentions": [{"id": "9302445_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 2, "end": 3}, "arguments": [{"entity_id": "9302445_3_Ent2", "role": "Treatment_Disorder", "text": "hypercalcemia", "start": 1, "end": 2}, {"entity_id": "9302445_3_Ent1", "role": "Treatment", "text": "discontinuation of rhGH and a single dose of intravenous pamidronate disodium", "start": 4, "end": 15}, {"entity_id": "9302445_3_Ent3", "role": "Treatment_Drug", "text": "rhGH", "start": 6, "end": 7}, {"entity_id": "9302445_3_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 12, "end": 13}, {"entity_id": "9302445_3_Ent4", "role": "Treatment_Drug", "text": "pamidronate disodium", "start": 13, "end": 15}, {"entity_id": "9302445_3_Ent0", "role": "Effect", "text": "has not recurred in 8 months of follow - up", "start": 16, "end": 26}]}], "entity_mentions": [{"id": "9302445_3_Ent2", "text": "hypercalcemia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9302445_3_Ent1", "text": "discontinuation of rhGH and a single dose of intravenous pamidronate disodium", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "9302445_3_Ent3", "text": "rhGH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9302445_3_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9302445_3_Ent4", "text": "pamidronate disodium", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9302445_3_Ent0", "text": "has not recurred in 8 months of follow - up", "entity_type": "Entity", "start": 16, "end": 26}], "lang": "en"}
{"doc_id": "9337441_1", "wnd_id": "9337441_1_1", "text": "Phenolphthalein - induced toxic epidermal necrolysis .", "tokens": ["Phenolphthalein", "-", "induced", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "9337441_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9337441_1_Ent1", "role": "Treatment", "text": "Phenolphthalein", "start": 0, "end": 1}, {"entity_id": "9337441_1_Ent2", "role": "Treatment_Drug", "text": "Phenolphthalein", "start": 0, "end": 1}, {"entity_id": "9337441_1_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "9337441_1_Ent1", "text": "Phenolphthalein", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9337441_1_Ent2", "text": "Phenolphthalein", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9337441_1_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "9337441_16", "wnd_id": "9337441_16_1", "text": "The patient 's previous rash and the temporal relation of this event and the ingestion of phenolphthalein , as well as the similarity of this case to other reports , point to phenolphthalein as the cause of TEN in this patient .", "tokens": ["The", "patient", "'s", "previous", "rash", "and", "the", "temporal", "relation", "of", "this", "event", "and", "the", "ingestion", "of", "phenolphthalein", ",", "as", "well", "as", "the", "similarity", "of", "this", "case", "to", "other", "reports", ",", "point", "to", "phenolphthalein", "as", "the", "cause", "of", "TEN", "in", "this", "patient", "."], "event_mentions": [{"id": "9337441_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 35, "end": 36}, "arguments": [{"entity_id": "9337441_16_Ent0", "role": "Subject", "text": "The patient 's previous rash", "start": 0, "end": 5}, {"entity_id": "9337441_16_Ent1", "role": "Subject_Disorder", "text": "rash", "start": 4, "end": 5}, {"entity_id": "9337441_16_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 14, "end": 15}, {"entity_id": "9337441_16_Ent3", "role": "Treatment", "text": "ingestion of phenolphthalein", "start": 14, "end": 17}, {"entity_id": "9337441_16_Ent4", "role": "Treatment_Drug", "text": "phenolphthalein", "start": 16, "end": 17}, {"entity_id": "9337441_16_Ent2", "role": "Effect", "text": "TEN", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "9337441_16_Ent0", "text": "The patient 's previous rash", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9337441_16_Ent1", "text": "rash", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9337441_16_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9337441_16_Ent3", "text": "ingestion of phenolphthalein", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "9337441_16_Ent4", "text": "phenolphthalein", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9337441_16_Ent2", "text": "TEN", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "9360190_2", "wnd_id": "9360190_2_1", "text": "Magnesium tocolysis as the cause of urinary calculus during pregnancy .", "tokens": ["Magnesium", "tocolysis", "as", "the", "cause", "of", "urinary", "calculus", "during", "pregnancy", "."], "event_mentions": [{"id": "9360190_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "9360190_2_Ent2", "role": "Treatment_Drug", "text": "Magnesium", "start": 0, "end": 1}, {"entity_id": "9360190_2_Ent1", "role": "Treatment", "text": "Magnesium tocolysis", "start": 0, "end": 2}, {"entity_id": "9360190_2_Ent0", "role": "Effect", "text": "urinary calculus during pregnancy", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "9360190_2_Ent2", "text": "Magnesium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9360190_2_Ent1", "text": "Magnesium tocolysis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9360190_2_Ent0", "text": "urinary calculus during pregnancy", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "9362107_2", "wnd_id": "9362107_2_1", "text": "On the next day , after a total dose of only 600 mg of danazol , gingival bleeding and purpura occurred .", "tokens": ["On", "the", "next", "day", ",", "after", "a", "total", "dose", "of", "only", "600", "mg", "of", "danazol", ",", "gingival", "bleeding", "and", "purpura", "occurred", "."], "event_mentions": [{"id": "9362107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 20, "end": 21}, "arguments": [{"entity_id": "9362107_2_Ent1", "role": "Treatment", "text": "On the next day , after a total dose of only 600 mg of danazol", "start": 0, "end": 15}, {"entity_id": "9362107_2_Ent3", "role": "Treatment_Dosage", "text": "a total dose of only 600 mg", "start": 6, "end": 13}, {"entity_id": "9362107_2_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 14, "end": 15}, {"entity_id": "9362107_2_Ent0", "role": "Effect", "text": "gingival bleeding and purpura", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "9362107_2_Ent1", "text": "On the next day , after a total dose of only 600 mg of danazol", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "9362107_2_Ent3", "text": "a total dose of only 600 mg", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9362107_2_Ent2", "text": "danazol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9362107_2_Ent0", "text": "gingival bleeding and purpura", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "9362107_3", "wnd_id": "9362107_3_1", "text": "We diagnosed this case as danazol induced thrombocytopenia .", "tokens": ["We", "diagnosed", "this", "case", "as", "danazol", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "9362107_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "9362107_3_Ent0", "role": "Subject", "text": "this case", "start": 2, "end": 4}, {"entity_id": "9362107_3_Ent2", "role": "Treatment", "text": "danazol", "start": 5, "end": 6}, {"entity_id": "9362107_3_Ent3", "role": "Treatment_Drug", "text": "danazol", "start": 5, "end": 6}, {"entity_id": "9362107_3_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9362107_3_Ent0", "text": "this case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9362107_3_Ent2", "text": "danazol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9362107_3_Ent3", "text": "danazol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9362107_3_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9366852_1", "wnd_id": "9366852_1_1", "text": "Skin necrosis secondary to low - molecular weight heparin in a patient with antiphospholipid antibody syndrome .", "tokens": ["Skin", "necrosis", "secondary", "to", "low", "-", "molecular", "weight", "heparin", "in", "a", "patient", "with", "antiphospholipid", "antibody", "syndrome", "."], "event_mentions": [{"id": "9366852_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 2, "end": 4}, "arguments": [{"entity_id": "9366852_1_Ent1", "role": "Effect", "text": "Skin necrosis", "start": 0, "end": 2}, {"entity_id": "9366852_1_Ent2", "role": "Treatment", "text": "low - molecular weight heparin", "start": 4, "end": 9}, {"entity_id": "9366852_1_Ent4", "role": "Treatment_Drug", "text": "low - molecular weight heparin", "start": 4, "end": 9}, {"entity_id": "9366852_1_Ent0", "role": "Subject", "text": "a patient with antiphospholipid antibody syndrome", "start": 10, "end": 16}, {"entity_id": "9366852_1_Ent3", "role": "Treatment_Disorder", "text": "antiphospholipid antibody syndrome", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "9366852_1_Ent1", "text": "Skin necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9366852_1_Ent2", "text": "low - molecular weight heparin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9366852_1_Ent4", "text": "low - molecular weight heparin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9366852_1_Ent0", "text": "a patient with antiphospholipid antibody syndrome", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9366852_1_Ent3", "text": "antiphospholipid antibody syndrome", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "9366852_4", "wnd_id": "9366852_4_1", "text": "We describe a patient with the antiphospholipid syndrome who had skin necrosis develop from low - molecular weight heparin therapy at sites distant from injection sites .", "tokens": ["We", "describe", "a", "patient", "with", "the", "antiphospholipid", "syndrome", "who", "had", "skin", "necrosis", "develop", "from", "low", "-", "molecular", "weight", "heparin", "therapy", "at", "sites", "distant", "from", "injection", "sites", "."], "event_mentions": [{"id": "9366852_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 12, "end": 13}, "arguments": [{"entity_id": "9366852_4_Ent0", "role": "Subject", "text": "a patient with the antiphospholipid syndrome", "start": 2, "end": 8}, {"entity_id": "9366852_4_Ent3", "role": "Treatment_Disorder", "text": "antiphospholipid syndrome", "start": 6, "end": 8}, {"entity_id": "9366852_4_Ent1", "role": "Effect", "text": "skin necrosis", "start": 10, "end": 12}, {"entity_id": "9366852_4_Ent4", "role": "Treatment_Drug", "text": "low - molecular weight heparin", "start": 14, "end": 19}, {"entity_id": "9366852_4_Ent2", "role": "Treatment", "text": "low - molecular weight heparin therapy at sites distant from injection sites", "start": 14, "end": 26}, {"entity_id": "9366852_4_Ent5", "role": "Treatment_Route", "text": "injection", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "9366852_4_Ent0", "text": "a patient with the antiphospholipid syndrome", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "9366852_4_Ent3", "text": "antiphospholipid syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9366852_4_Ent1", "text": "skin necrosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9366852_4_Ent4", "text": "low - molecular weight heparin", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "9366852_4_Ent2", "text": "low - molecular weight heparin therapy at sites distant from injection sites", "entity_type": "Entity", "start": 14, "end": 26}, {"id": "9366852_4_Ent5", "text": "injection", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "9375469_2", "wnd_id": "9375469_2_1", "text": "Therefore , we diagnosed her eruption as contact dermatitis due to sodium bisulfite .", "tokens": ["Therefore", ",", "we", "diagnosed", "her", "eruption", "as", "contact", "dermatitis", "due", "to", "sodium", "bisulfite", "."], "event_mentions": [{"id": "9375469_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 3, "end": 4}, "arguments": [{"entity_id": "9375469_2_Ent0", "role": "Effect", "text": "her eruption as contact dermatitis", "start": 4, "end": 9}, {"entity_id": "9375469_2_Ent1", "role": "Treatment", "text": "sodium bisulfite", "start": 11, "end": 13}, {"entity_id": "9375469_2_Ent2", "role": "Treatment_Drug", "text": "sodium bisulfite", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "9375469_2_Ent0", "text": "her eruption as contact dermatitis", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9375469_2_Ent1", "text": "sodium bisulfite", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9375469_2_Ent2", "text": "sodium bisulfite", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "9375469_3", "wnd_id": "9375469_3_1", "text": "We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops .", "tokens": ["We", "report", "a", "case", "of", "contact", "dermatitis", "due", "to", "sodium", "bisulfite", "in", "Tathion", "eye", "drops", "."], "event_mentions": [{"id": "9375469_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "9375469_3_Ent0", "role": "Effect", "text": "contact dermatitis", "start": 5, "end": 7}, {"entity_id": "9375469_3_Ent1", "role": "Treatment", "text": "sodium bisulfite", "start": 9, "end": 11}, {"entity_id": "9375469_3_Ent2", "role": "Treatment_Drug", "text": "sodium bisulfite", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9375469_3_Ent0", "text": "contact dermatitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9375469_3_Ent1", "text": "sodium bisulfite", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9375469_3_Ent2", "text": "sodium bisulfite", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9413296_1", "wnd_id": "9413296_1_1", "text": "A 25 - year - old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide .", "tokens": ["A", "25", "-", "year", "-", "old", "woman", "sought", "medical", "attention", "because", "of", "iliocaval", "manifestations", "of", "retroperitoneal", "fibrosis", "while", "she", "was", "taking", "methysergide", "."], "event_mentions": [{"id": "9413296_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 17, "end": 18}, "arguments": [{"entity_id": "9413296_1_Ent0", "role": "Subject", "text": "A 25 - year - old woman", "start": 0, "end": 7}, {"entity_id": "9413296_1_Ent2", "role": "Subject_Age", "text": "25 - year - old", "start": 1, "end": 6}, {"entity_id": "9413296_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "9413296_1_Ent4", "role": "Effect", "text": "iliocaval manifestations of retroperitoneal fibrosis", "start": 12, "end": 17}, {"entity_id": "9413296_1_Ent1", "role": "Subject", "text": "she", "start": 18, "end": 19}, {"entity_id": "9413296_1_Ent5", "role": "Treatment", "text": "methysergide", "start": 21, "end": 22}, {"entity_id": "9413296_1_Ent6", "role": "Treatment_Drug", "text": "methysergide", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9413296_1_Ent0", "text": "A 25 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9413296_1_Ent2", "text": "25 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9413296_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9413296_1_Ent4", "text": "iliocaval manifestations of retroperitoneal fibrosis", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "9413296_1_Ent1", "text": "she", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9413296_1_Ent5", "text": "methysergide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9413296_1_Ent6", "text": "methysergide", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9433539_1", "wnd_id": "9433539_1_1", "text": "A case is reported of an elderly woman who developed febrile agranulocytosis several weeks after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim .", "tokens": ["A", "case", "is", "reported", "of", "an", "elderly", "woman", "who", "developed", "febrile", "agranulocytosis", "several", "weeks", "after", "commencing", "ticlopidine", "but", "who", "had", "a", "favorable", "outcome", "after", "cessation", "of", "that", "drug", "and", "treatment", "with", "filgastrim", "."], "event_mentions": [{"id": "9433539_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "9433539_1_Ent0", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "9433539_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "9433539_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "9433539_1_Ent3", "role": "Effect", "text": "febrile agranulocytosis", "start": 10, "end": 12}, {"entity_id": "9433539_1_Ent5", "role": "Treatment_Time_elapsed", "text": "several weeks", "start": 12, "end": 14}, {"entity_id": "9433539_1_Ent4", "role": "Treatment", "text": "several weeks after commencing ticlopidine", "start": 12, "end": 17}, {"entity_id": "9433539_1_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 16, "end": 17}]}, {"id": "9433539_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "9433539_1_Ent7", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "9433539_1_Ent8", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "9433539_1_Ent9", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "9433539_1_Ent12", "role": "Treatment_Disorder", "text": "febrile agranulocytosis", "start": 10, "end": 12}, {"entity_id": "9433539_1_Ent10", "role": "Effect", "text": "a favorable outcome", "start": 20, "end": 23}, {"entity_id": "9433539_1_Ent11", "role": "Treatment", "text": "cessation of that drug and treatment with filgastrim", "start": 24, "end": 32}, {"entity_id": "9433539_1_Ent13", "role": "Treatment_Drug", "text": "filgastrim", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "9433539_1_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9433539_1_Ent7", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9433539_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9433539_1_Ent8", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9433539_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9433539_1_Ent9", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9433539_1_Ent3", "text": "febrile agranulocytosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9433539_1_Ent12", "text": "febrile agranulocytosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9433539_1_Ent5", "text": "several weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9433539_1_Ent4", "text": "several weeks after commencing ticlopidine", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "9433539_1_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9433539_1_Ent10", "text": "a favorable outcome", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "9433539_1_Ent11", "text": "cessation of that drug and treatment with filgastrim", "entity_type": "Entity", "start": 24, "end": 32}, {"id": "9433539_1_Ent13", "text": "filgastrim", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "9433539_2", "wnd_id": "9433539_2_1", "text": "Agranulocytosis associated with ticlopidine : a possible benefit with filgastim .", "tokens": ["Agranulocytosis", "associated", "with", "ticlopidine", ":", "a", "possible", "benefit", "with", "filgastim", "."], "event_mentions": [{"id": "9433539_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "9433539_2_Ent0", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "9433539_2_Ent1", "role": "Treatment", "text": "ticlopidine", "start": 3, "end": 4}, {"entity_id": "9433539_2_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9433539_2_Ent0", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9433539_2_Ent1", "text": "ticlopidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9433539_2_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "9494448_6", "wnd_id": "9494448_6_1", "text": "METHODS : We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine .", "tokens": ["METHODS", ":", "We", "report", "a", "patient", "who", "had", "an", "anaphylactic", "reaction", "during", "the", "intravenous", "infusion", "of", "cyclosporine", "."], "event_mentions": [{"id": "9494448_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "9494448_6_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "9494448_6_Ent1", "role": "Effect", "text": "anaphylactic reaction", "start": 9, "end": 11}, {"entity_id": "9494448_6_Ent4", "role": "Treatment_Route", "text": "intravenous infusion", "start": 13, "end": 15}, {"entity_id": "9494448_6_Ent2", "role": "Treatment", "text": "intravenous infusion of cyclosporine", "start": 13, "end": 17}, {"entity_id": "9494448_6_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9494448_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9494448_6_Ent1", "text": "anaphylactic reaction", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_6_Ent4", "text": "intravenous infusion", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9494448_6_Ent2", "text": "intravenous infusion of cyclosporine", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "9494448_6_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9517515_1", "wnd_id": "9517515_1_1", "text": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia .", "tokens": ["Development", "of", "essential", "thrombocythemia", "in", "a", "patient", "treated", "with", "interferon", "alfa", "and", "pentostatin", "for", "hairy", "cell", "leukemia", "."], "event_mentions": [{"id": "9517515_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "9517515_1_Ent1", "role": "Effect", "text": "essential thrombocythemia", "start": 2, "end": 4}, {"entity_id": "9517515_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "9517515_1_Ent4", "role": "Treatment_Drug", "text": "interferon alfa", "start": 9, "end": 11}, {"entity_id": "9517515_1_Ent6", "role": "Combination_Drug", "text": "interferon alfa", "start": 9, "end": 11}, {"entity_id": "9517515_1_Ent2", "role": "Treatment", "text": "interferon alfa and pentostatin", "start": 9, "end": 13}, {"entity_id": "9517515_1_Ent5", "role": "Treatment_Drug", "text": "pentostatin", "start": 12, "end": 13}, {"entity_id": "9517515_1_Ent7", "role": "Combination_Drug", "text": "pentostatin", "start": 12, "end": 13}, {"entity_id": "9517515_1_Ent3", "role": "Treatment_Disorder", "text": "hairy cell leukemia", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "9517515_1_Ent1", "text": "essential thrombocythemia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9517515_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9517515_1_Ent4", "text": "interferon alfa", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9517515_1_Ent6", "text": "interferon alfa", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9517515_1_Ent2", "text": "interferon alfa and pentostatin", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "9517515_1_Ent5", "text": "pentostatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9517515_1_Ent7", "text": "pentostatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9517515_1_Ent3", "text": "hairy cell leukemia", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "9545161_2", "wnd_id": "9545161_2_1", "text": "Administration of lamotrigine , especially in combination with valproic acid , may lead to the development of TEN .", "tokens": ["Administration", "of", "lamotrigine", ",", "especially", "in", "combination", "with", "valproic", "acid", ",", "may", "lead", "to", "the", "development", "of", "TEN", "."], "event_mentions": [{"id": "9545161_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 15, "end": 16}, "arguments": [{"entity_id": "9545161_2_Ent1", "role": "Treatment", "text": "Administration of lamotrigine", "start": 0, "end": 3}, {"entity_id": "9545161_2_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 2, "end": 3}, {"entity_id": "9545161_2_Ent6", "role": "Combination_Drug", "text": "lamotrigine", "start": 2, "end": 3}, {"entity_id": "9545161_2_Ent2", "role": "Treatment", "text": "with valproic acid", "start": 7, "end": 10}, {"entity_id": "9545161_2_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "9545161_2_Ent5", "role": "Combination_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "9545161_2_Ent0", "role": "Effect", "text": "TEN", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9545161_2_Ent1", "text": "Administration of lamotrigine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9545161_2_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9545161_2_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9545161_2_Ent2", "text": "with valproic acid", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9545161_2_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9545161_2_Ent5", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9545161_2_Ent0", "text": "TEN", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9545161_5", "wnd_id": "9545161_5_1", "text": "To date , eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature .", "tokens": ["To", "date", ",", "eight", "cases", "of", "TEN", "and", "one", "of", "SJS", "related", "to", "lamotrigine", "administration", "have", "been", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "9545161_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "9545161_5_Ent0", "role": "Effect", "text": "TEN", "start": 6, "end": 7}, {"entity_id": "9545161_5_Ent1", "role": "Effect", "text": "SJS", "start": 10, "end": 11}, {"entity_id": "9545161_5_Ent2", "role": "Treatment", "text": "lamotrigine", "start": 13, "end": 14}, {"entity_id": "9545161_5_Ent3", "role": "Treatment_Drug", "text": "lamotrigine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9545161_5_Ent0", "text": "TEN", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9545161_5_Ent1", "text": "SJS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9545161_5_Ent2", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9545161_5_Ent3", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9550246_2", "wnd_id": "9550246_2_1", "text": "Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect , including feelings of agitation and depression and periods of crying and insomnia .", "tokens": ["Six", "of", "13", "outpatients", "with", "schizophrenia", "who", "participated", "in", "a", "ten", "-", "week", "open", "trial", "of", "risperidone", "had", "an", "initial", "good", "response", "to", "the", "medication", "followed", "by", "development", "of", "intolerable", "affect", ",", "including", "feelings", "of", "agitation", "and", "depression", "and", "periods", "of", "crying", "and", "insomnia", "."], "event_mentions": [{"id": "9550246_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 27, "end": 28}, "arguments": [{"entity_id": "9550246_2_Ent1", "role": "Subject_Population", "text": "Six of 13", "start": 0, "end": 3}, {"entity_id": "9550246_2_Ent0", "role": "Subject", "text": "Six of 13 outpatients with schizophrenia", "start": 0, "end": 6}, {"entity_id": "9550246_2_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 5, "end": 6}, {"entity_id": "9550246_2_Ent5", "role": "Treatment_Duration", "text": "a ten - week", "start": 9, "end": 13}, {"entity_id": "9550246_2_Ent3", "role": "Treatment", "text": "a ten - week open trial of risperidone", "start": 9, "end": 17}, {"entity_id": "9550246_2_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 16, "end": 17}, {"entity_id": "9550246_2_Ent2", "role": "Effect", "text": "intolerable affect , including feelings of agitation and depression and periods of crying and insomnia", "start": 29, "end": 44}]}], "entity_mentions": [{"id": "9550246_2_Ent1", "text": "Six of 13", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9550246_2_Ent0", "text": "Six of 13 outpatients with schizophrenia", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9550246_2_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9550246_2_Ent5", "text": "a ten - week", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "9550246_2_Ent3", "text": "a ten - week open trial of risperidone", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "9550246_2_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9550246_2_Ent2", "text": "intolerable affect , including feelings of agitation and depression and periods of crying and insomnia", "entity_type": "Entity", "start": 29, "end": 44}], "lang": "en"}
{"doc_id": "9554064_4", "wnd_id": "9554064_4_1", "text": "We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression .", "tokens": ["We", "present", "a", "fatal", "case", "of", "subacute", "methanol", "toxicity", "with", "associated", "diffuse", "brain", "involvement", ",", "including", "bilateral", "putaminal", "necrosis", "and", "cerebral", "edema", "with", "ventricular", "compression", "."], "event_mentions": [{"id": "9554064_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "9554064_4_Ent1", "role": "Treatment", "text": "methanol", "start": 7, "end": 8}, {"entity_id": "9554064_4_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 7, "end": 8}, {"entity_id": "9554064_4_Ent0", "role": "Effect", "text": "diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression", "start": 11, "end": 25}]}], "entity_mentions": [{"id": "9554064_4_Ent1", "text": "methanol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9554064_4_Ent2", "text": "methanol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9554064_4_Ent0", "text": "diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression", "entity_type": "Entity", "start": 11, "end": 25}], "lang": "en"}
{"doc_id": "9562211_1", "wnd_id": "9562211_1_1", "text": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements .", "tokens": ["A", "28", "year", "old", "white", "schizophrenic", "male", "has", "been", "under", "risperidone", "monotherapy", "for", "about", "one", "year", "when", "he", "developed", "dyskinetic", "movements", "."], "event_mentions": [{"id": "9562211_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "9562211_1_Ent0", "role": "Subject", "text": "A 28 year old white schizophrenic male", "start": 0, "end": 7}, {"entity_id": "9562211_1_Ent1", "role": "Subject_Age", "text": "28 year old", "start": 1, "end": 4}, {"entity_id": "9562211_1_Ent2", "role": "Subject_Race", "text": "white", "start": 4, "end": 5}, {"entity_id": "9562211_1_Ent8", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 5, "end": 6}, {"entity_id": "9562211_1_Ent3", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "9562211_1_Ent6", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "9562211_1_Ent5", "role": "Treatment", "text": "risperidone monotherapy", "start": 10, "end": 12}, {"entity_id": "9562211_1_Ent7", "role": "Treatment_Duration", "text": "about one year", "start": 13, "end": 16}, {"entity_id": "9562211_1_Ent4", "role": "Effect", "text": "dyskinetic movements", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "9562211_1_Ent0", "text": "A 28 year old white schizophrenic male", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9562211_1_Ent1", "text": "28 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "9562211_1_Ent2", "text": "white", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9562211_1_Ent8", "text": "schizophrenic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9562211_1_Ent3", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9562211_1_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9562211_1_Ent5", "text": "risperidone monotherapy", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9562211_1_Ent7", "text": "about one year", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9562211_1_Ent4", "text": "dyskinetic movements", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "9562211_3", "wnd_id": "9562211_3_1", "text": "This report presents a potential case of risperidone - induced tardive dyskinesia .", "tokens": ["This", "report", "presents", "a", "potential", "case", "of", "risperidone", "-", "induced", "tardive", "dyskinesia", "."], "event_mentions": [{"id": "9562211_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9562211_3_Ent0", "role": "Subject", "text": "a potential case", "start": 3, "end": 6}, {"entity_id": "9562211_3_Ent2", "role": "Treatment", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "9562211_3_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "9562211_3_Ent1", "role": "Effect", "text": "tardive dyskinesia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "9562211_3_Ent0", "text": "a potential case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9562211_3_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9562211_3_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9562211_3_Ent1", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "961329_1", "wnd_id": "961329_1_1", "text": "A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported .", "tokens": ["A", "case", "of", "prolonged", "suxamethonium", "apnoea", "successfully", "terminated", "by", "the", "infusion", "of", "a", "commercial", "preparation", "of", "serumcholinesterase", "is", "reported", "."], "event_mentions": [{"id": "961329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "terminated", "start": 7, "end": 8}, "arguments": [{"entity_id": "961329_1_Ent0", "role": "Effect", "text": "prolonged suxamethonium apnoea", "start": 3, "end": 6}, {"entity_id": "961329_1_Ent2", "role": "Treatment_Drug", "text": "suxamethonium", "start": 4, "end": 5}, {"entity_id": "961329_1_Ent1", "role": "Treatment", "text": "the infusion of a commercial preparation of serumcholinesterase", "start": 9, "end": 17}, {"entity_id": "961329_1_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 10, "end": 11}, {"entity_id": "961329_1_Ent3", "role": "Treatment_Drug", "text": "serumcholinesterase", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "961329_1_Ent0", "text": "prolonged suxamethonium apnoea", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "961329_1_Ent2", "text": "suxamethonium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "961329_1_Ent1", "text": "the infusion of a commercial preparation of serumcholinesterase", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "961329_1_Ent4", "text": "infusion", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "961329_1_Ent3", "text": "serumcholinesterase", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9634122_3", "wnd_id": "9634122_3_1", "text": "This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal .", "tokens": ["This", "case", "illustrates", "the", "potential", "decoupling", "of", "PSA", "response", "from", "disease", "status", "in", "flutamide", "withdrawal", "."], "event_mentions": [{"id": "9634122_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "illustrates", "start": 2, "end": 3}, "arguments": [{"entity_id": "9634122_3_Ent0", "role": "Effect", "text": "potential decoupling of PSA response", "start": 4, "end": 9}, {"entity_id": "9634122_3_Ent2", "role": "Treatment_Drug", "text": "flutamide", "start": 13, "end": 14}, {"entity_id": "9634122_3_Ent1", "role": "Treatment", "text": "flutamide withdrawal", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9634122_3_Ent0", "text": "potential decoupling of PSA response", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9634122_3_Ent2", "text": "flutamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9634122_3_Ent1", "text": "flutamide withdrawal", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9660541_1", "wnd_id": "9660541_1_1", "text": "In rare cases mitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome , which is characterized by hemolytic anemia , thrombocytopenia and progressive renal failure .", "tokens": ["In", "rare", "cases", "mitomycin", "C", "(", "MMC", ")", "may", "induce", "cancer", "-", "associated", "hemolytic", "uremic", "syndrome", ",", "which", "is", "characterized", "by", "hemolytic", "anemia", ",", "thrombocytopenia", "and", "progressive", "renal", "failure", "."], "event_mentions": [{"id": "9660541_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 9, "end": 10}, "arguments": [{"entity_id": "9660541_1_Ent0", "role": "Subject", "text": "In rare cases", "start": 0, "end": 3}, {"entity_id": "9660541_1_Ent4", "role": "Treatment_Drug", "text": "mitomycin C", "start": 3, "end": 5}, {"entity_id": "9660541_1_Ent3", "role": "Treatment", "text": "mitomycin C ( MMC )", "start": 3, "end": 8}, {"entity_id": "9660541_1_Ent1", "role": "Effect", "text": "cancer - associated hemolytic uremic syndrome", "start": 10, "end": 16}, {"entity_id": "9660541_1_Ent2", "role": "Effect", "text": "hemolytic anemia , thrombocytopenia and progressive renal failure", "start": 21, "end": 29}]}], "entity_mentions": [{"id": "9660541_1_Ent0", "text": "In rare cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9660541_1_Ent4", "text": "mitomycin C", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9660541_1_Ent3", "text": "mitomycin C ( MMC )", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9660541_1_Ent1", "text": "cancer - associated hemolytic uremic syndrome", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9660541_1_Ent2", "text": "hemolytic anemia , thrombocytopenia and progressive renal failure", "entity_type": "Entity", "start": 21, "end": 29}], "lang": "en"}
{"doc_id": "9681092_10", "wnd_id": "9681092_10_1", "text": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration .", "tokens": ["The", "combination", "of", "cyclobenzaprine", "and", "fluoxetine", "resulted", "in", "significant", "QT", "prolongation", "in", "our", "patient", "that", "progressed", "to", "torsade", "de", "pointes", "after", "preoperative", "droperidol", "administration", "."], "event_mentions": [{"id": "9681092_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681092_10_Ent3", "role": "Treatment", "text": "The combination of cyclobenzaprine and fluoxetine", "start": 0, "end": 6}, {"entity_id": "9681092_10_Ent5", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent9", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent6", "role": "Treatment_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent10", "role": "Combination_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent1", "role": "Effect", "text": "significant QT prolongation", "start": 8, "end": 11}, {"entity_id": "9681092_10_Ent0", "role": "Subject", "text": "our patient", "start": 12, "end": 14}, {"entity_id": "9681092_10_Ent2", "role": "Effect", "text": "progressed to torsade de pointes", "start": 15, "end": 20}, {"entity_id": "9681092_10_Ent8", "role": "Treatment_Time_elapsed", "text": "preoperative", "start": 21, "end": 22}, {"entity_id": "9681092_10_Ent4", "role": "Treatment", "text": "preoperative droperidol administration", "start": 21, "end": 24}, {"entity_id": "9681092_10_Ent7", "role": "Treatment_Drug", "text": "droperidol", "start": 22, "end": 23}, {"entity_id": "9681092_10_Ent11", "role": "Combination_Drug", "text": "droperidol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9681092_10_Ent3", "text": "The combination of cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9681092_10_Ent5", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent9", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent10", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent1", "text": "significant QT prolongation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9681092_10_Ent0", "text": "our patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9681092_10_Ent2", "text": "progressed to torsade de pointes", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "9681092_10_Ent8", "text": "preoperative", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9681092_10_Ent4", "text": "preoperative droperidol administration", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "9681092_10_Ent7", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "9681092_10_Ent11", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9681092_8", "wnd_id": "9681092_8_1", "text": "Cyclobenzaprine shares anticholinergic effects , tachycardia , and dysrhythmic potential with the tricyclic antidepressants ( TCAs ) .", "tokens": ["Cyclobenzaprine", "shares", "anticholinergic", "effects", ",", "tachycardia", ",", "and", "dysrhythmic", "potential", "with", "the", "tricyclic", "antidepressants", "(", "TCAs", ")", "."], "event_mentions": [{"id": "9681092_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 9, "end": 10}, "arguments": [{"entity_id": "9681092_8_Ent1", "role": "Treatment", "text": "Cyclobenzaprine", "start": 0, "end": 1}, {"entity_id": "9681092_8_Ent3", "role": "Treatment_Drug", "text": "Cyclobenzaprine", "start": 0, "end": 1}, {"entity_id": "9681092_8_Ent0", "role": "Effect", "text": "anticholinergic effects , tachycardia , and dysrhythmic", "start": 2, "end": 9}, {"entity_id": "9681092_8_Ent2", "role": "Treatment", "text": "with the tricyclic antidepressants ( TCAs )", "start": 10, "end": 17}, {"entity_id": "9681092_8_Ent4", "role": "Treatment_Drug", "text": "tricyclic antidepressants", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9681092_8_Ent1", "text": "Cyclobenzaprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9681092_8_Ent3", "text": "Cyclobenzaprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9681092_8_Ent0", "text": "anticholinergic effects , tachycardia , and dysrhythmic", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "9681092_8_Ent2", "text": "with the tricyclic antidepressants ( TCAs )", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "9681092_8_Ent4", "text": "tricyclic antidepressants", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9681211_2", "wnd_id": "9681211_2_1", "text": "Leukaemoid monocytosis in M4 AML following chemotherapy and G - CSF .", "tokens": ["Leukaemoid", "monocytosis", "in", "M4", "AML", "following", "chemotherapy", "and", "G", "-", "CSF", "."], "event_mentions": [{"id": "9681211_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "9681211_2_Ent0", "role": "Effect", "text": "Leukaemoid monocytosis in M4 AML", "start": 0, "end": 5}, {"entity_id": "9681211_2_Ent1", "role": "Treatment", "text": "chemotherapy and G - CSF", "start": 6, "end": 11}, {"entity_id": "9681211_2_Ent2", "role": "Treatment_Drug", "text": "G - CSF", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "9681211_2_Ent0", "text": "Leukaemoid monocytosis in M4 AML", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9681211_2_Ent1", "text": "chemotherapy and G - CSF", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9681211_2_Ent2", "text": "G - CSF", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "9681211_3", "wnd_id": "9681211_3_1", "text": "We describe a patient with M4 AML treated with standard chemotherapy followed by G - CSF who developed marked monocytosis on day 8 of G - CSF therapy .", "tokens": ["We", "describe", "a", "patient", "with", "M4", "AML", "treated", "with", "standard", "chemotherapy", "followed", "by", "G", "-", "CSF", "who", "developed", "marked", "monocytosis", "on", "day", "8", "of", "G", "-", "CSF", "therapy", "."], "event_mentions": [{"id": "9681211_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "9681211_3_Ent0", "role": "Subject", "text": "a patient with M4 AML", "start": 2, "end": 7}, {"entity_id": "9681211_3_Ent3", "role": "Treatment_Disorder", "text": "M4 AML", "start": 5, "end": 7}, {"entity_id": "9681211_3_Ent2", "role": "Treatment", "text": "standard chemotherapy followed by G - CSF", "start": 9, "end": 16}, {"entity_id": "9681211_3_Ent4", "role": "Treatment_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "9681211_3_Ent7", "role": "Combination_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "9681211_3_Ent5", "role": "Treatment_Drug", "text": "G - CSF", "start": 13, "end": 16}, {"entity_id": "9681211_3_Ent8", "role": "Combination_Drug", "text": "G - CSF", "start": 13, "end": 16}, {"entity_id": "9681211_3_Ent1", "role": "Effect", "text": "marked monocytosis", "start": 18, "end": 20}, {"entity_id": "9681211_3_Ent6", "role": "Treatment_Time_elapsed", "text": "day 8", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "9681211_3_Ent0", "text": "a patient with M4 AML", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "9681211_3_Ent3", "text": "M4 AML", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9681211_3_Ent2", "text": "standard chemotherapy followed by G - CSF", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "9681211_3_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9681211_3_Ent7", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9681211_3_Ent5", "text": "G - CSF", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9681211_3_Ent8", "text": "G - CSF", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9681211_3_Ent1", "text": "marked monocytosis", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9681211_3_Ent6", "text": "day 8", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "9704170_3", "wnd_id": "9704170_3_1", "text": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium - dependent potassium permeability of cell membranes .", "tokens": ["Rhabdomyolysis", "associated", "with", "clozapine", "treatment", "in", "a", "patient", "with", "decreased", "calcium", "-", "dependent", "potassium", "permeability", "of", "cell", "membranes", "."], "event_mentions": [{"id": "9704170_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "9704170_3_Ent2", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "9704170_3_Ent3", "role": "Treatment", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9704170_3_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9704170_3_Ent0", "role": "Subject", "text": "a patient with decreased calcium - dependent potassium permeability of cell membranes", "start": 6, "end": 18}, {"entity_id": "9704170_3_Ent1", "role": "Subject_Disorder", "text": "decreased calcium - dependent potassium permeability of cell membranes", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "9704170_3_Ent2", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_3_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9704170_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9704170_3_Ent0", "text": "a patient with decreased calcium - dependent potassium permeability of cell membranes", "entity_type": "Entity", "start": 6, "end": 18}, {"id": "9704170_3_Ent1", "text": "decreased calcium - dependent potassium permeability of cell membranes", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "9719245_1", "wnd_id": "9719245_1_1", "text": "Excluding other causes , Pentasa - associated pancytopenia was considered .", "tokens": ["Excluding", "other", "causes", ",", "Pentasa", "-", "associated", "pancytopenia", "was", "considered", "."], "event_mentions": [{"id": "9719245_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "9719245_1_Ent1", "role": "Treatment", "text": "Pentasa", "start": 4, "end": 5}, {"entity_id": "9719245_1_Ent2", "role": "Treatment_Drug", "text": "Pentasa", "start": 4, "end": 5}, {"entity_id": "9719245_1_Ent0", "role": "Effect", "text": "pancytopenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9719245_1_Ent1", "text": "Pentasa", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9719245_1_Ent2", "text": "Pentasa", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9719245_1_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9754850_3", "wnd_id": "9754850_3_1", "text": "One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated .", "tokens": ["One", "should", "therefore", "be", "aware", "of", "possible", "extrapyramidal", "side", "effects", "with", "olanzapine", "that", "are", "reduced", "compared", "to", "classical", "neuroleptic", "drugs", "but", "not", "completely", "eliminated", "."], "event_mentions": [{"id": "9754850_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "9754850_3_Ent0", "role": "Effect", "text": "extrapyramidal side effects", "start": 7, "end": 10}, {"entity_id": "9754850_3_Ent1", "role": "Treatment", "text": "olanzapine", "start": 11, "end": 12}, {"entity_id": "9754850_3_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9754850_3_Ent0", "text": "extrapyramidal side effects", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9754850_3_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9754850_3_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9754850_5", "wnd_id": "9754850_5_1", "text": "We report on three patients with acute schizophrenia , who developed severe akathisia during treatment with olanzapine ( 20 - 25 mg / d ) .", "tokens": ["We", "report", "on", "three", "patients", "with", "acute", "schizophrenia", ",", "who", "developed", "severe", "akathisia", "during", "treatment", "with", "olanzapine", "(", "20", "-", "25", "mg", "/", "d", ")", "."], "event_mentions": [{"id": "9754850_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 15, "end": 16}, "arguments": [{"entity_id": "9754850_5_Ent1", "role": "Subject_Population", "text": "three", "start": 3, "end": 4}, {"entity_id": "9754850_5_Ent0", "role": "Subject", "text": "three patients with acute schizophrenia", "start": 3, "end": 8}, {"entity_id": "9754850_5_Ent4", "role": "Treatment_Disorder", "text": "acute schizophrenia", "start": 6, "end": 8}, {"entity_id": "9754850_5_Ent2", "role": "Effect", "text": "akathisia", "start": 12, "end": 13}, {"entity_id": "9754850_5_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 16, "end": 17}, {"entity_id": "9754850_5_Ent3", "role": "Treatment", "text": "olanzapine ( 20 - 25 mg / d )", "start": 16, "end": 25}, {"entity_id": "9754850_5_Ent6", "role": "Treatment_Dosage", "text": "20 - 25 mg / d", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "9754850_5_Ent1", "text": "three", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9754850_5_Ent0", "text": "three patients with acute schizophrenia", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9754850_5_Ent4", "text": "acute schizophrenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9754850_5_Ent2", "text": "akathisia", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9754850_5_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9754850_5_Ent3", "text": "olanzapine ( 20 - 25 mg / d )", "entity_type": "Entity", "start": 16, "end": 25}, {"id": "9754850_5_Ent6", "text": "20 - 25 mg / d", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "9760614_1", "wnd_id": "9760614_1_1", "text": "However , 1 eye had vitreous hemorrhage after repeated injections of tPA .", "tokens": ["However", ",", "1", "eye", "had", "vitreous", "hemorrhage", "after", "repeated", "injections", "of", "tPA", "."], "event_mentions": [{"id": "9760614_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "9760614_1_Ent0", "role": "Effect", "text": "1 eye had vitreous hemorrhage", "start": 2, "end": 7}, {"entity_id": "9760614_1_Ent1", "role": "Treatment", "text": "repeated injections of tPA", "start": 8, "end": 12}, {"entity_id": "9760614_1_Ent2", "role": "Treatment_Route", "text": "injections", "start": 9, "end": 10}, {"entity_id": "9760614_1_Ent3", "role": "Treatment_Drug", "text": "tPA", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9760614_1_Ent0", "text": "1 eye had vitreous hemorrhage", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "9760614_1_Ent1", "text": "repeated injections of tPA", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9760614_1_Ent2", "text": "injections", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9760614_1_Ent3", "text": "tPA", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9777751_6", "wnd_id": "9777751_6_1", "text": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide - induced hematologic adverse reactions .", "tokens": ["We", "conclude", "that", "the", "use", "of", "hemopoietic", "colony", "stimulating", "factors", "might", "be", "a", "suitable", "means", "to", "achieve", "the", "correction", "of", "severe", "thionamide", "-", "induced", "hematologic", "adverse", "reactions", "."], "event_mentions": [{"id": "9777751_6_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "achieve", "start": 16, "end": 17}, "arguments": [{"entity_id": "9777751_6_Ent3", "role": "Treatment", "text": "hemopoietic colony stimulating factors", "start": 6, "end": 10}, {"entity_id": "9777751_6_Ent5", "role": "Treatment_Drug", "text": "hemopoietic colony stimulating factors", "start": 6, "end": 10}, {"entity_id": "9777751_6_Ent4", "role": "Treatment_Disorder", "text": "severe thionamide - induced hematologic adverse reactions", "start": 20, "end": 27}]}, {"id": "9777751_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "9777751_6_Ent1", "role": "Treatment", "text": "thionamide", "start": 21, "end": 22}, {"entity_id": "9777751_6_Ent2", "role": "Treatment_Drug", "text": "thionamide", "start": 21, "end": 22}, {"entity_id": "9777751_6_Ent0", "role": "Effect", "text": "hematologic adverse reactions .", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "9777751_6_Ent3", "text": "hemopoietic colony stimulating factors", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9777751_6_Ent5", "text": "hemopoietic colony stimulating factors", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9777751_6_Ent4", "text": "severe thionamide - induced hematologic adverse reactions", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "9777751_6_Ent1", "text": "thionamide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9777751_6_Ent2", "text": "thionamide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9777751_6_Ent0", "text": "hematologic adverse reactions .", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "9804082_2", "wnd_id": "9804082_2_1", "text": "We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha - glucosidase inhibitor , voglibose .", "tokens": ["We", "observed", "3", "diabetic", "patients", "with", "intolerable", "dizziness", "followed", "by", "nausea", "and", "vomiting", "immediately", "after", "an", "initial", "administration", "of", "the", "alpha", "-", "glucosidase", "inhibitor", ",", "voglibose", "."], "event_mentions": [{"id": "9804082_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "9804082_2_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "9804082_2_Ent0", "role": "Subject", "text": "3 diabetic patients", "start": 2, "end": 5}, {"entity_id": "9804082_2_Ent4", "role": "Treatment_Disorder", "text": "diabetic", "start": 3, "end": 4}, {"entity_id": "9804082_2_Ent2", "role": "Effect", "text": "intolerable dizziness followed by nausea and vomiting", "start": 6, "end": 13}, {"entity_id": "9804082_2_Ent3", "role": "Treatment", "text": "an initial administration of the alpha - glucosidase inhibitor , voglibose", "start": 15, "end": 26}, {"entity_id": "9804082_2_Ent5", "role": "Treatment_Drug", "text": "voglibose", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "9804082_2_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9804082_2_Ent0", "text": "3 diabetic patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9804082_2_Ent4", "text": "diabetic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9804082_2_Ent2", "text": "intolerable dizziness followed by nausea and vomiting", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9804082_2_Ent3", "text": "an initial administration of the alpha - glucosidase inhibitor , voglibose", "entity_type": "Entity", "start": 15, "end": 26}, {"id": "9804082_2_Ent5", "text": "voglibose", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9824032_2", "wnd_id": "9824032_2_1", "text": "The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth .", "tokens": ["The", "cause", "of", "these", "previously", "unreported", "side", "effects", "of", "niacin", "therapy", "is", "uncertain", "but", "may", "be", "related", "to", "prostaglandin", "-", "mediated", "vasodilatation", ",", "hyperalgesia", "of", "sensory", "nerve", "receptors", ",", "and", "potentiation", "of", "inflammation", "in", "the", "gingiva", "with", "referral", "of", "pain", "to", "the", "teeth", "."], "event_mentions": [{"id": "9824032_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 16, "end": 17}, "arguments": [{"entity_id": "9824032_2_Ent1", "role": "Treatment", "text": "niacin", "start": 9, "end": 10}, {"entity_id": "9824032_2_Ent2", "role": "Treatment_Drug", "text": "niacin", "start": 9, "end": 10}, {"entity_id": "9824032_2_Ent0", "role": "Effect", "text": "prostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth", "start": 18, "end": 43}]}], "entity_mentions": [{"id": "9824032_2_Ent1", "text": "niacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9824032_2_Ent2", "text": "niacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9824032_2_Ent0", "text": "prostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth", "entity_type": "Entity", "start": 18, "end": 43}], "lang": "en"}
{"doc_id": "9824032_3", "wnd_id": "9824032_3_1", "text": "Two 65 - year - old white men with coronary heart disease , given niacin therapy for dyslipidemia for 5 months , developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment .", "tokens": ["Two", "65", "-", "year", "-", "old", "white", "men", "with", "coronary", "heart", "disease", ",", "given", "niacin", "therapy", "for", "dyslipidemia", "for", "5", "months", ",", "developed", "intense", "dental", "and", "gingival", "pain", "that", "was", "associated", "with", "increases", "in", "dose", "and", "that", "was", "relieved", "with", "discontinuance", "of", "niacin", "treatment", "."], "event_mentions": [{"id": "9824032_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "9824032_3_Ent2", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "9824032_3_Ent0", "role": "Subject", "text": "Two 65 - year - old white men with coronary heart disease", "start": 0, "end": 12}, {"entity_id": "9824032_3_Ent3", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "9824032_3_Ent4", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "9824032_3_Ent5", "role": "Subject_Gender", "text": "men", "start": 7, "end": 8}, {"entity_id": "9824032_3_Ent1", "role": "Subject_Disorder", "text": "coronary heart disease", "start": 9, "end": 12}, {"entity_id": "9824032_3_Ent10", "role": "Treatment_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "9824032_3_Ent7", "role": "Treatment", "text": "niacin therapy for dyslipidemia for 5 months", "start": 14, "end": 21}, {"entity_id": "9824032_3_Ent9", "role": "Treatment_Disorder", "text": "dyslipidemia", "start": 17, "end": 18}, {"entity_id": "9824032_3_Ent12", "role": "Treatment_Duration", "text": "5 months", "start": 19, "end": 21}, {"entity_id": "9824032_3_Ent6", "role": "Effect", "text": "intense dental and gingival pain", "start": 23, "end": 28}, {"entity_id": "9824032_3_Ent8", "role": "Treatment", "text": "increases in dose", "start": 32, "end": 35}, {"entity_id": "9824032_3_Ent11", "role": "Treatment_Dosage", "text": "increases in dose", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "9824032_3_Ent2", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9824032_3_Ent0", "text": "Two 65 - year - old white men with coronary heart disease", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9824032_3_Ent3", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9824032_3_Ent4", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9824032_3_Ent5", "text": "men", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9824032_3_Ent1", "text": "coronary heart disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9824032_3_Ent10", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9824032_3_Ent7", "text": "niacin therapy for dyslipidemia for 5 months", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "9824032_3_Ent9", "text": "dyslipidemia", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9824032_3_Ent12", "text": "5 months", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "9824032_3_Ent6", "text": "intense dental and gingival pain", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "9824032_3_Ent8", "text": "increases in dose", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "9824032_3_Ent11", "text": "increases in dose", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "9831311_2", "wnd_id": "9831311_2_1", "text": "High - dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia .", "tokens": ["High", "-", "dose", "phosphate", "treatment", "leads", "to", "hypokalemia", "in", "hypophosphatemic", "osteomalacia", "."], "event_mentions": [{"id": "9831311_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leads", "start": 5, "end": 6}, "arguments": [{"entity_id": "9831311_2_Ent4", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "9831311_2_Ent1", "role": "Treatment", "text": "High - dose phosphate", "start": 0, "end": 4}, {"entity_id": "9831311_2_Ent3", "role": "Treatment_Drug", "text": "phosphate", "start": 3, "end": 4}, {"entity_id": "9831311_2_Ent0", "role": "Effect", "text": "hypokalemia", "start": 7, "end": 8}, {"entity_id": "9831311_2_Ent2", "role": "Treatment_Disorder", "text": "hypophosphatemic osteomalacia", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9831311_2_Ent4", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9831311_2_Ent1", "text": "High - dose phosphate", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9831311_2_Ent3", "text": "phosphate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9831311_2_Ent0", "text": "hypokalemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9831311_2_Ent2", "text": "hypophosphatemic osteomalacia", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9840249_2", "wnd_id": "9840249_2_1", "text": "The pulmonary toxicity of gold salts is an uncommon cause of life - threatening respiratory failure .", "tokens": ["The", "pulmonary", "toxicity", "of", "gold", "salts", "is", "an", "uncommon", "cause", "of", "life", "-", "threatening", "respiratory", "failure", "."], "event_mentions": [{"id": "9840249_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "9840249_2_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 1, "end": 3}, {"entity_id": "9840249_2_Ent3", "role": "Treatment_Drug", "text": "gold", "start": 4, "end": 5}, {"entity_id": "9840249_2_Ent2", "role": "Treatment", "text": "gold salts", "start": 4, "end": 6}, {"entity_id": "9840249_2_Ent1", "role": "Effect", "text": "life - threatening respiratory failure", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "9840249_2_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9840249_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9840249_2_Ent2", "text": "gold salts", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9840249_2_Ent1", "text": "life - threatening respiratory failure", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "9840249_3", "wnd_id": "9840249_3_1", "text": "We report a case of severe respiratory failure due to gold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation .", "tokens": ["We", "report", "a", "case", "of", "severe", "respiratory", "failure", "due", "to", "gold", "salt", "toxicity", "in", "a", "patient", "suffering", "from", "rheumatoid", "arthritis", "requiring", "mechanical", "ventilation", "."], "event_mentions": [{"id": "9840249_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "9840249_3_Ent1", "role": "Effect", "text": "respiratory failure", "start": 6, "end": 8}, {"entity_id": "9840249_3_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 10, "end": 11}, {"entity_id": "9840249_3_Ent2", "role": "Treatment", "text": "gold salt", "start": 10, "end": 12}, {"entity_id": "9840249_3_Ent0", "role": "Subject", "text": "a patient suffering from rheumatoid arthritis", "start": 14, "end": 20}, {"entity_id": "9840249_3_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "9840249_3_Ent1", "text": "respiratory failure", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9840249_3_Ent4", "text": "gold", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9840249_3_Ent2", "text": "gold salt", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9840249_3_Ent0", "text": "a patient suffering from rheumatoid arthritis", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "9840249_3_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "9865241_3", "wnd_id": "9865241_3_1", "text": "The patient was initially treated with hydration and furosemide but developed congestive heart failure .", "tokens": ["The", "patient", "was", "initially", "treated", "with", "hydration", "and", "furosemide", "but", "developed", "congestive", "heart", "failure", "."], "event_mentions": [{"id": "9865241_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "9865241_3_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "9865241_3_Ent2", "role": "Treatment", "text": "furosemide", "start": 8, "end": 9}, {"entity_id": "9865241_3_Ent3", "role": "Treatment_Drug", "text": "furosemide", "start": 8, "end": 9}, {"entity_id": "9865241_3_Ent1", "role": "Effect", "text": "congestive heart failure", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "9865241_3_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9865241_3_Ent2", "text": "furosemide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_3_Ent3", "text": "furosemide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_3_Ent1", "text": "congestive heart failure", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "9876809_2", "wnd_id": "9876809_2_1", "text": "To report a probable case of ticlopidine - induced phenytoin toxicity .", "tokens": ["To", "report", "a", "probable", "case", "of", "ticlopidine", "-", "induced", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "9876809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "9876809_2_Ent0", "role": "Subject", "text": "a probable case", "start": 2, "end": 5}, {"entity_id": "9876809_2_Ent3", "role": "Treatment", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent4", "role": "Treatment_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent6", "role": "Combination_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent2", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent7", "role": "Combination_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9876809_2_Ent0", "text": "a probable case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9876809_2_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent4", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9883483_2", "wnd_id": "9883483_2_1", "text": "Thus , an immunological mechanism might be involved in the mechanism of pirmenol - induced QT prolongation and T wave inversion on the electrocardiogram .", "tokens": ["Thus", ",", "an", "immunological", "mechanism", "might", "be", "involved", "in", "the", "mechanism", "of", "pirmenol", "-", "induced", "QT", "prolongation", "and", "T", "wave", "inversion", "on", "the", "electrocardiogram", "."], "event_mentions": [{"id": "9883483_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9883483_2_Ent1", "role": "Treatment", "text": "pirmenol", "start": 12, "end": 13}, {"entity_id": "9883483_2_Ent2", "role": "Treatment_Drug", "text": "pirmenol", "start": 12, "end": 13}, {"entity_id": "9883483_2_Ent0", "role": "Effect", "text": "QT prolongation and T wave inversion", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "9883483_2_Ent1", "text": "pirmenol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9883483_2_Ent2", "text": "pirmenol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9883483_2_Ent0", "text": "QT prolongation and T wave inversion", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "9892272_4", "wnd_id": "9892272_4_1", "text": "The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma .", "tokens": ["The", "development", "of", "cutaneous", "ecchymosis", "associated", "with", "a", "sudden", "fall", "in", "hemoglobin", "after", "the", "administration", "of", "alteplase", "should", "strongly", "suggest", "the", "possibility", "of", "diffuse", "subfascial", "hematoma", "."], "event_mentions": [{"id": "9892272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "9892272_4_Ent0", "role": "Effect", "text": "cutaneous ecchymosis", "start": 3, "end": 5}, {"entity_id": "9892272_4_Ent1", "role": "Effect", "text": "a sudden fall in hemoglobin", "start": 7, "end": 12}, {"entity_id": "9892272_4_Ent3", "role": "Treatment", "text": "alteplase", "start": 16, "end": 17}, {"entity_id": "9892272_4_Ent4", "role": "Treatment_Drug", "text": "alteplase", "start": 16, "end": 17}, {"entity_id": "9892272_4_Ent2", "role": "Effect", "text": "diffuse subfascial hematoma", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "9892272_4_Ent0", "text": "cutaneous ecchymosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9892272_4_Ent1", "text": "a sudden fall in hemoglobin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "9892272_4_Ent3", "text": "alteplase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9892272_4_Ent4", "text": "alteplase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9892272_4_Ent2", "text": "diffuse subfascial hematoma", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "9925865_2", "wnd_id": "9925865_2_1", "text": "In patients with swallowing dysfunction and pneumonia , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred .", "tokens": ["In", "patients", "with", "swallowing", "dysfunction", "and", "pneumonia", ",", "a", "history", "of", "mineral", "oil", "use", "should", "be", "obtained", "and", "a", "diagnosis", "of", "ELP", "should", "be", "considered", "in", "the", "differential", "diagnoses", "if", "mineral", "oil", "use", "has", "occurred", "."], "event_mentions": [{"id": "9925865_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 24, "end": 25}, "arguments": [{"entity_id": "9925865_2_Ent0", "role": "Subject", "text": "In patients with swallowing dysfunction and pneumonia", "start": 0, "end": 7}, {"entity_id": "9925865_2_Ent2", "role": "Treatment", "text": "a history of mineral oil use", "start": 8, "end": 14}, {"entity_id": "9925865_2_Ent3", "role": "Treatment_Drug", "text": "mineral oil", "start": 11, "end": 13}, {"entity_id": "9925865_2_Ent1", "role": "Effect", "text": "ELP", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9925865_2_Ent0", "text": "In patients with swallowing dysfunction and pneumonia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9925865_2_Ent2", "text": "a history of mineral oil use", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "9925865_2_Ent3", "text": "mineral oil", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9925865_2_Ent1", "text": "ELP", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9925865_6", "wnd_id": "9925865_6_1", "text": "Treatment of ELP in children is generally supportive , with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil .", "tokens": ["Treatment", "of", "ELP", "in", "children", "is", "generally", "supportive", ",", "with", "the", "symptoms", "and", "roentgenographic", "abnormalities", "resolving", "within", "months", "after", "stopping", "the", "use", "of", "mineral", "oil", "."], "event_mentions": [{"id": "9925865_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "9925865_6_Ent3", "role": "Treatment_Disorder", "text": "ELP", "start": 2, "end": 3}, {"entity_id": "9925865_6_Ent0", "role": "Effect", "text": "symptoms and roentgenographic abnormalities resolving", "start": 11, "end": 16}, {"entity_id": "9925865_6_Ent1", "role": "Treatment", "text": "stopping the use of mineral oil", "start": 19, "end": 25}, {"entity_id": "9925865_6_Ent2", "role": "Treatment_Drug", "text": "mineral oil", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9925865_6_Ent3", "text": "ELP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9925865_6_Ent0", "text": "symptoms and roentgenographic abnormalities resolving", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "9925865_6_Ent1", "text": "stopping the use of mineral oil", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "9925865_6_Ent2", "text": "mineral oil", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9934637_4", "wnd_id": "9934637_4_1", "text": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive .", "tokens": ["Sunburn", "may", "sometimes", "be", "a", "major", "injury", "in", "psoralen", "users", "because", "high", "doses", "or", "inappropriate", "use", "of", "the", "drug", "may", "render", "the", "skin", "extremely", "sensitive", "."], "event_mentions": [{"id": "9934637_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "render", "start": 20, "end": 21}, "arguments": [{"entity_id": "9934637_4_Ent1", "role": "Effect", "text": "Sunburn", "start": 0, "end": 1}, {"entity_id": "9934637_4_Ent4", "role": "Treatment_Drug", "text": "psoralen", "start": 8, "end": 9}, {"entity_id": "9934637_4_Ent3", "role": "Treatment", "text": "psoralen users because high doses or inappropriate use", "start": 8, "end": 16}, {"entity_id": "9934637_4_Ent0", "role": "Subject", "text": "users", "start": 9, "end": 10}, {"entity_id": "9934637_4_Ent5", "role": "Treatment_Dosage", "text": "high doses", "start": 11, "end": 13}, {"entity_id": "9934637_4_Ent2", "role": "Effect", "text": "skin extremely sensitive", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "9934637_4_Ent1", "text": "Sunburn", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9934637_4_Ent4", "text": "psoralen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9934637_4_Ent3", "text": "psoralen users because high doses or inappropriate use", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "9934637_4_Ent0", "text": "users", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9934637_4_Ent5", "text": "high doses", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9934637_4_Ent2", "text": "skin extremely sensitive", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
